<SEC-DOCUMENT>0001628280-22-030869.txt : 20221128
<SEC-HEADER>0001628280-22-030869.hdr.sgml : 20221128
<ACCEPTANCE-DATETIME>20221128160633
ACCESSION NUMBER:		0001628280-22-030869
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221128
DATE AS OF CHANGE:		20221128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		221425407

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arwr-20220930.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353,d:f17c086bfc1e494d91287b00809be3a1--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:arwr="http://www.arrowheadresearch.com/20220930" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV8zLTEtMS0xLTg3MjA_2922c56f-0ffd-43da-b766-bf407015b667">2022</ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV80LTEtMS0xLTg3MjA_b381c79a-f016-45b5-88e1-bf6c2c3ec0e1">FY</ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV81LTEtMS0xLTg3MjA_a0716dcc-b3e2-4994-9bfe-9c14e24a3aab">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV82LTEtMS0xLTg3MjA_709f4c7a-3fd4-4bd6-a968-c3f1102a9c2b">false</ix:nonNumeric><ix:nonNumeric contextRef="ifb92b5d5298c4caeaca04ee1aa109a30_D20211001-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7421ed853be4b3d9e96b38143d48ac5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id99da0a6e99b4466a612f719b4091471_I20221116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7033dda081f6486dabd109e810a7b896_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i41f898dddb034047b93f962c444848c2_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ada9eeb31fe445ab0ddd2906a6caf3d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9805470dd04665b4e60fa414b2154c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74d9b7bcca044446b494a1d25fac4d68_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b91bb8802b14d459682008730c71bdb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9195ae78bd0c4e018feb06bc6f39941e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc91136601b54b3db1507e8c9cdb15f0_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18f5d11bc984e7794a39d04db8c9fb9_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161077d110d5481c9db46e19e59e25b2_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ac603c8f5b4a8e890cd249e848355a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i581a193e673a43ee927c51ce5fa8bc57_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565f0aec40984903ab31509ccc107152_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8471847377104689b2acf51a693ccb46_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27eb4fa099754665885890250ac463e9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i153aae9fbcc94761892a18a2f3831c92_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i359029c46a5a49938725dac7c0770303_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b52d362ef24d56892538907287fb19_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7897c16d6d54a919ae876c9750f0852_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9289c53cbc4f4abf44684d7a804d50_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1089994c19ef4e178fc178cb7fca23c2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76bd52f2644744feb3d658807f3cd6c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib80c3d1b3390496eb0b757a895741ff6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb486426d4d441729abee7d2481a2a1d_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca354a33143401aba048d9836285871_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i411e86d4599445cd8332b7c1f8beafc9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff05358bb4d14f5b937c35181dff107d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f294cd4e58b4aaba50d623ebeaf06c6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabdc3ed836bd43d192665281d701b948_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id483571f939d4e63b7389598f61b6608_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c33bdda82049d3a3cdcf2e2b470a41_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be7d6ac7c6843cfa78f8297acbba259_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5eb370c7c5f408f97b13ca719ad8160_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65482bab6bd34d03bbd7d32bad1c394b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46257ffa533499ababde9281223cdfe_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb92b5d5298c4caeaca04ee1aa109a30_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56df8fd74028436c99ef6ff3b54f10dc_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239542cd95804d368929cbe8296c90bf_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b56dc494ac43218654da036bf8f658_I20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63738435aba549e9813b380730f41e49_D20211122-20211122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2326885925904bb9bbf356f129cc9a0b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7692cd01c9aa41649a62cbfade2efe6f_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e25f65ec4394c019914b93112fd60a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afacc79e97d47baba530c5a7adb3b40_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ca7c57f3904478a1cd7317601e0d4e_I20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:context id="if3138c853e8a455f9a77625afebd539e_D20210618-20210618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd0a2669a28454588c20d1c395a052a_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3bde044abb649a48ecd1191afb3f05d_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0019512decda4b7990aafbc1a7e248d0_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0949381581ff4af3b82881ca7e331bf6_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c37b9188bae4800a6595d3418a0fae6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e4962b3a1642f3aa8710b99691c60d_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2fe6b533bcf74101bd5976bd6846dd09_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef38d1d9fc4434fadb646e8a3dfeb79_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871d9ae6597e4d0d95bc94bb785a706d_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86729ae38276427b8f27b306b25909e2_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie544bcf5262b43bc9e9b768016c61906_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05164f990274472cb23e6e2da5920f02_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id93baee844644d37b56a5574a3dfc2c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f1d06f484244cafbb6712b67dd5e5c7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb795196cbc24edfafc6f4b579915985_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0868f45959c4a9083e418da9c188745_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b7661cd1834368bdbc8265bf19edd4_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3ffe024b534c88b962b31bde7d7c6a_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc323ba26f8a48859fcb26ec988dac7d_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd2623ae6e34732b7abc8fb92562252_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21f342da4904bf7a53c62826f1b14b5_I20181003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5534ed7a218413bac198deed25bcfc0_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04804bc83aae49eeb388934d6474807c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadad9a7e9ae24932ba60d057d20788cd_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ca4cce11534def83440361284f2151_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f50957118724116aade42a087a6e5f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f6a7cc3aa148ba86425faae6df475a_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:context id="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fddaa78aa9e4413be71a69a9e690ee6_I20160928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c0415f2ff94135b02ad71902b05a2b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72f2076c3c244c595b91d7c4fc96de6_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbbbc50aed91458f9e1cd5ca2b297e7f_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2396a0b95284dc1b37555872c67d544_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885b30b505e24a9f94b50732d67bf577_D20220425-20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7aa5158d8a4572841de66b301948f3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44ad6fc7f3048128d384a807baf8f9f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib50cf07473c341bb83c937e0734c6bf8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f89654b9f74474292d999d71129a6fc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d9cb60633a4c7ba224716bf2e67384_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1623ebd76b9429f91c1adfbae86766c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b16903a80c34cbebbaa904142f4545d_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ec44177d044f55bd6f14baa4539fa4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2217a769eda4c6f894237f46441005d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b02e88c51804f51b4b08d70e9573b4f_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff24be97ac644b7db7e5782fc8875f11_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba50d541c9b45b1a0b65b7a3bc2d634_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a14a234b0c64f3db010016f3e349b47_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b2ef96e1ad4c0f884bfbb000ec421d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945e065f941c41089f590861be2be53b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df31e5a41964923a5bf827d1e46ccc8_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ad9b35ad9945e681373c342ced19be_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib800ee136c204f7ca7d6ef70fe9e6bd8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aec9e8e7c804df6bbe9ef108587e7e9_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="i20b2347df25f44adb7fd8c6f8ab94841_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i10f071832c694c79898be3703116f022_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598cccc6787b498eb6eeded5080d12fb_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98b23103c13b4614a1ee88bf196be447_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1cbc59142a346ab848b67c243bece56_I20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id417cd70ff1e486fa32a39bf2ea4e409_D20211220-20211220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d3f2b9861345109a3431f21d36390e_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if70fc35468fb4978af2a43b1fceb0798_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee2e0cf0d164b389f68d128f6660757_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b4626c667d49489d40619ab73dfd32_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac223b0321a49138fb4f0d6b53af948_D20211119-20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7836ff9fc4254208a4ff43eb773872c8_I20211119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:context id="ic89a1f5369f449baba38fde031911868_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31744253af624e368277cea062fec33b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16e72a6872cc4f52ad4d28a752176455_D20190101-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1c2d58f05843da801c500579193e65_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f3846145b84a9d86539d94479612f5_D20201101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32848b6466e0410c988feb7b33651971_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084e58e42b30496a98760c1737b0a332_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0350e114f99c470694c8188da7224d5d_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462548275c5d4e64805ca898b4d3310b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9641c69b3744bcdaab718353895bff8_I20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249abfa0135244269274c5ba0e2a360d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib209a739b3e74cc4867507f26036f5d2_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98c2c43432e94729a89fa4a887a1c799_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a79bc6396d84f5d9ba7d3576acf4bd7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe2f7bfc0e54741ba6777b6c90e7a87_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba56efe3069544b3b006005a13d5a1e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9166d3c1ac4c9484561dc49251117d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f46952ca97049a89f6fbd21071e26cf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f7c3935399043749e14bfd46faba122_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76168196746b4c5988651e89f27274b6_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5bb146412894240951a8f5f0074b9e2_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2132296e191446feb126e32a24da326d_D20220708-20220708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-08</xbrli:startDate><xbrli:endDate>2022-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7836f44fe8142e2a7dc14272ef0dcc0_I20220708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b1850ca53244f88adb790e0b1d0c38_I20220708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d5f88f4e904ac2940b5051a30bc4b1_D20201001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3514c3e5478e4ed1a2f4d1a8b0dcda20_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i299f22dc89ed4f02aad79a53bc36af3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f3b2544ed2e40fc89cdf37aadc3f4a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f75fded4dc34e48948a02b7e07fd82e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a7da1d717d40f485a1fb19c1bbb868_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9cfdc688ab47ae95c5b3623b07d4cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib874f688067b4ae3823dfe2d5cc52229_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9726349ec847475481516736bbee2e12_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3f870fa9724a6289cd90aaceca2dbe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e1acd9eb264a28a7f8a2ce38d04ff9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0729cf15b424ad69a05e5b53e463218_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c41638864d45ff8f4f22cf139c92d0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f3184cfed4429d8cbbef7071a35cda_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09e91a7f81146eb8f534664d90f3ab4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9a9acd15ab40458715e433c95945ee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6efcde85aa4cb69f080c834193155d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d30f7a7174940b5bc8c54c3a014461e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee4d084af8a45c0bc6632f602ca4885_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578ce9b283054d468a9fcb74aad58206_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4baaa4a1b1440a8316bc6202886db9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfc3811ca444047a8ad3417384b63d7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b153258fbf4c22ab083ac660ddd90f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b6aea9f3d64a28b6b8dde5934fa0fd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i072081357d81444787fc75a77eec30c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a57713d420442a29ad35a7c6f6eaecd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36da89f6527b4ee2b870bccdcf0fa0a6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d0fd8b1f204829b507748af614940f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i593bbbcd381b438f824786951159d60c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e47d68d528444408ac6eae19b74435a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic420c820ffc14e059589b2f7c7483c62_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb48d12728f43e8a186351de2899d14_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31add50b09e042ad9d4989277f1a52ba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fac4c8066e449919f984f9375260f9c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i680acdc5a46f4301848a1974ee5d87f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a9b850b4964639b775e3da5e3929bc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib584577ec6214ad49aac83e30cb1140e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib99f8ae8742d44808ca61f58e0458992_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb34bf154a434e759ce53d263414bc10_D20211001-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida71a393ea7a404baff5b677a2df560c_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98ad7600c774fbfa55d91feafc740d8_I20221109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if17c086bfc1e494d91287b00809be3a1_1"></div><div style="min-height:31.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU3_0f2a7030-e2ba-4ecf-8ebf-5145a9e124f5">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6MDAyYTdkNWIxZDgwNDliZDk0YTM0OGViZWI4NGY3YzEvdGFibGVyYW5nZTowMDJhN2Q1YjFkODA0OWJkOTRhMzQ4ZWJlYjg0ZjdjMV8wLTAtMS0xLTg3MjA_48ee65f2-df84-413a-b1b1-88f4e82064e0">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MTg5_c1dcb76a-2a2d-4a87-bbe0-199b81b68bce"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MTg5_cc66e0f9-78fb-4e2c-9615-cc9542e1ea79">September 30</ix:nonNumeric>, 2022</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YzU3ZmYxMDRiYmY0NDcwNTg1NzkyYzFhZjgzZTY1ZTEvdGFibGVyYW5nZTpjNTdmZjEwNGJiZjQ0NzA1ODU3OTJjMWFmODNlNjVlMV8wLTAtMS0xLTg3MjA_203a7e91-e783-4a73-a92c-1ce08adacfc5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU4_798c027f-f29a-475f-a527-c721058814c0">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU5_7ee9c85f-27eb-498e-a524-2de38d715e34">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YjIwODE4YmFiOWQ3NDE0MDhiOWQ3OGUyZGY5ZTk5YjMvdGFibGVyYW5nZTpiMjA4MThiYWI5ZDc0MTQwOGI5ZDc4ZTJkZjllOTliM18wLTAtMS0xLTg3MjA_f612db36-50b7-4594-aae9-ed6a27b25dcb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YjIwODE4YmFiOWQ3NDE0MDhiOWQ3OGUyZGY5ZTk5YjMvdGFibGVyYW5nZTpiMjA4MThiYWI5ZDc0MTQwOGI5ZDc4ZTJkZjllOTliM18wLTEtMS0xLTg3MjA_533dcdb9-6d04-4634-8c9f-a7246dfeea4f">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYy_c2fa3f48-f72f-46b2-b36c-d48260094f15">626</ix:nonNumeric>) <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUx_c656f990-8522-4c44-ad3c-13ec1d697070">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MDQ_5502a708-efd5-4511-b933-ec96efeb8c8c">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MDg_75962fe5-ee64-4bfd-830a-88914ea90508">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTE_4d714726-f014-4bf3-a134-4e44ec447a62">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTU_bd5040da-4275-4c4c-afbf-ca4474dc5991">California</ix:nonNumeric> <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTg_03950dd3-5b1a-47ab-9c77-de74bb7ce9f6">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTAtMS0xLTg3MjA_93828e87-043f-482e-8296-34acc678c3f1">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTEtMS0xLTg3MjA_060ae765-e61a-48ff-b186-bf61f6812fc1">ARWR</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTItMS0xLTg3MjA_4d2e2fd0-96bd-4def-a345-19d7491cade4">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUy_499496b3-1ba1-4c26-9520-f20be1a212bc">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUz_db4402b0-0884-4f3c-b3a3-1d2a36d2bf42">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYz_3cf7294e-6d52-4bc0-99f6-4f4b163e0b46">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU0_b91c1ecb-8a35-4dbd-ab55-a8aa851cfba6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8wLTAtMS0xLTg3MjA_d43d17f9-82d6-444b-93f7-2f37f5c6cff4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8wLTktMS0xLTg3MjA_92fb8355-a942-4aae-a6d3-6135e01ed5a1">Smaller reporting company</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8xLTAtMS0xLTg3MjA_4a5efbdb-4249-4382-b9e6-091ff3fc15ce">Emerging growth company</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYw_8db7407f-ef7d-40ea-aa29-ee736e0f853b">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzQ5_4133ff79-1d28-4968-9910-9550a93f66d8">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of issuer&#8217;s voting and non-voting outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="id7421ed853be4b3d9e96b38143d48ac5_I20220331" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMDIx_70cbf89a-c872-4755-9599-21c32bc69f09">4.1</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s common stock on March 31, 2022. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of November&#160;16, 2022, <ix:nonFraction unitRef="shares" contextRef="id99da0a6e99b4466a612f719b4091471_I20221116" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MDk5_3c8ac554-67d6-46fc-82ab-bfb5bb24eba3">106,005,722</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU2_aa75170e-ad90-4a1b-a2c8-23a557e1316a" escape="true">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</ix:nonNumeric></span></div><div style="text-indent:30.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_16">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_16">TEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_16">B</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_16">USINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_19">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_19">TEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_19">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_19">ISK </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_19">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_19">ACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_19">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_22">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_22">TEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">U</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">NRESOLVED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">TAFF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_22">OMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_22">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_25">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_25">TEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_25">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_25">ROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_25">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_28">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_28">TEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_28">L</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_28">EGAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_28">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_28">ROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_28">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_31">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_31">TEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">INE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">AFETY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_31">ISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_31">53</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_37">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_37">TEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">ARKET FOR THE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">EGISTRANT&#8217;S </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">OMMON </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">QUITY, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">ELATED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">TOCKHOLDER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">ATTERS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">SSUER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">URCHASES OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">QUITY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_37">ECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_37">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_40">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_40">TEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_40">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_40">eserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_40">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_43">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_43">TEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">ANAGEMENT&#8217;S </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">ISCUSSION AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">NALYSIS OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">ONDITION AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">ESULTS OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_43">PERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_43">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_64">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_64">TEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">Q</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">UANTITATIVE AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">Q</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">UALITATIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">ISCLOSURES </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">BOUT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">ARKET </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_64">ISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_64">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_67">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_67">TEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">TATEMENTS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">UPPLEMENTARY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_67">ATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_67">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_70">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_70">TEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">HANGES IN AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">ISAGREEMENTS WITH </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">CCOUNTANTS ON </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">CCOUNTING AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_70">ISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_70">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_73">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_73">TEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_73">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_73">ONTROLS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_73">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_73">ROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_73">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_76">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_76">TEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_76">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_76">THER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_76">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_76">NFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_76">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_79">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_79">TEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">ISCLOSURE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">EGARDING </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">OREIGN </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">J</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">UR</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">DICTIONS </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">T</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">HAT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">REVENT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_79">NSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_79">67</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_82">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_85">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_85">TEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">IRECTORS, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">XECUTIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">FFICERS, AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">ORPORATE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">G</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_85">OVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_85">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_88">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_88">TEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_88">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_88">XECUTIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_88">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_88">OMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_88">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_91">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_91">TEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">ECURITY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">WNERSHIP OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">ERTAIN </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">B</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">ENEFICIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">WNERS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">ANAGEMENT AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">ELATED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_91">TOCKHOLDERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_91">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_94">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_94">TEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">ERTAIN </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">ELATIONSHIPS, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">ELATED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">T</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">RANSACTIONS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">IRECTORS </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_94">NDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_94">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_97">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_97">TEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">RINCIPAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">CCOUNTANT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">EES AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_97">ERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_97">68</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_100">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_103">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_103">TEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">XHIBITS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">TATEMENT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_103">CHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_103">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_106">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_106">TEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_106">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_106">ORM 10-K </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_106">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_106">UMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_106">72</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_109">SIGNATURE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_112">INDEX TO FINANCIAL STATEMENTS AND SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_112">1</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results may differ materially from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of this Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise noted, (1) the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2) the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), and Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) (4) the term &#8220;common stock&#8221; refers to Arrowhead&#8217;s common stock, (5) the term &#8220;preferred stock&#8221; refers to Arrowhead&#8217;s preferred stock and (6) the term &#8220;stockholder(s)&#8221; refers to the holders of Arrowhead common stock. </span></div><div id="if17c086bfc1e494d91287b00809be3a1_16"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">BUSINESS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Arrowhead's pipeline of 12 development programs ranges from pre-clinical discovery to late-stage clinical development, and it is focused on developing its most advanced therapies for late-stage clinical trials. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. </span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:27pt"><img src="arwr-20220930_g1.jpg" alt="arwr-20220930_g1.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Interference and the Benefits of RNAi Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets. However, other drug targets have proven difficult to inhibit with traditional drug-based and biologic therapeutics. Developing effective drugs for these targets would have the potential to address large underserved markets for the treatment of many diseases. Using the ability to specifically silence any gene, RNAi therapeutics may be able to address previously &#8220;undruggable&#8221; targets, unlocking the market potential of such targets. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20220930_g2.jpg" alt="arwr-20220930_g2.jpg" style="height:340px;margin-bottom:5pt;vertical-align:text-bottom;width:454px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This figure depicts the mechanism by which gene silencing occurs. Double stranded RNAi triggers are introduced into a cell and are loaded into the RNA-induced silencing complex, (&#8220;RISC&#8221;). The strands are then separated, leaving an active RISC/RNAi trigger complex. This complex can then pair with and degrade the complementary messenger RNAs (&#8220;mRNA&#8221;) and stop the production of the target proteins. RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times, which results in a relatively long duration of effect for RNAi therapeutics.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key Benefits of RNAi as a Therapeutic Modality</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Silences the expression of disease associated genes; </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">Potential to address any target in the transcriptome including previously &#8220;undruggable&#8221; targets;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Rapid lead identification;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">High specificity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Opportunity to use multiple RNA sequences in one drug product for synergistic silencing of related targets; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RNAi therapeutics are uniquely suited for personalized medicine through target and cell specific delivery and gene knockdown.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted RNAi Molecule (TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">) Platform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead&#8217;s Targeted RNAi Molecule (TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. Targeting has been core to Arrowhead&#8217;s development philosophy and the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform builds on more than a decade of work on actively targeted drug delivery vehicles. Arrowhead scientists have discovered ways to progressively &#8220;TRiM&#8221; away extraneous features and chemistries and retain optimal pharmacologic activity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform is comprised of a highly potent RNA trigger identified using Arrowhead&#8217;s proprietary trigger selection rules and algorithms with the following components optimized, as needed, for each drug candidate: a high affinity targeting ligand; various linker and chemistries; structures that enhance pharmacokinetics; and highly potent RNAi triggers with sequence specific stabilization chemistries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics developed with the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform offer several advantages: simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety because there are less metabolites from smaller molecules, thereby reducing the risk of intracellular buildup. Arrowhead also believes that for RNAi to reach its true potential, it must target organs outside the liver. Arrowhead is leading this expansion with the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, which has shown the potential to reach multiple tissues, including liver, lung, tumor and muscle, and Arrowhead believes that it has the potential to reach other tissues as well.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20220930_g3.jpg" alt="arwr-20220930_g3.jpg" style="height:288px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Chemistries</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The structure and chemistries of the oligonucleotide molecules used to trigger the RNAi mechanism can be tailored for optimal activity. Arrowhead&#8217;s broad portfolio of RNA trigger structures and chemistries, including some proprietary structures, enable the Company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi trigger.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a component of the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, Arrowhead&#8217;s design philosophy for RNA chemical modifications is to start with a structurally simple molecule and add only selective modification and stabilization chemistries as necessary to achieve the desired level of target knockdown and duration of effect. The conceptual framework for the stabilization strategy starts with a more sophisticated RNAi trigger screening and selection process that identifies potent sequences rapidly in locations that others may miss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of Arrowhead's RNAi technologies enables Arrowhead to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologic. Arrowhead is focused on bringing the promise of RNAi to address diseases outside of the liver, and its pipeline now includes disease targets in the liver, lung, muscle and other undisclosed tissue types.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><img src="arwr-20220930_g4.jpg" alt="arwr-20220930_g4.jpg" style="height:329px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-APOC3</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including Very Low Density Lipoprotein (VLDL) and chylomicrons and a key regulator of triglyceride metabolism. Arrowhead believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Arrowhead is currently investigating ARO-APOC3 in two Phase 2b clinical trials and one Phase 3 clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hypertriglyceridemia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevated triglyceride levels are an independent risk factor for cardiovascular disease. Severely elevated triglycerides (often over 2,000 mg/dL) in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder, can result in potentially fatal acute pancreatitis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04720534</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04998201</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-APOC3 in Adults With FCS (PALISADE)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05089084</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-ANG3</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Arrowhead is currently investigating ARO-ANG3 in two Phase 2b clinical trials.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dyslipidemia and Hypertriglyceridemia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dyslipidemia and hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04832971</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (GATEWAY) </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05217667</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-ENaC2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-ENaC2 is designed to reduce production of the epithelial sodium channel alpha subunit (&#945;ENaC) in the airways of the lung. In cystic fibrosis patients, increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cystic Fibrosis:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cystic fibrosis (CF) is a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas. In CF lung disease, patients can have difficulty breathing and experience frequent and persistent lung infections.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-RAGE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various inflammatory pulmonary diseases. Arrowhead is currently investigating ARO-RAGE in a Phase 1/2 clinical trial. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study Name: Study of ARO-RAGE in Healthy Subjects and Patients With Asthma</span></div><div style="padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients With Asthma</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05276570</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-MUC5AC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-MUC5AC is designed to reduce production of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases. Arrowhead is currently investigating ARO-MUC5AC in a phase 1/2 clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-MUC5AC in Healthy Subjects and  Patients With Asthma</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2a Study to Evaluate the Effects of ARO-MUC5AC in Healthy Subjects and Patients with Asthma</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NCT05292950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-MMP7</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARO-MMP7 is designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic Pulmonary Fibrosis (IPF). Arrowhead is currently investigating ARO-MMP7 in a Phase 1/2 clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study Name: </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis</span></div><div style="padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis</span></div><div style="padding-left:27pt"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05537025</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-C3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-C3 is designed to reduce production of complement component 3 (C3) as a potential therapy for patients with various complement mediated or complement associated renal and hematological diseases. Arrowhead is currently investigating ARO-C3 in a Phase 1/2 clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paroxysmal Nocturnal Hematuria:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, clonal disorder involving hematopoietic stem cells and is characterized by destruction of red blood cells, blood clots, and impaired bone marrow function. Silencing hepatic C3 expression may be a viable therapeutic approach for systemic C3 inhibition in PNH.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Complement-Mediated Renal Disease:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%"> A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing C3 may be a therapeutic approach for treatment of these conditions. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Adult Patients With Complement-Mediated Renal Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05083364</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-DUX4</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facioscapulohumeral Muscular Dystrophy: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, Arrowhead believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and Arrowhead entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which Arrowhead retained rights to develop and commercialize ARO-HSD. Arrowhead has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, Arrowhead has received an upfront payment of $120 million and is eligible for additional payments of $30 million at the start of Phase 2 and $100 million upon achieving a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to Arrowhead of up to $190 million at first commercial sale, and up to $590 million in sales-related milestone payments. Arrowhead is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ARO-HSD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-HSD is designed to reduce production of HSD17B13, a hydroxysteroid dehydrogenase involved in the metabolism of hormones, fatty acids and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against nonalcoholic steatohepatitis (NASH) cirrhosis and alcoholic hepatitis and cirrhosis. Arrowhead completed a Phase 1/2 clinical trial and GSK is preparing to begin a Phase 2b clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonalcoholic Steatohepatitis: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NASH is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04202354</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and Arrowhead entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Arrowhead conducted all activities through the preclinical stages of development of ARO-XDH, and Horizon is now wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, Arrowhead received $40 million as an upfront payment and is eligible to receive up to $660 million in potential development, regulatory and sales milestones. Arrowhead is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ARO-XDH</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-XDH is designed to reduce production of xanthine dehydrogenase (XDH) as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the United States, there are more than nine million gout patients and approximately one-third of those patients are treated with oral urate-lowering therapies. However, a meaningful portion of treated patients do not respond sufficiently to treatment and therefore continue to experience painful and debilitating gout symptoms. XDH represents a clinically validated target that is the primary source of serum uric acid (sUA). High levels of sUA, if left untreated or undertreated, can potentially lead to serious long-term or even permanent damage to the bones, joints and organs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and Arrowhead entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and Arrowhead will co-develop Arrowhead&#8217;s ARO-AAT program, Arrowhead&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while Arrowhead will be eligible to receive tiered royalties of 20% to 25% on net sales. In January 2021, Arrowhead received $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestone payments of up to $595.0 million. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fazirsiran (formerly TAK-999 and ARO-AAT)</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fazirsiran is a subcutaneously administered RNAi therapeutic being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individuals. Fazirsiran is designed to reduce production of the mutant Z-AAT protein by silencing the AAT gene in order to prevent accumulation of Z-AAT in the liver, allow clearance of the accumulated Z-AAT protein, prevent repeated cycles of cellular damage, and possibly prevent or even reverse the progression of liver fibrosis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goal of Fazirsiran Treatment: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of fazirsiran treatment is prevention and potential reversal of Z-AAT accumulation-related liver injury and fibrosis. Reduction of inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and allow fibrotic tissue repair.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alpha-1 Antitrypsin Deficiency (AATD): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AATD is a genetic disorder associated with liver disease in children and adults, and pulmonary disease in adults. AAT is a circulating glycoprotein protease inhibitor that is primarily synthesized and secreted by liver hepatocytes. Its physiologic function is the inhibition of neutrophil protease to protect healthy lung tissues during inflammation and prevent tissue damage. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules in the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Treatments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and hepatocyte injury and liver disease. Lung disease in this patient population is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Safety, Tolerability and Effect on Liver Histologic Parameters of ARO-AAT (SEQUOIA)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency (AATD)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT03945292</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and Arrowhead entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;). Arrowhead also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson's venture capital arm (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to Arrowhead&#8217;s JNJ-3989 (ARO-HBV) program, Arrowhead&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapy for patients with chronic hepatitis B virus infection. Beyond Arrowhead&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which Arrowhead was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which Arrowhead would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in Arrowhead&#8217;s pipeline. Arrowhead was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application (&#8220;IND&#8221;) or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, Arrowhead has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0 million, and Arrowhead may receive up to $1.6 billion in development and sales milestone payments for the Janssen License Agreement, and up to $0.6 billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. Arrowhead is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low-teens under the Janssen Collaboration Agreement. During 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">JNJ-3989 (also referred to as JNJ-73763989 and formerly referred to as ARO-HBV)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JNJ-3989 is being developed in collaboration with Janssen as a potential therapy for patients with chronic hepatitis B infection, when used in combination with other therapeutic modalities. JNJ-3989 is a subcutaneous RNAi therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. Arrowhead believes this, especially the elimination of hepatitis B surface antigen (HBsAg), may allow the body&#8217;s natural immune defenses to clear the virus and potentially lead to a functional cure. JNJ-3989 is currently being investigated in multiple Phase 2 clinical trials being conducted by Janssen. The Phase 1/2a study and its preceding studies were conducted by Arrowhead. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT03982186</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04129554</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 in Healthy Chinese Adult Participants</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Randomized, Open-Label, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Chinese Adult Participants</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04586439</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-73763989</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04208386</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04535544</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog (NA) Regimen With or Without Pegylated Interferon Alpha-2a (PegIFN-&#945;2a) in Treatment-Naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection and Normal Alanine Aminotransferase (ALT)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04439539</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04585789</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 in Adult Participants With Renal Impairment</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-73763989 in Adult Participants</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04963738</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PENGUIN-2)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Patients With Chronic Hepatitis B Virus Infection</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05005507</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04667104</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">JNJ-75220795 (formerly referred to as ARO-JNJ1)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JNJ-75220795 (ARO-JNJ1) is an investigational therapeutic being developed by Janssen. It utilizes Arrowhead&#8217;s proprietary TRIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform and is designed to reduce expression in the liver of patatin like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with non-alcoholic steatohepatitis (NASH). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials:</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 ClinicalTrials.gov Identifier: NCT04844450</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">A Study of JNJ-75220795 in Japanese Participants </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants ClinicalTrials.gov Identifier: NCT05039710</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and Arrowhead entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization. Under the terms of the agreements taken together, Arrowhead has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in Arrowhead&#8217;s common stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. Arrowhead is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed Arrowhead that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. See Note 13 &#8212; Subsequent Events of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Olpasiran (formerly AMG 890 and ARO-LPA)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Amgen completed a Phase 2 clinical study evaluating the efficacy, safety, and tolerability of Olpasiran in subjects with elevated levels of lipoprotein(a). Amgen reported Phase 2 clinical results at the American Heart Association (AHA) Scientific Sessions in November 2022 and simultaneously published in the New England Journal of Medicine.  Amgen intends to evaluate Olpasiran in a  Phase 3 study to assess the impact of Olpasiran on major cardiovascular events in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a), in a double-blind, randomized, placebo-controlled, multicenter study. Amgen plans to begin enrolling subjects in December 2022, which will trigger a $25.0 million milestone payment to Arrowhead.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, Visirna and Arrowhead entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of Arrowhead&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), Arrowhead acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, Arrowhead is also eligible to receive potential royalties on commercial sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Other Key Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead controls approximately 523 issued patents (including 331 directed to RNAi trigger molecules; 76 directed to targeting groups or targeting compounds; and 4 for hydrodynamic gene delivery), including European validations, and approximately 726 currently pending patent applications worldwide from 80 different patent families. Arrowhead&#8217;s patent applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, GCC (Gulf Cooperation Council), Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Lebanon, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, Saudi Arabia, Singapore, South Korea, Thailand, Taiwan, Uruguay, Venezuela, Vietnam, and South Africa.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNAi Triggers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrowhead owns issued patents or has filed patent applications directed to RNAi trigger molecules, which serve as the foundation of Arrowhead&#8217;s TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, and are targeted to reduce expression of various gene targets, including the following: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HBV </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032, 2036, 2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAT</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;-ENaC </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOC3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANGPTL3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIF2&#945;</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034, 2036, 2040</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSD17B13</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PNPLA3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DUX4</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Factor 12</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RRM2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#946;-ENaC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031, 2040</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#946;-Catenin</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cx43</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCV</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIF1A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HRH1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSF1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030, 2032</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FRP-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRAS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P2X3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mob-5</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDtype4</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PI4Kinase</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TNF-&#945;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027, 2028</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery technology-related patents and patent applications, which include components used in Arrowhead&#8217;s TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Africa, South Korea, Singapore, Taiwan, and Uruguay. Arrowhead also controls a patent directed to hydrodynamic nucleic acid delivery that issued in the United States. The approximate year of expiration for each of these various groups of patents are set forth below: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="background-color:#eeece1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Targeting ligands and other RNAi delivery and platform technologies</span></td><td colspan="3" style="background-color:#eeece1;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (Galactose derivative trimer-PK)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (&#945;v&#946;3/&#945;v&#946;5 integrin)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034, 2038, 2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (&#945;v&#946;6 integrin)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037, 2038, 2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (Galactose derivative ligands)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037, 2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNAi agent design (5&#8242;-phosphate mimic)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physiologically labile linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologically cleavable linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trialkyne linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Muscle delivery platform</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041, 2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK/PD lipid modifiers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferrin targeting</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDLR targeting</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peptide targeting (CPP-Arg) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peptide targeting (YM3-10H)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeece1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hydrodynamic delivery</span></td><td colspan="3" style="background-color:#eeece1;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third iteration</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, Arrowhead may need to obtain additional patent licenses prior to commercialization of its candidates. Please see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Assets from Novartis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2015, Novartis and Arrowhead entered into an Asset Purchase and Exclusive License Agreement (the &#8220;RNAi Purchase Agreement&#8221;) pursuant to which Arrowhead acquired Novartis&#8217;s RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, Arrowhead acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis&#8217;s rights under a license from Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) (the &#8220;Alnylam-Novartis License&#8221;) and acquired a license to certain additional Novartis assets (the &#8220;Licensed Novartis Assets&#8221;). The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications. The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi-trigger design rules and modifications. Under the assigned Alnylam-Novartis License, Arrowhead acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam&#8217;s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2012 License to Alnylam</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for licenses obtained from Alnylam to certain RNAi intellectual property, in January 2012, Arrowhead granted Alnylam a worldwide, non-exclusive, sublicensable royalty-bearing license under its broad and target-specific DPC intellectual property rights to research, develop and commercialize RNAi-based products against a single undisclosed target in combination with DPC technology. Under the license to Alnylam, Alnylam may be obligated to pay Arrowhead development and sales milestone payments of up to the low double-digit millions of dollars for each licensed product that progresses through clinical trials, receives marketing approval and is the subject of a first commercial sale. Additionally, Alnylam may be obligated to pay Arrowhead low single-digit percentage royalties on sales of such products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exclusively Licensed Patent Rights from Roche</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2011, Arrowhead acquired the RNAi therapeutics business of Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. (collectively, &#8220;Roche&#8221;). The acquisition provided us with two primary sources of value:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Broad freedom to operate with respect to key patents directed to the primary RNAi-trigger formats: canonical, UNA, meroduplex, and dicer substrate structures; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A large team of scientists experienced in RNAi and oligonucleotide delivery. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this acquisition, Roche assigned to Arrowhead its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam dated July 8, 2007 (the &#8220;Alnylam License&#8221;); the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 (&#8220;MDRNA License&#8221;); and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (the &#8220;COH License&#8221;) (collectively the &#8220;RNAi Licenses&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi Licenses include licenses to patents related to modifications of double-stranded oligonucleotides, including modifications to the base, sugar, or internucleoside linkage, nucleotide mimetics, and end modifications, which do not abolish the RNAi activity of the double-stranded oligonucleotides. Also included are patents relating to modified double-stranded oligonucleotides, such as meroduplexes described in U.S. Patent No. 9,074,205 assigned to Marina Biotech (f/k/a MDRNA, Inc.), as well as U.S. Patent Nos. 8,314,227, 9,051,570, and 9,303,260 related to unlocked nucleotide analogs (&#8220;UNA&#8221;). The UNA patents were assigned by Marina Biotech to Arcturus Therapeutics, Inc., but remain part of the MDRNA License. The RNAi Licenses further include patents related to dicer substrates and uses of the double-stranded oligonucleotides that function through the mechanism of RNA interference, such as described in City of Hope&#8217;s U.S. Patent Nos. 8,084,599, 8,658,356, 8,691,786, 8,796,444, 8,809,515, and 9,518,262. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state, and local levels, and in other countries and jurisdictions, including the European Union (&#8220;EU&#8221;), extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. All of Arrowhead&#8217;s foreseeable product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of Arrowhead&#8217;s products and its R&amp;D activities and require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (the &#8220;FDA&#8221;) and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service Act, and the regulations promulgated under those statutes, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) completion of preclinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) submission to the FDA of an IND for human clinical testing, which must become effective without FDA objection before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current good clinical practice (&#8220;cGCP&#8221;) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) payment of user fees, as applicable, and securing FDA approval of the NDA; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) compliance with any post-approval requirements, such as any Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or post-approval studies required by the FDA. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Preclinical Studies and an IND </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies can include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Human Clinical Studies in Support of an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with cGCP and the integrity of the clinical data submitted. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Submission of an NDA to the FDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently $3.2 million for fiscal year 2023, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently $393,933 for fiscal year 2023. These fees are adjusted annually.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The FDA&#8217;s Decision on an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety and effectiveness of drug products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees. Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA&#8217;s implementing regulations at 21 C.F.R. Part 316. The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; In the September 2021 case Catalyst Pharmaceuticals, Inc. v. FDA, a federal circuit court set aside the FDA&#8217;s narrow interpretation and ruled that orphan drug exclusivity covers the full scope of the orphan-designated disease or condition regardless of whether the drug obtains approval only for a narrower use. The decision concerned amifampridine, a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS). Depending on how the FDA applies the decision beyond this case, it may limit the drugs that can receive exclusivity. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Expedited Review and Accelerated Approval Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of NDAs. For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition. The key benefits of Fast Track Designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria are met. The FDA may grant the NDA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may approve an NDA under the accelerated approval program if the drug treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;) established the Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will provide more intensive guidance on the drug development program and expedite its review. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Requirements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abbreviated New Drug Applications for Generic Drugs </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;). To reference that information, however, the ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD.&#8221; Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hatch-Waxman Patent Certification and the 30 Month Stay </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the applicant must certify with respect to each patent that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the required patent information has not been filed; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent has expired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Studies and Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Patent Term Restoration and Extension </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legislative Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 21st Century Cures Act (the &#8220;Cures Act&#8221;), which was signed into law in December 2016, includes provisions to accelerate the development and delivery of new treatments. For example, the Cures Act requires the FDA to establish a program to evaluate the potential use of real world evidence to help to support the approval of a new indication for an approved drug and to help to support or satisfy post-approval study requirements, to issue guidance on adaptive and novel clinical trial designs for new drugs, and to establish a process for qualifying drug development tools used to support FDA approval for marketing or investigational use of a drug. The Cures Act also permits the FDA to rely on qualified data summaries to support the approval of a supplemental application for an already approved drug. The FDA has continued to issue guidance focused on implementing the Cures Act requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drug Products in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any pharmaceutical product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy, labeling, clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising, marketing and other promotional practices involving pharmaceutical products, as well as commercial sales, distribution, authorization, approval and post-approval monitoring and reporting of its products. Whether or not a company obtains FDA approval for a pharmaceutical product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the pharmaceutical product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom (&#8220;UK&#8221;) formally left the EU on January 31, 2020 and the transition period, during which EU laws continued to apply to the UK, expired on December 31, 2020. This means EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. Following the transition period, the EU and the UK have concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was applied provisionally from January 1, 2021 and entered into force on May 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCA includes provisions affecting the life sciences sector (including on customs and tariffs), but areas for further discussion between the EU and the UK remain. In addition, there are some specific provisions concerning pharmaceuticals. These include the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;) and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 1, 2021, the EU laws which have been transposed into UK law through secondary legislation continue to be applicable in the UK as &#8220;retained EU law.&#8221; As there is no general power to amend these regulations, the UK government has enacted the Medicines and Medical Devices Act 2021. The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines and clinical trials of human medicines, among others, to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specified provisions of the Medicines and Medical Devices Act 2021 entered into force on February 11, 2021. The remaining provision came into effect within two months of February 11, 2021 or will otherwise come into effect as stipulated in subsequent statutory instruments. The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (&#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May 26, 2021, applies in all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) conducted a comprehensive consultation between September and November 2021 on proposals to develop a new UK regime for medical devices in the UK. The proposals include more closely aligning definitions for medical devices and in vitro medical devices with internationally recognized definitions and changing the classification of medical devices according to levels or risk. The proposals are intended to improve patient and public safety and increase the appeal of the UK market. The new regime is planned to come into force on July 1, 2023, which will align with the date from which the UK is due to stop accepting CE marked medical devices and require UKCA (&#8220;UK Conformity Assessed&#8221;) marking. It is contemplated that, in Northern Ireland, the amended regime could run in parallel with any existing or future EU rules in accordance with the Protocol on Ireland and Northern Ireland.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Drug and Biologic Development Process</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials in the EU is governed by the EU Clinical Trials Regulation (EU) No. 536/2014 (&#8220;CTR&#8221;) which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (Clinical Trials Directive) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated, it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;), and one or more Ethics Committees. The NCA of the EU member states in which the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through the a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application, and consult and coordinate with the other concerned EU member states. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU member states. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such EU member state. The CTR also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database (&#8220;CTIS&#8221;). The CTR includes a three-year transition period. Member states will work in CTIS immediately after the system has gone live. For one year, until January 31, 2023, clinical trial sponsors can still choose whether to submit an initial clinical trial application in line with the former system (Clinical Trials Directive) or via CTIS. From January 31, 2023 on, submission of initial clinical trial applications via CTIS becomes mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will be governed by the new Regulation and have to be transitioned to CTIS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new CTR, national laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practice (&#8220;GCP&#8221;), </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the ethical principles that have their origin in the Declaration of Helsinki</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the European Medical Agency (&#8220;EMA&#8221;) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Authorization Procedures </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area or &#8220;EEA&#8221;), after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under EU regulatory systems, an applicant can submit a MAA through, amongst others, a centralized or decentralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA by the European Commission (&#8220;EC&#8221;) that is valid for all EU member states and, after respective national implementing decisions, in the three additional member states of the EEA. The centralized procedure is compulsory for specific pharmaceutical products, including for medicines developed by means of certain biotechnological processes, products designated as orphan pharmaceutical products, advanced therapy pharmaceutical products and pharmaceutical products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For pharmaceutical products containing a new active substance not yet authorized in the European Economic Area before May 20, 2004 and indicated for the treatment of other diseases, pharmaceutical products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eligible for an accelerated assessment. Accelerated assessment might be granted by the CHMP in exceptional cases when a pharmaceutical product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the EC has final authority for granting the MA within 67 days after receipt of the CHMP opinion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a pharmaceutical product to the competent authorities in various EU member states simultaneously if such pharmaceutical product has not received marketing approval in any EU member state before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU member state, known as the reference EU member state, is appointed to review the application and provide an assessment report. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU member state and concerned EU member states. The reference EU member state prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Subsequently, each concerned EU member state must decide whether to approve the assessment report and related materials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an EU member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (&#8220;PSURs&#8221;) are routinely available to third parties requesting access, subject to limited redactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Data and Market Exclusivity in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCE&#8221;) approved in the EU qualify for eight years of data exclusivity and ten years of marketing exclusivity. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are deemed to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its pharmaceutical product. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Orphan Designation and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU member states and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;), addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, companies developing a new pharmaceutical product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> because the relevant disease or condition occurs only in adults) has been granted by the EMA. The marketing authorization application for the pharmaceutical product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Pharmaceutical products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a marketing authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of pharmaceutical products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU member states. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU member states governing the conduct of clinical trials, manufacturing approval, MA of pharmaceutical products and marketing of such products, both before and after grant of MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of an EU MA for a pharmaceutical product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed pharmaceutical products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to pharmaceutical products for which they hold MAs. The EMA reviews PSURs for pharmaceutical products authorized through the centralized procedure. If the EMA has concerns that the risk-benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the European Commission&#8217;s decision provides can undermine the on-going validity of the MA.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the pharmaceutical product or imposition of financial penalties or other enforcement measures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of pharmaceutical products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU member states may apply to the advertising and promotion of pharmaceutical products and may differ from one country to another. These laws require that promotional materials and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advertising in relation to pharmaceutical products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the pharmaceutical product. It forms an intrinsic and integral part of the marketing authorization granted for the pharmaceutical product. Promotion of a pharmaceutical product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion of pharmaceutical products is prohibited in the EU. Direct-to-consumer advertising of prescription-only pharmaceutical products is prohibited in the EU. Violations of the rules governing the promotion of pharmaceutical products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing and Reimbursement Environment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. An EU member state may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates, if any, to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, pharmaceutical products launched in the EU do not follow price structures of the United States and generally published and actual prices tend to be significantly lower. Publication of discounts by third-party payers or authorities and public tenders may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The so-called health technology assessment (&#8220;HTA&#8221;) of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given pharmaceutical product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual pharmaceutical products as well as their potential implications for the healthcare system. Those elements of pharmaceutical products are compared with other treatment options available on the market. The outcome of HTA regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to pharmaceutical products by the regulatory authorities of individual EU member states. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain reimbursement for such product in the EU member state in which such negative assessment was issued, but also in other EU member states. For example, EU member states that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific pharmaceutical product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2018, the European Commission adopted a proposal for a regulation on health technology assessment. This legislative proposal is intended to boost EU level cooperation among EU member states in assessing health technologies, including new pharmaceutical products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The proposal provides that EU member states will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. While EU member states could choose to delay participation in the joint work until three years after the rules enter into force, it will become mandatory after six years. The European Commission has stated that the role of the HTA regulation is not to influence pricing and reimbursement decisions in the individual EU member states, but there can be no assurance that the HTA regulation will not have effects on pricing and reimbursement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decisions. The HTA entered into force on January 11, 2022 and applies as of January 2025 followed by a further three-year transitional period during which EU member states must fully adapt to the new system. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some countries, including the EU member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain of the EU member states, pharmaceutical products that are designated as orphan pharmaceutical products may be exempted or waived from having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement approval. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">European Data Laws</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018 and related implementing laws in individual EU member states. The GDPR has a number of significant practical consequences, in particular for international data transfers, competent supervisory authorities and enforcement of the GDPR. The GDPR increased responsibility and liability in relation to personal data that we process.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collection, analysis and transfer of) personal data of individuals within the EU and in the EEA, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification obligations to the national data protection authorities and the security and confidentiality of the personal data. EU member states may also impose additional requirements in relation to health, genetic and biometric data through their national implementing legislation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also imposes specific restrictions on the transfer of personal data to countries outside of the EU/EEA that are not considered by the European Commission to provide an adequate level of data protection (including the United States). Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). In this respect, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EU/EEA. For example, following the Schrems II decision of the Court of Justice of the EU on July 16, 2020, in which the Court invalidated the Privacy Shield under which personal data could be transferred from the EU/EEA to U.S. entities who had self-certified under the Privacy Shield scheme, there is uncertainty as to the general permissibility of international data transfers under the GDPR. The Court did not invalidate the then current SCCs, but ruled that data exporters relying on these SCCs are required to verify, on a case-by-case basis, if the law of the third country ensures an adequate level of data protection that is essentially equivalent to that guaranteed in the EU/EEA. In light of the implications of this decision, we may face difficulties regarding the transfer of personal data from the EU/EEA to third countries. On June 4, 2021, the EU Commission has issued a new set of SCCs which replace the old sets of SCCs that were adopted under the previous European Data Protection Directive 95/46. Since September 27, 2021, it is no longer possible to conclude contracts incorporating these previous versions of the SCCs. In addition, for contracts concluded before September 27, 2021, it is still possible to rely on the previous SCCs until the end of an additional 15 months transitional period (until December 27, 2022), provided that the processing operations which are the subject matter of the contract remain unchanged and reliance on previous SCCs ensures that the transfer is subject to appropriate safeguards. In addition, when relying on SCCs, the data exporters are required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. On June 18, 2021, the European Data Protection Board has adopted recommendations to assist data exporters with such assessment and their duty to identify and implement supplementary measures where they are needed to ensure compliance with the EU level of protection to the personal data they transfer to third countries. On March 25, 2022, the EU Commission and the U.S. announced that they have agreed in principle on a new Trans-Atlantic Data Privacy Framework. Following this statement, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Signals Intelligence Activities&#8217; on October 7, 2022. Along with the Regulations issued by the Attorney General, the Executive Order implements into US law the agreement in principle announced in March 2022. On that basis, the European Commission will now prepare a draft adequacy decision and then launch its adoption procedure. While this new EU-US privacy framework is expected to entry into force in 2023, there is still some uncertainty around that new framework.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member states may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU member states may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both EU level and at the national level in individual EU member states concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the EU to the UK, the TCA provided for a transition period of up to six months as of January 1, 2021 to enable the European Commission to complete its adequacy assessment of the UK&#8217;s data protection laws. On June 28, 2021 the European Commission adopted two adequacy decisions for the UK: one under the GDPR and the other for the Law Enforcement Directive. Personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy of decisions are subject to a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies have to comply also with the UK&#8217;s data protection laws (including the GDPR as incorporated into UK national law), the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. Furthermore, transfers from the UK to other countries, including to the EEA, are subject to specific transfer rules under the UK regime. These UK transfer rules broadly mirror the EU GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (IDTA), the international data transfer addendum to the European Commission&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 25, 2022 and replaced the old EU SCCs. However, the transitional provisions, adopted with the IDTA and the Addendum, allow the continued use, until March 21, 2024, of any EU SCCs, valid as at December 31, 2020, as long as the contract was entered into before September 21, 2022.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Promotional Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the UK has left the EU, as mentioned above, it should be noted that the UK still has the strictest anti-bribery regime in Europe, the UK Bribery Act 2010. The Act is applicable English law and continues to apply to any company incorporated in or &#8220;carrying on business&#8221; in the UK, irrespective of where in the world the alleged bribery activity occurs. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legislation Regarding Marketing, Authorization and Pricing of Pharmaceutical Products in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other core legislation relating to the marketing, authorization and pricing of pharmaceutical products in the EU exists as regulations and directives, while the implementing acts and guidelines based on these may vary in each EU </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">member state. In addition, the respective national provisions of the member states, as well as self-committed codes of the pharmaceutical industry, must be observed. Such regulations and directives include the following: </span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2001/83/EC, establishing the requirements and procedures governing the marketing authorization for medicinal products for human use, as well as the rules for the constant supervision of products following authorization. This Directive has been amended several times, most recently by Directive 2012/26/EU regarding pharmacovigilance, and the Falsified Medicines Directive 2011/62/EU. </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 726/2004, as amended, establishing procedures for the authorization, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the EMA.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 469/2009, establishing the requirements necessary to obtain a Supplementary Protection Certificate, which extends the period of patent protection applicable to medicinal products at the EU-level. </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 89/105/EEC, ensuring the transparency of measures taken by the EU member states to set the prices and reimbursements of medicinal products. Specifically, while each member state has competence over the pricing and reimbursement of medicines for human use, they must also comply with this Directive, which establishes procedures to ensure that member state decisions and policies do not obstruct trade in medicinal products. The European Commission proposed to repeal and replace Directive 89/105/EEC, but this proposal was withdrawn in 2015. </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2003/94/EC, laying down the principles of good manufacturing practice in respect of medicinal products and investigational medicinal products for human use (the &#8220;GMP Directive&#8221;).</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/28/EC of April 8, 2005, laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products (the &#8220;GCP Directive&#8221;). </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directives 2004/9/EC and 2004/10/EC laying down principles of good laboratory practices (&#8220;GLP&#8221;) including on the organizational process under which non-clinical health and safety studies are performed.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2010/84/EU and Regulation (EU) 1235/2010 on pharmacovigilance laying down procedures for the authorization and supervision of medicinal products for human and veterinary use. </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2006/114/EC concerning misleading and comparative advertising. </span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/29/EC regulating unfair business-to-consumer commercial practices that occur before, during and after a business-to-consumer transaction.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1223/2009 on Cosmetic Products, setting mandatory requirements for cosmetics which are available on the market within the EU.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1901/2006 on Pediatric Use, laying down rules to ensure that medicines for use in children are researched, developed and authorized appropriately.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive (2004/109/EC) on Transparency laying down rules to improves the harmonization of information duties of issuers, whose securities are listed at a regulated market at a stock exchange within the EU.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pharmaceutical Coverage, Pricing and Reimbursemen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely between member states. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some member states may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play important roles in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Foreign Corrupt Practices Act prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers who bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys&#8217; fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. Department of Health and Human Services&#8217; Civil Monetary Penalty authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal false statements statute relating to healthcare matters imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply (e.g., in the EU, where the implementation of EU-wide regulations as well as independent national legislation may vary for each EU member state) to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by HHS Office of Inspector General; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers; and/or require disclosure of gifts or payments to physicians and other healthcare providers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various state and foreign laws also govern the privacy and security of health information in some circumstances; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Facilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California where its research and development activities, including the development of RNAi therapeutics, take place. Arrowhead&#8217;s principal executive offices are located in Pasadena, California. A summary of research and development resources is provided  below:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">329 R&amp;D personnel as of September 30, 2022;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">State-of-the-art laboratories consisting of 132,000 total square feet;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cell culture laboratories;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complete animal facilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Primate colony housed at the Wisconsin National Primate Research Center, an affiliate of the University of Wisconsin, and at other contract research organizations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In-house histopathology capabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal efficacy models for cardio metabolic, viral, lung and oncologic diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal safety screening and assessment;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In-house drug substance manufacturing capabilities to produce and release GMP material (API);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Polymer, peptide, oligonucleotide and small molecule synthesis, analytics capabilities (HPLC, NMR, LCMS, etc.);</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Drug metabolism and pharmacokinetics (DMPK), biodistribution, and clearance assessment and methodology capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Conventional and confocal microscopy, flow cytometry, Luminex platform, qRT-PCR and clinical chemistry analytics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, Arrowhead employed 397 full time employees based at three facilities in the United States, including Pasadena and San Diego, California, and Madison, Wisconsin. The following table presents total number of employees as of September 30 by location.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Site</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pasadena, CA</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Madison, WI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead continued to add additional employees in fiscal year 2022 with a focus on expanding its in-house manufacturing capacity, as well as increasing expertise and bandwidth in clinical and preclinical research and development. Arrowhead continually evaluates the business need and opportunity and balances in-house expertise and capacity with outsourced expertise and capacity. Currently, Arrowhead outsources substantial clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Pharmaceutical companies both large and small compete for a limited number of qualified applicants to fill specialized positions. To attract qualified applicants to the Company, Arrowhead offers a total compensation package consisting of base salary and cash target bonus targeting the 50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to 75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of market, and offers a comprehensive benefit package and equity compensation to every employee. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Actual bonus payout is based on performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of Arrowhead&#8217;s employees have obtained advanced degrees in their professions. Arrowhead supports its employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity and Inclusion  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead is committed maintaining a welcome, healthy and equitable environment where all employees can excel and contribute to its mission of bringing safe and effective medicine to patients in need. Arrowhead continues the formal training and processes initiated in 2021 to promote awareness of inclusion and diversity issues for management and employees, including anti-bias training and employee outreach and engagement. In fiscal year 2022, Arrowhead formed a Diversity, Equity, and Inclusion (DEI) committee comprised of a diverse group of employees across each of its worksites. Arrowhead&#8217;s DEI committee meets regularly, provides well-attended education and outreach opportunities to its employee base, and offers advice to its senior management concerning Arrowhead's efforts to build a more diverse, equitable, and inclusive workplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead&#8217;s website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.arrowheadpharma.com.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrowhead&#8217;s website address is not intended to function as a hyperlink and the information contained on its website is not, and should not be considered part of, and is not incorporated by reference into, this Annual Report on Form 10-K. Arrowhead&#8217;s reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and amendments to such periodic reports and Proxy Statements, are accessible through its website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of Arrowhead's website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding Arrowhead and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">RISK FACTORS</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s business involves various risks and uncertainties in addition to the normal risks of business, some of which are discussed in this section. It should be noted that the Company&#8217;s business may be adversely affected by general economic conditions and other forces beyond the Company&#8217;s control. In addition, other risks and uncertainties not presently known or that the Company currently believes to be immaterial may also adversely affect the Company&#8217;s business. Any such risks or uncertainties, or any of the following risks or uncertainties, that develop into actual events could result in a material and adverse effect on the Company&#8217;s business, financial condition, results of operations, or liquidity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information discussed below should be considered carefully with the other information contained in this Annual Report on Form 10-K and the other documents and materials filed by the Company with the SEC, as well as news releases and other information publicly disseminated by the Company from time to time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our prospects substantially depend on the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, our business could be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may not yield successful results for the product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials of our product candidates may not uncover all possible adverse events that patients may experience.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Topline data may not accurately reflect the complete results of a particular study or trial.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not enjoy the market exclusivity benefits of our orphan drug designations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on the attraction and retention of senior management and scientists with relevant expertise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Regulatory Review and Approval of Our Candidates</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough Therapy designation for ARO-AAT may not lead to a faster development or review process.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our licensees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technology licensed from various third parties may be subject to retained rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business Model</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we develop. Our drug candidates are in various stages of development and we have no approved products based on RNA interference and our delivery technologies. Accordingly, there is a limited amount of information about us upon which you can evaluate our business and prospects.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profitability</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside sources for various components and processes for our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing drugs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could suffer in the event of information technology system failures.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we use </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biological</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may result in financial losses or harm our reputation and may divert management resources.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Financial Condition</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funds to complete our research and development activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We could be subject to additional tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Investment and Securities</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not intend to declare cash dividends on our common stock.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stockholder equity interest may be substantially diluted in any additional equity issuances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Economic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and Industry Risks</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> global economic conditions, whether brought about by material global crises, health epidemics, military conflicts and war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is time consuming, expensive and risky.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our prospects substantially depend the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, our business could be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on the ability of our company and our licensees to timely complete clinical trials and obtain marketing approval for, and then successfully commercialize our clinical-stage product candidates. We are not permitted to market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of developing and commercializing our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining positive data that supports demonstration of efficacy, safety and tolerability profiles and durability of effect for our product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely enrollment of appropriate patients for the indications included in our current and future clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential variability of patient outcomes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to address any potential delays resulting from factors related to the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protection of our rights in our intellectual property portfolio, including our licensed intellectual property;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and the successful launch of commercial sales of our product candidates if and when approved for marketing, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile following any marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial acceptance by patients, the medical community and third-party payors; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with other therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. For development programs that are licensed to third parties, we generally do not have control over the design or conduct of clinical trials and will not have discretion over marketing decisions. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates from our lead programs, which would materially harm our business. If we do not receive marketing approvals for such product candidates, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scientific research and development requires significant amounts of capital and takes a long time to reach commercial viability if it can be achieved at all. To date, our research and development projects have not produced commercially viable drugs and may never do so. During the research and development process, we may experience technological barriers that we may be unable to overcome. Because we use platform technology to develop drug candidates, toxicology signals that may emerge in the course of testing of one particular candidate may apply broadly across our drug candidate platform. Further, certain underlying premises in our development programs are not proven and many of the drug targets that we are pursuing have not yet been validated clinically. For instance, the reduction of the production of mutant alpha-1 antitrypsin in the liver may not lead to a reduction of globules in the liver, and even if it leads to a reduction in such globules, this may not lead to other beneficial hepatic changes. It is also unknown at this time what changes in the liver may be required to gain regulatory approval and/or favorable reimbursement for a drug that reduces the production of mutant alpha-1 antitrypsin in the liver. Similar uncertainties and risks exist that are specific to each of our development programs. Because of these and similar uncertainties, it is possible that no commercial products will be successfully developed. If we are unable to successfully develop commercial products, we will be unable to generate revenue or build a sustainable or profitable business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of human therapeutic products in the United States and foreign jurisdictions is subject to extensive and time-consuming regulatory approval which requires, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">controlled research and human clinical testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the safety and efficacy of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government review and approval of a submission containing manufacturing, preclinical and clinical data; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adherence to cGMP regulations during production and storage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2011, we have focused substantially all of our efforts and financial resources on identifying, acquiring and developing our product candidates, including conducting lead optimization, nonclinical studies, preclinical studies and clinical trials, and providing general administrative support for these operations. And, the clinical-stage product candidates we currently have under development will require significant development, preclinical and clinical testing and investment of significant funds to gain regulatory approval before they can be approved for commercialization. The results of our research and human clinical testing of our products may not meet regulatory requirements. Some of our product candidates, if approved, may require the completion of post-market studies. There can be no assurance that any of our products will be further developed and approved. The process of completing clinical testing and obtaining required approvals will take several years and require the use of substantial resources. Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals. If we fail to obtain regulatory approvals for any or all of our products, we will not be able to market such product and our operations may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may not yield successful results for the product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must demonstrate our product candidates&#8217; safety and efficacy in humans for each target indication through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">after reviewing test results, we may abandon projects that we might previously have believed to be promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our regulators may suspend or terminate clinical trials because the participating subjects or patients are being exposed to unacceptable health risks; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that current clinical trials or any future clinical trials, whether conducted by us or our licensees, will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operation. Success in clinical trials in a particular indication does not ensure that a product candidate will be successful in other indications. Similarly, approval of a product candidate in a particular indication does not ensure that the product candidate will be successful in other indications. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events (&#8220;AEs&#8221;) associated with the use of our products or product candidates. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials, or have unexpected characteristics, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, the EMA, other applicable regulatory authorities or an institutional review board may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability relative to other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials of our product candidates may not uncover all possible adverse events that patients may experience.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. By design, clinical trials are based on a limited number of subjects and are of limited duration of exposure to the product, to determine whether the product candidate demonstrates the substantial evidence of efficacy and safety necessary to obtain regulatory approval. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered. It may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare significant AEs, and the duration of such studies may not be sufficient to identify when those events may occur. Other products have been approved by the regulatory authorities for which safety concerns have been uncovered following approval. Such safety concerns have led to labeling changes, restrictions on distribution through use of a REMS, or withdrawal of products from the market, and any of our product candidates may be subject to similar risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to date our current drug candidates have generally evidenced an acceptable safety profile in clinical trials, patients treated with our products, if approved, may experience previously unreported adverse reactions or minor incidences of adverse reactions may manifest with greater frequency in subsequent larger trials, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to obtain approval of our product candidates. If toxicities, adverse events or any other safety problems occur or are identified after our products, if any, reach the market, we may make the decision or be required by regulatory authorities to conduct additional clinical safety trials, amend the labeling of our products or add additional warnings to the labeling, recall our products, or even withdraw approval for our products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Topline data may not accurately reflect the complete results of a particular study or trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of earlier studies or clinical trials </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical and preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and interim results of clinical trials do not necessarily predict final results. The results of preclinical studies and clinical trials in one set of patients or disease indications, or from preclinical studies or clinical trials that we did not lead, may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, or after achieving positive results in pivotal trials, and we cannot be certain that we will not face similar setbacks. Even if early-stage clinical trials are successful, we may need to conduct additional clinical trials of our product candidates in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to obtain marketing approval for our product candidates for commercially viable indications, or at all, would substantially harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although for planning purposes we project the commencement, continuation and completion of our clinical trials, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Enrollment of clinical trials may be particularly difficult in orphan diseases or limited-sized patient populations. The FDA or other regulatory bodies may require additional, longer or broader clinical trials to establish safety and effectiveness, notwithstanding guidance the Company may have received from those bodies during clinical trial planning and execution. Further, the cost for conducting clinical trials is significant and if our cash resources become limited we may not be able to commence, continue </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or complete our clinical trials. We may not commence or complete clinical trials involving any of our product candidates as projected or may not conduct them successfully.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, healthcare providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer adequate coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly-approved drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. With respect to our partnered product candidates, we will be reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. For example, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) includes several measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with CMS (The Centers for Medicare &amp; Medicaid Services). We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not enjoy the market exclusivity benefits of our orphan drug designations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we may obtain orphan designations in the treatment of certain diseases our products are intended to treat, the designation may not be applicable to any particular product we might get approved and that product may not be the first product to receive approval for that indication. Under the Orphan Drug Act, the first product with an orphan designation receives market exclusivity, which prohibits the FDA from approving the &#8220;same&#8221; drug for the same indication. The FDA has stated that drugs can be the &#8220;same&#8221; even when they are not identical but has not provided guidance with respect to how </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it will determine &#8220;sameness&#8221; for RNAi drugs. It is possible that another RNAi drug could be approved for the treatment of a disease that one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product&#8217;s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Further, orphan drug exclusivity can be lost if the FDA later determines that the request for designation was materially defective or if the applicant is unable to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on the attraction and retention of senior management and scientists with relevant expertise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives and we do not maintain employment agreements with many senior employees. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists, management and other employees. This will depend in part on our ability to create and maintain a desirable workplace culture, which may be impacted by employee preferences for remote working. In addition, the market for qualified employees in the pharmaceutical industry is experiencing labor shortages and inflationary pressures are causing salaries and wages to increase, all of which exacerbates these competitive dynamics. If we are unable to find, hire and retain qualified individuals, we will have difficulty implementing our business plan in a timely manner, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Regulatory Review and Approval of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy designation for ARO-AAT may not lead to a faster development or review process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been granted a Breakthrough Therapy designation for ARO-AAT in the United States for the treatment of liver disease associated with AATD. Breakthrough Therapy designation is intended to facilitate the development and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions and additional drug development guidance with the FDA and its senior managers. Breakthrough Therapy designation applies to the combination of the drug candidate and the specific indication for which it is being studied. Product candidates that receive Breakthrough Therapy designation may receive more frequent interactions with the FDA regarding the product candidate&#8217;s development plan and clinical trials and may be eligible for the FDA&#8217;s Rolling Review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite receiving Breakthrough Therapy designation, ARO-AAT may not actually benefit from faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. Furthermore, such a designation does not increase the likelihood that ARO-AAT will receive marketing approval in the United States. The FDA may also rescind Breakthrough Therapy designation if it determines that ARO-AAT no longer meets the relevant criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our licensees conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our licensees currently conduct clinical trials outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from clinical trials conducted outside the United States or another jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval before a product can be marketed in that jurisdiction, even after establishing safety and efficacy in a clinical setting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeking foreign regulatory approval could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s) and the facilities where they are manufactured to continual review and periodic inspection. If previously unknown problems with a product, manufacturing and laboratory facilities or regulatory requirements are discovered, such as adverse events of unanticipated severity or frequency, problems with a manufacturing process or laboratory facility, or failure to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions or penalties on that product or on us. Such restrictions or penalties may include, among other things:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, the withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters or holds on clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">closure of the facility, enforcement of substantial fines, injunctions, or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to pending patents and have filed and expect to continue to file patent applications. Researchers sponsored by us may also file patent applications that we may need to license. Such patent applications may not be available for licensing or may not be economically feasible to license. Certain of our patents may not be granted or may not contain claims of the necessary breadth because, for example, prior patents exist. If a particular patent is not granted, the value of the invention described in the patent would be diminished. Further, even if these patents are granted, they may be difficult to enforce. Even if ultimately successful, efforts to enforce our patent rights could be expensive, distracting for management, cause our patents to be invalidated or held unenforceable, and thus frustrate commercialization of products. Even if patents are issued and are enforceable, others may develop similar, superior or parallel technologies to any technology developed by us and not infringe on our patents. Our technology may prove to infringe upon patents or rights owned by others. Patent prosecution and maintenance is expensive, and we may be forced to curtail prosecution or maintenance if our cash resources are limited. Thus, the patents held by or licensed to us may not afford us any meaningful competitive advantage. In addition, the laws of some foreign countries in which we do business, including through our joint ventures, do not protect intellectual property rights to the same extent or in the same manner as the laws of the United </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to adequately protect our owned intellectual property or derive sufficient value from our licensed or owned intellectual property, the value of your investment may decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements to incorporate third-party proprietary technologies into our drug products under development. These license agreements require us to pay royalties and satisfy other conditions. If we fail to satisfy our obligations under these agreements, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or may give our licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. However, if granted marketing approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our drug candidates infringing. If a claim should be brought and is successful, we may be required to pay substantial damages, be forced to abandon any affected drug candidates and/or seek a license from the patent holder. In addition, any patent infringement claims brought against us, whether or not successful, may cause us to incur significant expenses and divert the attention of our management and key personnel from other business concerns. These could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. We also expect to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology licensed from various third parties may be subject to retained rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. As our organization grows, so does the risk of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized disclosure of confidential information. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. However, we compete with a substantial number of other companies that may also compete for technologies we desire. In addition, many venture capital firms and other institutional investors, as well as other pharmaceutical and biotech companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business Model</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">lop. Our drug candidates are in various stages of development and we have no approved products based on RNA interference and our delivery technologies. Accordingly, there is a limited amount of information about us upon which you can evalua</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">te our business and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any product candidates. Because no drug candidates generated with our product platform have been approved, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execute product development activities using technologies that have not yet generated an approved product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build, maintain, and protect a strong intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Demonstrate safety and efficacy of our drug candidates in multiple human clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Receive FDA approval and approval from similar foreign regulatory bodies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gain market acceptance for the development and commercialization of any drugs we develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensure our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Effectively market any products for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK and Visirna. Our business strategy includes obtaining additional collaborations with other pharmaceutical and biotech companies to support the development of our RNAi therapeutics and other drug candidates. We do not possess all of the financial and development resources necessary to develop and commercialize all of the products that may result from our technologies. Unless we expand our product development capacity and enhance our internal marketing capability, we may need to make appropriate arrangements with strategic partners to develop and commercialize any drug candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and/or require us to share revenues and profits with our partners. If we do not find appropriate partners, or if our existing arrangements or future agreements are not successful, our ability to develop and commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success of the development and commercialization of product candidates in those programs will depend largely on the efforts of other parties and will be beyond our control, particularly as partnered programs progress and our licensees may elect to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assume greater control over these programs. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to control the amount and timing of resources that our collaborators may be willing or able to devote to the development or commercialization of our drug candidates or to their marketing and distribution; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our licensing and collaboration agreements with Amgen, Janssen, Takeda, Horizon, GSK and Visirna, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories. To the extent that (i) our partners&#8217; interests in advancing these candidates or targets changes, (ii) unforeseen scientific issues with the candidates arise, or (iii) the pace at which our partners move the candidates through clinical trials toward commercialization slows, our ability to collect milestones and royalties may be significantly diminished. This would further cause us to rely upon other sources of financing to continue to develop our other internal drug candidates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in strategic transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model has been to develop new technologies and to utilize the intellectual property created through the research and development process to develop commercially successful products. If the acquirers of our technologies fail to achieve performance milestones, we may not receive a significant portion of the total value of any sale, license or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our research and development efforts yield technologically feasible applications, we may not successfully develop commercial products. Drug development takes years of study in human clinical trials prior to regulatory approval, and, even if we are successful, it may not be on a timely basis. During our drug development period, superior competitive technologies may be introduced which could diminish or extinguish the potential commercial uses for our drug candidates. Additionally, the degree to which the medical community and consumers will adopt any product we develop is uncertain. The rate and degree of market acceptance of our products will depend on a number of factors, including the establishment and demonstration in the medical community of the clinical efficacy and safety of our products, their potential advantage over alternative treatments, and the costs to patients and third-party payors, including insurance companies and Medicare. Recent efforts in the United States and abroad to reduce overall healthcare spending has put significant pressure on the price of prescription drugs and certain companies have been publicly criticized for the relatively high cost of their therapies. These pressures may force us to sell any approved drugs at a lower price than we or analysts may anticipate or may result in lower levels of reimbursement and coverage from third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether significant commercial market acceptance for our products, if approved, will ever develop, and we cannot reliably estimate the projected size of any such potential market. Our revenue growth and achievement of consistent profitability will depend substantially on our ability to introduce products that will be accepted by the medical community. If we are unable to cost-effectively achieve acceptance of our technology among the medical establishment and patients, or if the associated products do not achieve wide market acceptance, our business will be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on outside sources for various components and processes for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties for various components and processes for our product candidates. We may not be able to achieve multiple sourcing because there may be no acceptable second source, other companies may choose not to work with us, or the component or process sought may be so new that a second source does not exist or does not exist on acceptable terms. There may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators which is beyond our control. If such third parties are unable to satisfy their commitments to us, the development of our products would be adversely affected. Therefore, it is possible that our development plans will have to be slowed down or stopped completely at times due to our inability to obtain required raw materials, components, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outsourced processes at an acceptable cost, if at all, or to get a timely response from vendors, particularly as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recent labor market and global supply chain constraints.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited manufacturing capabilities and experience and we rely, and expect to continue to rely, on third-party manufacturers for the production of some of our product candidates for clinical trials and potential future commercialization. If we were to experience an unexpected loss or interruption of supply for any of our product candidates, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Further, our drug candidates are composed of multiple components and require specialized formulations for which scale-up and manufacturing could be difficult. We have limited experience in such scale-up and manufacturing requiring us to depend on a limited number of third parties, who may not be able to deliver in a timely manner, or at all. In order to develop products, apply for regulatory approvals, and commercialize our products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Our internal GMP manufacturing capabilities are limited to small-scale production of material. There are a limited number of manufacturers that supply synthetic oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional expense to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our product candidates have not yet been manufactured for commercial use. If any of our product candidates become approved for commercial sale, we will need to establish either internal or third-party manufacturing capacity. Manufacturing partner requirements may require us to fund capital improvements, perhaps on behalf of third parties, to support the scale-up of manufacturing and related activities. We may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If we or our third-party manufacturers are unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a different manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If we or any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business. For example, recent global supply chain constraints have led to intermittent lab supply shortages, which are critical for our preclinical programs. While we are exploring alternative suppliers for certain critical materials, there can be no assurance that our efforts will be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of our approved products, if any, must comply with cGMP requirements relating to methods, facilities and controls used in the manufacturing, processing and packaging of the product, which are intended to ensure that drug products are safe and that they consistently meet applicable requirements and specifications. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our approved products, if any, may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. These requirements are enforced by the FDA and other health authorities through periodic announced and unannounced inspections of manufacturing facilities. A failure to comply with these requirements or to provide adequate and timely corrective actions in response to deficiencies identified in an inspection may result in enforcement action, including warning letters, fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, plant shutdown, or the delay, withholding, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We contract with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. We rely on these parties to carry out our clinical trials in compliance with GCP and other relevant requirements. Although we depend </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">heavily on these parties, we do not control them and therefore we cannot be assured that these third parties will adequately perform all of their contractual obligations to us. If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third parties to adhere to our protocols, GCP, or other regulatory requirements or if such third parties otherwise fail to meet deadlines or quality requirements, our development plans may be delayed or terminated. Further, if clinical study results are compromised, then we may need to repeat the affected studies, which could result in significant additional costs and delays to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have greater financial resources and may have more experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do. Our competitors may compete with us for lead clinical trial investigators, clinical trial site locations and patient enrollment. These competitors may also compete with us on recruiting scientific and management personnel. Because our products are in vario</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us stages </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of preclinical and clinical development, along with many of the competing products, and given unpredictability inherent in drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis that competition may be based.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward commercializing drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize products and compete effectively will depend, in part, on our ability to effectively manage future growth. We expect that as we increase the number of product candidates we are developing we will also need to expand our operations. This expected growth may place a strain on our administrative and operational infrastructure and information technology systems. As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We are currently planning to establish a sales and marketing infrastructure, although we have no institutional experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing rights, we must continue to develop a sales and marketing organization or outsource these functions to third parties. If we or our collaborators are unable to establish sales, marketing and distribution capabilities or enter into or maintain agreements with third parties to market and sell our product candidates, we may not be successful in commercializing our product candidates if and when they are approved. Further, as our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, information technology and management controls, reporting systems and procedures. We may not be able to effectively manage the expansion of our operations or implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could suffer in the event of information technology system failures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, ransomware and other cyber-attacks, human error, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations and loss of intellectual property. For example, the loss of preclinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. Further, cybersecurity breaches may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or private information, we could incur liability or regulatory penalties, including under laws and regulations governing the protection of health and other personally identifiable information, we could lose valuable trade secret rights, the development of our product candidates could be delayed, and we could suffer reputational damage and damage to key business relationships. The risk of a cyber-security breach or other informational technology disruption, particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We have experienced cyber-security attacks in the past, which to date have not had a material impact on our operations or development programs; however; there is no assurance that such impacts will not be material in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in Madison, Wisconsin and San Diego, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause interruption to our research and development and manufacturing efforts, injury to our employees and others, environmental damage, and liabilities under federal, state and local law. In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation claims may result in financial losses or harm our reputation and may divert management resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.51pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the market price of a stock is volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. We cannot predict with certainty the eventual outcome of such litigation, arbitration or third-party inquiry. We may not be successful in defending ourselves or asserting our rights in current or future lawsuits, investigations, or claims that have been or may be brought against us and, as a result, our business could be materially harmed. These lawsuits, arbitrations, investigations or claims may result in large judgments or settlements against us, any of which could have a negative effect on our financial performance and business. Additionally, lawsuits, arbitrations and investigations can be expensive to defend, whether or not the lawsuit, arbitration or investigation has merit, and the defense of these actions may divert the attention of our management and other resources that would otherwise be engaged in running our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including any arrangements that we enter into with healthcare providers, physicians, and third-party payers, are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such laws and regulations, including applicable U.S. federal and state healthcare laws and regulations, as well as foreign laws, such as the federal Anti-Kickback Statute, the False Claims Act, the Health Insurance Portability and Accountability Act of 1996, or the Foreign Corrupt Practices Act, may constrain our operation and the business or financial arrangements through which we can market, sell and distribute any drug candidates for which we obtain marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to confirm that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we become subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Financial Condition</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development efforts and prepare for the potential commercialization of our product candidates. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we successfully commercialize drug candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we do generate significant revenue, we may never achieve consistent profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funds to complete our research and development activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently does not generate the cash that is necessary to finance our operations. Subject to the success of the research and development programs of our Company and our partners, and potential licensing or partnering transactions, we may need to raise additional capital to:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund research and development infrastructure and activities relating to the development of our drug candidates, including preclinical and clinical trials and manufacturing to support these efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund a commercialization infrastructure and activities related to the sale, marketing, customer support, and distribution of our drug products if and when they become approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund our general and administrative infrastructure and activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue business development opportunities for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Add to and protect our intellectual property; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retain our management and technical staff.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital needs depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope, duration, and expenditures associated with our research and development, including the progression of our clinical trials, with late-stage trials generally requiring greater capital than early-stage trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory requirements for our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The extent to which our research and development and clinical efforts are successful;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expenditures to build out or contract for sales, marketing and distribution capabilities as we prepare for the potential commercialization of our product candidates, if any;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The outcome of potential partnering or licensing transactions, if any, and the extent to which our business development efforts result in the acquisition of new programs or technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing technological developments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intellectual property positions, if any, in our products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval process and regulatory standards for our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise additional funds through public or private equity offerings, debt financings or additional strategic alliances and licensing arrangements in the future to continue our operations. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it very difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our stockholders will result, which may substantially dilute the value of investment. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid before holders of equity securities received any distribution of corporate assets. In order to raise additional funds through alliance, joint venture or licensing arrangements, we may be required to relinquish rights to our technologies or drug candidates or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to further delay, reduce or eliminate one or more of our planned activities. These actions would likely reduce the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results have fluctuated and may continue to fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our operating results may fluctuate due to a variety of other factors, may of which are outside of our control and may be difficult to predict, including the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients in clinical trials and the timing of enrollment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our current and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we will or may incur to acquire or develop additional product candidates and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and outcomes of clinical trials for  product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing and potential future products that compete with any of our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays in regulatory review or approval of any of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize any of our product candidates, if approved, inside and outside of the United States, either independently or working with third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately support future growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unforeseen business disruptions that increase our costs or expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the changing and volatile global economic environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and fixed income securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, we h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad $482.3 million in cash, cash equivalents, fixed income securities and a certificate of deposit and we received an additional $250.0 million in proceeds from a royalty sale in November 2022. Ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r investments may also include commercial paper, securities issued by the U.S. government obligations, and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, and market and interest rate risks, particularly in the current economic environment. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred net losses. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation is generally allowed a deduction for net operating losses (NOLs) carried forward from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. As o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f September 30, 2022, we had federal and state NOL carryforwards of approximately $504.8 million and $626.5 million, resp</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ectively. As a result of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (&#8220;CARES Act&#8221;) and legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;), NOLs arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules. Under the CARES Act and 2017 Tax Act, federal NOLs incurred in 2018, 2019 and 2020 can generally be carried back five years, carried forward indefinitely and can offset 100% of future taxable income for tax years before January 1, 2021 and up to 80% of future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable income for tax years after December 31, 2020. Any NOLs arising on or after January 1, 2021, cannot be carried back, can generally be carried forward indefinitely and can offset up to 80% of future taxable income. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. These NOL carryforwards could expire unused before offsetting potential future income tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Section 382 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management's time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to additional tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and local taxes in the United States and other countries. Significant judgment is required in evaluating our tax positions. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. We may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Investment and Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of the Company that a holder of our common stock might consider in its best interest. For example, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 5,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these shares (&#8220;blank check&#8221; preferred). Such preferred stock may have rights, including economic rights, senior to our common stock. These factors could also reduce the price that certain investors might be willing to pay for shares of our common stock and result in the market price being lower than it would be without these provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to declare cash dividends on our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not distribute cash to our stockholders unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. The time frame for that is unpredictable and investors should not expect dividends in the near future, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our common stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations. Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed for trading on the Nasdaq Global Select Market, at various times our securities are relatively thinly traded. Investor trading patterns could serve to exacerbate the volatility of the price of our stock. For example, mandatory sales of our common stock by institutional holders could be triggered if an investment in our common stock no longer satisfies their investment standards and guidelines. It may be difficult to sell shares of our common stock quickly without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could result in major fluctuations in the price of the stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ause we are still a clinical-stage pharmaceutical company and have not yet commercialized a drug, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here are few objective metrics by which our progress may be measured. Consequently, we expect that the market price of our common stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements of developments related to our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and/or existing partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding the status of any or all of our collaborations or products, including clinical trial results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market perception and/or investor sentiment regarding our technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements of actions taken by regulatory authorities, such as the U.S. Food and Drug Administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding developments in the RNA interference or biotechnology fields in general;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding clinical trial results with our products or competitors&#8217; products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market perception and/or announcements regarding other companies developing products in the field of biotechnology generally or specifically RNA interference;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The issuance of competitive patents or disallowance or loss of our patent rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The addition or departure of key executives; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not have control over many of these factors but expect that they may influence our stock price. As a result, our stock price may be volatile and such volatility could result in the loss of all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder equity interest may be substantially diluted in any additional equity issuances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Economic and Industry Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is sensitive to global economic conditions, which can be adversely affected by public health crises (including the COVID-19 pandemic) and epidemics, political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where we source our components or raw materials. For example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from China mainland, as well as other business restrictions. Tariffs increase the costs of the components and raw materials we source. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain. These geopolitical risks could also adversely affect our joint venture in China.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, military conflicts or wars (such as the ongoing conflict between Russia and Ukraine) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. Additionally, the ongoing conflict between Russia and Ukraine has impacted our business decisions with respect to potential clinical trial sites in Europe. For example, a number of our clinical trial sites we had previously planned to use in Russia, Ukraine and Belarus were shut down and we have sought alternatives in other geographies. We cannot be certain of the overall impact of the conflict between Russia and Ukraine on our ability to conduct and complete our clinical trials as planned, and any interruptions of our clinical trials can result in significant delays or termination of the research, development or commercialization of our drug candidates, which could impair our ability to generate revenues and harm our business and financial condition. It is not possible to predict the short and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our operations and facilities, as well as operations of our suppliers and manufacturers, may be located in areas that are prone to earthquakes and other natural disasters. Such operations and facilities are also subject to the risk of interruption by fire, drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises (including the COVID-19 pandemic), and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products. Any insurance we maintain against damage to our property and the disruption of our business due to disaster may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. Further, because the Company relies on single or limited sources for the supply and manufacture of many critical components, a business interruption affecting such sources would exacerbate any negative consequences to the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any public health crises, including the COVID-19 pandemic, may affect our operations and those of third parties on which we rely, including our business partners and suppliers. In the past three years, the COVID-19 pandemic has had, and likely will continue to have, an adverse impact on the global economy, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking or might have to take again in the future to manage the pandemic. The extent to which the COVID-19 pandemic and measures taken in response thereto impact our business, results of operations and financial condition will depend on future developments which are highly uncertain and difficult to predict. These developments include, but are not limited to, future resurgences of the virus and its variants, actions taken to contain the virus or address its impact, and the timing, distribution and efficacy of vaccines and other treatments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without limiting the foregoing, we have experienced and/or may in the future experience: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties enrolling patients in our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or disruptions to the conduct of preclinical programs and clinical trials; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">constraints  on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse impacts on our workforce and/or key employees; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is time consuming, expensive and risky.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on technology related to new and improved pharmaceutical candidates. Product candidates that appear promising in the early phases of development, such as in animal and early human clinical trials, often fail to reach the market for a number of reasons, such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial results may be unacceptable, even though preclinical trial results were promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inefficacy and/or harmful side effects in humans or animals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The necessary regulatory bodies, such as the U.S. Food and Drug Administration, may not approve our potential product for the intended use, or at all; and/or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing and distribution may be uneconomical.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, any positive preclinical results in animals may not be replicated in human clinical studies. These programs may be also found to be unsafe in humans, particularly at higher doses needed to achieve the desired levels of efficacy. Also, the positive safety results from single dose human clinical studies may not be replicated in other human studies, including multiple dose studies. Clinical and preclinical study results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others, which often delays, limits, or prevents further clinical development or regulatory approvals of potential products. Clinical trials can take many years to complete, including the process of study design, clinical site selection and the recruitment of patients. As a result, we can experience significant delays in completing clinical studies, which can increase the cost of developing a drug candidate and shorten the time that an approved product may be protected by patents. If our drug candidates are not successful in human clinical trials, we may be forced to curtail or abandon certain development programs. If we experience significant delays in commencing or completing our clinical studies, we could suffer from significant cost overruns, which could negatively affect our capital resources and our ability to complete these studies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the world and particularly in the United States, the healthcare system is under significant financial pressure to reduce costs. The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. These effects could reduce or eliminate our ability to return value to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators. For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary. As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_22"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. Additionally, the Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities, which it currently anticipates to be available starting around April 2023. The following table summarizes the Company&#8217;s leased facilities as of September&#160;30, 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Office <br/>Space (sq.ft)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Monthly<br/>Expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Primary Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease<br/>Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease <br/>Term (year)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pasadena, California</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Headquarters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Madison, Wisconsin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office Space</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="if17c086bfc1e494d91287b00809be3a1_28"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">LEGAL PROCEEDINGS</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legal Proceedings are set forth in the Company&#8217;s financial statement schedules in Part IV, Item 15 of this Annual Report and are incorporated herein by reference. See Note 7 &#8212; Commitments and Contingencies of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div id="if17c086bfc1e494d91287b00809be3a1_31"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if17c086bfc1e494d91287b00809be3a1_37"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shares of the Company&#8217;s common stock are traded on The Nasdaq Global Select Market under the symbol &#8220;ARWR.&#8221; There were approximately 100 holders of record of the Company&#8217;s common stock as of November&#160;16, 2022.  </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has never paid dividends on its common stock and does not anticipate that it will do so in the foreseeable future. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Repurchases of Equity Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing. The graph compares the cumulative 5-year total return to stockholders on the Company&#8217;s common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The Company selected the Nasdaq Biotechnology Index because it believes the index reflects the market conditions within the industry in which the Company primarily operates. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on September 30, 2017, in each of the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The comparisons in the following graph are based on historical data and are not intended to forecast the possible future performance of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20220930_g5.jpg" alt="arwr-20220930_g5.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$100 investment in stock or index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARWR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">442.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,441.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">763.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#94;NBI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#94;IXIC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="if17c086bfc1e494d91287b00809be3a1_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.               RESERVED</span></div><div id="if17c086bfc1e494d91287b00809be3a1_43"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="if17c086bfc1e494d91287b00809be3a1_46"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi  mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, muscle and others; and the potential for improved safety and reduced risk of intracellular buildup, because there are less metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - ARO-APOC3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dyslipidemia - ARO-ANG3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - ARO-DUX4</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Muco-obstructive or inflammatory pulmonary conditions - ARO-RAGE and ARO-MUC5AC</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - ARO-MMP7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease - ARO-HSD (out-licensed to GSK)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Uncontrolled gout - ARO-XDH (out-licensed to Horizon)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - NJ-75220795 (ARO-JNJ1, out-licensed to Janssen) </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) - Fazirsiran (ARO-AAT, a collaboration with Takeda)</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic hepatitis B virus - JNJ-3989 (ARO-HBV, out-licensed to Janssen) </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - Olpasiran (AMG 890 or ARO-LPA, out-licensed to Amgen) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (&#8220;CROs&#8221;) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; If the clinical candidates progress through human testing, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support its growing programs. The bullets below highlight some of those key developments; however, it is not all-inclusive and is meant to be read in conjunction with the entirety of management&#8217;s discussion and analysis, the Company&#8217;s Consolidated Financial Statements and notes thereto, and all other items contained within this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patients in its PALISADE study, a Phase 3 clinical study to evaluate the safety and efficacy of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">filed for regulatory clearance to begin a Phase 1/2a study of ARO-C3 and subsequently dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the Company&#8217;s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">presented additional interim clinical data from AROHSD1001, AROAAT2002, and AROAPOC31001; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completed enrollment in Phase 2b ARCHES-2 study of investigational ARO-ANG3 for patients with mixed dyslipidemia;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-RAGE and subsequently dosed first subjects for treatment of Asthma; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-MUC5AC and subsequently dosed first subjects for treatment of muco-obstructive lung disease;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">filed for regulatory clearance to initiate Phase 1/2a study of ARO-MMP7 for treatment of idiopathic pulmonary fibrosis (IPF);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiated and dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholersterolemia;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. with Vivo Capital through which the Company and Vivo Capital intend to expand the reach of innovative medicines in Greater China;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">hosted a pulmonary research &amp; development (R&amp;D) day to discuss the Company&#8217;s emerging pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates that leverage its proprietary Targeted RNAi Molecule (TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) platform, including an announcement of its previously undisclosed candidate designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into an exclusive license agreement with GSK for ARO-HSD;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Janssen presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989 (JNJ-3989), formerly called ARO-HBV, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection (CHB);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">in conjunction with Takeda, announced results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD), and was recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress&#8482; 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL); and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completed the purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin and held a groundbreaking ceremony on the site. The site is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. Additionally, the Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities, which it currently anticipates to be available in April 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Financial Performance Summary</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $176.1 million for the year ended September&#160;30, 2022 as compared to net loss of $140.8 million for the year ended September 30, 2021. Net loss per share &#8211; diluted was $1.67 for the year ended September&#160;30, 2022 as compared to net loss per share &#8211; diluted of $1.36 for the year ended September 30, 2021. The increase in net losses for the year ended September 30, 2022 was due to an increase in research and development and general and administrative expenses as the Company&#8217;s pipeline of candidates has expanded and progressed through clinical trial phases, partially offset by an increase in revenue from its license and collaboration agreements, primarily from the License Agreements with GSK, Horizon and Takeda. For further information, see Part I, &#8220;Item 1. Business&#8221; and &#8220;Results of Operations - Revenue&#8221; below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $108.0 million of cash and cash equivalents, $268.4 million in short-term investments, $105.9 million of long-term investments and $691.9 million of total assets as of September 30, 2022, as compared to $184.4 million of cash and cash equivalents, $126.7 million of marketable securities, $56.6 million in short-term investments, $245.6 million of long-term investments and $710.1 million of total assets as of September 30, 2021. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management makes certain judgments and uses certain estimates and assumptions when applying U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) in the preparation of the Company&#8217;s Consolidated Financial Statements. On an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may vary from what the Company anticipates and different assumptions or estimates about the future could change its reported results. The Company believes the following accounting policies are the most critical to it, in that they require its most difficult, subjective or complex judgments in the preparation of the Company&#8217;s Consolidated Financial Statements. For further information, see Note 1, Organization and Significant Accounting Policies of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company has not yet achieved commercial sales of its drug candidates to date, however, this standard is applicable to its ongoing licensing and collaboration agreements. This is discussed further in Note 2, Collaboration and License Agreements of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application or a NDA in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we determine that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on the Company&#8217;s consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of FASB Topic 808&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $0 at September&#160;30, 2022 and 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent its right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,231&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,287&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,992&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176,063)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,848)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,553)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share-diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="if17c086bfc1e494d91287b00809be3a1_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2022 Compared to Year Ended September 30, 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the year ended September&#160;30, 2022 increased to $243.2 million, 75.9% from the same period of 2021. The increase was primarily driven by the revenue recognition associated with GSK, Horizon and Takeda license agreements, as discussed below. The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $120.0 million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million was fully recognized as of September 30, 2022. There were $0 in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has also performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $4.8 million in connection with these efforts for the year ended September&#160;30, 2022. There were $4.8 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2022 and 2021 were $26.7 million and $6.7 million, respectively. There were $0 in contract assets </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">recorded as accounts receivable and $6.7 million in contract liabilities recorded as deferred revenue as of September 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $2.5 million and $0 in connection with these efforts for the years ended September&#160;30, 2022 and 2021, respectively. There were $1.3 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $300.0 million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $85.8 million and $90.8 million in connection with these efforts for the years ended September 30, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $123.4 of contract liabilities recorded as deferred revenue, of which $67.4&#160;million was classified as current deferred revenue, as of September&#160;30, 2022. The Company also recorded $8.6 million as accrued expenses as of September 30, 2022 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of Janssen License Agreement and Janssen Collaboration Agreement, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets was not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company recognized $3.4&#160;million and $0.5 million of revenue associated with these efforts during September&#160;30, 2022 and 2021, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respectively. There were $0.1 million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September&#160;30, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amgen</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0 million milestone payment to the Company. There was no revenue recorded associated with the Company&#8217;s agreement with Amgen for the years ended September 30, 2022 and 2021. There were no contract assets and liabilities recorded as of September 30, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the years ended September&#160;30, 2022 and 2021 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in San Diego, California and Madison, Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&amp;D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2022</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,342&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,965&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Candidate costs increased $44.3 million to $136.9 million for the year ended September&#160;30, 2022 compared to $92.6 million for the year ended September&#160;30, 2021. This increase was primarily due to the progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher outsourced clinical trials, toxicity study and manufacturing costs. For example, the Company&#8217;s cardiometabolic candidates, ARO-ANG3 and ARO-APOC3, have advanced into Phase 2 and Phase 3 clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $21.6 million to $54.3 million for the year ended September&#160;30, 2022 compared to $32.7 million for the year ended September&#160;30, 2021. This increase was due to the growth of the Company&#8217;s discovery efforts and continued advancement into novel therapeutic areas and tissue types. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and stock compensation expense consist of salary, bonuses, payroll taxes, related benefits and stock compensation for the Company&#8217;s R&amp;D personnel. The increases in salaries and stock comp expenses were primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual increases and performance bonuses. Stock compensation expense was based upon the valuation of stock options and restricted stock units granted to employees, directors and certain consultants. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense included lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased $5.3 million to $12.9 million for the year ended September 30, 2022, compared to $7.7 million for the year ended September 30, 2021. This increase was mainly due to the additional lease expense as the Company expands discovery efforts to identify new drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of depreciation and amortization expense, a non-cash expense, relates to depreciation on lab equipment and leasehold improvements at the facilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these R&amp;D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods/services and the labor market. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the Company&#8217;s general and administrative expenses: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and others</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,521&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,931&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,590&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,431&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,981&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,450&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $3.0 million to $16.6 million for the year ended September&#160;30, 2022 compared to $13.7 million for the year ended September&#160;30, 2021. The increase was driven by the combination of annual increases, performance bonuses and increased headcount needed as the Company has grown. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and others expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, and communication and technology expenses. This expense increased $1.6 million to $14.7 million for the year ended September&#160;30, 2022 compared to $13.1 million for the year ended September&#160;30, 2021. The increase was mainly due to software implementation and additional recruiting and administrative expenses in support of additional headcount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs for the Company&#8217;s corporate headquarters in Pasadena, California. Facilities related expense increased $0.6 million to $2.9 million for the year ended September 30, 2022 compared to $2.3 million for the year ended September 30, 2021. The increase was primarily due to additional rental expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, increased by $37.6 million to $88.5 million for the year ended September&#160;30, 2022 compared to $50.9 million for the year ended September&#160;30, 2021. The increase in the current period was due to a performance award that was achieved earlier than anticipated, as well as a modification of certain performance awards to include market conditions. The fair value of market condition-based awards was expensed ratably over the service period and was not adjusted for actual achievement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these general &amp; administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods/services and the labor market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to interest income and realized and unrealized gain/loss on investments. Other income decreased $2.4 million to $5.8 million for the year ended September&#160;30, 2022 compared to $8.2 million for the year ended September 30, 2021. The decrease was due to lower yields on more recently purchased bonds and a realized loss on the sale of marketable securities, offset by various credits the Company received during 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2021 Compared to Year Ended September 30, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s Form 10-K for the year ended September 30, 2021 for a discussion of changes in its results of operations from the year ended September 30, 2020 to the year ended September 30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its common stock and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company plans to expand its facilities with its purchase of land in Verona, Wisconsin, and its entry into a new lease in San Diego, California. Each of these expansions is designed to increase the Company&#8217;s internal manufacturing and discovery capabilities, and each will require significant capital investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s  cash and cash equivalents decreased to $108.0 million at September&#160;30, 2022 compared to $184.4 million at September&#160;30, 2021. Cash invested in short-term fixed income securities was $268.4 million at September&#160;30, 2022 compared to $56.6 million at September&#160;30, 2021. Cash invested in long-term fixed income securities was $105.9 million at September&#160;30, 2022, compared to $245.6 million at September&#160;30, 2021. In April 2022, the Company sold all of its marketable securities for $122.3&#160;million. In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM&#8221; agreement), pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC. As of the year ended September&#160;30, 2022, no shares have been issued under the ATM agreement. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(240,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,631)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September&#160;30, 2022, cash flow used by operating activities was $136.1 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of the $120.0 million upfront payment from GSK. Cash used in investing activities was $5.4 million, which was primarily related to the purchase of property and equipment of $52.8 million, offset by net sales of investments of $47.4 million. Cash provided by financing activities of $$65.2 million was primarily related to the formation of the joint venture, Visirna, as well as cash received from stock option exercises. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;), pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0&#160;million upfront on November 9, 2022. See Note 13 &#8212; Subsequent Events of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September 30, 2021, the Company generated $171.3 million in cash from operating activities, which was primarily related to the Takeda license agreement&#8217;s $300.0 million upfront payment, partially offset by the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities was $141.7 million, which was primarily related to the purchase of investments of $240.7 million and purchase of property and equipment of $23.6 million, partially offset by maturities of fixed-income securities of $122.6 million. Cash provided by financing activities of $11.3 million was due to cash received from stock option exercises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $200.0&#160;million and $260.0&#160;million into the build out of the facilities with cash on hand. As part of this acquisition, the Company entered into a development agreement </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the City of Verona to construct certain infrastructure improvements within the tax incremental district and expects to be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona is expected to pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property. The Company also expects receive up to $2.5&#160;million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s  Form 10-K for the year ended September 30, 2021 for a discussion of cash flows from the year ended Sep 30, 2020.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_61"></div><div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to the Company&#8217;s future commitments for its facility-related obligations and collaboration and licensing agreements, see Notes 8 and 2, respectively, of Notes to the Company&#8217;s Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221; Commitments related to the Company&#8217;s clinical, manufacturing and business operation related agreements are $229.6 million as of the year ended September&#160;30, 2022, but many of these agreements are cancellable. </span></div><div id="if17c086bfc1e494d91287b00809be3a1_64"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to market risk exposures primarily due to its investing activities. The primary market risk exposure is change in interest rates. Adverse changes to rates may occur due to changes in the liquidity of a market or to changes in market perceptions of creditworthiness and risk tolerance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not hold any instruments for trading purposes and investment criteria are governed by its Investment Policy. As of September&#160;30, 2022 and 2021, the Company had cash and cash equivalents of $108.0 million and $184.4 million, respectively, and short-term and long-term investments and marketable securities of $374.3 million and $429.0 million, respectively. At times, the Company has invested its cash reserves in corporate bonds typically with maturities of less than 3 years and historically classified these investments as held-to-maturity. The Company has also invested in mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities. Due to the relatively short-term nature of the investments that the Company holds, it does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to its investment portfolio.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_67"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is included in Item 15 of this Annual Report on Form 10-K. </span></div><div id="if17c086bfc1e494d91287b00809be3a1_70"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_73"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of its Consolidated Financial Statements for external purposes in accordance with GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company&#8217;s assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of the Company&#8217;s management and directors; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that controls may become inadequate because either conditions change or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of September 30, 2022. In making this assessment, the Company used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that the Company&#8217;s internal control over financial reporting was effective as of September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rose, Snyder and Jacobs LLP, the independent registered public accounting firm that audited the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this 2022 Annual Report on Form 10-K, has issued an audit report on the effectiveness of the Company&#8217;s internal control over financial reporting as of September 30, 2022, which is included herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company&#8217;s process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_76"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_79"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_82"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="if17c086bfc1e494d91287b00809be3a1_85"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Company&#8217;s Definitive Proxy Statement, under the headings Proposal One &#8212; Election of Directors, Equity Compensation Plan Information, Corporate Governance, Environmental and Social Commitment, and, if applicable, Delinquent Section 16(a) Reports, to be filed for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s 2023 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2023 (the &#8220;Definitive Proxy Statement&#8221;).</span></div><div id="if17c086bfc1e494d91287b00809be3a1_88"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Executive Compensation.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_91"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Voting Securities of Principal Stockholders and Management.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_94"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the headings Review and Approval of Related-Party Transactions and Certain Relationships and Related Transactions, and Director Independence.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_97"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Audit Fees.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_100"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if17c086bfc1e494d91287b00809be3a1_103"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report on Form 10-K: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. All other schedules are omitted as the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the Consolidated Financial Statements or notes thereto. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Exhibits. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459020036812/arwr-ex11_467.htm">Open Market Sale Agreement, dated as of August 5, 2020, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex21.htm">Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form 10-K as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459015003902/arwr-ex21_20150331298.htm">Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2015</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex34.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex41.htm">Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312519304271/d807419ds3asr.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statement on Form S-3, as Exhibit 4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312517092797/d319463dex41.htm">Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 23, 2017</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex44_92.htm">Description of Registrant&#8217;s Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, as Exhibit 4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex104_153.htm">Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and Johnson &amp; Johnson Innovation-JJDC, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312512009893/d275001ddef14a.htm">Arrowhead Research Corporation 2004 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14C, as Annex B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 12, 2012</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312513481209/d647635ddef14a.htm">Arrowhead Research Corporation 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14C, as Annex A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 20, 2013</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex101.htm">Form of Stock Option Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex102.htm">Form of Restricted Stock Unit Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312521019640/d76219ddef14a.htm">Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14A, Exhibit A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 28, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">RSU Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">for Officers and Certain Other Employees (Arrowhead Pharmace</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">uticals, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm"> 2021 Incentive Pla</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">n</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> - Inducement Award)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of RSU Agreement for Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312506253375/dex1011.htm">Executive Incentive Plan, adopted December 12, 2006</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 14, 2006</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.10**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312508133616/dex101.htm">Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">June 13, 2008</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.11**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312509258134/dex108.htm">Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 22, 2009</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.12&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1036.htm">Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October 29, 2009 &#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.13&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1033.htm">Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459014003557/arwr-ex10_20140630353.htm">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">August 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1018_310.htm">First Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 14, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1019_309.htm">Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">December 14, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516776646/d272157dex101.htm">Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 25, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex101_156.htm">License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459019044376/arwr-ex1019_310.htm">Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-Q, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.20&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1020_311.htm">Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February 4, 2019&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.21&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex102_155.htm">Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.22&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1021_309.htm">Amendment No. 1 to Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated November 14, 2019&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex103_154.htm">Stock Purchase Agreement by and between Johnson &amp; Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.24&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex101_863.htm">Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc., dated October 7, 2020</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022019275/arwr-ex101_473.htm">First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">May 10, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.26&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex104_195.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">August 5, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex101_514.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Glaxosmithkline Intellectual Property, dated November 22, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Lease Agreement between University Research Park, Incorporated and Arrowhead Madison, Inc., dated January 8, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 9. 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1023_125.htm">Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual Report on Form 10-K, as Exhibit 10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1024_124.htm">Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1025_123.htm">Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1026_121.htm">Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual report on Form 10-K, as Exhibit 10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1027_122.htm">Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Annual report on Form 10-K, as Exhibit 10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex103_51.htm">Amendment No. 6 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated November 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex104_52.htm">Amendment No. 7 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated December 9, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019028760/arwr-ex101_67.htm">Office Lease by and between 177 Colorado Owner LLC and Arrowhead Pharmaceuticals, Inc., dated April 17, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">August 5, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">First Amendment to Office Lease by<a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex102_50.htm"> and between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC., dated October 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 4, 2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.38&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459020022860/arwr-ex101_202.htm">Sublease Agreement by and between Halozyme, Inc. and Arrowhead Pharmaceuticals, Inc. dated March 3, 2020&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">May 7, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex102_515.htm">Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and ARE-SD Region No. 72, LLC, dated November 19, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021057888/arwr-ex211_11.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20220930xex231.htm">Consent of Independent Public Registered Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20220930xex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20220930xex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20220930xex321.htm">Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20220930xex322.htm">Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2022, formatted in Inline XBRL (included as Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Indicates compensation plan, contract or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_106"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November&#160;28, 2022</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth A. Myszkowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglass Given</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglass Given</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Waddill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">William Waddill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marianne De Backer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marianne De Backer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS AND SCHEDULE</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_115">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> (PCAOB ID: <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTIvZnJhZzo4N2QwOTg5Y2FmZTM0MDFiOWJlODkzNGZlMjgzYjhkMS90YWJsZTplM2JhNDEwYmJlMGU0MDYyOWM3M2Y5OGU1NTRmMmE2OC90YWJsZXJhbmdlOmUzYmE0MTBiYmUwZTQwNjI5YzczZjk4ZTU1NGYyYTY4XzAtMC0xLTEtMTE1NTYvdGV4dHJlZ2lvbjo3ZTRkYmRiZTllOTY0ZDE1OWVhNzFlZWNjNDNhYTIwMV8zMjk4NTM0ODgzNDE3_06c805b8-f34e-4552-a820-877af3e8e6f2">468</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_115">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_124">Consolidated Balance Sheets </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_124">as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_124">September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_124">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_124"> and 202</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_124">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">Loss </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_127"> and 20</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_127">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">Consolidated Statements of Stockholders&#8217; Equity </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_130">, and 20</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_130">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133">Consolidated Statements of Cash Flows of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133">for the years ended September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_133"> and 20</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_133">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if17c086bfc1e494d91287b00809be3a1_136">Notes to Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if17c086bfc1e494d91287b00809be3a1_136">9</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of Arrowhead Pharmaceuticals, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company) as of September 30, 2022 and 2021, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended September 30, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended September 30, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of September 30, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated November 28, 2022, expressed an unqualified opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition &#8211; Revenue Recognized Over Time</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of the Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 and Note 2 to the Consolidated Financial Statements, the Company earns its revenue through license and collaboration agreements. For performance obligations related to services that are required to be recognized over time, the Company measures its progress to completion using various measures, including an input measure of total labor costs incurred divided by total labor costs expected to be incurred, time elapsed, and an output measure of total patient visits divided by total patient visits expected. The selection of measurement criteria is based on the nature and phase of trials being conducted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing revenue recognition is complex and highly judgmental due to the variability and uncertainty associated with the Company&#8217;s assessment of measure of progress. Changes in these estimates would have a significant effect on the amount of revenue recognized. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">How We Addressed the Matter in Our Audit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls that address the risk of material misstatement of license and collaboration agreement revenue including those associated with cost to complete estimates. We tested controls over management&#8217;s process to collect, review, and approve the data used in assessing revenue recognized over time. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the measures of progress used for performance obligations related to services that are required to be recognized over time, our audit procedures included, among others, evaluating the appropriateness of the Company&#8217;s accounting policy for each type of arrangement, testing the identified measure of performance by reading contracts with customers, including all amendments, and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently. We also tested the completeness and accuracy of the underlying data used for the measure of progress by testing and or analyzing the underlying data and conducting interviews of project personnel. </span></div><div style="margin-top:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTUvZnJhZzozZGE0OTk1MzA2MmM0MzdlYjljZWIzYWVkMjJmNTU2Ny90ZXh0cmVnaW9uOjNkYTQ5OTUzMDYyYzQzN2ViOWNlYjNhZWQyMmY1NTY3XzMyOTg1MzQ4OTMzODc_fb8fadf6-feef-48bf-9cea-31236ddf831f">Rose, Snyder &amp; Jacobs LLP</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2004.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTUvZnJhZzozZGE0OTk1MzA2MmM0MzdlYjljZWIzYWVkMjJmNTU2Ny90ZXh0cmVnaW9uOjNkYTQ5OTUzMDYyYzQzN2ViOWNlYjNhZWQyMmY1NTY3XzMyOTg1MzQ4OTMzODk_1fd8ce74-9cc6-43a8-9b11-46dde1c0946c">Encino, California</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 28, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of Arrowhead Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Arrowhead Pharmaceuticals, Inc. and its Subsidiaries (the Company&#8217;s) internal control over financial reporting as of September 30, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of September 30, 2022 and 2021 and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended September 30, 2022 and related notes, and our report dated November 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rose, Snyder &amp; Jacobs LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encino, CA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 28, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div id="if17c086bfc1e494d91287b00809be3a1_124"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMtMS0xLTEtODcyMA_32437954-bd58-4107-b52c-f765980c8fc8">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMtMy0xLTEtODcyMA_40785792-b3c9-4d40-9c89-b3428baf71ea">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzQtMS0xLTEtODcyMA_4f4ff155-1fca-4fc8-81b7-aa5e1465bb05">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzQtMy0xLTEtODcyMA_264b7732-f254-4cd2-b3e6-e42616924fb9">10,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMS0xLTEtMTQwNTQ_46ca5eab-565d-46bd-8ef9-e60d923ca651">268,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMy0xLTEtMTQwNTQ_585635e6-ecac-4d45-92d2-326134ccad04">56,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzctMS0xLTEtMTQwNjE_95d04933-a756-4fbf-8d49-d7eb34ddb268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzctMy0xLTEtMTQwNjE_1a7ea3f4-b72e-4a11-bdc9-81c7c4d3262a">126,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzUtMS0xLTEtODcyMA_39dd4c3d-ba4e-4c4f-a7c4-558afdaf98be">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzUtMy0xLTEtODcyMA_4587d0ea-1fd6-4068-aa54-fece9412c610">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMS0xLTEtODcyMA_03ed707c-1118-4493-a871-cec80190945e">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMy0xLTEtODcyMA_4a3df44a-d433-4e7d-82b9-b74a93e8eac5">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzktMS0xLTEtODcyMA_551f9552-391e-4cca-8cf0-a876412d3ed0">405,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzktMy0xLTEtODcyMA_01ee3d99-282e-4037-b792-a215fde2a933">384,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEwLTEtMS0xLTg3MjA_38b9bd11-c31d-4d42-b292-f53191af815a">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEwLTMtMS0xLTg3MjA_3fcb2535-85e2-4feb-8342-03ef18efa32f">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzExLTEtMS0xLTg3MjA_e99408c6-9cd8-4bec-b9c7-ca3194e9ce00">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzExLTMtMS0xLTg3MjA_5cbde035-8165-4372-9242-6b7b82826956">13,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEyLTEtMS0xLTg3MjA_58e13c22-e8b8-4b09-a8b1-936e27d5aee1">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEyLTMtMS0xLTg3MjA_78147cfa-74ab-4941-809e-3eeac2f3867e">245,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEzLTEtMS0xLTg3MjA_256a2bca-336f-489f-88a9-13690736eb0e">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEzLTMtMS0xLTg3MjA_2df41f5d-c81c-46fb-9e94-ecb07366a995">17,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE0LTEtMS0xLTg3MjA_b55442bd-3dc3-425b-b78e-51e3d764bf58">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE0LTMtMS0xLTg3MjA_b5623413-723f-4572-93a7-6b13adf0a90e">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE1LTEtMS0xLTg3MjA_2e1cfa87-6b44-4c40-b991-71e3051a717d">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE1LTMtMS0xLTg3MjA_87e7c041-0fa1-47b4-b9f9-a28f325c8f6f">710,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE4LTEtMS0xLTg3MjA_f148f3b4-609f-4cfb-ae15-c78d5df8de76">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE4LTMtMS0xLTg3MjA_d72f486d-336f-4d4b-b575-1257b7edf660">9,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE5LTEtMS0xLTg3MjA_49c9bc96-23f2-4c12-8e03-2e87981d337b">46,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE5LTMtMS0xLTg3MjA_cae61f38-4464-4883-8b1c-6806a0552375">14,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIwLTEtMS0xLTg3MjA_204f3012-bc2c-47f9-86f4-946adfa5f799">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIwLTMtMS0xLTg3MjA_97b05153-6436-45e7-93c4-7ba3ba325e70">9,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIxLTEtMS0xLTg3MjA_62d95e8c-cdce-4900-bad1-9cdb46f61fd6">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIxLTMtMS0xLTg3MjA_d149da14-5c0c-47c1-96e4-78f7fffd6073">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIyLTEtMS0xLTg3MjA_6d83e9de-2cc9-4746-a07c-3ce5150af043">74,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIyLTMtMS0xLTg3MjA_cb8ce456-74b8-4007-9f59-733a0862478b">111,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI0LTEtMS0xLTg3MjA_aab58056-52b7-4d5b-94b2-37b16c98e307">138,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI0LTMtMS0xLTg3MjA_4b232cd0-bff1-43ff-b84d-9b0541ed50e1">146,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI2LTEtMS0xLTg3MjA_a5a78e1c-8512-4ff5-8d0f-7a850cddac2e">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI2LTMtMS0xLTg3MjA_d087de7f-2d7c-4f8a-ad9a-45e15e987ae9">23,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI3LTEtMS0xLTg3MjA_88203b08-a24b-46fc-a36d-0ecb813dc2bf">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI3LTMtMS0xLTg3MjA_46aadbb5-29dd-454d-8b51-3b917ded8de3">131,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI4LTEtMS0xLTg3MjA_eabb2abc-435f-43d7-8a4b-3a7655a4cd30">134,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI4LTMtMS0xLTg3MjA_1ece59cd-a176-4184-9779-17b7eb78a30e">154,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI5LTEtMS0xLTg3MjA_d09b25c0-e68f-4c70-9c0e-6c812768f99c"></ix:nonFraction></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI5LTMtMS0xLTg3MjA_7b5e58e5-c416-4238-875f-4fbd29a4be01"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest and stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8xOA_ca7c9c56-b2dd-4b8c-b5b0-989a03931916"><ix:nonFraction unitRef="usdPerShare" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8xOA_ecd10626-953d-4133-96b0-8882a0cdf158">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8zMg_636963af-c27d-407b-8f69-1ec9b6455200"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8zMg_bb49a493-dd1d-4533-8ece-dc50d023c60c">145,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding  <ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV81NA_3d0f673e-e395-4074-9555-884ed2a3135d"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV81NA_f9378062-6e8f-41ff-89ae-a95e88b5d2d8">105,960</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV82MQ_82f85142-7674-4abf-b8cb-da321c56156c"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV82MQ_a48ece63-8f41-4691-b3ff-7e03163726ec">104,327</ix:nonFraction></ix:nonFraction> shares  </span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTEtMS0xLTg3MjA_3b3ad371-da1a-4547-81bc-583ccb183f8e">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTMtMS0xLTg3MjA_68c0ea58-1509-43a5-8b7e-bc3591861f0a">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMyLTEtMS0xLTg3MjA_3d1163c0-57a0-4399-b31f-7b90ae4ab2cc">1,219,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMyLTMtMS0xLTg3MjA_6d7be6c4-f506-46a6-a432-3eb0a6fa3d91">1,053,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMzLTEtMS0xLTg3MjA_f0ff8676-de97-4a42-a552-0b95272ac2f4">136</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMzLTMtMS0xLTg3MjA_aea5a2e1-9012-4ea0-ab72-e73171b86488">69</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM0LTEtMS0xLTg3MjA_f249c7c4-f12d-4e96-bf61-741b0db2ff1f">820,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM0LTMtMS0xLTg3MjA_832840e6-e9f0-4075-b5e4-f8716b39806a">644,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTEtMS0xLTkxNjc_aa3962f3-231b-4e4e-8e43-56830901143a">398,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTMtMS0xLTkxNjc_6b1b9517-c0c3-40bf-bcb5-ef92a61257f9">408,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTEtMS0xLTkxNzQ_216e695a-6216-4d09-ac3d-809d5051d8bf">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTMtMS0xLTkxNzQ_9ca2cd6a-6ec8-41cf-8575-42bcc95999a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncontrolling interest and stockholders' equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTEtMS0xLTg3MjA_b41391ad-8814-464a-986d-65b82d1a2e29">418,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTMtMS0xLTg3MjA_40d38e68-36fc-42c0-a685-671460bfe642">408,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTEtMS0xLTg3MjA_3bcfae95-a22b-4b34-b188-65a5d6d98ace">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTMtMS0xLTg3MjA_f3a16046-4dbf-4230-a62d-14febacbbad8">710,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItMS0xLTEtODcyMA_a93248f7-b1cf-4281-97eb-67a17b74c910">243,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItMy0xLTEtODcyMA_7aecdc81-7b83-4199-9ebd-73833ce7634a">138,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItNS0xLTEtODcyMA_87dce40e-89fa-4afe-a897-3c79adb37306">87,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtMS0xLTEtODcyMA_17f43c4d-f7b2-4e0d-9ada-e987f2c08120">297,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtMy0xLTEtODcyMA_5ca4b7ef-ffb6-4183-ad1b-eb270ee14347">206,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtNS0xLTEtODcyMA_e8c45d99-8006-43df-b865-28aec6fb785a">128,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtMS0xLTEtODcyMA_14876b95-f2b8-43ea-bebc-a1a21f79026a">124,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtMy0xLTEtODcyMA_f3d46897-3cca-48d7-926a-e2bfe10d5d4d">80,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtNS0xLTEtODcyMA_68ff0f14-edfd-4087-82f5-401583d4f1a3">52,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtMS0xLTEtODcyMA_1fc48167-f0ac-436f-aa27-ed032c1b6112">421,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtMy0xLTEtODcyMA_e325a650-172d-439e-8c5d-53d8462180ad">287,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtNS0xLTEtODcyMA_33935536-9efa-41f2-a91d-0f237820a1e1">181,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctMS0xLTEtODcyMA_986cc7a1-23f5-4e8b-9476-be706e0bab03">178,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctMy0xLTEtODcyMA_7d552c93-25ac-4bcb-ba5e-519979be1fe4">149,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctNS0xLTEtODcyMA_ba489b41-46d1-4072-b919-1e11727c9b9c">93,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktMS0xLTEtODcyMA_4a6d208b-c426-4f52-a5b4-422c014460f7">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktMy0xLTEtODcyMA_2d362d64-85bf-418d-87f2-fecbf37b10df">6,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktNS0xLTEtODcyMA_233e6617-8b91-4369-91bb-a91d2a735c69">9,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTEtMS0xLTg3MjA_65d75c02-cee4-464c-98ef-54dbbfcc7e4c">765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTMtMS0xLTg3MjA_0b698522-f3ab-4171-9d9f-87dc89b93adb">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTUtMS0xLTg3MjA_66c15eb3-9c2c-41d2-b735-3102a9ab1067">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTEtMS0xLTg3MjA_bf8536a7-ddd2-44c5-b5a6-92d6d373fb6a">5,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTMtMS0xLTg3MjA_35493a87-8e86-4b58-9865-3c43b2426e26">8,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTUtMS0xLTg3MjA_3719e178-6461-48a9-ba5c-c3de05179130">8,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTEtMS0xLTg3MjA_6b4f1c1d-9561-4506-8c9d-b50f26ae53b2">172,709</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTMtMS0xLTg3MjA_d3b8109b-5882-4a09-b5cf-bc4bb9bce063">140,846</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTUtMS0xLTg3MjA_54f6d050-7356-48cf-ba37-49965e12c475">84,551</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTEtMS0xLTg3MjA_32b1853f-c684-4267-8767-d148ddee2227">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTMtMS0xLTg3MjA_7a9e7f5a-83e3-447f-8089-e4d05c853b2a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTUtMS0xLTg3MjA_a194c7b5-dcf9-4abc-9c48-6fc4267788b7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss including noncontrolling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTEtMS0xLTg3MjA_32ebca50-f62d-479f-b69f-b24b934bfd9c">176,494</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTMtMS0xLTg3MjA_c6deb9fc-31d8-4fa7-bf2d-a4295dcc0a6d">140,848</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTUtMS0xLTg3MjA_f3b63913-e28d-4472-9848-2a27abfcda16">84,553</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTEtMS0xLTE0Mzg0_d282c3b3-c7df-4846-8ecb-a8c155a73d0c">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTMtMS0xLTE0Mzkz_0918ca25-18e8-436b-97d0-b1e4e1c621e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="INF" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTUtMS0xLTE0NDAz_a2bfae02-87b1-4f5e-949c-a2787cc674f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTEtMS0xLTE0NDEx_0a90c1e1-cccc-4cd0-88b8-e2be4b1196af">176,063</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTMtMS0xLTE0NDEx_70bb1c99-5b20-4da2-adff-fbbc4dcb7964">140,848</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTUtMS0xLTE0NDEx_70c3e7dd-b4ea-47a8-aad6-58dc107609ff">84,553</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share attriutable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTEtMS0xLTg3MjA_1242d106-5015-4728-86c9-86ebda0ac97b">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTMtMS0xLTg3MjA_fa0fea48-2765-40e4-897f-071d44146c57">1.36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTUtMS0xLTg3MjA_d99967e3-de58-4e60-b5d3-357242eb0ad1">0.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTEtMS0xLTg3MjA_7e62ebc5-c699-4452-90a2-6d7e0ca7722b">1.67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTMtMS0xLTg3MjA_c73060eb-a106-4431-9d54-8cca6ef1142e">1.36</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTUtMS0xLTg3MjA_f27c3158-8255-4af6-9908-72148132aaf9">0.84</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTEtMS0xLTg3MjA_72126ed5-2d54-4129-8993-4eed52e82d27">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTMtMS0xLTg3MjA_e0cf526a-2bb6-4bd7-b245-e14c886354ac">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTUtMS0xLTg3MjA_bc094309-6e00-48fe-8789-53f485864034">100,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTEtMS0xLTE0NDQ0_87e633c5-61d0-4fc7-a803-6714c2bfc4f9">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTMtMS0xLTE0NDQ0_cbecd19a-6fb4-413a-a5f7-6bbb02653b74">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTUtMS0xLTE0NDQ0_d2299778-60aa-4e06-8414-824143594a81">100,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTEtMS0xLTg3MjA_aa7e0c4c-fff5-4edc-90f8-8efc79ffe58f">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTMtMS0xLTg3MjA_9e78e4ed-d87e-4b06-9116-7d94228b12d9">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTUtMS0xLTg3MjA_958d098d-a564-4b59-84df-58976cdf411a">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTEtMS0xLTg3MjA_5d0b48cb-b603-49f7-aaca-dac3888d6141">176,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTMtMS0xLTg3MjA_0dba563e-8aaf-49c1-bace-9986ba3c8711">140,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTUtMS0xLTg3MjA_90188d08-3875-4261-a706-ca1f6313d438">84,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMS0xLTEtODcyMA_d8a6ed35-d2eb-4801-b9f6-90470ef56ceb">95,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMy0xLTEtODcyMA_f5d547d7-c3bd-4674-baea-77b0a8bc1cf4">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ada9eeb31fe445ab0ddd2906a6caf3d_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtNS0xLTEtODcyMA_62fe6467-bf65-454e-8c26-fa118ed36215">664,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a9805470dd04665b4e60fa414b2154c_I20190930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtNy0xLTEtODcyMA_df03b362-31b6-48b4-924e-bcead9a3b4e8">392</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74d9b7bcca044446b494a1d25fac4d68_I20190930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtOS0xLTEtODcyMA_855d1c60-c583-4b1a-b60a-93614229d15c">419,291</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b91bb8802b14d459682008730c71bdb_I20190930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMTEtMS0xLTg3MjA_41cc24f1-403b-4782-9120-c8a8dc02cff6">555</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMTMtMS0xLTg3MjA_42857561-4cfd-4cc4-8bd0-19c95544d145">244,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzItNS0xLTEtODcyMA_9bc456e6-84c6-44af-8491-369c35160486">43,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzItMTMtMS0xLTg3MjA_28c33854-5b3f-4210-84b8-efa39ad27ec9">43,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMS0xLTEtODcyMA_9069dc88-fbad-433e-96fe-1cf2ab9dd59c">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMy0xLTEtODcyMA_8d2e6df2-57e7-44e9-8a14-2433c3e710ef">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtNS0xLTEtODcyMA_bf022ddb-7f87-49b8-b235-a79a0762ebc5">7,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMTMtMS0xLTg3MjA_3dcc5d3d-6b5a-45dd-b31a-58e89ce099b2">7,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMS0xLTEtODcyMA_375dd613-ca96-42e4-a4ec-bf21f6d9567b">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMy0xLTEtODcyMA_1e7b3840-683b-41e4-a8d1-2a80c3105fd4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtNS0xLTEtODcyMA_68da341d-5bf8-441b-8615-34a82ec4f7b5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMTMtMS0xLTg3MjA_095d7c44-2c67-440c-aebe-0bb460535872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - issued for cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMS0xLTEtODcyMA_96be866b-1087-4676-a5b9-0f34377c7300">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMy0xLTEtODcyMA_cf005b6c-9709-4243-8002-36d3c76d4ea2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtNS0xLTEtODcyMA_95c790c4-aa03-4959-b1c4-da34b92cacec">250,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMTMtMS0xLTg3MjA_f7f4a0bd-3567-4ecb-93f3-aabf6270b719">250,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc91136601b54b3db1507e8c9cdb15f0_D20191001-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzYtNy0xLTEtODcyMA_41dfd3b7-04d7-40d9-b333-de0f381f1bb0">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzYtMTMtMS0xLTg3MjA_c36f10a1-dfc2-4261-9a3b-1e8f3cc2be12">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deconsolidation of Ablaris Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18f5d11bc984e7794a39d04db8c9fb9_D20191001-20200930" decimals="-3" name="arwr:NoncontrollingInterestIncreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTEtMS0xLTE0NjQ0_2711cb13-a784-4a0a-9120-9c42496ba73f">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="arwr:NoncontrollingInterestIncreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTMtMS0xLTE0NjQ0_88e6c993-74dc-4aa3-ada4-7214e16de017">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161077d110d5481c9db46e19e59e25b2_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctOS0xLTEtODcyMA_befcf672-ee4d-4531-b21f-a487132db6a5">84,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTMtMS0xLTg3MjA_451622a7-e2a9-4310-a0a7-eea96100e6b5">84,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMS0xLTEtODcyMA_8eebb5e3-74bb-4f5e-8ce1-0494e0bea6e3">102,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMy0xLTEtODcyMA_1303a24a-2597-4697-93cb-da8318fc1a81">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581a193e673a43ee927c51ce5fa8bc57_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtNS0xLTEtODcyMA_e7bee41e-188f-439d-8af9-3d613ec41ecd">965,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565f0aec40984903ab31509ccc107152_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtNy0xLTEtODcyMA_ae38d981-4c0c-4b2d-bbdf-9a9686146b3c">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8471847377104689b2acf51a693ccb46_I20200930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtOS0xLTEtODcyMA_625ef8fb-8fee-46c2-9685-546dc2248ba8">503,844</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27eb4fa099754665885890250ac463e9_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMTEtMS0xLTg3MjA_1016d51e-7840-4f02-badc-3078ca589c39">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMTMtMS0xLTg3MjA_67c10dba-b24a-4511-bc88-7d9b507fa096">461,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMS0xLTEtODcyMA_aef61665-19a3-4c26-b531-2e4e532b6cd5">102,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMy0xLTEtODcyMA_76a4eab0-22a9-44f0-9445-5ea4af7a5849">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581a193e673a43ee927c51ce5fa8bc57_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtNS0xLTEtODcyMA_1dde7e39-bf10-4a0c-994f-e73c3109daf7">965,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565f0aec40984903ab31509ccc107152_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtNy0xLTEtODcyMA_9f79ca1b-32ad-44ef-98f9-bf9448567440">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8471847377104689b2acf51a693ccb46_I20200930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtOS0xLTEtODcyMA_373f6d74-d144-48a8-9640-91d09891d54b">503,844</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27eb4fa099754665885890250ac463e9_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMTEtMS0xLTg3MjA_8055194e-48ad-4fe0-b6bc-1459efe250a2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMTMtMS0xLTg3MjA_eef405b6-e97e-4362-a71f-655b959ed23c">461,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzItNS0xLTEtODcyMA_000c40ff-9cce-4c34-bb65-93b434fc150b">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzItMTMtMS0xLTg3MjA_313b4ecf-25c6-4e98-a70e-676636091837">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMS0xLTEtODcyMA_46acdad0-881a-456b-a54d-767dfc501a2b">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMy0xLTEtODcyMA_696bcf7d-7c9f-46ff-9630-47e5a97dbd77">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtNS0xLTEtODcyMA_9ceaabd7-dbb5-4ad6-90a2-808c555d60a1">11,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMTMtMS0xLTg3MjA_45f96000-d463-441f-97c4-e917963e94be">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMS0xLTEtODcyMA_acfcfd44-f74e-430c-90f7-8f3f191ed1fc">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMy0xLTEtODcyMA_2298ac54-0416-432a-8d32-c04af998c9fc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtNS0xLTEtODcyMA_493b121b-a61d-49e3-92f0-1935452b7722">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMTMtMS0xLTg3MjA_498e9022-69a9-465c-a80d-95ce2dca9fda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8b52d362ef24d56892538907287fb19_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzYtNy0xLTEtODcyMA_7be577a1-5914-4456-a0e3-69d71bc53c94">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzYtMTMtMS0xLTg3MjA_26314fd5-8bb5-42c1-81c2-fddd33ea61ea">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7897c16d6d54a919ae876c9750f0852_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzgtOS0xLTEtODcyMA_b000639c-8946-4e21-b291-cf406ea26d43">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzgtMTMtMS0xLTg3MjA_e7ae4bb3-e99f-4ca3-9e81-58e6cd169853">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMS0xLTEtODcyMA_081c8410-e113-4b87-b68c-898f9952287d">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMy0xLTEtODcyMA_8c8efda1-35e2-448a-98cc-36cdac5c8bbb">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1089994c19ef4e178fc178cb7fca23c2_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktNS0xLTEtODcyMA_2f93e0bc-7ccd-4d18-b480-4f11248e272d">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktNy0xLTEtODcyMA_7e3cffcb-08e4-4ffb-ab5c-7180472943b9">69</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76bd52f2644744feb3d658807f3cd6c9_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktOS0xLTEtODcyMA_4928670b-d975-4208-b3b7-fb43c0c86d1b">644,692</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80c3d1b3390496eb0b757a895741ff6_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMTEtMS0xLTg3MjA_19fdd0a2-c11c-4ea3-94e9-1da6e19f27e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMTMtMS0xLTg3MjA_5ef60c7d-66e5-4913-a3c6-b858353c1dbe">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMS0xLTEtODcyMA_14f01243-f1ce-4779-bb9e-e2a303be9b72">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMy0xLTEtODcyMA_d9af9c86-f145-4f9b-a77e-624afd60f9a8">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1089994c19ef4e178fc178cb7fca23c2_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtNS0xLTEtODcyMA_a695e30b-2dcc-476b-b000-f61a28ad7f71">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtNy0xLTEtODcyMA_3c33185b-43ec-4b9d-89bb-d060263c6716">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76bd52f2644744feb3d658807f3cd6c9_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtOS0xLTEtODcyMA_d1bcc8e7-3210-43c0-9055-4ad21ca338f0">644,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80c3d1b3390496eb0b757a895741ff6_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMTEtMS0xLTg3MjA_257c30f5-dd57-4325-b561-8441b4b455b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMTMtMS0xLTkyNjA_c0119674-f815-47d4-855e-c906ec479701">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzItNS0xLTEtODcyMA_352071a8-38c5-45f9-9779-a6b221fdc966">120,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzItMTMtMS0xLTkyNjA_4e945e7a-fcc5-4474-a842-1e38e732a049">120,893</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtMS0xLTEtODcyMA_e3d2ef89-3d0b-439b-a2a1-4a935d1e7305">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtNS0xLTEtODcyMA_5b30573e-f9c6-40ed-8e36-44295d263fb5">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtMTMtMS0xLTkyNjA_b3d98891-c952-411f-aae8-1b0de9e173c2">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMS0xLTEtODcyMA_6937125e-0ede-4069-8d95-b2a1a2018f06">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMy0xLTEtODcyMA_5a8c83ef-047f-4504-96dd-d8d095de6ad4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtNS0xLTEtODcyMA_637ecbab-f70d-4d98-bfc7-61c1d66f2e27">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMTMtMS0xLTkyNjA_e38bf0c7-219b-442e-8e25-761a4c85165e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb486426d4d441729abee7d2481a2a1d_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzUtNy0xLTEtODcyMA_b8c9a313-3725-4090-9cca-6210b039528a">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzUtMTMtMS0xLTkyNjA_5f688856-222d-4316-afe1-835229afe1f7">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtNS0xLTEtMTQ2NjA_68e514a3-81ea-4b73-a751-6ff3f29b574e">39,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTEtMS0xLTE0NjYw_09625d35-30f5-44e9-b350-a557d986c4e0">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTMtMS0xLTE0NjYw_6a89c3d2-9fef-4b86-b6e4-e5d97778c936">60,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca354a33143401aba048d9836285871_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtOS0xLTEtODcyMA_b7875e16-0df3-40c8-b6fc-d20cdc8b9f1f">176,063</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTEtMS0xLTg3MjA_59e4b705-787a-467d-8bd5-aeea2108a303">431</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTMtMS0xLTkyNjA_fd068b87-68d9-4cb4-8b81-633a9863f4e0">176,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i411e86d4599445cd8332b7c1f8beafc9_I20220930" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMS0xLTEtODcyMA_861ee228-4b55-472b-9ddf-1c51c77ffe31">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i411e86d4599445cd8332b7c1f8beafc9_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMy0xLTEtODcyMA_6b9cd3b1-cd51-4b94-a626-743cee3e7988">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff05358bb4d14f5b937c35181dff107d_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctNS0xLTEtODcyMA_ffb85a34-bf4c-4101-adf2-7c14e5c9ea40">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f294cd4e58b4aaba50d623ebeaf06c6_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctNy0xLTEtODcyMA_43ad0a22-7632-42a6-ae82-9474b1f0a876">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabdc3ed836bd43d192665281d701b948_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctOS0xLTEtODcyMA_cd2c71c1-4b7b-4985-9c14-ec30c97858e6">820,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id483571f939d4e63b7389598f61b6608_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMTEtMS0xLTg3MjA_5a30279e-819e-42c0-8952-14e5a35819e7">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMTMtMS0xLTkyNjA_b9c278e9-691d-4366-a3fd-c22d7d1b0ce0">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtMS0xLTEtODcyMA_a78cb239-b173-4814-8cc0-200b2c9df0d6">176,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtMy0xLTEtODcyMA_b2bb941a-5ae6-4939-8d19-78d4bbdc140c">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtNS0xLTEtODcyMA_30084904-747f-4999-bf16-ac7a27f7cc38">84,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtMS0xLTEtODcyMA_2bc31f40-2880-4a46-9d72-93e71d78defc">120,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtMy0xLTEtODcyMA_ae6167d4-199e-4aa5-aa0e-c62a8ae8d129">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtNS0xLTEtODcyMA_13286722-4cc3-46b1-ac7c-8570e029395a">43,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) from investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMS0xLTEtMjMzODQ_e591f5c0-aa7f-47e8-a5ff-bb2d866455f4">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMy0xLTEtMjMzODQ_0a7bafcf-0249-461a-a213-cc57399f01cf">1,708</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtNS0xLTEtMjM1MTM_7cc27d7a-058c-4125-84e5-042997dd5184">20</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtMS0xLTEtODcyMA_1c4ccb8f-7df9-4845-bdb6-5d3cd8ff855c">10,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtMy0xLTEtODcyMA_d3bb6d5d-b400-49ae-9f4b-50c763515c5a">8,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtNS0xLTEtODcyMA_111fce78-b010-4ad7-917b-1fdc7330cb48">5,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of note premiums</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMS0xLTEtODcyMA_348f77c5-bf48-48d8-b62e-747f7efb06ae">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMy0xLTEtODcyMA_6036399b-36a0-4a3a-8476-a506ba9b6b65">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtNS0xLTEtODcyMA_1504e112-4b6b-42bf-991f-63f520527979">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtMS0xLTEtODcyMA_14551058-d312-4e95-b00a-699a8e593124">8,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtMy0xLTEtODcyMA_5ea1fec1-3a7b-4cad-af66-812513ed04b4">9,409</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtNS0xLTEtODcyMA_86441d65-9b04-4adf-992f-d1485430359c">184</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktMS0xLTEtODcyMA_29cac1fc-ef4e-489f-9e8d-26ef3c78b840">19,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktMy0xLTEtODcyMA_11dd3161-73ad-482c-9185-18c22eeb0320">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktNS0xLTEtODcyMA_72f6e1b5-856f-41d2-9bbf-2156d90624cf">387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTEtMS0xLTg3MjA_a371506b-3a00-48dd-84e2-a6d917b55a92">6,589</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTMtMS0xLTg3MjA_63b75c31-e233-4ee7-b55a-db117826bbd9">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTUtMS0xLTg3MjA_50cbef59-9339-4fe6-b5a1-8b127a6138a0">821</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTEtMS0xLTg3MjA_1c133b08-b176-4c45-8929-78545cb73de8">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTMtMS0xLTg3MjA_f0e9edf0-ccd1-46d1-b255-40fab73a4281">9,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTUtMS0xLTg3MjA_9a41ad48-4411-43ae-837b-60137c3fc614">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTEtMS0xLTg3MjA_674e9116-743d-4a2f-ae73-5fea01036a1b">112,501</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTMtMS0xLTg3MjA_f3fc5a9c-c064-4fb0-b53d-cea4729828e3">223,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTUtMS0xLTg3MjA_bf1bdd37-bba5-435d-8178-99b9a15e71f4">63,514</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTEtMS0xLTIzMzU3_05c20811-bd9b-4e69-80cd-0d2de87f3731">13,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTMtMS0xLTIzMzY2_6ba202c9-b653-45d0-81db-9bfb3aae533f">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTUtMS0xLTIzNTIx_de4b6a31-d855-44ee-ba42-72dfe25cbb58">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTEtMS0xLTg3MjA_5dbc8c0c-86ae-4be4-95b2-727a1487519a">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTMtMS0xLTg3MjA_bae00372-5ba7-487e-a043-ab75573d479c">169</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTUtMS0xLTg3MjA_c1fdc905-0980-4603-8c01-673c11d4acf1">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTEtMS0xLTg3MjA_ed0b3e53-cf6d-4351-aa3a-f5493d0b091c">136,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTMtMS0xLTg3MjA_d5322922-ea57-41d5-952e-afa3325a18be">171,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTUtMS0xLTg3MjA_c3d28064-982a-44b1-ad9e-8d8b1451af37">95,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTEtMS0xLTg3MjA_d2dd672e-a41c-4313-9d19-f89ae39cf4c9">52,777</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTMtMS0xLTg3MjA_2a8f26a2-2ceb-4dce-a9b4-76feeb714af1">23,567</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTUtMS0xLTg3MjA_8bd19033-e456-4217-bd08-cf13dd12aba6">11,952</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTEtMS0xLTg3MjA_8881e3bd-fe2b-4237-8252-19ed31d74971">223,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTMtMS0xLTg3MjA_33b3967d-710d-4ce2-9013-6dee9b647eb0">240,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTUtMS0xLTg3MjA_d40d2839-4e63-497d-89a8-1e0ba9a6caad">278,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTEtMS0xLTg3MjA_0a67ca1d-0c34-4733-bc92-68e5d540ab8d">270,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTMtMS0xLTg3MjA_34ea4881-14f2-49d3-aaaa-412da9d7375b">122,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTUtMS0xLTg3MjA_1ef78c8b-32e0-41cb-ba0c-c4dec42a39b0">50,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTEtMS0xLTg3MjA_35cf3d60-2d87-4cca-bdbd-77bce1770814">5,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTMtMS0xLTg3MjA_1b95a538-5f45-4bef-ae72-1d2ede626809">141,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTUtMS0xLTg3MjA_eeb4c316-9e03-41a8-a189-c5d8993e7094">240,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTEtMS0xLTg3MjA_453054f2-13b4-466f-9815-882d8deaf72b">5,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTMtMS0xLTg3MjA_61b4207c-f534-4d6a-9278-130ccfcca89c">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTUtMS0xLTg3MjA_c57bddbb-4f2e-44b3-a6f8-7fbba52cd0f0">7,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTEtMS0xLTg3MjA_3a506ea0-6b38-420d-b4e9-31a0684b5b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTMtMS0xLTg3MjA_21f9f42f-49fb-4738-99e2-58d5017be4ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTUtMS0xLTg3MjA_cfad3061-1e49-4fa5-9c27-215a0ae35793">250,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from investment in joint venture</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTEtMS0xLTE5NDIz_6066a79f-ee0b-4957-8954-e5aa720e281c">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTMtMS0xLTE5NDIz_8120e0f0-0c49-4385-96c0-ffaf43cbecf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTUtMS0xLTE5NDIz_8e98e9a2-cbaf-4fb6-b8b9-d7f938560ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTEtMS0xLTg3MjA_c91c2e4f-63d0-41e8-94d5-473242228509">65,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTMtMS0xLTg3MjA_6fb9bca3-e5be-42f5-af8a-f9a86e664186">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTUtMS0xLTg3MjA_2d5720cd-0244-440c-8cd9-dbc839cf6f77">257,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTEtMS0xLTg3MjA_472994a9-b5f9-4246-b0c5-3b4f931967b6">76,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTMtMS0xLTg3MjA_d3668952-275e-4453-a95a-14a07f18a7a1">40,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTUtMS0xLTg3MjA_ba1c7bdc-b587-4db6-a724-8721fe4d3e34">78,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMyLTEtMS0xLTIzNDE5_4f0bc459-02e3-4695-aa0f-784bb7ab73f2">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMzLTMtMS0xLTIzNDY5_799b32c6-fbbe-4c26-8ccd-1fe5dfeecc9d">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="INF" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMzLTUtMS0xLTIzNDk5_28ce1a3a-63fa-496a-95c6-e4e50f13ee7c">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTEtMS0xLTg3MjA_1ac30d81-99a7-44f0-b9a6-698ab2d66a81">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTMtMS0xLTg3MjA_bd3fbb47-77c9-4b7b-90c2-10dde8cda09e">143,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTUtMS0xLTg3MjA_d330dac0-dc3d-42f8-bdf9-671c4a1b25d2">221,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS AT END OF PERIOD</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTEtMS0xLTg3MjA_a974ba34-54bd-47ac-8127-0ce76d31dacb">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTMtMS0xLTg3MjA_6f0f072f-4c54-47d1-b001-1cbd54229937">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTUtMS0xLTg3MjA_ffdac880-3ef1-46bf-ad7f-17e89179ff3c">143,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplementary disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTEtMS0xLTg3MjA_803ebf05-0de5-4887-816e-e09f9b2d0fef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTMtMS0xLTg3MjA_364f6bf5-2c44-4e68-a00b-af8ec95bcc71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTUtMS0xLTg3MjA_f8f1a601-44d2-4328-a4e3-5bb93eb61316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Taxes (Paid) Refunded</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTEtMS0xLTg3MjA_44765a72-3de3-447e-878a-fda55c2440c5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTMtMS0xLTg3MjA_16a0324f-176d-4aa9-8528-4899ededef67">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTUtMS0xLTg3MjA_b908fb4e-2061-4b6e-8fb9-2b08e517fec9">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="if17c086bfc1e494d91287b00809be3a1_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzQ5MjMwMTM_8dca75cb-a2b2-4257-89e1-be9240284395" continuedAt="id99458628747438c9424bbf13255a5fa" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="id99458628747438c9424bbf13255a5fa" continuedAt="ifc32b97f4aff43d794d3f15377e74f13"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3MjA_f2f14d0c-03ed-4cc1-963d-7a9ef5747855" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-AAT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-XDH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity that the Company is the primary beneficiary in). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ifc32b97f4aff43d794d3f15377e74f13" continuedAt="ie1a88c3fdf9e4188b191d2269e7f25f5"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzg5OTU_da5a61c9-f0a1-4d9e-a973-73dab68f5a0e">108.0</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkwMzg_d3217e24-d110-4cb3-9489-598ad6b83ce2">7.3</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkwNjI_2d96b703-933c-4836-8ca3-8c29a6bc3d70">268.4</ix:nonFraction> million in short-term investments and $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkxMjg_52155fad-c976-4bd2-bf1c-6b9b77df8dc9">105.9</ix:nonFraction> million in long-term investments to fund operations. During the year ended September&#160;30, 2022, the Company&#8217;s cash and cash equivalents and investments balance decreased by $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkyNTg_c5e6aa71-5740-496b-8e11-c8860964ea27">131.1</ix:nonFraction> million which was primarily cash being used to fund the Company&#8217;s operations, offset by the $<ix:nonFraction unitRef="usd" contextRef="i38c33bdda82049d3a3cdcf2e2b470a41_D20211001-20220930" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwMTc_66de96c9-f26d-4250-a437-10f6b2248116">120.0</ix:nonFraction>&#160;million upfront payment received from Glaxosmithkline Intellectual Property Limited (Note 2) and $<ix:nonFraction unitRef="usd" contextRef="i6be7d6ac7c6843cfa78f8297acbba259_D20211001-20220930" decimals="-6" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwMzE_c5ca9502-244a-47f2-9ae6-426ebeff5757">60.0</ix:nonFraction>&#160;million cash infusion from the formation of Visirna (Note 2).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="id5eb370c7c5f408f97b13ca719ad8160_I20220930" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwNDQ_9b4f2775-a7f7-47fb-90c8-5257d1cfb46b">4.9</ix:nonFraction>&#160;billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ5_a543a91d-5566-4609-a1ed-bfd80e599864" continuedAt="i84145dbe151b4d7d9679a12aad523730" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84145dbe151b4d7d9679a12aad523730">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NzI_81e68c2d-aecc-487e-b69e-1dedf5492164" continuedAt="ida5c9ded476b407cb712364858ae0b3b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida5c9ded476b407cb712364858ae0b3b">At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company has determined that Visirna, in which the Company is the primary beneficiary, meets the definition of a business. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODYw_9cdf5492-c3a1-4f4d-9572-cecbedd751df" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments with short-term are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzIxOTkwMjMyOTU2OTU_d3217e24-d110-4cb3-9489-598ad6b83ce2">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzIxOTkwMjMyOTU3MDM_8263c41f-8380-418f-b8bf-bfa9c3669abe">2.4</ix:nonFraction> million restricted cash at September&#160;30, 2022 and September&#160;30, 2021, respectively, that are primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. The increase in 2022 was mainly due to the Company&#8217;s expansion plan in Verona, Wisconsin and San Diego, California.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU3_a1940df1-a647-49ed-95de-151d70b9f99a" continuedAt="i057e9e6ac7e9472984961a9541e9516d" escape="true">Concentration of Credit Risk</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ie1a88c3fdf9e4188b191d2269e7f25f5" continuedAt="i285b5decc6f84ab3be273cd31f684753"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i057e9e6ac7e9472984961a9541e9516d">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents and investments. As of September 30, 2022 and 2021, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $<ix:nonFraction unitRef="usd" contextRef="i65482bab6bd34d03bbd7d32bad1c394b_I20220930" decimals="INF" name="us-gaap:CashFDICInsuredAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzExMjQx_7a4b07a3-a724-45fe-b0f1-3fee66a3cbd7">250,000</ix:nonFraction> per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUz_7c77bf7e-0099-4dfe-9e43-9653d20d1c9e" continuedAt="iff91a6070ee1441f8d882c41859564e5" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all marketable debt securities for $<ix:nonFraction unitRef="usd" contextRef="ia46257ffa533499ababde9281223cdfe_D20220401-20220430" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzQ5NDAyODA_c4f0a2a9-0bdf-487d-a1ec-ce75db25b571">122.3</ix:nonFraction>&#160;million. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff91a6070ee1441f8d882c41859564e5">The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-then-temporary impairments of its investment for the years ended September 30, 2022, 2021, and 2020.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ0_0d56834f-1a09-4366-87d9-1cbd9ffbc0b6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4">three</span> to <ix:nonNumeric contextRef="i56df8fd74028436c99ef6ff3b54f10dc_D20211001-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjM1_65ec1bf9-95db-4480-8e3e-452f51e53ed3">seven years</ix:nonNumeric>. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during 2022, 2021, and 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU4_6b8728cf-e9d5-4fd9-b825-5c1fba14cbfc" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September 30, 2022 and 2021, intangible impairment assessments indicated that there was <ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NjE_9825197a-c701-4ca4-b710-48f9e4118731"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NjE_d637f8d7-31af-4484-868c-1ba2835a89e6">no</ix:nonFraction></ix:nonFraction> impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NzE_42ea4cf8-ea50-4953-b8a4-00fe4303af00" continuedAt="iae95059cd8fa4187b7e028219514d9ac" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i285b5decc6f84ab3be273cd31f684753" continuedAt="ib7544674b72748a692f3532c704b4867"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iae95059cd8fa4187b7e028219514d9ac" continuedAt="id68ea285fbac4d289180c8130b7e1289">recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. </ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id68ea285fbac4d289180c8130b7e1289">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="arwr:ContingentConsiderationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU0_afbc55f5-af6f-4f24-b2f2-7d248c605872" continuedAt="ic8d98e098b10461eb52d527092744b9d" escape="true">Contingent Consideration</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8d98e098b10461eb52d527092744b9d">The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE2OTg4_5eda82fe-0d96-497a-a8a8-32880a74bf8e"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE2OTg4_b2f0c1af-d86f-43d6-8be0-bf45f996dfb0">0</ix:nonFraction></ix:nonFraction> at September&#160;30, 2022 and 2021.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU5_c4687a50-9607-468b-b052-8c2624ead6ba" continuedAt="id71b8b36f963492781d9a3d5868fd7f8" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2018, the Company adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its ongoing licensing and collaboration agreements. See Note 2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ib7544674b72748a692f3532c704b4867" continuedAt="i87ac709b7f794e208fb9770ddf79ffb2"><ix:continuation id="id71b8b36f963492781d9a3d5868fd7f8"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div></ix:continuation><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ1_367aa5ca-3539-44f2-9735-6fb8f7e82535" continuedAt="i43b55c07da974a97a2a573ca0880c838" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i87ac709b7f794e208fb9770ddf79ffb2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i43b55c07da974a97a2a573ca0880c838">the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ2_cf3ca8c2-7dbb-4efd-a4f6-3e4ff9262e7a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUw_aa366b1c-6e93-4703-bef6-b112dcc87529" continuedAt="i31fdeb66284d415da4f36839897197ef" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i31fdeb66284d415da4f36839897197ef">During the years ended September&#160;30, 2022, 2021 and 2020, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ3_923b5d1d-6d7b-4018-b24d-a4244a853d74" continuedAt="iad1ddf7e3e4643e3b8797cb8ed75a575" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad1ddf7e3e4643e3b8797cb8ed75a575">Share-based compensation expenses for all grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</ix:continuation> </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ4_efa74e9b-6aaa-4051-bfb8-1416ef6a4be2" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUy_eb4bde2a-fb08-42df-aa4b-b075d8f65af9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update 2019-12, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ncome Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for change in tax laws or rates. The Company adopted the new standard which became effective for fiscal years and interim periods within those years that begin after December 15, 2020. The adoption of the new standard did not have any material impact on the Company&#8217;s Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_145"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzE0MzMy_bc0bbfdf-7c58-4c27-bdd7-407fb8de1a7d" continuedAt="ia72108ae054e4549aa07a459b6beea2f" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ia72108ae054e4549aa07a459b6beea2f" continuedAt="i6dd9b6a3a7c6425f9e1676e2a9d74671">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i6dd9b6a3a7c6425f9e1676e2a9d74671" continuedAt="i95beeef94d5a49909d9f7df95bece710"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i239542cd95804d368929cbe8296c90bf_I20211122" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1NjY_c24beca8-f1cb-4d6d-89fb-45a990df65f5">120.0</ix:nonFraction> million and is eligible for additional payments of $<ix:nonFraction unitRef="usd" contextRef="i239542cd95804d368929cbe8296c90bf_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableAtStartOfPhaseTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1OTU_9fe64b6c-fc95-4491-bd86-7854cbb661fb">30.0</ix:nonFraction> million at the start of Phase 2 and $<ix:nonFraction unitRef="usd" contextRef="i239542cd95804d368929cbe8296c90bf_I20211122" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1ODE_34f7a129-d89c-4101-b351-0b7373bf5500">100.0</ix:nonFraction> million upon achieving  a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial readout positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="ia4b56dc494ac43218654da036bf8f658_I20211122" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg2MTA_9821f96b-7d42-40d5-ad89-55c1f4dd63a6">190.0</ix:nonFraction> million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="ia4b56dc494ac43218654da036bf8f658_I20211122" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg2MjU_b69e3203-fd99-4d89-837b-84b63e1e6bf3">590.0</ix:nonFraction> million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study, (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2MjQ_8c8b8a53-3ae3-4c92-a931-c05ce961639d">120.0</ix:nonFraction>&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NTQ_8c8b8a53-3ae3-4c92-a931-c05ce961639d">120.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122" decimals="INF" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2Nzk_8c8b8a53-3ae3-4c92-a931-c05ce961639d">120.0</ix:nonFraction>&#160;million was fully recognized as of September&#160;30, 2022. There were $<ix:nonFraction unitRef="usd" contextRef="i2326885925904bb9bbf356f129cc9a0b_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NTc_55427bb7-389f-4e38-b248-98f8d2b76d29">0</ix:nonFraction> in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i2326885925904bb9bbf356f129cc9a0b_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NjE_9b9c489b-f1bb-4e41-8068-88c17cace649">0</ix:nonFraction> in contract liabilities recorded as deferred revenue as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has also performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7692cd01c9aa41649a62cbfade2efe6f_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMDg_028b4b21-0712-4b3c-b0ff-d3ba085c6bed">4.8</ix:nonFraction>&#160;million in connection with these efforts for the year ended September&#160;30, 2022. There were $<ix:nonFraction unitRef="usd" contextRef="i9e25f65ec4394c019914b93112fd60a8_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5OTA_6f662bec-e8c0-4524-b798-004c4052ba01">4.8</ix:nonFraction>&#160;million of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i9e25f65ec4394c019914b93112fd60a8_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMDQ_6948b759-9819-4365-941d-1ed55f40932c">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue as of September 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of ARO-XDH, and Horizon is now wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5afacc79e97d47baba530c5a7adb3b40_I20210731" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTA5NzY_c12883eb-7546-4827-9761-fb082ce101aa">40.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id0ca7c57f3904478a1cd7317601e0d4e_I20210618" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTA5OTE_67077e2d-1c04-447b-b09c-879d3acf3b06">660.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTE4ODY_4561850a-dc9b-45e8-82ef-83bd88ebf0c2">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTE5MTc_cd557f98-c4ce-4ae7-8958-b722aec98e21">one</ix:nonFraction> performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTIxODg_911a2c66-f470-44b3-b12a-9bf6435d7d9a">40.0</ix:nonFraction> million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $<ix:nonFraction unitRef="usd" contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4ODg_911a2c66-f470-44b3-b12a-9bf6435d7d9a">40.0</ix:nonFraction> million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4OTA_50092fe9-9883-46dd-b157-8f22b1e2f5c1">one</ix:nonFraction> distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i3dd0a2669a28454588c20d1c395a052a_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4OTk_9e43d2b4-47ef-43cb-a9fb-ea93c0a40b9b">26.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic3bde044abb649a48ecd1191afb3f05d_D20201001-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5MTQ_51f50bd1-ae93-4ecb-b3c8-653b634e4ee5">6.7</ix:nonFraction>&#160;million, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5Mjg_3d6de71b-ce1c-462f-a073-a4fc12feb84e">0</ix:nonFraction> in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NDA_79c3e286-6eac-42e8-a119-2e06d27c35dd">6.7</ix:nonFraction>&#160;million in contract liabilities recorded as deferred revenue as of September 30, 2022. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i95beeef94d5a49909d9f7df95bece710" continuedAt="id1be1934f7944de4a0ab7c36ca78d400"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i0019512decda4b7990aafbc1a7e248d0_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NTQ_48eaccf5-9ffa-4f6a-844b-2c422403ea1d">2.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0949381581ff4af3b82881ca7e331bf6_D20201001-20210930" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5Njg_e20c668d-9766-4bc5-b65f-fd12f710b33f">0</ix:nonFraction> in connection with these efforts for the years ended September&#160;30, 2022 and 2021, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i0c37b9188bae4800a6595d3418a0fae6_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NzI_6df57a52-0030-4416-9788-5585149d2811">1.3</ix:nonFraction>&#160;million of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i0c37b9188bae4800a6595d3418a0fae6_I20220930" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5ODY_a5d635bf-3c70-439d-b5d9-c1d0255855e3">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue as of September 30, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i17e4962b3a1642f3aa8710b99691c60d_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4NjA_793ddf47-0212-4790-9bee-964207a15d03">20</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2fe6b533bcf74101bd5976bd6846dd09_D20201007-20201007" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4NjY_7a427e9f-f071-4cd2-a877-47ab46f39015">25</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8ef38d1d9fc4434fadb646e8a3dfeb79_I20210131" decimals="-5" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4OTg_91c4f052-dc4e-4152-8cd5-3353439a8a9a">300.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i871d9ae6597e4d0d95bc94bb785a706d_I20210131" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2ODI_33263781-ff11-4e26-b8d8-ba9d6d928e72">595.0</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MTU_d5296387-20c9-4bde-8ab6-b8c7c5de794a">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MjM_2d321ee0-1c60-40f7-abad-89bae5b996d3">one</ix:nonFraction> performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2OTg_11fd96a7-f418-473a-a8c6-3af8d081a8c9">300.0</ix:nonFraction>&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3Mjg_11fd96a7-f418-473a-a8c6-3af8d081a8c9">300.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i86729ae38276427b8f27b306b25909e2_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3MzE_b3e373e7-deb4-49c9-a3fc-be7ddd5c9bd4">85.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie544bcf5262b43bc9e9b768016c61906_D20201001-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NDY_6bf72373-6908-46b3-9eb8-e3223b3d662b">90.8</ix:nonFraction>&#160;million in connection with these efforts for the years ended September 30, 2022 and 2021, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i05164f990274472cb23e6e2da5920f02_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NjE_c23ba1f7-7591-4743-ad35-cb75e984fbe6">0</ix:nonFraction> of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="id93baee844644d37b56a5574a3dfc2c8_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NzM_4e75a90f-f754-4ad8-a919-37ccb1f84692">123.4</ix:nonFraction> million of contract liabilities recorded as deferred revenue, of which $<ix:nonFraction unitRef="usd" contextRef="id93baee844644d37b56a5574a3dfc2c8_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3ODE_bc095c67-99a3-447b-a8a7-799cf8937293">67.4</ix:nonFraction>&#160;million was classified as current deferred revenue, as of September&#160;30, 2022. The Company also recorded $<ix:nonFraction unitRef="usd" contextRef="i6f1d06f484244cafbb6712b67dd5e5c7_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3OTY_5b93eaf8-9848-4158-8a4a-634d93571bf1">8.6</ix:nonFraction>&#160;million as accrued expenses that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson's venture capital arm (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application (&#8220;IND&#8221;) or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="usd" contextRef="ibb795196cbc24edfafc6f4b579915985_D20181003-20181003" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTY0OTI_6c5f6515-bf54-4af7-a4cf-4000166a5dde">175.0</ix:nonFraction> million as an </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="id1be1934f7944de4a0ab7c36ca78d400" continuedAt="ie8d2cd11e3c54db89a419b9a4394eca3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment, $<ix:nonFraction unitRef="usd" contextRef="ic0868f45959c4a9083e418da9c188745_D20181003-20181003" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTY1MDg_da92400b-86ed-48d2-ad17-a54dd3c9f638">75.0</ix:nonFraction> million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="usd" contextRef="i37b7661cd1834368bdbc8265bf19edd4_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MzI_46cc016b-5f66-48ba-ae83-f328aed98fa8">73.0</ix:nonFraction>&#160;million, and the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="i5e3ffe024b534c88b962b31bde7d7c6a_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4NDc_0eebb63a-8103-4273-a5d8-76dcae7fab59">1.6</ix:nonFraction>&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="usd" contextRef="idc323ba26f8a48859fcb26ec988dac7d_I20181003" decimals="INF" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4NjE_375daae3-4e2e-481a-9353-6ff4e28a531c">0.6</ix:nonFraction>&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of Janssen License Agreement and Janssen Collaboration Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="iccd2623ae6e34732b7abc8fb92562252_D20181003-20181003" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTYxOTk_46530fa8-5702-4766-b7e8-67eec7a87cba">one</ix:nonFraction> distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTcyMDI_c5eeace3-fb4d-4c45-855d-4be79d998734">252.7</ix:nonFraction> million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="usd" contextRef="if21f342da4904bf7a53c62826f1b14b5_I20181003" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTczMTQ_8f382736-021b-4bf2-a9c1-cd7331b5cb20">25.0</ix:nonFraction> million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTc0ODI_5da08bb5-e002-4bd3-b22f-16a3fd8686d2">252.7</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were <ix:nonFraction unitRef="usd" contextRef="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMjE_159dbbcc-f78f-4310-bf29-f19262ab3e43"><ix:nonFraction unitRef="usd" contextRef="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMjE_8960cfe2-9fcb-416d-a596-52416eaa5512">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $<ix:nonFraction unitRef="usd" contextRef="ia5534ed7a218413bac198deed25bcfc0_I20210531" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzY2MTI3_6a4ac7ea-2069-404c-98e2-b8901bdb3ace">10.0</ix:nonFraction>&#160;million milestone payment to the Company. This $<ix:nonFraction unitRef="usd" contextRef="i04804bc83aae49eeb388934d6474807c_I20210930" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzY2MTIz_47e84311-3ec2-4be4-8117-58db97e7b6c2">10.0</ix:nonFraction>&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="iadad9a7e9ae24932ba60d057d20788cd_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMzA_3c14f648-2a38-48ba-a9f3-49bb83b8a09c">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i36ca4cce11534def83440361284f2151_D20201001-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNDQ_b6b6831c-2e3a-4358-921a-a9f39f9fdc28">0.5</ix:nonFraction>&#160;million of revenue associated with these efforts during September&#160;30, 2022 and 2021, respectively. There were $<ix:nonFraction unitRef="usd" contextRef="i5f50957118724116aade42a087a6e5f4_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNTg_742c2f49-c342-421f-919a-abab1b34cc8e">0.1</ix:nonFraction>&#160;million of contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="usd" contextRef="i5f50957118724116aade42a087a6e5f4_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNzI_a76bc793-177a-46ca-ad27-1ee778bf502f">0</ix:nonFraction> of contract liabilities recorded as current deferred revenue as of September&#160;30, 2022.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="id8f6a7cc3aa148ba86425faae6df475a_I20160928" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxMDM_850e597e-47c0-4079-97d3-d4285ab846c9">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMDU_bea83525-c46a-41c6-bf78-0b78a1926299">35.0</ix:nonFraction>&#160;million in upfront payments, $<ix:nonFraction unitRef="usd" contextRef="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMjA_1e25fb81-f745-471a-a642-9c21be6091c1">21.5</ix:nonFraction>&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $<ix:nonFraction unitRef="usd" contextRef="i8fddaa78aa9e4413be71a69a9e690ee6_I20160928" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMzU_82519a32-4baf-4fea-93e7-2aa0a591dc7f">30.0</ix:nonFraction>&#160;million in milestone payments, and may receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i00c0415f2ff94135b02ad71902b05a2b_I20220930" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyNTA_1e26aa0a-c7a3-45ef-a60c-4c8dfb2bdabb">400.0</ix:nonFraction>&#160;million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="ie72f2076c3c244c595b91d7c4fc96de6_I20200731" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxNzM_f715b1a2-99b1-4e55-838d-7262fe2b803d">20.0</ix:nonFraction>&#160;million milestone payment to the Company. There were <ix:nonFraction unitRef="usd" contextRef="idbbbc50aed91458f9e1cd5ca2b297e7f_D20201001-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODc_85651699-4b63-46c9-a82b-340afd728ef4"><ix:nonFraction unitRef="usd" contextRef="ib2396a0b95284dc1b37555872c67d544_D20211001-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODc_8ea67638-16f6-4ecc-a3df-2f8c3fee8402">no</ix:nonFraction></ix:nonFraction> revenue recorded associated with the Company&#8217;s agreement with Amgen for the years ended September 30, 2022 and 2021. There were <ix:nonFraction unitRef="usd" contextRef="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODg_24d7ea4b-3d19-4905-9f38-bf3207ca6890"><ix:nonFraction unitRef="usd" contextRef="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODg_cdfa7461-d31a-4bae-9abc-306b5d974c30">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September 30, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ie8d2cd11e3c54db89a419b9a4394eca3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $<ix:nonFraction unitRef="usd" contextRef="i885b30b505e24a9f94b50732d67bf577_D20220425-20220425" decimals="-5" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyNjY_58d91809-c919-4749-9483-933f1631b325">60.0</ix:nonFraction>&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_151"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI1Ng_1049f01d-6a26-45be-85ce-6eefed95c446" continuedAt="i2c4700051f0d40e0a723be4522957887" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i2c4700051f0d40e0a723be4522957887"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI1Nw_1cf0722c-d15a-4810-84c1-d0a1a719b558" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:FurnitureAndFixturesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzItMS0xLTEtODcyMA_fabc4277-2832-44d6-b4a6-21444d61dd26">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:FurnitureAndFixturesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzItMy0xLTEtODcyMA_99e75460-6a05-47bb-8dba-5a473952cf86">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMS0xLTEtMTE5MzA_df5088df-1825-42fb-8e82-8afe55851d2e">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:Land" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMy0xLTEtMTE5MzI_5ab12957-0beb-41ef-b17a-15d2ab8d7ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzMtMS0xLTEtODcyMA_5721ec5b-224d-47f5-9a7a-6db8bb36ca47">38,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzMtMy0xLTEtODcyMA_5d2f5323-adeb-4c3d-a64c-97b2bd9aa514">27,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMS0xLTEtODcyMA_eb0d097b-cdda-41ea-ba9f-80be114bfc45">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMy0xLTEtODcyMA_890ff271-b40a-4dfe-be1e-030bc6bb1e41">41,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzUtMS0xLTEtODcyMA_5a9d42eb-357e-46bf-b120-3afe000b7d61">56,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:ConstructionInProgressGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzUtMy0xLTEtODcyMA_312e9eff-1ee3-4109-86b4-c8b1f06b8b64">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzYtMS0xLTEtODcyMA_e9a7dac3-6d37-40f2-b637-8ebe441d9d05">141,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzYtMy0xLTEtODcyMA_48504903-7594-4131-8362-a68e474888a0">71,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzctMS0xLTEtODcyMA_040c5674-c93d-4be7-a33c-620fe520f37b">31,554</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzctMy0xLTEtODcyMA_937d52e9-977a-4a79-aa03-b7cf875fd9f5">22,864</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzgtMS0xLTEtODcyMA_fc1d37a0-550e-4a00-88fb-c9de9bd4aac7">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzgtMy0xLTEtODcyMA_66a69ffa-c4b3-464c-9bc8-a2b03e678352">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzIyOQ_3f94b908-8112-40d1-ab27-6af7f4daa3e8">8.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzIzMw_e7e4c56b-9b33-4446-afba-3b017d6e80fc">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI0MA_d682fcf5-031f-42cc-bd0c-9efb585ef8bb">4.2</ix:nonFraction> million respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during 2022 was mainly due to the developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90ZXh0cmVnaW9uOjg2MzBlYjFlOWJlMTQ5ZGQ4MWQ4ZTJiYzcyZDkyMjIyXzEzMTI_a554a1ac-8c5e-4a53-a614-cb6f8a2060bf" continuedAt="ia047fa2cdb374491adf3ef681bb461bf" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="ia047fa2cdb374491adf3ef681bb461bf"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90ZXh0cmVnaW9uOjg2MzBlYjFlOWJlMTQ5ZGQ4MWQ4ZTJiYzcyZDkyMjIyXzEzMTM_05c6192c-12c5-4659-802e-4a1ab6e0d3c6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtMS0xLTEtMTIxMjc_43977965-2b63-404c-8aee-15752569dabd">218,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtMy0xLTEtMTIxMjc_dabc9d77-6b0a-4bbe-ae8f-c5b4d31eeb3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtNS0xLTEtMTIxMjc_70397efb-12ac-416a-8bdc-0551820f385a">3,661</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtNy0xLTEtMTIxMjc_cc4b9a82-ba91-426d-a431-4503dd3b4126">214,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certifiate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtMS0xLTEtMTIxMjc_f0285747-d8b2-4205-8eda-bbb5755dd62d">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtMy0xLTEtMTIxMjc_9de822f4-bf6e-4c16-8d63-a2c9ee7a5d19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtNS0xLTEtMTIxMjc_e7e7a428-3708-4f58-8283-46fc54140ba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtNy0xLTEtMTIxMjc_8c07a0c1-a56e-4afb-8fb1-4b629170dc9b">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctMS0xLTEtMTIxMjc_f49b7bf0-1704-45dd-b767-3caaf84a0fbb">268,391</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctMy0xLTEtMTIxMjc_6b9033f0-6f09-4601-8a5b-42abdd830d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctNS0xLTEtMTIxMjc_a584e4cf-1a6c-4e51-bde3-bbcb519a343b">3,661</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctNy0xLTEtMTIxMjc_179a018c-b3ae-4aeb-9c5d-9336f5f23610">264,730</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTEtMS0xLTEyMTI3_73170470-8641-4af6-9cd6-439b698ddc10">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTMtMS0xLTEyMTI3_2e15d977-211a-48d7-820b-c97a2e1364f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTUtMS0xLTEyMTI3_f57fb093-a780-46fb-855b-c31b802239fd">5,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTctMS0xLTEyMTI3_98cfebaa-bf4e-4fbf-be1d-62009b07ebd8">100,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTEtMS0xLTEyMTI3_b9e3afbb-4df4-4485-9a7d-d42ce2fc58b4">105,872</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTMtMS0xLTEyMTI3_a3cf0f36-dfea-4471-8ddd-251494b9513b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTUtMS0xLTEyMTI3_e2598e2c-10e2-49d3-902f-eb2c099d110b">5,569</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTctMS0xLTEyMTI3_a0b556a7-167f-4ba5-ada0-d42fac41b4f2">100,303</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTEtMS0xLTEyMTI3_b283e30c-af58-4b3d-84c7-c2773a295ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTMtMS0xLTEyMTI3_f0f5423f-3ee3-48c5-8daf-c6f80b9b5339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTUtMS0xLTEyMTI3_0874ffc4-2bd7-462f-a2a8-aaa47e20abd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTctMS0xLTEyMTI3_32ade154-fb79-4b8a-a500-776fdc168cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtMS0xLTEtMTIxNjg_fa06cfa5-7939-4683-ac6a-1293f73af2ec">56,627</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtMy0xLTEtMTIxNjg_96b1f13c-3132-4532-9433-d8e0ae2d8f11">803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtNS0xLTEtMTIxNjg_bb901f27-7a7f-479c-a294-bb14c3623133">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtNy0xLTEtMTIxNjg_17f94eb9-c018-444e-9c82-5ccb606970d5">57,430</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtMS0xLTEtMTIxNjg_694a1296-74b5-4b4b-9d3b-7dfecd92de23">56,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtMy0xLTEtMTIxNjg_2b17eefc-0fca-4ba1-950a-1804309fd009">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtNS0xLTEtMTIxNjg_93c564d8-e1ee-4568-9b3f-43edf0e27c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtNy0xLTEtMTIxNjg_c5ece433-3553-47c8-83f2-db0cb2c8a119">57,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktMS0xLTEtMTIxNjg_6695839a-d106-44b6-92ac-9b7f75a4d297">195,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktMy0xLTEtMTIxNjg_44612bc8-1340-4e51-8efc-51861b09456f">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktNS0xLTEtMTIxNjg_8eb514af-0520-4d49-ac21-aaf7e589ae4c">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktNy0xLTEtMTIxNjg_316f6c62-61dd-4c6a-914b-7a3a15ca2994">196,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certificate of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTEtMS0xLTEyMTY4_1f380e3c-c9ec-49be-9595-64beaf51defa">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTMtMS0xLTEyMTY4_c86c8096-9c59-40d6-9ac8-1a9c073fd248">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTUtMS0xLTEyMTY4_de619fe2-e3f0-4210-bd59-517c34924c58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTctMS0xLTEyMTY4_2b84f27b-ef2d-4ab6-ad16-37052e51ae4d">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTEtMS0xLTEyMTY4_38edee3e-8de6-4ea4-a851-900834f2149e">245,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTMtMS0xLTEyMTY4_c04a0fef-4944-404d-97c4-d6f7c5f2c04f">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTUtMS0xLTEyMTY4_2d0a722e-cc4e-4b60-8fca-6c368a5edc0a">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTctMS0xLTEyMTY4_b483f3e9-3b37-45cf-bf4b-806ede27cde1">246,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTEtMS0xLTEyMTY4_10e176d9-0908-4102-95bb-aac4d8b78c2d">127,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTMtMS0xLTEyMTY4_8b271b70-d3af-4f74-8917-fa656634dfef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTUtMS0xLTEyMTY4_ffe24d12-5fc2-4325-b525-02947adec9bb">753</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTctMS0xLTEyMTY4_9f4b29fb-3d07-4824-88af-23af30efe329">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzkxMQ_2c286b2b-94a5-44f2-bf96-b7fd52a292fd" continuedAt="ie75f2322a98d4b9490636e4a803f9645" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ie75f2322a98d4b9490636e4a803f9645"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzMyOTg1MzQ4ODYzMzk_ade54a8b-f9f9-43a8-adcf-1d9caad86122" continuedAt="ibdaa7ce90f05473cbceb22ac6ef578aa" escape="true">The following table presents the components of intangible asset: </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ibdaa7ce90f05473cbceb22ac6ef578aa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtMS0xLTEtMTMwMDg_d276faf8-47a6-43cc-ba83-87b6128056bc">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtMy0xLTEtMTMwMDg_270e87e7-6999-4d6a-9dd3-5aa4966cb560">11,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtNS0xLTEtMTMwMDg_50120928-10f9-4bdc-85d3-f3968f758d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtNy0xLTEtMTMwMDg_ec4f986d-6ef7-419f-a756-a2ff4898ee3a">9,958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i58d9cb60633a4c7ba224716bf2e67384_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtOS0xLTEtMTMwMDg_0e00b322-62ca-449a-96af-579ce2670bf7">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtMS0xLTEtMTMwMDg_5af63f96-0dd4-4407-988c-29d1bf607629">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtMy0xLTEtMTMwMDg_83da24af-b40f-4d4b-9395-e708b7e810a7">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtNS0xLTEtMTMwMDg_50e4e09e-67d5-41e5-b4ae-d8bf2333f7da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtNy0xLTEtMTMwMDg_da8a1866-81ca-41d4-a824-3c396808e745">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b16903a80c34cbebbaa904142f4545d_D20211001-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtOS0xLTEtMTMwMDg_ebb60600-e9bb-43a4-988b-18c482f1ec71">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtMS0xLTEtMTMwMDg_228865e4-8868-4893-9df7-16beabdc89ea">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtMy0xLTEtMTMwMDg_43677e23-949e-4243-b4a8-a6ba862494ca">12,895</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtNS0xLTEtMTMwMDg_e38cec87-e19f-493a-8ab9-553d54bb87f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtNy0xLTEtMTMwMDg_792020e4-6083-4a60-a57b-434a26d592ce">11,962</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2217a769eda4c6f894237f46441005d_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtMS0xLTEtMTMwMDg_3331e100-ecce-46a8-bf60-632e3f5f0fe0">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2217a769eda4c6f894237f46441005d_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtMy0xLTEtMTMwMDg_dcf1c490-ae0e-4e21-ba8c-9730698df1bf">10,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2217a769eda4c6f894237f46441005d_I20210930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtNS0xLTEtMTMwMDg_0135cb14-4f37-4d72-86ed-e4611d6d2a7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2217a769eda4c6f894237f46441005d_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtNy0xLTEtMTMwMDg_cab6fcd7-4055-47c9-aefe-85b923e58b54">11,511</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b02e88c51804f51b4b08d70e9573b4f_D20201001-20210930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtOS0xLTEtMTMwMDg_638e6f9f-72b3-488a-8b61-0abf0f645c5d">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktMS0xLTEtMTMwMDg_bb8df758-db04-4b7f-8d0d-913e2c54e00c">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktMy0xLTEtMTMwMDg_2d7f73d0-6564-47ef-bc30-5ea7a4afc9a1">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktNS0xLTEtMTMwMDg_f826560d-44d2-438a-99fc-fefa8bc2315e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktNy0xLTEtMTMwMDg_40f46b5e-eec2-4121-b344-86871111cd1f">2,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ba50d541c9b45b1a0b65b7a3bc2d634_D20201001-20210930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktOS0xLTEtMTMwMDg_13d1e8ad-a5dd-4d31-b710-699765c81fe9">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTEtMS0xLTEzMDA4_e5ccf3ea-614f-489c-978f-46bebfddce41">24,857</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTMtMS0xLTEzMDA4_2744f313-4f98-49e7-bdad-5663daa4e58d">11,194</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTUtMS0xLTEzMDA4_b89eb183-ea79-4454-8b33-4d929940d73c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTctMS0xLTEzMDA4_fbc353e9-74cc-43d6-87ed-3b8a6fccc57b">13,663</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_6c9b3826-942e-4750-a5aa-c401dba58847"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_a878774b-b823-49ca-a05b-9244d3484248"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_e06e0753-4f85-4f3a-94aa-6dc6b3d2e9d2">1.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzMyOTg1MzQ4ODYzMzg_e1e46fe4-bc72-4866-882e-6e021adbf807" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzMtMi0xLTEtMTMyMzM_d3f6a374-e1f8-4db4-a23a-499373299022">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzQtMi0xLTEtMTMyMzM_ef737378-112a-47b6-83e8-9cb5e0ad750d">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzUtMi0xLTEtMTMyMzM_09d53972-6fe9-466f-b99b-dec10c7fb45c">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzYtMi0xLTEtMTMyMzM_09898828-10dc-4887-9cb2-51c240b72e54">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzctMi0xLTEtMTMyMzM_790cb2ca-83e3-474c-92b8-3b372287d330">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzgtMi0xLTEtMTMyMzM_89954f59-9f6f-4e78-9754-a88054ee3e00">3,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzktMi0xLTEtMTMyMzM_ab394812-2b98-49af-be26-bf9ca34b2dd5">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEzOTM_21099de8-0946-4e00-81d2-23edf580b58c" continuedAt="ic93d19315ccc4f699131e742ecb99707" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic93d19315ccc4f699131e742ecb99707" continuedAt="iaea83b22931946ecbf3d1ed657fdaf45"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzMyOTg1MzQ4ODU2NjU_9653bb0f-4172-441a-a984-528526491ec5" continuedAt="i6af723eb99444fb9bba64b70b07c47d9" escape="true">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="iaea83b22931946ecbf3d1ed657fdaf45" continuedAt="i2cbf9dd01cb246e5a957e65558e14850"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><ix:continuation id="i6af723eb99444fb9bba64b70b07c47d9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"></td><td style="width:27.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMS0xLTEtMTMyNjQ_8f316c3b-4570-4b2c-96dc-6796afdcb459">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMi0xLTEtMTMyNjQ_c2a6156f-75f1-4ba6-9fe2-7ee214f5867d">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMy0xLTEtMTMyNjQ_78dadb89-f1b8-45d4-8b8f-2ec2742cfcb6">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItNC0xLTEtMTMyNjQ_9ea06d60-46bd-4d32-b776-0b18fdacc6e4">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMS0xLTEtMTMyNjQ_fa12398f-25b8-4a5e-99c8-91ca29d05afb">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMi0xLTEtMTMyNjQ_208afa53-b355-49e8-b248-8428401086ed">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMy0xLTEtMTMyNjQ_5a53ce25-616b-4c4e-983e-9e3d5cc52054">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtNC0xLTEtMTMyNjQ_b962158d-bf3b-4f25-91c2-23647eb3753f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMS0xLTEtMTMyNzI_b3c0507e-fa6d-4db5-abf4-f98cfae9ec40">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMi0xLTEtMTMyNzI_4fb23784-de89-4913-a533-7d265c6c1e4b">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMy0xLTEtMTMyNzI_ff4713b3-4b2d-4eb9-b3a4-c9c3d7790525">104,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctNC0xLTEtMTMyNzI_aa8a3bea-2502-43c7-b042-e50ac92e6782">104,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMS0xLTEtMTMyNzI_9b0d2b79-6fb7-4bd4-9e3f-8c53bcb5a44f">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMi0xLTEtMTMyNzI_f49bbe4a-824c-4211-87de-2e078983fdd5">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMy0xLTEtMTMyNzI_9c275814-fb2d-483e-994f-bb895d3cd077">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtNC0xLTEtMTMyNzI_0d6da3ac-ac94-48c9-9743-265257dd3fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic4b2ef96e1ad4c0f884bfbb000ec421d_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzIxOTkwMjMyNTc4NzQ_be7c5c0d-1e7e-4be0-80af-1bb834d560cc">14,000,392</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i945e065f941c41089f590861be2be53b_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzMwMg_307fbcf5-017f-4aca-ac5d-b1cdef23ded9">15,228,479</ix:nonFraction> shares of common stock at September&#160;30, 2022 and 2021, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2cbf9dd01cb246e5a957e65558e14850">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i7df31e5a41964923a5bf827d1e46ccc8_I20200831" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzc5OA_5ce1f4db-b555-4690-ba32-c6f0add824e2">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="i81ad9b35ad9945e681373c342ced19be_D20200801-20200831" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEwODA_71659253-9a73-4cc5-9072-d06812bd2f68">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="ib800ee136c204f7ca7d6ef70fe9e6bd8_I20220930" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEzNDM_efad2696-2c27-41ef-87e1-82410bc1e20a">no</ix:nonFraction> shares have been issued under the ATM Agreement</ix:continuation>.</span></div><div id="if17c086bfc1e494d91287b00809be3a1_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzE2MTE_8baec2f6-82a3-42dd-aa7c-abb419be8056" continuedAt="i9b7215cdef5548fd8ce56bb3344c4994" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i9b7215cdef5548fd8ce56bb3344c4994" continuedAt="i93db15062fe04ed3a459c29b1390669b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzM5Mg_db6facf2-584c-41af-b9e4-6a90dc8f5bef">no</ix:nonFraction> contingent liabilities recorded as of the year ended September&#160;30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of <ix:nonFraction unitRef="acre" contextRef="i7aec9e8e7c804df6bbe9ef108587e7e9_D20211220-20211220" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MDY_da66640f-8dfd-4c07-82b9-890202084e25">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="i20b2347df25f44adb7fd8c6f8ab94841_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MTA_22f9bda9-c7d3-4500-bd91-aa73f2526616">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="i10f071832c694c79898be3703116f022_I20211220" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MTk_1c57ce23-8173-4f4d-b91e-1467e2680534">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $<ix:nonFraction unitRef="usd" contextRef="i598cccc6787b498eb6eeded5080d12fb_I20211220" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3Mjg_327f3bd8-2d9c-43cd-aade-6bb032a80c88">200.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i98b23103c13b4614a1ee88bf196be447_I20211220" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3NDI_8fe250f1-a357-4bbd-8b9f-8fead7c5dea4">260.0</ix:nonFraction>&#160;million into the build out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $<ix:nonFraction unitRef="usd" contextRef="ib1cbc59142a346ab848b67c243bece56_I20211220" decimals="-5" name="arwr:TaxIncrementFinancingAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4OTIzNDI_30bf06ad-0312-4702-bfbb-4fa8e207a080">16.0</ix:nonFraction>&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also receive up to $<ix:nonFraction unitRef="usd" contextRef="id417cd70ff1e486fa32a39bf2ea4e409_D20211220-20211220" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4OTIzNTU_eb7d2f79-342a-4d51-ad0f-ef628159cfc1">2.5</ix:nonFraction>&#160;million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License Commitments</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i93db15062fe04ed3a459c29b1390669b">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company made milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i24d3f2b9861345109a3431f21d36390e_D20211001-20220930" decimals="INF" name="arwr:MilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjQ0Mzg_67f463b3-86cd-424d-a373-1277fa803e45">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if70fc35468fb4978af2a43b1fceb0798_D20201001-20210930" decimals="-5" name="arwr:MilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjM5Njk_fffce75b-c1b5-48ca-afaf-b26772f3685c">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ieee2e0cf0d164b389f68d128f6660757_D20191001-20200930" decimals="INF" name="arwr:MilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjQ0MzM_0d10e6a3-01a5-4012-a374-21255dd1ba8c">0</ix:nonFraction> for the years ended September&#160;30, 2022, 2021, and 2020, respectively. The Company did not reach any milestones during the years of 2022 and 2020. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><div id="if17c086bfc1e494d91287b00809be3a1_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzQwNjk_2e342d87-7f71-461d-bb5c-01c75563f729" continuedAt="ie6677d7dfe9848619ebfe0dcac6821b8" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ie6677d7dfe9848619ebfe0dcac6821b8" continuedAt="id02011c6a0124d6c87ce450fe8f387ab"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new <ix:nonNumeric contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjI1ODU_d871941c-6e13-4e63-b75c-510124e06d12">15</ix:nonNumeric>-year lease for approximately <ix:nonFraction unitRef="sqft" contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNTk4Mjk_76ee8485-f2c1-4b35-9000-8eb2ef218fbd">144,000</ix:nonFraction> square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#8217;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $<ix:nonFraction unitRef="usd" contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA1MDA_1845d0f6-20bc-462d-98e3-54db6e25c5f7">119.0</ix:nonFraction> million over the initial <ix:nonNumeric contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyMjk_d871941c-6e13-4e63-b75c-510124e06d12">15</ix:nonNumeric>-year term. The Company also estimates payments for operating expenses to be approximately $<ix:nonFraction unitRef="usd" contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" decimals="-5" name="arwr:EstimatedPaymentsForOperatingExpensesYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA2MTQ_4d2da4f5-cf51-419d-bade-ad7abf84c839">3.0</ix:nonFraction> million for the first year of the lease, and these payments will continue throughout the initial <ix:nonNumeric contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyMzU_d871941c-6e13-4e63-b75c-510124e06d12">15</ix:nonNumeric>-year term. The Company expects to pay approximately $<ix:nonFraction unitRef="usd" contextRef="i1ac223b0321a49138fb4f0d6b53af948_D20211119-20211119" decimals="-5" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA3NjI_9b3e4832-6278-4799-9e26-ae04a98b3935">31.0</ix:nonFraction> million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyNDE_d871941c-6e13-4e63-b75c-510124e06d12">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="i7836ff9fc4254208a4ff43eb773872c8_I20211119" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA5ODA_57b4f3dd-8795-4982-87d0-9caca1d76f0c">one</ix:nonFraction> additional <ix:nonNumeric contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyNDQ_97b616f2-8c4a-4ebc-920e-69eb31960ade">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="ic89a1f5369f449baba38fde031911868_I20190930" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQzMDI_72ed345f-38b5-452e-99fb-30d1f0ec8695">one</ix:nonFraction> term of <ix:nonNumeric contextRef="ic89a1f5369f449baba38fde031911868_I20190930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQzMTQ_ef94b330-8314-4a06-abf3-6a1968ce9f73">five years</ix:nonNumeric>. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately <ix:nonFraction unitRef="sqft" contextRef="i31744253af624e368277cea062fec33b_I20190930" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQ1MjI_33ef445b-5a57-49aa-bccd-4868bb5b42bd">24,000</ix:nonFraction> square feet of office with a lease expiration date of April&#160;30, 2027. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleases space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional <ix:nonFraction unitRef="sqft" contextRef="i16e72a6872cc4f52ad4d28a752176455_D20190101-20200531" decimals="INF" name="arwr:AdditionalLandSubjectToLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc2NzE_8eb44de0-2e1c-4c46-bd1c-689ca8462a1b">40,000</ix:nonFraction> square feet and to extend the lease expiration date to September&#160;30, 2031. The lease contains <ix:nonFraction unitRef="option" contextRef="i6d1c2d58f05843da801c500579193e65_I20220930" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc3NTQ_fc2e0d46-f0b8-4378-b0b3-a4a0f222155b">two</ix:nonFraction> options to renew for <ix:nonFraction unitRef="option" contextRef="i6d1c2d58f05843da801c500579193e65_I20220930" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ5MDI2OTg_d121ea82-825f-4d8d-81d1-e988983a8aca">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="i6d1c2d58f05843da801c500579193e65_I20220930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc3OTI_1d5d0f30-ca51-4d7c-8f05-5d001fd327d1">five years</ix:nonNumeric>. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional <ix:nonFraction unitRef="sqft" contextRef="i58f3846145b84a9d86539d94479612f5_D20201101-20201231" decimals="INF" name="arwr:AdditionalLandSubjectToLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc5MTI_4229a157-f2f7-4e9a-ac8a-3b75cb083438">10,743</ix:nonFraction> square feet for the remainder of the term.</span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ5MDIwMTg_fe814052-caa0-4f65-9ae5-e1522712b051" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzQtMy0xLTEtMTc1NTI_5d7dd049-ad55-4efe-acd6-9f74f4af8cd3">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzQtNC0xLTEtMTc1NTI_ebd64a17-6b3a-4c92-b235-dab3de2ab6d9">17,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzYtMy0xLTEtMTc1NDQ_607de04f-7c92-42f4-809d-d8c9a4d87844">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzYtNC0xLTEtMTc1NDQ_2493eb25-e457-44ef-8660-384461ecfbfb">2,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzctMy0xLTEtMTc1NDQ_e668ab53-44b1-4897-80e2-9605d5620db1">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzctNC0xLTEtMTc1NDQ_74a7acd7-4dc5-4a7d-89b1-2633cfeef266">23,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32848b6466e0410c988feb7b33651971_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtMy0xLTEtMTc1ODg_6f005386-f42a-4026-b24b-9a9848be4b7b">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtNC0xLTEtMTc1ODg_a8d82a18-efd6-45b8-b770-46c47e02b6fb">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084e58e42b30496a98760c1737b0a332_D20191001-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtNS0xLTEtMTc1ODg_65c2687a-d89a-4036-b57d-5f5fb9bf4be7">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0350e114f99c470694c8188da7224d5d_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtMy0xLTEtMTc1ODg_e986b531-4c3b-4651-ab2f-8306f51da1ed">1,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtNC0xLTEtMTc1ODg_9b0f335a-d379-4bf8-8443-e2dced322017">1,498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtNS0xLTEtMTc1ODg_e099ad5b-2a28-40f5-9878-8ffcc4364154">1,474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32848b6466e0410c988feb7b33651971_D20211001-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtMy0xLTEtMTc1ODg_f32f7d9b-05e8-4dfe-9d9f-f0169ef8af9d">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtNC0xLTEtMTc1ODg_98cadd86-6aec-438a-adc2-f473123a20b1">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084e58e42b30496a98760c1737b0a332_D20191001-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtNS0xLTEtMTc1ODg_54778e5b-f895-4c03-9d4f-ffc5efe543b4">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0350e114f99c470694c8188da7224d5d_D20211001-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctMy0xLTEtMTc1ODg_2145d025-3ad9-423d-b947-06b11eb5dadd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctNC0xLTEtMTc1ODg_f58d4f5a-b510-43ca-a2d1-ad5859ad52d4">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctNS0xLTEtMTc1ODg_600097e2-02cd-4b0b-9640-7ab2cfa0cf55">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktMy0xLTEtMTc1ODg_d0f5c9be-bf48-4314-b8f9-ca714386f3b9">9,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktNC0xLTEtMTc1ODg_c3e186ad-fb95-497f-a21b-91dfab391996">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktNS0xLTEtMTc1ODg_22998c79-dded-4b51-ad2c-53145fee076a">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzEwOTk1MTE2NDY5MDA_d40ac91d-05b1-4d38-8503-17132c3bfdd1">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzEwOTk1MTE2NDY5MDY_1365ddb0-a7e7-48fe-a307-12f28e336ae0">0</ix:nonFraction> short-term lease cost during the years ended September&#160;30, 2022, and 2021, respectively. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="id02011c6a0124d6c87ce450fe8f387ab"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzQwNzA_9b7b0fd1-e5ea-4d24-8e1b-9d843aaed856" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"><tr><td style="width:1.0%"></td><td style="width:81.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzEtMS0xLTEtODcyMA_7d74cbfd-f7f4-41b2-bede-f9e187445259">5,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzItMS0xLTEtODcyMA_87ca8710-f129-493f-a9f8-1885ba8c8966">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzMtMS0xLTEtODcyMA_d27d50f6-419f-4df1-9570-c0b57fe4c59b">11,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzQtMS0xLTEtODcyMA_bc03067f-ca9b-4114-bc30-ae14d60e2cd2">12,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzUtMS0xLTEtODcyMA_2b3d7bec-6a91-4db9-85d4-6ef8c9a19169">11,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzYtMS0xLTEtODcyMA_b60ae689-adcf-4191-ac37-24f28957aa42">102,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzctMS0xLTEtODcyMA_d320ac83-505e-4394-b7b8-5a9a7666ca1b">151,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzgtMS0xLTEtODcyMA_9345ccbd-8874-4f89-93e1-4c31defb5cab">70,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzktMS0xLTEtODcyMA_fcee779f-398e-465c-99b6-dc1646a4b9f8">81,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"><tr><td style="width:1.0%"></td><td style="width:66.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzQtMi0xLTEtMTc2NTY_7063798a-1d11-4aa3-965d-1254bb6aa683">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzQtMy0xLTEtMTc2NTY_df334cb2-59ec-4ca5-990b-5a1324702259">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzctMi0xLTEtMTc2NjQ_913062df-1199-4787-b1e3-128399b3cbf8">7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzctMy0xLTEtMTc2NjQ_d00cb1bc-d07a-4a07-8298-416ce0ab4ab4">8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzgtMi0xLTEtMTc2NjQ_fd521ac4-74ea-4164-b018-c8fb91c7f3bd">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzgtMy0xLTEtMTc2NjQ_5a459adb-9fcc-4fcc-b33d-845451867299">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div id="if17c086bfc1e494d91287b00809be3a1_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4Mzc_069ce7b6-8d98-4190-950d-c58bdaa7a2b5" continuedAt="i5adde8ccadc94d2ba443b1d8cc4e10a2" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i5adde8ccadc94d2ba443b1d8cc4e10a2" continuedAt="ie5846bf3c8f749ff8182e224ab6044ff"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzE4MA_2ac0bc40-7ab9-4ec6-8354-701aa8ea9e08">175,083</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzE4Nw_54252e7f-19b1-4669-9861-9ecde30d6a7c">4,072,137</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of September&#160;30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="if9641c69b3744bcdaab718353895bff8_I20210318" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNjc1NTE_35588de2-3f9a-4897-812e-cbc55c36e37d">8,000,000</ix:nonFraction> shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzAxNjM_1d4fae93-7e6f-4799-b305-41345a418046">7,190,077</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="ib209a739b3e74cc4867507f26036f5d2_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzAxOTA_cdcba48c-7265-41e7-a742-bc668d08ceff">131,897</ix:nonFraction> shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were <ix:nonFraction unitRef="shares" contextRef="i98c2c43432e94729a89fa4a887a1c799_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzEzNjk_a5ea95eb-892c-4c6d-af7a-501a8bd58c9e">778,425</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="i0a79bc6396d84f5d9ba7d3576acf4bd7_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzE0MDU_04c44359-3d90-44fd-ad2d-08e3fdfc0d9d">838,625</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTA5NTI_c40f42a5-67de-4e1d-ab10-20d089b33396" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzItMS0xLTEtMTU0OTQ_3eb8efd3-c966-4fc5-aff6-5212388c16a7">175,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzItMi0xLTEtMTU0OTg_551d2d3c-4608-4641-9f68-1fabae130b57">2,543,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzMtMy0xLTEtMTU1MzY_2cd9acb7-11fd-4187-806b-e14645a37955">3,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzMtNy0xLTEtMjQ1OTk_7d62e7e7-0edc-493e-94d0-d82c95ef4e59">2,721,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fe2f7bfc0e54741ba6777b6c90e7a87_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMS0xLTEtMTY1MjY_9ae05db4-5d71-463f-a6cd-a69fdccfa734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba56efe3069544b3b006005a13d5a1e0_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMi0xLTEtMTU1Mjc_f78461d8-9ce7-4b55-9469-bd14a8d3b977">3,145,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d9166d3c1ac4c9484561dc49251117d_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMy0xLTEtMTU1NDA_c5b9dc9a-5c46-43b5-b923-8cc59c509606">923,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtNy0xLTEtMjQ2MDc_2d59aace-bc42-4717-85dd-af842bf4af55">4,069,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtMS0xLTEtMTY1MjY_86084ff6-85e9-4cca-aa7b-7d891d4dc573">175,083</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtMy0xLTEtMTY1MjY_080376ee-865a-412e-ac4e-b69b1ac3ba00">5,689,187</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtNS0xLTEtMTY1MjY_0b6056c7-4e14-40bd-b7f3-21a8883cb9db">926,545</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtNy0xLTEtMjQ2MDc_87fdf785-3d5e-4d8e-aa5d-28f0d9a6580d">6,790,815</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ie5846bf3c8f749ff8182e224ab6044ff" continuedAt="iddaaf181bb404faf9c3a9ca4100d2630"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzQ_39f4c49c-af46-4d46-885a-8cf9062ba997" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September 30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzEtMS0xLTEtODcyMA_bb205a66-6edc-4f7c-b9fe-9f7840dbd1df">3,456,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzEtMy0xLTEtODcyMA_bbb20d2f-b430-4fe5-81f7-528bd6b9d4ff">19.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzItMS0xLTEtODcyMA_ec43af9c-e981-4bd4-af94-eb1e7691606c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzItMy0xLTEtODcyMA_755dcf87-8563-472b-940f-981c25823666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzMtMS0xLTEtODcyMA_17719df2-2e0a-4c5a-8882-afdcd78b8bbe">128,635</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzMtMy0xLTEtODcyMA_77b9d53c-4033-40bc-bb4a-e80c8a17d6a4">47.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzQtMS0xLTEtODcyMA_c8fd5ced-bb81-4207-9589-0f2cdd04b2c9">606,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzQtMy0xLTEtODcyMA_c8d565dc-bbde-4712-b465-dbf7a574056d">8.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtMS0xLTEtODcyMA_bba9c2d9-4d45-4ac8-95df-27b765bf26d7">2,721,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtMy0xLTEtODcyMA_83fd37e0-2d88-4955-86a4-9edb8085f0e3">20.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtNS0xLTEtODcyMA_44c41bbc-1ff6-4f13-b32a-d692adfcf32e">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtNy0xLTEtODcyMA_5578cbb4-2de9-4a01-8b64-6ff9c8c26bba">48,114,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtMS0xLTEtODcyMA_879a69bb-9eb3-4f0f-bbca-218e7556a4c6">2,351,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtMy0xLTEtODcyMA_159711cf-4854-4674-b4df-3a99e6290c7f">16.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtNS0xLTEtODcyMA_d441e138-ffe9-438d-942b-9edf95944328">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtNy0xLTEtODcyMA_9f80c787-e8d4-4139-8ae5-8a6e0b58c945">46,889,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#8217;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on September 30, 2022. The total intrinsic value of the options exercised during the years ended September&#160;30, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzODE_737c20fa-7350-425d-aa92-f2885cd6d197">27.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzODY_b067391f-86be-4fdc-b75e-480c5be8ac3a">66.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzOTQ_d324e26b-47c6-4dd6-b6d1-c5105c0aa50f">44.1</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options for the years ended September&#160;30, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MTQ_2e5f6e8f-c511-43e4-b399-c87cdf4185bc">10.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MTg_bdf7bf7c-df27-4e03-8462-baccd3a56cb4">12.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MjU_64e63c5e-d0b0-4540-9c58-82051a47f4b0">9.7</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8f7c3935399043749e14bfd46faba122_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMwNTY_7204d07d-f228-42b6-977f-0d8181a33108">12.0</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMxNTE_d49e77a3-1d96-4130-ab45-c1beacddbbe5">1.5</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzU_f46bad93-01ed-44f2-8985-516207592f9c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItMS0xLTEtODcyMA_d422eb74-0cca-4c48-b0fe-15995318435f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItMy0xLTEtODcyMA_7f22bda0-45ee-43ed-8cdb-7b1dc2b2d878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItNS0xLTEtODcyMA_fbc2dc9e-4720-40c4-b6ff-46a274b499e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmY0MWRmM2FjNDAwOTQ2MWI5MzU4NWI2ZWZjNmRjZTNkXzQ_6edb29c3-ddc7-47a9-88d7-ea10a6ecde34">0.4</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmY0MWRmM2FjNDAwOTQ2MWI5MzU4NWI2ZWZjNmRjZTNkXzk_3126a71d-c38d-4621-88a1-80716fca746f">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjcyMDJkZmYxYTE3ZjQyM2Y5YjA0NmUxNWJkYWZjZGNiXzQ_c67ea011-57ed-491f-b709-9bb20ef0efcc">0.40</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjcyMDJkZmYxYTE3ZjQyM2Y5YjA0NmUxNWJkYWZjZGNiXzk_0ebf9be9-d4b9-46da-ae12-d4acabd83402">1.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmM4ODllNzBmMzkzYTQ1NTliMThhOWE4OTBhMWRhZWVjXzQ_13fb6421-6f36-40fc-92fe-4058e658fd16">86.2</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmM4ODllNzBmMzkzYTQ1NTliMThhOWE4OTBhMWRhZWVjXzk_8ea890d5-52bb-4a4f-b192-15048a8cc7dc">90.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjIxYzQ2ZTQ4MThlYzQ4ZGNiZjI2ZDVlZjNhMWIwYjYwXzMyOTg1MzQ4ODMzNDg_186de4da-14ca-4777-9157-4bb40e73a895">90.0</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjIxYzQ2ZTQ4MThlYzQ4ZGNiZjI2ZDVlZjNhMWIwYjYwXzMyOTg1MzQ4ODMzNTY_b1aaa6c7-fd15-4610-9733-01433b6f21de">92.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzUtMy0xLTEtODcyMA_dd569202-04b1-441f-accb-5b5f864a5698">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzUtNS0xLTEtODcyMA_a9f397e0-6d86-4953-8c20-ebd595abc151">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzYtMy0xLTEtODcyMA_003c9e5c-18a4-4593-a1f1-bb5dc300f278">48.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzYtNS0xLTEtODcyMA_1a8b555a-3b29-4bd0-aae0-a14825fa42de">36.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is <ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQxMTc_3f8b3470-643d-4439-85b8-def8fb975a68">zero</ix:nonFraction> as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="iddaaf181bb404faf9c3a9ca4100d2630" continuedAt="ib5ef5e9a28304ff89cc30c1a5d274e7a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzY_0d42a78f-511d-46f7-8d57-01b8b42c3bb1" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzEtMS0xLTEtODcyMA_7e169931-b383-464d-98e9-112acf0f9a3e">3,831,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzEtMy0xLTEtODcyMA_0ca2560b-51f2-4abc-9d53-ea9351fba254">61.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzItMS0xLTEtODcyMA_a845c679-4186-4ac0-a0d4-00ef973be75b">1,396,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzItMy0xLTEtODcyMA_18cdff8f-6738-4b6b-bee7-31f80d3c2305">57.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzMtMS0xLTEtODcyMA_00d96541-fe0b-42cf-a9a7-820db19a6f08">1,027,088</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzMtMy0xLTEtODcyMA_1be337b9-66be-4476-890a-b6332035a22a">49.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzQtMS0xLTEtODcyMA_6ef74e9a-09d2-434d-8856-19fb675a6070">131,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzQtMy0xLTEtODcyMA_9ad5412f-cc6f-423f-9109-7b64dadc6e35">64.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzUtMS0xLTEtODcyMA_562c822c-d1b5-4e28-86fb-5f9723334f19">4,069,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzUtMy0xLTEtODcyMA_428b5c8e-9dfd-48cd-bf32-54b7d2d6f0e3">62.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of <ix:nonFraction unitRef="shares" contextRef="ia5bb146412894240951a8f5f0074b9e2_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2MTk_8c7b62c5-9cf6-4e2b-826b-18e071f577e5">800,000</ix:nonFraction> shares, equal in value of $<ix:nonFraction unitRef="usd" contextRef="i2132296e191446feb126e32a24da326d_D20220708-20220708" decimals="-5" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTMzMjI_8f23d8c9-8539-4343-b18a-4c9c2fb1e649">38.4</ix:nonFraction>&#160;million, that was 100% market-based awards. The revised awards consist of <ix:nonFraction unitRef="shares" contextRef="ia7836f44fe8142e2a7dc14272ef0dcc0_I20220708" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2Mjg_2b89fd3c-eed2-4554-951e-22052d30dafe">99,521</ix:nonFraction> RSUs and <ix:nonFraction unitRef="shares" contextRef="i74b1850ca53244f88adb790e0b1d0c38_I20220708" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2MzY_052fc47e-9edf-487e-894f-79653260522f">149,282</ix:nonFraction> performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5ef5e9a28304ff89cc30c1a5d274e7a">For the years ended September&#160;30, 2022, 2021 and 2020, the Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NDQ_684a6c58-a779-428b-bb4e-8e919038580d">113.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie8d5f88f4e904ac2940b5051a30bc4b1_D20201001-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NDg_26f6ce38-a18e-4f91-8698-602bf1b09987">64.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3514c3e5478e4ed1a2f4d1a8b0dcda20_D20191001-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NTU_22b5b5d7-d1ad-4fb1-901f-d6ef4ef29df6">33.7</ix:nonFraction> million, respectively, related to shares of RSUs. As of September&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyODA2NDQ_ee8403a5-cb3e-41b3-b5eb-e03b3276838f">140.7</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyODA3OTI_67bbf4bb-9101-411a-b73d-6d6049478047">2.4</ix:nonNumeric> years.</ix:continuation> </span></div><div id="if17c086bfc1e494d91287b00809be3a1_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90ZXh0cmVnaW9uOmQ0MzQyMjYxMjMxZjQ4ZDhhOTU4MDYyYzZkNTcwMzlhXzMyODg_9dc03f0c-0bc9-41f7-877f-dac435f4b11b" continuedAt="i65530fe31e1948dc81b665221598078b" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i65530fe31e1948dc81b665221598078b" continuedAt="i691f3eece27e477d9591de9673db9f23"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i691f3eece27e477d9591de9673db9f23"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the transfer. At September&#160;30, 2022 and 2021, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90ZXh0cmVnaW9uOmQ0MzQyMjYxMjMxZjQ4ZDhhOTU4MDYyYzZkNTcwMzlhXzMyODk_1ae56bb9-6bb3-49f8-a475-274d6e55deb4" continuedAt="i6340befd07ec435791ec89c6ba0804de" escape="true">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="i6340befd07ec435791ec89c6ba0804de"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299f22dc89ed4f02aad79a53bc36af3a_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtMS0xLTEtMTMzNDA_d56d24cb-027b-4ec4-a9de-246f8cf06474">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f3b2544ed2e40fc89cdf37aadc3f4a8_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtMy0xLTEtMTMzNDA_d95c623a-d0e8-4527-a7cf-49c2e9cb30d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f75fded4dc34e48948a02b7e07fd82e_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtNS0xLTEtMTMzNDA_a97b0999-ad4f-4b73-8f2e-6440610d591c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a7da1d717d40f485a1fb19c1bbb868_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtNy0xLTEtMTMzNDA_5ac9c4db-8b84-44cb-b404-9de14ef2459e">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9cfdc688ab47ae95c5b3623b07d4cc_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtMS0xLTEtMTMzNDA_fe86d637-fc97-47a3-9957-2d18bbc224b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib874f688067b4ae3823dfe2d5cc52229_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtMy0xLTEtMTMzNDA_24a9b6de-9ff0-4ccf-ae6f-35e4f30d778c">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9726349ec847475481516736bbee2e12_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtNS0xLTEtMTMzNDA_3b4724c9-f4be-49cb-bcf1-163b2cd74574">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3f870fa9724a6289cd90aaceca2dbe_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtNy0xLTEtMTMzNDA_77de5dc6-8322-477d-83d1-435a7abbe4da">41,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e1acd9eb264a28a7f8a2ce38d04ff9_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtMS0xLTEtMTMzNDA_82844afb-765a-4505-81cc-7070d761df64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0729cf15b424ad69a05e5b53e463218_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtMy0xLTEtMTMzNDA_f0af141e-b9dd-4424-99a8-dddfc5756514">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c41638864d45ff8f4f22cf139c92d0_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtNS0xLTEtMTMzNDA_b4e6a7f5-904a-462e-b3b8-2318b02eff56">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f3184cfed4429d8cbbef7071a35cda_I20220930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtNy0xLTEtMTMzNDA_530579ce-32f8-495a-be55-797b33c5a6de">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09e91a7f81146eb8f534664d90f3ab4_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctMS0xLTEtMTMzNDA_1cb5bd25-09ad-4c34-8a1f-c8efbf08284b">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9a9acd15ab40458715e433c95945ee_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctMy0xLTEtMTMzNDA_23778ad3-bd66-4866-9a14-0b78db764805">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6efcde85aa4cb69f080c834193155d_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctNS0xLTEtMTMzNDA_66ec13b1-513b-4080-881c-d700e126f726">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d30f7a7174940b5bc8c54c3a014461e_I20220930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctNy0xLTEtMTMzNDA_fec1f036-3634-44fe-939d-5d1a4e346b8f">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee4d084af8a45c0bc6632f602ca4885_I20220930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtMS0xLTEtMTMzNDA_2b8984d7-3474-47a3-ac10-130059dcfdc6">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578ce9b283054d468a9fcb74aad58206_I20220930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtMy0xLTEtMTMzNDA_60fac0d4-1a79-42a2-b3fe-70011782eca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4baaa4a1b1440a8316bc6202886db9_I20220930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtNS0xLTEtMTMzNDA_f686a965-192e-49d8-af1b-cfa0205a2450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdfc3811ca444047a8ad3417384b63d7_I20220930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtNy0xLTEtMTMzNDA_2bff73fc-01df-475d-b1d0-28abea16483c">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b153258fbf4c22ab083ac660ddd90f_I20210930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtMS0xLTEtMTMzODM_3d792de9-36e2-4d49-8911-5e3bc24144a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b6aea9f3d64a28b6b8dde5934fa0fd_I20210930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtMy0xLTEtMTMzODM_4a45cfcd-c672-49a7-b52c-cc24d1cebf75">254,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072081357d81444787fc75a77eec30c7_I20210930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtNS0xLTEtMTMzODM_82b6c36d-ed78-430c-abae-8a2b4b46f3dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a57713d420442a29ad35a7c6f6eaecd_I20210930" decimals="INF" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtNy0xLTEtMTMzODM_b3b8b903-3029-4298-8c14-1292ab25dabd">254,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36da89f6527b4ee2b870bccdcf0fa0a6_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctMS0xLTEtMTMzODM_8402bb77-1861-4bea-a381-29264ff8d27a">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d0fd8b1f204829b507748af614940f_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctMy0xLTEtMTMzODM_937a11ac-e4b1-4190-8591-944908a0b9ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i593bbbcd381b438f824786951159d60c_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctNS0xLTEtMTMzODM_1765324a-e593-4bbd-b9b4-da0a4cfb8d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e47d68d528444408ac6eae19b74435a_I20210930" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctNy0xLTEtMTMzODM_b0b79646-b91b-4ee6-9be5-332610a1bbd5">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic420c820ffc14e059589b2f7c7483c62_I20210930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtMS0xLTEtMTMzODM_98fda6d6-3ccd-42cb-a4ff-ee0b6ba52e58">160,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb48d12728f43e8a186351de2899d14_I20210930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtMy0xLTEtMTMzODM_d7db2fb1-c046-472c-a97b-82283073190b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31add50b09e042ad9d4989277f1a52ba_I20210930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtNS0xLTEtMTMzODM_528f1fb2-98de-4607-9dfe-efcfd2f34653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fac4c8066e449919f984f9375260f9c_I20210930" decimals="INF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtNy0xLTEtMTMzODM_ce1cc4ad-350f-498a-9388-83790b4ec4e0">160,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680acdc5a46f4301848a1974ee5d87f6_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktMS0xLTEtMTY0MTg_e971e2fd-3c05-46c8-b100-a9f60044602d">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a9b850b4964639b775e3da5e3929bc_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktMy0xLTEtMTY0MTg_fa40b485-cc1a-4bc6-bd3c-e25d3e62f886">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib584577ec6214ad49aac83e30cb1140e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktNS0xLTEtMTY0MTg_39cc980a-9f47-4f9b-bdfe-b35cf3bffa85">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99f8ae8742d44808ca61f58e0458992_I20210930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktNy0xLTEtMTY0MTg_ef605276-1593-4052-8ce4-918006acc9c8">126,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2022, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.</span></div></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzM2Nzc_3eafdd0e-43cc-42cb-979b-321073dd1a75" continuedAt="id809ddc4bebe4aa78c121723d4f52904" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="id809ddc4bebe4aa78c121723d4f52904" continuedAt="i9eb9c0e792ef44bfa4b84c3ffb7b333e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyODU_b8fb0c2f-e894-4965-bf8a-faeb870b0844" continuedAt="i98a446c4e44c4b6b9d40e79cce3408b5" escape="true">The provision for income taxes consisted of the following components:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><ix:continuation id="i9eb9c0e792ef44bfa4b84c3ffb7b333e" continuedAt="ib50bb4d080e84f06896d6ee86ae3db33"><div style="margin-top:12pt"><ix:continuation id="i98a446c4e44c4b6b9d40e79cce3408b5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzQtMS0xLTEtMTc5MDg_07ef1c8c-36bf-45f7-b509-6ff7f49df8ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzQtMy0xLTEtMTc5MDg_a0d9d461-f6f0-484d-90c6-38e58c08ff40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzUtMS0xLTEtMTc5MDg_ec4dd582-619d-4fc1-9b8b-2f6a5d3f0435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzUtMy0xLTEtMTc5MDg_98764d4d-86ef-4543-8898-8e66381cf3eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzYtMS0xLTEtMTc5MDg_ae710e2a-c367-4ce9-b90e-ff16fa0151f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzYtMy0xLTEtMTc5MDg_160cf226-bd95-461e-98f3-a366730d8298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzgtMS0xLTEtMTc5MDg_98a67c21-9395-4c58-94a3-950e8181df6e">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzgtMy0xLTEtMTc5MDg_7812064a-6005-46ca-b36c-e9d7a3ab3ab7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzktMS0xLTEtMTc5MDg_f94b0880-869b-4a74-90b4-281905106b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzktMy0xLTEtMTc5MDg_50640528-32b9-4da2-9a33-ab7a1771a172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTEtMS0xLTE4NzQy_aec4c3d1-7ed5-4eca-9347-68469a00c49a">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTMtMS0xLTE4NzU0_c3cd6057-4a98-4bb0-968c-1476256a5949">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTEtMS0xLTIyMzEy_768d2250-6661-46b2-9951-3e0df998a960">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTMtMS0xLTIyMzEy_9afe440d-a6a4-48e4-9052-cb1fc6be85dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEzLTEtMS0xLTIyMzEy_7c23ec44-bbf1-4d7f-b449-d61d327b0162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEzLTMtMS0xLTIyMzEy_b55c929f-cf04-4da6-8d76-b36494b0a5cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzE0LTEtMS0xLTIyMzIz_66a7725a-c3f3-4ba3-b0ee-87fa060e5bed">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzE0LTMtMS0xLTIyMzIz_0fea7f93-05d0-4683-8917-b63ce3b9fb6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTEtMS0xLTE4NzQy_e3710ef3-3b46-4d80-a1e5-ca26105f264c">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTMtMS0xLTE4NzU0_7d2d3ba7-79cf-4bd4-abad-de016a40cd95">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTEtMS0xLTE3OTA4_bcd29522-0be2-4a8b-bab0-44b27def30e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTMtMS0xLTE3OTA4_544b2a09-ce2a-458f-9741-d988b0fcdc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzExLTEtMS0xLTE3OTA4_9f72b810-fa80-493d-b603-13ee945f49ac">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzExLTMtMS0xLTE3OTA4_dedf6c7e-7e61-402c-ae54-4e000b3878f7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyODY_3be709d8-00b0-4c34-8d77-126040052eed" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItMS0xLTEtMTc5MDg_122f278a-20e7-420d-961c-1a488049672c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItMy0xLTEtMTc5MDg_de7c37cb-758b-42e6-868d-00d21bb9211d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItNS0xLTEtMTg2NzY_e59c2d9b-adb5-4267-a72d-06c96813f1a0">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtMS0xLTEtMTc5MDg_ac53a138-236e-4a0c-8e09-d20eb0b283ca">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtMy0xLTEtMTc5MDg_1900b26a-2899-4dd6-b4de-6eac7d6946d2">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtNS0xLTEtMTg2NzY_34d59692-7a2b-4937-8624-76421204da53">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" sign="-" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtMS0xLTEtMTc5MDg_de8a405f-6a75-47fc-89b4-5fd4a13d1233">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtMy0xLTEtMTc5MDg_d5dac325-f873-41a5-b5ae-37b8990e1285">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtNS0xLTEtMTg2NzY_47f076b2-f455-4af2-9500-059df97d173f">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtMS0xLTEtMTc5MDg_64f23be3-2536-42e7-a4bf-e8f2eecc5e56">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtMy0xLTEtMTc5MDg_039a6fea-9f22-4b4b-9b08-975299ce578a">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtNS0xLTEtMTg2NzY_d178ff54-1761-4b50-bff9-e75ac301f4d1">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctMS0xLTEtMTc5MDg_9d87a0b5-ac00-467d-a364-3a14fbdca3fb">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctMy0xLTEtMTc5MDg_07073ed9-c9e8-462d-b3ac-d39e66c83c2b">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctNS0xLTEtMTg2NzY_cb1ac397-49a1-4fcd-8db6-d587bc6e56f5">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTEtMS0xLTE3OTA4_d3f3403f-d662-4137-8adb-f811a499db93">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTMtMS0xLTE3OTA4_fb7d418c-e7ac-4905-8305-dc9e029811e1">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTUtMS0xLTE4Njc2_a537cef9-ffef-4348-b903-7078c47c0563">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="ib50bb4d080e84f06896d6ee86ae3db33" continuedAt="i2fff35371b6141c3a5e7f016b49e5df4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzM2Nzg_8a1b8596-bd0a-4d55-9c23-3b91c7a48e04" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzQtMS0xLTEtODcyMA_5022e8d6-9efd-4f6c-b13d-b7f7bb564593">2,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzQtMy0xLTEtODcyMA_fcc90529-d64f-4fb1-9da2-0890bba8f028">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzUtMS0xLTEtODcyMA_57b62b53-472f-46e9-a624-3900cda197d5">41,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzUtMy0xLTEtODcyMA_596268da-f3e6-4413-9591-986615f91ba9">22,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized Research &amp; Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzYtMS0xLTEtODcyMA_ac9e32e8-1e30-4cba-8dcb-dd693f850d55">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzYtMy0xLTEtODcyMA_ee808ee6-7366-4f73-a945-89fd9b7d96f2">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California Alternative Minimum Tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzctMS0xLTEtODcyMA_c0b76f3a-ebc9-46e5-8d7b-50e9fefe2882">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzctMy0xLTEtODcyMA_fce35c24-0ce9-4ff2-9777-12bf7d6e2a13">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzktMS0xLTEtODcyMA_da6c775f-168c-4e6c-bb71-86a8d556c82b">171,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzktMy0xLTEtODcyMA_b8afc7ca-8a56-4c5f-b440-5d7e2b34a245">185,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEwLTEtMS0xLTg3MjA_784ef9f6-e9b4-44c0-a7ec-fabfef2125f2">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEwLTMtMS0xLTg3MjA_b40a59e7-51a7-4288-bf4e-0476a886bcb2">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzExLTEtMS0xLTg3MjA_0c176101-7fcb-439d-964f-7338e2557aca">38,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzExLTMtMS0xLTg3MjA_d159003b-275b-41ee-9dce-196b221e80b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of Use Assets/Lease Liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEyLTEtMS0xLTg3MjA_ca777e0e-570c-4d8d-9dc4-b02d0dc0c31c">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEyLTMtMS0xLTg3MjA_9bd2fbd8-1582-49af-b150-6c817cb2e505">1,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEzLTEtMS0xLTg3MjA_e70ec1e2-4c92-4538-835e-9b3ba2a3b047">1,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEzLTMtMS0xLTg3MjA_565d70b8-4b6e-4909-9731-df360b463054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE0LTEtMS0xLTg3MjA_6c5cbb4d-a2db-44ac-ab2d-622e831afd5d">262,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE0LTMtMS0xLTg3MjA_91617777-18cd-4287-bfd3-9006da06f0b8">216,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE1LTEtMS0xLTg3MjA_7e803097-274f-484f-903f-831ca5b07cd3">242,394</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE1LTMtMS0xLTg3MjA_4f44fe92-903d-4fde-b91f-5c9d0e80d27a">194,255</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE3LTEtMS0xLTg3MjA_3ab95cfd-e09a-4ee9-96bc-d8f35073f367">1,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE3LTMtMS0xLTg3MjA_c0d23ae4-95f8-4eac-83a0-16f774bbd712">6,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="arwr:DeferredTaxLiabilitiesStateTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE4LTEtMS0xLTg3MjA_6b7a34d8-e922-48d3-bea0-a90fff9094cb">19,390</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="arwr:DeferredTaxLiabilitiesStateTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE4LTMtMS0xLTg3MjA_0779edd9-11ee-4218-b444-4b4ef97f6beb">15,644</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE5LTEtMS0xLTg3MjA_75880378-9c94-4a20-ab27-f9f2474cedc3">20,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE5LTMtMS0xLTg3MjA_b39010cb-8188-42ef-b525-f75163507111">22,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzIwLTEtMS0xLTg3MjA_06c90ba0-2587-48da-a0e7-62dcdce7df07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzIwLTMtMS0xLTg3MjA_5e5eb7df-f70d-450e-a179-c359b60bee61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded, in accordance with the applicable accounting standards, that it is more-likely-than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a <ix:nonFraction unitRef="number" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="INF" name="arwr:PercentageOfValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzEyNDQ_bc2456c4-8ce7-435e-b7f7-6ea799bbff12">100</ix:nonFraction>% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from the Company&#8217;s estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset. This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="arwr:FederalNetOperatingLossCarryForward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzIxNzE_e16c24c5-1ca5-47bf-8ab3-92526f23b66e">504.8</ix:nonFraction> million and gross state NOL carry forwards of $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="arwr:StateNetOperatingLossCarryForwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzIyMTI_c0c07f4d-7758-45c3-871a-c4504dad749b">626.5</ix:nonFraction> million. The NOLs expire at various dates through 2042.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjk_2ad9657c-6dd0-414a-9332-430231971784" continuedAt="i4dc382910e70451f956b7c64e983e16f" escape="true">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="i2fff35371b6141c3a5e7f016b49e5df4"><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4dc382910e70451f956b7c64e983e16f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMS0xLTEtMTg4MTA_f330da59-0926-434a-af27-c60cb3d7ec26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMi0xLTEtMTg4MTA_a995c008-3e49-4422-9983-166146aebd31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMy0xLTEtMTg4MTA_3e219ff9-8cc4-4f1d-ac51-b63ff4e1cf14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMS0xLTEtMTg4MTA_44867010-2824-4995-b9bc-ff7fb366dbff">3,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMi0xLTEtMTg4MTA_7eb582d1-90d2-47e3-a8c7-9d9072c0aa07">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMy0xLTEtMTg4MTA_f7ad461a-8cb7-4d9c-820b-175ecd966f44">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMS0xLTEtMTg4MTA_9fb295ba-15dc-41b6-8f6d-582ae05a00c6">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMi0xLTEtMTg4MTA_4204f193-ca03-454a-8969-d19e7236831d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMy0xLTEtMTg4MTA_f9a17793-a8de-4bc2-bd18-24c4abe3cfa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at September 30, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyOTA_248fa6de-4b36-41e6-af0e-849b94616213">3.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i7033dda081f6486dabd109e810a7b896_I20210930" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMDQ_a94ca005-bce1-4064-b1ab-0c52ea3c83da">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMDg_a2328591-ebcc-4efc-9f4b-9bdd85b1b851">0</ix:nonFraction> respectively, that if the Company recognized, would affect its effective tax rate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. During the years ended September 30, 2022 and 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMTI_74d79f26-ed0d-42dd-bfd4-e280d01d1131"><ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMTI_d99590ce-c30c-49c8-9132-16c8dbf34791">1.4</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjY_85fa2cc4-165b-4e0d-a03a-a641a126f956"><ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjY_ca197836-6202-4b1f-8fa1-222697fcaa2b">0</ix:nonFraction></ix:nonFraction>, respectively, of accrued interest and penalties related to gross unrecognized tax benefits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not foresee any material changes to its gross unrecognized tax benefits within the next twelve months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and its subsidiaries file income tax returns with the Internal Revenue Service, the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the Internal Revenue Service and by state tax authorities until the net operating losses are settled. The Company is under examination by the state of California for the years 2018 and 2019.</span></div></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzg5OQ_926f8372-6be1-482b-8021-a0056adc42f2" continuedAt="i8bb5cf958f394b2991f51672d4a6564f" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i8bb5cf958f394b2991f51672d4a6564f"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#8217;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to <ix:nonFraction unitRef="number" contextRef="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzQ2NQ_2e1f9b25-f50c-49cd-af50-d0e94a97518a">100</ix:nonFraction>% of each participant&#8217;s first <ix:nonFraction unitRef="number" contextRef="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzQ5Ng_3a121cfd-4319-4be7-bad7-25eadc530562">3</ix:nonFraction>% of compensation contributed plus <ix:nonFraction unitRef="number" contextRef="icb34bf154a434e759ce53d263414bc10_D20211001-20220930" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzUzMg_afe89d8f-1e4d-4892-a102-1170939dc15c">50</ix:nonFraction>% of each participant&#8217;s next <ix:nonFraction unitRef="number" contextRef="icb34bf154a434e759ce53d263414bc10_D20211001-20220930" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzU2Mg_d91cace5-8257-4e17-b298-ec70a1d0ea9c">2</ix:nonFraction>% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2022, 2021, and 2020, the Company recorded expenses for the matching contributions under this plan of $<ix:nonFraction unitRef="usd" contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY4MA_79a3a891-e92e-4510-b506-65a9801bdfe0">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY4NA_eee843e9-58c1-48d3-9a6d-b2b3c151e648">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY5MQ_3747b422-8355-422a-8fb5-d92e59c3159d">0.9</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div></ix:continuation><div id="if17c086bfc1e494d91287b00809be3a1_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMwMTg_3c119295-c202-44ff-b02f-d652ddd0525c" continuedAt="i23596c9065c14bb8abf8d5f038cff0d0" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i23596c9065c14bb8abf8d5f038cff0d0" continuedAt="i222905bd201940df9f98dbf79d06d194"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;), pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="ida71a393ea7a404baff5b677a2df560c_D20221109-20221109" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAxOTI_6fab7f21-e845-4c96-842b-599cb9b6c8ca">410.0</ix:nonFraction>&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMDY_14040944-26de-4b2c-b27c-732790a4df20">250.0</ix:nonFraction>&#160;million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMzM_759fadb7-7712-4fe2-96b7-1fd1c9186571">160.0</ix:nonFraction>&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNDc_c432bbd1-907a-4958-a851-6deaf55b4d6c">50.0</ix:nonFraction>&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMjA_b0b659b5-8ae6-4839-aea7-ea572ea59f50">50.0</ix:nonFraction>&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNjA_fb4a57a4-3ac9-4143-846f-5f0d9d3db633">60.0</ix:nonFraction>&#160;million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNzM_9167e093-5f34-4b49-b502-f905bae46b35">70.0</ix:nonFraction>&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Royalty Pharma Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The above description of the Royalty Pharma Agreement is a summary of the material terms, does not purport to be complete and is qualified in its entirety by reference </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i222905bd201940df9f98dbf79d06d194">to the Royalty Pharma Agreement, which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2022.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>arwr-20220930xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0651867b94a04a0d9d93c5a0fa0cdc92_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-164039 and 333-161344), Forms S-3 (Nos. 333-235324, 333-228598, 333-214315, 333-214311, 333-213484, 333-202737, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-144109, 333-137329, 333-132310, 333-124065, and 333-113065), and Forms S-8 (Nos. 333-256255, 333-238616, 333-230621, 333-223836, 333-210117, 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, and 333-120072) of Arrowhead Pharmaceuticals, Inc. of our report dated November 28, 2022, with respect to the consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries as of September 30, 2022 and September 30, 2021, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the years in the three-year period ended September 30, 2022, and the effectiveness of internal control over financial reporting as of September 30, 2022, which reports appear in the September 30, 2022 annual report on Form 10-K of Arrowhead Pharmaceuticals, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rose, Snyder &#38; Jacobs LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Encino, California</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 28, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>arwr-20220930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9277cbf116fa4dc1830fa35b42e5726b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.  </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>arwr-20220930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i720ab062917d4dce8dde01c558e52891_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kenneth A. Myszkowski,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>arwr-20220930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6b1f282437924273b12c9728b2895d00_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND 18 U.S.C. SECTION 1350 </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Annual Report on Form 10-K of the Company for the year ended September 30, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>arwr-20220930xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icb7a1c4aeb4c47fa82efae9987ab1eb5_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND 18 U.S.C. SECTION 1350 </font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Annual Report on Form 10-K of the Company for the year ended September 30, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;28, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kenneth A. Myszkowski</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arwr-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arrowheadresearch.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.arrowheadresearch.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000009 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment">
        <link:definition>0000010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>0000011 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>0000012 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>0000017 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans">
        <link:definition>0000019 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>0000022 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables">
        <link:definition>0000023 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>0000024 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>0000025 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>0000026 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>0000027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>0000028 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>0000029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables">
        <link:definition>0000030 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails">
        <link:definition>0000031 - Disclosure - Organization and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
        <link:definition>0000032 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
        <link:definition>0000033 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>0000034 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
        <link:definition>0000035 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>0000036 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
        <link:definition>0000037 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetails" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
        <link:definition>0000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>0000040 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000041 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>0000042 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails">
        <link:definition>0000043 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000044 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>0000046 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>0000047 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>0000047 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>0000048 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000049 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails">
        <link:definition>0000051 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000054 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionsforIncomeTaxesDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails">
        <link:definition>0000055 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000058 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>0000060 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>0000061 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" abstract="false" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TechnologyLicenseCommitmentsMember" abstract="true" name="TechnologyLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OutsideOfEquityCompensationPlansMember" abstract="true" name="OutsideOfEquityCompensationPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ3989AROHBVAgreementMember" abstract="true" name="JNJ3989AROHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_UpfrontMilestonePaymentReceived" abstract="false" name="UpfrontMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfValuationAllowance" abstract="false" name="PercentageOfValuationAllowance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JNJ75220795AROJNJ1Member" abstract="true" name="JNJ75220795AROJNJ1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_RestrictedStockUnitsPerformanceBasedMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROXDHAgreementMember" abstract="true" name="AROXDHAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" abstract="false" name="MilestonePaymentReceivableAtStartOfPhaseTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AdditionalLandSubjectToLease" abstract="false" name="AdditionalLandSubjectToLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAward" abstract="false" name="TaxIncrementFinancingAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" abstract="false" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ContingentConsiderationPolicyPolicyTextBlock" abstract="false" name="ContingentConsiderationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RestrictedStockUnitsMarketBasedMember" abstract="true" name="RestrictedStockUnitsMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROXDHSupplyAgreementMember" abstract="true" name="AROXDHSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_EstimatedPaymentsForOperatingExpensesYearOne" abstract="false" name="EstimatedPaymentsForOperatingExpensesYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" abstract="false" name="BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" abstract="false" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FederalNetOperatingLossCarryForward" abstract="false" name="FederalNetOperatingLossCarryForward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_OlpasiranAndAROAMG1AgreementMember" abstract="true" name="OlpasiranAndAROAMG1AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_AROENacAndAROHIF2CandidatesMember" abstract="true" name="AROENacAndAROHIF2CandidatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VeronaTechnologyParkMember" abstract="true" name="VeronaTechnologyParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_StateNetOperatingLossCarryForwards" abstract="false" name="StateNetOperatingLossCarryForwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxLiabilitiesStateTaxes" abstract="false" name="DeferredTaxLiabilitiesStateTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" abstract="false" name="DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROHSDAgreementMember" abstract="true" name="AROHSDAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NoncontrollingInterestIncreaseFromDeconsolidation" abstract="false" name="NoncontrollingInterestIncreaseFromDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_EmployeeContributionsUpToThreePercentMember" abstract="true" name="EmployeeContributionsUpToThreePercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_EmployeeContributionNextTwoPercentMember" abstract="true" name="EmployeeContributionNextTwoPercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfAcresOfLandPurchased" abstract="false" name="NumberOfAcresOfLandPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ResearchEquipmentGross" abstract="false" name="ResearchEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arwr-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65d1d22b-531d-42ef-8317-0eab14f63d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f0dbb2d8-01f0-4bf0-9618-a7df657c9527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65d1d22b-531d-42ef-8317-0eab14f63d72" xlink:to="loc_us-gaap_CommonStockValue_f0dbb2d8-01f0-4bf0-9618-a7df657c9527" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a8b4c3b1-e0a3-4b01-b885-41a7c2d5ddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65d1d22b-531d-42ef-8317-0eab14f63d72" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a8b4c3b1-e0a3-4b01-b885-41a7c2d5ddbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074f3692-9d0c-4153-ada0-c2a6111c6581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65d1d22b-531d-42ef-8317-0eab14f63d72" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_074f3692-9d0c-4153-ada0-c2a6111c6581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8936ba8e-01af-4190-8e16-40ae0e0402f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65d1d22b-531d-42ef-8317-0eab14f63d72" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8936ba8e-01af-4190-8e16-40ae0e0402f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0a4e0ca2-2ced-4391-8d29-e27ad572d22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0a4e0ca2-2ced-4391-8d29-e27ad572d22e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3560208-f86c-49be-ab0d-b1225a7ea765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3560208-f86c-49be-ab0d-b1225a7ea765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d98686f-d9f1-42b4-bbc9-c66fc695c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7d98686f-d9f1-42b4-bbc9-c66fc695c67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a88b1a62-c02a-429a-9f57-7effd63b5f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_a88b1a62-c02a-429a-9f57-7effd63b5f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0bfd5ce-261c-4776-a106-78bff4286b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_AssetsCurrent_d0bfd5ce-261c-4776-a106-78bff4286b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dbdaa2a9-1893-4547-9dca-4f08d96c268f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b310b657-f87f-4ea2-9f8c-1f90f05ab45c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dbdaa2a9-1893-4547-9dca-4f08d96c268f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_70acc650-7aa4-44dd-a1d5-7175c3544d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0ae3069-bb1e-4fbf-b47b-9aa141c820a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_70acc650-7aa4-44dd-a1d5-7175c3544d30" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0ae3069-bb1e-4fbf-b47b-9aa141c820a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9b98079b-3116-477a-b6f7-31eee561ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_70acc650-7aa4-44dd-a1d5-7175c3544d30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9b98079b-3116-477a-b6f7-31eee561ec6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e34433f-01c0-404f-884c-163985eaa84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e1c15827-12ce-4b40-87b1-d6aa5346a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e34433f-01c0-404f-884c-163985eaa84a" xlink:to="loc_us-gaap_StockholdersEquity_e1c15827-12ce-4b40-87b1-d6aa5346a2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_88790238-f58d-462a-a502-7804615033ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5e34433f-01c0-404f-884c-163985eaa84a" xlink:to="loc_us-gaap_MinorityInterest_88790238-f58d-462a-a502-7804615033ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e5248583-2433-462b-ac8a-460ec7ab6314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:to="loc_us-gaap_AccountsPayableCurrent_e5248583-2433-462b-ac8a-460ec7ab6314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4dc659b3-05b1-4a0e-8076-8f0364c56c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4dc659b3-05b1-4a0e-8076-8f0364c56c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac142d31-9f31-48fe-a003-0915be72b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ac142d31-9f31-48fe-a003-0915be72b11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c294f9a-ca52-49ee-98dc-41747e10e91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8c294f9a-ca52-49ee-98dc-41747e10e91b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4ed3defd-2f35-4109-a7ad-17e32076acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00c2005f-02f1-470c-a1fe-a71a14240dea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4ed3defd-2f35-4109-a7ad-17e32076acf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2a2d5615-20e3-4f1e-8e23-291516ff2d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2a2d5615-20e3-4f1e-8e23-291516ff2d24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_77f87da7-acc3-4d81-b15e-53009528a786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_77f87da7-acc3-4d81-b15e-53009528a786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb92e22f-2dea-4b2e-ac80-ed78fb94bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb92e22f-2dea-4b2e-ac80-ed78fb94bd34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_def314bb-5364-4233-a7c9-98f21626e642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_def314bb-5364-4233-a7c9-98f21626e642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_795d77b6-1778-41ca-9a79-6c306ea463c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_795d77b6-1778-41ca-9a79-6c306ea463c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1fe0ebdd-a747-488a-a870-d4390d2d9738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c21b2919-bc2b-4641-820b-64aee7a11928" xlink:to="loc_us-gaap_OtherAssetsCurrent_1fe0ebdd-a747-488a-a870-d4390d2d9738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c67f3a-ca8b-4028-b0ac-95f69c24acdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c482c768-cf1f-4482-b9ea-c26898dc5348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c67f3a-ca8b-4028-b0ac-95f69c24acdd" xlink:to="loc_us-gaap_LiabilitiesCurrent_c482c768-cf1f-4482-b9ea-c26898dc5348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_19ed6bf8-6d26-466b-a0c1-487dbe2f29e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c67f3a-ca8b-4028-b0ac-95f69c24acdd" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_19ed6bf8-6d26-466b-a0c1-487dbe2f29e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51e4a1c8-50d6-4234-83ad-94b00720b777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c67f3a-ca8b-4028-b0ac-95f69c24acdd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51e4a1c8-50d6-4234-83ad-94b00720b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23f775c2-7a05-432b-8a54-8dce522cf3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f9c67f3a-ca8b-4028-b0ac-95f69c24acdd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23f775c2-7a05-432b-8a54-8dce522cf3da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c5993db-3bec-4700-bd21-eaaaf78259b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a51f493a-8f16-4527-892c-5585a621f3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c5993db-3bec-4700-bd21-eaaaf78259b6" xlink:to="loc_us-gaap_OperatingIncomeLoss_a51f493a-8f16-4527-892c-5585a621f3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_efeacf5a-5c03-44f7-aeb9-ffbb0cb709f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c5993db-3bec-4700-bd21-eaaaf78259b6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_efeacf5a-5c03-44f7-aeb9-ffbb0cb709f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_29a9b312-8a5d-477f-b979-44c3a5fa876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85cc39c0-ad65-4d4d-88f0-924a94ae946e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29a9b312-8a5d-477f-b979-44c3a5fa876d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_85cc39c0-ad65-4d4d-88f0-924a94ae946e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dcd3bee5-bb3e-47f0-ae41-8c0bbd569e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_29a9b312-8a5d-477f-b979-44c3a5fa876d" xlink:to="loc_us-gaap_OperatingExpenses_dcd3bee5-bb3e-47f0-ae41-8c0bbd569e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_92ffde05-6a39-4800-8676-3ae88d971e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8aa61c5c-e55d-4b0c-b4bc-afbba507093e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_92ffde05-6a39-4800-8676-3ae88d971e0c" xlink:to="loc_us-gaap_ProfitLoss_8aa61c5c-e55d-4b0c-b4bc-afbba507093e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6ea9deda-cf91-4b08-8711-0c83f225ab32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_92ffde05-6a39-4800-8676-3ae88d971e0c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6ea9deda-cf91-4b08-8711-0c83f225ab32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0d66efdd-7f89-4710-90f8-07868a6c33d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_af340a3f-6173-42f6-bd80-da96f4892fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d66efdd-7f89-4710-90f8-07868a6c33d6" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_af340a3f-6173-42f6-bd80-da96f4892fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_71136894-ef71-47c9-8e71-5e295100e080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0d66efdd-7f89-4710-90f8-07868a6c33d6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_71136894-ef71-47c9-8e71-5e295100e080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_560eab3d-cddc-43d4-85c7-8aedb2be8c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_005d7f00-563a-48c9-a41c-504fa50194ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_560eab3d-cddc-43d4-85c7-8aedb2be8c4c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_005d7f00-563a-48c9-a41c-504fa50194ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_498fd199-73a4-4f08-897a-4523d4162843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_560eab3d-cddc-43d4-85c7-8aedb2be8c4c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_498fd199-73a4-4f08-897a-4523d4162843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_354930ea-8138-4747-a13c-5c12b3e207a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b2e84042-8528-4fe6-8f59-b82d1ac3f184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_354930ea-8138-4747-a13c-5c12b3e207a8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b2e84042-8528-4fe6-8f59-b82d1ac3f184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_caff4d13-e7eb-4408-99eb-f34b369f9567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_354930ea-8138-4747-a13c-5c12b3e207a8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_caff4d13-e7eb-4408-99eb-f34b369f9567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_816b4e7b-2e8d-453e-8729-394da390028f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7a143bba-9bd9-4b23-abdc-19a85f0bb510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_816b4e7b-2e8d-453e-8729-394da390028f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7a143bba-9bd9-4b23-abdc-19a85f0bb510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_95cd74bc-3df4-47b1-a44c-abcf02a04d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_816b4e7b-2e8d-453e-8729-394da390028f" xlink:to="loc_us-gaap_ProfitLoss_95cd74bc-3df4-47b1-a44c-abcf02a04d79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f1ed6a4-96a4-4998-82a4-3990f30e9d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25eceb0b-6cd1-4594-ac80-efdd2851a29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f1ed6a4-96a4-4998-82a4-3990f30e9d2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_25eceb0b-6cd1-4594-ac80-efdd2851a29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_055d958a-b793-4e35-b31f-9b0e71fafa15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f1ed6a4-96a4-4998-82a4-3990f30e9d2f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_055d958a-b793-4e35-b31f-9b0e71fafa15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_d4e76fba-d991-4af8-ba99-e04ee3b4721c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f1ed6a4-96a4-4998-82a4-3990f30e9d2f" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_d4e76fba-d991-4af8-ba99-e04ee3b4721c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c8002589-aeea-4a58-8c4a-085d4fcec391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c8002589-aeea-4a58-8c4a-085d4fcec391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_cfa7d19a-833f-4688-9c9b-dcbc8e38e583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_GainLossOnInvestments_cfa7d19a-833f-4688-9c9b-dcbc8e38e583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d959fba8-29ee-4499-98ef-60720c498511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d959fba8-29ee-4499-98ef-60720c498511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85c59b87-5dc2-4337-8d39-9c13295cb514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_85c59b87-5dc2-4337-8d39-9c13295cb514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e773a157-8f49-4d03-9240-c2611186d792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e773a157-8f49-4d03-9240-c2611186d792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c60dc0bf-60e1-44ee-a902-f568b8bafe1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_ShareBasedCompensation_c60dc0bf-60e1-44ee-a902-f568b8bafe1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_71315842-1d70-4814-8773-eaca48104f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_71315842-1d70-4814-8773-eaca48104f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_952689cb-0a20-4d86-90b2-e6f6660f8bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_952689cb-0a20-4d86-90b2-e6f6660f8bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1c530721-f96d-4dd7-b8b7-dbb43007f7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1c530721-f96d-4dd7-b8b7-dbb43007f7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_34c883d4-f30f-4c5d-9413-5d6e408b0147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_DepreciationAndAmortization_34c883d4-f30f-4c5d-9413-5d6e408b0147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_363b09d1-c939-4e82-8c83-985268fb33c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_363b09d1-c939-4e82-8c83-985268fb33c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c1560280-5b74-4930-8a0f-28f7d3dd95cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0df2188a-280e-4183-8184-730046ddfd12" xlink:to="loc_us-gaap_ProfitLoss_c1560280-5b74-4930-8a0f-28f7d3dd95cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d4f73215-dda0-498b-bd0d-94890ae81109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5d1239e-c75c-498c-86f5-92778206aae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d4f73215-dda0-498b-bd0d-94890ae81109" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5d1239e-c75c-498c-86f5-92778206aae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c968b0db-6211-446f-8547-fce7e6300418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d4f73215-dda0-498b-bd0d-94890ae81109" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c968b0db-6211-446f-8547-fce7e6300418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b29ca07-13be-4f15-ae68-2e2e8ca59888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_d4f73215-dda0-498b-bd0d-94890ae81109" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b29ca07-13be-4f15-ae68-2e2e8ca59888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d6f2cb-fbc6-476f-9433-b2ee08ec809d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4460ff2-c276-459d-a4d3-6f2cb640e7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d6f2cb-fbc6-476f-9433-b2ee08ec809d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4460ff2-c276-459d-a4d3-6f2cb640e7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_6235b429-86dc-4841-aa3e-11f253d7fb86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d6f2cb-fbc6-476f-9433-b2ee08ec809d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_6235b429-86dc-4841-aa3e-11f253d7fb86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6e04793a-8011-48bc-a9dd-36bf6e0c0c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b6d6f2cb-fbc6-476f-9433-b2ee08ec809d" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6e04793a-8011-48bc-a9dd-36bf6e0c0c3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_d01909ee-0d69-4a5f-8dd6-7a19f218a7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_d01909ee-0d69-4a5f-8dd6-7a19f218a7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_f9821dcf-8ea5-4c70-9d0b-c1732576bb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:to="loc_us-gaap_Land_f9821dcf-8ea5-4c70-9d0b-c1732576bb2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_08358f70-b7bc-4199-ad18-64da96060209" xlink:href="arwr-20220930.xsd#arwr_ResearchEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:to="loc_arwr_ResearchEquipmentGross_08358f70-b7bc-4199-ad18-64da96060209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_6970060e-7157-416d-8e3b-58361a52a96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_6970060e-7157-416d-8e3b-58361a52a96b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_fb3005cf-51fd-49d0-93c7-7c9e84979615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_bb80e4c9-f802-40c0-8e10-3321ecd8b516" xlink:to="loc_us-gaap_ConstructionInProgressGross_fb3005cf-51fd-49d0-93c7-7c9e84979615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f14eafda-fad2-4999-939a-1958b78242da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7df8c51f-be1a-49c9-99ba-f3b342ba8ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f14eafda-fad2-4999-939a-1958b78242da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7df8c51f-be1a-49c9-99ba-f3b342ba8ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7fb9520b-88a4-4137-81b0-c614b5701da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f14eafda-fad2-4999-939a-1958b78242da" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7fb9520b-88a4-4137-81b0-c614b5701da9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4adcc489-af8d-4446-b3d6-7c8461ca66d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9141dc22-0073-4233-a026-fe6cedb0bc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4adcc489-af8d-4446-b3d6-7c8461ca66d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9141dc22-0073-4233-a026-fe6cedb0bc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68b8604a-21b1-4951-9780-20de12a73516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4adcc489-af8d-4446-b3d6-7c8461ca66d2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_68b8604a-21b1-4951-9780-20de12a73516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a6af71ff-5f92-4b7c-b997-dc43c91cde3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4adcc489-af8d-4446-b3d6-7c8461ca66d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a6af71ff-5f92-4b7c-b997-dc43c91cde3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_609c6825-9968-4997-bf81-51f74214d2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_c8442f9f-6d6a-4810-9239-ce8be9cc9d17" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_609c6825-9968-4997-bf81-51f74214d2c4" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_c8442f9f-6d6a-4810-9239-ce8be9cc9d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_16009f62-9615-42ec-a826-b9fcbcaa60e6" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_609c6825-9968-4997-bf81-51f74214d2c4" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_16009f62-9615-42ec-a826-b9fcbcaa60e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_e1608dc9-d23d-4a77-8a0d-396e278e3895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_609c6825-9968-4997-bf81-51f74214d2c4" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_e1608dc9-d23d-4a77-8a0d-396e278e3895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0163e387-9232-4141-8372-498d71a62ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_76560130-7670-4593-8636-94b5cd105e84" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0163e387-9232-4141-8372-498d71a62ce5" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_76560130-7670-4593-8636-94b5cd105e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e7d0fd76-fe2d-4c60-94d6-8ccfdd9f8319" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0163e387-9232-4141-8372-498d71a62ce5" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_e7d0fd76-fe2d-4c60-94d6-8ccfdd9f8319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_eb1e8e0d-4e5b-47ff-ac06-c89bae83b021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_0163e387-9232-4141-8372-498d71a62ce5" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_eb1e8e0d-4e5b-47ff-ac06-c89bae83b021" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5087f11c-9788-42b6-83c2-34f7bc8d6866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10566f35-0b9d-4923-aa6a-84bfca0b363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5087f11c-9788-42b6-83c2-34f7bc8d6866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_10566f35-0b9d-4923-aa6a-84bfca0b363d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1c13847-315c-45aa-8b09-dc2931c24454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5087f11c-9788-42b6-83c2-34f7bc8d6866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c1c13847-315c-45aa-8b09-dc2931c24454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_c7f94101-fc45-4771-9218-c85de6b8c33b" xlink:href="arwr-20220930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5087f11c-9788-42b6-83c2-34f7bc8d6866" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_c7f94101-fc45-4771-9218-c85de6b8c33b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b99b8f34-cb70-4df2-8b08-9f27b1761c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b99b8f34-cb70-4df2-8b08-9f27b1761c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0d2379e8-6d48-43bb-97db-ac954cd8f58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0d2379e8-6d48-43bb-97db-ac954cd8f58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b82dbe15-81f9-4d1a-90ed-3c8fe326f4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b82dbe15-81f9-4d1a-90ed-3c8fe326f4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bf73eb6c-e11c-4e1d-a2cd-6e8d743d187d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bf73eb6c-e11c-4e1d-a2cd-6e8d743d187d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_77b3a550-bab1-40e4-ac95-bde5260ce044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_77b3a550-bab1-40e4-ac95-bde5260ce044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_72e23021-643e-49b5-a422-4d5937d6bdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_22232b12-6e5c-4fb9-aefb-33fdc3233cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_72e23021-643e-49b5-a422-4d5937d6bdd6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d309d244-3c2e-4508-a02b-f9859fecb679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a4b60db0-823b-4d42-b4de-afefd72d0784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d309d244-3c2e-4508-a02b-f9859fecb679" xlink:to="loc_us-gaap_VariableLeaseCost_a4b60db0-823b-4d42-b4de-afefd72d0784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4597ca1c-a809-42eb-8c34-32b196155d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d309d244-3c2e-4508-a02b-f9859fecb679" xlink:to="loc_us-gaap_OperatingLeaseCost_4597ca1c-a809-42eb-8c34-32b196155d98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27e4d0e9-f48f-4b63-9724-97cc80945412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_27e4d0e9-f48f-4b63-9724-97cc80945412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f7094da4-44d9-4403-b2dd-a7045abaab62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f7094da4-44d9-4403-b2dd-a7045abaab62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_14a73e41-c1f7-4143-b0d2-392977c9d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_14a73e41-c1f7-4143-b0d2-392977c9d2b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6aa75140-0f9f-4991-9fa3-4338cf92a75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6aa75140-0f9f-4991-9fa3-4338cf92a75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f412f944-da92-491d-869c-8eb6073ac1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f412f944-da92-491d-869c-8eb6073ac1f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_64f35719-9179-42b0-b7eb-f20dffe0d399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95a669c-6cb4-469a-87d9-af2c4c799c1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_64f35719-9179-42b0-b7eb-f20dffe0d399" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5d0480-9b03-4cdb-8a94-af99d349d6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b21ef1d3-be14-4cfa-8320-2eef01685e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5d0480-9b03-4cdb-8a94-af99d349d6f4" xlink:to="loc_us-gaap_OperatingLeaseLiability_b21ef1d3-be14-4cfa-8320-2eef01685e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_631fdbdf-190a-49ea-8fa4-178819170af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5d0480-9b03-4cdb-8a94-af99d349d6f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_631fdbdf-190a-49ea-8fa4-178819170af8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_2929f7b2-718d-4435-b6a7-38a8b62265ea" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_474baab4-8d78-4ea2-9e6e-01becb4af9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_2929f7b2-718d-4435-b6a7-38a8b62265ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_474baab4-8d78-4ea2-9e6e-01becb4af9a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b595fc32-5995-4a30-a4f0-e9d2967b663b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_2929f7b2-718d-4435-b6a7-38a8b62265ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b595fc32-5995-4a30-a4f0-e9d2967b663b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesProvisionsforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8247cdb6-8c2b-4f77-90ce-5c7b7b9bb518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c3eafe5-bf3e-4af2-b36c-539ec941b9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8247cdb6-8c2b-4f77-90ce-5c7b7b9bb518" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6c3eafe5-bf3e-4af2-b36c-539ec941b9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e6c9b23-3775-4765-8272-3f11df48b6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8247cdb6-8c2b-4f77-90ce-5c7b7b9bb518" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e6c9b23-3775-4765-8272-3f11df48b6ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f592424-3090-4073-9cd2-f3ff8aa5ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_61be3645-a253-475d-a9a6-87896e35f7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f592424-3090-4073-9cd2-f3ff8aa5ad94" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_61be3645-a253-475d-a9a6-87896e35f7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_22b13b65-1c97-4c8e-8853-3e0ba4d87a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f592424-3090-4073-9cd2-f3ff8aa5ad94" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_22b13b65-1c97-4c8e-8853-3e0ba4d87a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_69a2e13b-8163-4f31-9d99-03a321e91943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f592424-3090-4073-9cd2-f3ff8aa5ad94" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_69a2e13b-8163-4f31-9d99-03a321e91943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_674f5eca-8299-430d-8f6e-1fd021472cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_87af638f-6784-4605-8c6f-06d0ffb10c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_674f5eca-8299-430d-8f6e-1fd021472cce" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_87af638f-6784-4605-8c6f-06d0ffb10c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b42d19fc-d204-4039-939e-f9ad7faba82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_674f5eca-8299-430d-8f6e-1fd021472cce" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b42d19fc-d204-4039-939e-f9ad7faba82d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_3bbf6eb8-f50d-40b5-ac4c-b1c1c03bb8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a7576eef-18af-4ce7-aff1-c5dd266e5805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_3bbf6eb8-f50d-40b5-ac4c-b1c1c03bb8cf" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a7576eef-18af-4ce7-aff1-c5dd266e5805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_131a10c6-ae5e-4087-8ad1-ed9e1b093118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_3bbf6eb8-f50d-40b5-ac4c-b1c1c03bb8cf" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_131a10c6-ae5e-4087-8ad1-ed9e1b093118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_343006e6-216c-4465-bb05-0d3fb84e0620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7216f925-60af-4372-ad96-40f3a3a587d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_343006e6-216c-4465-bb05-0d3fb84e0620" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7216f925-60af-4372-ad96-40f3a3a587d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5d981be0-d527-4e90-8b72-1eaf4cbd1d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_343006e6-216c-4465-bb05-0d3fb84e0620" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5d981be0-d527-4e90-8b72-1eaf4cbd1d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b511e37e-006c-4cfe-b98e-44f9d6ecc892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_343006e6-216c-4465-bb05-0d3fb84e0620" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b511e37e-006c-4cfe-b98e-44f9d6ecc892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d8496d20-8499-4b9b-ba59-50ef7832d159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a49f359-3a5b-4869-b8bf-5f577e7bfe2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d8496d20-8499-4b9b-ba59-50ef7832d159" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a49f359-3a5b-4869-b8bf-5f577e7bfe2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e02bb535-cee4-413d-bbb3-6583d58ce8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_d8496d20-8499-4b9b-ba59-50ef7832d159" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e02bb535-cee4-413d-bbb3-6583d58ce8ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dd2e71a6-4da6-4ea5-864b-4146c41e4901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dd2e71a6-4da6-4ea5-864b-4146c41e4901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_502cbb4c-20c3-45b4-8c0f-ad75e19b9063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_502cbb4c-20c3-45b4-8c0f-ad75e19b9063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_925f5f9f-0c5b-4abe-93a2-0bcffc7b3875" xlink:href="arwr-20220930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_925f5f9f-0c5b-4abe-93a2-0bcffc7b3875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_87399b73-f10f-4a54-9be9-0e04a789bc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_87399b73-f10f-4a54-9be9-0e04a789bc8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1a76484e-82b5-4bff-90ec-f0a57aba694b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_16e12b96-d7bf-47ba-b5d2-37793210bf50" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1a76484e-82b5-4bff-90ec-f0a57aba694b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_93d04359-61b3-4d64-8f61-3b8c6cf4f470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_93d04359-61b3-4d64-8f61-3b8c6cf4f470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b9ce5367-b866-4b11-9d34-8f38adeb11e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b9ce5367-b866-4b11-9d34-8f38adeb11e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c5db537d-be7a-43d0-ab85-cbee67d82c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_c5db537d-be7a-43d0-ab85-cbee67d82c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_05638bb5-bcea-467e-9a5b-450691e553f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_05638bb5-bcea-467e-9a5b-450691e553f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_cb4cdc09-047a-4d3e-986a-555856f751c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_cb4cdc09-047a-4d3e-986a-555856f751c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7c9f952d-d4ab-45a3-a38e-6ba58430eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7c9f952d-d4ab-45a3-a38e-6ba58430eefb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_694dda38-82e5-4fc9-8f78-7ec53d7e52b0" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_694dda38-82e5-4fc9-8f78-7ec53d7e52b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_60b76a57-2ebc-4a9c-9937-705250d4930f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_60b76a57-2ebc-4a9c-9937-705250d4930f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_24135976-e76b-4eb5-b584-ce2c43bfe29e" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ae1b6db-8c2b-4994-a7cc-f84fdc3a3269" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_24135976-e76b-4eb5-b584-ce2c43bfe29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9013177-c3f6-4b21-8aad-f1268372d418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d01b168-453b-4281-93fc-d330cb0db9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9013177-c3f6-4b21-8aad-f1268372d418" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6d01b168-453b-4281-93fc-d330cb0db9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_98f00d43-1a38-4b5d-adbc-c7da642f1990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9013177-c3f6-4b21-8aad-f1268372d418" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_98f00d43-1a38-4b5d-adbc-c7da642f1990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_89c54931-c646-4074-9f98-6245671f3545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9013177-c3f6-4b21-8aad-f1268372d418" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_89c54931-c646-4074-9f98-6245671f3545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fa0a2491-6c58-4363-b19a-8e3f89f4e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1d67df86-2750-42b5-8c94-626f195fe821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_fa0a2491-6c58-4363-b19a-8e3f89f4e268" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1d67df86-2750-42b5-8c94-626f195fe821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes_3246fae9-e94b-4fd5-835b-4b586a137baf" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_fa0a2491-6c58-4363-b19a-8e3f89f4e268" xlink:to="loc_arwr_DeferredTaxLiabilitiesStateTaxes_3246fae9-e94b-4fd5-835b-4b586a137baf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arwr-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ibdc7d7c23c71483db006e81b29a6eda7_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_868a1d3a-4381-4476-9da6-653d5685a2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_868a1d3a-4381-4476-9da6-653d5685a2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_222768f2-d308-46cf-97b8-b29b07facfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_SharesOutstanding_222768f2-d308-46cf-97b8-b29b07facfd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9a63660-96bf-42d4-98c9-d925ac2ac05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9a63660-96bf-42d4-98c9-d925ac2ac05d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b5e2f42-b99d-4202-8d24-5ac3b88f7372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b5e2f42-b99d-4202-8d24-5ac3b88f7372" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac321b57-b46d-43bb-83f2-afddc3e8ec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac321b57-b46d-43bb-83f2-afddc3e8ec3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_57f2bf71-f819-460b-88aa-6c697d0dd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_57f2bf71-f819-460b-88aa-6c697d0dd29e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_b6a0c0c2-941d-4de0-84a0-ea25b7e4c9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_b6a0c0c2-941d-4de0-84a0-ea25b7e4c9cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3c1b2085-88fe-4067-b30b-7493f9d485af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3c1b2085-88fe-4067-b30b-7493f9d485af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_92a730ae-4805-4c38-905b-73e6d416515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_92a730ae-4805-4c38-905b-73e6d416515a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d89bd327-6864-4453-ba2d-b58a65244968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d89bd327-6864-4453-ba2d-b58a65244968" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_7c83cf0e-0e3d-474e-9539-14ec344929cf" xlink:href="arwr-20220930.xsd#arwr_NoncontrollingInterestIncreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_7c83cf0e-0e3d-474e-9539-14ec344929cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_45252fc7-2a08-4758-bfb2-9f0ac1ebe671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_45252fc7-2a08-4758-bfb2-9f0ac1ebe671" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_47287c2d-8b42-4a25-bdb6-bea23bcadfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_ProfitLoss_47287c2d-8b42-4a25-bdb6-bea23bcadfd1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dcf925f0-d31f-48f6-9083-3028dd2175cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bd8efdad-0416-4c84-a424-4af1edac5a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:to="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:to="loc_us-gaap_EquityComponentDomain_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:to="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e2365215-8cd3-4a2e-8d07-db4bad37849b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_CommonStockMember_e2365215-8cd3-4a2e-8d07-db4bad37849b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f15ed765-28f4-4928-ab63-dafde792a840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f15ed765-28f4-4928-ab63-dafde792a840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205b7ada-9f1e-4d6a-88f6-c1eff5ae4833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205b7ada-9f1e-4d6a-88f6-c1eff5ae4833" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad7bace0-dc99-4785-a815-c9a5b16e9b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_RetainedEarningsMember_ad7bace0-dc99-4785-a815-c9a5b16e9b5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b1f7b7eb-7cbb-435d-9553-b6842bb3140a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b1f7b7eb-7cbb-435d-9553-b6842bb3140a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#OrganizationandSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="extended" id="ib252cac8d75a4d029ad101bd534f576c_OrganizationandSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3215f5cf-0a95-400d-a06b-b3bee847baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3215f5cf-0a95-400d-a06b-b3bee847baa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_26c6c758-bafb-4162-9ead-9a41c69e7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_26c6c758-bafb-4162-9ead-9a41c69e7e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_394b6716-3111-49b4-9913-c4336115b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_394b6716-3111-49b4-9913-c4336115b34b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e8f9822f-8b9e-447d-a974-45be95591962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e8f9822f-8b9e-447d-a974-45be95591962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_e833cd1d-a343-4b58-b7c1-4353cc8e86ab" xlink:href="arwr-20220930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_e833cd1d-a343-4b58-b7c1-4353cc8e86ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_3cddcfee-1b7c-4ab0-8840-0944ca6d0562" xlink:href="arwr-20220930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_3cddcfee-1b7c-4ab0-8840-0944ca6d0562" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_95df9368-b887-4715-a785-77c0288a1efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_95df9368-b887-4715-a785-77c0288a1efc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d45cb6aa-98f9-4d8a-b2bd-e320c5426aec" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d45cb6aa-98f9-4d8a-b2bd-e320c5426aec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_71eb53a9-67d6-41ff-9107-5f3f18d866fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_CashFDICInsuredAmount_71eb53a9-67d6-41ff-9107-5f3f18d866fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_96dfdf0d-4eec-4034-8528-fdcb378f85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_96dfdf0d-4eec-4034-8528-fdcb378f85fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bcf65456-83ce-4cae-a4e8-b6f33fb7a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bcf65456-83ce-4cae-a4e8-b6f33fb7a0d1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_20ebcd73-3547-4afd-8ddd-17983422d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_20ebcd73-3547-4afd-8ddd-17983422d2ea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b4a24d0-be32-49eb-ba65-763bc861ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b4a24d0-be32-49eb-ba65-763bc861ee44" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_efbe2689-c6df-4c57-b21c-bb66b5594377_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:to="loc_dei_EntityDomain_efbe2689-c6df-4c57-b21c-bb66b5594377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:to="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_a5a5ccd6-1020-4422-84c2-542b68889cca" xlink:href="arwr-20220930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_a5a5ccd6-1020-4422-84c2-542b68889cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_4553edd4-2c04-42e6-9463-8118d4ec1c75" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_4553edd4-2c04-42e6-9463-8118d4ec1c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b21dc1d0-2164-4b8d-909c-8655621a60f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b21dc1d0-2164-4b8d-909c-8655621a60f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_5826ae24-126d-4dcb-a2bf-f66378fbed67" xlink:href="arwr-20220930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_5826ae24-126d-4dcb-a2bf-f66378fbed67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28868a1c-d16e-43e6-ae8d-efbbd86151b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:to="loc_srt_RangeMember_28868a1c-d16e-43e6-ae8d-efbbd86151b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:to="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f77423ce-d146-44de-b632-90a08ecdbba4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:to="loc_srt_MinimumMember_f77423ce-d146-44de-b632-90a08ecdbba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37bedc8c-a42b-4a10-bd74-9f0760d2ed96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:to="loc_srt_MaximumMember_37bedc8c-a42b-4a10-bd74-9f0760d2ed96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_00271c84-61ef-413e-a83c-6c138e758a6f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_00271c84-61ef-413e-a83c-6c138e758a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_544a9a55-e6ee-40c3-8514-077ff29dbc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_544a9a55-e6ee-40c3-8514-077ff29dbc0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended" id="i8cf56114bfae4310ac8b0de959d783db_CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_df9e7338-5baf-49b7-af80-1289b42ffa38" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentEarned_df9e7338-5baf-49b7-af80-1289b42ffa38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_58074fe4-dd9d-4dac-8d89-5e55e14f2189" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_58074fe4-dd9d-4dac-8d89-5e55e14f2189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_a276eac8-bec0-471f-aee4-d6ef3a4ff385" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_a276eac8-bec0-471f-aee4-d6ef3a4ff385" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_ec4e44ab-49be-440d-99ab-c78c6ce87a2f" xlink:href="arwr-20220930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_ec4e44ab-49be-440d-99ab-c78c6ce87a2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_248f3048-0d03-4bae-9b97-03a7d499a869" xlink:href="arwr-20220930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_SalesRelatedMilestonePayments_248f3048-0d03-4bae-9b97-03a7d499a869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_19b2d25d-a596-426a-854a-ab23dc08e1cf" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_InitialTransactionPrice_19b2d25d-a596-426a-854a-ab23dc08e1cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c230093-9929-4c90-a041-c1cf64724a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c230093-9929-4c90-a041-c1cf64724a1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9337aa7a-8226-4e5d-b7df-71ac512e4297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9337aa7a-8226-4e5d-b7df-71ac512e4297" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c2a6de8-ac2a-4879-a69a-8d6b78962e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c2a6de8-ac2a-4879-a69a-8d6b78962e7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_819167f5-c1d6-46cd-9688-62fa5c34d2b9_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:to="loc_dei_EntityDomain_819167f5-c1d6-46cd-9688-62fa5c34d2b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:to="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f76db261-8f8b-42b3-9b94-f11659f7ef57" xlink:href="arwr-20220930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f76db261-8f8b-42b3-9b94-f11659f7ef57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89cd9085-43e6-4106-a1b5-701a1d25438c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89cd9085-43e6-4106-a1b5-701a1d25438c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1cffd285-39c2-453d-bd41-733f4819cd95" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1cffd285-39c2-453d-bd41-733f4819cd95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_ad79b900-6a85-49a5-b5cf-76364a6d6bb9" xlink:href="arwr-20220930.xsd#arwr_AROHSDAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:to="loc_arwr_AROHSDAgreementMember_ad79b900-6a85-49a5-b5cf-76364a6d6bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87d3c13f-8843-4dd3-a0a5-e1518799ad02_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:to="loc_srt_RangeMember_87d3c13f-8843-4dd3-a0a5-e1518799ad02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:to="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6031c57a-690d-4ffa-bf4e-99c3a5445b81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:to="loc_srt_MaximumMember_6031c57a-690d-4ffa-bf4e-99c3a5445b81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended" id="i59bc42c7fe164f8d8b76f988631712a9_CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_2d953406-3070-418e-a935-129b50f866ac" xlink:href="arwr-20220930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_2d953406-3070-418e-a935-129b50f866ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_133ade12-6f8f-429a-a1c4-dacd4661aa01" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_133ade12-6f8f-429a-a1c4-dacd4661aa01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_c1a4ba61-3796-4aff-ae49-15e9d90209cd" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_NumberOfDistinctBundle_c1a4ba61-3796-4aff-ae49-15e9d90209cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_f9409490-311f-457e-adae-470874156ed9" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_f9409490-311f-457e-adae-470874156ed9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_98c216d2-0b4b-493d-9959-3a588cadd26e" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_InitialTransactionPrice_98c216d2-0b4b-493d-9959-3a588cadd26e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_014dde1e-d53b-4bcc-83b6-e00f762f7d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_014dde1e-d53b-4bcc-83b6-e00f762f7d1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e2ebd5ff-dc25-4e2c-a4f8-5efe557700a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e2ebd5ff-dc25-4e2c-a4f8-5efe557700a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbff676f-dde4-45c3-b4fa-12769c197a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbff676f-dde4-45c3-b4fa-12769c197a25" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8fe07f5a-6161-4132-950c-324f97c072aa_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:to="loc_dei_EntityDomain_8fe07f5a-6161-4132-950c-324f97c072aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:to="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_018451ad-aeb6-45b0-9575-dc7f8906cfe6" xlink:href="arwr-20220930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_018451ad-aeb6-45b0-9575-dc7f8906cfe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:to="loc_srt_RangeMember_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:to="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e70b776-f5f6-4f35-aeea-0c9f776d8165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:to="loc_srt_MaximumMember_2e70b776-f5f6-4f35-aeea-0c9f776d8165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950728f1-4e9b-477b-8891-d152c29815d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_950728f1-4e9b-477b-8891-d152c29815d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_3b9cd488-e0b7-4ebc-8aea-0e8298218912" xlink:href="arwr-20220930.xsd#arwr_AROXDHAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_AROXDHAgreementMember_3b9cd488-e0b7-4ebc-8aea-0e8298218912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_d312eac3-852c-4ec6-bfb7-4dc8366e2ed1" xlink:href="arwr-20220930.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_LicenseAgreementMember_d312eac3-852c-4ec6-bfb7-4dc8366e2ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember_9c410eae-a302-46a3-acdb-112b2d0054c7" xlink:href="arwr-20220930.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_AROXDHSupplyAgreementMember_9c410eae-a302-46a3-acdb-112b2d0054c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended" id="i5fc927b3557b46448dc79883ddb75d39_CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_06a43578-db8d-493e-b846-c952e37fb61d" xlink:href="arwr-20220930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_06a43578-db8d-493e-b846-c952e37fb61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_aa55d362-128e-4e3b-b941-8d9d5b7543a4" xlink:href="arwr-20220930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_aa55d362-128e-4e3b-b941-8d9d5b7543a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_ac545c1f-ef6c-423e-b9eb-fa6ba44dde2c" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_ac545c1f-ef6c-423e-b9eb-fa6ba44dde2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_4143a4a6-f8ec-4f9e-84d8-7a5a6e6b47fe" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_NumberOfDistinctBundle_4143a4a6-f8ec-4f9e-84d8-7a5a6e6b47fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_a19f584f-4be5-425e-bb61-4922a632d4ec" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_a19f584f-4be5-425e-bb61-4922a632d4ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_0a2886d6-2b9a-41fe-98b2-df414fc7fcf9" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_InitialTransactionPrice_0a2886d6-2b9a-41fe-98b2-df414fc7fcf9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9e660df-8d04-4663-8796-6f94b29d0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9e660df-8d04-4663-8796-6f94b29d0bd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e41a1694-b808-40dc-baf2-8514495dbd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e41a1694-b808-40dc-baf2-8514495dbd5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eead14ab-4ac5-4566-8e6a-9d0b58d7d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eead14ab-4ac5-4566-8e6a-9d0b58d7d4bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21f7205b-7561-4e7e-86d9-ddb5dc40dac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21f7205b-7561-4e7e-86d9-ddb5dc40dac6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_78edfce2-4901-44a7-b3c2-564a8c04333b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:to="loc_dei_EntityDomain_78edfce2-4901-44a7-b3c2-564a8c04333b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:to="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ecc0b884-1144-4563-8de3-c7af50783744" xlink:href="arwr-20220930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ecc0b884-1144-4563-8de3-c7af50783744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f359fe-1ef2-4254-bd0f-1981c86e270a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f359fe-1ef2-4254-bd0f-1981c86e270a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_c961d40e-d87a-42d5-90ea-a6cabcb36f20" xlink:href="arwr-20220930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_c961d40e-d87a-42d5-90ea-a6cabcb36f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0a5320e-25f4-4de6-92aa-719281fb6088_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:to="loc_srt_RangeMember_e0a5320e-25f4-4de6-92aa-719281fb6088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:to="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_43eb6de0-081f-4950-b919-365db7cdc61c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:to="loc_srt_MinimumMember_43eb6de0-081f-4950-b919-365db7cdc61c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab0b55f1-c847-4943-984e-57210776751d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:to="loc_srt_MaximumMember_ab0b55f1-c847-4943-984e-57210776751d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_52806433-c2c4-4fad-ae31-9213db0917f5" xlink:href="arwr-20220930.xsd#arwr_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:to="loc_arwr_DeferredRevenueMember_52806433-c2c4-4fad-ae31-9213db0917f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b42e7bdf-bd77-4c02-9b10-474dd3279c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b42e7bdf-bd77-4c02-9b10-474dd3279c84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended" id="i471c84509c8a494d90f1364c30b25a29_CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_18760cd0-8b8e-4e70-8284-9e102df09dcc" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_18760cd0-8b8e-4e70-8284-9e102df09dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3510ee8f-894c-4f1e-8af0-0114039ec987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3510ee8f-894c-4f1e-8af0-0114039ec987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_862a2e1d-32d8-4830-b303-6aadd6c20f57" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_MilestonePaymentEarned_862a2e1d-32d8-4830-b303-6aadd6c20f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_f1c41ea0-f4bb-4abd-9e23-5dc1905fac27" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_f1c41ea0-f4bb-4abd-9e23-5dc1905fac27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_08795cf8-fab9-4975-b599-a9a7cbe43ad5" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_08795cf8-fab9-4975-b599-a9a7cbe43ad5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_7eba2a52-629f-4c33-a69e-9b8c571c6f9b" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_InitialTransactionPrice_7eba2a52-629f-4c33-a69e-9b8c571c6f9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f6c071b8-84d0-43ab-aa43-b5aeee699976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f6c071b8-84d0-43ab-aa43-b5aeee699976" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_59aba88c-1767-45e3-98f9-3fa0c7a0163a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_59aba88c-1767-45e3-98f9-3fa0c7a0163a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de951785-d10b-4b2b-97da-036863bf55bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de951785-d10b-4b2b-97da-036863bf55bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:to="loc_dei_EntityDomain_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:to="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_97ffbad5-d6f6-4252-beee-318507992426" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_97ffbad5-d6f6-4252-beee-318507992426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_9433a4f3-2a2d-47d4-b133-6a35ca191fb2" xlink:href="arwr-20220930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_9433a4f3-2a2d-47d4-b133-6a35ca191fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_00b6b1c0-36bb-4caa-81e1-404b2c57a786" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_00b6b1c0-36bb-4caa-81e1-404b2c57a786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b6ba49-45ac-470b-8e96-2447d4bc4411_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b6ba49-45ac-470b-8e96-2447d4bc4411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1f8bd83b-bf0f-4e5a-8151-2c9f0b80c9dd" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1f8bd83b-bf0f-4e5a-8151-2c9f0b80c9dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_1c784e36-76f6-4bf7-8c0b-22e1e9759426" xlink:href="arwr-20220930.xsd#arwr_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_LicenseAgreementMember_1c784e36-76f6-4bf7-8c0b-22e1e9759426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_54f491e2-390a-4a24-8abc-e9f27a609a75" xlink:href="arwr-20220930.xsd#arwr_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_CollaborationAgreementMember_54f491e2-390a-4a24-8abc-e9f27a609a75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_001986fd-b6d3-4280-9b7e-4cd24315fe54" xlink:href="arwr-20220930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_001986fd-b6d3-4280-9b7e-4cd24315fe54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_026702fc-a3c9-4627-873b-386ac5fd0182" xlink:href="arwr-20220930.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_026702fc-a3c9-4627-873b-386ac5fd0182" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ce49765-c2c0-473a-be68-06b02f99e26a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9ce49765-c2c0-473a-be68-06b02f99e26a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_85263bed-bc43-49cf-8fd6-ab7b0a1239e3" xlink:href="arwr-20220930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_85263bed-bc43-49cf-8fd6-ab7b0a1239e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d51952e7-2894-40e0-a69c-f7c81676b7c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:to="loc_srt_RangeMember_d51952e7-2894-40e0-a69c-f7c81676b7c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:to="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b1b3963-3f3f-4ddb-a94d-77c4e38ef08d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:to="loc_srt_MaximumMember_6b1b3963-3f3f-4ddb-a94d-77c4e38ef08d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended" id="if3e4b28e17ed48d587cafe9b0a085377_CollaborationandLicenseAgreementsAmgenIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_e2f2d1da-1427-44ed-9e96-ba2ca9adf573" xlink:href="arwr-20220930.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_NumberOfAgreements_e2f2d1da-1427-44ed-9e96-ba2ca9adf573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_37787eb6-0c9f-4c93-9a6e-bc5f54838430" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_37787eb6-0c9f-4c93-9a6e-bc5f54838430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30312105-f679-4cd9-af42-0969a9c310a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30312105-f679-4cd9-af42-0969a9c310a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_3a2fab31-b0f5-42d1-b9ec-468574d59807" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_MilestonePaymentReceived_3a2fab31-b0f5-42d1-b9ec-468574d59807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_88d31adb-b32a-4464-945e-3a027b4bd7b8" xlink:href="arwr-20220930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_88d31adb-b32a-4464-945e-3a027b4bd7b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0aa3d0b-3940-4b32-ba55-9ec02a2ae9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0aa3d0b-3940-4b32-ba55-9ec02a2ae9ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c638c0f1-29d6-4313-a26b-ab0257c71acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c638c0f1-29d6-4313-a26b-ab0257c71acd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_443c2d3f-6fc9-4827-8c11-6d0bd3c90186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_443c2d3f-6fc9-4827-8c11-6d0bd3c90186" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_87584379-4d3c-4183-a76d-7c1644702152_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:to="loc_dei_EntityDomain_87584379-4d3c-4183-a76d-7c1644702152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:to="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_e7cb9dd5-f826-449c-9ecb-e77881adf441" xlink:href="arwr-20220930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:to="loc_arwr_AmgenIncorporatedMember_e7cb9dd5-f826-449c-9ecb-e77881adf441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1d5e5a26-618d-4eca-bbc1-4426e2f77fe7" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1d5e5a26-618d-4eca-bbc1-4426e2f77fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_3174276c-a30d-4b73-9b66-b0c3ed36a82c" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_OlpasiranAgreementMember_3174276c-a30d-4b73-9b66-b0c3ed36a82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0034f932-0f0a-4f50-9aeb-6035cf726d57" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0034f932-0f0a-4f50-9aeb-6035cf726d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1e318c8-af19-4a7a-bb9b-a24de5895d05_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:to="loc_srt_RangeMember_d1e318c8-af19-4a7a-bb9b-a24de5895d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:to="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1239f430-3c0f-4446-a0dd-e9df5a543769" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:to="loc_srt_MaximumMember_1239f430-3c0f-4446-a0dd-e9df5a543769" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended" id="i1d5672ea83fc4085a1bee1acf1954346_CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_94f881c7-fce1-499c-b7d9-26ed7eb512e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_94f881c7-fce1-499c-b7d9-26ed7eb512e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59333875-7045-43e0-931c-d79aa659e0f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59333875-7045-43e0-931c-d79aa659e0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_a5e976a4-3daa-42d0-bc4d-6ce40581a187" xlink:href="arwr-20220930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_a5e976a4-3daa-42d0-bc4d-6ce40581a187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0fb74539-f358-4908-8206-d18d5dc26f6a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0fb74539-f358-4908-8206-d18d5dc26f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_33138575-a369-4600-8ce8-d2af4868de6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_33138575-a369-4600-8ce8-d2af4868de6f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended" id="ia806856550ba40a293799cf5aaf1ae8d_InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4490e45f-b3e6-4650-ae65-7134b7ba0626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4490e45f-b3e6-4650-ae65-7134b7ba0626" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_925c2466-f3a5-43e2-91ff-db667ef4e004" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_925c2466-f3a5-43e2-91ff-db667ef4e004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_fff685b3-4239-4cb8-9be9-e481e44f92be" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_fff685b3-4239-4cb8-9be9-e481e44f92be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_991042a9-70ba-466a-87c9-eb6aca7179e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_991042a9-70ba-466a-87c9-eb6aca7179e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_85b05bdb-e2b6-4c6c-89d8-5ad151603cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_85b05bdb-e2b6-4c6c-89d8-5ad151603cc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_5d026c3c-e1e9-4248-a0ed-5aee91b30337" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_5d026c3c-e1e9-4248-a0ed-5aee91b30337" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_5d2b44eb-fa6a-4090-a09b-6f16cad1fa7f" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_5d2b44eb-fa6a-4090-a09b-6f16cad1fa7f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_f7e32fec-fe11-4fe7-99c5-ff6d52736b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_f7e32fec-fe11-4fe7-99c5-ff6d52736b99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5064982a-9b89-472f-a1d0-6958081e92d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5064982a-9b89-472f-a1d0-6958081e92d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_83a58dad-35a8-4123-8f7b-9afc4fcbe177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_83a58dad-35a8-4123-8f7b-9afc4fcbe177" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f6f0df62-48f8-4588-b5ec-f049eb4eddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f6f0df62-48f8-4588-b5ec-f049eb4eddbf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_754846d9-8d4b-440b-85d3-79930c417430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_754846d9-8d4b-440b-85d3-79930c417430" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f690d16-8519-417d-932f-8bfeac5e966a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f690d16-8519-417d-932f-8bfeac5e966a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_fcef71b2-c518-457b-bd81-3464b4670568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:to="loc_us-gaap_DebtSecuritiesMember_fcef71b2-c518-457b-bd81-3464b4670568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a30ee7e8-780e-4f63-a4dc-e751458f98e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a30ee7e8-780e-4f63-a4dc-e751458f98e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i0763fe83b1524d31a8262c39849187a1_IntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1e1a55a-3d72-4608-b0b6-28e740555fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1e1a55a-3d72-4608-b0b6-28e740555fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5ab553-bf4e-4588-a4c9-c48371bb2526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5ab553-bf4e-4588-a4c9-c48371bb2526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_e1563312-4ec7-4858-8dc1-0c8fb65de24a" xlink:href="arwr-20220930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_e1563312-4ec7-4858-8dc1-0c8fb65de24a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8cf3915-16e2-4415-8c5c-cb0ac6bdc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8cf3915-16e2-4415-8c5c-cb0ac6bdc1e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8b15a34e-c2b2-41d2-9335-a23247478f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8b15a34e-c2b2-41d2-9335-a23247478f8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f5471140-a4f1-446a-8eb1-ce081633fc74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f5471140-a4f1-446a-8eb1-ce081633fc74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_45248684-5d1a-43cc-9b87-0fb33d845a31" xlink:href="arwr-20220930.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:to="loc_arwr_NovartisMember_45248684-5d1a-43cc-9b87-0fb33d845a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60694241-a451-4c23-b709-f6c35dce0806_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60694241-a451-4c23-b709-f6c35dce0806_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_8ac5822a-889b-448e-b4bb-4a8fa648f0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:to="loc_us-gaap_PatentsMember_8ac5822a-889b-448e-b4bb-4a8fa648f0e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cdff5e89-10fb-4728-9a00-007489069964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:to="loc_us-gaap_LicensingAgreementsMember_cdff5e89-10fb-4728-9a00-007489069964" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended" id="i16b340efbd0a4369897e4f23a2eaa310_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_04d221dc-e40d-49c8-8892-a86b5cc9dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_04d221dc-e40d-49c8-8892-a86b5cc9dc51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a01bc10f-6a61-4a12-9053-621a5707ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a01bc10f-6a61-4a12-9053-621a5707ac0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2e080419-86ee-429d-bc5c-aa9898692726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesIssued_2e080419-86ee-429d-bc5c-aa9898692726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f5dbb35f-1594-471d-96fe-f5c1c81d73af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f5dbb35f-1594-471d-96fe-f5c1c81d73af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8b89b8df-b810-4fc8-b964-4d63162a2a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8b89b8df-b810-4fc8-b964-4d63162a2a4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d5f15ed7-a98c-4ac3-80e6-59912d19a260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d5f15ed7-a98c-4ac3-80e6-59912d19a260" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fd70cf69-1639-423e-8c8a-8cb8ed8e06dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fd70cf69-1639-423e-8c8a-8cb8ed8e06dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b7ad3b55-75a0-43ce-a602-c9661935452a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b7ad3b55-75a0-43ce-a602-c9661935452a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f277446f-374a-446f-ba93-b925c1fe3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f277446f-374a-446f-ba93-b925c1fe3f84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_433d206f-df92-4f15-9742-90913df691ee" xlink:href="arwr-20220930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_433d206f-df92-4f15-9742-90913df691ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_a47373e4-d7d5-468f-8464-24b9b902eba6" xlink:href="arwr-20220930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_a47373e4-d7d5-468f-8464-24b9b902eba6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8310a6a9-8c7d-4545-8d91-17a00d2c7e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_SharesIssued_8310a6a9-8c7d-4545-8d91-17a00d2c7e65" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a48b6e5f-80de-419b-ab3c-76999127af3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:to="loc_us-gaap_PlanNameDomain_a48b6e5f-80de-419b-ab3c-76999127af3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:to="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_69e2afe9-8770-4205-bd88-3ea6b17c90a2" xlink:href="arwr-20220930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_69e2afe9-8770-4205-bd88-3ea6b17c90a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d142a85-3f96-4001-b5f9-28db1b3ceff3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d142a85-3f96-4001-b5f9-28db1b3ceff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_1a277590-20cf-4daf-a244-0901695579df" xlink:href="arwr-20220930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:to="loc_arwr_AtTheMarketAgreementMember_1a277590-20cf-4daf-a244-0901695579df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6114b7df-dd16-4c9f-ae28-f2b9feaad18a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:to="loc_srt_RangeMember_6114b7df-dd16-4c9f-ae28-f2b9feaad18a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:to="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_641a565d-2d09-4057-bff5-3eb8058f3e49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:to="loc_srt_MaximumMember_641a565d-2d09-4057-bff5-3eb8058f3e49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="idd00a6cd7eae4543ae41cef665f58f22_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_cb317d16-2cbe-4379-92d5-cd9385ecf3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_cb317d16-2cbe-4379-92d5-cd9385ecf3c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ddb5d7d2-6efd-4be7-bb1b-193e3def9e0f" xlink:href="arwr-20220930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ddb5d7d2-6efd-4be7-bb1b-193e3def9e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_f6c4014c-49ba-405c-a4c1-cd9bec8f4ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_AreaOfLand_f6c4014c-49ba-405c-a4c1-cd9bec8f4ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_3950ef04-a7dc-48a1-a034-2c1b4565af9e" xlink:href="arwr-20220930.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_3950ef04-a7dc-48a1-a034-2c1b4565af9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_1cba4137-ef60-4d14-94b8-4159fecea188" xlink:href="arwr-20220930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_TaxIncrementFinancingAward_1cba4137-ef60-4d14-94b8-4159fecea188" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7ddf373d-48ff-4801-9dc9-63b54f62f244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7ddf373d-48ff-4801-9dc9-63b54f62f244" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_9f527e3d-60ad-46c6-8d72-20a3231d3ca7" xlink:href="arwr-20220930.xsd#arwr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_MilestonePayments_9f527e3d-60ad-46c6-8d72-20a3231d3ca7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_312e1d5a-d651-49ff-9761-3ea5f012ed2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:to="loc_srt_SegmentGeographicalDomain_312e1d5a-d651-49ff-9761-3ea5f012ed2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:to="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_37f3e3db-1dc8-44b1-909d-6453c4cc3bba" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:to="loc_stpr_WI_37f3e3db-1dc8-44b1-909d-6453c4cc3bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6970293-36b6-463b-939b-d1c1f15a8dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6970293-36b6-463b-939b-d1c1f15a8dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_1c32ed49-9782-400f-9d63-3284851832a6" xlink:href="arwr-20220930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_VeronaTechnologyParkMember_1c32ed49-9782-400f-9d63-3284851832a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_264a1e0a-f86a-433f-be41-3cd854bfe19b" xlink:href="arwr-20220930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_DrugManufacturingFacilityMember_264a1e0a-f86a-433f-be41-3cd854bfe19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_658064dd-f2a7-445c-9ea6-348b5ab76657" xlink:href="arwr-20220930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_658064dd-f2a7-445c-9ea6-348b5ab76657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_2ee63da7-580d-4a07-99e4-55919273ec4e" xlink:href="arwr-20220930.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_FacilitiesMember_2ee63da7-580d-4a07-99e4-55919273ec4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3dde09cf-1ed5-43be-b79a-70dc906625ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:to="loc_srt_RangeMember_3dde09cf-1ed5-43be-b79a-70dc906625ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:to="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5bfbd202-a3f4-45da-bc18-1c51e4048d78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:to="loc_srt_MinimumMember_5bfbd202-a3f4-45da-bc18-1c51e4048d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8855c874-0db2-4d31-9924-b1d17b93ac70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:to="loc_srt_MaximumMember_8855c874-0db2-4d31-9924-b1d17b93ac70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:to="loc_us-gaap_OtherCommitmentsDomain_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:to="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_0bbd310e-af2d-4a53-b6b2-56d736a9b70f" xlink:href="arwr-20220930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_0bbd310e-af2d-4a53-b6b2-56d736a9b70f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df43d40e-e61f-446e-a3f5-2dc0689ff4b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df43d40e-e61f-446e-a3f5-2dc0689ff4b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember_27554e25-4d17-4ddc-956d-b1f750762f26" xlink:href="arwr-20220930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:to="loc_arwr_AROENacAndAROHIF2CandidatesMember_27554e25-4d17-4ddc-956d-b1f750762f26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended" id="id95090839d344b5e8e0b11a598aa3bec_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92b8aba1-3e07-4dbb-b774-89b54d0bab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92b8aba1-3e07-4dbb-b774-89b54d0bab1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_0ff558ad-24c8-4d56-9248-e23bdc0a6c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_0ff558ad-24c8-4d56-9248-e23bdc0a6c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ca0e9de-d60c-4ffa-9ab5-403c591e1783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ca0e9de-d60c-4ffa-9ab5-403c591e1783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_aaba427f-e8f0-4071-bd76-1e3d7235a3ac" xlink:href="arwr-20220930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_aaba427f-e8f0-4071-bd76-1e3d7235a3ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_b091ca43-cb04-4384-b74f-9012f501b5b4" xlink:href="arwr-20220930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_b091ca43-cb04-4384-b74f-9012f501b5b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_acbe17ea-aba0-400e-bdc6-0d252fca41ad" xlink:href="arwr-20220930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_NumberOfOptionsToRenew_acbe17ea-aba0-400e-bdc6-0d252fca41ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dd4490d4-1ddd-4651-91c1-8e03cc169ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dd4490d4-1ddd-4651-91c1-8e03cc169ee9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease_4788c0c9-b778-4295-ba74-cc2947db64ba" xlink:href="arwr-20220930.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_AdditionalLandSubjectToLease_4788c0c9-b778-4295-ba74-cc2947db64ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_34a0bb44-8721-42c0-a3ae-941206bd328f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_ShortTermLeaseCost_34a0bb44-8721-42c0-a3ae-941206bd328f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2158f408-172c-406a-8dba-ad7a413a3d5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2158f408-172c-406a-8dba-ad7a413a3d5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_3035fb0a-419e-41d2-b06c-d6d624c29842" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_3035fb0a-419e-41d2-b06c-d6d624c29842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_951ad722-0686-49c0-870f-409c1a12bbef" xlink:href="arwr-20220930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_951ad722-0686-49c0-870f-409c1a12bbef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_6241f32c-99bb-40e3-8cdf-0767450e5ab2" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_6241f32c-99bb-40e3-8cdf-0767450e5ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f0a6644b-2220-4f0b-a4a8-f42002089892_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:to="loc_srt_SegmentGeographicalDomain_f0a6644b-2220-4f0b-a4a8-f42002089892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:to="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a99c1866-fbc4-414a-98c0-1a25702e8d3a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:to="loc_stpr_CA_a99c1866-fbc4-414a-98c0-1a25702e8d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_00f2ddda-98da-489f-8ea9-9bcc9e3edd94" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:to="loc_stpr_WI_00f2ddda-98da-489f-8ea9-9bcc9e3edd94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48a026af-3646-40cb-a022-fec7867edefc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:to="loc_srt_RangeMember_48a026af-3646-40cb-a022-fec7867edefc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:to="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a566dc4c-55bb-46fa-92de-040f4a710c6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:to="loc_srt_MaximumMember_a566dc4c-55bb-46fa-92de-040f4a710c6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef312a89-b378-4842-94b2-e911dc88116a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef312a89-b378-4842-94b2-e911dc88116a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_38a2ea69-5c7b-4f81-b707-20363ddafb6a" xlink:href="arwr-20220930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:to="loc_arwr_ColoradoOwnerLLCMember_38a2ea69-5c7b-4f81-b707-20363ddafb6a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended" id="i8ee44c1317fe494a9edbc18099eb3828_LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26804b4b-aec7-41a7-947a-99ad87b9c318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26804b4b-aec7-41a7-947a-99ad87b9c318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a6914fc-93a3-4176-896c-fb3790c5dd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a6914fc-93a3-4176-896c-fb3790c5dd7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d42b66b-feea-4111-ba4d-b26a4c7a5c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d42b66b-feea-4111-ba4d-b26a4c7a5c82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:to="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f2471b26-1f1a-4caa-b7eb-8bcd3856ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_OperatingLeaseCost_f2471b26-1f1a-4caa-b7eb-8bcd3856ba5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_593ce25e-45f6-4562-b6f9-077b7895fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_VariableLeaseCost_593ce25e-45f6-4562-b6f9-077b7895fc9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b5c789f1-576e-4efe-afdb-ce57283c7b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_LeaseCost_b5c789f1-576e-4efe-afdb-ce57283c7b00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73e96eb9-8027-4c11-8685-7984067f2daf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73e96eb9-8027-4c11-8685-7984067f2daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af869ccb-c5b3-46ad-a3e7-f6a8ed0d26ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af869ccb-c5b3-46ad-a3e7-f6a8ed0d26ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d569b3bb-4e96-4748-a6a4-396969bf3738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d569b3bb-4e96-4748-a6a4-396969bf3738" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i1280859d63904a1e9aa4e388718079a1_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b006d0ba-e9f3-48fc-ba1f-196eda6e24d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b006d0ba-e9f3-48fc-ba1f-196eda6e24d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450fedfb-1497-4c6c-a474-e8c393d075f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450fedfb-1497-4c6c-a474-e8c393d075f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb63706c-776b-4165-89d4-b238e2775781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb63706c-776b-4165-89d4-b238e2775781" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2609a3c9-ca27-4cc7-9eac-01e195272dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2609a3c9-ca27-4cc7-9eac-01e195272dee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b09c2ae7-19a7-4e36-93b5-66d37cc33575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b09c2ae7-19a7-4e36-93b5-66d37cc33575" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67bf0d72-16c3-402e-815d-88513f2912fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67bf0d72-16c3-402e-815d-88513f2912fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672534c9-8f20-4fe1-96a5-a9cffdab0ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672534c9-8f20-4fe1-96a5-a9cffdab0ee6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10ffae89-7b3c-45cd-a30e-cc8f689b41ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10ffae89-7b3c-45cd-a30e-cc8f689b41ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_d6206c1b-89ad-4703-8f6e-d64631e565cf" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_d6206c1b-89ad-4703-8f6e-d64631e565cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6001ee3-1241-4727-9eb2-bdc5d45861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6001ee3-1241-4727-9eb2-bdc5d45861e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_33ad8a1b-9b3d-4f02-ad27-7a0a7cb65bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_33ad8a1b-9b3d-4f02-ad27-7a0a7cb65bc5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ebe2abaf-4195-4745-a036-78acb5e530a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:to="loc_us-gaap_PlanNameDomain_ebe2abaf-4195-4745-a036-78acb5e530a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:to="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_febd3af6-8f3b-466a-b2d6-ce572e60f442" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_febd3af6-8f3b-466a-b2d6-ce572e60f442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ba2c1a0b-4c31-4bc8-82bb-0b8419176a86" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ba2c1a0b-4c31-4bc8-82bb-0b8419176a86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_078c6d08-888d-4af6-8d92-a8f3c0b82117" xlink:href="arwr-20220930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_078c6d08-888d-4af6-8d92-a8f3c0b82117" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_1cd91b33-5c81-40f3-bf7b-24dc580a3b22" xlink:href="arwr-20220930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_1cd91b33-5c81-40f3-bf7b-24dc580a3b22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e30e73f-210e-4170-a492-c319b026258c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e30e73f-210e-4170-a492-c319b026258c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_05202647-94a8-4155-84c2-268c65960f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_05202647-94a8-4155-84c2-268c65960f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebdfb627-39b3-471a-b951-6aafe4b30278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebdfb627-39b3-471a-b951-6aafe4b30278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember_3784d887-d73c-432d-b4d6-090a5351b906" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember_3784d887-d73c-432d-b4d6-090a5351b906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_97f5b237-f4c7-4a5c-91d4-b7facc001d15" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_97f5b237-f4c7-4a5c-91d4-b7facc001d15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_d30f8e24-eb37-4a8a-a5e3-a0299e77ff7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:to="loc_srt_ChiefExecutiveOfficerMember_d30f8e24-eb37-4a8a-a5e3-a0299e77ff7e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended" id="i7dbafaf456cc4fe184fb8229c4085686_StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b0047ef-64e6-4e7b-90ec-a013055901df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b0047ef-64e6-4e7b-90ec-a013055901df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_272389df-7c27-4133-92fa-31bd6ecc566a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_272389df-7c27-4133-92fa-31bd6ecc566a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_8696dd51-d74b-4715-9c3f-3838d0b56e5f" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_8696dd51-d74b-4715-9c3f-3838d0b56e5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:to="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_180e3757-4501-415c-a84b-6a5fcea0d4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_180e3757-4501-415c-a84b-6a5fcea0d4ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:to="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8652b749-7b97-4800-b4e9-e75a2331a130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:to="loc_us-gaap_PlanNameDomain_8652b749-7b97-4800-b4e9-e75a2331a130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:to="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_1b1fd3af-420e-4a27-9c96-b6205633e052" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_1b1fd3af-420e-4a27-9c96-b6205633e052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ad66f713-f1e5-4c36-af3a-6ad30f758ba0" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ad66f713-f1e5-4c36-af3a-6ad30f758ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_7a94eef8-2cbf-49fe-909f-d736e1c1527c" xlink:href="arwr-20220930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_7a94eef8-2cbf-49fe-909f-d736e1c1527c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended" id="i18009f778e4d46f6934ad0aafbad0d13_StockBasedCompensationSummaryofRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa98ce83-c7f6-4067-94fa-4030f1475843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa98ce83-c7f6-4067-94fa-4030f1475843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ca06f6-ae6e-4c0b-a26a-73b822845e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ca06f6-ae6e-4c0b-a26a-73b822845e3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f0ff659-dcef-4b3b-9ee5-45287126af54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f0ff659-dcef-4b3b-9ee5-45287126af54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64e4d1dc-b8c7-402e-9898-0d949c878c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64e4d1dc-b8c7-402e-9898-0d949c878c61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20480271-e472-4b81-906d-93c0f5fdd7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8652c2e6-6dbc-489e-9ae2-434759b9a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8652c2e6-6dbc-489e-9ae2-434759b9a5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3368f2ae-6798-46c5-a9f1-48e8486865ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3368f2ae-6798-46c5-a9f1-48e8486865ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae865231-f830-41b3-9238-f4144802f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae865231-f830-41b3-9238-f4144802f23f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a6c71810-4d66-41d1-ba5d-9741e3b086a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a6c71810-4d66-41d1-ba5d-9741e3b086a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2541ea36-8eae-4219-aeb9-e7115b6bb9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:to="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6225c095-8f89-4d2d-98e6-833f73a4407e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6225c095-8f89-4d2d-98e6-833f73a4407e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ccd2eed5-ba77-4093-b036-a603b8011469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ccd2eed5-ba77-4093-b036-a603b8011469" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i75c0d86e81d042d4832fcb0a0bfbd095_FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f886e206-d11f-4848-ada1-10b4bdd81058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f886e206-d11f-4848-ada1-10b4bdd81058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_586dd9da-cd7f-4071-92c7-d39f111bc814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_586dd9da-cd7f-4071-92c7-d39f111bc814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e32baf5-e90d-4728-9a6c-eae8e50475d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e32baf5-e90d-4728-9a6c-eae8e50475d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66a3a640-478b-48fb-b59d-9280aa7c6904_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66a3a640-478b-48fb-b59d-9280aa7c6904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f901de1c-9ed2-4c8d-a57e-8e985a10e2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f901de1c-9ed2-4c8d-a57e-8e985a10e2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_15247518-142b-4275-bbea-91f73dab9229_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_15247518-142b-4275-bbea-91f73dab9229_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_32880bc2-3010-4f9f-944d-cbfabe410d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_32880bc2-3010-4f9f-944d-cbfabe410d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_67b609c8-893e-4929-a4b5-7a8d67ecab38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_67b609c8-893e-4929-a4b5-7a8d67ecab38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b4e2d3b0-95fa-4cba-9393-81ecf896b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b4e2d3b0-95fa-4cba-9393-81ecf896b856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aef2694c-e145-431c-b861-9076c5446b7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_aef2694c-e145-431c-b861-9076c5446b7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7358cef0-ae14-45a6-9c1f-8b8e44709b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7358cef0-ae14-45a6-9c1f-8b8e44709b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_ac4213cc-3183-4778-8250-f750fb6f972b" xlink:href="arwr-20220930.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_arwr_CommercialNotesMember_ac4213cc-3183-4778-8250-f750fb6f972b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9d7c4795-6e24-466e-88e3-bb1945ada0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9d7c4795-6e24-466e-88e3-bb1945ada0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d8b11b00-2973-4be7-a627-96e96fd768bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d8b11b00-2973-4be7-a627-96e96fd768bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cc581e89-ca54-46a2-b386-3019b3c798da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cc581e89-ca54-46a2-b386-3019b3c798da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4a945bee-ed51-4e2d-85e2-93c7cb6cc5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4a945bee-ed51-4e2d-85e2-93c7cb6cc5f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended" id="ie28c6f51488642ed8dc24ec46b94b4ac_EmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1f43bd-58e0-4068-b979-89f95fde5804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1f43bd-58e0-4068-b979-89f95fde5804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf62f80f-6a30-4b70-ab49-80c468eeec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf62f80f-6a30-4b70-ab49-80c468eeec4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7947df02-8b76-4cb4-8e1f-b778337d1abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7947df02-8b76-4cb4-8e1f-b778337d1abf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_7419fb9b-43c6-454c-899e-b95e26d3dd96" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_7419fb9b-43c6-454c-899e-b95e26d3dd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_74e93c47-bc17-45b3-b603-a063170368c7" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_74e93c47-bc17-45b3-b603-a063170368c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" id="i23b024dd0a9f489a823ba753ffc6a5db_SubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_338ed402-e499-4051-aec5-9a640c38cc75" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_InitialTransactionPrice_338ed402-e499-4051-aec5-9a640c38cc75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_1bc23735-e80c-4803-b4c4-a5546e604066" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_1bc23735-e80c-4803-b4c4-a5546e604066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_08181230-95fa-4385-8ca2-f3dfc7e5599c" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivable_08181230-95fa-4385-8ca2-f3dfc7e5599c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_a0bc1d94-56b1-404c-b6bd-8d34d4301b44" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_a0bc1d94-56b1-404c-b6bd-8d34d4301b44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_2012c9db-083a-47e1-bfe2-32c4101da273" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_2012c9db-083a-47e1-bfe2-32c4101da273" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_a4ca2486-f452-4569-936f-554629ddfd83" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_a4ca2486-f452-4569-936f-554629ddfd83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_634d1535-61de-4945-a0e2-3caad62cf2b5" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_RoyaltyPaymentThreshold_634d1535-61de-4945-a0e2-3caad62cf2b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9487157e-8a4e-4b61-92ec-1a57100fd79a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9487157e-8a4e-4b61-92ec-1a57100fd79a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_e5a6ba62-f357-4039-8f4f-587d8f9dde70" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_e5a6ba62-f357-4039-8f4f-587d8f9dde70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6eadb5c4-d01f-48ec-8740-15a25e6775db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6eadb5c4-d01f-48ec-8740-15a25e6775db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aee2749d-6ae6-437f-a34e-a1073216b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:to="loc_us-gaap_SubsequentEventMember_aee2749d-6ae6-437f-a34e-a1073216b3a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_80211295-3e16-4727-85dc-567ddacc1695_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:to="loc_srt_RangeMember_80211295-3e16-4727-85dc-567ddacc1695_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:to="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2839ea1e-8aba-4fef-8e99-0a9f4bf4812c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:to="loc_srt_MaximumMember_2839ea1e-8aba-4fef-8e99-0a9f4bf4812c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arwr-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_84cf0b13-70f2-40a3-9788-44088ddc0fcf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6c9a165a-7002-4c01-a65a-c90768088213_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c1128eaf-1529-40f5-94c3-2155f8424d7b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_370b2909-316f-45c7-b40a-8d3dc25d0c1e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6d6c4ce9-5b9c-43e8-b78f-2b60f80a4908_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a50ea747-bc82-41ed-8587-0091a3bfd235_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c793f262-fa07-4fbb-a4d4-aa75193a6033_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_44aa4ef1-3b87-4d4a-90f0-4282a84601d6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3bf824e5-fce7-461f-b3d0-bf6c9481a818_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_246c2716-e1c2-446c-b147-32b39bbcb7c0_totalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_6a0259e3-66d6-4a2f-8d72-6a9ffcbbd243_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_d152ff78-41f4-48ea-a0a2-d91fc8d0803d_terseLabel_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_label_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments [Member]</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology license commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:href="arwr-20220930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:to="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ba3ff3f4-212c-4f5c-81d0-f91b219dd319_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_86cbbaad-c5e0-4ac5-a8ed-fd844e8cb706_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_59c0baa6-db50-4927-92b4-df649391cac8_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable At Start Of Phase Two</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable at start of phase two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:to="lab_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_c5994f2a-1c2a-414a-8ba8-b1c5dd313cd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) from investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b3356eaf-9576-4c9a-8b09-067893713b9d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e7010ded-7a21-44f8-b5e1-5519d86c586b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_20ded8f9-c163-4f32-9e01-45e80a46d8dd_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1029da0e-438d-427f-927d-fff390b6e6ff_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_b5a6ea3c-6f9e-478c-9d99-2c6e00e38927_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax increment financing award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward" xlink:href="arwr-20220930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAward" xlink:to="lab_arwr_TaxIncrementFinancingAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7af05165-2e6e-4997-94ce-e310ad7f1898_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c15fd94f-15d1-4d77-af1d-425483422147_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_be995e10-f5a8-48cb-b108-483ec42daa91_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cd3877df-d10d-40a8-9164-4e09f8d18b9c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7c0056d0-a523-4ca4-a607-0b21f3bf381b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ec6b2cf8-6d09-45e9-b8b1-a014971c36be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74ab00ea-2efc-477e-9f15-0bd7735ab7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_02581aeb-4b81-40cd-9d65-65d4b869caf0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_55a4a44b-f83d-444d-b8e8-e1975afc6dac_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1e72e168-fcc1-4b8c-ab24-ab0597cb62c7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_234149fe-a480-48bf-87c0-2891d137fe79_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_7dac7830-feec-4a3e-a955-728901f22017_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_57930f82-e3c3-41d0-836d-0c1c6d07731e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_2a457920-3e1b-4bf0-8d35-d9a7395e77de_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b482f139-4024-4f50-ab24-3cf953573aef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_18e928a7-149b-4d28-bf0d-09580491873f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5758b0ee-5faa-4ec6-bb1d-02554a4f6c7f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_132930db-b26a-48d7-afbe-7c85b6f8e9b2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_18b44fc2-9989-4428-a7bc-f7aba26e73c9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attriutable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_aa817d45-211f-4b81-a3fa-47ae95663db0_terseLabel_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional office space for lease (in sq ft)</link:label>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_label_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Land Subject To Lease</link:label>
    <link:label id="lab_arwr_AdditionalLandSubjectToLease_documentation_en-US" xlink:label="lab_arwr_AdditionalLandSubjectToLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional land subject to lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease" xlink:href="arwr-20220930.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalLandSubjectToLease" xlink:to="lab_arwr_AdditionalLandSubjectToLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9a092de0-b859-40e3-a02f-c4ad0a5cf001_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_14506706-5306-42a4-8e2b-c1a039a217c5_terseLabel_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_label_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based [Member]</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_documentation_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:to="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_48b455d9-ccb0-4ce2-a5ba-86f7f4cb0f3a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ef784ac9-8525-4cc7-972c-32f66f1bd8ed_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_28d72b86-b0c6-4937-931f-7f5eb6657e88_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7533a4ea-b1f5-4b1b-a338-1c874c2eb458_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROHSDAgreementMember_e0310227-5f6d-42a2-8493-836eb4705b64_terseLabel_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O H S D Agreement</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_label_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O H S D Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROHSDAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROHSDAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AROHSD agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember" xlink:href="arwr-20220930.xsd#arwr_AROHSDAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROHSDAgreementMember" xlink:to="lab_arwr_AROHSDAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_a0ba4431-f827-46a0-b597-378b95bb4c13_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20220930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_97620c76-e1ec-41ea-aeb9-1368e94b0d6f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2a2fc8ce-e044-45a2-ac1d-b0d427fde6da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4c50aec2-8cbd-4456-a2c0-d6375456f9b0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_b6ebe3bd-02da-43d0-b701-ee120c9a7877_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_eda7c3e1-fadd-49c6-8522-12bc242c5a2f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7eabe870-c873-41a2-a09f-ea3dc1fbfdb0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8d81537e-b000-49f4-bd34-defa8280e5d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e5209d74-8db6-4aad-9942-3b98beac1f1f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a12c2ba7-d4be-4d09-ad1f-0a1ec5a731ea_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_de1e8ae7-1fee-4ed5-b6dd-64feac5bab3b_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_5d1a3fff-9f1a-4d44-83e9-ea9eb77d431f_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned area of site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0512b24-2f60-435e-bc66-3e001c4b960d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_cced3769-7d6f-40d8-9c23-362ecd581a62_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20220930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock_5ee0c845-df39-4521-b37a-77e28eecf9c8_terseLabel_en-US" xlink:label="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Policy [Policy Text Block]</link:label>
    <link:label id="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:href="arwr-20220930.xsd#arwr_ContingentConsiderationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:to="lab_arwr_ContingentConsiderationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_338c7dd2-de27-455a-b0da-f203afbfc7d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9fead11f-7308-4653-ab06-1f20e1ad76d7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_637e168a-56f0-46d9-8605-de5d9fe45e60_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_d4d59b11-03ca-4e78-b0c2-53639d09095a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_605b3ab8-aa59-43e8-bef1-8f6ea54851da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_c53e66a7-2cb2-4b62-85d4-5f5cfc057b0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_96f25b5f-1b37-4b33-bc94-b0334203e1dd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a9e56b5f-01b4-49b2-b692-412a3fb25ac1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_85cef06b-386e-4516-b096-16d1a8e58da9_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_1824c866-b391-450b-a50e-40b317e23cae_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_9b14573f-6e98-4bd0-ab1b-af7b19dd7216_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20220930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_244f6a8c-b47e-4448-aef2-d4f29ee75404_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4c60c006-7933-4f90-b8a8-62db8c37b40e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_db87ee25-3909-4bd4-92e6-ecff415a837e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3c3b4499-550b-4ddf-bae8-23194cc4343f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_914a0b35-091e-495d-9a60-e76b42c9bfb2_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of note premiums</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_faf35ff2-93a0-417b-aa65-8442d3fdff4c_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20220930.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_43d7643d-728e-4d2f-bee1-0e29707447fb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - issued for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_55942068-42a1-4685-afe7-5a0b724d2565_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b4b7ae7b-07a6-4c21-acc4-1acf09a98bb9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e16dd67-5c5b-45d0-b39d-31b9398a1acd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_0e63fc94-54c5-4f4d-b7de-e5c835edc978_terseLabel_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_label_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based [Member]</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_documentation_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:to="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f93e1df1-1172-4534-b21f-07e798af79ec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1ddcac49-278c-4eb9-b1a2-3deae66ce26c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_aed9a146-6118-4728-b1a8-cae59211dea9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ef29b61c-8368-42d5-bc35-7e17d5f71cbc_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a85d2377-6649-4a2b-969c-61f50fc304d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_502c3342-79ae-46ff-8a1d-3d6072293b76_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5106396a-6410-4616-9958-099add785867_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2cbc59e2-e312-4ab6-8e0d-8711c7492ccb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4557b0ec-4c01-4311-8dc8-09c744abfc90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_740024a3-a936-40f7-938b-74f127fd64a4_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7d7ae2a6-3519-4e11-9908-b6706fa1e06e_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_430426e0-b5c6-4d87-984b-e459db0533a8_verboseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_51c91ad5-2c96-4b7c-a8e8-6790dd1de905_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04b0789d-cca5-453d-9f53-5fe9053a7349_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_579f350c-0609-49f0-ab3e-0f93ea9b8152_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_a8b5d34b-25bf-484f-814e-cdd007541b3c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_730e5490-01c4-4c7a-9f1b-75737d1ba34b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_79f7f66d-77da-42bb-92ac-85767a05cc40_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c74f4399-4152-435b-a86d-b5e3cfdbb49d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_11e65638-0d31-4a17-b28a-a5e0cd2faba0_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_28022531-d277-4f6a-ac42-5c7e7dae4a49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_96cb2c7b-2eac-433e-b123-3463d3e674a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_38f211fb-9dd0-4d7c-881b-c546d297b880_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-term, Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20220930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_713d25f8-d406-44a3-8097-4cbb5593b08f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b8bffde-11eb-48c2-aca0-952b356dea0f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_c3652248-a087-4630-97bd-76c49fda54b3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross" xlink:to="lab_us-gaap_FurnitureAndFixturesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_75af11e8-01b8-4243-a6c1-bedd0441e3dd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6eed3e4f-704c-4836-a071-9ef3dcd09d6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_93dbcfc8-8aac-4052-ae3f-402523d0317d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7c914163-1408-4aa9-9855-660dff9c0d36_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b65b2961-10f1-4285-ad35-3f36113cc71b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f00342b4-0c1a-4882-a66b-0e54bbb7d03f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_974f8c83-3ae5-40c2-a056-72625f27eacf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1d9e9765-bb29-48bc-9bfb-df79bc597f34_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_74459014-4604-4ada-8c43-c74b702447c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_95527bb3-9772-492c-b7da-7dff3fc6970a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_7758a340-fe6f-468f-b445-b2a3fed89c87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dcb11d46-e4e1-4968-9b4a-89a2e0c0d222_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_4e81c9e6-2c39-43fe-9a82-97d524175a23_terseLabel_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:href="arwr-20220930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfValuationAllowance_8103ac37-46fe-4b20-be97-bbee312d92ed_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_arwr_PercentageOfValuationAllowance_label_en-US" xlink:label="lab_arwr_PercentageOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Valuation Allowance</link:label>
    <link:label id="lab_arwr_PercentageOfValuationAllowance_documentation_en-US" xlink:label="lab_arwr_PercentageOfValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of valuation allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfValuationAllowance" xlink:href="arwr-20220930.xsd#arwr_PercentageOfValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfValuationAllowance" xlink:to="lab_arwr_PercentageOfValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9dba8c19-b0bc-4613-856c-d2d38c12890a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Value Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_62fcf599-627b-481b-ae51-d75117ae2164_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f70f177-6bf8-4bd9-8121-efc331b9407b_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal:</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_c62ceaeb-59fe-457a-8e0f-1ad34d51b99b_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a9ee3ff2-1ca2-4954-a33f-5e580511eb2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2f0d7195-4ab2-40ca-933a-325e85765daf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b6a5fa6b-4289-4bd8-8d46-eabf09a2a178_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8782fda-8244-43cf-b6a5-d22a4d2ef4d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4679e4fa-862e-4b3f-8603-71c4fea94b42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a42516e1-ac49-4a79-8bbd-b1a0915815f9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_9d74221a-0028-411f-84bf-70411bb85c89_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8f88723e-998a-4fd4-b586-470feb0b8dd3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_cba4f855-2c9c-4a1d-a895-a9a18791c7ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_cfec1a45-fc00-41da-b631-08b690d248fb_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c278bf39-ef23-44db-b49f-5da0465565ff_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7bc6f35c-4076-4040-9d39-58db9a2b4ffc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - issued for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6c237806-2daa-41a7-a11c-89a54de29a9c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2dd579c2-c690-4565-8cb3-5341198ad0f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_71112bb8-d3dd-41ee-981a-7cf39eaf16a9_terseLabel_en-US" xlink:label="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Ablaris Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_label_en-US" xlink:label="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Deconsolidation</link:label>
    <link:label id="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_documentation_en-US" xlink:label="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:href="arwr-20220930.xsd#arwr_NoncontrollingInterestIncreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:to="lab_arwr_NoncontrollingInterestIncreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_3f8d0e37-c66d-4dae-9049-24cfb1407f57_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AuditInformationAbstract_label_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arwr_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract" xlink:href="arwr-20220930.xsd#arwr_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AuditInformationAbstract" xlink:to="lab_arwr_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fe2c119e-f8d5-40f7-9e0d-2a76849de8e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_8bf67e90-cbdf-41c0-b557-60fa42f3857b_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20220930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_23af4c43-bca9-4ce4-9a56-d2a2bf9ac436_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3d875a92-0035-4517-b78c-de14e5124c2b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df295e8f-c1cf-49d4-877f-6684228e7aec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncontrolling interest and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42bb5efc-9251-479e-8db4-071bf22dde70_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_833a9c23-9db8-4712-a30f-47b4f44fb04e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b3179b6d-bfc9-4255-a3bd-129e22734ce3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_144d055a-9a09-4973-8876-4036fc99adb6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1b099887-6ca8-4ead-9286-be77da95295e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a375901f-0de4-4b73-9c05-5130b173600c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c9fe6634-4135-4507-ba3f-3c9a28d221c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1c8bbbaf-ae14-4f43-bb71-5e9c66d13dae_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2e61b74f-9761-4a5b-8b37-7ab16d59a1cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_5dcf6321-8c91-41c8-820f-0bbedb048dc0_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAndAROAMG1AgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="lab_arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e341aafd-cf3f-46ac-b427-e99c0d454942_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b0002d12-c5fc-4f2c-860c-125bf18a7e2a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3784574d-f23f-421d-963e-2f9277c3022a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_1da5343b-fd34-4030-a12c-6e805b0fc462_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20220930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_907ab273-8278-406d-82cb-c42a2340da04_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20220930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5a9543b1-a77b-4e37-964f-e925bc10f33e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4deda9c7-bcd5-4faa-9ed5-7e5e743978bb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_5d3a685e-8fa1-4476-aa22-b400b286dabe_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_09320535-af33-4cf7-b55b-be4aa693ab00_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c0dbee1c-c203-4b35-a1b4-0e36a7aba672_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_c50d689d-6b13-49bc-8e0b-aeb91e2c763b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_df501619-d8d3-4e29-9a3b-8f5efa02913b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5fe8b501-2ded-495d-b083-40c9c490279b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_c54ac422-4075-4dbd-ac96-8a6e48d1b708_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5785dba7-7faf-4fec-9513-d3e53b3cc216_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_aae3aaef-f676-493e-80c9-390a1c967ec1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c2d2d671-87c9-472c-abb5-1cab6c19a8df_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_27946602-8439-4f8f-b6a2-29a50a384733_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAgreementMember_337a9294-69e0-444c-bb9b-275ee03e5386_terseLabel_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember" xlink:href="arwr-20220930.xsd#arwr_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAgreementMember" xlink:to="lab_arwr_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_384f3f52-a6c6-4d19-9298-782b805f89a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investment in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_c0013b63-4022-46eb-8654-5f84d8f881c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront capital</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_522feb57-fa76-4a0b-857e-c6953a77a7d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_b1cdbbcc-9a62-4c99-96bd-8cb0dd871853_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20220930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_33de0117-0544-4a58-ba30-7e702476c9df_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_a3129b65-0f6a-4898-af2c-265684ebf597_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6dadfe9b-c00d-4b4a-a2ca-ccca887224d8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ab7c7435-3f9c-4c58-8826-e8425e262ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_dcf8feae-1ffe-4427-8dcc-8c50a79b5964_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9a63bf71-0ec7-4426-96d3-4e4925e07108_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_130ece0f-81a2-4a98-8e1a-badaa0e1416e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b475a982-b5bb-4e60-9104-ab842e621e73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a4c1fc2b-e539-455b-84ba-24f7578e4aba_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1cd86e6b-4473-4dbc-945d-af2c917ab141_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e4b0293e-cf2d-4b35-88cd-5d0cb0d86ea4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5b4f7f3-ee02-4412-99d1-1cfe668c8676_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_816bbd02-aae7-4acd-a36a-a1efc0b3d2c1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_fc5eae32-1388-4bc3-a9d8-73e0a242a45c_negatedLabel_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_label_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities State Taxes</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_documentation_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:to="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_d9ba8901-7e41-4336-b16b-765f0996fdfa_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_79d6b8e5-4878-4597-a5b6-c3dd4a8c2434_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_6f3e3bf8-2e95-4511-9e96-5eb001f63cc6_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Research &amp; Development</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets In Process Research And Development Cost</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:to="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_c87ddb44-9394-4815-9839-93d125d008ea_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_badd40b4-c2c2-4b75-8119-f9a944376c6b_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Adjusted Bases</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3640256e-4c00-476b-89a7-704ab2c90666_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_062ad676-aa7c-49c8-95ec-c19a0ea60dc1_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1b68bd21-7aa2-4832-9fd5-7cfa8ea85e6f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_85a62301-51aa-49c4-a9b3-9dfb5b58194e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_2d71d59e-60f2-4046-9500-4d0f4a02c562_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign:</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8abacd0b-c063-468b-8a52-1468b365ce32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7f20a12e-f8a0-4eb6-ae1b-2d1ef253890f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_527dbb78-a48c-477f-9ca9-d6889b7cb56c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_3f677173-d3d0-41aa-a39e-f6b701a22b2b_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0917c415-e894-4b3d-800d-62fe637862e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9c109842-0279-43dd-b83d-4e194b36b678_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_322e97f3-abc6-4d72-b07c-9aad39dca715_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6958b687-d17a-4ca5-a311-4ee771d7adba_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_32ea2c0f-6e45-4d01-849f-ef6691198d44_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20220930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_24371cec-edbf-4d4b-9982-795fec1af2f0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a58cc99b-5b92-49c4-a45a-6c72e664bb40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_f240a612-137d-44fa-9675-2269f5771deb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Alternative Minimum Tax</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_5c616d4c-94f8-43d6-adc3-fbc7bced37ac_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20220930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_ee324c24-266d-43fe-a90e-7e031c398702_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Use Assets/Lease Liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Right Of Use Assets Or Lease Liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets right of use assets/ lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:to="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_e2a92944-0af4-4db4-ad5f-9ab1b449fb2b_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_bc1b4bc7-f96b-404a-b121-8ac2a31e2f30_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cdaca2bf-133a-4587-9d58-4fb6da8facec_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_d7591190-3539-4b94-9ec6-efd3cd88a6ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount insured in FDIC per account</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d8b87dc7-71f9-4f8b-a93b-c4e9f1498701_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_944ead6b-9002-49e8-ad47-cfe97fd4b44f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7f7b68e3-82db-4675-9b1b-76a3ba313419_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d7ae87c2-2a6a-4634-9913-bccc49351541_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d9bbb52a-e113-42a0-96a8-a88bd2d317c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a41e08d1-a95d-4cbf-b6ed-1e0872efcc93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ff03b41d-48b3-4153-98d8-101bdea94ec5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e703bff2-8349-4f7d-857f-543a0b530e0e_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a73c1d6e-fcd5-4966-abe1-491c92d10321_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_f7fd701d-3b64-4050-828f-cda417cd18d3_terseLabel_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_label_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:label id="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_documentation_en-US" xlink:label="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:href="arwr-20220930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="lab_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c9d9957c-efde-4d07-ad84-4e408ac59ff5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_302d47aa-6f80-446f-bc46-df32c5c8dec8_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_61359208-8fba-41bf-b9fc-2db99003f692_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits costs</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_70b67d54-fb80-44c4-8eca-f9571c4aa820_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_5400933a-ef2c-4928-8426-b73ae07328d2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_08c93e70-4657-42dd-a9f3-755f5bacc182_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9355ed0a-a19b-4e1f-9dfd-c91bdd71362a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05cc44d2-f435-40e5-9617-5d6330d82d88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_46f517d8-b105-43cc-aade-2ac707d46e92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_417f3905-8a08-40d2-8e23-3a0d7f6d41a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cef49d5e-f243-4522-98fc-9f5f4e9117ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4112ccea-dc21-4664-8be7-c6807e6c7478_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_584b9548-aac9-45fe-bccd-7eceb2bb4011_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d5831acb-a51c-4b79-b731-9c1482698cff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_e11fc3cd-a449-489e-b82d-4fdd578c1973_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20220930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_e82f3a3d-cadf-479d-baa2-f921ec437013_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda License Agreement</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20220930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8c623bea-ffe7-4a81-b6c4-c4844ce46ca4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_941eac78-f8b5-4d3f-aadc-9b15735aa57a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f7489555-f9ac-4acb-aed0-873a46979c39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8af2d38a-4e7f-4df0-b11d-b0d4a09de68e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45e03b10-c448-4874-9595-77261ae07b0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_8c084421-64c1-4edf-bd23-667306bbd0a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a24f30c5-2fa4-4313-a9a7-dd6ec9faa046_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_85b7e962-73b2-431c-9f29-c5f5f5e6028e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_888b2954-51dd-4ea1-b9f8-8b70904e734c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_a319db67-dc2c-4050-b550-042ef9196e28_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_27c1ea19-3678-4494-861d-9253d989c21f_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_dca34276-75ec-428b-ba9c-57a57ad8217a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_accfb36f-1ee5-4046-baf7-88e8be0429e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9b6953f7-f67e-4d84-88f6-d253bee9dc51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5857acd-eb58-45ab-ab8b-bf424a670140_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_3581f672-c417-43aa-a073-a1517c3d5d80_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20220930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_69e5163e-a391-488b-901f-d81f0c87cfac_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1aaf39fb-82c5-4088-b958-69b48d8d4ad2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_10a74469-2f06-4ccb-8678-1de1840a6c52_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b9aa4116-0039-4c0c-8eb7-ff847ffdf60e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_490a128f-3ffe-450b-a90a-29916abbb923_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_70c4ed5d-ea48-476e-826e-488bad4d135c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_0c551f42-8288-4928-8cf7-9eb1d0954e02_terseLabel_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived" xlink:href="arwr-20220930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontMilestonePaymentReceived" xlink:to="lab_arwr_UpfrontMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c4d64153-a1d2-451c-8053-a463d4df7da2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c78698a7-ebf3-4266-ae86-a304186abd46_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePayments_0449580c-c167-4b3d-976f-7c75d5f54a1a_verboseLabel_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_label_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_documentation_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments" xlink:href="arwr-20220930.xsd#arwr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePayments" xlink:to="lab_arwr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8983863f-96b7-466b-8019-f0b0bbb0b262_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_eaff6f78-9692-464e-bc53-7b71859c23d7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cd6cdc68-002f-4a56-a258-ccb050473708_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a5bc15b9-bb6a-43c9-a1ef-5871a9f1a4e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_e72c5810-3dfd-468e-b5e9-89961c40f7cf_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9aa15013-656b-4ed4-a7e2-c47331d0f615_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2df34bed-7b57-45dd-9363-b586d6a52874_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1f663073-c9d8-4ecc-a46d-a53be968faf1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_08bdb8a1-4163-4e0e-bb9c-dee9dd66c183_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a9c84b4e-e619-4e6c-9b74-32fecc33ffe0_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d7e30c3b-724b-4633-a3c3-b911c0f61ab5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0f1b48f0-7d1d-4a19-96e9-ed2f0d562f8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3201ebda-813f-457a-b450-c677f1991170_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2af7141f-ab60-42ab-ae2a-146c15f5e23f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_97bf0360-b4f1-42b7-9d14-1eed41f594cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4cd12c36-7a54-42e8-b21a-15aae2f96cae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_782ac878-b695-40a8-b46c-c1598f520e2b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_034ac074-c567-46e3-95d1-a9abb6b0d455_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dbf2796e-72d3-48a6-8b03-ec10b905141b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_2cb91c23-16bb-4d1f-a21e-4770c8cf91ad_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_92af1fab-52e4-4d7b-ad4d-c708808187e4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c26af949-c180-4f98-b97e-57a739e5baf9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_487ecf84-b2dc-49ac-a0e1-b2004823edf6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b02de926-31dd-4df5-9d09-5e272dec7c5b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f55bd76c-17ea-4557-9ebd-090db1e964d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_03078a7c-5741-4b97-b930-ec3bb60ccd80_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f76867e3-97c5-470d-8d60-72db70f4f001_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a038291a-fa41-49ac-ac43-1f876705c0a0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_17016125-2ee7-4920-8ead-3a04695bce40_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20220930.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_d011d7b5-21ed-4bff-890c-6bd3bbef905c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_6ec8fec6-2620-4ba7-9d1a-f84eed70d732_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6d93b93b-4d34-4970-ab62-5c9a809b6e50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_3e391249-b8e2-4075-9094-8ad6531105c3_terseLabel_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_label_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans [Member]</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_documentation_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of equity compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:href="arwr-20220930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:to="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_7ced66c6-2d57-43fd-b4df-6e355eee00b6_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20220930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_218ccd7f-d027-4ab6-ad6c-f5bbd95d102b_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20220930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e1797583-6969-47b2-8ac3-77a814401661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4da5ec2a-a802-434d-8dc0-bb216e51a27d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6d775a68-9281-40de-bc31-996d52fcf654_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_93aa600d-8646-4cde-beea-212b33b2b041_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_f587cb4f-2b6a-49b2-8c4c-a0921300efce_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ddf90a9a-1589-483e-a7c6-8ce8b3f26208_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_861d0950-bb5c-4090-b857-13f8a88cbc95_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70323af1-f2bc-43e4-84ad-be32c835b473_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0d2b8bf-00da-468d-944b-3c8d3c8fcce3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60e6c905-31fa-4152-be80-c27e13058728_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cfb673b7-4952-4b5e-a135-9d0a250c40da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cefd41f3-d0a0-48a9-8fd0-a725f5f1f761_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_8bffa84d-1d33-42b7-8512-564c16a6d1f6_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_5a382388-f880-4e4e-be56-c8a6f3d69365_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20220930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_0a5c99e8-2612-4661-9edd-d52e6d352d01_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20220930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_44b9fcf2-ca36-41b8-a166-5eebb80ee3c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_96a6fac1-64ec-485b-8de9-3005ddf6725c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b4149227-50e5-4cfc-8a5d-dc697e2236ae_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_fa98c1d6-0a97-4a46-bf8e-2836c0b51a1e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b524d111-c659-4e0e-b1c4-e71a04107526_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_483c6388-e459-46a9-91d6-0e98a0482741_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e6af19c8-0893-4d86-be8d-db4b8df89807_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_3f21ea0d-d7a4-46ba-9c6b-2ce65ad0740e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAgreementMember_2cb367cb-e788-4288-87ec-c650981c48b5_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember" xlink:href="arwr-20220930.xsd#arwr_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAgreementMember" xlink:to="lab_arwr_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_791335df-fa26-47be-9e2a-c307ab84a5dc_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_a2f9ffcc-c661-4503-8172-432a08d9c029_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3817dda0-2544-4b1e-9444-0a38efd77efd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_5ff7072e-b9d1-46cc-b477-02f8733739b9_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7cda839f-76a3-40ad-a990-e5198606cbb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_22f39fcf-e8f0-4925-9207-b7a2293085e4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_db70f3d6-60ff-4777-a828-97f53b50343f_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20220930.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd2e013a-761b-4dd5-aa5a-bcf6415c8601_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_05be3c63-3577-40b3-a2ba-f43a63d9021b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_788cf5f9-ae09-4f29-a3f2-2ea57143a739_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FederalNetOperatingLossCarryForward_5fe4976e-6be4-4635-acbb-0f9069ca095a_terseLabel_en-US" xlink:label="lab_arwr_FederalNetOperatingLossCarryForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross federal net operating loss carry forwards</link:label>
    <link:label id="lab_arwr_FederalNetOperatingLossCarryForward_label_en-US" xlink:label="lab_arwr_FederalNetOperatingLossCarryForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Net Operating Loss Carry Forward</link:label>
    <link:label id="lab_arwr_FederalNetOperatingLossCarryForward_documentation_en-US" xlink:label="lab_arwr_FederalNetOperatingLossCarryForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal net operating loss carry forward.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FederalNetOperatingLossCarryForward" xlink:href="arwr-20220930.xsd#arwr_FederalNetOperatingLossCarryForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FederalNetOperatingLossCarryForward" xlink:to="lab_arwr_FederalNetOperatingLossCarryForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHAgreementMember_f7be3360-84e3-4d5d-af75-c8c54109d190_terseLabel_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember" xlink:href="arwr-20220930.xsd#arwr_AROXDHAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHAgreementMember" xlink:to="lab_arwr_AROXDHAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_edcaea1e-43ef-4865-b04a-8cdfe497d7e1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_8ac5357c-853d-4667-bc3b-b2a4478cef8c_negatedTerseLabel_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_label_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_documentation_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:href="arwr-20220930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:to="lab_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dfdf6d54-9160-42f4-97fc-b465ddfe1f26_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_b31e6c14-05ca-41be-ad8f-d5df8f3b8e29_terseLabel_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]</link:label>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and use of estimates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:href="arwr-20220930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:to="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e923f335-9db3-41ff-93c6-bf9275b6f92c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca9d9241-6a93-41af-92ef-fef8b96f3927_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0cbc8ae2-0e82-49ac-b5a1-a4f1f29b62a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ce74ffef-9561-466c-b5f3-0912233a4265_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets subject to amortization</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d2aeb246-2131-4146-9a15-4d986ba4bf3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2b7364db-16f8-41c7-a449-7305cc418093_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_3c4cda8d-e980-47b4-b368-16f1f767119d_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_d4e29d92-c725-46dd-912b-387645971e6f_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b3828b5b-c663-4fbb-9a4e-c8a9bc6928c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_73e94cbe-e337-4391-a270-d89e110f28ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_eeedc230-d9c5-45e4-bdf9-1b3eeecee060_terseLabel_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember" xlink:href="arwr-20220930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockPurchaseAgreementMember" xlink:to="lab_arwr_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_dcd21d57-95cc-4954-be3f-ce5c75b05ab6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8955dd0e-6f22-4515-a8b6-f5cbb7c15845_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c57a1eba-59ff-462f-a73f-e6b0b1461bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec60b66f-f3ee-4beb-bc08-8019f73d133f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f856818d-79eb-4c52-a866-924688a7cd35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1a4d924f-aecc-4965-a109-e5fb76dcd090_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_3b852b37-1cf8-467d-9604-bb1446c79be0_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3ae5d099-34b9-4938-bee8-0c55dafdaf38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1dd66a11-9e3a-42f8-9117-7eacef3c4f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_367e15c6-66cd-4225-8053-d54ba4beebc9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ce752093-6810-47eb-86f8-4d9038fb273f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7dfbf6db-458e-42ec-9fdf-798c7d5828b7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_968416a6-b529-494a-aa05-efcb3003977b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_735d33d8-e964-424d-99d4-275eb4f52b91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d96608e4-2c31-444a-9582-0b5136dc7331_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_48e07d7a-d376-4be4-a630-77aa2b9f30c8_terseLabel_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_label_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park [Member]</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_documentation_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona technology park.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember" xlink:href="arwr-20220930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VeronaTechnologyParkMember" xlink:to="lab_arwr_VeronaTechnologyParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f812c964-0e10-4940-bd1a-a75d5fc94e72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e5cf42c0-ea48-4308-8ae6-7b95ead9490d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_63ded79b-e6fb-451a-93cc-0024b73c00e6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_eae7f82e-f13e-4d8c-aa68-f85da006c3f2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_d3d82a7b-d738-49e7-9736-aecc66e37839_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20220930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_5de78ae0-886e-4691-9f28-4725e4a03e10_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8c1fc94f-cacd-49bb-85fd-6b90b5a8eab5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57a34218-08d8-41f0-8537-668e7b61479c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fc5c40cc-1e37-4062-a33c-0c730b218842_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e1fd9201-c950-410d-8c81-8f9692cb685f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f73e4793-5ac1-4462-869d-b7559cd94516_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligation due to discontinuation of clinical trials</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ca66976d-1f1a-44e3-ab77-b3adb424c3a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7e02b2a4-f0d6-4606-81e2-f3af2efac1c1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_27c4556c-b4f4-460f-8284-abae1febfe30_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_88c0370f-76cf-4497-9f82-671af4b4260e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f2d916c7-7ace-4885-85ff-6b4faa29c19d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_df1583d2-362a-49ef-a799-0edbbe7f4c7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_90833f15-e77e-413a-bd54-ffb284d72bee_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_16879a8e-5cb6-482d-baec-efbad4d1c0f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes (Paid) Refunded</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_12dcf883-7ca2-46a3-b8b5-376138337fda_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_262c01a7-a162-4097-8056-e14d5d470e77_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State:</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_6b070478-253e-4c96-8079-0f111cf76b19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_b033875f-aae5-491a-b204-035dcdd46d4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_4466cbf9-54f9-4dd7-80b0-dd4e7d045899_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e90706b0-77ed-4aa5-96d8-d812ac57b72e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bc35507d-d162-44b7-9afd-224f23198766_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredRevenueMember_80185246-2e75-444d-88ab-bb4d6b0592dd_terseLabel_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_label_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_arwr_DeferredRevenueMember_documentation_en-US" xlink:label="lab_arwr_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember" xlink:href="arwr-20220930.xsd#arwr_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredRevenueMember" xlink:to="lab_arwr_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4ba8e757-1d38-4103-ba1b-ae6ef90de255_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_de4afa83-86f3-4a9e-9522-7c10eef3c915_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b7ac5b41-4eaa-4383-a48f-1ac9ef12599f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f972e67e-09e6-452a-a1c8-9509cedf874d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_aca31e14-da72-415a-8688-9e3896ac9ec6_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_ff57f1d9-8134-4959-8152-ed7534c8e5c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3d291bfd-3729-4fb9-988c-e90f60ade0de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4df82029-2898-46f7-904a-2b0b075c8cc7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_c6b4f761-94d6-44e8-8859-9aa9a2ff90f8_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b386c685-3551-4a31-9583-2c1b39ceb67d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_566aa95e-2e68-4dbc-af0d-f22163609fd2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_56dadbbf-dd4c-4ea4-9236-bc1cc1811433_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_370f6162-1c7c-45d3-89cb-d0defbbca65b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d43f7455-8ffb-4b77-b911-710547fe5d15_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_e48570c0-6e14-49fc-add5-eef3a25bbe8c_totalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Federal</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_00b94db3-3f70-4922-a4b6-f5c358e19382_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_c8898f3c-7cca-4f2a-a8cd-b4cb48460b8e_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20220930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c0dbd08c-ed4d-40f0-aa98-c18750932235_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0ae85c59-6e6d-445a-a933-f2ae373363bd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4d5b5d6b-8f7c-43c6-a0bb-8a2412fd0d76_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_af3c205a-b095-4034-988c-11e9e86074e6_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_6db6429b-678c-4dbb-a8e4-8c2fa8d04402_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_bd687b98-2879-4ae6-b138-c5389f9e7f65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_8551b2b9-4423-4169-a101-9525356be3b7_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0a534e8d-5159-43b8-8ae3-1bd3a225a6d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentGross_e7d0107e-62e1-4105-a94c-76402d5f822c_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_label_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment Gross</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross" xlink:href="arwr-20220930.xsd#arwr_ResearchEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentGross" xlink:to="lab_arwr_ResearchEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_ef9e03b9-eaf6-411a-b65b-0432365b2faf_terseLabel_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH Supply Agreement</link:label>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_label_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O X D H Supply Agreement [Member]</link:label>
    <link:label id="lab_arwr_AROXDHSupplyAgreementMember_documentation_en-US" xlink:label="lab_arwr_AROXDHSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-XDH supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember" xlink:href="arwr-20220930.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROXDHSupplyAgreementMember" xlink:to="lab_arwr_AROXDHSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d282ecd0-ab0f-40b1-b02d-94dbe10bee97_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6a54f0e7-fa85-484f-9936-41c3e9fa6b46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_604fb259-3d6d-4c62-bfe7-4fedd9cae357_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20220930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3656abe4-2637-436e-a08e-0e216dfe5448_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f4d8a335-7939-44ae-8cff-67671075b727_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_e285c2e4-cc0f-4e02-9775-558f7a073b61_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions up to 3%</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions Up To Three Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contributions up to three percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:to="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_941f42d8-3e03-4ef7-aa9d-3a19a7a812f5_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land purchased (in acres)</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_label_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Acres Of Land Purchased</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_documentation_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acres of land purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased" xlink:href="arwr-20220930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAcresOfLandPurchased" xlink:to="lab_arwr_NumberOfAcresOfLandPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f30bef91-213f-4d6f-8dad-3030d6d71abe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_087fdf91-ce1b-4b67-8907-e0757cb8271e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f477acfb-20c4-40f7-b23e-f462ee3dbc2f_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_36652386-baad-43c4-8d74-4e8c28cdca82_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions Next 2%</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contribution Next Two Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution next two percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:to="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9663a27c-e277-46ad-b526-42f1a807a9dd_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c00706f6-69a3-4b37-88c8-5ae995ecb1af_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_940a6ffd-21cb-4b5d-b5d1-6d1c796f2699_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8cbb5621-9560-49e0-8a49-0f42b8e19f00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9c288a36-c120-40c9-8d3b-febebbca8626_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest and stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_42f46989-b5e6-471d-aeb3-34d52493f48a_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_fca3b486-b96c-4f94-a2a2-7533fee9b9f7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_7cb60ac2-9025-4e16-879c-bf0b024aceb0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_25bf76ca-63d5-4223-8e27-c449137ebbb5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_5a666249-c1c9-4a9c-a72b-81f7312b92ce_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_94c8d7f9-379d-4c09-894c-28be51f31549_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b2691308-3fb3-4629-bab1-e789cb74f80c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c062040c-50c9-41d6-98c3-0b47375743fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd7f32d7-3102-4038-8e84-2fcd593f9860_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_9b5aa65b-92d6-4b64-9d96-2a32ff8e9fb4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e749b027-6625-41b6-856b-af659348b8ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1c02416d-1104-43c6-b788-f6347c0c5912_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_ae04b909-8a89-4d98-a8cf-84940f837409_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20220930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_75757b4c-1d4d-4341-b280-bc01163fb519_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_199eef64-f6af-4f10-8d89-baa32d87bc23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cfc8cc93-3c04-49c5-82f1-623a62600ccf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_88d9432c-e8ab-46d5-8dc3-d9dad6d67cfc_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20220930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0a0aa0e8-25c5-4a6b-9939-f1ed325d19b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_5c5050d0-ae9d-45e4-acd8-c662dffde70d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d2d42f88-41d4-4029-b5d8-c969059075ba_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0e229ff7-3e00-4dff-b6c0-593b3e3b3034_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e9a8f7f1-7f6e-495d-8a33-02c9eb6a72ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_e942c9a1-9ecf-4b4e-b848-d23912b10526_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20220930.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_42024278-fc77-45fc-a704-e855a2ff7c23_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_06597449-3a81-4891-818e-ee8d732c6c68_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b8416f3e-f428-4011-ac12-91bbb02dd681_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_33c47324-dcce-4e81-a879-89b65e73ed8a_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_20f43746-4bc5-4eec-96c2-17995e5e4dde_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_9951c379-1233-433a-9202-ce0913aeef32_terseLabel_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_label_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:href="arwr-20220930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:to="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_64f859c9-5ead-463e-9866-e0f0fc132f9a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_d3d2e932-3ffc-4525-862a-7060da9ca4f3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_760fd18a-3d9c-4f26-addd-22f9130040ea_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_7e154869-dfce-43f4-be60-f3402909f5fa_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_21337f5f-074d-417c-8583-9177ce635987_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5e0982ba-53e6-4d4b-908f-141385a6a0a6_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_25db5736-1a23-4923-9fa1-d9674d7b37bb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3c437190-d12a-4e1d-b841-b5aff65bd65b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Net Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1fc52ef2-b904-4600-b8e2-41352a1f20fb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_566ddd69-1668-4be5-95c8-0e68a1d2aeba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_53cf6d29-60c7-4123-8e2c-e34971da1f2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_e43256e6-aff0-4306-9f76-a58a938acec7_terseLabel_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-ENaC and ARO-HIF2 Candidates</link:label>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_label_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O E Nac And A R O H I F2 Candidates [Member]</link:label>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_documentation_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-ENac and ARO-HIF2 Candidates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember" xlink:href="arwr-20220930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROENacAndAROHIF2CandidatesMember" xlink:to="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_74c43309-5b3a-4c92-93bc-4acedcff9723_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d9b913d5-fd34-4cde-9453-898eb2b0fae4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_983467a0-e763-47b2-afb7-15466603487a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4f278f43-2943-4971-82ed-deec395e047f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_ee6bc115-8aa3-41fb-b836-993cbf0ebbbf_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20220930.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a4ed9981-1b75-4534-aab5-901aed273d50_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_8e2590c9-c79d-4e3b-9e61-ff39090638db_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_885d513a-b087-4216-988c-8333fbac189b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_07233bb7-3d31-4236-8606-43f1a82e1691_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b98b4b49-5388-44df-98f0-95a514c61147_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_0c5a5b6a-3a85-4042-9db2-1bc1c2f0d748_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_f182ae4a-5bc5-4c20-9bec-18de3db76cd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_759a0adf-104a-4f79-bc55-18419bbd55c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_70c8aafa-bd76-4909-a59f-4e737648276c_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b1fe7947-9175-489e-9da2-6efc925b83d7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7c85a51a-03b4-4c22-89bd-ad6f731d71c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_921c8a75-8c6f-4385-bfa5-f69dcbd28310_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6fc1b987-1563-4ce4-84a7-1f2fd8ba21b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_42d76c61-0d37-4346-b2a7-692d1d8dd928_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9947447c-5bb2-46eb-880a-1e8900ee14d7_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7e2faf7f-14f8-4832-8c61-e7954f5a7aad_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_49207861-8421-4554-8863-d4656fc896ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_13a74cd7-c94d-4cd9-9850-9d51768a3a1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_70514f48-f6fd-4bfd-b26a-3186d7572328_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License agreements</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementMember" xlink:to="lab_arwr_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_876e7009-b8b9-49bf-b18e-af8afb3ff150_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_fd1a395f-a561-4ac1-932b-db68022560e6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ea7e4c49-9714-4931-8d4a-278de7d18ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_397b0679-1e8c-4b94-8ae6-13932a618722_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f78ace83-a2e2-438e-9810-76984293f148_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ebca08bd-725d-4af6-9a56-21e41d8e4881_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_0723471c-52a1-4747-96f7-5b1b85ce3a5a_terseLabel_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-75220795 (ARO-JNJ1)</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_label_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J75220795 A R O J N J1 [Member]</link:label>
    <link:label id="lab_arwr_JNJ75220795AROJNJ1Member_documentation_en-US" xlink:label="lab_arwr_JNJ75220795AROJNJ1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ 75220795 ARO JNJ1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member" xlink:href="arwr-20220930.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ75220795AROJNJ1Member" xlink:to="lab_arwr_JNJ75220795AROJNJ1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_StateNetOperatingLossCarryForwards_c1503db8-aa09-46d5-9c90-264fde3aecbc_terseLabel_en-US" xlink:label="lab_arwr_StateNetOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross state net operating loss carry forwards</link:label>
    <link:label id="lab_arwr_StateNetOperatingLossCarryForwards_label_en-US" xlink:label="lab_arwr_StateNetOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Net Operating Loss Carry Forwards</link:label>
    <link:label id="lab_arwr_StateNetOperatingLossCarryForwards_documentation_en-US" xlink:label="lab_arwr_StateNetOperatingLossCarryForwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State net operating loss carry forwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_StateNetOperatingLossCarryForwards" xlink:href="arwr-20220930.xsd#arwr_StateNetOperatingLossCarryForwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_StateNetOperatingLossCarryForwards" xlink:to="lab_arwr_StateNetOperatingLossCarryForwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_97e93166-ca51-4ac7-b041-9a22c4a3f08d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_52e4ac1b-4a31-409e-9429-809af0646901_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_01c955c2-2797-414a-8fd5-eb35594f0308_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0840be09-92ae-47c5-8b1d-b769a9a83d01_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_93237bcf-8e1e-4bf0-b24a-b90965a43528_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_aece9009-b2f7-4d47-887d-34709cb9a54f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e3bcdede-a116-406a-8b4b-6808487d318d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7b173238-9ace-49ea-9481-6c91202e61a4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_692ef8bc-bab2-4c5f-a00f-0266e18f0c89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_4193dbe3-cb32-4a0a-988f-a54e82038e91_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_ea22d254-486f-4b60-ba04-a7e34417532e_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_1504c288-d4e1-4a7a-bd3c-3fc46c4fbe2e_terseLabel_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JJDC</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20220930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_33b197ad-0787-4fdb-8bc3-c5076e12f5b6_terseLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity award value</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d625d07b-58ed-4651-b152-257514df4c15_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d2d05042-739e-44d6-87f1-6fe51c359d17_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_fda7a624-4057-4140-b842-36b9dafe6b04_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_8a0e4df4-ea0b-4eac-81f7-44f845a24542_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bf010122-90dd-44b0-aef5-ad90c69cf607_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cf798d12-e91f-489c-9587-47a8d1293087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_230bd3be-a46b-4c77-b6b2-529a93f1fc7d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_61d52c31-a6b1-4744-8340-ed76cd8e82d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_942e78b2-f484-4490-95d3-7f2819b41e3f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_7740d4ac-97dd-4761-8f89-3d1ea24f096a_terseLabel_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses year one</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_label_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Payments For Operating Expenses Year One</link:label>
    <link:label id="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne_documentation_en-US" xlink:label="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated payments for operating expenses year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:href="arwr-20220930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:to="lab_arwr_EstimatedPaymentsForOperatingExpensesYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c94074fc-c987-4ea1-856d-abfb8e2b67b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9a3bcb89-6d65-4eb3-ae42-6d9944f0f1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf88ab85-f2e7-4572-be3b-9e816a42d0ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b3f352f-7584-4796-8ebd-882919ba26e9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4c6f85d-acfe-4f0a-adda-22a5f9a5f1c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d3cc34ca-f375-48f2-b381-003d588e9912_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_c5bff723-efe6-42cf-bd21-978d9a1b72b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_9ac9e96d-4a27-4707-8322-ca47edf18c8d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_83298b60-fabf-4b1a-b4e7-ca6419a3d6de_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fbdcff4a-89f4-4240-ab16-9af9c06f4d4b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3d8c5cd2-88b2-4e0d-be10-729bf47828eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_1911a58b-9089-4ffc-8bc9-c0d9712f867d_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_bd973114-bb42-4898-ae3c-178514e4801d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_63c63acf-f5a5-46ad-92f6-18fea4d9af7d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_42a9c6cc-34a5-4f24-a7f3-e86bfb41a39a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_2383e0bb-eb44-4b0f-9108-d7bee859863e_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20220930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_67527dd8-9d50-4262-8a01-354838252ae0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_73b07aad-c108-4a05-aa14-dbce80e77c34_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8c918606-535a-4ea8-be52-8bb28454c467_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ecc20400-dc71-4484-9e75-297580191629_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_8dde6fe8-ff70-4346-a168-625d7b8fa84b_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_2e589f2e-d8a7-4f76-8482-99d8a8de8ed2_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2f9c5f90-4dbf-4b88-84a2-71e49c694d47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c454c16-1229-4382-927c-55dbfc33cdb2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_032be0b1-1baa-48fe-893d-1c363c4dbfc4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_894e54c9-352e-47d6-a69d-516baab2fd46_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arwr-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c366d81e-0879-406a-90bc-8d490185d69a,g:9d381718-0dc0-411c-90ec-901bb668c353-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="simple" xlink:href="arwr-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d1b998b3-a961-4459-9926-e6e8858818d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentType_d1b998b3-a961-4459-9926-e6e8858818d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f343ce17-d779-4dd9-9f4a-49f69e62e4c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentAnnualReport_f343ce17-d779-4dd9-9f4a-49f69e62e4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6739c1c7-b7e0-430e-a028-2dc84842e138" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentPeriodEndDate_6739c1c7-b7e0-430e-a028-2dc84842e138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c1e2bea8-6a9d-4dfe-9b6f-896bd2a079e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_CurrentFiscalYearEndDate_c1e2bea8-6a9d-4dfe-9b6f-896bd2a079e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1a2314f5-0f39-426e-b47a-e4ab1522aaf4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentTransitionReport_1a2314f5-0f39-426e-b47a-e4ab1522aaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3ae48a3b-9b0d-44a5-bc14-7fcc3c51f2cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityFileNumber_3ae48a3b-9b0d-44a5-bc14-7fcc3c51f2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_188bca1f-2d0d-4f37-83cd-23f522305516" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityRegistrantName_188bca1f-2d0d-4f37-83cd-23f522305516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_deb0601b-33e4-49ce-88bc-dde5fff852b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityIncorporationStateCountryCode_deb0601b-33e4-49ce-88bc-dde5fff852b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_499edac0-5b2a-4561-a3b0-73bf81e3117b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityTaxIdentificationNumber_499edac0-5b2a-4561-a3b0-73bf81e3117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5d9efe74-643f-4452-a0d0-9e7c690c811f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_CityAreaCode_5d9efe74-643f-4452-a0d0-9e7c690c811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c4d63447-ff47-42f2-ab05-92db0c24f969" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_LocalPhoneNumber_c4d63447-ff47-42f2-ab05-92db0c24f969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3225dc3-1394-452f-86a1-25e0e50f2e36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityAddressAddressLine1_e3225dc3-1394-452f-86a1-25e0e50f2e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_82b291e7-e62e-45de-9b4c-be0ddadf018e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityAddressAddressLine2_82b291e7-e62e-45de-9b4c-be0ddadf018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1006320f-1d46-46bf-a24c-0317bb2fac6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityAddressCityOrTown_1006320f-1d46-46bf-a24c-0317bb2fac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9fd8b652-aff8-4533-a115-2e6194ad4bb9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityAddressStateOrProvince_9fd8b652-aff8-4533-a115-2e6194ad4bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4a40cb8c-7a14-43d3-83f2-ac79ffe38ede" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityAddressPostalZipCode_4a40cb8c-7a14-43d3-83f2-ac79ffe38ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1c6c3ab7-11ce-48c5-bd5a-90f11d1c6e0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_Security12bTitle_1c6c3ab7-11ce-48c5-bd5a-90f11d1c6e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_caedbf02-690b-468d-b4ff-bb69fcde490d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_TradingSymbol_caedbf02-690b-468d-b4ff-bb69fcde490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_47b1b2f1-f242-4e4c-a12d-cc8ad9a8fdfd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_SecurityExchangeName_47b1b2f1-f242-4e4c-a12d-cc8ad9a8fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7d9ec873-af83-446c-b6aa-138695dff18d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7d9ec873-af83-446c-b6aa-138695dff18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7c1781a1-e403-4ba7-8bb1-e0ba3770b03f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityVoluntaryFilers_7c1781a1-e403-4ba7-8bb1-e0ba3770b03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f122386c-94a4-4e59-8a9a-8893a53efac7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityCurrentReportingStatus_f122386c-94a4-4e59-8a9a-8893a53efac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b262253a-5430-4dfc-bf25-938bff61c704" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityInteractiveDataCurrent_b262253a-5430-4dfc-bf25-938bff61c704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_58c6e107-974e-41b2-a00f-684a1f5b047e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityFilerCategory_58c6e107-974e-41b2-a00f-684a1f5b047e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6eff38ca-4141-4312-a306-62a54434a94f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntitySmallBusiness_6eff38ca-4141-4312-a306-62a54434a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_95e6ec54-4554-4d17-936d-93c0d43138fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityEmergingGrowthCompany_95e6ec54-4554-4d17-936d-93c0d43138fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_7d002577-ff27-43c3-92c1-0344fd79afa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_IcfrAuditorAttestationFlag_7d002577-ff27-43c3-92c1-0344fd79afa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2480d30f-3156-438d-802a-df89f927c2f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityShellCompany_2480d30f-3156-438d-802a-df89f927c2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_889a5c16-da32-4601-aec2-8465c6cd23fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityPublicFloat_889a5c16-da32-4601-aec2-8465c6cd23fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1af4b596-efd9-4968-a477-e53bf6795248" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1af4b596-efd9-4968-a477-e53bf6795248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3b36c1f1-8fbe-46c2-a26e-a21b55d7fd40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3b36c1f1-8fbe-46c2-a26e-a21b55d7fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cf2f2274-f896-419a-bf6a-6792505f3f4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentFiscalYearFocus_cf2f2274-f896-419a-bf6a-6792505f3f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_88c9475e-5b82-4ed0-aa24-edb2333375de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_DocumentFiscalPeriodFocus_88c9475e-5b82-4ed0-aa24-edb2333375de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5310c7a7-3d20-4511-9983-05a073d5efa7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_EntityCentralIndexKey_5310c7a7-3d20-4511-9983-05a073d5efa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_da25438a-941c-4fdd-b919-bcbd2a60ce62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a676a9c0-3087-4f64-83a8-3c662ceba3ba" xlink:to="loc_dei_AmendmentFlag_da25438a-941c-4fdd-b919-bcbd2a60ce62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="simple" xlink:href="arwr-20220930.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract_39aeddbf-9ca5-4fc1-9b67-15f6436c4ffc" xlink:href="arwr-20220930.xsd#arwr_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_29b62a19-8afd-46ec-81c7-344e14af0508" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_39aeddbf-9ca5-4fc1-9b67-15f6436c4ffc" xlink:to="loc_dei_AuditorName_29b62a19-8afd-46ec-81c7-344e14af0508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_05fd8a35-5726-44e4-9380-e067c6f8f7b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_39aeddbf-9ca5-4fc1-9b67-15f6436c4ffc" xlink:to="loc_dei_AuditorLocation_05fd8a35-5726-44e4-9380-e067c6f8f7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a41e8dd8-fd70-4ff5-af00-e1c57c40204a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_39aeddbf-9ca5-4fc1-9b67-15f6436c4ffc" xlink:to="loc_dei_AuditorFirmId_a41e8dd8-fd70-4ff5-af00-e1c57c40204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a5cfbbb5-92d3-4e8e-90c1-e29110dc65e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a5cfbbb5-92d3-4e8e-90c1-e29110dc65e2" xlink:to="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df19957d-953b-45cf-a768-823aba69466b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df19957d-953b-45cf-a768-823aba69466b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8121face-006b-4ae2-9db6-a2b300539073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8121face-006b-4ae2-9db6-a2b300539073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_5cd58aa9-e8cd-4aab-ac16-d3f8632c2b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_5cd58aa9-e8cd-4aab-ac16-d3f8632c2b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7691e4fd-152e-47e7-ac5e-cef7422d213a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7691e4fd-152e-47e7-ac5e-cef7422d213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4472d5c1-d695-4ddb-8e82-0ec505b62072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4472d5c1-d695-4ddb-8e82-0ec505b62072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c16f151e-934b-4cb8-bbd7-cb6b15d1e2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_OtherAssetsCurrent_c16f151e-934b-4cb8-bbd7-cb6b15d1e2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ff5f3798-5b3b-4fce-9387-f1312ebe0b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3534a1b0-67d1-4d9f-8cee-95812392272e" xlink:to="loc_us-gaap_AssetsCurrent_ff5f3798-5b3b-4fce-9387-f1312ebe0b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_27181455-1f7d-4662-a56e-cd3090aae291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_27181455-1f7d-4662-a56e-cd3090aae291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4353fe08-fa56-4abd-932e-e161986a4e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4353fe08-fa56-4abd-932e-e161986a4e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7c1febef-92f0-436c-a5c2-44d5c239a00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_7c1febef-92f0-436c-a5c2-44d5c239a00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0f1b6fb1-57d5-48e3-b9ee-5d5258c5736d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0f1b6fb1-57d5-48e3-b9ee-5d5258c5736d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d73d9f7-3b80-4e8b-9efa-e7e9a584a6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d73d9f7-3b80-4e8b-9efa-e7e9a584a6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dd222b5a-08af-46e6-b666-9b7bf879dfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aba7c790-1529-4a45-a9b4-2e24a4f457be" xlink:to="loc_us-gaap_Assets_dd222b5a-08af-46e6-b666-9b7bf879dfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a5cfbbb5-92d3-4e8e-90c1-e29110dc65e2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0949163e-b557-44ff-b72c-1c5d2b37ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_AccountsPayableCurrent_0949163e-b557-44ff-b72c-1c5d2b37ce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4999ede9-be02-4916-be5b-8e20fae46666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4999ede9-be02-4916-be5b-8e20fae46666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9778453-edf7-4a87-8dcd-53e9dff1e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d9778453-edf7-4a87-8dcd-53e9dff1e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd221282-24ec-4064-95b3-99ff3e9b3efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dd221282-24ec-4064-95b3-99ff3e9b3efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_781c8b12-401b-4fb8-ac4a-4451f0915c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_781c8b12-401b-4fb8-ac4a-4451f0915c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d9729876-ff40-4887-b79a-5f1ca6d65ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39618ddf-7225-4a25-b996-625f4a3b4f34" xlink:to="loc_us-gaap_LiabilitiesCurrent_d9729876-ff40-4887-b79a-5f1ca6d65ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_6bbe7da2-703d-4512-b6aa-7ee3cf700e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_6bbe7da2-703d-4512-b6aa-7ee3cf700e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82fdefce-70d9-4cdf-97b3-b840e90d0353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6bbe7da2-703d-4512-b6aa-7ee3cf700e02" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82fdefce-70d9-4cdf-97b3-b840e90d0353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3ac4f90f-707a-44a9-941a-72e195a22bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6bbe7da2-703d-4512-b6aa-7ee3cf700e02" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3ac4f90f-707a-44a9-941a-72e195a22bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c8af5f87-48bf-41db-8f74-19160aecc61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6bbe7da2-703d-4512-b6aa-7ee3cf700e02" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c8af5f87-48bf-41db-8f74-19160aecc61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c67ff645-978a-45f3-806a-f306445f5be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c67ff645-978a-45f3-806a-f306445f5be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d1d389e7-1740-49f0-a39b-b603d4e12af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_CommonStockValue_d1d389e7-1740-49f0-a39b-b603d4e12af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_56b43d8d-57ac-4dd9-af00-c55176d2b12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_56b43d8d-57ac-4dd9-af00-c55176d2b12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1df1b927-47a1-4fbe-9199-acac7747f4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1df1b927-47a1-4fbe-9199-acac7747f4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f99a48a-61c3-43ed-a164-e726c596fe57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0f99a48a-61c3-43ed-a164-e726c596fe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70acf563-d90b-4245-8905-34e0b0532d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_StockholdersEquity_70acf563-d90b-4245-8905-34e0b0532d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c4933a80-10f9-4525-a23a-5b7353a60161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_MinorityInterest_c4933a80-10f9-4525-a23a-5b7353a60161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d478ec4-419a-4220-9eb5-2fa2daabdeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ea369205-1b75-49ff-b062-e9313b414d34" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d478ec4-419a-4220-9eb5-2fa2daabdeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3da5ed7d-bbba-4626-9705-a2b45f4ef76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3380894e-5b53-44db-a64b-4bca91c26893" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3da5ed7d-bbba-4626-9705-a2b45f4ef76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3243223d-cb7e-4450-b8ce-0c7f7e8f95bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5bb59ef9-a2dd-4e77-9460-c694de73b9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3243223d-cb7e-4450-b8ce-0c7f7e8f95bb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5bb59ef9-a2dd-4e77-9460-c694de73b9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_661e676d-5fb5-4d12-90f6-c7c0d27e7bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3243223d-cb7e-4450-b8ce-0c7f7e8f95bb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_661e676d-5fb5-4d12-90f6-c7c0d27e7bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7508094c-7f9e-4995-9103-e683bf40adc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3243223d-cb7e-4450-b8ce-0c7f7e8f95bb" xlink:to="loc_us-gaap_CommonStockSharesIssued_7508094c-7f9e-4995-9103-e683bf40adc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1cf5b154-7edf-4134-91c0-318981d0c4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3243223d-cb7e-4450-b8ce-0c7f7e8f95bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1cf5b154-7edf-4134-91c0-318981d0c4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4ba1f41-cfa5-4004-abc8-07c605ef2620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4ba1f41-cfa5-4004-abc8-07c605ef2620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e99a8be3-03ca-438d-943b-9585a5e75a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e99a8be3-03ca-438d-943b-9585a5e75a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7517a1e4-0854-4598-892a-02f7a8b14775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e99a8be3-03ca-438d-943b-9585a5e75a26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7517a1e4-0854-4598-892a-02f7a8b14775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_086ea381-6b1a-44f9-8fad-ffefbf98a0af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e99a8be3-03ca-438d-943b-9585a5e75a26" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_086ea381-6b1a-44f9-8fad-ffefbf98a0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b292f764-fa0b-48ba-8adf-ebefb61b6c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e99a8be3-03ca-438d-943b-9585a5e75a26" xlink:to="loc_us-gaap_OperatingExpenses_b292f764-fa0b-48ba-8adf-ebefb61b6c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28682c76-f136-44a1-87c8-3eec609b4356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_OperatingIncomeLoss_28682c76-f136-44a1-87c8-3eec609b4356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c752d95c-d369-4506-8875-d88a93f755b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c752d95c-d369-4506-8875-d88a93f755b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_41e0d111-1cc6-4313-877d-dfa0bc4884e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c752d95c-d369-4506-8875-d88a93f755b0" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_41e0d111-1cc6-4313-877d-dfa0bc4884e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b2461f5f-e664-4e0f-a324-217aa4909c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c752d95c-d369-4506-8875-d88a93f755b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b2461f5f-e664-4e0f-a324-217aa4909c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3c522830-97cd-455f-bcdb-cbc561f16c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c752d95c-d369-4506-8875-d88a93f755b0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3c522830-97cd-455f-bcdb-cbc561f16c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be744fb7-94f3-42f4-bf57-68696a353add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_be744fb7-94f3-42f4-bf57-68696a353add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_41b3138f-f1ac-4352-a6cd-01d60e719929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_41b3138f-f1ac-4352-a6cd-01d60e719929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8df0e80d-d1e4-45cf-93e5-3ffe34f2d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_ProfitLoss_8df0e80d-d1e4-45cf-93e5-3ffe34f2d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8124836c-959d-4fd8-ae36-26c0ec424a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8124836c-959d-4fd8-ae36-26c0ec424a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f655476-4cb2-46d2-a487-f95204c2f465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_NetIncomeLoss_6f655476-4cb2-46d2-a487-f95204c2f465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_229844b3-6dcf-44a5-b620-f85447bbca53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_229844b3-6dcf-44a5-b620-f85447bbca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef6d2c02-2e64-455f-abb2-80babff4f3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_229844b3-6dcf-44a5-b620-f85447bbca53" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef6d2c02-2e64-455f-abb2-80babff4f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_104a8954-e1f5-42a0-b16b-c464b36371f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_229844b3-6dcf-44a5-b620-f85447bbca53" xlink:to="loc_us-gaap_EarningsPerShareDiluted_104a8954-e1f5-42a0-b16b-c464b36371f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fabdd2c7-51b5-4290-bbf7-623f526509e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fabdd2c7-51b5-4290-bbf7-623f526509e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f2ecc14-38be-4053-84fa-2a54d28a16b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fabdd2c7-51b5-4290-bbf7-623f526509e4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f2ecc14-38be-4053-84fa-2a54d28a16b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad0eb916-c66c-4e3f-925b-9aa0d2fce50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fabdd2c7-51b5-4290-bbf7-623f526509e4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad0eb916-c66c-4e3f-925b-9aa0d2fce50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_df7108c8-560e-443c-bc3c-f6bd9923c4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1474ae7d-07a8-4514-973d-86fb33ed3a3e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_df7108c8-560e-443c-bc3c-f6bd9923c4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61e882b4-c30b-4fb4-b1e7-ec13388d4aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_df7108c8-560e-443c-bc3c-f6bd9923c4cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_61e882b4-c30b-4fb4-b1e7-ec13388d4aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_19f5bd32-8a6e-4cf7-bc70-af60da6eb72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_df7108c8-560e-443c-bc3c-f6bd9923c4cd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_19f5bd32-8a6e-4cf7-bc70-af60da6eb72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d573618d-493c-4d0c-ba80-5cf0de2a89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d573618d-493c-4d0c-ba80-5cf0de2a89c0" xlink:to="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7c9f8ce1-7f9e-43a3-a1fe-7bd4c188cd9e" xlink:to="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e2365215-8cd3-4a2e-8d07-db4bad37849b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_CommonStockMember_e2365215-8cd3-4a2e-8d07-db4bad37849b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f15ed765-28f4-4928-ab63-dafde792a840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f15ed765-28f4-4928-ab63-dafde792a840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205b7ada-9f1e-4d6a-88f6-c1eff5ae4833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_205b7ada-9f1e-4d6a-88f6-c1eff5ae4833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ad7bace0-dc99-4785-a815-c9a5b16e9b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_RetainedEarningsMember_ad7bace0-dc99-4785-a815-c9a5b16e9b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b1f7b7eb-7cbb-435d-9553-b6842bb3140a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_139e5fd5-0a10-4053-8b0f-3b541440e439" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b1f7b7eb-7cbb-435d-9553-b6842bb3140a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_277b4ce1-1f4c-4f88-ba3e-393a31689e92" xlink:to="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9823dfea-e808-41e7-9ac8-7164b57b4b89" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_868a1d3a-4381-4476-9da6-653d5685a2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_868a1d3a-4381-4476-9da6-653d5685a2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_222768f2-d308-46cf-97b8-b29b07facfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_SharesOutstanding_222768f2-d308-46cf-97b8-b29b07facfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9a63660-96bf-42d4-98c9-d925ac2ac05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d9a63660-96bf-42d4-98c9-d925ac2ac05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b5e2f42-b99d-4202-8d24-5ac3b88f7372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7b5e2f42-b99d-4202-8d24-5ac3b88f7372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac321b57-b46d-43bb-83f2-afddc3e8ec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ac321b57-b46d-43bb-83f2-afddc3e8ec3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_57f2bf71-f819-460b-88aa-6c697d0dd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_57f2bf71-f819-460b-88aa-6c697d0dd29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_b6a0c0c2-941d-4de0-84a0-ea25b7e4c9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_b6a0c0c2-941d-4de0-84a0-ea25b7e4c9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3c1b2085-88fe-4067-b30b-7493f9d485af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3c1b2085-88fe-4067-b30b-7493f9d485af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_92a730ae-4805-4c38-905b-73e6d416515a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_92a730ae-4805-4c38-905b-73e6d416515a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d89bd327-6864-4453-ba2d-b58a65244968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d89bd327-6864-4453-ba2d-b58a65244968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_7c83cf0e-0e3d-474e-9539-14ec344929cf" xlink:href="arwr-20220930.xsd#arwr_NoncontrollingInterestIncreaseFromDeconsolidation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_arwr_NoncontrollingInterestIncreaseFromDeconsolidation_7c83cf0e-0e3d-474e-9539-14ec344929cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_45252fc7-2a08-4758-bfb2-9f0ac1ebe671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_45252fc7-2a08-4758-bfb2-9f0ac1ebe671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_47287c2d-8b42-4a25-bdb6-bea23bcadfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_ProfitLoss_47287c2d-8b42-4a25-bdb6-bea23bcadfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dcf925f0-d31f-48f6-9083-3028dd2175cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dcf925f0-d31f-48f6-9083-3028dd2175cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bd8efdad-0416-4c84-a424-4af1edac5a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f596f31e-d173-4f39-926d-b5ba287944eb" xlink:to="loc_us-gaap_SharesOutstanding_bd8efdad-0416-4c84-a424-4af1edac5a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_767f106a-7259-44ec-a0bb-8781bd990b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_767f106a-7259-44ec-a0bb-8781bd990b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1f151547-d121-4e35-a40c-777fcd570609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_767f106a-7259-44ec-a0bb-8781bd990b9a" xlink:to="loc_us-gaap_ProfitLoss_1f151547-d121-4e35-a40c-777fcd570609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_767f106a-7259-44ec-a0bb-8781bd990b9a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_30ad700b-186f-4789-9110-8110436bf759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:to="loc_us-gaap_ShareBasedCompensation_30ad700b-186f-4789-9110-8110436bf759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_193f6a10-6f9b-4f06-8c4d-7113a45221e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:to="loc_us-gaap_GainLossOnInvestments_193f6a10-6f9b-4f06-8c4d-7113a45221e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e96f3ff9-6ca5-42d2-a0f7-9a4bc38e2209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:to="loc_us-gaap_DepreciationAndAmortization_e96f3ff9-6ca5-42d2-a0f7-9a4bc38e2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_92276a7f-6a81-406a-a97d-32b6f9ec114b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_92276a7f-6a81-406a-a97d-32b6f9ec114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1bf4d4d9-f683-4b73-a58c-46669308ad79" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9893b50c-1a81-4ca1-b61d-b419384972d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9893b50c-1a81-4ca1-b61d-b419384972d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aab01f8c-ce44-4308-8d4d-41d653ad3a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aab01f8c-ce44-4308-8d4d-41d653ad3a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_630ab0bc-97bf-40f3-8a55-4eb022ee6386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_630ab0bc-97bf-40f3-8a55-4eb022ee6386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d44c6160-5361-4afe-89f0-804e3fb06811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d44c6160-5361-4afe-89f0-804e3fb06811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_90b732d6-681c-44d8-8cc0-9fb929029d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_90b732d6-681c-44d8-8cc0-9fb929029d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2abfeb1b-e4e4-4860-b6fc-da3537aa32a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2abfeb1b-e4e4-4860-b6fc-da3537aa32a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a866836b-b4d6-46f9-a0d2-89a32f697658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb47832d-dc3d-43e4-896f-d367f339c3da" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a866836b-b4d6-46f9-a0d2-89a32f697658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49cc7d86-5f6a-438d-af3c-bdd347575b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_767f106a-7259-44ec-a0bb-8781bd990b9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49cc7d86-5f6a-438d-af3c-bdd347575b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b217e9a4-2e27-4223-92cd-c02009fda1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b217e9a4-2e27-4223-92cd-c02009fda1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_26030b4a-8105-43a3-b166-42834aefa53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_26030b4a-8105-43a3-b166-42834aefa53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c665f7b8-3a3b-495d-aa60-3283b3beb5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c665f7b8-3a3b-495d-aa60-3283b3beb5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f99dc71-6814-4591-8605-7fbdb0ac57e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7e8e9277-45b7-4fce-9e82-f9295d7af538" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f99dc71-6814-4591-8605-7fbdb0ac57e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29c71ef7-f604-4687-82f4-2bd3d0925ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29c71ef7-f604-4687-82f4-2bd3d0925ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_72c58e84-6c87-49b1-b77a-a2d2917d373f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_72c58e84-6c87-49b1-b77a-a2d2917d373f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_985cd757-e603-4bdd-b1e7-ff769a182508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_985cd757-e603-4bdd-b1e7-ff769a182508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9122a93e-0001-447e-8a6e-c3581777f3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f5e427b8-052d-4eee-a140-0b04a70d1488" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9122a93e-0001-447e-8a6e-c3581777f3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3ec4106c-1500-489b-9c79-88f5587185e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3ec4106c-1500-489b-9c79-88f5587185e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd3d877-0805-4aac-bf4a-993b7516ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fd3d877-0805-4aac-bf4a-993b7516ff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1a0b7ba-271e-41fc-87c0-73580e684ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1a0b7ba-271e-41fc-87c0-73580e684ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fc6f61e-4d3d-449e-b250-6358007ae90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fc6f61e-4d3d-449e-b250-6358007ae90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_efc0a2f0-21b4-4a0f-97e8-523c892263ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ab514422-1901-4877-8fbe-5eb8a371704d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_efc0a2f0-21b4-4a0f-97e8-523c892263ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f1d67ced-eb2d-4102-9512-3719b7a426b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_efc0a2f0-21b4-4a0f-97e8-523c892263ef" xlink:to="loc_us-gaap_InterestPaidNet_f1d67ced-eb2d-4102-9512-3719b7a426b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9b1cfc91-17e9-42e9-a856-6212d9b63dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_efc0a2f0-21b4-4a0f-97e8-523c892263ef" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9b1cfc91-17e9-42e9-a856-6212d9b63dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20220930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1c87b19e-26ba-44bb-8b04-036dfc522eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c18b044e-b785-4c76-9612-99d21d2ebdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c87b19e-26ba-44bb-8b04-036dfc522eb5" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c18b044e-b785-4c76-9612-99d21d2ebdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c6371716-64e4-45d4-8c74-1c9bc6fd6f0f" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_19aee2d2-8352-4f22-bf9e-28572edc4cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c6371716-64e4-45d4-8c74-1c9bc6fd6f0f" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_19aee2d2-8352-4f22-bf9e-28572edc4cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="arwr-20220930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23218c3d-1c21-4bd4-bbb7-a6088a4f0f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9591681c-9119-404f-a73e-52eadb0088f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23218c3d-1c21-4bd4-bbb7-a6088a4f0f41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9591681c-9119-404f-a73e-52eadb0088f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20220930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_c5e5f9e5-8a35-4b89-8f55-42afc8a09b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1ea175e5-0090-4b4b-8524-638a748f7cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_c5e5f9e5-8a35-4b89-8f55-42afc8a09b93" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1ea175e5-0090-4b4b-8524-638a748f7cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2b268f16-2ee2-4d07-9662-8283ef777bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b297d62f-be21-4590-853f-684054662d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2b268f16-2ee2-4d07-9662-8283ef777bdd" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b297d62f-be21-4590-853f-684054662d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89bf75ff-74d5-4b65-8166-b6d703d795a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_48bc5a5f-51a5-4cd6-a3a2-c3bb3228fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89bf75ff-74d5-4b65-8166-b6d703d795a9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_48bc5a5f-51a5-4cd6-a3a2-c3bb3228fba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41de7803-bd3c-4a58-9483-30fa2fef854a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1ab34706-372f-43e2-952d-f0904e18de19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41de7803-bd3c-4a58-9483-30fa2fef854a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1ab34706-372f-43e2-952d-f0904e18de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9131ca25-d0c7-4c6b-b562-5e4fb879ff1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5037f233-d60e-4a23-8f33-958e96b68214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9131ca25-d0c7-4c6b-b562-5e4fb879ff1b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5037f233-d60e-4a23-8f33-958e96b68214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90ab39ed-9c40-4350-a0d5-bd57f293ea78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d20a1577-9f4f-4d34-8723-fbe2602da8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90ab39ed-9c40-4350-a0d5-bd57f293ea78" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d20a1577-9f4f-4d34-8723-fbe2602da8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_16a842be-d4a2-448c-86b8-ec68634d2095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2c362f12-ffd1-4a97-82fd-139b5bdd0180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_16a842be-d4a2-448c-86b8-ec68634d2095" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2c362f12-ffd1-4a97-82fd-139b5bdd0180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_df78bbf8-69bb-45bf-b5db-d9eb7f9c6e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_69582f14-ac5f-46c6-a3bd-7f758d9f37d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_df78bbf8-69bb-45bf-b5db-d9eb7f9c6e8c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_69582f14-ac5f-46c6-a3bd-7f758d9f37d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="arwr-20220930.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_996479c8-5929-4fa7-99e5-3312b1ddb511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6cb6d73b-5f20-4038-8811-2df8fde0257f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_996479c8-5929-4fa7-99e5-3312b1ddb511" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6cb6d73b-5f20-4038-8811-2df8fde0257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="simple" xlink:href="arwr-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ecdc18be-d4a1-4d13-9516-4a2873fd0575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ac1729e6-cd23-4e3b-a12c-04614712ad58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ecdc18be-d4a1-4d13-9516-4a2873fd0575" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ac1729e6-cd23-4e3b-a12c-04614712ad58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20220930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_891d6b58-ea9e-49f2-8697-135f6b828471" xlink:href="arwr-20220930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_891d6b58-ea9e-49f2-8697-135f6b828471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_38ef1b99-dc51-43e9-8588-c49c3e9626a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_38ef1b99-dc51-43e9-8588-c49c3e9626a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_07c9d6b9-c75c-4ac5-9454-da620120f8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_07c9d6b9-c75c-4ac5-9454-da620120f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_97c69123-4186-4998-8dc5-a69f7a9a81db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_97c69123-4186-4998-8dc5-a69f7a9a81db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_7f0cb8fe-347f-45ac-81d5-77b965d3ac83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_7f0cb8fe-347f-45ac-81d5-77b965d3ac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_059a85f6-7f82-4550-93a6-c8dd4100bf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_059a85f6-7f82-4550-93a6-c8dd4100bf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_55c671be-872b-42e2-906c-bb291f293c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_55c671be-872b-42e2-906c-bb291f293c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4892c7c1-7e81-4d6d-9c76-e66321a84eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4892c7c1-7e81-4d6d-9c76-e66321a84eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ContingentConsiderationPolicyPolicyTextBlock_dbdefa4c-eea9-4dbf-aa7e-29d27641abb9" xlink:href="arwr-20220930.xsd#arwr_ContingentConsiderationPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_arwr_ContingentConsiderationPolicyPolicyTextBlock_dbdefa4c-eea9-4dbf-aa7e-29d27641abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_65f8042d-35c5-40c3-96bf-7625c74506a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_65f8042d-35c5-40c3-96bf-7625c74506a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_7f8e759e-9212-433d-aeb0-57edfe518fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_7f8e759e-9212-433d-aeb0-57edfe518fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_960fc5b2-0936-4b30-a966-16cff9919237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_960fc5b2-0936-4b30-a966-16cff9919237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ecad1ad4-4739-47ad-a416-f10d15df7843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ecad1ad4-4739-47ad-a416-f10d15df7843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_073a023e-42e6-4a6e-bb0d-cf8b449b9d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_073a023e-42e6-4a6e-bb0d-cf8b449b9d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ffbc416e-110a-4442-a673-0e512d8885fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ffbc416e-110a-4442-a673-0e512d8885fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8e9f1946-d0a3-4be1-9052-016a14b2660d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_26e02d2f-7161-456a-bba7-b9a1c4f2cd8e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8e9f1946-d0a3-4be1-9052-016a14b2660d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e88c725d-478c-4fe7-af26-80569b3eafda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_7d497b68-e283-4ec2-877f-978c005ca9ae" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e88c725d-478c-4fe7-af26-80569b3eafda" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_7d497b68-e283-4ec2-877f-978c005ca9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e6f4898-bada-447f-a4d1-9eebb77ecb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e1924e92-5e83-4f06-a21d-c03ca4152ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e6f4898-bada-447f-a4d1-9eebb77ecb3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e1924e92-5e83-4f06-a21d-c03ca4152ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_e9d2ea62-1a54-4b44-8506-8e8867a9a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_bcc15b84-7354-4d76-80bd-9c16dd96c901" xlink:href="arwr-20220930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_e9d2ea62-1a54-4b44-8506-8e8867a9a30c" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_bcc15b84-7354-4d76-80bd-9c16dd96c901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b85be843-3f5f-4eec-8de2-45d7c941c697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9bab1bb0-4a67-422a-8281-be271cde2835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b85be843-3f5f-4eec-8de2-45d7c941c697" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9bab1bb0-4a67-422a-8281-be271cde2835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f8fccaca-b4a8-4576-aebb-3ceb5a6955e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b85be843-3f5f-4eec-8de2-45d7c941c697" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f8fccaca-b4a8-4576-aebb-3ceb5a6955e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_32039c89-fd57-4962-a4a1-b81182989872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_cea4bcb0-242a-4d58-8fed-c67957d97dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32039c89-fd57-4962-a4a1-b81182989872" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_cea4bcb0-242a-4d58-8fed-c67957d97dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_406062f2-772e-4f35-9fee-1e0fd70655d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_37374eff-8ef4-4d05-be36-2e4195892e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_406062f2-772e-4f35-9fee-1e0fd70655d4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_37374eff-8ef4-4d05-be36-2e4195892e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9a11bae1-45f3-4e84-beb0-31c588e13414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_406062f2-772e-4f35-9fee-1e0fd70655d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9a11bae1-45f3-4e84-beb0-31c588e13414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f4e7ea-5d24-4fca-b65e-7a1ceafc8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2a9c2b2f-6cfa-47a0-b9cc-1c05128569f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f4e7ea-5d24-4fca-b65e-7a1ceafc8b6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2a9c2b2f-6cfa-47a0-b9cc-1c05128569f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dec50d31-1572-43d2-b3ad-aed7625d05db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f4e7ea-5d24-4fca-b65e-7a1ceafc8b6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dec50d31-1572-43d2-b3ad-aed7625d05db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ca34e9a8-d9a7-4bc7-b834-e475f1197268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f4e7ea-5d24-4fca-b65e-7a1ceafc8b6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ca34e9a8-d9a7-4bc7-b834-e475f1197268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4a3b9571-636e-4278-aeff-8b070e478a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8f4e7ea-5d24-4fca-b65e-7a1ceafc8b6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4a3b9571-636e-4278-aeff-8b070e478a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_404f6457-f000-4dbd-ac23-5bac79cb9bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8580d0f3-5a4a-4a03-9a74-971ed4da3ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_404f6457-f000-4dbd-ac23-5bac79cb9bc8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8580d0f3-5a4a-4a03-9a74-971ed4da3ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddcadde5-6ba8-4d2f-b6ae-933e1865e764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_004f65b6-1b9b-4846-b3ca-e9392fbfd35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddcadde5-6ba8-4d2f-b6ae-933e1865e764" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_004f65b6-1b9b-4846-b3ca-e9392fbfd35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2ebdc824-d299-49e3-a8cb-151677a411e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddcadde5-6ba8-4d2f-b6ae-933e1865e764" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2ebdc824-d299-49e3-a8cb-151677a411e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_104be6ae-294c-489c-9203-479f3052fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddcadde5-6ba8-4d2f-b6ae-933e1865e764" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_104be6ae-294c-489c-9203-479f3052fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_65d1098d-4ea5-4b1d-8110-155bef950e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddcadde5-6ba8-4d2f-b6ae-933e1865e764" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_65d1098d-4ea5-4b1d-8110-155bef950e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#OrganizationandSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bfc6cd9-5782-4150-8261-cfae09be84e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bfc6cd9-5782-4150-8261-cfae09be84e0" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_efbe2689-c6df-4c57-b21c-bb66b5594377" xlink:to="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_a5a5ccd6-1020-4422-84c2-542b68889cca" xlink:href="arwr-20220930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_a5a5ccd6-1020-4422-84c2-542b68889cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_4553edd4-2c04-42e6-9463-8118d4ec1c75" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4267f702-c400-41b4-9b20-e9e120ebd927" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_4553edd4-2c04-42e6-9463-8118d4ec1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21dc1d0-2164-4b8d-909c-8655621a60f7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_5826ae24-126d-4dcb-a2bf-f66378fbed67" xlink:href="arwr-20220930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac398ff-bdc6-41b3-b5d9-8bccce5524c3" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_5826ae24-126d-4dcb-a2bf-f66378fbed67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28868a1c-d16e-43e6-ae8d-efbbd86151b9" xlink:to="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f77423ce-d146-44de-b632-90a08ecdbba4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:to="loc_srt_MinimumMember_f77423ce-d146-44de-b632-90a08ecdbba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37bedc8c-a42b-4a10-bd74-9f0760d2ed96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf84fef7-9fa0-4384-8e1f-2210b21be95c" xlink:to="loc_srt_MaximumMember_37bedc8c-a42b-4a10-bd74-9f0760d2ed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_00271c84-61ef-413e-a83c-6c138e758a6f" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_544a9a55-e6ee-40c3-8514-077ff29dbc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d6e551c8-2f6d-475c-9e79-b1c3e23f0385" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_544a9a55-e6ee-40c3-8514-077ff29dbc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:href="arwr-20220930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_6bc67afd-f164-4c48-a543-a0ccdea8648e" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3215f5cf-0a95-400d-a06b-b3bee847baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3215f5cf-0a95-400d-a06b-b3bee847baa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_26c6c758-bafb-4162-9ead-9a41c69e7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_26c6c758-bafb-4162-9ead-9a41c69e7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_394b6716-3111-49b4-9913-c4336115b34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_394b6716-3111-49b4-9913-c4336115b34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e8f9822f-8b9e-447d-a974-45be95591962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_e8f9822f-8b9e-447d-a974-45be95591962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_e833cd1d-a343-4b58-b7c1-4353cc8e86ab" xlink:href="arwr-20220930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_e833cd1d-a343-4b58-b7c1-4353cc8e86ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_3cddcfee-1b7c-4ab0-8840-0944ca6d0562" xlink:href="arwr-20220930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_3cddcfee-1b7c-4ab0-8840-0944ca6d0562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_95df9368-b887-4715-a785-77c0288a1efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_95df9368-b887-4715-a785-77c0288a1efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d45cb6aa-98f9-4d8a-b2bd-e320c5426aec" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d45cb6aa-98f9-4d8a-b2bd-e320c5426aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_71eb53a9-67d6-41ff-9107-5f3f18d866fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_CashFDICInsuredAmount_71eb53a9-67d6-41ff-9107-5f3f18d866fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_96dfdf0d-4eec-4034-8528-fdcb378f85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_96dfdf0d-4eec-4034-8528-fdcb378f85fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bcf65456-83ce-4cae-a4e8-b6f33fb7a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_bcf65456-83ce-4cae-a4e8-b6f33fb7a0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_20ebcd73-3547-4afd-8ddd-17983422d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_20ebcd73-3547-4afd-8ddd-17983422d2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b4a24d0-be32-49eb-ba65-763bc861ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_0ffd394a-012e-40e3-a901-939152546a35" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b4a24d0-be32-49eb-ba65-763bc861ee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_aade56e0-3ccb-4abb-984b-62c9a139f191" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_aade56e0-3ccb-4abb-984b-62c9a139f191" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_819167f5-c1d6-46cd-9688-62fa5c34d2b9" xlink:to="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f76db261-8f8b-42b3-9b94-f11659f7ef57" xlink:href="arwr-20220930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0a3a3b6d-6b20-4c85-b0ba-0141a9944b8e" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_f76db261-8f8b-42b3-9b94-f11659f7ef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89cd9085-43e6-4106-a1b5-701a1d25438c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1cffd285-39c2-453d-bd41-733f4819cd95" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1cffd285-39c2-453d-bd41-733f4819cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROHSDAgreementMember_ad79b900-6a85-49a5-b5cf-76364a6d6bb9" xlink:href="arwr-20220930.xsd#arwr_AROHSDAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_09bf37f3-07a1-46f3-8fc9-6d19706d2f12" xlink:to="loc_arwr_AROHSDAgreementMember_ad79b900-6a85-49a5-b5cf-76364a6d6bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87d3c13f-8843-4dd3-a0a5-e1518799ad02" xlink:to="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6031c57a-690d-4ffa-bf4e-99c3a5445b81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0840a93c-cbca-407d-9000-6681b34f6364" xlink:to="loc_srt_MaximumMember_6031c57a-690d-4ffa-bf4e-99c3a5445b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7222522e-db61-426a-adf8-cde4e465deb0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_df9e7338-5baf-49b7-af80-1289b42ffa38" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentEarned_df9e7338-5baf-49b7-af80-1289b42ffa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_58074fe4-dd9d-4dac-8d89-5e55e14f2189" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableAtStartOfPhaseTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo_58074fe4-dd9d-4dac-8d89-5e55e14f2189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_a276eac8-bec0-471f-aee4-d6ef3a4ff385" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_a276eac8-bec0-471f-aee4-d6ef3a4ff385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_ec4e44ab-49be-440d-99ab-c78c6ce87a2f" xlink:href="arwr-20220930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_ec4e44ab-49be-440d-99ab-c78c6ce87a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_248f3048-0d03-4bae-9b97-03a7d499a869" xlink:href="arwr-20220930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_SalesRelatedMilestonePayments_248f3048-0d03-4bae-9b97-03a7d499a869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_19b2d25d-a596-426a-854a-ab23dc08e1cf" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_arwr_InitialTransactionPrice_19b2d25d-a596-426a-854a-ab23dc08e1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c230093-9929-4c90-a041-c1cf64724a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_0c230093-9929-4c90-a041-c1cf64724a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9337aa7a-8226-4e5d-b7df-71ac512e4297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9337aa7a-8226-4e5d-b7df-71ac512e4297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c2a6de8-ac2a-4879-a69a-8d6b78962e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b7b6e35-9e98-418a-869a-96b37ff3d3f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c2a6de8-ac2a-4879-a69a-8d6b78962e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_4003d74b-f518-4f7a-89d1-5fb3026f0ae5" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_4003d74b-f518-4f7a-89d1-5fb3026f0ae5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8fe07f5a-6161-4132-950c-324f97c072aa" xlink:to="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_018451ad-aeb6-45b0-9575-dc7f8906cfe6" xlink:href="arwr-20220930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1f355508-68fe-4950-8da9-5b09cfe9f3de" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_018451ad-aeb6-45b0-9575-dc7f8906cfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_06ccb649-3dcf-4e3c-8a4c-4c5c43af1bec" xlink:to="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2e70b776-f5f6-4f35-aeea-0c9f776d8165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ed58687-ed6b-4c5d-b65e-bbba03d060e6" xlink:to="loc_srt_MaximumMember_2e70b776-f5f6-4f35-aeea-0c9f776d8165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_950728f1-4e9b-477b-8891-d152c29815d8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHAgreementMember_3b9cd488-e0b7-4ebc-8aea-0e8298218912" xlink:href="arwr-20220930.xsd#arwr_AROXDHAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_AROXDHAgreementMember_3b9cd488-e0b7-4ebc-8aea-0e8298218912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_d312eac3-852c-4ec6-bfb7-4dc8366e2ed1" xlink:href="arwr-20220930.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_LicenseAgreementMember_d312eac3-852c-4ec6-bfb7-4dc8366e2ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROXDHSupplyAgreementMember_9c410eae-a302-46a3-acdb-112b2d0054c7" xlink:href="arwr-20220930.xsd#arwr_AROXDHSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7334f8db-a05e-4245-b977-26a78fe406ae" xlink:to="loc_arwr_AROXDHSupplyAgreementMember_9c410eae-a302-46a3-acdb-112b2d0054c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7fb19cd2-c044-4069-bc20-8819e39c7cb1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_2d953406-3070-418e-a935-129b50f866ac" xlink:href="arwr-20220930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_2d953406-3070-418e-a935-129b50f866ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_133ade12-6f8f-429a-a1c4-dacd4661aa01" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_133ade12-6f8f-429a-a1c4-dacd4661aa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_c1a4ba61-3796-4aff-ae49-15e9d90209cd" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_NumberOfDistinctBundle_c1a4ba61-3796-4aff-ae49-15e9d90209cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_f9409490-311f-457e-adae-470874156ed9" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_f9409490-311f-457e-adae-470874156ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_98c216d2-0b4b-493d-9959-3a588cadd26e" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_arwr_InitialTransactionPrice_98c216d2-0b4b-493d-9959-3a588cadd26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_014dde1e-d53b-4bcc-83b6-e00f762f7d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_014dde1e-d53b-4bcc-83b6-e00f762f7d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e2ebd5ff-dc25-4e2c-a4f8-5efe557700a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e2ebd5ff-dc25-4e2c-a4f8-5efe557700a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbff676f-dde4-45c3-b4fa-12769c197a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cee5eab1-6557-47bf-b0bb-e778ae44a594" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cbff676f-dde4-45c3-b4fa-12769c197a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_3bb54a35-d007-446e-9bdc-82b9c3c6932a" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_3bb54a35-d007-446e-9bdc-82b9c3c6932a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_78edfce2-4901-44a7-b3c2-564a8c04333b" xlink:to="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ecc0b884-1144-4563-8de3-c7af50783744" xlink:href="arwr-20220930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e2683af2-ee40-4939-819a-06366367f760" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_ecc0b884-1144-4563-8de3-c7af50783744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_18f359fe-1ef2-4254-bd0f-1981c86e270a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_c961d40e-d87a-42d5-90ea-a6cabcb36f20" xlink:href="arwr-20220930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbc93c8a-4dd0-4791-8a5f-1158fa25b6ba" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_c961d40e-d87a-42d5-90ea-a6cabcb36f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e0a5320e-25f4-4de6-92aa-719281fb6088" xlink:to="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_43eb6de0-081f-4950-b919-365db7cdc61c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:to="loc_srt_MinimumMember_43eb6de0-081f-4950-b919-365db7cdc61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ab0b55f1-c847-4943-984e-57210776751d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4ec3a415-6085-4c5f-8487-bae891cd2d1e" xlink:to="loc_srt_MaximumMember_ab0b55f1-c847-4943-984e-57210776751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d53a8fdc-f773-4ddb-97f6-5a5b8cb94222" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredRevenueMember_52806433-c2c4-4fad-ae31-9213db0917f5" xlink:href="arwr-20220930.xsd#arwr_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:to="loc_arwr_DeferredRevenueMember_52806433-c2c4-4fad-ae31-9213db0917f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_b42e7bdf-bd77-4c02-9b10-474dd3279c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c4e079d-e3de-4ce6-9dea-c124020c8e9a" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_b42e7bdf-bd77-4c02-9b10-474dd3279c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc3525ce-e89b-4648-94e5-67bac586c76b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_06a43578-db8d-493e-b846-c952e37fb61d" xlink:href="arwr-20220930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_06a43578-db8d-493e-b846-c952e37fb61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_aa55d362-128e-4e3b-b941-8d9d5b7543a4" xlink:href="arwr-20220930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_aa55d362-128e-4e3b-b941-8d9d5b7543a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_ac545c1f-ef6c-423e-b9eb-fa6ba44dde2c" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_ac545c1f-ef6c-423e-b9eb-fa6ba44dde2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_4143a4a6-f8ec-4f9e-84d8-7a5a6e6b47fe" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_NumberOfDistinctBundle_4143a4a6-f8ec-4f9e-84d8-7a5a6e6b47fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_a19f584f-4be5-425e-bb61-4922a632d4ec" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_a19f584f-4be5-425e-bb61-4922a632d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_0a2886d6-2b9a-41fe-98b2-df414fc7fcf9" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_arwr_InitialTransactionPrice_0a2886d6-2b9a-41fe-98b2-df414fc7fcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9e660df-8d04-4663-8796-6f94b29d0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9e660df-8d04-4663-8796-6f94b29d0bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e41a1694-b808-40dc-baf2-8514495dbd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_e41a1694-b808-40dc-baf2-8514495dbd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eead14ab-4ac5-4566-8e6a-9d0b58d7d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_eead14ab-4ac5-4566-8e6a-9d0b58d7d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21f7205b-7561-4e7e-86d9-ddb5dc40dac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57db9b6e-31c5-4e5a-91aa-aa16127eb053" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21f7205b-7561-4e7e-86d9-ddb5dc40dac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d8dfa3d4-1e62-43d4-bad5-2fe03f2bc22a" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d8dfa3d4-1e62-43d4-bad5-2fe03f2bc22a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a3b66e2e-b2b7-45dc-aed9-711d555f7a5e" xlink:to="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_97ffbad5-d6f6-4252-beee-318507992426" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_97ffbad5-d6f6-4252-beee-318507992426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_9433a4f3-2a2d-47d4-b133-6a35ca191fb2" xlink:href="arwr-20220930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_9433a4f3-2a2d-47d4-b133-6a35ca191fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_00b6b1c0-36bb-4caa-81e1-404b2c57a786" xlink:href="arwr-20220930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b8d14666-7bb1-4750-8a14-b2c5759bd40e" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_00b6b1c0-36bb-4caa-81e1-404b2c57a786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13b6ba49-45ac-470b-8e96-2447d4bc4411" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1f8bd83b-bf0f-4e5a-8151-2c9f0b80c9dd" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1f8bd83b-bf0f-4e5a-8151-2c9f0b80c9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAgreementMember_1c784e36-76f6-4bf7-8c0b-22e1e9759426" xlink:href="arwr-20220930.xsd#arwr_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_LicenseAgreementMember_1c784e36-76f6-4bf7-8c0b-22e1e9759426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAgreementMember_54f491e2-390a-4a24-8abc-e9f27a609a75" xlink:href="arwr-20220930.xsd#arwr_CollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_CollaborationAgreementMember_54f491e2-390a-4a24-8abc-e9f27a609a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_001986fd-b6d3-4280-9b7e-4cd24315fe54" xlink:href="arwr-20220930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_001986fd-b6d3-4280-9b7e-4cd24315fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ75220795AROJNJ1Member_026702fc-a3c9-4627-873b-386ac5fd0182" xlink:href="arwr-20220930.xsd#arwr_JNJ75220795AROJNJ1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625598-e6a1-4a23-8d67-c86ef9bbbbbf" xlink:to="loc_arwr_JNJ75220795AROJNJ1Member_026702fc-a3c9-4627-873b-386ac5fd0182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9ce49765-c2c0-473a-be68-06b02f99e26a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_85263bed-bc43-49cf-8fd6-ab7b0a1239e3" xlink:href="arwr-20220930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d3d87c5c-e89c-4d86-84dd-c44bc9833818" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_85263bed-bc43-49cf-8fd6-ab7b0a1239e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d51952e7-2894-40e0-a69c-f7c81676b7c7" xlink:to="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b1b3963-3f3f-4ddb-a94d-77c4e38ef08d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5ef57803-d2e0-4f83-8943-ea694376eedd" xlink:to="loc_srt_MaximumMember_6b1b3963-3f3f-4ddb-a94d-77c4e38ef08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd55825f-ee19-4b17-af23-42ff9df2d67e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_18760cd0-8b8e-4e70-8284-9e102df09dcc" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_18760cd0-8b8e-4e70-8284-9e102df09dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3510ee8f-894c-4f1e-8af0-0114039ec987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3510ee8f-894c-4f1e-8af0-0114039ec987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_862a2e1d-32d8-4830-b303-6aadd6c20f57" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_MilestonePaymentEarned_862a2e1d-32d8-4830-b303-6aadd6c20f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_f1c41ea0-f4bb-4abd-9e23-5dc1905fac27" xlink:href="arwr-20220930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_f1c41ea0-f4bb-4abd-9e23-5dc1905fac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_08795cf8-fab9-4975-b599-a9a7cbe43ad5" xlink:href="arwr-20220930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_08795cf8-fab9-4975-b599-a9a7cbe43ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_7eba2a52-629f-4c33-a69e-9b8c571c6f9b" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_arwr_InitialTransactionPrice_7eba2a52-629f-4c33-a69e-9b8c571c6f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f6c071b8-84d0-43ab-aa43-b5aeee699976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_f6c071b8-84d0-43ab-aa43-b5aeee699976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_59aba88c-1767-45e3-98f9-3fa0c7a0163a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_59aba88c-1767-45e3-98f9-3fa0c7a0163a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de951785-d10b-4b2b-97da-036863bf55bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_419e3b90-f79d-41d1-91ce-fd1688423945" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de951785-d10b-4b2b-97da-036863bf55bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d757cd20-bf97-4923-ad41-d302c08d7152" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d757cd20-bf97-4923-ad41-d302c08d7152" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_87584379-4d3c-4183-a76d-7c1644702152" xlink:to="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_e7cb9dd5-f826-449c-9ecb-e77881adf441" xlink:href="arwr-20220930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f5a63b3e-238c-44f6-8225-2af4bcec9b19" xlink:to="loc_arwr_AmgenIncorporatedMember_e7cb9dd5-f826-449c-9ecb-e77881adf441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d942aeb9-b989-4cc6-a2d9-e0fd5f6c5430" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementMember_1d5e5a26-618d-4eca-bbc1-4426e2f77fe7" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_CollaborationAndLicenseAgreementMember_1d5e5a26-618d-4eca-bbc1-4426e2f77fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_3174276c-a30d-4b73-9b66-b0c3ed36a82c" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_OlpasiranAgreementMember_3174276c-a30d-4b73-9b66-b0c3ed36a82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0034f932-0f0a-4f50-9aeb-6035cf726d57" xlink:href="arwr-20220930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2f7be9c-6478-47e1-b20c-fd6a9e1255b3" xlink:to="loc_arwr_OlpasiranAndAROAMG1AgreementMember_0034f932-0f0a-4f50-9aeb-6035cf726d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d1e318c8-af19-4a7a-bb9b-a24de5895d05" xlink:to="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1239f430-3c0f-4446-a0dd-e9df5a543769" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ccc809a1-f135-4ebd-b76b-3da453581435" xlink:to="loc_srt_MaximumMember_1239f430-3c0f-4446-a0dd-e9df5a543769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d2be04b9-0a47-45b5-ba4c-b036f097aeee" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_e2f2d1da-1427-44ed-9e96-ba2ca9adf573" xlink:href="arwr-20220930.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_NumberOfAgreements_e2f2d1da-1427-44ed-9e96-ba2ca9adf573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_37787eb6-0c9f-4c93-9a6e-bc5f54838430" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_37787eb6-0c9f-4c93-9a6e-bc5f54838430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30312105-f679-4cd9-af42-0969a9c310a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30312105-f679-4cd9-af42-0969a9c310a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_3a2fab31-b0f5-42d1-b9ec-468574d59807" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_MilestonePaymentReceived_3a2fab31-b0f5-42d1-b9ec-468574d59807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_88d31adb-b32a-4464-945e-3a027b4bd7b8" xlink:href="arwr-20220930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_88d31adb-b32a-4464-945e-3a027b4bd7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0aa3d0b-3940-4b32-ba55-9ec02a2ae9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0aa3d0b-3940-4b32-ba55-9ec02a2ae9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c638c0f1-29d6-4313-a26b-ab0257c71acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c638c0f1-29d6-4313-a26b-ab0257c71acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_443c2d3f-6fc9-4827-8c11-6d0bd3c90186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e387dbff-5a34-4c34-8372-f5eb11b06b4c" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_443c2d3f-6fc9-4827-8c11-6d0bd3c90186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_f6ab69a5-7d15-4b13-ba66-0196dff0d9e2" xlink:href="arwr-20220930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_f6ab69a5-7d15-4b13-ba66-0196dff0d9e2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59333875-7045-43e0-931c-d79aa659e0f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_a5e976a4-3daa-42d0-bc4d-6ce40581a187" xlink:href="arwr-20220930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b590320-c50c-4730-84d6-4f402ef8e0aa" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_a5e976a4-3daa-42d0-bc4d-6ce40581a187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0fb74539-f358-4908-8206-d18d5dc26f6a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_33138575-a369-4600-8ce8-d2af4868de6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_02d98688-bb59-4a51-9296-0c71b7a5dc65" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_33138575-a369-4600-8ce8-d2af4868de6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_23477662-939b-41c4-bafb-ea557e51c9c6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_94f881c7-fce1-499c-b7d9-26ed7eb512e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce6dbd5-b803-438e-935a-f255950dce4c" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_94f881c7-fce1-499c-b7d9-26ed7eb512e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_f4c0f214-94b9-4bc5-ae3b-5b47f030466d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_f4c0f214-94b9-4bc5-ae3b-5b47f030466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_91d3c178-45d3-4d7c-8fc4-24c3e7bd8b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_Land_91d3c178-45d3-4d7c-8fc4-24c3e7bd8b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_8080c685-1459-4962-99fd-0988d96d23a0" xlink:href="arwr-20220930.xsd#arwr_ResearchEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_arwr_ResearchEquipmentGross_8080c685-1459-4962-99fd-0988d96d23a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_5c0aae7a-1d52-4a7a-8188-f9cd22b7a959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_5c0aae7a-1d52-4a7a-8188-f9cd22b7a959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a7f14be7-4d94-4367-96e2-aadb38483d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_ConstructionInProgressGross_a7f14be7-4d94-4367-96e2-aadb38483d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_616c4844-b5b3-4cb4-9a63-b439af9a2f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_616c4844-b5b3-4cb4-9a63-b439af9a2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fe817808-088a-4804-b0ed-ff54f179db34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fe817808-088a-4804-b0ed-ff54f179db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3f89309d-3595-408f-9e11-d1c960d1e376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_285474ad-0007-4a88-9afc-6816eaa5d661" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3f89309d-3595-408f-9e11-d1c960d1e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fceb276a-1709-444a-a2d8-882f55aa0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f8d37ecd-fd57-4a6d-a9ae-6362d736d856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fceb276a-1709-444a-a2d8-882f55aa0fc6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f8d37ecd-fd57-4a6d-a9ae-6362d736d856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_32a30867-ee7a-441f-bfcc-578945da6bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_32a30867-ee7a-441f-bfcc-578945da6bf3" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f690d16-8519-417d-932f-8bfeac5e966a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_fcef71b2-c518-457b-bd81-3464b4670568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:to="loc_us-gaap_DebtSecuritiesMember_fcef71b2-c518-457b-bd81-3464b4670568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a30ee7e8-780e-4f63-a4dc-e751458f98e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_099ebe65-6140-4229-998f-e537d4bcae9f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a30ee7e8-780e-4f63-a4dc-e751458f98e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:href="arwr-20220930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_e7f1d1f3-503b-4036-ad36-9e29dd1bb447" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4490e45f-b3e6-4650-ae65-7134b7ba0626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_4490e45f-b3e6-4650-ae65-7134b7ba0626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_925c2466-f3a5-43e2-91ff-db667ef4e004" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_925c2466-f3a5-43e2-91ff-db667ef4e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_fff685b3-4239-4cb8-9be9-e481e44f92be" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_fff685b3-4239-4cb8-9be9-e481e44f92be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_991042a9-70ba-466a-87c9-eb6aca7179e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_991042a9-70ba-466a-87c9-eb6aca7179e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_85b05bdb-e2b6-4c6c-89d8-5ad151603cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_85b05bdb-e2b6-4c6c-89d8-5ad151603cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_5d026c3c-e1e9-4248-a0ed-5aee91b30337" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_5d026c3c-e1e9-4248-a0ed-5aee91b30337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_5d2b44eb-fa6a-4090-a09b-6f16cad1fa7f" xlink:href="arwr-20220930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_5d2b44eb-fa6a-4090-a09b-6f16cad1fa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_f7e32fec-fe11-4fe7-99c5-ff6d52736b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_f7e32fec-fe11-4fe7-99c5-ff6d52736b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5064982a-9b89-472f-a1d0-6958081e92d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5064982a-9b89-472f-a1d0-6958081e92d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_83a58dad-35a8-4123-8f7b-9afc4fcbe177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_83a58dad-35a8-4123-8f7b-9afc4fcbe177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f6f0df62-48f8-4588-b5ec-f049eb4eddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f6f0df62-48f8-4588-b5ec-f049eb4eddbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_754846d9-8d4b-440b-85d3-79930c417430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_e3e351bd-0279-4986-8541-444f57298a7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_754846d9-8d4b-440b-85d3-79930c417430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b581af63-f2ff-4bc1-b06d-b56ac43b2003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b581af63-f2ff-4bc1-b06d-b56ac43b2003" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f5471140-a4f1-446a-8eb1-ce081633fc74" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_45248684-5d1a-43cc-9b87-0fb33d845a31" xlink:href="arwr-20220930.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d2f66053-5e9b-4090-9cdb-ba6f66344725" xlink:to="loc_arwr_NovartisMember_45248684-5d1a-43cc-9b87-0fb33d845a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_60694241-a451-4c23-b709-f6c35dce0806" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_8ac5822a-889b-448e-b4bb-4a8fa648f0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:to="loc_us-gaap_PatentsMember_8ac5822a-889b-448e-b4bb-4a8fa648f0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_cdff5e89-10fb-4728-9a00-007489069964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e45803-cafb-4e7c-bf78-6ccd618d9f14" xlink:to="loc_us-gaap_LicensingAgreementsMember_cdff5e89-10fb-4728-9a00-007489069964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebe4e152-2696-4bc9-bdfb-783e1092bd79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1e1a55a-3d72-4608-b0b6-28e740555fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1e1a55a-3d72-4608-b0b6-28e740555fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5ab553-bf4e-4588-a4c9-c48371bb2526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5ab553-bf4e-4588-a4c9-c48371bb2526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_e1563312-4ec7-4858-8dc1-0c8fb65de24a" xlink:href="arwr-20220930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_e1563312-4ec7-4858-8dc1-0c8fb65de24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8cf3915-16e2-4415-8c5c-cb0ac6bdc1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a8cf3915-16e2-4415-8c5c-cb0ac6bdc1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8b15a34e-c2b2-41d2-9335-a23247478f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2ac3ee3e-b93c-4da4-8563-cb46cd583571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8b15a34e-c2b2-41d2-9335-a23247478f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_93c4ccae-bb95-4f76-b2b1-c26e595e97d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b581af63-f2ff-4bc1-b06d-b56ac43b2003" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_93c4ccae-bb95-4f76-b2b1-c26e595e97d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1e98f476-b47c-456c-a09c-eedabf278f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1e98f476-b47c-456c-a09c-eedabf278f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21e2e81-60c5-4578-a223-232d47cf516a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b21e2e81-60c5-4578-a223-232d47cf516a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_40b85e5f-6cd5-480e-aea8-22176ff39fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_40b85e5f-6cd5-480e-aea8-22176ff39fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b630d168-b8c8-421e-bcb6-8bc026b80856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b630d168-b8c8-421e-bcb6-8bc026b80856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9bf7c9cc-01cd-4069-bbc9-f1973ab059b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_9bf7c9cc-01cd-4069-bbc9-f1973ab059b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e8354a56-eaab-49ca-aa07-0ea67fa841ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e8354a56-eaab-49ca-aa07-0ea67fa841ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_29fa9011-2f96-4700-9d2f-5e999bca3fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_78b4cf86-c194-439e-b509-055d34f058bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_29fa9011-2f96-4700-9d2f-5e999bca3fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4c91c3a2-3b3c-4b64-a5d0-48959d7b88ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4c91c3a2-3b3c-4b64-a5d0-48959d7b88ed" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a48b6e5f-80de-419b-ab3c-76999127af3e" xlink:to="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_69e2afe9-8770-4205-bd88-3ea6b17c90a2" xlink:href="arwr-20220930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d57a4ea1-3e61-4b55-a278-92b3aea2cf70" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_69e2afe9-8770-4205-bd88-3ea6b17c90a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d142a85-3f96-4001-b5f9-28db1b3ceff3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_1a277590-20cf-4daf-a244-0901695579df" xlink:href="arwr-20220930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6ab102e4-9b8f-4ca6-8d31-6e65135d5081" xlink:to="loc_arwr_AtTheMarketAgreementMember_1a277590-20cf-4daf-a244-0901695579df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6114b7df-dd16-4c9f-ae28-f2b9feaad18a" xlink:to="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_641a565d-2d09-4057-bff5-3eb8058f3e49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c672ba0-c9f9-49cb-a75b-584804050d7e" xlink:to="loc_srt_MaximumMember_641a565d-2d09-4057-bff5-3eb8058f3e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9fe672c-640a-45d7-828b-00dae8577090" xlink:to="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_04d221dc-e40d-49c8-8892-a86b5cc9dc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_04d221dc-e40d-49c8-8892-a86b5cc9dc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a01bc10f-6a61-4a12-9053-621a5707ac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a01bc10f-6a61-4a12-9053-621a5707ac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2e080419-86ee-429d-bc5c-aa9898692726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesIssued_2e080419-86ee-429d-bc5c-aa9898692726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f5dbb35f-1594-471d-96fe-f5c1c81d73af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f5dbb35f-1594-471d-96fe-f5c1c81d73af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8b89b8df-b810-4fc8-b964-4d63162a2a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8b89b8df-b810-4fc8-b964-4d63162a2a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d5f15ed7-a98c-4ac3-80e6-59912d19a260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d5f15ed7-a98c-4ac3-80e6-59912d19a260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fd70cf69-1639-423e-8c8a-8cb8ed8e06dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fd70cf69-1639-423e-8c8a-8cb8ed8e06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b7ad3b55-75a0-43ce-a602-c9661935452a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b7ad3b55-75a0-43ce-a602-c9661935452a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f277446f-374a-446f-ba93-b925c1fe3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f277446f-374a-446f-ba93-b925c1fe3f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_433d206f-df92-4f15-9742-90913df691ee" xlink:href="arwr-20220930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_433d206f-df92-4f15-9742-90913df691ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_a47373e4-d7d5-468f-8464-24b9b902eba6" xlink:href="arwr-20220930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_a47373e4-d7d5-468f-8464-24b9b902eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_8310a6a9-8c7d-4545-8d91-17a00d2c7e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9cc84ec9-25ca-410f-bad8-271a6459464f" xlink:to="loc_us-gaap_SharesIssued_8310a6a9-8c7d-4545-8d91-17a00d2c7e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5aeb12a-ef72-45fe-b0db-b33ed94cf14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e5aeb12a-ef72-45fe-b0db-b33ed94cf14b" xlink:to="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_312e1d5a-d651-49ff-9761-3ea5f012ed2f" xlink:to="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_37f3e3db-1dc8-44b1-909d-6453c4cc3bba" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bf562065-a3ca-4765-a3f0-1724f5e719b7" xlink:to="loc_stpr_WI_37f3e3db-1dc8-44b1-909d-6453c4cc3bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6970293-36b6-463b-939b-d1c1f15a8dbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_1c32ed49-9782-400f-9d63-3284851832a6" xlink:href="arwr-20220930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_VeronaTechnologyParkMember_1c32ed49-9782-400f-9d63-3284851832a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_264a1e0a-f86a-433f-be41-3cd854bfe19b" xlink:href="arwr-20220930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_DrugManufacturingFacilityMember_264a1e0a-f86a-433f-be41-3cd854bfe19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_658064dd-f2a7-445c-9ea6-348b5ab76657" xlink:href="arwr-20220930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_658064dd-f2a7-445c-9ea6-348b5ab76657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_2ee63da7-580d-4a07-99e4-55919273ec4e" xlink:href="arwr-20220930.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_074be389-84e5-45c4-a161-3680736b6c0f" xlink:to="loc_arwr_FacilitiesMember_2ee63da7-580d-4a07-99e4-55919273ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3dde09cf-1ed5-43be-b79a-70dc906625ad" xlink:to="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5bfbd202-a3f4-45da-bc18-1c51e4048d78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:to="loc_srt_MinimumMember_5bfbd202-a3f4-45da-bc18-1c51e4048d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8855c874-0db2-4d31-9924-b1d17b93ac70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2299269e-4c47-426c-be37-fc19b10d1d6d" xlink:to="loc_srt_MaximumMember_8855c874-0db2-4d31-9924-b1d17b93ac70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e2ba2bb2-9c17-4c65-8d28-68edb6e4c6c3" xlink:to="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_0bbd310e-af2d-4a53-b6b2-56d736a9b70f" xlink:href="arwr-20220930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_e83ff7a1-c12f-4209-8d02-67109593be7e" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_0bbd310e-af2d-4a53-b6b2-56d736a9b70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df43d40e-e61f-446e-a3f5-2dc0689ff4b3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember_27554e25-4d17-4ddc-956d-b1f750762f26" xlink:href="arwr-20220930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4cc34c05-8fd1-489f-b5a7-ea96cbfbf0bc" xlink:to="loc_arwr_AROENacAndAROHIF2CandidatesMember_27554e25-4d17-4ddc-956d-b1f750762f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fb91894b-1651-45a4-9ccd-35764014624b" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_cb317d16-2cbe-4379-92d5-cd9385ecf3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_cb317d16-2cbe-4379-92d5-cd9385ecf3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_ddb5d7d2-6efd-4be7-bb1b-193e3def9e0f" xlink:href="arwr-20220930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_ddb5d7d2-6efd-4be7-bb1b-193e3def9e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_f6c4014c-49ba-405c-a4c1-cd9bec8f4ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_AreaOfLand_f6c4014c-49ba-405c-a4c1-cd9bec8f4ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_3950ef04-a7dc-48a1-a034-2c1b4565af9e" xlink:href="arwr-20220930.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_3950ef04-a7dc-48a1-a034-2c1b4565af9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_1cba4137-ef60-4d14-94b8-4159fecea188" xlink:href="arwr-20220930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_TaxIncrementFinancingAward_1cba4137-ef60-4d14-94b8-4159fecea188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7ddf373d-48ff-4801-9dc9-63b54f62f244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7ddf373d-48ff-4801-9dc9-63b54f62f244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_9f527e3d-60ad-46c6-8d72-20a3231d3ca7" xlink:href="arwr-20220930.xsd#arwr_MilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_bce71065-233b-48a4-a2a5-199e1745c699" xlink:to="loc_arwr_MilestonePayments_9f527e3d-60ad-46c6-8d72-20a3231d3ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_af47a6ca-dfcc-4169-a61d-9190833ff9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_af47a6ca-dfcc-4169-a61d-9190833ff9fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2158f408-172c-406a-8dba-ad7a413a3d5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_3035fb0a-419e-41d2-b06c-d6d624c29842" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_3035fb0a-419e-41d2-b06c-d6d624c29842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_951ad722-0686-49c0-870f-409c1a12bbef" xlink:href="arwr-20220930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_951ad722-0686-49c0-870f-409c1a12bbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_6241f32c-99bb-40e3-8cdf-0767450e5ab2" xlink:href="arwr-20220930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89d6da8f-1263-49ee-a27c-88e85f4747b5" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_6241f32c-99bb-40e3-8cdf-0767450e5ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f0a6644b-2220-4f0b-a4a8-f42002089892" xlink:to="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_a99c1866-fbc4-414a-98c0-1a25702e8d3a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:to="loc_stpr_CA_a99c1866-fbc4-414a-98c0-1a25702e8d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_00f2ddda-98da-489f-8ea9-9bcc9e3edd94" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7f1b7c32-d58f-4868-9a40-66858d66b283" xlink:to="loc_stpr_WI_00f2ddda-98da-489f-8ea9-9bcc9e3edd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_48a026af-3646-40cb-a022-fec7867edefc" xlink:to="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a566dc4c-55bb-46fa-92de-040f4a710c6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2815a87-44c7-48bc-b0c9-85f4e87865a0" xlink:to="loc_srt_MaximumMember_a566dc4c-55bb-46fa-92de-040f4a710c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ef312a89-b378-4842-94b2-e911dc88116a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_38a2ea69-5c7b-4f81-b707-20363ddafb6a" xlink:href="arwr-20220930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8a13b9b-370b-4187-9dba-87d366de86b9" xlink:to="loc_arwr_ColoradoOwnerLLCMember_38a2ea69-5c7b-4f81-b707-20363ddafb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_473f73b0-c48a-4678-b04d-9dbaced8bd04" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92b8aba1-3e07-4dbb-b774-89b54d0bab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_92b8aba1-3e07-4dbb-b774-89b54d0bab1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_0ff558ad-24c8-4d56-9248-e23bdc0a6c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_0ff558ad-24c8-4d56-9248-e23bdc0a6c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ca0e9de-d60c-4ffa-9ab5-403c591e1783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ca0e9de-d60c-4ffa-9ab5-403c591e1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_aaba427f-e8f0-4071-bd76-1e3d7235a3ac" xlink:href="arwr-20220930.xsd#arwr_EstimatedPaymentsForOperatingExpensesYearOne"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_EstimatedPaymentsForOperatingExpensesYearOne_aaba427f-e8f0-4071-bd76-1e3d7235a3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_b091ca43-cb04-4384-b74f-9012f501b5b4" xlink:href="arwr-20220930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_b091ca43-cb04-4384-b74f-9012f501b5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_acbe17ea-aba0-400e-bdc6-0d252fca41ad" xlink:href="arwr-20220930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_NumberOfOptionsToRenew_acbe17ea-aba0-400e-bdc6-0d252fca41ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dd4490d4-1ddd-4651-91c1-8e03cc169ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_dd4490d4-1ddd-4651-91c1-8e03cc169ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalLandSubjectToLease_4788c0c9-b778-4295-ba74-cc2947db64ba" xlink:href="arwr-20220930.xsd#arwr_AdditionalLandSubjectToLease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_arwr_AdditionalLandSubjectToLease_4788c0c9-b778-4295-ba74-cc2947db64ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_34a0bb44-8721-42c0-a3ae-941206bd328f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_66729509-0801-4e70-bdbf-d96cdd2969b5" xlink:to="loc_us-gaap_ShortTermLeaseCost_34a0bb44-8721-42c0-a3ae-941206bd328f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9b3c7062-09df-458c-8224-2ee29633edd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9b3c7062-09df-458c-8224-2ee29633edd9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73e96eb9-8027-4c11-8685-7984067f2daf" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af869ccb-c5b3-46ad-a3e7-f6a8ed0d26ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af869ccb-c5b3-46ad-a3e7-f6a8ed0d26ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d569b3bb-4e96-4748-a6a4-396969bf3738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_77388cf0-6dac-4b38-ac48-ffc9fa6698d2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d569b3bb-4e96-4748-a6a4-396969bf3738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_dc4a0f7c-584a-46d2-a360-339fb05c03e8" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26804b4b-aec7-41a7-947a-99ad87b9c318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26804b4b-aec7-41a7-947a-99ad87b9c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a6914fc-93a3-4176-896c-fb3790c5dd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7a6914fc-93a3-4176-896c-fb3790c5dd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d42b66b-feea-4111-ba4d-b26a4c7a5c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_9e3db865-c6a7-47fa-9d63-01b8dd9c0f87" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d42b66b-feea-4111-ba4d-b26a4c7a5c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_e14901bb-06bb-4433-815d-608566df81de" xlink:to="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f2471b26-1f1a-4caa-b7eb-8bcd3856ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_OperatingLeaseCost_f2471b26-1f1a-4caa-b7eb-8bcd3856ba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_593ce25e-45f6-4562-b6f9-077b7895fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_VariableLeaseCost_593ce25e-45f6-4562-b6f9-077b7895fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b5c789f1-576e-4efe-afdb-ce57283c7b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_32f2b54b-65df-412f-bdc6-62de5796fa69" xlink:to="loc_us-gaap_LeaseCost_b5c789f1-576e-4efe-afdb-ce57283c7b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ef12b6b2-0ec1-4d1a-b99f-4dc014a2efd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ef12b6b2-0ec1-4d1a-b99f-4dc014a2efd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f4b52550-6981-45f8-82de-95720318307d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f4b52550-6981-45f8-82de-95720318307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a185331-2fd6-4dea-9891-a0631fd69c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a185331-2fd6-4dea-9891-a0631fd69c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f7149da4-662f-4286-b896-a899f90f88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f7149da4-662f-4286-b896-a899f90f88b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5481524f-1826-4e1d-af5f-11188b9ec47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5481524f-1826-4e1d-af5f-11188b9ec47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9503572c-c282-410a-a6ae-4b64ec8253e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9503572c-c282-410a-a6ae-4b64ec8253e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b823fda-983f-46fe-8c6c-8a2582c0c771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b823fda-983f-46fe-8c6c-8a2582c0c771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ab787656-29e3-415f-96ec-7bc4c733b315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ab787656-29e3-415f-96ec-7bc4c733b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_63023451-83de-4351-ad05-937e223ebedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d47a2d7-52a6-4996-a8cb-0ef0d22b5c6a" xlink:to="loc_us-gaap_OperatingLeaseLiability_63023451-83de-4351-ad05-937e223ebedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d0cbbc96-c6de-47f7-9f1c-fe61cf35ad56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8d2ec5cf-0733-45d2-b3bb-27b7d5598a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0cbbc96-c6de-47f7-9f1c-fe61cf35ad56" xlink:to="loc_us-gaap_OperatingLeasePayments_8d2ec5cf-0733-45d2-b3bb-27b7d5598a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9dcae3e-31c1-4278-bc75-f173735ca87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0cbbc96-c6de-47f7-9f1c-fe61cf35ad56" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a9dcae3e-31c1-4278-bc75-f173735ca87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d0073096-24f6-4dc8-b015-364a8a370b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d0cbbc96-c6de-47f7-9f1c-fe61cf35ad56" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d0073096-24f6-4dc8-b015-364a8a370b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_196fd257-aca9-4b61-83d5-acd151a3e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_196fd257-aca9-4b61-83d5-acd151a3e7a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ebe2abaf-4195-4745-a036-78acb5e530a3" xlink:to="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_febd3af6-8f3b-466a-b2d6-ce572e60f442" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_febd3af6-8f3b-466a-b2d6-ce572e60f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ba2c1a0b-4c31-4bc8-82bb-0b8419176a86" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ba2c1a0b-4c31-4bc8-82bb-0b8419176a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_078c6d08-888d-4af6-8d92-a8f3c0b82117" xlink:href="arwr-20220930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_078c6d08-888d-4af6-8d92-a8f3c0b82117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_1cd91b33-5c81-40f3-bf7b-24dc580a3b22" xlink:href="arwr-20220930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e71da7a5-60f2-4a25-84e5-7c083e65e960" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_1cd91b33-5c81-40f3-bf7b-24dc580a3b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e30e73f-210e-4170-a492-c319b026258c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_05202647-94a8-4155-84c2-268c65960f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_05202647-94a8-4155-84c2-268c65960f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ebdfb627-39b3-471a-b951-6aafe4b30278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ebdfb627-39b3-471a-b951-6aafe4b30278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember_3784d887-d73c-432d-b4d6-090a5351b906" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember_3784d887-d73c-432d-b4d6-090a5351b906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_97f5b237-f4c7-4a5c-91d4-b7facc001d15" xlink:href="arwr-20220930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3eb339f-62e7-4be1-ab85-a1ec6b01d06f" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_97f5b237-f4c7-4a5c-91d4-b7facc001d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_30a3fdf1-7f78-4ac7-8e61-b88f7c22bfec" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_d30f8e24-eb37-4a8a-a5e3-a0299e77ff7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7c1d643a-c207-474a-855a-e1dd75be0d34" xlink:to="loc_srt_ChiefExecutiveOfficerMember_d30f8e24-eb37-4a8a-a5e3-a0299e77ff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bf9bb3c-2f2d-451b-a847-d43517d4770d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b006d0ba-e9f3-48fc-ba1f-196eda6e24d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b006d0ba-e9f3-48fc-ba1f-196eda6e24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450fedfb-1497-4c6c-a474-e8c393d075f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_450fedfb-1497-4c6c-a474-e8c393d075f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb63706c-776b-4165-89d4-b238e2775781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_eb63706c-776b-4165-89d4-b238e2775781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2609a3c9-ca27-4cc7-9eac-01e195272dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2609a3c9-ca27-4cc7-9eac-01e195272dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b09c2ae7-19a7-4e36-93b5-66d37cc33575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b09c2ae7-19a7-4e36-93b5-66d37cc33575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67bf0d72-16c3-402e-815d-88513f2912fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67bf0d72-16c3-402e-815d-88513f2912fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672534c9-8f20-4fe1-96a5-a9cffdab0ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_672534c9-8f20-4fe1-96a5-a9cffdab0ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10ffae89-7b3c-45cd-a30e-cc8f689b41ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10ffae89-7b3c-45cd-a30e-cc8f689b41ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_d6206c1b-89ad-4703-8f6e-d64631e565cf" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_d6206c1b-89ad-4703-8f6e-d64631e565cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6001ee3-1241-4727-9eb2-bdc5d45861e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f6001ee3-1241-4727-9eb2-bdc5d45861e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_33ad8a1b-9b3d-4f02-ad27-7a0a7cb65bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e82b411-bdbd-4dc6-a1cd-ca873ad7db0f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_33ad8a1b-9b3d-4f02-ad27-7a0a7cb65bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbd09e29-1f6c-4860-be6b-e06615ad320d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbd09e29-1f6c-4860-be6b-e06615ad320d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:to="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_131d7ad8-7d88-4a3e-9aa3-8c63b09e01fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_180e3757-4501-415c-a84b-6a5fcea0d4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca60b658-747e-423a-ae46-0c81596b40ed" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_180e3757-4501-415c-a84b-6a5fcea0d4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:to="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8652b749-7b97-4800-b4e9-e75a2331a130" xlink:to="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_1b1fd3af-420e-4a27-9c96-b6205633e052" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_1b1fd3af-420e-4a27-9c96-b6205633e052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ad66f713-f1e5-4c36-af3a-6ad30f758ba0" xlink:href="arwr-20220930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_ad66f713-f1e5-4c36-af3a-6ad30f758ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_7a94eef8-2cbf-49fe-909f-d736e1c1527c" xlink:href="arwr-20220930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8ba4f439-1199-434e-b319-e8ecd9a0b329" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_7a94eef8-2cbf-49fe-909f-d736e1c1527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ae6ff07-7533-45f9-8534-7072c9bfe4a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b0047ef-64e6-4e7b-90ec-a013055901df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2b0047ef-64e6-4e7b-90ec-a013055901df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_272389df-7c27-4133-92fa-31bd6ecc566a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_272389df-7c27-4133-92fa-31bd6ecc566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_8696dd51-d74b-4715-9c3f-3838d0b56e5f" xlink:href="arwr-20220930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_90c3ec53-20f6-47c5-a5a2-56f7c453d5f4" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_8696dd51-d74b-4715-9c3f-3838d0b56e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8e455ac-db5d-49de-a96c-67a36db99e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f8e455ac-db5d-49de-a96c-67a36db99e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9b5f314d-4c67-40a1-9976-253dc0134515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9b5f314d-4c67-40a1-9976-253dc0134515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1f1eac8d-d4dd-40c5-b560-e9a883948de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1f1eac8d-d4dd-40c5-b560-e9a883948de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907a37c-908a-48a3-9627-ced187b74aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907a37c-908a-48a3-9627-ced187b74aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49e9fe4f-93ff-4ec1-97b8-cd087800bee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_cd408a55-cd64-49ae-a620-60afbd815580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49e9fe4f-93ff-4ec1-97b8-cd087800bee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78a4b25c-18b7-478b-a7b2-87bce976f602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78a4b25c-18b7-478b-a7b2-87bce976f602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_526e3fa3-3fc2-46b6-aabc-43471739effb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_526e3fa3-3fc2-46b6-aabc-43471739effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_874a4e35-f412-4335-ada7-196b6ba24a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_874a4e35-f412-4335-ada7-196b6ba24a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c85b1fc9-2b8c-4c51-a981-09f9f74deedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c85b1fc9-2b8c-4c51-a981-09f9f74deedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3fb5b3d8-f86a-4cbe-b6d2-01f8e45ae385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3fb5b3d8-f86a-4cbe-b6d2-01f8e45ae385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0708b33-e9ed-4ff4-a5d3-396325db008b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_624fe76f-4b03-42b5-b5ba-af0665cbc94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0708b33-e9ed-4ff4-a5d3-396325db008b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5d94122b-02d9-45ea-9fe4-6581ff3065a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5d94122b-02d9-45ea-9fe4-6581ff3065a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_36747424-8376-4220-bad2-f94d3d6b88ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_36747424-8376-4220-bad2-f94d3d6b88ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afd3ee26-c4b8-4d04-a528-3dcc92bf292c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_afd3ee26-c4b8-4d04-a528-3dcc92bf292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0225a068-8159-47f2-984e-87c68001ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0225a068-8159-47f2-984e-87c68001ed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_881dad57-2a65-43db-8851-4ebf095176df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9287437c-18d5-4d7a-b8f4-bd7e9cdc311b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_881dad57-2a65-43db-8851-4ebf095176df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bab4c13f-a633-41a3-955b-d6d15600b1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bab4c13f-a633-41a3-955b-d6d15600b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_90a1c156-1479-461e-ba0a-961fc56582a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_90a1c156-1479-461e-ba0a-961fc56582a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_61c38a08-7646-459c-84ce-24ba2fcc2d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_61c38a08-7646-459c-84ce-24ba2fcc2d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2a60bd9e-ca7e-4a4e-8b68-932599d1ed25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2a60bd9e-ca7e-4a4e-8b68-932599d1ed25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_18f18fe7-29a3-4449-b172-068303f63b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_18f18fe7-29a3-4449-b172-068303f63b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e758eb8f-0c69-4be6-9f53-a09b2faf5834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e758eb8f-0c69-4be6-9f53-a09b2faf5834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb7dab2-fac9-400e-9045-a0fa030eced1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ef78cd8-729b-45b7-a763-22ddcb1b0d77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_feb7dab2-fac9-400e-9045-a0fa030eced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5e713c6-4ea9-4d6a-91df-a999d79f53a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5e713c6-4ea9-4d6a-91df-a999d79f53a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:to="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6225c095-8f89-4d2d-98e6-833f73a4407e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ccd2eed5-ba77-4093-b036-a603b8011469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d34be501-9bc1-461b-b85a-92b5bfa382ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ccd2eed5-ba77-4093-b036-a603b8011469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d47189e6-cc97-4f03-b6cc-1bd8ca063070" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa98ce83-c7f6-4067-94fa-4030f1475843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa98ce83-c7f6-4067-94fa-4030f1475843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ca06f6-ae6e-4c0b-a26a-73b822845e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ca06f6-ae6e-4c0b-a26a-73b822845e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f0ff659-dcef-4b3b-9ee5-45287126af54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3f0ff659-dcef-4b3b-9ee5-45287126af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64e4d1dc-b8c7-402e-9898-0d949c878c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_64e4d1dc-b8c7-402e-9898-0d949c878c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20480271-e472-4b81-906d-93c0f5fdd7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f394c64d-6307-48c0-a9b7-03aa76beff2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20480271-e472-4b81-906d-93c0f5fdd7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_28aff5d3-5f27-4e36-89d8-9d2204d7e368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8652c2e6-6dbc-489e-9ae2-434759b9a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8652c2e6-6dbc-489e-9ae2-434759b9a5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3368f2ae-6798-46c5-a9f1-48e8486865ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3368f2ae-6798-46c5-a9f1-48e8486865ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae865231-f830-41b3-9238-f4144802f23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ae865231-f830-41b3-9238-f4144802f23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a6c71810-4d66-41d1-ba5d-9741e3b086a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a6c71810-4d66-41d1-ba5d-9741e3b086a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2541ea36-8eae-4219-aeb9-e7115b6bb9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2da4a80-1702-4bfc-97bb-22a9bee870df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2541ea36-8eae-4219-aeb9-e7115b6bb9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_184a8828-f7d2-4234-bd41-be1878bf2a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_184a8828-f7d2-4234-bd41-be1878bf2a60" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_66a3a640-478b-48fb-b59d-9280aa7c6904" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f901de1c-9ed2-4c8d-a57e-8e985a10e2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_480b97d8-f5f2-4d8c-85e6-6a07258aaf04" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f901de1c-9ed2-4c8d-a57e-8e985a10e2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_15247518-142b-4275-bbea-91f73dab9229" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_32880bc2-3010-4f9f-944d-cbfabe410d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_32880bc2-3010-4f9f-944d-cbfabe410d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_67b609c8-893e-4929-a4b5-7a8d67ecab38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_67b609c8-893e-4929-a4b5-7a8d67ecab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b4e2d3b0-95fa-4cba-9393-81ecf896b856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c4a1b8da-faa2-4d12-8000-2a97336a47fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b4e2d3b0-95fa-4cba-9393-81ecf896b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_aef2694c-e145-431c-b861-9076c5446b7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7358cef0-ae14-45a6-9c1f-8b8e44709b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7358cef0-ae14-45a6-9c1f-8b8e44709b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_ac4213cc-3183-4778-8250-f750fb6f972b" xlink:href="arwr-20220930.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_arwr_CommercialNotesMember_ac4213cc-3183-4778-8250-f750fb6f972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9d7c4795-6e24-466e-88e3-bb1945ada0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9d7c4795-6e24-466e-88e3-bb1945ada0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d8b11b00-2973-4be7-a627-96e96fd768bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4972f0f2-57ec-404e-9a62-6c8434bd0789" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d8b11b00-2973-4be7-a627-96e96fd768bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_cc581e89-ca54-46a2-b386-3019b3c798da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4a945bee-ed51-4e2d-85e2-93c7cb6cc5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1935ac2b-73db-4775-b667-d613772f31af" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4a945bee-ed51-4e2d-85e2-93c7cb6cc5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca4700b9-4294-4c17-8423-0d20202c45f4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f886e206-d11f-4848-ada1-10b4bdd81058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f886e206-d11f-4848-ada1-10b4bdd81058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_586dd9da-cd7f-4071-92c7-d39f111bc814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_586dd9da-cd7f-4071-92c7-d39f111bc814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e32baf5-e90d-4728-9a6c-eae8e50475d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdcc3235-8996-4fc5-b9fb-6b960a6905ac" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4e32baf5-e90d-4728-9a6c-eae8e50475d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesProvisionsforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_29d53848-2684-450b-a3a9-6aae9af6b989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_29d53848-2684-450b-a3a9-6aae9af6b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6d334c55-0cf7-4e77-ac70-fb90d5bc90ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_29d53848-2684-450b-a3a9-6aae9af6b989" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6d334c55-0cf7-4e77-ac70-fb90d5bc90ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d71ab4e-4e18-4f0e-aafb-22943df8e4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_29d53848-2684-450b-a3a9-6aae9af6b989" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d71ab4e-4e18-4f0e-aafb-22943df8e4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fd53c099-3aa3-43f3-b5ae-38432f12c441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_29d53848-2684-450b-a3a9-6aae9af6b989" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_fd53c099-3aa3-43f3-b5ae-38432f12c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_72755452-d1b8-4cb4-b73c-a3790a3f1a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_72755452-d1b8-4cb4-b73c-a3790a3f1a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b4161d6f-0b4a-4a1e-b80b-57f261318e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_72755452-d1b8-4cb4-b73c-a3790a3f1a3d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b4161d6f-0b4a-4a1e-b80b-57f261318e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1e441306-49dc-444b-8d2c-b421d09953b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_72755452-d1b8-4cb4-b73c-a3790a3f1a3d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1e441306-49dc-444b-8d2c-b421d09953b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_12fe3aa6-a32a-4c06-9dcd-f4a3d0343d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_72755452-d1b8-4cb4-b73c-a3790a3f1a3d" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_12fe3aa6-a32a-4c06-9dcd-f4a3d0343d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee5bd0c2-0d4e-404a-889f-3916cf1ff626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee5bd0c2-0d4e-404a-889f-3916cf1ff626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_12ccc399-6685-4e39-a707-067f181ebcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee5bd0c2-0d4e-404a-889f-3916cf1ff626" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_12ccc399-6685-4e39-a707-067f181ebcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8baba8e3-f6b3-4983-a67d-bd4de3522b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee5bd0c2-0d4e-404a-889f-3916cf1ff626" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8baba8e3-f6b3-4983-a67d-bd4de3522b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_ad151478-030c-4d27-9b1a-bec04eb30f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee5bd0c2-0d4e-404a-889f-3916cf1ff626" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_ad151478-030c-4d27-9b1a-bec04eb30f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a573124e-b94e-4088-8f29-5cee5e942cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a573124e-b94e-4088-8f29-5cee5e942cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d06d135d-2eee-46de-af97-87fb2f3ffb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a573124e-b94e-4088-8f29-5cee5e942cd3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d06d135d-2eee-46de-af97-87fb2f3ffb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8068d6c7-78ca-435f-b400-eb1674c1d85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a573124e-b94e-4088-8f29-5cee5e942cd3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8068d6c7-78ca-435f-b400-eb1674c1d85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96d614cb-3b9e-4676-b12d-d920bf58eb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fba984d5-3836-44e4-a95d-6263b4654805" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96d614cb-3b9e-4676-b12d-d920bf58eb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4dba6226-7eea-4c06-9481-7e34ed461c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4dba6226-7eea-4c06-9481-7e34ed461c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e2871847-cc1a-43a2-bdd2-09c63bb2e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e2871847-cc1a-43a2-bdd2-09c63bb2e60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_e3f48747-b1af-45f5-8bcf-40122e0734db" xlink:href="arwr-20220930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_e3f48747-b1af-45f5-8bcf-40122e0734db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d4a53303-eb9c-4029-b6ac-22cb6179adff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d4a53303-eb9c-4029-b6ac-22cb6179adff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5377a114-070e-4216-b5ed-f854226cd917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5377a114-070e-4216-b5ed-f854226cd917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_95fa6652-ab0e-42df-9ed7-7c5329d4a359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b1ce238-704f-4b70-a998-022bc14168a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_95fa6652-ab0e-42df-9ed7-7c5329d4a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ae14daf1-5a0a-43a4-9769-d2a6fd88ab33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ae14daf1-5a0a-43a4-9769-d2a6fd88ab33" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_35931e65-3ded-4989-ae85-1fb6e3e66f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_35931e65-3ded-4989-ae85-1fb6e3e66f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0585309f-34fc-47ec-9e9d-1bdfef00fb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0585309f-34fc-47ec-9e9d-1bdfef00fb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_3427fe9d-7b70-48f2-ba3e-a7e4d45edd8a" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_3427fe9d-7b70-48f2-ba3e-a7e4d45edd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_276326b5-84f7-4534-8f53-fdddf6fc3aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_276326b5-84f7-4534-8f53-fdddf6fc3aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_797c64c8-af5b-4f74-9be1-ea7f9b2b1070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_797c64c8-af5b-4f74-9be1-ea7f9b2b1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e0756ad5-020b-4726-be0f-a6a355355541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e0756ad5-020b-4726-be0f-a6a355355541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_da30e30f-41c7-4ef1-ad18-354522a981c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_da30e30f-41c7-4ef1-ad18-354522a981c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_4f07eb33-0c4c-4117-acaf-9064c30c8acc" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_4f07eb33-0c4c-4117-acaf-9064c30c8acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3e2bb080-5d37-4916-aeca-07d345ba55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3e2bb080-5d37-4916-aeca-07d345ba55d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_52b7dbbf-f7c2-49f4-9653-156bdaa6e073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_49e8cd18-946e-411e-b2b3-12219a5ee7e7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_52b7dbbf-f7c2-49f4-9653-156bdaa6e073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_48c20cb9-c9c5-496e-abd7-d23ecd04a9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ae14daf1-5a0a-43a4-9769-d2a6fd88ab33" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_48c20cb9-c9c5-496e-abd7-d23ecd04a9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fc4ad23-df5a-4e73-9ee8-adf9993aa66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ae14daf1-5a0a-43a4-9769-d2a6fd88ab33" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fc4ad23-df5a-4e73-9ee8-adf9993aa66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1411edba-8742-43c9-a03f-6f12a9d185af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fc4ad23-df5a-4e73-9ee8-adf9993aa66b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1411edba-8742-43c9-a03f-6f12a9d185af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes_86939316-67c2-4dbc-b1c5-275b66f63196" xlink:href="arwr-20220930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fc4ad23-df5a-4e73-9ee8-adf9993aa66b" xlink:to="loc_arwr_DeferredTaxLiabilitiesStateTaxes_86939316-67c2-4dbc-b1c5-275b66f63196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a5f06b49-4194-466c-9c27-4e2e9b92054d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_7fc4ad23-df5a-4e73-9ee8-adf9993aa66b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a5f06b49-4194-466c-9c27-4e2e9b92054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_08bfa122-8ab8-4883-9195-612fec6e17ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ae14daf1-5a0a-43a4-9769-d2a6fd88ab33" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_08bfa122-8ab8-4883-9195-612fec6e17ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfValuationAllowance_81c4acb7-ae5d-420d-8094-acc8e7746197" xlink:href="arwr-20220930.xsd#arwr_PercentageOfValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_arwr_PercentageOfValuationAllowance_81c4acb7-ae5d-420d-8094-acc8e7746197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FederalNetOperatingLossCarryForward_c04bce9d-470b-4d95-961d-1256ef23f11e" xlink:href="arwr-20220930.xsd#arwr_FederalNetOperatingLossCarryForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_arwr_FederalNetOperatingLossCarryForward_c04bce9d-470b-4d95-961d-1256ef23f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_StateNetOperatingLossCarryForwards_eb5fed57-d5a8-4a18-9bde-63abe2b1235b" xlink:href="arwr-20220930.xsd#arwr_StateNetOperatingLossCarryForwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_arwr_StateNetOperatingLossCarryForwards_eb5fed57-d5a8-4a18-9bde-63abe2b1235b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_dd8b8073-2877-4c2c-9c43-4ee86a377596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_dd8b8073-2877-4c2c-9c43-4ee86a377596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_960067ac-ad1a-4aa0-82fd-70dbb3cb2a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_960067ac-ad1a-4aa0-82fd-70dbb3cb2a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_23ddeec8-d33a-4819-b53e-2c8af2283ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ad3f8d2-a8ee-445d-8177-a877c228dbfa" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_23ddeec8-d33a-4819-b53e-2c8af2283ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1a432e9c-f5de-41f5-a0d9-3318957a251a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_96a94642-e451-4593-aaf9-2844b9e14a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a432e9c-f5de-41f5-a0d9-3318957a251a" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_96a94642-e451-4593-aaf9-2844b9e14a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a057e9d3-6572-40d0-bfce-523712dec176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_96a94642-e451-4593-aaf9-2844b9e14a1e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a057e9d3-6572-40d0-bfce-523712dec176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_42bee2f6-f41a-4cca-b4c2-d2a8b26ab646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_96a94642-e451-4593-aaf9-2844b9e14a1e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_42bee2f6-f41a-4cca-b4c2-d2a8b26ab646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_09de88d2-022b-4bcc-be9c-201b4e223612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_96a94642-e451-4593-aaf9-2844b9e14a1e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_09de88d2-022b-4bcc-be9c-201b4e223612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6844d883-0dbc-420d-b4fa-cef4f483bfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6844d883-0dbc-420d-b4fa-cef4f483bfcd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_97e3a3ee-d1f2-4c08-8eb5-c8c3a84e9455" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_7419fb9b-43c6-454c-899e-b95e26d3dd96" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_7419fb9b-43c6-454c-899e-b95e26d3dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_74e93c47-bc17-45b3-b603-a063170368c7" xlink:href="arwr-20220930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_60380b37-781a-49e4-b5be-4885b9e38406" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_74e93c47-bc17-45b3-b603-a063170368c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bbcc84e3-8382-4fb4-a0ad-4ce6620d743e" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1f43bd-58e0-4068-b979-89f95fde5804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6c1f43bd-58e0-4068-b979-89f95fde5804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf62f80f-6a30-4b70-ab49-80c468eeec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_bf62f80f-6a30-4b70-ab49-80c468eeec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7947df02-8b76-4cb4-8e1f-b778337d1abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ae040648-7b78-4303-bbe5-d8f057d19439" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7947df02-8b76-4cb4-8e1f-b778337d1abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20220930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e6ab082c-6936-4855-9c75-f6b7fae841a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e6ab082c-6936-4855-9c75-f6b7fae841a2" xlink:to="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9487157e-8a4e-4b61-92ec-1a57100fd79a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_e5a6ba62-f357-4039-8f4f-587d8f9dde70" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbf8ae24-345b-4788-90cd-1f84db740acf" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_e5a6ba62-f357-4039-8f4f-587d8f9dde70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6eadb5c4-d01f-48ec-8740-15a25e6775db" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aee2749d-6ae6-437f-a34e-a1073216b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1864daec-23d4-42b4-a847-056a41139e0e" xlink:to="loc_us-gaap_SubsequentEventMember_aee2749d-6ae6-437f-a34e-a1073216b3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_80211295-3e16-4727-85dc-567ddacc1695" xlink:to="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2839ea1e-8aba-4fef-8e99-0a9f4bf4812c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_73000404-5694-482f-94ee-d83739043c8e" xlink:to="loc_srt_MaximumMember_2839ea1e-8aba-4fef-8e99-0a9f4bf4812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_bf1da4b8-0a9e-4b33-a220-a82e6f525213" xlink:to="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_338ed402-e499-4051-aec5-9a640c38cc75" xlink:href="arwr-20220930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_InitialTransactionPrice_338ed402-e499-4051-aec5-9a640c38cc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_1bc23735-e80c-4803-b4c4-a5546e604066" xlink:href="arwr-20220930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_1bc23735-e80c-4803-b4c4-a5546e604066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_08181230-95fa-4385-8ca2-f3dfc7e5599c" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivable_08181230-95fa-4385-8ca2-f3dfc7e5599c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_a0bc1d94-56b1-404c-b6bd-8d34d4301b44" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_a0bc1d94-56b1-404c-b6bd-8d34d4301b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_2012c9db-083a-47e1-bfe2-32c4101da273" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_2012c9db-083a-47e1-bfe2-32c4101da273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_a4ca2486-f452-4569-936f-554629ddfd83" xlink:href="arwr-20220930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_a4ca2486-f452-4569-936f-554629ddfd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_634d1535-61de-4945-a0e2-3caad62cf2b5" xlink:href="arwr-20220930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fee3099e-3825-4818-bf1a-13a4a32558f6" xlink:to="loc_arwr_RoyaltyPaymentThreshold_634d1535-61de-4945-a0e2-3caad62cf2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>arwr-20220930_g1.jpg
<TEXT>
begin 644 arwr-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH 0KD
MTFW;1OQ7-_%GQW#\,OAAX@\17 W0Z'83WSK_ 'A'&SX_'&/QHITW.:C'=Z$U
M)*,7)]#YC_X*'_\ !433?V2[H^%?#-I:Z_X\DC$DL<KG[)I*,,JTVTY:0C!6
M,$'')*@KN_.CQ]_P48^-WQ'OI)KSXBZ]9K(<^1IC+I\4?LHB ;\V)]Z\D\8>
M,M2^(OBW5/$&L3M=:MKEU)?WDS=7ED8LWX<X [  =JSZ_I'(.#<OP6&BJM-3
MJ=6U?7ROLOZ9^3YIGF(Q%1M2<8]$G;[^[/1?^&P/BU_T4_X@?^#VX_\ BZ/^
M&P/BU_T4_P"('_@]N/\ XNO.J*]_^Q,!_P ^8_\ @*_R/+^N5_YW][/1?^&P
M/BU_T4_X@?\ @]N/_BZ/^&P/BU_T4_X@?^#VX_\ BZ\ZHH_L3 ?\^8_^ K_(
M/KE;^9_>ST7_ (; ^+7_ $4_X@?^#VX_^+H_X; ^+7_13_B!_P"#VX_^+KSJ
MBC^Q,!_SYC_X"O\ (/KE;^9_>ST7_AL#XM?]%/\ B!_X/;C_ .+H_P"&P/BU
M_P!%/^('_@]N/_BZ\ZHH_L3 ?\^8_P#@*_R#ZY6_F?WL]%_X; ^+7_13_B!_
MX/;C_P"+H_X; ^+7_13_ (@?^#VX_P#BZ\ZHH_L3 ?\ /F/_ ("O\@^N5OYG
M][/1?^&P/BU_T4_X@?\ @]N/_BZ/^&P/BU_T4_X@?^#VX_\ BZ\ZHH_L3 ?\
M^8_^ K_(/KE;^9_>ST7_ (; ^+7_ $4_X@?^#VX_^+H_X; ^+7_13_B!_P"#
MVX_^+KSJBC^Q,!_SYC_X"O\ (/KE;^9_>ST7_AL#XM?]%/\ B!_X/;C_ .+H
M_P"&P/BU_P!%/^('_@]N/_BZ\ZHH_L3 ?\^8_P#@*_R#ZY6_F?WL]%_X; ^+
M7_13_B!_X/;C_P"+H_X; ^+7_13_ (@?^#VX_P#BZ\ZHH_L3 ?\ /F/_ ("O
M\@^N5OYG][/1?^&P/BU_T4_X@?\ @]N/_BZ/^&P/BU_T4_X@?^#VX_\ BZ\Z
MHH_L3 ?\^8_^ K_(/KE;^9_>ST7_ (; ^+7_ $4_X@?^#VX_^+H_X; ^+7_1
M3_B!_P"#VX_^+KSJBC^Q,!_SYC_X"O\ (/KE;^9_>ST7_AL#XM?]%/\ B!_X
M/;C_ .+H_P"&P/BU_P!%/^('_@]N/_BZ\ZHH_L3 ?\^8_P#@*_R#ZY6_F?WL
M]%_X; ^+7_13_B!_X/;C_P"+H_X; ^+7_13_ (@?^#VX_P#BZ\ZHH_L3 ?\
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MO^_B_P#Q-']IZA_T%-2_[^+_ /$T?59=PYT>GYHS7F']IZA_T%-2_P"_B_\
MQ-']IZA_T%-2_P"_B_\ Q-'U67<.='I^:,UYA_:>H?\ 04U+_OXO_P 31_:>
MH?\ 04U+_OXO_P 31]5EW#G1Z?FC->8?VGJ'_04U+_OXO_Q-']IZA_T%-2_[
M^+_\31]5EW#G1Z?FC->8?VGJ'_04U+_OXO\ \31_:>H?]!34O^_B_P#Q-'U6
M7<.='I^:,UYA_:>H?]!34O\ OXO_ ,31_:>H?]!34O\ OXO_ ,31]5EW#G1Z
M?FC->8?VGJ'_ $%-2_[^+_\ $T?VGJ'_ $%-2_[^+_\ $T?59=PYT>GYHS7F
M']IZA_T%-2_[^+_\31_:>H?]!34O^_B__$T?59=PYT>GYHS7F']IZA_T%-2_
M[^+_ /$T?VGJ'_04U+_OXO\ \31]5EW#G1Z?FC->8?VGJ'_04U+_ +^+_P#$
MT?VGJ'_04U+_ +^+_P#$T?59=PYT>GYHS7F']IZA_P!!34O^_B__ !-']IZA
M_P!!34O^_B__ !-'U67<.='I^:,UYA_:>H?]!34O^_B__$T?VGJ'_04U+_OX
MO_Q-'U67<.='I^:,UYA_:>H?]!34O^_B_P#Q-']IZA_T%-2_[^+_ /$T?59=
MPYT>GYHS7F']IZA_T%-2_P"_B_\ Q-']IZA_T%-2_P"_B_\ Q-'U67<.='I^
M:,UYA_:>H?\ 04U+_OXO_P 31_:>H?\ 04U+_OXO_P 31]5EW#G1Z?FC->8?
MVGJ'_04U+_OXO_Q-']IZA_T%-2_[^+_\31]5EW#G1Z?FC->8?VGJ'_04U+_O
MXO\ \31_:>H?]!34O^_B_P#Q-'U67<.='I^:,UYA_:>H?]!34O\ OXO_ ,31
M_:>H?]!34O\ OXO_ ,31]5EW#G1Z?FC->8?VGJ'_ $%-2_[^+_\ $T?VGJ'_
M $%-2_[^+_\ $T?59=PYT>GYHS7F']IZA_T%-2_[^+_\31_:>H?]!34O^_B_
M_$T?59=PYT>GYHS7F']IZA_T%-2_[^+_ /$T?VGJ'_04U+_OXO\ \31]5EW#
MG1Z?FC->8?VGJ'_04U+_ +^+_P#$T?VGJ'_04U+_ +^+_P#$T?59=PYT>GYH
MS7F']IZA_P!!34O^_B__ !-']IZA_P!!34O^_B__ !-'U67<.='I^:,UYA_:
M>H?]!34O^_B__$T?VGJ'_04U+_OXO_Q-'U67<.='I^:,UYA_:>H?]!34O^_B
M_P#Q-']IZA_T%-2_[^+_ /$T?59=PYT>GT5YA_:>H?\ 04U+_OXO_P 32QZS
MJ43975+[=_M,K#\BM+ZI+N'.CTX'-%<;X>^(,T-REOJGELLC!([E!M 8] X[
M9]1Q["NRSBL94Y0=F-23V"BBBI&%%%% !1110 4444 %%%% !1110 4444 -
M/3\:\B_;W_Y,M^*?_8K:@?\ R7>O73T_&O(_V^?^3*_BG_V*VH_^D[UUY=_O
M=+_%'\T<N._W>?HS\&:***_K>G\*/Q%A1115 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W#_P0^_Y*+\3/
M^P/8?^E+U^A]?GA_P1 _Y*-\3/\ L#6'_I2U?6?Q9_;=\!?!7]H3PE\,M=NM
M1C\3^,Q&;(0VADMX?-D:.+S7R"N]U91M#8QDX'-?S[QK)+.*M_[O_I*/U#AG
M_<8^K_,]<HKP_P#;U^,/C7X _"O2O%'A&_T.UB@URRT_4K:_TXW4EY'<W$<(
M$;;U$>W<Q)(8G@#%7/VN?'OQ/^'ZW5YX*C\$Z+X9\/Z/>:QK'B'Q-NGA5X<^
M79)#&ZNK/@$RG(&0,$C!^3YDKGT![)17G/P__:*T_4OV4]%^*7BR./PEIUUH
M$6N:E',Q9=/5D#$#C<P.1M&,D,HY)KS;QU^WPEY\$?'VJZ#X5\=^&-?T'PK=
M>)-&D\4^&Y+:SU**-?EE1MQ4@DJ=CE&(/2CF74#Z/HKY2\'?\%%(O"&E^)M3
M\=R7&I6>GZEX>TBTMM"T,_:8+G4=.%R0093YP+[L;0",@ -GC<U+]O&U\9W?
M@F/PXNI>&[R\^(,7@SQ%I/B31&2_M6:%Y3$5$H$)90&$N6 &>.#4^TB!](T5
MXMX%_;M\)?$GQK8:=HNA^/KW1-6U!M*T_P 4IX?E;0KZZ4E2B3@EMN58>84"
M?*?FQS7/>._^"F_@+P)!K-\="^(6K>'-$U+^QIO$6GZ$9='EO1((V@2X9U!*
ML<%B I(P&)(!KGCO<#Z*HKR;]FGXT:W\6/'OQ@TW5_L/V;P-XP?0],\B'RV^
MS"".0>8<G>V6//%0#]M3PUJ/Q>\3^!](T?Q=KVL^$XYEOI=.TT36Z7$<!G-O
MG>&#E1A691&SG:'S1S+<#V"BOE#]G+_@I+_PE?[//@?5/%GAOQ;J_C_Q?->Q
M6NC>'M!\R?4XK>4A[J"+S-HMT4JC.S#,B2  XKM-*_X*-^ -:^&5QXEM[#QD
M[#Q))X2L]%_L<_VQJFI(BNT,-MNSP&YWE=N#G'&4IQ8'O=%>"Z/_ ,%&OA[=
M:)X\OM6MO%OA5?AP;./6;;6M)-M=K/=;A#;QPAF9Y2RD8P <@@E>:Z?X!_M>
M>%_V@O$6HZ'96>O>'_$FE6R7T^CZY:+;79M7;:LZ;'='3=P<-E20"!FGS)[
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MQX=@6=[W0(+>:^DV?N86GWF.'=GF38F\KCA70Y^85R_C7]H6S\+>*[[1M/\
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M;K9XH;B $# RJ3A,]]F3S1S)NP'9T4450!1110 4444 %%%% !1110 4444
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M%YXATF'^R9)WMX=.T7['J-W')!Y*VMW<++LN($Y8%H_,/0M@#%K6_P#@H/\
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M!S4?C#]H7P'\/?%']B:]XQ\.:/J_EB9K2[ODCD1""P+ GY<@9 ;!/;-+ECU
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M'<Q8Y<#N0"!WH]T#DK?]D;3-+UOX?7%EJU^EMX,C\G4(IE5V\2*LINH?/(P
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M>LS0?VM/A;XJ\6QZ!I?Q$\&ZCKD]Z-.BL+75(I;B6Y.<1*JDDM\K=...M.Z
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MWO/$4]OXW\0^)='UBQ<2.EY=/#+(\]PLBCAE9PQ.0>>*R/&G[;7Q;^(G@]]
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M$/B%J_C[XM:;I$*^ ?!/CK1]7MA!<ZS%JT!O[J8/%-9E4%Q;0R!09HWQ]XJ
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M<[$?YE4C(!XKU;XC?"/P_P#%;[&^MV<TUUIQ;[)>6MY/97EJ' #K'/ Z2JK
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M$OE>?RJO(JL6"29R,'! %??A.33GFDD!RS')W')ZGUIM7&/*@"BBBK ****
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M_GM#_P!_!_C1]MA_Y[0_]_!_C7IG]@:?_P ^=K_WY7_"C^P-/_Y\[7_ORO\
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M +\K_A1_8&G_ //G:_\ ?E?\*/K4>P>S9YG]MA_Y[0_]_!_C1]MA_P">T/\
MW\'^->F?V!I__/G:_P#?E?\ "C^P-/\ ^?.U_P"_*_X4?6H]@]FSS/[;#_SV
MA_[^#_&C[;#_ ,]H?^_@_P :],_L#3_^?.U_[\K_ (4?V!I__/G:_P#?E?\
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M:_\ ?E?\*/K4>P>S9YG]MA_Y[0_]_!_C0=0MT',\/_?P5Z9_8&G_ //G:_\
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M_P!9*/\ SXC]W_ /V3_X5/\ L;_\^?P1_P# JR_^+H_X5/\ L;_\^?P1_P#
MJR_^+K\;/+']U?RH\L?W5_*C_4#%?]!L_O?^8?ZR4?\ GQ'[O^ ?LG_PJ?\
M8W_Y\_@C_P"!5E_\71_PJ?\ 8W_Y\_@C_P"!5E_\77XV>6/[J_E1Y8_NK^5'
M^H&*_P"@V?WO_,/]9*/_ #XC]W_ /V3_ .%3_L;_ //G\$?_  *LO_BZ/^%3
M_L;_ //G\$?_  *LO_BZ_&SRQ_=7\J/+']U?RH_U Q7_ $&S^]_YA_K)1_Y\
M1^[_ (!^R?\ PJ?]C?\ Y\_@C_X%67_Q='_"I_V-_P#GS^"/_@59?_%U^-GE
MC^ZOY4>6/[J_E1_J!BO^@V?WO_,/]9*/_/B/W?\  /V3_P"%3_L;_P#/G\$?
M_ JR_P#BZ/\ A4_[&_\ SY_!'_P*LO\ XNOQL\L?W5_*CRQ_=7\J/]0,5_T&
MS^]_YA_K)1_Y\1^[_@'[)_\ "I_V-_\ GS^"/_@59?\ Q='_  J?]C?_ )\_
M@C_X%67_ ,77XV>6/[J_E1Y8_NK^5'^H&*_Z#9_>_P#,/]9*/_/B/W?\ _9/
M_A4_[&__ #Y_!'_P*LO_ (NC_A4_[&__ #Y_!'_P*LO_ (NOQL\L?W5_*CRQ
M_=7\J/\ 4#%?]!L_O?\ F'^LE'_GQ'[O^ ?LG_PJ?]C?_GS^"/\ X%67_P 7
M1_PJ?]C?_GS^"/\ X%67_P 77XV>6/[J_E1Y8_NK^5'^H&*_Z#9_>_\ ,/\
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M>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU%
M"T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HH
MWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4F\>HHWCU% "T4
MF\>HHWCU% "T4F\>HH#9H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP\5>(-7M-(DOO$$%K;2VMM<,LCW%R8]L"0L1 @VLTFT,, TO:1 ^Z/[*M?\
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M!<7$<$=Y+:>7^[A/F!P!(SA2NY1DX/: >S_V5:_\^\?_ 'S1_95K_P ^\?\
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MTNHY+9H-2OEB2%5E1_+2"$#8J%5W,Q(/&!U+ ?>7]E6O_/O'_P!\T?V5:_\
M/O'_ -\U\"_ML_'WX@? ;]I)O ^A_$#XG7%W:^%]*@\/M;16$EMJFM7%S-$C
M:HTJ*BI*$ )3;R.@K>_:._:A^(_@_1_CEI&EZ[JUOXVTV[\(Z'H]O"T'V73M
M0U"-3.MG\F\!F$F?,9NV,5/M /MS^RK7_GWC_P"^:>_AZ%5'^AJ.,C,?45\%
M:U_P4:\6>)_%/[/DVAW<D&GQII\OQ*6-5VI/=7G]G"WER.")HIWP,'D'TKI?
MBS\'?%UCJ/Q)TSP3:^)M*U?6/B/;3:?>^=>20I96>F+J!52[E5AENU:,E< O
M*4YP%![3L!]FG0[< '[-'R,CY>HH_LJU_P"?>/\ [YKX@O=5^*6I_LZ_'#QC
MJ5[XK\'^()[>S^)WA]0TT"Z4JB8-I3YPK*(;9!)">\H)7)KZYTOXQZ;)\!;/
MX@:COM=+FT&'7K@1QEVC1X%E*JO5CSM [G%5&I<#IO[*M?\ GWC_ .^:/[*M
M?^?>/_OFO$?'GQB^)$5WX#%YX*G\(Z?XA\7:59M<P:U#?3Q6\LAWV][$(U\K
MS%P/W;2 ,-I8=:QG_P""D'AD:I/>#_A%E\*6U\]B]Q)XNLTUIE24PM<KII&\
MQ;@2%,@E*#<(^@J>9=P/H?\ LJU_Y]X_^^:/[*M?^?>/_OFO"OBE^TU?7OAC
MXK6EO87^AQ^!59!?Z?K-NFK;DFA <V\D3&&*8.3%+ME5T#9V'%=1XM^/_B2W
MO_%%QX7\ R^)] \&S3VFH7KZQ'97%[/ FZ>.S@9&\[R_NDN\89@P7=BJYD!Z
M;_95K_S[Q_\ ?-']E6O_ #[Q_P#?->,V/[5/B3Q;>/'X;^'G]JPV?AK3/$U]
M<W6NQV4,,5Y;O.+9,Q,7G4(V!A4.,EER!53QU^WAH>C:[I^FZ&/#,US=:-9Z
M[,_B/Q3;>'XHH+M-\$49D5VEF* D@*$08W."0*/:+>X'N/\ 95K_ ,^\?_?-
M']E6O_/O'_WS7E>C?M5#XF:'X;;P!H/_  D^J>(K*?46@N-3CM+/2H()OL\K
M3W*B4$^>#&@B5]^"P^49JU^SU\0/$?CGXB_$NW\1V-YHS:+J>GVUOIDT\=PE
MDK6$3R&&5 !)'(Y+AC@\\A2,4<RZ >E?V5:_\^\?_?-']E6O_/O'_P!\UX'\
M*_C9XTTZT\02:KI5QXB\2>(_&>I:1X=TF/6D-I;P6C2"0F0P(+:")$!8GS6D
M)! RVVMOQ-^U5K?@V Z5J/@.1?&_]J:=IT>D0ZQ'):7D=\TJ0W45V8QF,/"Z
MN'C5TVG@\9/: >P_V5:_\^\?_?-']E6O_/O'_P!\UP?Q[_:!B_9S^#$?B;6]
M)GO]4GGM=-MM'TV<2O>ZA<,$CMHI7"@@N3\Y4?*I.WM7@O\ PV9XR^'W[5WB
M:;XG:'JO@3PMX4^&<GB"[\/PZC!JL%S.M\D:W$$L87<[!Q%M;;ALY&,-0ZEM
M /K;^RK7_GWC_P"^:/[*M?\ GWC_ .^:^4?@E_P5U\'_ !(\22V&O:;:>'4D
MT>[UVTFL-=@UG$%M$9I8KA(E4P3^6K$)\P)4C=FG_L]?\%9_#/QT^*6@^&YM
M#M]('BY9?[%D@U^WU"Y$B(9%BO+>-0UJ[J#CEP#P2*GGB!]5_P!E6O\ S[Q_
M]\T?V5:_\^\?_?-?+OPW_P""DVL>*/ 7A'QSKWPFU7PW\./%FH1Z2NOC7;>Z
M:TN)9F@CD:V"+)]G:0;?,.#G/RD8)]:_:1_:.N/@AKGA/PWHGA>Z\9^-_&]W
M/;:1H\-['91LD">9//-/("L<<:D9."3GI57C:]P/2/[*M?\ GWC_ .^:/[*M
M?^?>/_OFOF'6?^"DFI>%O _CC4-6^%NJ6&M^!?%.E^%[C1?[9AEFNIKU<ATE
M5/+P.-O.'#*<KSC0N/\ @HHWASP[XMM?$'P]U;3OB!X8\26/A6'PO:ZI!>-J
ME[?(9+58[D!8P"@8L2/EV]Z/:1 ^CO[*M?\ GWC_ .^:/[*M?^?>/_OFOG7X
M _'/XA>//VZ?%_AGQCHM[X-LM*\%65_%X?;4H-1M5N'NBC74,\2C>&7Y><$%
M6&. :W_BO^UIKNG?%GQ)X'\!_#W4_'6H>$-*CU#Q#=PZK;V":7Y\;/!'$)0?
M/G*J7V#:,#&<T>TTN![7_95K_P ^\?\ WS1_95K_ ,^\?_?-?,/[%_[8.K^*
M?AI\'-%\2I=:_P"(/&W@[5?$MWK4UPJN6L[AT\MHPG)9<#<",;>AJW\*O^"B
M%]\8M>^'5CI'P_;_ (KCPU+XKO9YM<2.+0;&&]DMIW?,69=HCW@* 6+!<#!:
MI51/J!])_P!E6O\ S[Q_]\T?V5:_\^\?_?-?,"_\%'M=N?#/AKQ=#\(=8'P[
M\:>(+30]$UZ?7($EG6>X\E;F6U"&2)&(8IR=V,$KD9Y[PE^VE\1?AQJ?QRU3
M4O!>N>/_  7X \<ZA!<ZLFK6ULVB:;$L?[FWMV&^?RAN=AD8##YB<X/:+N!]
M@?V5:_\ /O'_ -\T?V5:_P#/O'_WS7QQJ'_!1^U^"WC+XQZUKFHWGB301K^A
MZ;X,T\SQVL*"\TW[2<S,,0Q8_>.[YQV'->O_ +&_[<>B?M?2^)-.M;.VT[7_
M  H86OH+/5(]4LIHI@?+E@N8PH<95E8%5*D=.:I23=K@>T?V5:_\^\?_ 'S1
M_95K_P ^\?\ WS7SQ\5OV]M7\)WWQ'N/"GPPU3QIX:^%!DM_$6KKK-O8B.[2
M(2210PNI>58U(\QAR!DA6XSS'Q9_X*RZ!\-[[PYIUOH%C=:OJGANR\3:A%J7
MB.#2H+"*ZA65+>*61#]HGVMG:%48QDC.!/M%W ^KO[*M?^?>/_OFC^RK7_GW
MC_[YKYHU#_@I#)XJN?!R?#GX>ZCXX_X3/PC<^+8%DU:'3&LHK:9XIXI=ZL,J
M4894G<VT 8.1D?$/_@K?X4\,^'O DNE:-#<ZIXXT)?$0M]9UN'1K;3+8NT>R
M2X=6#RETD"JJ\A<D@&CFCW ^KO[*M?\ GWC_ .^:/[*M?^?>/_OFN#_9X_:6
MT/\ :5^ =K\0-!MK\6,\=QYMDRK)<Q30;A+"-I*NV5^4J<-N4CK7SK/_ ,%%
M[GXZ_ I/$6AVE]X.^R^,=#TMFT[6;6[O6CNKIHWM[F%XMT#87YU*8(8;)&^:
MJ<DE>X'V-_95K_S[Q_\ ?-']E6O_ #[Q_P#?-?$OA#_@IL_P9^$NG6_BJ5?%
M7C#Q%XIU^WLFU35H=)L[2QM+QHD,URZD*!C8BA&8D&N\TC_@IW9^/_ O@74?
M!G@B\\3ZSXT\27?A,Z2FKP0_8KZ"$2Y%P5,4L+!E82# V$G&1MH]LNX'T]_9
M5K_S[Q_]\T?V5:_\^\?_ 'S7SEH7_!1/_A+/ _A^/2? .JWWQ'\1Z]J/AJ#P
MF-3A18;K3\&[DDO&'EBW12IWA23G 7BI_&_[0WC(^*/@Y#K?AWQ-\-M0U[QM
M+HFHZ6M]:7=MJ<26K2!A,%;S;9B."HC;(/L:GVB[@?0W]E6O_/O'_P!\T?V5
M:_\ /O'_ -\U\P_ W_@I5<?%+4O EQK?PWU#PIX5^(<FHVNE:VVLPW:FXL5D
M>8/"J*ZQ[8VPYZD'Y<#-,'_!2'79=!\'^)U^$.L0^ ?B!XAM-#T+7)M<MQ)*
MEQ,8EN)K8(7B#89D&3N"G++QDYH]P/J'^RK7_GWC_P"^:/[*M?\ GWC_ .^:
MLR+Y<A7T.*2M *_]E6O_ #[Q_P#?-']E6O\ S[Q_]\U8HH K_P!E6O\ S[Q_
M]\TY-,MXS\L2H?5,J?S%344 :&A>,;KP[.OVB:2ZT_.'\P[I(!_>#=2!W!_#
MTKT*.3>NX?,&&01WKRW:'&TCY6X(]:[CX>W#77@ZQ+98JACR?16*C]!7#B::
M7O(T@^AN4445RF@4444 %%%% !1110 4444 %%%% !1110 T]/QKR/\ ;Y_Y
M,L^*?_8K:C_Z3O7KAZ?C7D?[?/\ R97\4_\ L5M1_P#2=ZZ\N_WNE_BC^:.7
M'?[O/T9^#-%%%?UO3^%'XBPHHHJ@"BBB@ K[ \6?M'?$SX#_ +''[/\ #X!U
MK5]'MM0TG5);U;&Q2X69UO6"E]T;] 3Z=:^/Z^M/B%^TWX_^ G[&_P"S[;>#
M/%&I>'H-2TC59+M+58\3LEZ0I.Y3T!/3UKY7B6C*K/#4XQC.\WI+X?AEOH_R
M/6RVHHQJ2DW'W5JM]UYK\S/_ &E=3UGXQ?L8>$_'GQ$TN#3_ (B77BI])T_4
M&L%L;K7],\C<TLL:JN\1R[5$FW^9)X_]H/\ 8C7]EN#6;?QE\0/#-KX@M8A/
MI&C6EO-<7&LQ94>:2!MMT)+A?-.6\MCC&,^8^//BQXH^,?BVUU3Q9X@U;Q%J
M"NB)/?3F0Q)O!VH.BCV4 5[)_P %)M<A;_@HSXNNM2W7%A8ZEIR3H1G-O'!;
MET ]-N[CW-<.'P^,PE>GA5-1BU.;45HK.-HJZT6K[>5M+;3E1K4W5M=IQBFW
MW3NW;KH8?A_]CJRT7PII.K?$KXB^'/AG_P )!;B\TW3KRTN+_4I[=ON3200C
M,,;?PESDXZ5R/Q[_ &=-6^ <&DZC)J&D^)O"_B*%Y](U_2)C+9WX3[Z D!DE
M7^*-AD>^#78?\%(M-U*P_:_\5:MJ4C7&F^)6AU+0[[.;>^TYX4\@POT**HVX
M'0J:L7EE=>$_^"8E['K@DMX_%/C6&^\+VTX*O)'#:LEW<Q*?^61)"%AP6-.C
MF6+C2I8N53F]HTN6RLK_ ,KM>\>MV[I/1="6'I.4J2A;EO[UWT[]->EK%C7/
MV!+CX;V^FZIX\\>^%O!?AG6+*UO+'4KB*:XFU!IHEE,4%K&#(YB#J'?A 6 S
M7)?&7]EVX^''@6#QEX=\3:'X_P# ]Q<_8FUG2!)&;&X_AANH) )(68<KG(.1
MSR,^A_\ !37PKX@TOQ5\.-<U*.Z;PW?>!]*MM)N&R;>)TA!FA!Z*^Y@Y'4AE
M/:L?]F2SNO#O[(_QY\0:H'A\):QHEMHMF9>(M1U8SAX!$#P[Q*'8D?=!YK&C
MF6+6$IXYUE+F<4XI*SNTK+KS+UM=-6L5/"T?:N@H6LF[W=]%?TM^)7\0_L-+
M\/\ X<Z'XI\:?$+PSX9T7Q9H<6JZ.K6T]U=ZA))#YIM5A0;AL!0/*<)F10,\
MXK_';P'\3OB7\0OAGX=UC4V\;Z]XB\+:?/H%O;QA&MK2X5FC@<[5&Y K%W.1
M@9+8%:7_  4 OGGL?@G;EF,=K\+=(*+V4N)"Q'UP,_0>E?0/POUVST?]K?X7
MQR6MM>:MJ?P,M;+1()YS;I<7[VSF.'S 04,BK(@92#\W'-<$LVQ<*5/&U&I2
MM-I62MR[6>^JWUU-HX6C.;HQ]U7BGJ];_A^!\^2_L8>%;?4_^$?D^.GP[C\;
M"3[.=,,-S]A6?IY!O]OE!MWRYQC/>N \/_!B?PM\??\ A$/&VK6?@+4-'O52
M[FU"WFN(XY4=&2,"!69O,!!5P-I!!S@UU\WQS\ P:RVB3?LV^%X]664VCZ<=
M:U3[2)<[3%Y>_=NSQC&:7]LKQ9KWBK]IS2H_$_A?3?".N:/::7IT^GV-^;T)
M&FUH?,D8EO-$;JK!CN&T9YKU,'BL?4FZ-5NTHMW?)=-6UBHMW6O5.VFIC5I8
M>*YH)732TO;YW2U]&=#_ ,%.? EA:_MA^*KC2_$MEXBUC6]72*71;.SN1>:<
M_DPJB.SH$D+D@*(RW6L?4OV+M#^'^--\>_%[P5X+\821J[:$UK/J#V)89"7<
MT*E(7QC(^;&:]&\?>(M)\(?\%II=2UYX8=+M?%UOYDLQ CA9K6-8W8G@!9&0
MY[8S7S7\?/"VN_#SXU>*-)\6K<0^((]5N'NC<YWW+/(S"8$_>5P0P8<$$5GE
M=;$3HT<(JSBE3C*]E=WTLKJUH]=+ZK7N8F%-2G6Y+^\U:[LO/>]WTZ'??$C]
MA?Q9\)V\!KK&H:)_Q<+6FTG3)+28W,!7?"L=R)5^62"03HRE>< @@'BM[Q7^
MP-;_  \^(MOX)\2?%+PCI/C6^U2+3[725M+FX!CE<I%/-*HV0"3Y6",2P612
M<9KNM1\(>(O!?P$_9'L_$4-U:S3>-9[JRMKE2LMO9RWEJ\0*GE002P![.*\/
M_;9OI[K]LCXG3>=-YR>)[L))N^9-DA5,'MM"KCTP*G+\PQ^+JJBJR6D]8Q6K
MC+ECO?2V_P"95?#X>E%SY/Y=&WI=7>W6YP?BKP;JG@OQMJ7AV_LY$UC2[Z33
M9[8#+^>CF,H!WRPX]<BMOX[_  =NO@%\2[SPGJ&I:?J6J:7%";TV6XQVD\D:
MR- 2>KQ[@&(XSD=J^L]!\.Z3\4=>\-_M2:I':RZ+X=T*2^\56H8#SO$FGB.W
MMXMN/^7EW@E'^X<GFOBOQ-XFOO&WB74M:U29KK4M8NI;Z\F8Y,LTCEW/YDU[
M.49I7QM;EV4%::_OWU7RLWYIHX<7A84(=^9WCZ=_G?\  HT445]*>:%%%% !
M1110!]P_\$0/^2C?$S_L#6'_ *4M7Z'%%9U8JI9,[6*@E,]<'J,U^>/_  1
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M!D4+E \U\,?\$V_A]I7A[X>Z)K+7_B_P]\-;&]L]-TG6HX9[.YDNI"[W$Z!
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M^&/A"]\;7LT7B3Q'X;'B:2V\/Z)?7MM]E\V2-I8_D+JJ^6Q;S,;0">F*/<W
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MVV^[;_162\D@K5G4:;Z))?+^KA1117<8A1110 4444 ?</\ P1 _Y*-\3/\
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MS\/V_@+4->T._P!,\7I8P-.+;1]6M)'N%5T1]KM*(P%+KDLP R!G) +Y8I6
M\*\'_L1_$">P^''A3Q;XN\)7W@+X/W*WGA_^R].G@U74Y8H7BMOM;.QCC5 _
MS>5GS,<UZQ^RA\#=0_9\_96\+^ -1O;*^OM!TV:REN;4/]GD9Y)7W+N ;'[P
M9R!T-=I=?$7P]I^N6^EW&OZ%;:I>2FW@LI=0A2YFE !,:QEMS. PRH!/(]:?
MK?C[0?"^L6>G:GKNB:;J&H9-I:W=_%!/=8Z^6C,&?\ :%%+5 ?+_ .S1_P $
MW+_X8)_9_B_5-#UO0[SX;/X$O[>S$N^5WOY[DRKO4#8$E '\6]<XQS4.B?\
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MUG4].T?3XB%>ZO[J.V@0GH"[D*">W- %^BJ#>*M+0Z;G4]-_XG3;=._TJ/\
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MXJZ+X;_9.^*'A&[EF76O%6H:/<Z=&L):.1+625IMS]%P'7&>M=3X?^)'P_\
MV@_@_P"&?"GQ&UK4O!?B/P/ ^GZ-XFM]/?4;2\T\L76TNX4/F QL3L=.Q((]
M?/Q.!J0K2=6FY4O:7:2;NN2*3LMTFM4D]=>AT4ZRE!)-*?+H[VL[MO7HVCTS
M]F?]IV\_:$\-_%2Q\>:?I>O>++'P!JUQI/B,V,4-\(A"/-MYRBJLH^XZ.PW(
M58 _-69^R)^TEXX\'?L,_&6/3==:V7P;:Z,=&'V.W?[%Y]ZPE^]&=^X$_?W8
MSQBL[X3?$KX+_LU^%_'^CZ7KVM>,]>\6^%+_ $I?$)TE[*QMGDC BM;>!B93
MYC\O-)@ 1J .37F7P7^+6B^"/V8_C#X7U":X36/&EMI,6E1I 725K>[,LN]A
MPF%Z9ZURK+U5=7V5%\CG3:36EE)<S2:T5MU;N^II]8<.3GE[W+*[3\M+M;L]
M=_9B_:9\=>%_V*_CG>6.O-;W6CWNDWED_P!CMV\F6\O9C<MAHR#O/9@0O\(%
M<M\(_$D/P"_9QO/C%]AT_6OB#XL\2SZ-H=QJ%HEQ;Z*(X_/N;P1$;&F9GVKD
M87J!U!XCX4?%;1?"/[+_ ,7?"M]+,FK^,6T9M+C2$M'(+6XDDFW/T3"L,9ZU
MH? SXO\ A2_^$FJ_##XCG5+3PO?ZBNLZ3K&FP"XN?#^H!/+=S$2/-AD3 =0<
M\9')R.[$9?.,JTHT_==2+DDM90Y8WM;=7W775=;&-/$J2A%RU47:[T3N[>FF
MSZ;GHGP%_:KU[]K/XDZ7\,_B[+;^,]!\9S?V;:WLMC!#J&@W<@(AN;::-%(
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M5IEMX:\5^$?$OBVVM9IM.\N/-Y#"PQ,(7= 5R!\Z*<X&2,5J>$/VO?A?X_\
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MVC0^(]92%[*Q\TLTXF!,/S % 9 "4#,"X'R@UVU7RI@>!7OA&P^)6C:M9Q_
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MOZXIRYZ<6C\1FK2L%%%%:$A1110 4444 %%%% !1110 4444 %%%% !1110
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M()0^%)("G/>L#2/V;]>7QW9ZA?0:7<6L'BC0M;(><.0EEHALI' (^^+C!7U
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MT0AOLY(+S$=-V. OMWKNZX,344M$:074****YC0**** "BBB@ HHHH ****
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M@?\ H)C]R_S/Q[_LRZ_Y]+K_ +\M_A1_9EU_SZ77_?EO\*_83_A\Q^S_ /\
M06UC_P $%U_\11_P^8_9_P#^@MK'_@@NO_B*/]=,W_Z )?>_\@_L/ _]!,?N
M7^9^/?\ 9EU_SZ77_?EO\*/[,NO^?2Z_[\M_A7["?\/F/V?_ /H+:Q_X(+K_
M .(H_P"'S'[/_P#T%M8_\$%U_P#$4?ZZ9O\ ] $OO?\ D']AX'_H)C]R_P S
M\>_[,NO^?2Z_[\M_A1_9EU_SZ77_ 'Y;_"OV$_X?,?L__P#06UC_ ,$%U_\
M$4?\/F/V?_\ H+:Q_P"""Z_^(H_UTS?_ * )?>_\@_L/ _\ 03'[E_F?CW_9
MEU_SZ77_ 'Y;_"C^S+K_ )]+K_ORW^%?L)_P^8_9_P#^@MK'_@@NO_B*/^'S
M'[/_ /T%M8_\$%U_\11_KIF__0!+[W_D']AX'_H)C]R_S/Q[_LRZ_P"?2Z_[
M\M_A1_9EU_SZ77_?EO\ "OV$_P"'S'[/_P#T%M8_\$%U_P#$4?\ #YC]G_\
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MNO\ ORW^%?L)_P /F/V?_P#H+:Q_X(+K_P"(H_X?,?L__P#06UC_ ,$%U_\
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M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** #/-13S+#$SL0JJ,DGH!2R'#?A7F_[7WBRX\!?LM_$+6;
M-VCNM-\/WUQ$ZG#(RP.01[CM6F'H^TJQI+[32^]V,ZU14X.;Z*Y^57_!2W]O
MO5OVI_B=J7AS1[Z:W^'>AW+6UK;0OA-8DC8AKJ7'WU+ ^6IX"@-C<>/ERFQ)
MY4*K_= %.K^J\IRNA@,+'#X=6Y?Q\WYL_%\;BJF)JNI4=VPHHHKU3C"BBB@
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M^O\ A1_PL70O^@E!^O\ A7$^8WK1YC>M'U6'F'M#MO\ A8NA?]!*#]?\*/\
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M8NA?]!*#]?\ "N)\QO6CS&]:/JL/,/:';?\ "Q="_P"@E!^O^%'_  L70O\
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MT/YUZ5:7:7UK'-&VZ.90Z'U!&17-5I.#\BHRN34445F4%%%% !1110 4444
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M=!1117":A1110 4444 %%%% !1110 4444 %%%% #3T_&O(_V^1_QA9\4_\
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M"@M_B:B0Z';P^(&:>TG:W:X5[S,.U(#''*V8R[KA05);C?MOVDO$,T<OA_\
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M_A[1](U2YT/5O"-UK]MKJZ>LUB''E-#.6\U7,"JY#KM#%V0#J2"7(!@^*O\
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MC..*OV_QVTH_!34/']YI^OZ3H&G6,NINM_9>3=R6L:>9YRQ;B=K)\RAL,1U
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ME_#.Z\+7$5A=Z7>:G--=W-DUW91JUBRK'<*K*RI(?E#*P8'&,]#ZC12Y$E9
M>0V7[.FN:WXUL?%GB77=)O/$L>M6%_.EA920V%O9V<5TD5K KLTA8O=22-)(
M223@  "K.H_"+QUX<UGQ%%X-\5^'M,T/Q7>S:E<KJFDR7=[I%Q.JK.]JR2)&
MX8KO"S*0C$\LORCU6BGRH#R/3_@!XB^$>H02_#;7-#L[232K+2KZP\1V4UW%
M+]CC,4%S')"\;K+Y9VNIRC8!&TCG-\,?LU^,O VEZ3J5CXPT/4O&FEZUK.I2
M7FI:5(NGZE#J<@DEBDBB</$R%(RK(Q^Y@Y!)KVZBCE0'C>F?LW^(O"-OI6MZ
M)XGTH>.K6ZU.[U">\TUVTG5?[0E2:>$PHXEB17CB,;*Y8>7\V[<<;^I?"GQ/
MXR\"6-GXD\2:??ZQ#XBL=<DDM; V]G;16UQ',+2!-Q?;B,@/(S,6<DX&%'HM
M%'*@.5^,7PVD^*'A2&UL]0.CZMI>H6^KZ5?^2)UM;N!]T;/&2!)&<LK+D$JQ
MP0<&O-?&?[.'CWXMW>LW7BKQ7X45M0\*WOANULM)TJ>.ULVN)H)#<,\LC22'
M]S@KP!\N.YKW2BAQ3 \[^,7P A^,WB=)[Z_>VTU_#FH:#/'"O^D!KF6VD2=&
M.5!C-OG!!R2.V:P[WX1?$SQMXF\'R^*?&7A&?2O"6NV^L2QZ7HDT%QK9B210
M9F>5EB;Y]P6,;2V<G  KV"BCE3 \C\,_ :^\6_ W7M/\1S3:+XG\9:M+XAO;
MBV9)WTR[$Z26BKU200)!;)C[K!&'>JGC3]G[QM\:-.O$\;>)O##R6NEZA8Z3
M#HNESV\ N+NV:V:[N?-D=F*QNP$49"C>3EN,>ST4<J X#]H?PS>:E^R[XRT;
M3H9[N^E\-7%E;16T>^663R"BA%YRQ.,#!K-TSX2^-/%'B?PW/XT\2Z!J.C^$
M[E=2L8-,TN2UNM1NUA>**6[9Y&1=@D<[(0 SD$D ;:]1HHY4!XMX-_9V\7?!
MZSTB;P=XC\-C4ET.TT368M9TZ>:SO?LID\FYA\J1)(Y%$KJ5)*L",X(R;_@3
M]G;6/#?A[PE!JOB6WUG4O#_BZ^\47EZ+'[.+_P"T_;/W:Q@D1D?:AW(PA]<U
MZU11RI >5W_[/6I1PW-[I6O6UAXBMO%U[XKTFYELS/:Q_:8O)>UN(]P+HT;.
MI9&5@2I7I@T;S]G7Q%XXU^+Q!XK\0:+=>((K[2WBATRQDATZSL[*[^U&%!([
M2/++(<F1S@84!0 <^Q44<J \YU?X&7.IZ;\7+<:E;H?B8I6!C$Q_L_.FQV7S
M\_/RF_C'!QUK4N/A9--\0? ^M"]A6/PAI=YITD'EG-T9X[= RG.%"^03@_WA
MZ5V5%/E0'AGQ&_9@\9Q?'3Q%XX^&WCK2?"5UXXTJWTKQ%;ZIHIU)'^SJR07-
MMB1-DJHS##90]2.U>377_!)P#X:?#2T&K^#M:\2_#_2;G19O^$AT*2_T;5;>
M:YEN WDB1)(Y8VD.&5N<D$8K[,HJ73BP/FFQ_8%O_A_HWP_U7P)KWA7PMX^\
M"O>LUU#X=\O1-62]54N(Y+-)-R?*D85U?=\G/7C,\+_\$^_%=OXDM=:U_P ?
M:3K6L_\ "S(/B'=W4>DO;+.([0P&V6,.0IR00<D;5&<FOJFBE[.('S[^R?\
ML4W_ .SK\8_%WC"]US07;Q3:);2:9X>TR73=.FE64R&]E@:5T6X887$05 -V
M!\U?05%%6DDK( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7;?#+_D2;/ZR?\
MHQJX:><6T+.>B]AW/8#W->A>#]+?1_#=G;R?ZQ(\N/1B=Q'YDUR8K8TI[FK1
M117$:!1110 4444 %%%% !1110 4444 %%%% ",,BL+XB>#+7XA^!=8T&\&Z
MUUBRFLI1ZI(A0_SK>HHC*49*<=T3.*DN5G\[?Q2^&&K?!3XCZUX2UR%H-4\/
MW;V<X*D"3;]V1<]4=2KJ>X85S]?ME^W3_P $X?"O[:-A#J,EPWAWQA81>5;:
MQ!$)/-C&2(IX\CS(\DD<AER<'!(/YY^.?^"-OQR\(ZJT-EH^A^(K?=A;FQU:
M&)7&>"5G,;#Z<_6OZ'X=XYP&*P\8XF:A46Z;LK^3>EG]Y^5YGP_B:%5N"<H]
M&M?O1\LT5]%?\.F_C]_T(\/_ (/+#_X]1_PZ;^/W_0CP_P#@\L/_ (]7T/\
MK+E7_01#_P "7^9Y?]FXS_GV_N9\ZT5]%?\ #IOX_?\ 0CP_^#RP_P#CU'_#
MIOX_?]"/#_X/+#_X]1_K+E7_ $$0_P# E_F']FXS_GV_N9\ZT5]%?\.F_C]_
MT(\/_@\L/_CU'_#IOX_?]"/#_P"#RP_^/4?ZRY5_T$0_\"7^8?V;C/\ GV_N
M9\ZT5]%?\.F_C]_T(\/_ (/+#_X]1_PZ;^/W_0CP_P#@\L/_ (]1_K+E7_01
M#_P)?YA_9N,_Y]O[F?.M%?17_#IOX_?]"/#_ .#RP_\ CU'_  Z;^/W_ $(\
M/_@\L/\ X]1_K+E7_01#_P "7^8?V;C/^?;^YGSK17T5_P .F_C]_P!"/#_X
M/+#_ ./4?\.F_C]_T(\/_@\L/_CU'^LN5?\ 01#_ ,"7^8?V;C/^?;^YGSK1
M7T5_PZ;^/W_0CP_^#RP_^/4?\.F_C]_T(\/_ (/+#_X]1_K+E7_01#_P)?YA
M_9N,_P"?;^YGSK17T5_PZ;^/W_0CP_\ @\L/_CU'_#IOX_?]"/#_ .#RP_\
MCU'^LN5?]!$/_ E_F']FXS_GV_N9\ZT5]%?\.F_C]_T(\/\ X/+#_P"/4?\
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MH#T(K[(/@_6/^?&/_P "5_PKM-)TRWT#2H;.UACMK.SC6.*&) J1(HPJJHX
M    ]*NK7\]9KG-7'8JIB9*W,]NRV2^2/U/ 8&.&H1I1>WY]3S[_ (0W6?\
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M[_X0W6?^?&/_ ,"5_P */^$-UG_GQC_\"5_PKT2BCZU+L@]FCSO_ (0W6?\
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M_P "5_PH_P"$-UG_ )\8_P#P)7_"O1**/K4NR#V:/._^$-UG_GQC_P# E?\
M"C_A#=9_Y\8__ E?\*]$HH^M2[(/9H\[_P"$-UG_ )\8_P#P)7_"C_A#=9_Y
M\8__  )7_"O1**/K4NR#V:/._P#A#=9_Y\8__ E?\*/^$-UG_GQC_P# E?\
M"O1**/K4NR#V:/._^$-UG_GQC_\  E?\*/\ A#=9_P"?&/\ \"5_PKT2BCZU
M+L@]FCSO_A#=9_Y\8_\ P)7_  H_X0W6?^?&/_P)7_"O1**/K4NR#V:/._\
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2112&%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>arwr-20220930_g2.jpg
<TEXT>
begin 644 arwr-20220930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E M4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HQDX)Z<CKZU63QM:"^:RNK"^MK@$@*T8()'7D''<?G6D8NDW-:&%J*5N_\
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M0 4444 %%%% !129 (!(R>@]:6@ HHHH **** "BBB@ HHHH **** "BBB@
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MWX9R*W],UBTU5&\ARLJ??A<8=?J/ZBNRUCG::+]%%% @HHHH **** "BBB@
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MT=%5+:^CN.#\K^GK5NL&FMSI335T%%%%(84444 %%%% !1110 4444 %%%%
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M+1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2YGH<[KTY2Y8.[\CJJ*9#*L\$<R?=D4,/H:?6)84444 %%%% !1110 4444
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M%6JKEY="XRTT,2W\*:9"X>59;IAT\]\C\A@?I6T %4*H  & !VI:* N%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0@'.Q<"L.!/.NE7KD]_2IANV74V43>MUV6\:]]O-2445B;K0**** "BBB@
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M-!@-OH5FK??:,2/_ +S?,?U-.O;V2WDV*H^M.G25MM2ZV(DKQ3T\B\ %
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MH+J_><[4RJ^@[TZST]IB'DX3^=:J*CK(PE-RTB16EF]R^3PO<FMV.-8D"(,
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MBBB@!&564JP!!Z@BJ$VA:5<-NDT^V+>HC /Z5H44 9/_  C&C9S]A3_OIO\
M&K=KIEC9<VMI#$?5$ /YU;HH **** "BBB@ HHHH ***1F"J68@ =2: %K/O
M;\1 QQ'+=SZ5#>:CG,</3N:K6MF]R^3PO<FM8PMK(QE-O2(VWMY+J7V[FMZ*
M)88PB#@?K1%$D*!$&!3ZF4[EPARA1114%A1110 4444 %%%% !1110 4444
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M[N$O:1[KC<A<QR8&-ORD#: >>IQ7H]SI]G>6RVUQ;120(R.L;+\H*D%2![$
MCZ5%-H^G7 OA-90O]O01W6Y<^<H! #>HP2* /*?$S3SW'C=_[-M);&5;/[7=
M2'=+:HT*YD1,?,5!W#YAR*OS1SZ3XVUWQ%8&2?\ LTVD=X@.3/:-"-Y]V7 <
M?1AWKT@Z1IQ2\4V4)6]0)<@H,2J%V@-ZC;Q]*=;:996;S/;VL4;3*BR%5^^%
M7:H/K@<4 >3P7,=[X"\,:%':S:A;ZC>7%Q<0VH5C);1S.YX) P6,8Z]Z[?X<
MW\UUX2BL[I9$O-,E>QF24 ./+/R[L9Y*%#^-;ECH6E:8T+6.GV]N88C!%Y:
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MIII?#S<+V%:RJJ*%48 [4M%3*39T1BH[!1114E!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arwr-20220930_g3.jpg
<TEXT>
begin 644 arwr-20220930_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" '0!"0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[%/Q"\9>!?#-GXN\6>'=&EO(=-GO1:0,B@&XE:0XP(HO,DQU.P#O0!W/A?\
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M#_P_T7XT_$?]DNWT']G?6[J C4;;7/,UJSLYV AN'C+9^8,-N^*-6.!N&02
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M=U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6Q%*C'GK7MY6O\KG'CL2J%%U'OT.:\+?\%1_#?C+PY;:O9>'=;?3WN+BWNI
M,FU\H[1)@#YHV8$*PZX.,XK-U/\ X*T>#M7\/0/X:M)]1U:=)7:U/S/#&@!,
MRJ"#(GWAQ@\=*_.WXN_#_P 1Z3;>%_#_ (=\37OA[2)V_LV*[M[GS%,2SRR
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M[1?B&Y\)_L^^.=4L[>XNKS3O#]_<V\$$;22S2);2,J(J@LS$@  #))K\U?\
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M]4^.GA3QM\?OV@OBE^T3'X%G6YT/1?$<K+IT,J$%&D5I)"X!4$J"H; W9'%
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M/'/A6V:TM;SP_J4C63QDG)-MYB!9#N(+HPW# 8' P ?FI^U'^W%X]_X*H?\
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M7-97O:S/2:***Z3Z@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7 *[5KRO_@D3\1?@QX$_X*D_MG:Y^TCJ_@C1_C5;^-KF/2;GQE/##]GT@23
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0ANYVY(!K[F^*GQ#G\9_&*S\,2Z1X9T_4-1TV:XU'4YX_MT<#[3-)M<<N>
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M.'G=27O=>OX'])/Q$\53>$?#/V^WM/MCQW,$31DD8229(V88!/RAB?PK?3C
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M9+;EOMJM1Y+3JU<7&O"^F_DOU/?%/RTM%%?0'Z&%%%% !1110 4444 %%%%
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MT.B@#Y@^!7_!&;]E[]FWXFQ>,/!GP0\#Z-XCMY/-M[TVS7+6;]FA65G6(^Z
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M#7A;QWNU1[(O+=?OHXV,;("-Q+QXRI/09.!BO0O!_P"SO;^*_BGK/PQT3Q#
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MG2NIK[25252TI.[/U; 8=4:$:=K.VHJMS3@<TRE5L"I.L?1110 4A.*6D/-
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MW%[YVCWXCDMXIG.^TF^XZ+VV-A6 [,6]:Z.LWQ=X7M/&GAVZTR_C\VTO$V2
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M1\$_B!I=YX/\.^&-2\#^'A-ID^GVFFQ6J7\$WR/</LQN8*0!(0!D '.*\/\
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M[3_[-=QX;T+Q!XOO]8UW7-.B\/Z7="W&JS/I$OE^>[D1I!&P\QY7!$84D G
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M6MTNM-JDVJ0;>+B9V12DC'.4RV,?>- 'U-1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (5W5C^/!<?\
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ML:^5_A1I'[4G[._P8TOX7Z;X-^''C2?PS9+HNA>.;OQ')I]J;*)1';37NGK
MTIG2-4$B1/MD920R;L#[!HH \&^$G[/7BGPQ^V?XT^(NO2:-<V?B3P7H.A^9
M9AD:2]LY;Q[AA$V2D1,Z%,NQZ@],GR/Q1^P!\0[J;XC^(/#^K^'M(\:CXN1_
M$SP3->>9/93JFG064EK>A1OC2:+[3$2F63>K#)&*^U:* /BWXU_##]HO]K;Q
MQ\(IM5\'>"?ASX8^'GC_ $KQ3K=I_P )&=8O=<CMO,SY+K B0HC-N"MEY"%'
MR#.=;P5_P3KU#Q-^P_\ &+X2^,;VWTZ7XD>+_$FNV=]IS>?]B6\U22]L9F4A
M07C/DLR=,J5SWKZ\HH ^&?VG?AY^UG^U3^R+XG^$UQX5^&'A?7M:TDZ=J7C!
M/$,EW9:LHVB3[+9>0LENTX!&9780AC_K"!7H/COX%_$OX#_M4ZW\6/A9H>A>
M,['QYHEAI/B[PMJ6JG2[EKG3UE6SO;.Z,;Q_ZN9XY(I  V$8,""#]2T4 ?,7
MQ-^&WQJ_:?\ V//C'X8\7Z-X(\,:WXVT.[TGPSI.G:E+>#3UDMVCS>WC(JR.
MTAS^[B"JHQEB<UP?Q[_X)^:BG[0>C_%/2_AG\./BY-=>#[+PGXC\->*&BA=3
M9L\EM=V%S+#*B,#--')&RJ'4QD,"O/VS10!\(-^P#XZ\8_#PR-X$^#WPXN[S
MXB>%O$4/A[PO:)$NGZ5I>HQ7,RW5\D*&\N7 D95\M8T^55/+-7HO[0OP'^+>
MF_M4^//BO\,K+PU?:S>_">+PCX=AU6^,$:ZNNHSW"R3X1L0(DJMQDL5*X&<U
M]544 ?!G@3]A3QW\0/V"M?\ V??%/@G2O!]MJFFM?R^+9?$J>(+C6/$'VF.\
M:\O+?[/'YBRW2EY 6/R#8.,$3>%_V-O&7BKQ7X6L;O\ 9N_9L^'2:5J%O=Z_
MXHL[6UUC[?%$RN\>G69M8VA>5EP))G/DJ20'8 U]VT4 ?)VC?#'XS?LE?%GX
MAMX \&^%_B9X$^(>OS>*[2WO?$']B:CX=U*Y5!=I(S0RI/;/(GFH4Q(F]U(8
M;371?\$X/V=_B/\ L_:'\6Y_BA>>&K[Q%\0/B-J'BZ*30C)]CCMKBULHHX@)
M '!C-NR<\L%#'!8@?1]% 'S1^W5\ OBK\2?BU\&?&?PIN?#$.I_#/6-1U*_M
MM=D=;?5;>>P>W-IE%9D,A;'F 'RR =K#(K)TWX-?%G]J+]I'X=>,OB?X:\/_
M  Z\)_":XN-6TK0=/UPZU?:SJ\UN]JD\TZQ1QQVT,4TVU "[NX+;0N#]6T4
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MOMSQ(+EX%(1W YP3R5!SC/:KM%<_-I8WZZCD/RBG5&.*>K9- "T444 %%%%
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M;X _MN>!OB[\.OAY<ZEXH\(:#XR\=^'=-UQ/#,VNVYOX&N[:.<1+&6$CX\S
M.WG&<5\?V$7Q(_8Y^.?QB\-?$E/ MOX>_:0\-ZOX@T%_"T5Q%I]GXCL]-*WL
M#+<$MYEW:HMQQPS6LN,DFN4_93U?]CX?\$0M MM=?P@EJ_@VT_X2"WO"A\4-
MKAM4Y53_ *6;TSE3 4^;'E>7\N* /MW]H_\ :5\5? 2[\<:HFA>&]4\)>#OA
MYJ/BXL=:\K5KF^M=S+;?9=A(MF16S/NX; VFN:\9?MU:G\)O@Q\4?B%XMTWP
M=IGA?P=X>LM;T%%\31_;=7FET[[4]G<HR 6TADVQQ<N95;<!Z_'_ (W/C"#P
MEXB'Q#:Z_P"$X3]BR_\ [<^V,/M*W/F2;_.[>9D'>?[P:N@U'0=.\1? #]N&
M*^L+*_B@^'V@7"174"3"*1/!Z%' 8$!E/(/4$<4 ???[.W[0OAS]HWX9:/XB
MT+6=$U!M1TRUU"ZMK#4(KLV!GC#B-RA.,'<O(&2AXX-=CIOB/3]:N;R&SO[.
M[FTZ;[-=I!,LC6LNT-LD )*MM93@X."#WK\]?BIXJL?^";WPY^"?[1NDZ(/^
M$._X0:R\&^.=,TFR DNXYK99])N51!S(NH-Y!/)VZ@Q)XKZA_P"">_[.^H?
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M0 /<FN8TW]H?P!K/Q&E\'VGCCPA=>+8,^9HL.L6[ZA'@9.8 _F#CG[M>/_\
M!8*,R?\ !+7X]J/.^;P3J(_<_P"L_P!2WW?]KT]\5\M_M(K^R[9?\$IH+?X?
MOX;/B=-.@/@!='V#QE_PE94&S9 /]+%^;K;YIDPV#)YOR;J /T1\0?&/PCX2
MUN#3=5\4^'=-U&ZNH;&&TNM2AAGFN)@3%"J,P8R. 2J@98 X!K/UK]I#X>>&
M_B+;^#]1\>>#;#Q9=E5@T6XUJVBU"4MC:%@9Q(2<C'R\U\C?LO\ P7C\5_\
M!1_]H7QCX@T?2M0^)FA^#_!MA;W-Q$LJ6%T^G7$LIB!RJ%IU7+#G" 9Q7R'\
M#/!-AJ?_  3PUZ/XG>/?V9-+O97O3\0X?%WA&YG\86NO&23[09Y!?+<27JRD
M>0T2 D"+RAMVT ?L[;>(+"]U:[L(;VTEOK (US;I,K2VX<$H77.5#!3C(YP<
M=*X#XJ?%[6=)\6^#K'PA'X/UNWO_ !*-&\1F^UY;2?2X?L\DK?9XPK&:Z!$9
M\@[3L9F[5\<?'/7?$?\ P3N^'_PD_:'>?7OB%<P>"[7P#XZQIDEO?^)&FC#:
M/?2VQ)>.9;]EA<.2RKJ$F?N8I^N_L[77[,OA_P#8YT;7KG^T?&FM_%Z3Q%XL
MOVY;4=:O=)U2>[D)YR%=MB^B1(!T% 'VYXU_:(\ ?#'Q)8Z)XE\<>$?#VM:D
M!]DL-3UBWM+JYR<#9'(X9LGC@=:Z>\\1:?IVJ6=C<7UG!>ZCO^R6\DRK+=;!
MN?RU)RVT')P#@=:_/S]EW3/V>(_AO\91\>!\.3\2KWQ-K9^)0\9&V%ZUM]KF
M%EM^T?/]B%B+;R/*^3'W?GW5ROP#\5W'P9\,_L6^,?B-J%SH7A#3]0\5Z#IF
MK>(G:&2ST^]BD70H[R67'ER2VD$2 R$$DH"=QH _2>\\9:1IU_=6MQJFG07-
MC:_;[F&2Y19+>WRP\YU)RL>58;CQ\IYXKQ_XR?MP^&_"7P\\)^)?!FH^'?'V
ME^)/&>E>$9+G2M7BN+>V-Y<"%I/,B+@M'G.W-?+_ ,?O^%=?M;?M;_M%6]UX
M[TS2_A]:_!S3/"'B3Q9:7<3V6AWT^HWDZ0O-GRBZQO$[QEL;90&P&KB)_B;:
M:[X6M_"DGA_X9P^)O GQM\!66K>)_ 4$4.B^+?,DA>WG"(/W=Q'%A)("SB/*
MX8JPH _3:S\8Z3?>&?[9AU73IM(\II_MZ7*-;>6N=S^8#MVC!R<X&#4\/B"P
MN-$74DO;5].D@%RMTLJF%HBNX2!\[=NWG.<8YK\U/B;X:UOP'\7?$7[$>A6E
M]:>'/C#XA_X2W1[]%/V?2_!]S*]SXAM$<<(R7*O!&G]W5(\?=K] /C)X#.I_
ML^^*?#>BVD2?:O#MYIEA:1+L1=UJ\4<:@< ?= '2@#H[KQOHUCX976IM7TR'
M1GC29;][I%M61\!&$A.W:VY<'.#N&.M8?C_]H/P%\*+6XG\4>-O"7AN&TFCM
MIWU35[>T6&5UWI&QD<89E^8 \D<CBOSM^*G[0G@7XA?\$(_!/@'1O%.BZIXT
MUO2?#7@NS\.074;ZM+K$-Y9PS61M0?-66)H9=X*_*L;,>!FO9?V:_P!GKPC\
M0?\ @J[^U9XK\0:)I>O:MI__  C&E67V^W6YCL(GT@--Y:."JM)E0S8W%449
MQQ0!]E2^--'@\*G77U734T06XO#J#72"U$!7<)?-SLV8YW9QCO7CFK_MT>%=
M5^)WPMT7P5K/AKQUIWQ#U^]T*ZU'1]8ANX]*DM],NK[GRBP+-]GV;21@-FO@
M[3[71M%^#?PPT'QT+2V_9L\)?'3Q;HGB2SG&-*L(HKN\&B078^ZNGQWA52K?
MNE/D!OE&*]>^-,?P+F_X*S_LKW'@$^%_^%@F_P!;343X9,1A?3AH%_Y0O?L_
M[K<' \GS/GQYFWY=U 'VQIW[07@/4M5:P@\;>$;B_2)+AK:/6+=Y5B>7R4<J
M'R%:4A <8+':.>*Z74/$%AI-Y:6]U>VEM<:A*8;6*694>YD"ERB G+-M5C@<
MX!/:ORC^!?PB\,_#7_@A)9^,]/T2R@N'\:)XK\3ZC!:A[N:WM?&'G7$TK@%V
M2&&$L1T58SCI7U+^T!\=/!7Q\_;&_9?T?P3XI\/^+]2M_$&H>+9H]'OHKW[+
MI:Z->P?:Y#&6"1-+<0HK,1N+X&2#@ ^DO%7[0_@#P+XYLO#&M^./"&C^)=2*
MBTTF^UBWM[VZ+'"[(7<.V3TP.>U:FK?%#PUH/@ZX\17WB'0[/0+3=Y^ISWT4
M=G#M8HVZ4L$&&!4Y/!!'6OSP_8DU;]G?PY^R_P"-=(_:$N/A]#\8-3UK4O\
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MZ HKRG]GS]MWX7?M3>&==U?P-XMM-6LO#$GEZQ]H@FTZ73/D\P/-%<I'(B%
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MZT#QSX+\(:K\.;;2VT+5]>T/49[-)&)&H?:@JJ"$?9&FUADR C< :^Q_A_\
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M'!P.IP>.*\A\8_!F#P;_ ,&W>A>&]'\.RV]S9> ]#NX]/ALF%PEZ)K2=I?+
MW><)LR$XR&R:_1H@TUV\M<DXH ^4/V/_ (9P:?\ \%)?VJ_%L^D-%J6IS>%K
M"#4);8J9;:/2$=HXW(Y3S78L%/WNO(KYMT3PG??#GPY\._'.O^&M7U3X7_"[
MXZ>-;_7]'MM-EN3IL5Q=WL5AJPM54M)!:2RF0[%)59O,4?)7Z8'QGI"&_!U3
M3@=*&;T&Z3_0QC/[WGY..?FQ5K3]1@U:TBGM9HI[>90\<L3ATD4]"&!P10!\
M'_$_]H#X?_M6?\%(_P!ES5OA_I5WXOE\+:MKRW_C2STR8:=I,,NAW8%B]TR*
M&DE?8WE@D+L&[!90>(_:,^"?BWXN_"C]M#2]&T_Q$YG^*.A:K-9Z?9)-=ZSI
MMI9Z++=QVL4JF.=FBAE C(99"NP@YQ7Z7"/:N!CZ8HDR@SU% 'YK?VKX5_:L
M^+/PIT'2OCS\7/BGJNE^*++Q%;:?IGA'3M/_ .$6^RDR-/?3FRB-I %_<O#N
M623S=@1LG'VW^V9H?@WQ3^RIXUL/B'_:J>"[W3&BU:3389I;RWB)7][$L2O)
MOC;:X(4[=F2, UZ7!<+<%PKJQ0[7 ()4XZ'TJ7'% 'YE>-_C5XS_ &@/^"7G
M[6^A7&IS?%#1_#&CS:7X5\>6FBM8W'C6"2R61T>%5"RSV[MY+RPJ$D."%4AA
M7J.L^-=%_9-_;WM?B'\3M-O;;PSXJ^'.E:%X:\82VDEQ8^&9[>2:2]TZ9D5C
M:M<^9!*'("R?9RI;*@5]Q[3QS_\ 7HV_+CB@#\KOB!XCT+X[_'[]M'Q?X \)
M:W!HOB;X!QVL.O'2IK:#QE=I_:B&>V#(K2A04AWXRYCRN5VD]7H7[7?PAU?_
M ()0Z5\&8_ FL3^-[[P';>&H?A,/#4ZZI_:$EFB(AB,?EI&)6$QNBVQ5'F;M
MPK])MIHV?-F@#\J_VE?A1XK\,0_'/1M9M-3UG6]/_9@\-:/>7L,,DXU+4(;F
M_6<1O@^8Y8;B!D_,">M=1\=?"VJ3?LG?\%$XHM+U-IM3U1C9QI:R%[T?\(_I
MBYB &7Y!'RYY!'45^EF#05.W_"@#X(_X*"Z]XG_8VUGX>?'7P'I=QJ_B'Q+H
MD/PLU/1X<;]1N+U=VC7!4]3;7Y(;OY5U+_=KZL_9 _9OL/V4/V:/"7@&RE:[
M?0;("^O7.9-2OI&,MU=.>I:6=Y)"3_?JU\5OV==+^,'Q.^'_ (EU>[OI/^%<
MZA<:OI^FJR_8[F]DMWMTN)E*DLT*22&/!&&<GGC'H,:>6@'7WH _/[]N#]G?
MQI)^U7>>!?!FDZC_ ,(#^UI%:V'CG5;)BJ^'7TT#[=.Q'W3?:8/L@.0=Z*:K
M_LC?LO\ C/0?VMM*^$&O:+=?\*5_9@NKCQ!X(U*XR\6L?VB'72;09^\VEV[7
MD>[G!-N>, U^A=!Z4 ?F[X?\,:HG[ ?ANW_LK4Q<K^T8;HPBV<2+%_PFLS^;
MC&=FWYMW3;SG%>X_L)_#:WT3]MS]K;Q+)I36^HZUXRTNW6^EMBC7-M%HUGM5
M'(^:,.\G3C<3WKZOVFE H ^7?^"0&A7'AC]CC^S;BQN=-2P\8^*(;6UFA,/D
MV_\ ;=X8PJ$#";2-N!C!&*^HZ:%^?/Y<=*=0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!B^/M4.C>#]6N?)FN##:2,L42DO*=IPHZ\DX
M%?C]^VQXS?\ 9%\5:S9Z]:>,[F(6B"63399YS!&<!7D6,JH0G< 2,G82<@5^
MO7C#5-1TW4]'CT^#SOMVHI#=.REEMX!&[.W'3.T*#ZL*XG]H_P#9"\'_ +4'
MA^6P\26C?OU1)9K<A'F1&WJK'&2H;M]?6OH^'LWA@*C]LKQE^%CP\YRV>+BG
M3>JOIW///^"<?[3%K\6?@-8174T%L]C+]DL49!"[V^=L09!]U^,$>U?2V:^3
M+S]DV7]FK1;U_",S0;UW"[>/>EF@<NTC*#RP&T*,=<\8K&B_;\U#X4_#G6-3
MU2YLM?-G'-)8M+F![YECWHC!02A8<=/PKFQE"&+Q4JF#5U)[%X2O/"T(T\5T
M1]F9HKY._9+_ ."O?PM_:;\+VMW=ZA!X0O[L+Y%AJ,V)IP4#,VW **&RHW@9
MQD5]0Z5XJTS7@?L.H65[CKY$Z28^N":X,5@,3AI\E>#BST*&,HUE>G),T**:
M&^6G5R'2%%%"G!H B7^M<[XZUG4]!M;"ZTRW6[3^T(8KZ+:6?[,[;&=/="RM
MZ;5;O72,,&J7B%KI= OC8[/MPMY#;;UROF[3LR.XW8XIQ=FB96M8MCI3#UK.
M\#:I=:WX,TJ\O[=K._NK.&:Z@88,,K1J74CV)(_"M)EQ0TT[,:=U<2HSUJ2F
M%:0QDE-7K3V7=3#Q0&QX9_P4@\)ZEXR_8]\40Z9*8Y;0Q7<P$>\O D@,@ _W
M<_AFOQ^^+G[6'CKQ/X/NO">H>/H[F'4D6RN-+U%+9+A;8<^6LI7S"I&P8Y9@
MHR:_?.2TCU&WEMIE#Q7$;1NIZ,IX(_$5^4_[9?\ P0EU#5_B:=>\+7&G2: E
MS/=KYC,VH0M)RL99NJCG!!]!VK[?A+-,+3IRPV)LG>Z;/"S;"SE+VL-K'@G@
M3]@S]I?X_>"UO-.E\476DM9P06L_]M>4A5F"C]VSYV)&1\N/NUZA!_P18_:'
M'@;4K.7Q1:"VCL_-BTFTUF417UQ&<JN =F2?F#$C! K>\7_'7XD?\$^?#7@2
MPTJZEUS6+H7.GQ17!D>&0")09Y(U;:VP\ $Y)'%<?K7_  5)_:>\7Z_8R1:I
M'HFG2W(LXVMM&B59&)"OYA((0C<N"3QWKW\14S.7[S#JFX=['FT:E"W+54KA
MI'_!$C]IGQGX?TZ?6/%FC6DEM8EUL[_6)I9TG;L'56",>-W;C%=-\'_^"/\
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M\4/"U[XRO/@YX4\-^&Y#=W\/@O2II+WQ/,$*I'))=1@6EN&/F,L?F2,55?,
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M%%W(;+4HYXXXX_M;:=+B=#N;8AVY.TDY&!RU:R_$O2R/^8A_X 3_ /Q%<O\
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M^\(^-M/UG0Y4USSIKR:[;4I'8(D:I"3',&5Y" @^4QC=GFOV;_9J\'7G@3X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=$(SC]G4QDXR?Q'S5^P7^PUXP^%OQ&/CGXESV,FN6VG/86-I:7+S0V@>1BQ
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MIWA'Q;I7F6GEO%I$<-L3N>*:Q6W.^(8.'4KR0<9(/<5FZ#IW@&_U"*>"0O\
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M6Y5 6*DKOXQR<#@5L6?_  ;C:A9V$J_\+)MO,NIK>2Y5+"79.4.2Q)<L"&Y
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M=JD&Y(EV1*=H'RHORJ/X1P,4 ?F3_P %.](_9'B_X)R:==> Q\,XKR.YT5O
M\WA7R/[4D?[=:@8,/[YHC%N\[S>,9W_-BO=?AU^S5X%^,G_!6K]HC7?%OAK1
MO%-YI?AOPKIMG#JUI'>6]I'+!>-*5BD#*'?"@OC.U<9P37TUHO[+WPU\/:UJ
MNI6/P[\"V.I:Z-NI7=OH-K'-J(W!\3.$#2?, WS$\@'K77VGA^PL-7N]0@LK
M2&_U 1K=7,<*K-<B,$('<#+;03C)XR<=: /RC^!?[*7P_M?^")WQY\077AK2
M-2UC3)O&KZ3J-[ MQ>:+%IM]>)IT5K.P,D$=JL$?E+&0$(R,9K&^,FB)\9/A
M'^T_I^JW,^?%WC?X41ZC/!*8+A_M-CH'FLLBX*N0[888()XP:_6NW\!Z'9^&
M[G1HM&TJ+2+WS?M%BEI&MM/YI+2[XP-K;RS%LCYBQSG-0_\ "L_#9BN4_P"$
M?T39>R037"_88L3O $$#.-OS&,1H$)Y78N,8% 'RU\>?@3X(_9__ &N?V6[W
MP5X4\/\ A.\F\2:GX>EETJQCM'NK!]$O96MY2@!D3S+>&3#Y^:,-US7R%\*_
M#7AW3O\ @FK\!/B$VL_"6^\0> /"OB2<^"?B \/]F^)])DU!S=B N<P72^2B
MI.J./WA1UVOD?KGJ&@6.K7EG<75E:7-QITIFM)985=[60J4+QDC*L59ER,'#
M$=#7+^)/V<_A[XRTG2+#5_ ?@W5;'0)3/I=M>:+;3Q:;(3NWP*R$1MGG*@'-
M 'PY\6M,\%?&#]K_ /9=\8VO@C2]*B\1?"?Q)JUM9W^E0B\L$6QTZ2VB?*Y#
MVX?:O]SYL8S7F_AOX'^%?@]_P1$_9WN(='_L_P !^(9_#%_\6M0TV%_MM]H,
M^9KHW,L8\Y[;SW@$W)VV_F #8"*_4Z^\*Z7JFJVU_<Z;87%]9Q206]Q+;H\L
M$<F!(B,1E5;:NX X.!GI3]-\.:?HV@PZ5:6%G:Z9;P"VBLX8%2"*(#:(U0#:
M% XV@8Q0!^<O[?.E?LX6?Q'_ &99? H\"0>,S\5O#B:2O@O[.!+8>?\ /]K%
MK\IM -I0R\"7R]G)-87_  4*^&GAC3M=_;NU*#P]H-OJ4?PMT";[7%911W"O
M-_:?FMY@7<&DVC<<Y;:,]!7Z&>"/V9_AQ\-6N#X=^'W@CP_]KN8KR?\ LW0K
M6U\^>([HY6\M!N=&)*L>5)R#70ZMX!T+7AJ7V[1=)O?[9@2VU#S[..3[=$F[
M9'+D'S%7<V%;(&X^M 'Q+I&C_#C5/^"E/CE_C>GA^6\@\(Z(OPVC\5K"=+&E
MF!O[1:S$_P"Z^T_;,B;'[P1B#^$U\[_M(^$?#FO?L;_M=:%\.YF@^!VI^-?"
MMKX=DTZ0C2X=1EO;%=8&F.IP(!*8^8CL68S;.E?JK\1O@WX0^,6B0Z;XN\*^
M&_%.G6[B6*UU?3(;Z")P,!E2564''<"K2_#CP\G@^#P\-!T4:!:K&D.F"RC^
MQPB-@R!8MNP!64$8'! (Z4 ?)O[37P-\%_LX_M%?LKW_ ('\+:!X4O\ _A.9
MO#IN-,LH[>:XL)](OFE@E=0&E5FAB<[RV70-UYKZL\"_%#0?B3=:Y#H>K6.J
M2>&]1DTC4Q;2;_L5Y&JL\#^DBAUR.VX5IZMX>L=;FLYKNQL[N;3IOM-H\T*R
M-;2[2N^,D':VUF&X8.&([UB_"7X2:%\%?"TFC^'=/&GV$U[<ZE*ID:62>YN9
MGGGED=B69WD=F))[XZ 4 ?*7[:2^%+G_ (*1_"*'XQ_8F^%;>&M1/AI-8"_V
M"_BL3Q8^U[_W7GBRW_9_.XW>=M^?%>5+:_!S3_\ @KIK'_"JO['6]?X)Z\WB
M*+0!'_8BSB[L_**^5^Y%V4SYH3YM@A+]J_1+QOX"T/XE^&;G1O$>BZ3X@TB\
M %Q8:E9QW5M. <C?'("K<^HK.\&?!+P9\.M,M;+P_P"$?#&A6=E!+;6UOI^E
M06L=O%*P:6-%10%5V52P'#$ G.* /R]T#]E[P%\+_P#@VJT;Q7I?AS1T\7Z=
MX$T_Q9;^(_LZ'58M222*XCN%NB/-4HP 7# !!M'R\5] Z(_PTUS_ (*6?$Z3
MXW?\(W-X@?P]HTO@"/Q9Y7V#^Q#:@WK6*S_N?.^W>=YY7]YM$.<)BOM)_ &A
M2>#AX=;1=)/A]8%M1IALX_L8B7&(_*QLV# PN,<5G?$WX)^#?C3HL&G>,/"7
MAGQ9I]K)YL-KK.EP7T,+XQN5)58 XXR!0!\2_P#!)BR^&MC^WC^V+#\)FL?^
M$-CU;PR85T\YTZ.X.GW!G%ICY/(\PMCR_DR7V\5UO[0$?@.[_P""IV@Q?&H:
M4WA__A!@WPZ3Q#M.A-J8NIO[4R)?W!OA#]CV;_F\K?L_CKZ^\,> ="\%;_['
MT72=)\R*&!_L5G'!OCA4K$AV 95%)"CHH.!BH?B%\,?#?Q:\-/HWBGP]H?B;
M2)&#O8ZM817ELY'0F.167(['% 'YD6MKX6TW_@HS^T^O[,BZ:OB?_A0JM"GA
M_9]@CUO[;=[/L83]SYI_=EQ'QYO7YMU>K?!K3_V))?V!?#D^HK\-%\+/IULU
M]<:N8T\2'4 5\PW#C_3O[1%QNW8/FB3..U?;O@WX3>%OAS#;)X>\-:!H*6=H
M+"W73M.AM1;VP<N(4V*-L>\EMHXR2<9-9+_LU?#J7XD_\)D_@#P2WB_S/-&N
M'0K4ZEOZ;OM&SS-WONH ^3=!C^&5]_P4T^*R?&6/PU)K::3HS?#=/%BQFR_L
M'[*IN6L/M/[OSS?>=Y^W][@19^7%>;?\% -+^'5Y^R3;6OP)O? ^E_"YOB[I
MR_$^XLK66[\-VT.P&87$,#HC6?VC[$+A8'6/:7WG'F"OT*^)WP7\(?&S2HM/
M\9>$_#7BW3[>3S8K;6M+@OX8W_O*LJL WN!6CHG@'0_#'A"/P_IFBZ3I^@PP
M&VCTRULXX;-(B"#&(E 0(03\N,<T ?G3X"^&MMI'[=?P?N[;XG?L^6?B*T%[
M)-9?"_PA/:76K:*+23SH;Z6&[DABLU;RG22=>)401G+&LOX!>&OAOX!@\;?
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M$#><_/@9SBOU?QBLC5/A[H&MG4S>Z'H]V=:CCAU SV4<GV](\^6LN1^\"Y.
MV0,G% 'P3^T+JGA#]G7]N>V\>D_#'XF?\)MXF\-Z!KWAJ\2";QCX0U0QQ6]C
M=Z:?F=H55XYI+<JI5?-E1\%EIOP5D\)? G]O)/"NBS?##XH6'Q:U[Q/?Z/XB
MT[R9?%_@W5&CEGO[:_D3<9;/(DA67*/&3'$RL-K5]TW/P5\&WGQ&@\83>$O#
M,OBZUB\B#6WTN!M1ACP5V+<%?,"X)& V,&F^'O@GX.\'^-]2\3:1X1\,:9XE
MUI=FHZM9Z7!!?7ZY!Q+,JAY!D#[Q/2@#\US\<?!>E?\ !O#J/P^?Q+HW_";V
MG@VX\!/X;%U&=6.MB5[06(M<^:9FFP%7;D@ANAS6G\7_ (>^(=1_X*7:S9>*
M?$7P;T.33O &AV_@RU^)>@2:I8R6P24:F^GDW$4"SBXVK-PTOEF'G837Z%G]
MG3X?R?$W_A-6\">#3XR!##7CHEM_:8.,9^T[/-Z<?>Z5?^)?P>\)?&?18]-\
M8>%O#GBS3HI/.2UUG38;Z%'Z;@DJLH/OC- 'YH?#/]GSP_XQ^!/Q,TP?&KX3
MVVA_\+-TS5/"L5OX=>Q\ 6WB"UA$DVGQ17%P\=Y:W+C=*D$@6.82%/G7%?:/
M_!-'XQ:7\:/V6;;4=*\'>'O!*Z;K.IZ/>6'AYD?1)[RVNY(KBZL)$55EM9I0
M\B/M&0QSR":];U;X*>#=?^'D?A"^\)>&+WPG$BQ)HL^EP2:<B*<JHMRIC !Z
M#;Q6SX<\,Z;X.T&TTK2-/LM+TNPB6"UL[.!8(+:->%1$4!54=@!@4 7J***
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MXK\,:H]_I>FFUET1X[G3K79;H2^(XBF8LEB%4;R22:^A_B1^R3\;OVEM(L?
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M8Y;CV?8!V'ITH Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M17._$SQ[#\-?"5WJ\\,UQ':KDQQ?>;O_ (TXQ<I**W8TKNQOROLQ[UA^)_B7
MH7@J(/JVL:9IJ-T-S<K'GZ9/K7QWX]_;^O\ XM> HO%WA?4'T?PU'I\\UYIE
MQ$/M-UL=D.)!\T9W*<=BN1UKX[B^-R?$+XQ>-;TW*:WH.C:/ FJV22"2PE>0
M,MK>62G[[1X=I Q&W([D5[V%R&=36J[>1K"E?<^^_P!H'_@H[H6D>-]1\"^&
MYY/[:M](N-3NKXD1BSCC QL###,21C..C$9Q7YR_MC?\%3/$GQE^";Z+KDNN
MZ!'))9W>FW%R@2+Q$(GQ+ HB&[;.!PS  @L!S7J?P3_8,^-OQV^&CH(-.@A\
M37L>I+XGUFX6X6YL8XC## 8T(D/R_,,  [SD]ZW?A_\ \$5OBK\0_C3X/M_B
MUXDTR^\ >#K;]VVG"-;N]:/*PQR-C+*J;@.!C<#R1FO>4,LP--QNI37WW+ER
MQCIN>6?%']FWQI^VIX,M_ OP\>!M772SJU[*K2VH*RG>@>5OO_+^[&XY)4<8
MYI_['G_!!KXL'X?:U)KFM6?A :LP5_#]W#FU>15\II_+3(#",DJP[GD8K]BO
M!WP[T7P#I=O9Z/IEE80VMNEJGE0JK&-!A5+ 9.*D\5>%(?%.G+:RSW]M&LT4
MX>SN7MY,HP8#<I!VDC!'<$BO&EQ/76E)**_$Q=6<M9[G$_LI_LO>&/V1_@[I
MG@_PK8QV5K9QH;B126:[FV@-*S,223CN>E>DJFT5D'P+;$_\?.K?^#&;_P"*
MI?\ A!K<?\O6K?\ @QG_ /BJ^?J5'4FYSE=LR<G?8UU!8],4NS'_ .JL@^"H
M&_Y>=6_\&,W_ ,51_P (3;C_ )>=6_\ !C-_\54:=PN^QLYHS6-_PA=O_P _
M6K?^#&?_ .*H_P"$*@_Y^=6_\&,W_P 51IW"[[&SFC-8W_"%0?\ /SJW_@QF
M_P#BJ/\ A"H/^?G5_P#P8S?_ !5&G<+OL0@?\7*B_P"P8_\ Z.6M\=*R]+\)
MVNDZD;J,W4D[1^5OFN9)=JYS@;B<<BM0#%#Z#0M%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P/\ M9?"KP)\?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLKXY_:]^%/PQU"_M/$GQ,^'WA^YTN>.VO8=3\1V=I):32+N2.19) 4=EY"L
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M@;\+G.T8 /L:QU>WUO3HKFTEANK6YC6:":)P\<R,,JZL."",$$=B*\#\,?\
M!0WP#JO[5WQ%^&=_XK\#:<? 6F:;>&[F\06ZR7$MP;D3PLC,-A@,$889)'FK
MN R,XG_!'V-++]AC1]-@^6PT'Q!K^E6$6XD6MK!K%Y'#"N>BH@55'95 Z"OD
MG_@JC\/O#]SI_P"W1_Q)]*CEF^'_ (.5YX[2-)AY]Y?+*1(!N!<8W'.3@9/
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M=U;'C+]I_P"&_P ./'-KX7\0^/\ P3H/B2^VBUTK4==M;6]N=W"[(7<.=W;
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MC)XL\8> -9\-^.?@/;P77BCP?)?13F2*?#07%G=HNR>WE0L5?8K;HV1E5@:
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M)^(?B6TUG7O!WA37-8T\@VE]J.D6]U<VN#D;)'4LN#TP176T4 8_B_P)I'Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1M'TS55U:XT>UA>XN#>W$ZJD;S-<3J5C0%56$ DECC[16W51T_,T[R@?7\Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arwr-20220930_g4.jpg
<TEXT>
begin 644 arwr-20220930_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (#! <# 2(  A$! Q$!_\0
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MJ+PKJY\0^!$NA\)T<^#7L&-]</\ V5(?M6-GDDY^?<3N^7UKS"7QMX7^&_\
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M ,@4H_X*Q_M!M(4'Q/O]PY*_V=89'_D"KW_!1GXD^'_&WC6UL-"\:>&_%/\
M8FI:A!-::5X)'AUM(Q(JB*20?\?7W"H;ML)_CJ3Q#K*>+?\ @E-IUS<:7H4%
MYH/Q CT>VN[33HH+E[;[$\I6651OD)=R26//'H* ,_\ X>N_M#?]%-U'_P %
MEA_\8H_X>N_M#?\ 13=1_P#!98?_ !BOGJB@#Z%_X>N_M#?]%-U'_P %EA_\
M8H_X>N_M#?\ 13=1_P#!98?_ !BOGJB@#Z%_X>N_M#?]%-U'_P %EA_\8H_X
M>N_M#?\ 13=1_P#!98?_ !BOGJB@#Z%_X>N_M#?]%-U'_P %EA_\8H_X>N_M
M#?\ 13=1_P#!98?_ !BOGJB@#Z%_X>N_M#?]%-U'_P %EA_\8H_X>N_M#?\
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MT[_\%8/VA(DRWQ.U!0.I.FV  _\ (%-'_!6;]H(Q[_\ A:-]LSC=_9VGX_\
M1%5/^"8VB67B/]O+X<6.HV=KJ%E<7LZRV]S"LL4H^R3D;E8$'! /([5]1^!-
M8^&_QB_:_P#A]H\%UX"\2^*++PWXE3Q3K6BZ%]BT:4>5(;,&%E :6! =SA:
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M^'KO[0W_ $4W4?\ P66'_P 8I#_P5@_:$#A?^%G:AN(R!_9MAD_^0*W/#'[
M7AWX_0^#]6^$OCC4M9\,^(O$Q\*W\VO:6ME=Z7<"![DRA$8K+&88W( (;. >
MO'=^&?@-\*/$_P"R1XBT;P+XGUGQ&NI_$K0M"N]3U30H[._TSS)?*<PG)W1N
M#N ^4Y&&% 'E/_#UW]H;_HINH_\ @LL/_C%'_#UW]H;_ **;J/\ X+;#_P",
M5=B_8#37YOB/8:)KEU<ZSX0^(UGX!TR&XCCCBOOM$QB$\Q'*,,9PO%9OQ.^"
M/P.^%_C&7P_'\4/&6I>(O#FMP:=K$(\,(MM<A9@ES]E8R9!CPQ'F\-C ZYH
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M#688([EPZYW PN\;QYSM=3S@\ C% 'H'_#UW]H;_ **;J/\ X++#_P",4?\
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M_;6S9RJ7# NK98D,,$'GK7[1_P##OSX)_P#1,?!__@ M'_#OSX)_]$Q\'_\
M@ M 'XO>(_VZOB;XL^#A\#7VMVLNC2646F3W"Z?"NHW=G$<QVTMT!YCQ+_=)
MZ#!)YSG>&/VO/''@^^^'-S8WFG)+\*4GC\.%[)6%N)F+2>9_STY8XSTK]LO^
M'?GP3_Z)CX/_ / !:/\ AWY\$_\ HF/@_P#\ %H _%KX2_MN?$/X,:'J6DZ7
M?Z3J&AZK?/J<VE:SI4.I6,=TS%FFBCE!\MB2?ND#V[UA>*/VF/&/CGXY67Q%
MUS4;?6/%&G7,%U;R75I&;:(P$-"@@4!/+0@83&*_<+_AWY\$_P#HF/@__P
M%H_X=^?!/_HF/@__ , %H _$+PY^U)XW\,?%;7O&D6K?:M;\3QWL.J_;(_/M
MKV.[!$Z-"3MVG/ _AP,=*T;G]LKQY>Z$VESWFESZ9)X0C\#26DFGHT,NF1L7
MC#+WF1B2LOW@37[6?\._/@G_ -$Q\'_^ "T?\._/@G_T3'P?_P" "T ?C?K7
M_!0CXA>)-!T?3]0M? MZNA+8I:7,_AFV>["V;1O K3$;RH,:Y&?F&0>":Y70
M/VKO'/AWXT:QX^CU9;GQ%K_VQ=1^UQ>=:7:72E9HV@)V;"&X7HN%QTK]NO\
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M[.OG?:Q%Y(;S.NW9_#TSS7[K?\._/@G_ -$Q\'_^ "T?\._/@G_T3'P?_P"
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M?%7PYXENM5BU/1+JXU"PL;"\CO='ANH+P68VVT\B."&N$''F]3@9Z"H/!/\
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M]$Q\'_\ @ M'_#OSX)_]$Q\'_P#@ M 'X 45^_\ _P ._/@G_P!$Q\'_ /@
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M^W?$EQ;SWL=K#801VUNMO;V=M"NV*&*->$11T'N:_=7_ (=^?!/_ *)CX/\
M_ !:/^'?GP3_ .B8^#__   6@#\ **_?_P#X=^?!/_HF/@__ , %H_X=^?!/
M_HF/@_\ \ %H _ "BOW_ /\ AWY\$_\ HF/@_P#\ %H_X=^?!/\ Z)CX/_\
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M_A\_\/\ _H6O%_\ WQ;_ /QVOS6HH_UOS+^9?<@_XB9GO\\?_ 4?I3_P^?\
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M_OBW_P#CM'_#Y_X?_P#0M>+_ /OBW_\ CM?FM11_K?F7\R^Y!_Q$S/?YX_\
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M /T+7B__ +XM_P#X[1_P^?\ A_\ ]"UXO_[XM_\ X[7YK44?ZWYE_,ON0?\
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M_P#WQ;__ !VOS6HH_P!;\R_F7W(/^(F9[_/'_P !1^E/_#Y_X?\ _0M>+_\
MOBW_ /CM'_#Y_P"'_P#T+7B__OBW_P#CM?FM11_K?F7\R^Y!_P 1,SW^>/\
MX"C]*?\ A\_\/_\ H6O%_P#WQ;__ !VC_A\_\/\ _H6O%_\ WQ;_ /QVOS6H
MH_UOS+^9?<@_XB9GO\\?_ 4?I3_P^?\ A_\ ]"UXO_[XM_\ X[1_P^?^'_\
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MSW^>/_@*/TI_X?/_  __ .A:\7_]\6__ ,=H_P"'S_P__P"A:\7_ /?%O_\
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MQ=^U%40_\(G\<?\ H=/AS_X3-U_\ET?\(G\<?^AT^'/_ (3-U_\ )= '2/\
ML\^'Y-7^VDZ@9O\ A)AXM_X^./MHMOLPXQ_J_+'W?7G-<[J7[&OAV_FU.TCU
MKQ;9^%-;N9+O4/"UOJ(32+N260R3#:4,L<<KLS/%%*D;EWRI#,"W_A$_CC_T
M.GPY_P#"9NO_ )+H_P"$3^./_0Z?#G_PF;K_ .2Z /7(XUAC"JH55&  , "G
M5Y#_ ,(G\<?^AT^'/_A,W7_R71_PB?QQ_P"AT^'/_A,W7_R70!Z]17D/_")_
M''_H=/AS_P"$S=?_ "71_P (G\<?^AT^'/\ X3-U_P#)= 'KU%>0_P#")_''
M_H=/AS_X3-U_\ET?\(G\<?\ H=/AS_X3-U_\ET >O5^1_P 9/V$?BI9?%'75
M@\'ZQJ%N;V5H;FTMVFBG0L2K*R@CD8..HS@\U^B7_")_''_H=/AS_P"$S=?_
M "71_P (G\<?^AT^'/\ X3-U_P#)=>-G&2TLQC&-1M<O;S/EN)^%,/G<*<:\
MW'D;M:W6U]UY'YC_ /##OQ9_Z$/Q)_X R?X4?\,._%G_ *$/Q)_X R?X5^G'
M_")_''_H=/AS_P"$S=?_ "71_P (G\<?^AT^'/\ X3-U_P#)=>#_ *C8;_GY
M+\/\CX__ (A'@/\ G_/_ ,E_R/S'_P"&'?BS_P!"'XD_\ 9/\*/^&'?BS_T(
M?B3_ , 9/\*_3C_A$_CC_P!#I\.?_"9NO_DNC_A$_CC_ -#I\.?_  F;K_Y+
MH_U&PW_/R7X?Y!_Q"/ ?\_Y_^2_Y'YC_ /##OQ9_Z$/Q)_X R?X4?\,._%G_
M *$/Q)_X R?X5^G'_")_''_H=/AS_P"$S=?_ "71_P (G\<?^AT^'/\ X3-U
M_P#)='^HV&_Y^2_#_(/^(1X#_G_/_P E_P C\Q_^&'?BS_T(?B3_ , 9/\*/
M^&'?BS_T(?B3_P  9/\ "OTX_P"$3^./_0Z?#G_PF;K_ .2Z/^$3^./_ $.G
MPY_\)FZ_^2Z/]1L-_P _)?A_D'_$(\!_S_G_ .2_Y'YC_P###OQ9_P"A#\2?
M^ ,G^%'_  P[\6?^A#\2?^ ,G^%?IQ_PB?QQ_P"AT^'/_A,W7_R71_PB?QQ_
MZ'3X<_\ A,W7_P ET?ZC8;_GY+\/\@_XA'@/^?\ /_R7_(_,?_AAWXL_]"'X
MD_\  &3_  H_X8=^+/\ T(?B3_P!D_PK]./^$3^./_0Z?#G_ ,)FZ_\ DNC_
M (1/XX_]#I\.?_"9NO\ Y+H_U&PW_/R7X?Y!_P 0CP'_ #_G_P"2_P"1^8__
M  P[\6?^A#\2?^ ,G^%'_##OQ9_Z$/Q)_P" ,G^%?IQ_PB?QQ_Z'3X<_^$S=
M?_)='_")_''_ *'3X<_^$S=?_)='^HV&_P"?DOP_R#_B$> _Y_S_ /)?\C\Q
M_P#AAWXL_P#0A^)/_ &3_"C_ (8=^+/_ $(?B3_P!D_PK]./^$3^./\ T.GP
MY_\ "9NO_DNC_A$_CC_T.GPY_P#"9NO_ )+H_P!1L-_S\E^'^0?\0CP'_/\
MG_Y+_D?F/_PP[\6?^A#\2?\ @#)_A1_PP[\6?^A#\2?^ ,G^%?IQ_P (G\<?
M^AT^'/\ X3-U_P#)='_")_''_H=/AS_X3-U_\ET?ZC8;_GY+\/\ (/\ B$>
M_P"?\_\ R7_(_,?_ (8=^+/_ $(?B3_P!D_PH_X8=^+/_0A^)/\ P!D_PK].
M/^$3^./_ $.GPY_\)FZ_^2Z/^$3^./\ T.GPY_\ "9NO_DNC_4;#?\_)?A_D
M'_$(\!_S_G_Y+_D?F/\ \,._%G_H0_$G_@#)_A1_PP[\6?\ H0_$G_@#)_A7
MZ<?\(G\<?^AT^'/_ (3-U_\ )='_  B?QQ_Z'3X<_P#A,W7_ ,ET?ZC8;_GY
M+\/\@_XA'@/^?\__ "7_ "/S'_X8=^+/_0A^)/\ P!D_PH_X8=^+/_0A^)/_
M  !D_P *_3C_ (1/XX_]#I\.?_"9NO\ Y+H_X1/XX_\ 0Z?#G_PF;K_Y+H_U
M&PW_ #\E^'^0?\0CP'_/^?\ Y+_D?F/_ ,,._%G_ *$/Q)_X R?X4?\ ##OQ
M9_Z$/Q)_X R?X5^G'_")_''_ *'3X<_^$S=?_)='_")_''_H=/AS_P"$S=?_
M "71_J-AO^?DOP_R#_B$> _Y_P __)?\C\Q_^&'?BS_T(?B3_P  9/\ "C_A
MAWXL_P#0A^)/_ &3_"OTX_X1/XX_]#I\.?\ PF;K_P"2Z/\ A$_CC_T.GPY_
M\)FZ_P#DNC_4;#?\_)?A_D'_ !"/ ?\ /^?_ )+_ )'YC_\ ##OQ9_Z$/Q)_
MX R?X4?\,._%G_H0_$G_ ( R?X5^G'_")_''_H=/AS_X3-U_\ET?\(G\<?\
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MS_\ )?\ (_,?_AAWXL_]"'XD_P# &3_"C_AAWXL_]"'XD_\  &3_  K]./\
MA$_CC_T.GPY_\)FZ_P#DNC_A$_CC_P!#I\.?_"9NO_DNC_4;#?\ /R7X?Y!_
MQ"/ ?\_Y_P#DO^1^8_\ PP[\6?\ H0_$G_@#)_A1_P ,._%G_H0_$G_@#)_A
M7Z<?\(G\<?\ H=/AS_X3-U_\ET?\(G\<?^AT^'/_ (3-U_\ )='^HV&_Y^2_
M#_(/^(1X#_G_ #_\E_R/S'_X8=^+/_0A^)/_  !D_P */^&'?BS_ -"'XD_\
M 9/\*_3C_A$_CC_T.GPY_P#"9NO_ )+H_P"$3^./_0Z?#G_PF;K_ .2Z/]1L
M-_S\E^'^0?\ $(\!_P _Y_\ DO\ D?F/_P ,._%G_H0_$G_@#)_A1_PP[\6?
M^A#\2?\ @#)_A7Z<?\(G\<?^AT^'/_A,W7_R71_PB?QQ_P"AT^'/_A,W7_R7
M1_J-AO\ GY+\/\@_XA'@/^?\_P#R7_(_,?\ X8=^+/\ T(?B3_P!D_PH_P"&
M'?BS_P!"'XD_\ 9/\*_3C_A$_CC_ -#I\.?_  F;K_Y+H_X1/XX_]#I\.?\
MPF;K_P"2Z/\ 4;#?\_)?A_D'_$(\!_S_ )_^2_Y'YC_\,._%G_H0_$G_ ( R
M?X4?\,._%G_H0_$G_@#)_A7Z<?\ ")_''_H=/AS_ .$S=?\ R71_PB?QQ_Z'
M3X<_^$S=?_)='^HV&_Y^2_#_ "#_ (A'@/\ G_/_ ,E_R/S'_P"&'?BS_P!"
M'XD_\ 9/\*/^&'?BS_T(?B3_ , 9/\*_3C_A$_CC_P!#I\.?_"9NO_DNC_A$
M_CC_ -#I\.?_  F;K_Y+H_U&PW_/R7X?Y!_Q"/ ?\_Y_^2_Y'YC_ /##OQ9_
MZ$/Q)_X R?X4?\,._%G_ *$/Q)_X R?X5^G'_")_''_H=/AS_P"$S=?_ "71
M_P (G\<?^AT^'/\ X3-U_P#)='^HV&_Y^2_#_(/^(1X#_G_/_P E_P C\Q_^
M&'?BS_T(?B3_ , 9/\*/^&'?BS_T(?B3_P  9/\ "OTX_P"$3^./_0Z?#G_P
MF;K_ .2Z/^$3^./_ $.GPY_\)FZ_^2Z/]1L-_P _)?A_D'_$(\!_S_G_ .2_
MY'YC_P###OQ9_P"A#\2?^ ,G^%'_  P[\6?^A#\2?^ ,G^%?IQ_PB?QQ_P"A
MT^'/_A,W7_R71_PB?QQ_Z'3X<_\ A,W7_P ET?ZC8;_GY+\/\@_XA'@/^?\
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M+H ]>HKS_P"'.@_$W3_$@D\5>(_"&IZ3Y3 P:;HLUI/OXVG>\[C YR-OXT4
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M<?!KPAX;\0^%O@UJO@&Q8+X6T^_L]/ETN E@N+)&!C&6(&(^I(% 'QA\<_\
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M_ 2V_P#C]'_#X_X8?] CQG_X"6W_ ,?K\QJ*^/\ ]<<Q[K[C\Q_XB?GG>/\
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M_@/_  3].?\ A\?\,/\ H$>,_P#P$MO_ (_1_P /C_AA_P! CQG_ . EM_\
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M?_'Z_,:BC_7',>Z^X/\ B)^>=X_^ _\ !/TY_P"'Q_PP_P"@1XS_ / 2V_\
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MBBBMCI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'VJUCE ($BA@#VR,U)7Y+MH?L&^H4444 %%%% !1110 4444 %%%% !1110
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M_P"_5C_\DT?ZC8?_ )^R^Y!_Q"/!?\_Y_<C\K/\ ACOXI_\ 1/O&/_@GN/\
MXBC_ (8[^*?_ $3[QC_X)[C_ .(K]4_^&B=9_P"B5?$;_OU8_P#R31_PT3K/
M_1*OB-_WZL?_ ))H_P!1L/\ \_9?<@_XA'@O^?\ /[D?E9_PQW\4_P#HGWC'
M_P $]Q_\11_PQW\4_P#HGWC'_P $]Q_\17ZI_P##1.L_]$J^(W_?JQ_^2:/^
M&B=9_P"B5?$;_OU8_P#R31_J-A_^?LON0?\ $(\%_P _Y_<C\K/^&._BG_T3
M[QC_ .">X_\ B*/^&._BG_T3[QC_ .">X_\ B*_5/_AHG6?^B5?$;_OU8_\
MR31_PT3K/_1*OB-_WZL?_DFC_4;#_P#/V7W(/^(1X+_G_/[D?E9_PQW\4_\
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MB?>,?_!/<?\ Q%?JG_PT3K/_ $2KXC?]^K'_ .2:/^&B=9_Z)5\1O^_5C_\
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M@+X-T+4T6/4=(T:UM+E%;<$D2)58 ]#@@\UV5>7_ /#1.L_]$J^(W_?JQ_\
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M_)-'_#1.L_\ 1*OB-_WZL?\ Y)H ]0HKR_\ X:)UG_HE7Q&_[]6/_P DT?\
M#1.L_P#1*OB-_P!^K'_Y)H ]0HKR_P#X:)UG_HE7Q&_[]6/_ ,DT?\-$ZS_T
M2KXC?]^K'_Y)H ]0HKR__AHG6?\ HE7Q&_[]6/\ \DT?\-$ZS_T2KXC?]^K'
M_P"2: /4**\O_P"&B=9_Z)5\1O\ OU8__)-'_#1.L_\ 1*OB-_WZL?\ Y)H
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M (:)UG_HE7Q&_P"_5C_\DT >H45Q/@/XNZCXTU\65SX&\7^'X_+9_M>I);"
M$8^7]W,[9/;CM10!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK7UEH*Z'%&P$0_<FV0.P&&\SD,%^6@#Z=HHHH **** "BBB@ KYV^(7_  5
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MB_\ CM'_  ]V^%'_ #S\3_\ @'%_\=K\MJ*/]<LQ_N_=_P $/^(HYW_<_P#
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MF/\ =^[_ ((?\11SO^Y_X#_P3]2?^'NWPH_YY^)__ .+_P".T?\ #W;X4?\
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M#>)M>\ ^'O#GCKP-XS\*7GV0ZK:#^T+*<H1OWQS7.X@C."NT@XZCBOG;X_\
MQWTOXM7?PUT_4M;USQ7I_@O34TFXO[BS6TNIK07,DBQ*OFR9*)(55BW0*,<5
MUX;@;!XIPK474C![J25]KIII<MGVW.:OQCBL,ITJJIRFMG%NV]FFGK==]C]W
M/!?[>7P;^(5SY6D?$?PK=OY\5K_Q^",>;)O,:9; W-L? [[378_%WXV^$_@)
MX536_&.NV'A[29)UMENKMRJ-*P8A> >2%8_@:_#G]H76/@1J/[+FO?\ "F-)
M\=Z7=1Z[IIU5O$$T3K)'Y5]Y8B\LGD-NSGM7$^+/V\/&/C?]CUO@_P"+Y+S5
M[6QU&UU/1KVZ<FXLHTCD4P,6Y>(K*"G]W&!\I $Q\/H5I1G1E)1YK24DE)+3
M56TZ[=ON*?'$Z47"K&+ERW3BVXWUT?7IOW^\_H0\"^.M(^)GA&PU[0;^WU31
M]4B$UI=P',<Z=,C\C6M7@_\ P3$_Y,"^%?\ V X__0FKWBOSC'4%0Q-2C':,
MFON=C[W!UG6P\*LMY)/[U<****Y3H"BBB@ HHHH **\LUSXV^.]-UJ[M[7X/
M>)=0MH)GCBNH]9TQ$N4!($@5IPP##G# 'GD55_X7W\0O^B)>*O\ P>Z3_P#)
M% 'KM%>1?\+[^(7_ $1+Q5_X/=)_^2*/^%]_$+_HB7BK_P 'ND__ "10!Z[1
M7D7_  OOXA?]$2\5?^#W2?\ Y(H_X7W\0O\ HB7BK_P>Z3_\D4 >NT5Y%_PO
MOXA?]$2\5?\ @]TG_P"2*/\ A??Q"_Z(EXJ_\'ND_P#R10!Z[17D7_"^_B%_
MT1+Q5_X/=)_^2*/^%]_$+_HB7BK_ ,'ND_\ R10!Z[17D7_"^_B%_P!$2\5?
M^#W2?_DBC_A??Q"_Z(EXJ_\ ![I/_P D4 >NT5Y%_P +[^(7_1$O%7_@]TG_
M .2*/^%]_$+_ *(EXJ_\'ND__)% 'KM%>1?\+[^(7_1$O%7_ (/=)_\ DBC_
M (7W\0O^B)>*O_![I/\ \D4 >NT5Y%_POOXA?]$2\5?^#W2?_DBC_A??Q"_Z
M(EXJ_P#![I/_ ,D4 <S\3?#L/A+]H[7/$OC#P-JOCS0=6TFTLM#GLM(&L?V,
MT9E^TVS6^"T?G,T;^:JE7QM=E\M,\U\9_A+XQT;P5HEW\(/"$_A&^\>Z;!X+
MUBT,T$,GA&Q>1VBU,HCM&TEG')<JL<;'YKB, [4->E_\+[^(7_1$O%7_ (/=
M)_\ DBC_ (7W\0O^B)>*O_![I/\ \D4 >%^(_@IHOP[\4_%CPC#\(]>U^VU;
M3=*TWPA)9:()(%6'3([:/;?MA+8Q2KDNSJR%=XR<9^N?A[I.I:#X!T.QUB]_
MM+5[+3X(+Z[_ .?J=8U623_@3 G\:\Z_X7W\0O\ HB7BK_P>Z3_\D4?\+[^(
M7_1$O%7_ (/=)_\ DB@#UVBO(O\ A??Q"_Z(EXJ_\'ND_P#R11_POOXA?]$2
M\5?^#W2?_DB@#UVBO(O^%]_$+_HB7BK_ ,'ND_\ R11_POOXA?\ 1$O%7_@]
MTG_Y(H ]=HKR+_A??Q"_Z(EXJ_\ ![I/_P D4?\ "^_B%_T1+Q5_X/=)_P#D
MB@#UVBO(O^%]_$+_ *(EXJ_\'ND__)%'_"^_B%_T1+Q5_P"#W2?_ )(H ]=K
M\<?C7^RK\1M$^*^OP'P5XGN@+Z4I-::9-<0S*6.UU=%*D$8(Y[\\U^F/_"^_
MB%_T1+Q5_P"#W2?_ )(H_P"%]_$+_HB7BK_P>Z3_ /)%>)G624\QC%3DX\M]
MO,^4XJX3HYY"G&K-P<&[6UWM?\D?E+_PS9\1/^A#\9_^".Z_^(H_X9L^(G_0
MA^,__!'=?_$5^K7_  OOXA?]$2\5?^#W2?\ Y(H_X7W\0O\ HB7BK_P>Z3_\
MD5X'^HU'_GZ_N1\9_P 0BPO_ $$2^Y'Y2_\ #-GQ$_Z$/QG_ .".Z_\ B*/^
M&;/B)_T(?C/_ ,$=U_\ $5^K7_"^_B%_T1+Q5_X/=)_^2*/^%]_$+_HB7BK_
M ,'ND_\ R11_J-1_Y^O[D'_$(L+_ -!$ON1^4O\ PS9\1/\ H0_&?_@CNO\
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M^,__  1W7_Q%?JU_POOXA?\ 1$O%7_@]TG_Y(H_X7W\0O^B)>*O_  >Z3_\
M)%'^HU'_ )^O[D'_ !"+"_\ 01+[D?E+_P ,V?$3_H0_&?\ X([K_P"(H_X9
ML^(G_0A^,_\ P1W7_P 17ZM?\+[^(7_1$O%7_@]TG_Y(H_X7W\0O^B)>*O\
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M *$/QG_X([K_ .(H_P"&;/B)_P!"'XS_ /!'=?\ Q%?JU_POOXA?]$2\5?\
M@]TG_P"2*/\ A??Q"_Z(EXJ_\'ND_P#R11_J-1_Y^O[D'_$(L+_T$2^Y'Y2_
M\,V?$3_H0_&?_@CNO_B*DM/V9?B+<W4<:^ _&6YV"C.B7(&2<<G97ZK?\+[^
M(7_1$O%7_@]TG_Y(H_X7W\0O^B)>*O\ P>Z3_P#)%'^HU#_GZ_N0?\0BPO\
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M$2\5?^#W2?\ Y(H_X7W\0O\ HB7BK_P>Z3_\D4 >NT5Y%_POOXA?]$2\5?\
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MF-U*<C.) .BBOTJ_X7W\0O\ HB7BK_P>Z3_\D4?\+[^(7_1$O%7_ (/=)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP[) DEO;V5J5Q;YGE>.7:&\O-C*"2LA-?4/VN+_GI'_WT*/M<7_/2/\ [Z%
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MB!&Y\ROKC[7%_P ](_\ OH4?:XO^>D?_ 'T* )**C^UQ?\](_P#OH4?:XO\
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M&W_^,4?\.7/@S_T$/%W_ (,;?_XQ1_Q%O(.\_P#P'_@A_P 0!XK[4_\ P/\
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M]]"C[7%_STC_ .^A0!)14?VN+_GI'_WT*/M<7_/2/_OH4 245']KB_YZ1_\
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M7_Z"U_X _P#Y(/\ B9/#?] $O_!B_P#D#]L/^&-_A;_T(GAS_P !11_PQO\
M"W_H1/#G_@**_$__ (7YXX_Z&_Q)_P"#&7_XJC_A?GCC_H;_ !)_X,9?_BJ/
M^(*U_P#H+7_@#_\ D@_XF3PW_0!+_P &+_Y _;#_ (8W^%O_ $(GAS_P%%'_
M  QO\+?^A$\.?^ HK\3_ /A?GCC_ *&_Q)_X,9?_ (JC_A?GCC_H;_$G_@QE
M_P#BJ/\ B"M?_H+7_@#_ /D@_P")D\-_T 2_\&+_ .0/VP_X8W^%O_0B>'/_
M  %%'_#&_P +?^A$\.?^ HK\3_\ A?GCC_H;_$G_ (,9?_BJ/^%^>./^AO\
M$G_@QE_^*H_X@K7_ .@M?^ /_P"2#_B9/#?] $O_  8O_D#]L/\ AC?X6_\
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MD\-_T 2_\&+_ .0/VP_X8W^%O_0B>'/_  %%'_#&_P +?^A$\.?^ HK\3_\
MA?GCC_H;_$G_ (,9?_BJ/^%^>./^AO\ $G_@QE_^*H_X@K7_ .@M?^ /_P"2
M#_B9/#?] $O_  8O_D#]L/\ AC?X6_\ 0B>'/_ 44?\ #&_PM_Z$3PY_X"BO
MQ/\ ^%^>./\ H;_$G_@QE_\ BJ/^%^>./^AO\2?^#&7_ .*H_P"(*U_^@M?^
M /\ ^2#_ (F3PW_0!+_P8O\ Y _;#_AC?X6_]")X<_\  44?\,;_  M_Z$3P
MY_X"BOQ/_P"%^>./^AO\2?\ @QE_^*H_X7YXX_Z&_P 2?^#&7_XJC_B"M?\
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M>ET4 >:?\,;_  M_Z$3PY_X"BC_AC?X6_P#0B>'/_ 45Z710!YI_PQO\+?\
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M  M_Z$3PY_X"BC_AC?X6_P#0B>'/_ 45Z710!YI_PQO\+?\ H1/#G_@**/\
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MW_0>T;_P-B_^*H VJ*Q?^%C^'O\ H/:-_P"!L7_Q5'_"Q_#W_0>T;_P-B_\
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M $'M&_\  V+_ .*KX$_5S:HK%_X6/X>_Z#VC?^!L7_Q5'_"Q_#W_ $'M&_\
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MPL?P]_T'M&_\#8O_ (J@#:HK%_X6/X>_Z#VC?^!L7_Q5'_"Q_#W_ $'M&_\
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MUAH$HGT*R<='@1A^*BK=<AX&UKPSX"\':;HL'BBUO8-+MTMHY[W4XYKB15&
M7?(W''>M7_A8_A[_ *#VC?\ @;%_\57Y94MSOEV/TVG?E7-N;5%8O_"Q_#W_
M $'M&_\  V+_ .*H_P"%C^'O^@]HW_@;%_\ %5!9M45B_P#"Q_#W_0>T;_P-
MB_\ BJ/^%C^'O^@]HW_@;%_\50!M45B_\+'\/?\ 0>T;_P #8O\ XJC_ (6/
MX>_Z#VC?^!L7_P 50!M45B_\+'\/?]![1O\ P-B_^*H_X6/X>_Z#VC?^!L7_
M ,50!M45FZ9XPTG6[KR+/5-.NYL%O+AN4D; ZG .:* -*BBB@ HHHH ****
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MWW73V\YC,CM<>0P*IN1V)(^P* /.O^&0?A3_ -$U\"?^"*V_^(H_X9!^%/\
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M_P!D/_GW^$W_ ()8?_C5?C]11_Q!G*_^?]3_ ,E_^1#_ (F-SS_H&I?^3_\
MR1^P/_"P_P!D/_GW^$W_ ()8?_C5'_"P_P!D/_GW^$W_ ()8?_C5?C]11_Q!
MG*_^?]3_ ,E_^1#_ (F-SS_H&I?^3_\ R1^P/_"P_P!D/_GW^$W_ ()8?_C5
M'_"P_P!D/_GW^$W_ ()8?_C5?C]11_Q!G*_^?]3_ ,E_^1#_ (F-SS_H&I?^
M3_\ R1^P/_"P_P!D/_GW^$W_ ()8?_C5'_"P_P!D/_GW^$W_ ()8?_C5?C]1
M1_Q!G*_^?]3_ ,E_^1#_ (F-SS_H&I?^3_\ R1^P/_"P_P!D/_GW^$W_ ()8
M?_C5'_"P_P!D/_GW^$W_ ()8?_C5?C]11_Q!G*_^?]3_ ,E_^1#_ (F-SS_H
M&I?^3_\ R1^P/_"P_P!D/_GW^$W_ ()8?_C5'_"P_P!D/_GW^$W_ ()8?_C5
M?C]11_Q!G*_^?]3_ ,E_^1#_ (F-SS_H&I?^3_\ R1^P/_"P_P!D/_GW^$W_
M ()8?_C5'_"P_P!D/_GW^$W_ ()8?_C5?C]11_Q!G*_^?]3_ ,E_^1#_ (F-
MSS_H&I?^3_\ R1^P/_"P_P!D/_GW^$W_ ()8?_C5'_"P_P!D/_GW^$W_ ()8
M?_C5?C]11_Q!G*_^?]3_ ,E_^1#_ (F-SS_H&I?^3_\ R1^T?PUTO]F/XP^(
M/[*\-:-\*=6U/89%M8M)MA*ZCJ55D!;'?&<5Z!_PR#\*?^B:^!/_  16W_Q%
M?D9_P3><I^VQ\/\ :2/^)D!P?56!_0D?C7[<5^4<><*T<AQL,/AYN491YM;7
M6K73T/WCPKX[Q/%.6U<7BZ<82A/E]V]G[L7?6[6_<\Z_X9!^%/\ T37P)_X(
MK;_XBC_AD'X4_P#1-? G_@BMO_B*]%HKX<_3CSK_ (9!^%/_ $37P)_X(K;_
M .(H_P"&0?A3_P!$U\"?^"*V_P#B*]%HH \Z_P"&0?A3_P!$U\"?^"*V_P#B
M*/\ AD'X4_\ 1-? G_@BMO\ XBO1:* /.O\ AD'X4_\ 1-? G_@BMO\ XBC_
M (9!^%/_ $37P)_X(K;_ .(KT6B@#SK_ (9!^%/_ $37P)_X(K;_ .(H_P"&
M0?A3_P!$U\"?^"*V_P#B*]%HH \Z_P"&0?A3_P!$U\"?^"*V_P#B*/\ AD'X
M4_\ 1-? G_@BMO\ XBO1:* /.O\ AD'X4_\ 1-? G_@BMO\ XBC_ (9!^%/_
M $37P)_X(K;_ .(KT6B@#SK_ (9!^%/_ $37P)_X(K;_ .(H_P"&0?A3_P!$
MU\"?^"*V_P#B*]%HH \Z_P"&0?A3_P!$U\"?^"*V_P#B*/\ AD'X4_\ 1-?
MG_@BMO\ XBO1:* /.O\ AD'X4_\ 1-? G_@BMO\ XBC_ (9!^%/_ $37P)_X
M(K;_ .(KT6B@#SK_ (9!^%/_ $37P)_X(K;_ .(H_P"&0?A3_P!$U\"?^"*V
M_P#B*]%HH \Z_P"&0?A3_P!$U\"?^"*V_P#B*/\ AD'X4_\ 1-? G_@BMO\
MXBO1:* /.O\ AD'X4_\ 1-? G_@BMO\ XBC_ (9!^%/_ $37P)_X(K;_ .(K
MT6B@#SK_ (9!^%/_ $37P)_X(K;_ .(H_P"&0?A3_P!$U\"?^"*V_P#B*]%H
MH \Z_P"&0?A3_P!$U\"?^"*V_P#B*/\ AD'X4_\ 1-? G_@BMO\ XBO1:* /
M.O\ AD'X4_\ 1-? G_@BMO\ XBC_ (9!^%/_ $37P)_X(K;_ .(KT6B@#SK_
M (9!^%/_ $37P)_X(K;_ .(H_P"&0?A3_P!$U\"?^"*V_P#B*]%HH \Z_P"&
M0?A3_P!$U\"?^"*V_P#B*/\ AD'X4_\ 1-? G_@BMO\ XBO1:* /.O\ AD'X
M4_\ 1-? G_@BMO\ XBC_ (9!^%/_ $37P)_X(K;_ .(KT6B@#SK_ (9!^%/_
M $37P)_X(K;_ .(H_P"&0?A3_P!$U\"?^"*V_P#B*]%HH \Z_P"&0?A3_P!$
MU\"?^"*V_P#B*/\ AD'X4_\ 1-? G_@BMO\ XBO1:* /.O\ AD'X4_\ 1-?
MG_@BMO\ XBC_ (9!^%/_ $37P)_X(K;_ .(KT6B@#SK_ (9!^%/_ $37P)_X
M(K;_ .(H_P"&0?A3_P!$U\"?^"*V_P#B*]%HH \Z_P"&0?A3_P!$U\"?^"*V
M_P#B*/\ AD'X4_\ 1-? G_@BMO\ XBO1:* /.O\ AD'X4_\ 1-? G_@BMO\
MXBC_ (9!^%/_ $37P)_X(K;_ .(KT6B@#SK_ (9!^%/_ $37P)_X(K;_ .(H
M_P"&0?A3_P!$U\"?^"*V_P#B*]%HH \Z7]D/X4JV?^%:^!..>="M?_B*\O\
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MTWAKP-#?Z%9WLVD_;[K78[21KR)2&S#Y;$6XE'E&3)DR"RPLN"?.OV0_VO\
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MZ'X._P#"&:M_T#KS_OT:/^$,U;_H'7G_ 'Z-?O%_PT9\/?\ H>_!O_@ZMO\
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M/^_1H_X0S5O^@=>?]^C7[Q?\-&?#W_H>_!O_ (.K;_XNC_AHSX>_]#WX-_\
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M (:,^'O_ $/?@W_P=6W_ ,77YQQCQ7+/\7#$RI^SY8\MKWZMWO9=^Q^Q>'7
M<.%,!4P4:SJN<^9OEY>B5K7?;N=G17&?\-&?#W_H>_!O_@ZMO_BZ/^&C/A[_
M -#WX-_\'5M_\77R)^@'9T5QG_#1GP]_Z'OP;_X.K;_XNC_AHSX>_P#0]^#?
M_!U;?_%T =G17&?\-&?#W_H>_!O_ (.K;_XNC_AHSX>_]#WX-_\ !U;?_%T
M=G17&?\ #1GP]_Z'OP;_ .#JV_\ BZ/^&C/A[_T/?@W_ ,'5M_\ %T =G17&
M?\-&?#W_ *'OP;_X.K;_ .+H_P"&C/A[_P!#WX-_\'5M_P#%T =G17&?\-&?
M#W_H>_!O_@ZMO_BZ/^&C/A[_ -#WX-_\'5M_\70!V=%<9_PT9\/?^A[\&_\
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M (.K;_XNC_AHSX>_]#WX-_\ !U;?_%T =G17&?\ #1GP]_Z'OP;_ .#JV_\
MBZ/^&C/A[_T/?@W_ ,'5M_\ %T =G17&?\-&?#W_ *'OP;_X.K;_ .+H_P"&
MC/A[_P!#WX-_\'5M_P#%T =G17&?\-&?#W_H>_!O_@ZMO_BZ/^&C/A[_ -#W
MX-_\'5M_\70!V=%<9_PT9\/?^A[\&_\ @ZMO_BZ/^&C/A[_T/?@W_P '5M_\
M70!V=%<9_P -&?#W_H>_!O\ X.K;_P"+H_X:,^'O_0]^#?\ P=6W_P 70!V=
M%<9_PT9\/?\ H>_!O_@ZMO\ XNC_ (:,^'O_ $/?@W_P=6W_ ,70!V=%<9_P
MT9\/?^A[\&_^#JV_^+H_X:,^'O\ T/?@W_P=6W_Q= '9T5QG_#1GP]_Z'OP;
M_P"#JV_^+H_X:,^'O_0]^#?_  =6W_Q= '9T5QG_  T9\/?^A[\&_P#@ZMO_
M (NC_AHSX>_]#WX-_P#!U;?_ != '9T5QG_#1GP]_P"A[\&_^#JV_P#BZ/\
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M_P @'_$Q?$7_ #XH_P#@,_\ Y8?L!_PU_P#LH?\ /SX)_P#"6E_^1J/^&O\
M]E#_ )^?!/\ X2TO_P C5^/]%'_$&LG_ .?M7[X__(!_Q,7Q%_SXH_\ @,__
M )8?L!_PU_\ LH?\_/@G_P ):7_Y&H_X:_\ V4/^?GP3_P"$M+_\C5^/]%'_
M !!K)_\ G[5^^/\ \@'_ !,7Q%_SXH_^ S_^6'[ ?\-?_LH?\_/@G_PEI?\
MY&H_X:__ &4/^?GP3_X2TO\ \C5^/]%'_$&LG_Y^U?OC_P#(!_Q,7Q%_SXH_
M^ S_ /EA^P'_  U_^RA_S\^"?_"6E_\ D:C_ (:__90_Y^?!/_A+2_\ R-7X
M_P!%'_$&LG_Y^U?OC_\ (!_Q,7Q%_P ^*/\ X#/_ .6'[ ?\-?\ [*'_ #\^
M"?\ PEI?_D:C_AK_ /90_P"?GP3_ .$M+_\ (U?C_11_Q!K)_P#G[5^^/_R
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M (4%X%_Z$KPE_P"">W_^(KK:* .2_P"%!>!?^A*\)?\ @GM__B*/^%!>!?\
MH2O"7_@GM_\ XBNMHH Y+_A07@7_ *$KPE_X)[?_ .(H_P"%!>!?^A*\)?\
M@GM__B*ZVB@#DO\ A07@7_H2O"7_ ()[?_XBC_A07@7_ *$KPE_X)[?_ .(K
MK:* .2_X4%X%_P"A*\)?^">W_P#B*/\ A07@7_H2O"7_ ()[?_XBNMHH Y+_
M (4%X%_Z$KPE_P"">W_^(H_X4%X%_P"A*\)?^">W_P#B*ZVB@#DO^%!>!?\
MH2O"7_@GM_\ XBC_ (4%X%_Z$KPE_P"">W_^(KK:* .2_P"%!>!?^A*\)?\
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M_P"">W_^(KK:* .2_P"%!>!?^A*\)?\ @GM__B*/^%!>!?\ H2O"7_@GM_\
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M%+P[XM\<^/\ 6]3TKP-X.:(7[V*B74=5NYV^2&,MD;FSEF.3EATY(^SX>R/
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M]"5X2_\ !/;_ /Q%=;17YL?H1R7_  H+P+_T)7A+_P $]O\ _$4?\*"\"_\
M0E>$O_!/;_\ Q%=;10!R7_"@O O_ $)7A+_P3V__ ,11_P *"\"_]"5X2_\
M!/;_ /Q%=;10!R7_  H+P+_T)7A+_P $]O\ _$4?\*"\"_\ 0E>$O_!/;_\
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M%"^-O^A2\1?^"^7_ .)H_P"%"^-O^A2\1?\ @OE_^)K]L_\ AL;X3?\ 12_
MO_@\MO\ XNC_ (;&^$W_ $4OP+_X/+;_ .+K]!_XC76_Z!%_X&__ )$_)O\
MB6S#?]!\O_!:_P#DS\3/^%"^-O\ H4O$7_@OE_\ B:/^%"^-O^A2\1?^"^7_
M .)K]L_^&QOA-_T4OP+_ .#RV_\ BZ/^&QOA-_T4OP+_ .#RV_\ BZ/^(UUO
M^@1?^!O_ .1#_B6S#?\ 0?+_ ,%K_P"3/Q,_X4+XV_Z%+Q%_X+Y?_B:/^%"^
M-O\ H4O$7_@OE_\ B:_;/_AL;X3?]%+\"_\ @\MO_BZ/^&QOA-_T4OP+_P"#
MRV_^+H_XC76_Z!%_X&__ )$/^);,-_T'R_\ !:_^3/Q,_P"%"^-O^A2\1?\
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M&^$W_12_ O\ X/+;_P"+H_X;&^$W_12_ O\ X/+;_P"+H_XC76_Z!%_X&_\
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MXV_Z%+Q%_P""^7_XFOVS_P"&QOA-_P!%+\"_^#RV_P#BZ/\ AL;X3?\ 12_
MO_@\MO\ XNC_ (C76_Z!%_X&_P#Y$/\ B6S#?]!\O_!:_P#DS\3/^%"^-O\
MH4O$7_@OE_\ B:/^%"^-O^A2\1?^"^7_ .)K]L_^&QOA-_T4OP+_ .#RV_\
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MQOA-_P!%+\"_^#RV_P#BZ/\ AL;X3?\ 12_ O_@\MO\ XN@#TFBN-\$?M#^
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ME_T*_AW_ ,%L/_Q-'_"G_"7_ $*_AW_P6P__ !-='10!SG_"G_"7_0K^'?\
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M=#;Q+:V\4;[F0O*7E2(C 2@#[S_X0;1?^@/I?_@)'_A1_P (-HO_ $!]+_\
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M !%G*O\ GU4^Z/\ \D?K-_P@VB_] ?2__ 2/_"C_ (0;1?\ H#Z7_P" D?\
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M2_\ P$C_ ,*_)G_AY%\:?^AXN_\ P"M?_C5'_#R+XT_]#Q=_^ 5K_P#&J/\
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M_H#Z7_X"1_X4?\(-HO\ T!]+_P# 2/\ PK5HH RO^$&T7_H#Z7_X"1_X4?\
M"#:+_P! ?2__  $C_P *U:* ,K_A!M%_Z ^E_P#@)'_A1_P@VB_] ?2__ 2/
M_"M6B@#*_P"$&T7_ * ^E_\ @)'_ (4?\(-HO_0'TO\ \!(_\*U:* ,K_A!M
M%_Z ^E_^ D?^%'_"#:+_ - ?2_\ P$C_ ,*U:* ,K_A!M%_Z ^E_^ D?^%'_
M  @VB_\ 0'TO_P !(_\ "M6B@#*_X0;1?^@/I?\ X"1_X4?\(-HO_0'TO_P$
MC_PK5HH RO\ A!M%_P"@/I?_ ("1_P"%'_"#:+_T!]+_ / 2/_"M6B@#*_X0
M;1?^@/I?_@)'_A1_P@VB_P#0'TO_ ,!(_P#"M6B@#*_X0;1?^@/I?_@)'_A1
M_P (-HO_ $!]+_\  2/_  K5HH RO^$&T7_H#Z7_ . D?^%'_"#:+_T!]+_\
M!(_\*U:* ,K_ (0;1?\ H#Z7_P" D?\ A1_P@VB_] ?2_P#P$C_PK5HH RO^
M$&T7_H#Z7_X"1_X4?\(-HO\ T!]+_P# 2/\ PK5HH RO^$&T7_H#Z7_X"1_X
M4?\ "#:+_P! ?2__  $C_P *U:* ,K_A!M%_Z ^E_P#@)'_A1_P@VB_] ?2_
M_ 2/_"M6B@#*_P"$&T7_ * ^E_\ @)'_ (4?\(-HO_0'TO\ \!(_\*U:* ,K
M_A!M%_Z ^E_^ D?^%>%?M4_MF_"K]E6Y_L[4--L-8\1% _\ 9EE:Q%X0<$&5
MR,)D'('+8YVXYKZ"U6[;3]+N9T3S'AB:14_O$ G%?B[\-=!/QV\#>(_B#=^&
M]2^*/C.[\4K:ZCH]M>S0OIUI*AD^UL(OWA\R4F)6/[N/;R#D5\5QGGF,P-&%
M+ )>TGS:M-V4;7LDFV]=-'U;1^M>%G!.7YU.OC<V<O84'!<L6HN4JC:BG*32
MC'W7=MJ[LD[L]VUS_@KS>:I?8TGX?^#M/@W<"XMC</C_ '@4'_CM=YX0_P""
M@NJI::7>:WX#\.QV.KH9K67^S_*%W&K;6:,DX(# C/J*\.B^ ?P\OOB#XYT;
MP7IEKXPU[P[JT-GI^@7?B9X'U&R$.ZXGMI5V_:+E928S&K8 C+*&S7;ZCX%L
MHOV8_AYXLUJVOVTGPII%[:2:+!*5O?.EU.X6(3MC,,"%=KR[<E@% !;(_"LV
MQ7%4XU:T,PDI0BY7B_=]V<8RO[O*TDW*R3>VFJ3_ &7,N&^#U"C2P^ Y>>48
M^]\?OTY3A9<[E=M*-Y6C>^NC:^U_@'\7?!7QZL6^Q:+I]I?0KNEMI+6,D#U!
MQS7HW_"#:+_T!]+_ / 2/_"OBS_@EY'=:[\1=0O$4BTM+1C(0?E4L<*OZG'^
MZ:^Z*_6_"+B+-,ZX?6*S=WJ*<HJ5K<\5:TFEI>]T[)+38_G+CS(L/E&<3P6%
M^%).V]K]#*_X0;1?^@/I?_@)'_A1_P (-HO_ $!]+_\  2/_  K5HK]//C3*
M_P"$&T7_ * ^E_\ @)'_ (4?\(-HO_0'TO\ \!(_\*U:* ,K_A!M%_Z ^E_^
M D?^%'_"#:+_ - ?2_\ P$C_ ,*U:* ,K_A!M%_Z ^E_^ D?^%'_  @VB_\
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M<+2A@H\SC)MJZ6C7G9'YCT5^AW_#E/0_^AXO_P#P6K_\=H_X<IZ'_P!#Q?\
M_@M7_P".U\1_JGFG_/O_ ,FC_F?DW_$.<_\ ^?/_ )-#_P"2/SQHK]#O^'*>
MA_\ 0\7_ /X+5_\ CM'_  Y3T/\ Z'B__P#!:O\ \=H_U3S3_GW_ .31_P P
M_P"(<Y__ ,^?_)H?_)'YXT5^AW_#E/0_^AXO_P#P6K_\=H_X<IZ'_P!#Q?\
M_@M7_P".T?ZIYI_S[_\ )H_YA_Q#G/\ _GS_ .30_P#DC\\:*_0[_ARGH?\
MT/%__P""U?\ X[1_PY3T/_H>+_\ \%J__':/]4\T_P"??_DT?\P_XASG_P#S
MY_\ )H?_ "1^>-%?H=_PY3T/_H>+_P#\%J__ !VC_ARGH?\ T/%__P""U?\
MX[1_JGFG_/O_ ,FC_F'_ !#G/_\ GS_Y-#_Y(_/&BOT._P"'*>A_]#Q?_P#@
MM7_X[1_PY3T/_H>+_P#\%J__ !VC_5/-/^??_DT?\P_XASG_ /SY_P#)H?\
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M_P"?/_DT/_DC\\:*_0[_ (<IZ'_T/%__ ."U?_CM'_#E/0_^AXO_ /P6K_\
M':/]4\T_Y]_^31_S#_B'.?\ _/G_ ,FA_P#)'YXT5^AW_#E/0_\ H>+_ /\
M!:O_ ,=H_P"'*>A_]#Q?_P#@M7_X[1_JGFG_ #[_ /)H_P"8?\0YS_\ Y\_^
M30_^2/SQHK]#O^'*>A_]#Q?_ /@M7_X[1_PY3T/_ *'B_P#_  6K_P#':/\
M5/-/^??_ )-'_,/^(<Y__P ^?_)H?_)'YXT5^AW_  Y3T/\ Z'B__P#!:O\
M\=H_X<IZ'_T/%_\ ^"U?_CM'^J>:?\^__)H_YA_Q#G/_ /GS_P"30_\ DC\\
M:*_0[_ARGH?_ $/%_P#^"U?_ ([1_P .4]#_ .AXO_\ P6K_ /':/]4\T_Y]
M_P#DT?\ ,/\ B'.?_P#/G_R:'_R1^>-.B_U@K]#/^'*>A_\ 0\7_ /X+5_\
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M/QHWAWXJ:5J2^ -)NM>U=A8WD8.GVW^ON[8O"!>0Q\9>V\Q?F7GYAGB?!?\
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M:E&M2=XR2:?D]4>2?\*E^+'_ $5ZS_\ "/M__CU'_"I?BQ_T5ZS_ /"/M_\
MX]7K=%6:GDG_  J7XL?]%>L__"/M_P#X]1_PJ7XL?]%>L_\ PC[?_P"/5ZW1
M0!Y)_P *E^+'_17K/_PC[?\ ^/4?\*E^+'_17K/_ ,(^W_\ CU>MT4 >2?\
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M0!Y)_P *E^+'_17K/_PC[?\ ^/4?\*E^+'_17K/_ ,(^W_\ CU>MT4 >2?\
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M*>DVQ:7P?X0U5Q_!9>(IH6/T\VU _457MUV?W,R_LBITJ4W_ -Q(+\VD9?\
MPJ7XL?\ 17K/_P (^W_^/4?\*E^+'_17K/\ \(^W_P#CU5=:_:PU?P#%O\5?
M"7XDZ?"N2]UI-K!KENBCJQ%K*TV/^V57?A+^W/\ "3XX:NVF^'/'FA7&L1G;
M)I=U*;'4(V]&MIPDH/\ P&I6*H\W*Y6?9Z/[F;5.',SC1>(C1<Z<=Y0M.*]9
M0YHKYL9_PJ7XL?\ 17K/_P (^W_^/4?\*E^+'_17K/\ \(^W_P#CU>MT5T'B
M'!?#KP'X[\.^(?M'B'Q_;^)-/\ME^QIX?BLCN/1O,61CQZ8YHKO:* "BBB@
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M#--_\&$/_P 71_8N/_Y\R_\  6'^JV<_] M3_P  ?^1\T45]+_\ #IWXO?\
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M45]+_P##IWXO?] S3?\ P80__%T?\.G?B]_T#--_\&$/_P 71_8N/_Y\R_\
M 6'^JV<_] M3_P  ?^1\T45]+_\ #IWXO?\ 0,TW_P &$/\ \71_PZ=^+W_0
M,TW_ ,&$/_Q=']BX_P#Y\R_\!8?ZK9S_ - M3_P!_P"1\T45]+_\.G?B]_T#
M--_\&$/_ ,71_P .G?B]_P! S3?_  80_P#Q=']BX_\ Y\R_\!8?ZK9S_P!
MM3_P!_Y'S117TO\ \.G?B]_T#--_\&$/_P 71_PZ=^+W_0,TW_P80_\ Q=']
MBX__ )\R_P# 6'^JV<_] M3_ , ?^1\T45]+_P##IWXO?] S3?\ P80__%T?
M\.G?B]_T#--_\&$/_P 71_8N/_Y\R_\  6'^JV<_] M3_P  ?^1\T45]+_\
M#IWXO?\ 0,TW_P &$/\ \71_PZ=^+W_0,TW_ ,&$/_Q=']BX_P#Y\R_\!8?Z
MK9S_ - M3_P!_P"1\T45]+_\.G?B]_T#--_\&$/_ ,71_P .G?B]_P! S3?_
M  80_P#Q=']BX_\ Y\R_\!8?ZK9S_P! M3_P!_Y'S117TO\ \.G?B]_T#--_
M\&$/_P 72I_P2<^+S. =-TT#/4ZA#Q_X]1_8N/\ ^?,O_ 6'^JV<_P#0+4_\
M!?\ D?=__!/G_DSKP1_U[3?^E,M>RUPO[,_PJN?@C\"?#?A:\N(KJ\TFV*SR
M19V&1W:1@N<$@%R <#(&<"NZK]FR^G*GA:=.:LU%)_<?U'DU&='+Z%&JK2C"
M*:[-1284445UGI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?(O_!:B*[D_8_MF@W_9X_$%JUWMZ!/+
MF"Y]O,,?XXKY;_8FBU_5OV*?B/8?"^26/XFG7+:;4$LI%CU*XTC8 !;G(;[^
M_.TYY8=2*_3GXP_"K1_CA\,]8\*:_ 9]*URV:VG"G#ID?*Z'LZL P/8J*_)C
MXR?\$[_C/^RSX^>Z\.6&OZY96[L;#7O#?F>?Y9Z>8D9\R-NF1@J3T)K]$R/Z
MIFN0UL@K5O8SD[J5[7V_'3;T:O9GY]Q-@\12QJQ\(.4'%Q?+\4=U=;VWW]4>
MO_&+Q+K_ ,*OV!+63XM&YD^)D]_>6G@V/491)JMI:7$'D3O*<EM@C>4C<<@^
M4#V%9'_!%^&+PA\77U.= )O%QFT'3L]X[:'[7=./8-]F3ZL:\B\'?L0?&W]H
M?Q%-JNO:%XPB@C3?>:OKD4LMSY8ZK#%(?,F?^ZBX7)Y*C)KW/]E+X0_$[P'^
MV3X#U:;X6>+M#\!^&H9-$L(IEB9[."<,KW4[!\-(\CF64CIT7(05[E#+,'E>
M05,FIXI5)\K<FY+HKQBM=W+IYR;M=)^-@GB)XVAB94I*,>6*NFV]DY2=NW7T
M2O9GZ75XK^VW^W=X+_83\ VNL>*_M]Y>ZL98]*TNQBWW&HR1A=X#'"(J[TW,
MQ&-PQD\5[57F7[3W[('P_P#VPO",.C>/M!CU>&S\PV5PLC0W6GN^T,\,JD,I
M.U<]CM&0:_%\6J[HR6'LI]+['[MPW/*89G1EGL9RPR?OJG93:L]KZ;VOJG:]
MFG9GYX?#']J;]I7_ (+!?$+5=&\#ZS:?"'X=Z3(B:O?::Q>ZMD?)6,S\22S,
MH/RQ^6HQECTSZK\</V:_!7_!*#X3+\0O#B^$-6\21CR9M7\::=<:[XA\0Z@^
M/)@M&69!"6(;.U3@<G[IS]"0?L=W_P"SUKFDZQ\$9]$T%+'2(-$U+PWJ<3_V
M;KMO 6,$IEC_ 'D-VGF2?OMKAPY#J< C'^(GA[Q)\4?'_AOQ'XI_9Q@\0:]X
M-E,VCW?_  F%I+!92D@F2)'*#=D AFCW# ]!7@+ SA3;Q#<JW233:7G%).UN
MVEWY'[16XQPF+QM.GDT:>'RM?%0C.E2J3LOAK2JRBZCD_M7J1A%II.::.$^&
M?[;7Q9C\8>'=#\;?\(?_ ,)?/IZ:YKW@OPUX?NKO4M!L&&X-=7<MVEM;,5*_
MZSH6P W4])\1_P#@KEX'\,?LC7OQ4T[2=?,%]=2:7X7L=4MA:2^)[M1C= H9
MF-NK [Y<  (V,G&:WCOX(#XF^.M7\2Z[^RM!J&M^(+06.IW3^+;%3J$(4($F
M59 KX4  L"1@>@J'X>_ &'X6>+='UW0OV4X+/5O#]FUAIERWBZRF:Q@8$%(Q
M)*P48)' S@D=*U53%QO&,G;75QFWTL_AWM=VT5^RW\RK@N&Z\H8C$4(\RY6X
M0KX6$';F<H*2K.2BY<L8S:E.,%)OFDURZWPF_P""EVB:=^RO9_$3XB3;-+\I
M8YM?TK3I(](U6]=V7['IT<CM<W!5E9-^P*QC8Y Z=-X$_P""CWA#Q++XGN-<
MT;Q)X*T#PGIZ:C?Z[K26XTR+<<"V,T4LB_:L$$P#+@<$ \5YHG[+&CKX0N?#
M[?LC:?-HEU*\YL9O%5C+!%([%F:)6D(B))/,>WJ:TM2^!(USP<_A_4OV6SJ^
MC/ +9;34O&=I>I!&,8$7FRL8L8&"FT^]7#$8M)7>R_EGJ_/W=MO/?<Y,5DO#
M-2=24(-<\W_R_P *N6G>+7*E7MSVYD[^[K%I1LT['QK_ ."G,]OX3\/67PY\
M">)-2\9_$0$^$%U^S^P6%W NUI=0G'F>=%:1Q-YA:1(]R]#C)'GO[17Q]_9\
M_:3^!5KK'Q%\#ZM\0[%;J+0H/%WA[P\T"ZAJK93RM+E:1;F0>8K!3'O3(P6-
M=5;_ ++^F6VKVM^/V38'O+.Q.F1S2^,;21C:G_E@^Z4[X\<;7R,<=*JVO[(^
MC:?I^E6MO^R7%%#H5TU[IB+XVME%A,W):(B;,8)Y(7C/.*QJ2Q52ZG9I]'";
M73IR>OX+35OV,OH\.8*5*IA.>G4A+FYX8C#1F[MZ<RQ-U9*"5K+F=2333A&/
ML7["/[+^K_LL>"-6TBX\8^)_%/A^_GBN]#M?$$OFW^A0E/GM)&#,I*L>JX&<
M\=S[M7"? .S\2Z;X4-KKWAKP[X0LK4)#I>E:5?->&UA .1*_EHF[.,! 1[FN
M[KW<+"$*2C!67S_74_&^(L;B<7F-7$XR:G4DU=QY;/1*_N>ZWW:;N[N[>H44
M45T'BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:^*OA!XVUO
MQ#=W=A\5==T>SGD+Q646CZ?*ELIZ*&>(L0/<DUZ510!Y+_PHOXA?]%H\1_\
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MQ"_Z+1XC_P#!%IG_ ,9KUJB@#R7_ (47\0O^BT>(_P#P1:9_\9H_X47\0O\
MHM'B/_P1:9_\9KUJB@#R7_A1?Q"_Z+1XC_\ !%IG_P 9H_X47\0O^BT>(_\
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M $6CQ'_X(M,_^,T?\*+^(7_1:/$?_@BTS_XS7P[_ ,/C/BI_SX>#?_!?-_\
M'Z/^'QGQ4_Y\/!O_ (+YO_C]'^N67?WON#_B*&2=Y_\ @/\ P3[B_P"%%_$+
M_HM'B/\ \$6F?_&:/^%%_$+_ *+1XC_\$6F?_&:^'?\ A\9\5/\ GP\&_P#@
MOF_^/T?\/C/BI_SX>#?_  7S?_'Z/]<LN_O?<'_$4,D[S_\  ?\ @GW%_P *
M+^(7_1:/$?\ X(M,_P#C-'_"B_B%_P!%H\1_^"+3/_C-?#O_  ^,^*G_ #X>
M#?\ P7S?_'Z/^'QGQ4_Y\/!O_@OF_P#C]'^N67?WON#_ (BADG>?_@/_  3[
MB_X47\0O^BT>(_\ P1:9_P#&:/\ A1?Q"_Z+1XC_ /!%IG_QFOAW_A\9\5/^
M?#P;_P""^;_X_1_P^,^*G_/AX-_\%\W_ ,?H_P!<LN_O?<'_ !%#).\__ ?^
M"?<7_"B_B%_T6CQ'_P""+3/_ (S1_P *+^(7_1:/$?\ X(M,_P#C-?#O_#XS
MXJ?\^'@W_P %\W_Q^C_A\9\5/^?#P;_X+YO_ (_1_KEEW][[@_XBADG>?_@/
M_!/N+_A1?Q"_Z+1XC_\ !%IG_P 9H_X47\0O^BT>(_\ P1:9_P#&:^'?^'QG
MQ4_Y\/!O_@OF_P#C]'_#XSXJ?\^'@W_P7S?_ !^C_7++O[WW!_Q%#).\_P#P
M'_@GW%_PHOXA?]%H\1_^"+3/_C-'_"B_B%_T6CQ'_P""+3/_ (S7P[_P^,^*
MG_/AX-_\%\W_ ,?H_P"'QGQ4_P"?#P;_ ."^;_X_1_KEEW][[@_XBADG>?\
MX#_P3[B_X47\0O\ HM'B/_P1:9_\9H_X47\0O^BT>(__  1:9_\ &:^'?^'Q
MGQ4_Y\/!O_@OF_\ C]'_  ^,^*G_ #X>#?\ P7S?_'Z/]<LN_O?<'_$4,D[S
M_P# ?^"?<7_"B_B%_P!%H\1_^"+3/_C-'_"B_B%_T6CQ'_X(M,_^,U\._P##
MXSXJ?\^'@W_P7S?_ !^C_A\9\5/^?#P;_P""^;_X_1_KEEW][[@_XBADG>?_
M (#_ ,$^XO\ A1?Q"_Z+1XC_ /!%IG_QFC_A1?Q"_P"BT>(__!%IG_QFOAW_
M (?&?%3_ )\/!O\ X+YO_C]'_#XSXJ?\^'@W_P %\W_Q^C_7++O[WW!_Q%#)
M.\__  '_ ()]Q?\ "B_B%_T6CQ'_ ."+3/\ XS1_PHOXA?\ 1:/$?_@BTS_X
MS7P[_P /C/BI_P ^'@W_ ,%\W_Q^C_A\9\5/^?#P;_X+YO\ X_1_KEEW][[@
M_P"(H9)WG_X#_P $^XO^%%_$+_HM'B/_ ,$6F?\ QFC_ (47\0O^BT>(_P#P
M1:9_\9KX=_X?&?%3_GP\&_\ @OF_^/T?\/C/BI_SX>#?_!?-_P#'Z/\ 7++O
M[WW!_P 10R3O/_P'_@GW%_PHOXA?]%H\1_\ @BTS_P",T?\ "B_B%_T6CQ'_
M ."+3/\ XS7P[_P^,^*G_/AX-_\ !?-_\?H_X?&?%3_GP\&_^"^;_P"/T?ZY
M9=_>^X/^(H9)WG_X#_P3[B_X47\0O^BT>(__  1:9_\ &:/^%%_$+_HM'B/_
M ,$6F?\ QFOAW_A\9\5/^?#P;_X+YO\ X_1_P^,^*G_/AX-_\%\W_P ?H_UR
MR[^]]P?\10R3O/\ \!_X)]Q?\*+^(7_1:/$?_@BTS_XS1_PHOXA?]%H\1_\
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MZY9=_>^X/^(H9)WG_P" _P#!/N+_ (47\0O^BT>(_P#P1:9_\9H_X47\0O\
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MCW^6(&KG_"J_'O\ T5.__P#!#8__ !%>D44 >;_\*K\>_P#14[__ ,$-C_\
M$4R?X3>/9X60?%;4HRPQN30;#<ON,H1^E>ET4 >2_P#"B_B%_P!%H\1_^"+3
M/_C-'_"B_B%_T6CQ'_X(M,_^,UZU10!Y+_PHOXA?]%H\1_\ @BTS_P",T?\
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MKO:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(/B?\
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M (<M^,?^AI\,_P#?4_\ \:H_X<M^,?\ H:?#/_?4_P#\:H_U<S+_ )\O\/\
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M]]3_ /QJC_5S,O\ GR_P_P P_P!1\^_Z!I?>O\SXOHK[0_X<M^,?^AI\,_\
M?4__ ,:H_P"'+?C'_H:?#/\ WU/_ /&J/]7,R_Y\O\/\P_U'S[_H&E]Z_P S
MXOHK[0_X<M^,?^AI\,_]]3__ !JC_ARWXQ_Z&GPS_P!]3_\ QJC_ %<S+_GR
M_P /\P_U'S[_ *!I?>O\SXOHK[0_X<M^,?\ H:?#/_?4_P#\:H_X<M^,?^AI
M\,_]]3__ !JC_5S,O^?+_#_,/]1\^_Z!I?>O\SXOHK[0_P"'+?C'_H:?#/\
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M]9HH \F_X9JU_P#Z+#\3/^^M._\ D2C_ (9JU_\ Z+#\3/\ OK3O_D2O6:*
M/)O^&:M?_P"BP_$S_OK3O_D2C_AFK7_^BP_$S_OK3O\ Y$KUFB@#R;_AFK7_
M /HL/Q,_[ZT[_P"1*/\ AFK7_P#HL/Q,_P"^M._^1*]9HH \F_X9JU__ *+#
M\3/^^M._^1*/^&:M?_Z+#\3/^^M._P#D2O6:* /)O^&:M?\ ^BP_$S_OK3O_
M )$H_P"&:M?_ .BP_$S_ +ZT[_Y$KUFB@#R;_AFK7_\ HL/Q,_[ZT[_Y$H_X
M9JU__HL/Q,_[ZT[_ .1*]9HH \F_X9JU_P#Z+#\3/^^M._\ D2C_ (9JU_\
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MO_D2C_AFK7_^BP_$S_OK3O\ Y$KUFB@#R;_AFK7_ /HL/Q,_[ZT[_P"1*/\
MAFK7_P#HL/Q,_P"^M._^1*]9HH \F_X9JU__ *+#\3/^^M._^1*/^&:M?_Z+
M#\3/^^M._P#D2O6:* /)O^&:M?\ ^BP_$S_OK3O_ )$H_P"&:M?_ .BP_$S_
M +ZT[_Y$KUFB@#R;_AFK7_\ HL/Q,_[ZT[_Y$H_X9JU__HL/Q,_[ZT[_ .1*
M]9HH \F_X9JU_P#Z+#\3/^^M._\ D2C_ (9JU_\ Z+#\3/\ OK3O_D2O6:*
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M\SX_HK[ _P"',?Q$_P"@_P"#?_ JY_\ C%'_  YC^(G_ $'_  ;_ .!5S_\
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M_P"@:7X?YGQ_17V!_P .8_B)_P!!_P &_P#@5<__ !BC_AS'\1/^@_X-_P#
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M>&O^^9__ (Y1_P /I/&/_0K>&O\ OF?_ ..4?ZWY9_,__ 6'_$3,A_Y^2_\
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MO?&S_P *5/\ XS7RA_P^D\8_]"MX:_[YG_\ CE'_  ^D\8_]"MX:_P"^9_\
MXY1_K?EG\S_\!8?\1,R'_GY+_P !E_D?5_\ PQ:__17OC9_X4J?_ !FC_ABU
M_P#HKWQL_P#"E3_XS7RA_P /I/&/_0K>&O\ OF?_ ..4?\/I/&/_ $*WAK_O
MF?\ ^.4?ZWY9_,__  %A_P 1,R'_ )^2_P# 9?Y'U?\ \,6O_P!%>^-G_A2I
M_P#&:/\ ABU_^BO?&S_PI4_^,U\H?\/I/&/_ $*WAK_OF?\ ^.4?\/I/&/\
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MKO/8/$O^&+7_ .BO?&S_ ,*5/_C-'_#%K_\ 17OC9_X4J?\ QFO;:* /$O\
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M*G_QFO;:* /$O^&+7_Z*]\;/_"E3_P",T?\ #%K_ /17OC9_X4J?_&:]MHH
M\2_X8M?_ **]\;/_  I4_P#C-'_#%K_]%>^-G_A2I_\ &:]MHH \2_X8M?\
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ML[_Z!I_<?*%%?5__  YU^*?_ #_>#_\ P/F_^,T?\.=?BG_S_>#_ /P/F_\
MC-']@9C_ ,^9?<'^IV=_] T_N/E"BOJ__ASK\4_^?[P?_P"!\W_QFC_ASK\4
M_P#G^\'_ /@?-_\ &:/[ S'_ )\R^X/]3L[_ .@:?W'RA17U?_PYU^*?_/\
M>#__  /F_P#C-'_#G7XI_P#/]X/_ / ^;_XS1_8&8_\ /F7W!_J=G?\ T#3^
MX^4**^K_ /ASK\4_^?[P?_X'S?\ QFC_ (<Z_%/_ )_O!_\ X'S?_&:/[ S'
M_GS+[@_U.SO_ *!I_<?*%%?5_P#PYU^*?_/]X/\ _ ^;_P",T?\ #G7XI_\
M/]X/_P# ^;_XS1_8&8_\^9?<'^IV=_\ 0-/[CY0HKZO_ .'.OQ3_ .?[P?\
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M:Q+P7#2"6/+!6D2".0HI>OLB@#Q3_AAC0/\ H=/B]_X76I?_ !VC_AAC0/\
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M/NC_ /)'Z(?\,,:!_P!#I\7O_"ZU+_X[1_PPQH'_ $.GQ>_\+K4O_CM?G?\
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MX+^27W+_ ##_ (BSE7_/JI]T?_DC]$/^&&- _P"AT^+W_A=:E_\ ':/^&&-
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M =M_\;H_UWP7\DON7^8?\19RK_GU4^Z/_P D?HA_PPQH'_0Z?%[_ ,+K4O\
MX[1_PPQH'_0Z?%[_ ,+K4O\ X[7R1^Q)^WW\3_'7[1WA[0?$&O\ ]M:5K,_V
M:>&>UA3:"#AE9%4@@X/<'&,<YK](J]_*LVHYA2=6BFDG;7^F?9<.\1X;.</+
M$89-*+LU*U[V3Z-]SQ3_ (88T#_H=/B]_P"%UJ7_ ,=H_P"&&- _Z'3XO?\
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MY\/=+\5Z5\2/VA]9\*WMU]@NI;7QW%%)IDS F(%9;23<C@$!L\, #U%>3_\
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M0_XA-FW_ #\I_?+_ .0/R%HK]>O^';?P5_Z$J/\ \&=Y_P#'J/\ AVW\%?\
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M (=M_!7_ *$J/_P9WG_QZC_4C'?SP^]__(A_Q";-O^?E/[Y?_('YT?\ !/\
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M_P!G:;/\(-9N-4UK4KOQ7<:M<:RDUE);/#;1"UACB5G8.1A%P,8X%=1\#_\
M@G'K/P_^%7[4^A:VWA'4;KXY^+/$&O:,XA:2.UAO[5884N=\>=RNI+!=P Z$
MFOL+-&:Z*F>8J4>31+1?=)R_-F,<OI1?-U_S5CX4TC_@FGXE\(_LU? #0VT3
M1=;^)7P9\(C0;3Q9I_B^YT>XTN=H8XIA$&M)TGMY @W"6//R@!>36QXL_84^
M(WC'X8_">]\:0^%_'?QG^'ME?11>-M$UJ7PE)ILURV&$$"6L\,D31!%DWQC<
M8\B,;B!]IYHS3>>8EM-VO=OKUO=7OI%\SO%63ZIE/ TWW_#_ "W\SX:^(_\
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MS_P< ?M00?%OP[HW[/7@"VN/%WC+5-5AO-4L]+B-S+;>6#Y-L N?WK.P9A_
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M_P"&>_B?_P!%X\1?^$WI?_QJC_AGOXG_ /1>/$7_ (3>E_\ QJO::* /%O\
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M_P"C@M9_\$&D_P#QJOGK[;-_SUD_[ZH^VS?\]9/^^J/]?9_\^/\ R;_[4/\
MB'L/^?\ _P"2_P#VQ]"_\*4^(G_1P6L_^"#2?_C5'_"E/B)_T<%K/_@@TG_X
MU7SU]MF_YZR?]]4?;9O^>LG_ 'U1_K[/_GQ_Y-_]J'_$/8?\_P#_ ,E_^V/H
M7_A2GQ$_Z."UG_P0:3_\:H_X4I\1/^C@M9_\$&D__&J^>OMLW_/63_OJC[;-
M_P ]9/\ OJC_ %]G_P ^/_)O_M0_XA[#_G__ .2__;'T+_PI3XB?]'!:S_X(
M-)_^-4?\*4^(G_1P6L_^"#2?_C5?/7VV;_GK)_WU1]MF_P">LG_?5'^OL_\
MGQ_Y-_\ :A_Q#V'_ #__ /)?_MCZ%_X4I\1/^C@M9_\ !!I/_P :H_X4I\1/
M^C@M9_\ !!I/_P :KYZ^VS?\]9/^^J/MLW_/63_OHT?Z^S_Y\?\ DW_VH?\
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MKVFB@#Q;_AGOXG_]%X\1?^$WI?\ \:H_X9[^)_\ T7CQ%_X3>E__ !JO::*
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M&]\/:5?ZWXO\5>,/B!KOA_2'\5:]<7%EIMIIS3R99FWO\L*;0B#?(V"S *S
M ]2_X9[^)_\ T7CQ%_X3>E__ !JC_AGOXG_]%X\1?^$WI?\ \:KSW1_V\O'$
MGQ-F\*:AX$T"&XT.^UI-?U"UUQ[BVLK+3(-,GDN(D\D22R3)J!5(<!E91N;&
M34GB?]N[QE\+?#?A#Q=XJ\&>'QX,\9Z7J&LQ#2]:>XU338+;2I]2CC:(Q!+B
M21(=I,3;48_Q##4 =]_PSW\3_P#HO'B+_P )O2__ (U1_P ,]_$__HO'B+_P
MF]+_ /C5>1_%+]K[XH^(_P!FGXERVOA67PCKMCX/N==TS6)K'4[2SL'0*&MF
M>YMXF>Y57W(\0:-]IR% ^;VCX4?'[7/$GQ]U[P)XETO3-$N])TV"\L2KW&_7
M4\N SWEL6C$3VRS3&(J)#+&R+O4"5#0!3_X9[^)__1>/$7_A-Z7_ /&J/^&>
M_B?_ -%X\1?^$WI?_P :KVFB@#Q;_AGOXG_]%X\1?^$WI?\ \:H_X9[^)_\
MT7CQ%_X3>E__ !JO::* /%O^&>_B?_T7CQ%_X3>E_P#QJC_AGOXG_P#1>/$7
M_A-Z7_\ &J]IHH \6_X9[^)__1>/$7_A-Z7_ /&J/^&>_B?_ -%X\1?^$WI?
M_P :KVFB@#Q;_AGOXG_]%X\1?^$WI?\ \:H_X9[^)_\ T7CQ%_X3>E__ !JO
M::* /%O^&>_B?_T7CQ%_X3>E_P#QJC_AGOXG_P#1>/$7_A-Z7_\ &J]IHH \
M6_X9[^)__1>/$7_A-Z7_ /&J/^&>_B?_ -%X\1?^$WI?_P :KVFB@#Q;_AGO
MXG_]%X\1?^$WI?\ \:H_X9[^)_\ T7CQ%_X3>E__ !JO::* /%O^&>_B?_T7
MCQ%_X3>E_P#QJC_AGOXG_P#1>/$7_A-Z7_\ &J]IHH \6_X9[^)__1>/$7_A
M-Z7_ /&J/^&>_B?_ -%X\1?^$WI?_P :KVFB@#Q;_AGOXG_]%X\1?^$WI?\
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M ,D3_P#':/\ 5/-?^?7_ )-'_,/]<,I_Y^_^2R_R/GFBOH;_ (8CM_\ H/\
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MJ6)J1@G_ #-+\SUFBO$_^'BWP8_Z':W_ /!?=_\ QJC_ (>+?!C_ *':W_\
M!?=__&JYO[5P7_/Z/_@2_P SA_UBRK_H)I_^!Q_S/;**\3_X>+?!C_H=K?\
M\%]W_P#&J/\ AXM\&/\ H=K?_P %]W_\:H_M7!?\_H_^!+_,/]8LJ_Z":?\
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M? _CKPQIOABUTRQMYUO=5%I<>#G@ \Q?+/(P02,8R1_=P:\7_P""A/QHT_\
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M_P"&4O%/_1<OBC^6F_\ R+7M=% 'BG_#*7BG_HN7Q1_+3?\ Y%H_X92\4_\
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M^6F__(M>UT4 >*?\,I>*?^BY?%'\M-_^1:/^&4O%/_1<OBC^6F__ "+7M=%
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M+NUV/@>BOMG_ (<K^)?^AOT/_OW+_P#$T?\ #E?Q+_T-^A_]^Y?_ (FOA_\
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MDTWQOXH\&?9(;%I#HXMO]+W-/C?YT4GW<'&,?>.:]!_X<)+_ -%/_P#+?_\
MNFOHW]A']@6R_8EMO$#Q^(9_$-]X@,*RRFT%K'$D6\J F]SDF1LG=V''7/R?
M'''>28_)*^#PE;FG+ELN62VE%[M);(^\\,O"[B;*N)<-F&88;DI0YKOG@]X2
MBM(R;W:Z&S_PREXI_P"BY?%'\M-_^1:Y;XP? G7?A_X/?4+_ .)_CCQ5;A_+
M-AJ@L_L[$JV'/E0(V1CCYL<GBOI2N>^)_P /XOB9X2ETN6=K;>P=) N[:PR.
M1D9&">]?S/FN'G7P=6C3UE*+2/[.RC$0H8VE6JZ1C)-GQ)17T#_PQ"O_ $,2
M_P#@ ?\ X[1_PQ"O_0Q+_P" !_\ CM?E/^JF:_\ /K_R:/\ F?KW^M^4_P#/
MW_R67^1\_45] _\ #$*_]#$O_@ ?_CM'_#$*_P#0Q+_X '_X[1_JIFO_ #Z_
M\FC_ )A_K?E/_/W_ ,EE_D?/U='\*/#5SXQ\;VNFV>M:GX>N;O*IJ.G^7]IM
MN^4\Q63)QCE3P37KW_#$*_\ 0Q+_ . !_P#CM=!\,OV5HOA[XPM=6;6&NS:D
ME8UMO+W$@CDEVXYS^%=> X8S*GBJ=2=.R4DWK'9/U.+,>*LKJ82K3A4NW%I:
M2W:]#/\ ^&4O%/\ T7+XH_EIO_R+1_PREXI_Z+E\4?RTW_Y%KVNBOUL_'3Q3
M_AE+Q3_T7+XH_EIO_P BT?\ #*7BG_HN7Q1_+3?_ )%KVNB@#Q3_ (92\4_]
M%R^*/Y:;_P#(M'_#*7BG_HN7Q1_+3?\ Y%KVNB@#Q3_AE+Q3_P!%R^*/Y:;_
M /(M'_#*7BG_ *+E\4?RTW_Y%KVNB@#Q3_AE+Q3_ -%R^*/Y:;_\BT?\,I>*
M?^BY?%'\M-_^1:]KHH \4_X92\4_]%R^*/Y:;_\ (M'_  REXI_Z+E\4?RTW
M_P"1:]KHH \4_P"&4O%/_1<OBC^6F_\ R+1_PREXI_Z+E\4?RTW_ .1:]KHH
M \4_X92\4_\ 1<OBC^6F_P#R+1_PREXI_P"BY?%'\M-_^1:]KHH \4_X92\4
M_P#1<OBC^6F__(M'_#*7BG_HN7Q1_+3?_D6O:Z* /%/^&4O%/_1<OBC^6F__
M "+1_P ,I>*?^BY?%'\M-_\ D6O:Z* /%/\ AE+Q3_T7+XH_EIO_ ,BT?\,I
M>*?^BY?%'\M-_P#D6O:Z* /%/^&4O%/_ $7+XH_EIO\ \BT?\,H^*?\ HN/Q
M1_+3?_D6O:Z* /%/^&4?%/\ T7'XH_EIO_R+1_PRCXI_Z+C\4?RTW_Y%KVNB
M@#Q3_AE'Q2/^:Y?%'\M-_P#D6C_AE+Q3_P!%R^*/Y:;_ /(M>UT4 >*?\,I>
M*?\ HN7Q1_+3?_D6C_AE+Q3_ -%R^*/Y:;_\BU[710!XI_PREXI_Z+E\4?RT
MW_Y%H_X92\4_]%R^*/Y:;_\ (M>UT4 >*?\ #*7BG_HN7Q1_+3?_ )%H_P"&
M4O%/_1<OBC^6F_\ R+7M=% 'BG_#*7BG_HN7Q1_+3?\ Y%H_X92\4_\ 1<OB
MC^6F_P#R+7M=% 'FWPO^!.N?#[Q4-1O_ (F^-_%=N(FC^P:J+/[.2<8?]U C
M9&./FQS17I-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arwr-20220930_g5.jpg
<TEXT>
begin 644 arwr-20220930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY-)T7P#KFF^$3,I'E^=I\\$&W/1DLH2' QS<Y[UZ+_P1$_Y1G?&+_L8-9_\
M3-:T >6_L6_%3_@LY^W1X<\1>-_@Q^V!H]JOAJ\CAN[3Q!:VT+SR2(SJ(ECL
M)(R,*1\Q4 D=N:^C/^"4W_!2/X[?'_XO>*?V2/VL=(M!XU\+V]S*FK6MJEN\
MKVUPL%S;SQQ?N_,5W!#1A5(5AC(!/QG_ ,$J/VO?VH?V;_ 'C/PU^SE^QOKG
MQ,EUK4K>6;5-/MKN6WTR9(G5$E$$#@[L[L&1"0IQZCZ[_P""1W[!?[0WPX^-
M7C/]MC]K'2UTGQ1XO2[6ST1G0S![NY6YN;J54)$1+*%2/)8!GW!?ER =-_P6
M4_;*^-GP#T[X>_ _]E[Q++I_CSQUK^(I+.WAEF^S*5A2$+,K*IFGF0!L9_<L
M,C)JO_P12_;A^+7[3WA#QM\,?VB?%DNJ^,O">K1SQW%Y:Q03/93 H8RD:*"8
MIHG!)&1YR ]!7S;XT_:F^ OQ*_X+;W7Q@^/OQ)M-'\$?"TRV&A3W<,LR3W-D
M&C14$2.?^/R6:X5L8VQCGIG#^!G[2/P5^"W_  6NN?'_ ,"_']KJWP_^)6L-
M975Y:Q20QHVI!'9&615*"._V-TP$';L ?1G_  71_;)_:3_96NOAGIO[/_Q-
MG\-IKL>K2:LUM96\K7!A-F(@3-&^T+YLG"XSNYS@8\Y_:6\=?\%K_P#@GGX5
ML_CC\2_VD/"OC;PT-3BM;ZU@T^&>-'?)19E>T@E5&*[=T3YR1DC(JO\ \'*?
M_(:^#F/^?;7O_0M/KR[_ (*"?%S_ (*"^)_$W@W]GG_@I+JMIX"\$:WJD=W)
MJ?A?1H+N"18SL:8^5,3*8?,!:+>I 97V,=F0#[:_:B_;D^('B+_@D4_[:'P2
MU*7PKX@U2PTR2*2*..<V4SZE#:W4:>:C*RY\U Q7."#P>F#\.O\ @H3\5?AG
M_P $9](_;*^(=\GBGQM<B\L[6XOX$CCN+HZO<VD#2K"$&V.)%8A0"XCQD%MU
M6O\ @IM\*? /P._X(U:M\)_A=,9M T2QT*#3+EIA(;F/^T[5C.67AFD9C(2
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MJVY:^W*_(K]I.6V;_@X<\/CQN5^P)XH\.+IGVC[N[^S[8P[<_P#3T3C_ &J
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M !H&O?L=_M(>&_"_@\:1!$-+U.0)*+H,_FN<V4V005P=_;&!CGXG_9!^.?\
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MIJ4_ASQ7I\MMHT%_!;"WT^WL;NW 5KB1%(7S(EV[LX['!KWW]CKX?>+/A/\
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M?]KWP%^UEX<^*W[6?P\FTK0?A]H5RGAI;W6K.[!N&>3RH46":0A4:YN)PQP
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M[U#3Y[;3A>PVYD2*ZC=\/,Z("%!."PSC R<"OH^B@#P[_@FW\'?B)\ ?V)/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK<2Y_:KFLOCI^S!\'?B=KGB6]\"ZYX<G\.:MJ>KPQZQ+I][%'<WVF+?.FP7
MB218IY067[0FYN P /JGQY\2O"'PT@TJX\87UQ FM:[:Z/IQM]/GN-]W</LB
M1A"C>6I/61\(O\3"M'3_ !+X<U?5=0T'2M?LKJ^TF2./5;*WND>6S>2,2(LJ
M DQED97 8#*L".#FOD6Y^.'V;X4>"].^%WCOXCV.H6O[1'A[P_XNTCQ_J#2:
MMIPFEB,VGRRY;SH'C='#>9*K"4X<C"JOP4\#7/PT_:N_::^*EC\0/&.JS^$K
MZPO8=%N]<+V^IM)X=BF5)T"9DV%MD7(V*B#G;0!]C45\-?LT:_\ MI^/-/\
MA/\ ''1?#OQ1U"?Q->:??^/=3\0^+M"?PW=Z1=QEYVM;"*]::V\KS$:'9"DN
M(]L@)9@/N6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS7T-XSBC'_!47P++H8'VL_!O7!KYC^]]C&HV/V;?[><9-N>^['>@#Z&HHHH
MX/X@_M/? #X5>(V\)?$3XJ:7I&I)"DK6=W(P<(W*MP#P:H^'/VP_V8_%^N6W
MAKPU\9]&O+^\DV6UK#*Q:1L9P/E] :[;5O!'@O7KPZAKGA#2[VX*A3/=Z?'(
MY Z#<RDXKQ']I7PQX:\,_&KX+KX;\/6.GBZ\;R)="QM$B\Y1;L0K[0-PSS@T
M >X?\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M6M<UV\U2^GABSY<)N+R6601+N.(PP4$DXSS7?44 %%%% !7A?[6'_);/@?\
M]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-0![I1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFE16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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MA.?0_%OA0WFFVMY#97EC:(;>UD4Q6TOV2:U51OD+2H23(QPU?8=% 'QEXO\
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MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
MGQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0
MH_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__
M )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ*
M (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQ
MA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_
ML[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y
M\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (
M?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_
M[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[
M3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8
M?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[
M.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]
M"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0KB_C[\=?@9^S!\-+
M[XN?'+Q9IN@:'8C#7%TH+SR$$K##& 6FE;!PB L<$XP"1Y!_P4-_X*D?L_?\
M$^_"C0>*;U=?\;WEL9-$\$Z=<@7$H.=LUPV"+:#/\; LV#L5\''Y_P#P(_8H
M_;:_X+8_%"T_:E_;>\6ZAX8^&,<A?0=,M8C ;BW)!\G3;=\B*(@#==R!F? Q
MYN"4_1.&N!5C,#_;.=U?JN C]M_'5?\ +2CO)O\ FLTM7K9VYJN(Y9<E-7E^
M7J5/B[^T_P#MM?\ !<SXIW7[/'[(O@VX\&_":TN%&MW]T?*22'/RRZE/'G.0
M,I9Q;LGD^9LWK^C'[ O_  3(_9T_8#\%"P\#:.FM>*KVW":]XTU6V4W=V>"8
MXQR+>#(R(D/.%+L[#=7L'P3^!OPF_9S^'-A\)O@IX&L?#^@::F+:PL8\;F.-
MTDC'+2R-C+2.2S'DDUUE3Q-QT\PP2R?)J7U7 1VIKXJC_FJRWE)[VNTM-[)A
M2P_++GF[R_+T(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ*_/3I(?[.T__ )\8
M?^_0H_L[3SUL8?\ OT*FHH _(7_@J)^PG\3?^"=_QVM/^"F'["%J=/T:WU+[
M1XKT"TM]T&E2R-B1C$N UA/DJ\? C9OE(5E\O]!OV!OVUO@[^WS\"+/XM_#^
MVM[34K?;;>*/#LA5IM)O=N6C;@;HVY:.3 #KZ,K*OM6MZ)H_B71KOPYXBTJW
MOM/O[:2WOK*[A62*XA=2KQNC AE9200>"#BOQH_:=^!?QM_X(1_M@67[6'[,
MMK=:G\(?%%[]FU#19IG,44;MO?2[AN<$ ,]O.<L-N#N*OYG[-E>)P_B=D\,G
MQLE',Z$;8>HW;VT%K[&;_F7V)/\ /FYN&:>$GSQ^![KMYG[-_P!G:?\ \^,/
M_?H4?V=I_P#SXP_]^A7%?LU_M'_"K]K#X-:/\<O@WKZW^C:Q!N"M@36DP_UE
MM,@)V2HW#+TZ$$J03W=?D&)PV(P>(G0KQ<9P;4DU9IK1IKNCM34E=$/]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A4U%8#(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ
M* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#G
MQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H
M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
M(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0I\5M;0$F"W1
M">I1 ,T^B@ HHHH **** "BBB@ HHK(\?>._"?PO\$ZK\1O'>L+I^BZ'82WN
MJ7SQNX@@C4L[[4!9L 'A02>@!- &O12*0RAAW'<4M !1110 4444 %%%% !7
MA?[6'_);/@?_ -CW+_Z3-7NE>%_M8?\ );/@?_V/<O\ Z3-0![I1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU;.U)15D8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q16 S'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<*YO#,,$_>CHXOX9Q?Q0DNL7^#LUJDS.K2C6ARR/C#_@D#_P5)T3]N_X9?\
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8H
MK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
M@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/
M^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -B
MBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^
M$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X
M0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBOD?_ (*2_P#!77X%_L"Z-/X0L7@\5_$>XM]U
MAX3M+CY;/<,K->R+GR4P00G^L<$8 4EU]7)LDS3B',(8++Z3J59;)?FWLDNK
M=DB)U(4X\TG9'N/[4/[6'P*_8Z^&%Q\6/CUXV@TG3H\I9VR_/=:A-C(@MX@=
MTLA]!PH^9BJ@L/R?\7?%']OO_@OY\4IOAS\)M+G\!?!/2K]1J$T[M]D0*0P>
M[D7'VVZQAEMD^1"5)V\S'?\ V7O^":_[6W_!5WXGV_[8_P#P4C\6ZMIGA&XQ
M+H?AP!K:XOK4G<D-M#_RXV9_OX\R4?,,E_.K]:_AI\,?A]\&_ ^G?#7X6>#[
M#0=!TF 0Z?I>FVXCBA7J>!U8G)+'+,22222:_498KAWPO3A@W#%YJM'4^*CA
MWU4$_CJ+^9Z)]M8ODM5Q?Q>[#MU?_ /+?V'_ /@G]^SS^P3\/!X/^#GAWS=4
MNXE_M_Q5J"*U_JD@_ON!\D8/W8EPB]<%BS'V^BBOR7,,QQV:XR>+QE1U*DW=
MRD[M_P!=%LEHM#LC&,(VBK(****XR@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .&_:0_9U^%?[5GP<UGX'?&/P^M_HFLV^
MU]N!-:RCF.XA<@[)4;#*WX$$$@_DM^S9\;?C?_P0<_;"O/V6OVDKJ[U7X/\
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MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_
M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X2
M75_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X
M275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH
M V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^E
MH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8H
MK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?
M^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O
M?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6
M@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_
MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
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MVGG"A*<N>MJ^BZ(V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:_+3K-BBL?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/'O@9^QA^VY_P6W^*-I^U#^VOXKO_"WPOBD+:#IEK$8/M%N2"8=-MWR(XR
MUW(&+X&/-Q\GZV_!#X%?"7]G#X<6'PE^"?@:R\/Z!IJ8M[&RCQN8@;I)'.6E
MD; +2.2S'J375P00VT*6UM"L<<:A8XT4!54#   Z"G5\]Q7QMF/$[AAU%4<+
M3TIT(:0@N[VYI=Y/N[)7L:4:$:6N[>["BBBOC#<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /R\_X+*?\$V/&W@GQD/^"EO[$2W6D>+O#UT-4\8:=HJ[9':/YCJD" 8+
M@ ^>F")%RY!/F;_J#_@EI_P4G\$_\%"?@P+V\:UTSQ_X?ACB\8>'XVP-QX6\
M@!.3!(0>.3&V4)/RL_U$RJZE'4$$8((X(K\?_P#@I/\ L5?%C_@E]^T19?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME&5.\MY0R/ 'P0_;V_X+X_%*W^+OQXUNY\#?!C3+UCI=O;(RVP0$JT=C$_\
MQ]7!&5>[D&U3N ^Z(:_67]FK]EWX'_LC?#&U^$OP&\#VVBZ5;X>=T&^XOIL
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
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M#=E_X#'_ !K8HH Q_L7C?_H-V7_@,?\ &K6E0:_#(YUB_@F4K\@BBVD&KU%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%_M8?\ );/@?_V/
M<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U 'NE%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17/?%/X
MM?#+X(>";SXC_%WQUIGAS0K!<W6IZM=K#$I[*"Q^9ST5%RS'@ GBOS"_:?\
M^"[7QI_:+\;G]FW_ ()7_"C5M4U2_9H8_%T^DF:[E7H9+6U8%8(QP3/<= 22
MD>-U?5\,\%Y_Q74?U*G:G'XZLWRTX+JY3>FBULKNVMC&K7IT5[SU[=3[Y_:^
M_;Y_9@_8>\*_\)#\>?B'#:WL\)?3/#>G@3ZGJ&,_ZJ $';D8\QRL8/!85^9W
MC3]M/_@J!_P69\47OPE_8V\"W?@#X;><;?5=6AO&@7RSU^W:B%!Y4Y-M;C<5
M8@K*!NKU']D'_@@%JOB[Q5_PT%_P4Q^(]]XP\2ZA,+JZ\*0ZO).'DX_X_KW=
MOG(Z&.(A1M \QUXK],?!G@GP=\.?"]EX)^'_ (5T_1-'TZ$16&EZ59I;V]N@
M_A2- %4?05]I_:? _ 7NY7!9AC5_R^FOW%-_].X?;:>TGILXOH8<N(Q'Q^['
MMU?J?&W[!7_!#/\ 9>_9%^Q>//B7;1?$7QU#MD75-9LQ]@T^4<_Z+:ME=P.,
M2R;WR R^7G%?;M%%?G.><09SQ)C7B\RKRJS?5[)=HI:17DDD=5.G3I1M!6"B
MBBO&+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KXF_X+#_\$LM+_;C^'7_"U?A-806?Q5\,69.E3J1&-;MERWV&5^,.#DQ2
M$X5B5)"N67[9HKV,ASW,N&LUIYA@)\M2#^376,EUBUHU^I%2G"K!QEL?GC_P
M1?\ ^"INJ?'>R/[&G[4]]/8_%/PNDEKIUUJX,<^N0P95XI0^#]MA"D.#\SJI
M?EED-?H=7YM_\%H?^"7WB/QG>C]OG]CVUNM-^(_AEX[_ ,06&B9CN-32##)?
M6^SG[7$%!(',J*,?.H#^Q?\ !([_ (*@^'/V^_A3_P (OXWNK6P^)_AJT0>)
M-,3"+J,(PHU"!?[C$@2(/]6YQPK)G[SB[(LMSS*_]:L@ART9.V(HK>A4?5?]
M.YO6+V6VGPQYZ-25.?L:F_1]U_F?85%%%?E9UA1110 4444 %%%% !1110 4
M444 %%%% !7SCXW_ &H/C_XV^*]WHO[+WP0O/$?A[X<^,)--^(5VVLV%I+JT
MJZ>SO86:7)SF.2YM96E9H@QB,:DABU?1U?#O[6GC[]F/PCXP\;_$3]G/]H7Q
M!X*^.=L98V\*>'K>Y<^*M3MU\N""XTF:)H[Q9"JQK<1H/E</YA44 >^?$O\
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M#//- 'NO_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
MGQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T_
M_GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*
M/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?
M^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?
M&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_W
MU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0
M?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )
MCX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?
M]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0
M?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/
M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M_P#/C#_WZ%?GATE/_A,?#'_0:@_[ZJQI^MZ3JKM'IU_',R#+!#T%2?V=I_\
MSXP_]^A3XK:V@),%NB$]2B 9H ?1110 4444 %%%% !1110 5AGX=>$V^)*_
M%IM/<ZZFAG2$NC.^U;0S"8H$SMR7526QG@#.*W** &26]O+(DTL",\9/ENR@
ME<]<'M2RQ13QF*:-71AAE89!'TIU% "(B1H(XT"JHPJ@8 'I38+>"VC$-M D
M: \*B@#\A3Z* "BBB@ KPO\ :P_Y+9\#_P#L>Y?_ $F:O=*\+_:P_P"2V? _
M_L>Y?_29J /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO$EQ=V^EDQ3:]!!AD9"N#]LA"@QL/F=5"<D1[?5O^":O[9?Q<^+W[/7A2/\
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M_L>Y?_29J /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFU*O/MS=*<7W>NZO%G(\1.J^6BK^;V_X)X5K/QE_X*L?\%Q]:N/"/P=\/O\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M5L44 8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;5L5B>/_'V@?#K0'UW79_\
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@
M#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ
MM:5H%EH\CR6LL[%UP?-F+#]:O44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\ 8]R_^DS4
M >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
MI_\ "8^&/^@U!_WU5C3];TG57:/3K^.9D&6"'H*D_L[3_P#GQA_[]"GQ6UM
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MW2M_M.2?>NGZSX5\-_P*53,JR^U/]S1OW45>;]):,5L95W:BOO9^5"_L'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^HW_ )7]GK:W&$22.X$RD.RH5"R%E^7GH_A!^TUXT\3_ !GNOV?/C?\ !?\
MX0GQ3_PCO]O:/':^(H]4L]2L%F$$I2=8HBLL<CQAHRG1PP+#F@#V&BBB@ KP
MO]K#_DMGP/\ ^Q[E_P#29J]TKPO]K#_DMGP/_P"Q[E_])FH ]THHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGB6X;4?&ABG&JZ_-<A0D)<; Y^4Y')'4<5]>UX7^UA_R6SX'_P#8]R_^DS4
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M**_/#I,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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M(_Y^;W_P+:K6E:!9:/(\EK+.Q=<'S9BP_6KU% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXG?""^\":-X6\$7.A^']%UK5+.YOKR[O+B&6YN6%G++''$B6Z1J"^YB[-@
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MO_(^#_V#_P#@AS\!_P!F>:U^(OQ_\*2_$SQLC"8'48%_LFPEZYBMW)\]@?\
MEI-G. RHAK[S3Q%JD2"./P;=JJC"JI4 #TK:HK\[S[B/.^)\:\5F=>52?2^T
M5VC%:17DDCIITJ=*-H*QC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%>
M(:&/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***H^(?$-AX;L#?7Q8Y;;'&G5V]/
M_KU$YPI0<I.R1%2I"E!SF[)%ZBN6T3XHZ=JE^EC>6#6WF-MCD,@89/3/ Q74
MUGA\30Q4>:E*Z,L-B\/BX<U&5T%%%%;G0%%%% !1110 4444 %%%% !1110
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MJG]GOQ7\)]4^..D?%/3AX7T.66+6]3O1);?V?+&0'AGBF59(9067]VZASO7
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ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
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MK']M:IX6\-6>FZIJ,4; WDL5M%%). Q+89XRV"2?FYZ5W'V+QO\ ]!NR_P#
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M'DFM*698"M3E.%16C:[VM?;<UH9QEF(I2J4ZJY8VN]K7VO>VY]%T5\=^%/\
M@M9_P3S\8;5L/VQ]"M7/!CU;PSJ5GM/NTUNJ_B"17T)XY^+_ (1^%YTT?$WX
MZ>#?#9UD.=(77]4@LC>[ I?RA,ZF3:'3.W.-ZYZBMZ>)PU6+E"::79IG32QF
M$KQ<J=2,DM[-.QZ!17(^&?&">-(OM'@[XG^'=6CQG?IEQ'.,?5&-:WV+QO\
M]!NR_P# 8_XULFFKHZ$U)71L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (TQFQ16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO
M_ 8_XU:TJ#7X9'.L7\$RE?D$46T@T 7J*** "BBB@ HHHH **** "O _$_\
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M2;% D&#\Q.#Z\5!X<_X(Y?\ !,OPMM_LS]D+PW+MZ?VE/=7GY_:)GS7MFD?
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M,G!KZN_X*I?%?_@IY\,=4\$W7_!//X9-X@L3;W[^,!_9-O>9?=;BV7;(PD&
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MJEGJ5@LP@E*3K%$5ECD>,-&4Z.&!8<T >PT444 %>%_M8?\ );/@?_V/<O\
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MVH_V=K[X,WG[1&G?&?P]=^!K#S/MGBNSU))K&/9((VS*A(.'(7CN:_EVL_\
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M=<O/#C>'/VB93.NEVIL;"WQMU!2F([DM;KNM-RY?Z\-@U[9K?[;W[&OAK/\
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MS-JM+VV&P-1QG'>TK2B_-NUGW(H95DV"E+DCK).+O)NZ>ZU9Z!X<_P"#9O\
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M+H5ZTJV6M>']4BO+2X,<C12!)H69'*R(Z-@G#(RG!!%?C+H/_!G5^Q;;D?\
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MU59/G>59?A71Q6 A7=V^9RE%VLM-.FGXBJ4YRE>,K'X7?\1BO[0W@7CXM_\
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MYE(Y':M"O/\ ]EO_ )(3H7_;U_Z52UZ!7+3DYTU)]44PHHHJP"BBB@ HHHH
M*^'?VM/'W[,?A'QAXW^(G[.?[0OB#P5\<[8RQMX4\/6]RY\5:G;KY<$%QI,T
M31WBR%5C6XC0?*X?S"HK[BK#/PZ\)M\25^+3:>YUU-#.D)=&=]JVAF$Q0)G;
MDNJDMC/ &<4 ?+O_  4T^//@GP_^P^_@;XQ>,M#T#QUX@L?#]^_AB;4$69G3
M5+*2Y\I"272,I+EAGB,G/%7_ (W?&_X2V7[2/P/_ &P+?X@Z9>?#*33/$OA^
M[\:6MT)--L+JX^S&!I9ERL:O):30[R0H90"1FOJ^FRQ13QF*:-71AAE89!'T
MH _/+XI78^(7CGQ[^W!X'M+K5/A[I'QH\ :B-7L;5Y%U#3M&C>+4+Z!5&9X8
MGNS^\4%6%LY!(4D>X>#OB+X%_:=_X* ^'OB1\#O$]IXC\,^!?AIJ=MK/B72)
M?.LC>W]U:F&R69?E>41V\DK*"=@VYP3BOIY$2-!'&@55&%4#  ]*;!;P6T8A
MMH$C0'A44 ?D* 'T444 9>K>"/!>O7AU#7/"&EWMP5"F>[T^.1R!T&YE)Q7B
M/C2PUCX*>(O ?P[U#6$UO_A+=:;2XKXVQMVLU6(N'9=S^;TQC*?4U]!5X7^U
MA_R6SX'_ /8]R_\ I,U<^(PF'Q22JQO;U_0Y\3A,/BX<M:-T=3IG[,7@+4=:
MN];^*^@>'O%\DB1)IJZMX9AD%@JERPC,ID(W%@21CE1[8W].^ WP-T=632?@
MQX3M0^-XMO#MLF['KM09ZUUE%;T5]7I*G3=HKI<TITJ5*"C!))&%9_"[X9Z?
M*9]/^'6A0.5VEX=(A4D>F0M7+?PAX3LYEN;3POIT4B_=DCLHU8?0@5HT5;G.
M6[-"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:BI A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH \__P"&6_@3_P!"+_Y4[K_X[6[X*^$OP\^'GVG_ (1#
MPVEK]LV?:-\\DN[9NV_ZQFQC<W3&<_2NCHK.-*E%W44GZ!=D/]G:?_SXP_\
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8
M?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[
M.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?
M&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'
M^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^
M_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T
M_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'
M_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^S
MM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0
MJ:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__
M )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_O
MT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@#+\2^"
M?"WB_1)_#OB'1HI[.XV^=$I,9;:P8?,A##E0>#7)_P##+?P)_P"A%_\ *G=?
M_':] HJ)4Z<W>23 S_"WA;0?!6@P>&?#-C]FL;;=Y$'FL^W<Q<\N23\S$\GO
M6A115))*R ****8!1110 4444 %%%% !1110 4444 %%%% !7A?[6'_);/@?
M_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-0![I1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5\_?MY?&_Q?\*8_ WA#3O']CX%\/>--=N-,\3_$?4].%S#H,8M7
M>%,.RQ1//(!&LLIV)@D@G&/H&O)/VO?C5X@^!O@)/%,OP#'COPM*K6_B>"+5
M[6&:V\R2&*W46]R ERDCR,K#>I4A?E8,2H!YUK7B3XF?LD?LA>$OAWX!^+FC
M>,]4UOQ+HG@SX;>)I='1+>TM;DPVT,LZQ3,MTT,:32;U*B3:@*\,6WOAGXW^
M.WPF_:SM/V;/C%\6O^$ZTKQ3X)NM<\/Z[=Z%:V%W:7=I<PQ7%JRVJI')$R7"
M2*Q4,I4J2W6O)-,_8F^.>F_"CQ)XM\#_  TTGPK?P?&+1_'O@'X1P:W$UI8"
MQ$2SVIG3]Q!)=8G<K'F*-F0;L9*^N_#3PE\8OC'^UA9_M*?$[X07W@31O"W@
MBYT/P_HNM:I9W-]>7=Y<0RW-RPLY98XXD2W2-07W,79L  "@#Z HHHH \O\
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M\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\
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M_AKGXX?]&,^._P#P)@KWJB@#P7_AKGXX?]&,^.__  )@H_X:Y^.'_1C/CO\
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MX:Y^.'_1C/CO_P "8*]ZHH \%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\
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MX:Y^.'_1C/CO_P "8*/^&N?CA_T8SX[_ / F"O>J* /!?^&N?CA_T8SX[_\
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MX@6.Q2QKVWP'XU\/?$GP/HWQ$\(WGVG2M>TJWU'3+@KCS+>:-9(VQVRK XH
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M)VO^(_#'AG3M21Y]:M4TRP$;PJN2T;R1F,. 1G/I7V3'%'#&(H8U1%&%51@
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524010016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,005,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523887408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Rose, Snyder & Jacobs LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Encino, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528316304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 108,005,000<span></span>
</td>
<td class="nump">$ 184,434,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,410,000<span></span>
</td>
<td class="nump">10,255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">268,391,000<span></span>
</td>
<td class="nump">56,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,728,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,289,000<span></span>
</td>
<td class="nump">4,362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">20,204,000<span></span>
</td>
<td class="nump">2,191,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">405,299,000<span></span>
</td>
<td class="nump">384,597,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">110,297,000<span></span>
</td>
<td class="nump">48,675,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">11,962,000<span></span>
</td>
<td class="nump">13,663,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">105,872,000<span></span>
</td>
<td class="nump">245,595,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">58,291,000<span></span>
</td>
<td class="nump">17,346,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">691,939,000<span></span>
</td>
<td class="nump">710,148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,868,000<span></span>
</td>
<td class="nump">9,457,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">46,856,000<span></span>
</td>
<td class="nump">14,001,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">12,251,000<span></span>
</td>
<td class="nump">9,773,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,776,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">74,099,000<span></span>
</td>
<td class="nump">111,055,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">138,850,000<span></span>
</td>
<td class="nump">146,536,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">78,800,000<span></span>
</td>
<td class="nump">23,295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">55,950,000<span></span>
</td>
<td class="nump">131,495,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">134,750,000<span></span>
</td>
<td class="nump">154,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares</a></td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,219,213,000<span></span>
</td>
<td class="nump">1,053,386,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(136,000)<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(820,755,000)<span></span>
</td>
<td class="num">(644,692,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</a></td>
<td class="nump">398,520,000<span></span>
</td>
<td class="nump">408,822,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">19,819,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders' equity</a></td>
<td class="nump">418,339,000<span></span>
</td>
<td class="nump">408,822,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</a></td>
<td class="nump">$ 691,939,000<span></span>
</td>
<td class="nump">$ 710,148,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524110032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">105,960,000<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">105,960,000<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527981232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 243,231,000<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
<td class="nump">$ 87,992,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">297,307,000<span></span>
</td>
<td class="nump">206,342,000<span></span>
</td>
<td class="nump">128,875,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">124,431,000<span></span>
</td>
<td class="nump">80,981,000<span></span>
</td>
<td class="nump">52,276,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">421,738,000<span></span>
</td>
<td class="nump">287,323,000<span></span>
</td>
<td class="nump">181,151,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(178,507,000)<span></span>
</td>
<td class="num">(149,036,000)<span></span>
</td>
<td class="num">(93,159,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">5,033,000<span></span>
</td>
<td class="nump">6,120,000<span></span>
</td>
<td class="nump">9,191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">765,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
<td class="num">(583,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">5,798,000<span></span>
</td>
<td class="nump">8,190,000<span></span>
</td>
<td class="nump">8,608,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense and noncontrolling interest</a></td>
<td class="num">(172,709,000)<span></span>
</td>
<td class="num">(140,846,000)<span></span>
</td>
<td class="num">(84,551,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">3,785,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including noncontrolling interest</a></td>
<td class="num">(176,494,000)<span></span>
</td>
<td class="num">(140,848,000)<span></span>
</td>
<td class="num">(84,553,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(431,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (176,063,000)<span></span>
</td>
<td class="num">$ (140,848,000)<span></span>
</td>
<td class="num">$ (84,553,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net loss per share attriutable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
<td class="nump">100,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
<td class="nump">100,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (67,000)<span></span>
</td>
<td class="num">$ (87,000)<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (176,561,000)<span></span>
</td>
<td class="num">$ (140,935,000)<span></span>
</td>
<td class="num">$ (84,143,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522744928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2019</a></td>
<td class="nump">$ 244,036<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 664,086<span></span>
</td>
<td class="num">$ (392)<span></span>
</td>
<td class="num">$ (419,291)<span></span>
</td>
<td class="num">$ (555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,506,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">7,469<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash</a></td>
<td class="nump">250,479<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">250,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NoncontrollingInterestIncreaseFromDeconsolidation', window );">Deconsolidation of Ablaris Therapeutics, Inc.</a></td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(84,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">461,779<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">965,410<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(503,844)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">11,305<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,053,386<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(644,692)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">120,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">606,220<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Interest in joint venture</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(176,494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,063)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,219,213<span></span>
</td>
<td class="num">$ (136)<span></span>
</td>
<td class="num">$ (820,755)<span></span>
</td>
<td class="nump">$ 19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NoncontrollingInterestIncreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase From Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NoncontrollingInterestIncreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247526783920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including noncontrolling interest</a></td>
<td class="num">$ (176,494,000)<span></span>
</td>
<td class="num">$ (140,848,000)<span></span>
</td>
<td class="num">$ (84,553,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">120,893,000<span></span>
</td>
<td class="nump">76,673,000<span></span>
</td>
<td class="nump">43,383,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net loss (gain) from investments</a></td>
<td class="nump">4,432,000<span></span>
</td>
<td class="num">(1,708,000)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">10,421,000<span></span>
</td>
<td class="nump">8,267,000<span></span>
</td>
<td class="nump">5,942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of note premiums</a></td>
<td class="nump">2,910,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">8,845,000<span></span>
</td>
<td class="num">(9,409,000)<span></span>
</td>
<td class="num">(184,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(19,291,000)<span></span>
</td>
<td class="num">(360,000)<span></span>
</td>
<td class="num">(387,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(6,589,000)<span></span>
</td>
<td class="nump">2,628,000<span></span>
</td>
<td class="num">(821,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">17,750,000<span></span>
</td>
<td class="nump">9,522,000<span></span>
</td>
<td class="nump">1,989,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(112,501,000)<span></span>
</td>
<td class="nump">223,258,000<span></span>
</td>
<td class="num">(63,514,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">13,428,000<span></span>
</td>
<td class="nump">3,192,000<span></span>
</td>
<td class="nump">1,124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
<td class="nump">715,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(136,131,000)<span></span>
</td>
<td class="nump">171,312,000<span></span>
</td>
<td class="num">(95,801,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(52,777,000)<span></span>
</td>
<td class="num">(23,567,000)<span></span>
</td>
<td class="num">(11,952,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(223,391,000)<span></span>
</td>
<td class="num">(240,703,000)<span></span>
</td>
<td class="num">(278,964,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">270,751,000<span></span>
</td>
<td class="nump">122,592,000<span></span>
</td>
<td class="nump">50,138,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,417,000)<span></span>
</td>
<td class="num">(141,678,000)<span></span>
</td>
<td class="num">(240,778,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">5,186,000<span></span>
</td>
<td class="nump">11,305,000<span></span>
</td>
<td class="nump">7,469,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from investment in joint venture</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">65,186,000<span></span>
</td>
<td class="nump">11,305,000<span></span>
</td>
<td class="nump">257,948,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(76,362,000)<span></span>
</td>
<td class="nump">40,939,000<span></span>
</td>
<td class="num">(78,631,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(88,000)<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">184,434,000<span></span>
</td>
<td class="nump">143,583,000<span></span>
</td>
<td class="nump">221,804,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">108,005,000<span></span>
</td>
<td class="nump">184,434,000<span></span>
</td>
<td class="nump">143,583,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes (Paid) Refunded</a></td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524851232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-AAT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-XDH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity that the Company is the primary beneficiary in). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had $108.0 million in cash and cash equivalents (including $7.3 million in restricted cash), $268.4 million in short-term investments and $105.9 million in long-term investments to fund operations. During the year ended September&#160;30, 2022, the Company&#8217;s cash and cash equivalents and investments balance decreased by $131.1 million which was primarily cash being used to fund the Company&#8217;s operations, offset by the $120.0&#160;million upfront payment received from Glaxosmithkline Intellectual Property Limited (Note 2) and $60.0&#160;million cash infusion from the formation of Visirna (Note 2).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $4.9&#160;billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company has determined that Visirna, in which the Company is the primary beneficiary, meets the definition of a business. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments with short-term are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were $7.3 million and $2.4 million restricted cash at September&#160;30, 2022 and September&#160;30, 2021, respectively, that are primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. The increase in 2022 was mainly due to the Company&#8217;s expansion plan in Verona, Wisconsin and San Diego, California.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents and investments. As of September 30, 2022 and 2021, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all marketable debt securities for $122.3&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-then-temporary impairments of its investment for the years ended September 30, 2022, 2021, and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4">three</span> to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during 2022, 2021, and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September 30, 2022 and 2021, intangible impairment assessments indicated that there was no impairment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $0 at September&#160;30, 2022 and 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2018, the Company adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its ongoing licensing and collaboration agreements. See Note 2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended September&#160;30, 2022, 2021 and 2020, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expenses for all grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update 2019-12, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ncome Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for change in tax laws or rates. The Company adopted the new standard which became effective for fiscal years and interim periods within those years that begin after December 15, 2020. The adoption of the new standard did not have any material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524166208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTSGlaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0 million and is eligible for additional payments of $30.0 million at the start of Phase 2 and $100.0 million upon achieving  a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial readout positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study, (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized as of September&#160;30, 2022. There were $0 in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has also performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $4.8&#160;million in connection with these efforts for the year ended September&#160;30, 2022. There were $4.8&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of ARO-XDH, and Horizon is now wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$660.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2022 and 2021 were $26.7&#160;million and $6.7&#160;million, respectively. There were $0 in contract assets recorded as accounts receivable and $6.7&#160;million in contract liabilities recorded as deferred revenue as of September 30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $2.5&#160;million and $0 in connection with these efforts for the years ended September&#160;30, 2022 and 2021, respectively. There were $1.3&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop its ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $595.0&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the initial transaction price totaled $300.0&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $85.8&#160;million and $90.8&#160;million in connection with these efforts for the years ended September 30, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $123.4 million of contract liabilities recorded as deferred revenue, of which $67.4&#160;million was classified as current deferred revenue, as of September&#160;30, 2022. The Company also recorded $8.6&#160;million as accrued expenses that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (the &#8220;Janssen Collaboration Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson's venture capital arm (&#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#8217;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application (&#8220;IND&#8221;) or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0 million as an </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upfront payment, $75.0 million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $1.6&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $0.6&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of Janssen License Agreement and Janssen Collaboration Agreement, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of September&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#8217;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company recognized $3.4&#160;million and $0.5&#160;million of revenue associated with these efforts during September&#160;30, 2022 and 2021, respectively. There were $0.1&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September&#160;30, 2022.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to the Company&#8217;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments, $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $30.0&#160;million in milestone payments, and may receive up to an additional $400.0&#160;million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0&#160;million milestone payment to the Company. There were no revenue recorded associated with the Company&#8217;s agreement with Amgen for the years ended September 30, 2022 and 2021. There were no contract assets and liabilities recorded as of September 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528001056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,373&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,554)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,864)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2022, 2021, and 2020 was $8.7 million, $6.6 million and $4.2 million respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the construction in progress during 2022 was mainly due to the developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524857568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certifiate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certificate of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524861088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible asset: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,194&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,663&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2022, 2021, and 2020 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"/><td style="width:60.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524833312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITYThe following table summarizes the Company&#8217;s shares of common stock and preferred stock:<div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,000,392 and 15,228,479 shares of common stock at September&#160;30, 2022 and 2021, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div>In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September&#160;30, 2022, no shares have been issued under the ATM Agreement<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524874944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of the year ended September&#160;30, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company intends to invest between $200.0&#160;million and $260.0&#160;million into the build out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will also receive up to $2.5&#160;million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License Commitments</span></div>The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company made milestone payments of $0, $2.4 million, $0 for the years ended September&#160;30, 2022, 2021, and 2020, respectively. The Company did not reach any milestones during the years of 2022 and 2020. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524880720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a new 15-year lease for approximately 144,000 square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#8217;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#8217;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office with a lease expiration date of April&#160;30, 2027. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleases space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September&#160;30, 2031. The lease contains two options to renew for two terms of five years. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional 10,743 square feet for the remainder of the term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:33.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses associated with the Company&#8217;s operating leases. There was $0.3 million and $0 short-term lease cost during the years ended September&#160;30, 2022, and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"><tr><td style="width:1.0%"/><td style="width:81.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,802&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,944&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,368)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"><tr><td style="width:1.0%"/><td style="width:66.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524749520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 175,083 and 4,072,137 shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of September&#160;30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was 7,190,077 shares, which includes 131,897 shares that were forfeited under the 2013 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were 778,425 shares reserved for options and 838,625 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,543,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,145,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,083&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,689,187&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926,545&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,790,815&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September 30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,456,239&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.60&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,635)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.73&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(606,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,114,746&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,351,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,889,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#8217;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on September 30, 2022. The total intrinsic value of the options exercised during the years ended September&#160;30, 2022, 2021, and 2020 was $27.6 million, $66.9 million and $44.1 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options for the years ended September&#160;30, 2022, 2021, and 2020 was $10.8 million, $12.4 million and $9.7 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $12.0 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 1.5 years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 &#8211; 1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 &#8211; 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 &#8211; 90.4%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.0 &#8211; 92.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.64&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.35&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,831,850&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.24&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,396,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,027,088)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.88&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,431&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.96&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of 800,000 shares, equal in value of $38.4&#160;million, that was 100% market-based awards. The revised awards consist of 99,521 RSUs and 149,282 performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).</span></div>For the years ended September&#160;30, 2022, 2021 and 2020, the Company recorded stock-based compensation expense of $113.6 million, $64.2 million and $33.7 million, respectively, related to shares of RSUs. As of September&#160;30, 2022, there was $140.7 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.4 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524725072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the transfer. At September&#160;30, 2022 and 2021, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2022, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524749520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following components:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-13.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-2.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,479&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,454&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized Research &amp; Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California Alternative Minimum Tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of Use Assets/Lease Liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,259&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242,394)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194,255)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,390)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,644)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,478)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,004)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded, in accordance with the applicable accounting standards, that it is more-likely-than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from the Company&#8217;s estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset. This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of $504.8 million and gross state NOL carry forwards of $626.5 million. The NOLs expire at various dates through 2042.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at September 30, 2022, 2021 and 2020 were $3.5&#160;million, $0 and $0 respectively, that if the Company recognized, would affect its effective tax rate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. During the years ended September 30, 2022 and 2021, the Company recognized $1.4&#160;million and $0, respectively, of accrued interest and penalties related to gross unrecognized tax benefits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not foresee any material changes to its gross unrecognized tax benefits within the next twelve months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and its subsidiaries file income tax returns with the Internal Revenue Service, the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the Internal Revenue Service and by state tax authorities until the net operating losses are settled. The Company is under examination by the state of California for the years 2018 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247526072016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#8217;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#8217;s first 3% of compensation contributed plus 50% of each participant&#8217;s next 2% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2022, 2021, and 2020, the Company recorded expenses for the matching contributions under this plan of $1.7 million, $1.3 million and $0.9 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524908128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;), pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0&#160;million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#8217;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Royalty Pharma Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The above description of the Royalty Pharma Agreement is a summary of the material terms, does not purport to be complete and is qualified in its entirety by reference </span></div>to the Royalty Pharma Agreement, which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247519135472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div>At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company has determined that Visirna, in which the Company is the primary beneficiary, meets the definition of a business. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments with short-term are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were $7.3 million and $2.4 million restricted cash at September&#160;30, 2022 and September&#160;30, 2021, respectively, that are primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. The increase in 2022 was mainly due to the Company&#8217;s expansion plan in Verona, Wisconsin and San Diego, California.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit RiskFinancial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents and investments. As of September 30, 2022 and 2021, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all marketable debt securities for $122.3&#160;million. </span></div>The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-then-temporary impairments of its investment for the years ended September 30, 2022, 2021, and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4">three</span> to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during 2022, 2021, and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets subject to amortization</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September 30, 2022 and 2021, intangible impairment assessments indicated that there was no impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are </span></div>recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text">Contingent ConsiderationThe consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $0 at September&#160;30, 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2018, the Company adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its ongoing licensing and collaboration agreements. See Note 2.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangement</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, </span></div>the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. </span></div>During the years ended September&#160;30, 2022, 2021 and 2020, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based CompensationShare-based compensation expenses for all grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update 2019-12, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ncome Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for change in tax laws or rates. The Company adopted the new standard which became effective for fiscal years and interim periods within those years that begin after December 15, 2020. The adoption of the new standard did not have any material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524966080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-APOC3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ANG3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-ENAC2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-HSD</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-AAT</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-XDH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-75220795</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524833312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,500&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,373&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,554)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,864)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524861088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term, Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certifiate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,430&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held to maturity certificate of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247524678400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible asset: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(amounts in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,194&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,663&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"/><td style="width:60.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527948224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"><tr><td style="width:1.0%"/><td style="width:27.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247529469424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"/><td style="width:33.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.080%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.388%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2022:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"><tr><td style="width:1.0%"/><td style="width:81.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,802&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,800&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,297&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,944&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70,368)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"><tr><td style="width:1.0%"/><td style="width:66.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.758%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527971568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,543,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,145,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,083&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,689,187&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926,545&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,790,815&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September 30, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,456,239&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.60&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,635)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.73&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(606,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,114,746&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,351,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,889,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 &#8211; 1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 &#8211; 1.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 &#8211; 90.4%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.0 &#8211; 92.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.64&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.35&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,831,850&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.24&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,396,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,027,088)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.88&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(131,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,431&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.96&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247525000496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527942320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provisions for Income Taxes</a></td>
<td class="text">The provision for income taxes consisted of the following components:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes, net of federal effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-13.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-2.0&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued Compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,479&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,454&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized Research &amp; Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California Alternative Minimum Tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible Assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of Use Assets/Lease Liabilities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,259&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242,394)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194,255)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,390)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,644)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,478)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,004)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Gross Unrecognized Tax Benefits</a></td>
<td class="text">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523033824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,005,000<span></span>
</td>
<td class="nump">$ 184,434,000<span></span>
</td>
<td class="nump">$ 143,583,000<span></span>
</td>
<td class="nump">$ 221,804,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,391,000<span></span>
</td>
<td class="nump">56,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,872,000<span></span>
</td>
<td class="nump">245,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Net increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets subject to amortization, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration obligation due to discontinuation of clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount insured in FDIC per account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522468144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2021</div></th>
<th class="th"><div>Oct. 03, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="nump">$ 111,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,231,000<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
<td class="nump">$ 87,992,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo', window );">Milestone payment receivable at start of phase two</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | A R O H S D Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableAtStartOfPhaseTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable at start of phase two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableAtStartOfPhaseTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROHSDAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528060880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,231,000<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
<td class="nump">$ 87,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,099,000<span></span>
</td>
<td class="nump">111,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,700,000<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | ARO-XDH Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon Therapeutics Ireland DAC | Maximum | ARO-XDH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROXDHSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROXDHSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522952560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,231<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,950<span></span>
</td>
<td class="nump">131,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,099<span></span>
</td>
<td class="nump">111,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">$ 90,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=arwr_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523110464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,099,000<span></span>
</td>
<td class="nump">111,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,231,000<span></span>
</td>
<td class="nump">138,287,000<span></span>
</td>
<td class="nump">$ 87,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">Janssen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | J N J3989 A R O H B V Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-75220795 (ARO-JNJ1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ75220795AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247519033200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,231<span></span>
</td>
<td class="nump">138,287<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,099<span></span>
</td>
<td class="nump">111,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran and ARO-AMG1 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527182512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522426880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Computers, software, office equipment and furniture</a></td>
<td class="nump">$ 2,182<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">38,283<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">42,017<span></span>
</td>
<td class="nump">41,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">56,373<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
<td class="nump">141,851<span></span>
</td>
<td class="nump">71,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(31,554)<span></span>
</td>
<td class="num">(22,864)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 110,297<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527107760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522486336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">$ 268,391<span></span>
</td>
<td class="nump">$ 56,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(3,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">264,730<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">105,872<span></span>
</td>
<td class="nump">245,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(5,569)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">100,303<span></span>
</td>
<td class="nump">246,643<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable debt securities, Adjusted Basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">127,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable debt securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable debt securities, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">126,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">218,391<span></span>
</td>
<td class="nump">56,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(3,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">214,730<span></span>
</td>
<td class="nump">57,430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">105,872<span></span>
</td>
<td class="nump">195,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="num">(5,569)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">100,303<span></span>
</td>
<td class="nump">196,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527930608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,962,000<span></span>
</td>
<td class="nump">$ 13,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857,000<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">12,895,000<span></span>
</td>
<td class="nump">11,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">11,962,000<span></span>
</td>
<td class="nump">13,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728,000<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,770,000<span></span>
</td>
<td class="nump">10,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 9,958,000<span></span>
</td>
<td class="nump">$ 11,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="nump">977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,004,000<span></span>
</td>
<td class="nump">$ 2,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527930608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 11,962,000<span></span>
</td>
<td class="nump">$ 13,663,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247519056528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,392<span></span>
</td>
<td class="nump">15,228,479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528300912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>a </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAward', window );">Tax increment financing award</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">State income tax credits</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments | ARO-ENaC and ARO-HIF2 Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of facilities</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of facilities</a></td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Verona Technology Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased (in acres) | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Drug Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">Wisconsin | Laboratory And Office Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522612784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ft&#178; </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne', window );">Estimated payments for operating expenses year one</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalLandSubjectToLease', window );">Additional office space for lease (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalLandSubjectToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional land subject to lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalLandSubjectToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EstimatedPaymentsForOperatingExpensesYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated payments for operating expenses year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EstimatedPaymentsForOperatingExpensesYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523091824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 58,291<span></span>
</td>
<td class="nump">$ 17,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">2,776<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">78,800<span></span>
</td>
<td class="nump">23,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">9,763<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
<td class="nump">$ 3,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528098784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 5,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">11,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">12,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">11,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="nump">102,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">151,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(70,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 81,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247526426480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247518966752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="nump">$ 44.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.6<span></span>
</td>
<td class="nump">$ 64.2<span></span>
</td>
<td class="nump">$ 33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,069,431<span></span>
</td>
<td class="nump">3,831,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">99,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember', window );">Restricted Stock Units, Market-Based | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Equity award value</a></td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember', window );">Performance-Based Restricted Stock Units | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">149,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,072,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,190,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247517758976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">2,721,384<span></span>
</td>
<td class="nump">3,456,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">6,790,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">175,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">2,543,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">5,689,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">926,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">4,069,431<span></span>
</td>
<td class="nump">3,831,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">3,145,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">923,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523036960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">3,456,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(128,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(606,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares) | shares</a></td>
<td class="nump">2,351,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">47.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">8.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">20.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 48,114,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 46,889,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527131456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.20%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.40%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.64<span></span>
</td>
<td class="nump">$ 36.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527035632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">3,831,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,396,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,027,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(131,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">4,069,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 61.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">57.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">49.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">64.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 62.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247518628416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 126,728,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,728,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">39,262,000<span></span>
</td>
<td class="nump">160,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">1,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">41,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">271,333,000<span></span>
</td>
<td class="nump">254,073,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,728,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">39,262,000<span></span>
</td>
<td class="nump">160,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">1,973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">41,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">271,333,000<span></span>
</td>
<td class="nump">254,073,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to maturity securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247519137184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provisions for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Total Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">304,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="nump">304,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">3,481,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total Foreign</a></td>
<td class="nump">3,481,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Total:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">3,785,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 3,785,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522315760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">At U.S. federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal effect</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent', window );">Stock compensation</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(13.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">29.30%<span></span>
</td>
<td class="nump">43.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247528012320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued Compensation</a></td>
<td class="nump">$ 2,961,000<span></span>
</td>
<td class="nump">$ 2,371,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">41,479,000<span></span>
</td>
<td class="nump">22,454,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost', window );">Capitalized Research &amp; Development</a></td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">324,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax', window );">California Alternative Minimum Tax</a></td>
<td class="nump">483,000<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">171,319,000<span></span>
</td>
<td class="nump">185,431,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">2,973,000<span></span>
</td>
<td class="nump">3,562,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">38,810,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities', window );">Right of Use Assets/Lease Liabilities</a></td>
<td class="nump">2,844,000<span></span>
</td>
<td class="nump">1,938,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital Loss</a></td>
<td class="nump">1,679,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">262,872,000<span></span>
</td>
<td class="nump">216,259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(242,394,000)<span></span>
</td>
<td class="num">(194,255,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(1,088,000)<span></span>
</td>
<td class="num">(6,360,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxLiabilitiesStateTaxes', window );">State taxes</a></td>
<td class="num">(19,390,000)<span></span>
</td>
<td class="num">(15,644,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liability</a></td>
<td class="num">(20,478,000)<span></span>
</td>
<td class="num">(22,004,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets/ lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxLiabilitiesStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxLiabilitiesStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247523036672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FederalNetOperatingLossCarryForward', window );">Gross federal net operating loss carry forwards</a></td>
<td class="nump">$ 504,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_StateNetOperatingLossCarryForwards', window );">Gross state net operating loss carry forwards</a></td>
<td class="nump">626,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,481,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, penalties related to uncertain tax positions</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest related to uncertain tax positions</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FederalNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FederalNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_StateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522487472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Gross Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase for prior period tax positions</a></td>
<td class="nump">3,481,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 3,481,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247522816256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefits costs</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember', window );">Employee Contributions up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember', window );">Employee Contributions Next 2%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140247527144800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Royalty Pharma Agreement - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 09, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>arwr-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20220930.xsd" xlink:type="simple"/>
    <context id="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7421ed853be4b3d9e96b38143d48ac5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id99da0a6e99b4466a612f719b4091471_I20221116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7033dda081f6486dabd109e810a7b896_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i41f898dddb034047b93f962c444848c2_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7ada9eeb31fe445ab0ddd2906a6caf3d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7a9805470dd04665b4e60fa414b2154c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i74d9b7bcca044446b494a1d25fac4d68_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0b91bb8802b14d459682008730c71bdb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9195ae78bd0c4e018feb06bc6f39941e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc91136601b54b3db1507e8c9cdb15f0_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic18f5d11bc984e7794a39d04db8c9fb9_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i161077d110d5481c9db46e19e59e25b2_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66ac603c8f5b4a8e890cd249e848355a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i581a193e673a43ee927c51ce5fa8bc57_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i565f0aec40984903ab31509ccc107152_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8471847377104689b2acf51a693ccb46_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i27eb4fa099754665885890250ac463e9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i153aae9fbcc94761892a18a2f3831c92_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i359029c46a5a49938725dac7c0770303_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8b52d362ef24d56892538907287fb19_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7897c16d6d54a919ae876c9750f0852_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc9289c53cbc4f4abf44684d7a804d50_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1089994c19ef4e178fc178cb7fca23c2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i76bd52f2644744feb3d658807f3cd6c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib80c3d1b3390496eb0b757a895741ff6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb486426d4d441729abee7d2481a2a1d_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ca354a33143401aba048d9836285871_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i411e86d4599445cd8332b7c1f8beafc9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff05358bb4d14f5b937c35181dff107d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5f294cd4e58b4aaba50d623ebeaf06c6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iabdc3ed836bd43d192665281d701b948_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id483571f939d4e63b7389598f61b6608_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i38c33bdda82049d3a3cdcf2e2b470a41_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6be7d6ac7c6843cfa78f8297acbba259_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5eb370c7c5f408f97b13ca719ad8160_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i65482bab6bd34d03bbd7d32bad1c394b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia46257ffa533499ababde9281223cdfe_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ifb92b5d5298c4caeaca04ee1aa109a30_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56df8fd74028436c99ef6ff3b54f10dc_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i239542cd95804d368929cbe8296c90bf_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="ia4b56dc494ac43218654da036bf8f658_I20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="i63738435aba549e9813b380730f41e49_D20211122-20211122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="i2326885925904bb9bbf356f129cc9a0b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROHSDAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7692cd01c9aa41649a62cbfade2efe6f_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9e25f65ec4394c019914b93112fd60a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5afacc79e97d47baba530c5a7adb3b40_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="id0ca7c57f3904478a1cd7317601e0d4e_I20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="if3138c853e8a455f9a77625afebd539e_D20210618-20210618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="i3dd0a2669a28454588c20d1c395a052a_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3bde044abb649a48ecd1191afb3f05d_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0019512decda4b7990aafbc1a7e248d0_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0949381581ff4af3b82881ca7e331bf6_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c37b9188bae4800a6595d3418a0fae6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROXDHSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17e4962b3a1642f3aa8710b99691c60d_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i2fe6b533bcf74101bd5976bd6846dd09_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i8ef38d1d9fc4434fadb646e8a3dfeb79_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i871d9ae6597e4d0d95bc94bb785a706d_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="i86729ae38276427b8f27b306b25909e2_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie544bcf5262b43bc9e9b768016c61906_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i05164f990274472cb23e6e2da5920f02_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id93baee844644d37b56a5574a3dfc2c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">arwr:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f1d06f484244cafbb6712b67dd5e5c7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibb795196cbc24edfafc6f4b579915985_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="ic0868f45959c4a9083e418da9c188745_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i37b7661cd1834368bdbc8265bf19edd4_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="i5e3ffe024b534c88b962b31bde7d7c6a_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="idc323ba26f8a48859fcb26ec988dac7d_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="iccd2623ae6e34732b7abc8fb92562252_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="if21f342da4904bf7a53c62826f1b14b5_I20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia5534ed7a218413bac198deed25bcfc0_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i04804bc83aae49eeb388934d6474807c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iadad9a7e9ae24932ba60d057d20788cd_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i36ca4cce11534def83440361284f2151_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f50957118724116aade42a087a6e5f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ75220795AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id8f6a7cc3aa148ba86425faae6df475a_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="i8fddaa78aa9e4413be71a69a9e690ee6_I20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="i00c0415f2ff94135b02ad71902b05a2b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie72f2076c3c244c595b91d7c4fc96de6_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="idbbbc50aed91458f9e1cd5ca2b297e7f_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2396a0b95284dc1b37555872c67d544_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i885b30b505e24a9f94b50732d67bf577_D20220425-20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="ica7aa5158d8a4572841de66b301948f3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie44ad6fc7f3048128d384a807baf8f9f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib50cf07473c341bb83c937e0734c6bf8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8f89654b9f74474292d999d71129a6fc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i58d9cb60633a4c7ba224716bf2e67384_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib1623ebd76b9429f91c1adfbae86766c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5b16903a80c34cbebbaa904142f4545d_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic4ec44177d044f55bd6f14baa4539fa4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic2217a769eda4c6f894237f46441005d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3b02e88c51804f51b4b08d70e9573b4f_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff24be97ac644b7db7e5782fc8875f11_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ba50d541c9b45b1a0b65b7a3bc2d634_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a14a234b0c64f3db010016f3e349b47_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic4b2ef96e1ad4c0f884bfbb000ec421d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i945e065f941c41089f590861be2be53b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7df31e5a41964923a5bf827d1e46ccc8_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i81ad9b35ad9945e681373c342ced19be_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ib800ee136c204f7ca7d6ef70fe9e6bd8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7aec9e8e7c804df6bbe9ef108587e7e9_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i20b2347df25f44adb7fd8c6f8ab94841_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i10f071832c694c79898be3703116f022_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i598cccc6787b498eb6eeded5080d12fb_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="i98b23103c13b4614a1ee88bf196be447_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="ib1cbc59142a346ab848b67c243bece56_I20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="id417cd70ff1e486fa32a39bf2ea4e409_D20211220-20211220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="i24d3f2b9861345109a3431f21d36390e_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if70fc35468fb4978af2a43b1fceb0798_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieee2e0cf0d164b389f68d128f6660757_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36b4626c667d49489d40619ab73dfd32_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i1ac223b0321a49138fb4f0d6b53af948_D20211119-20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i7836ff9fc4254208a4ff43eb773872c8_I20211119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="ic89a1f5369f449baba38fde031911868_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i31744253af624e368277cea062fec33b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i16e72a6872cc4f52ad4d28a752176455_D20190101-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i6d1c2d58f05843da801c500579193e65_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i58f3846145b84a9d86539d94479612f5_D20201101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32848b6466e0410c988feb7b33651971_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i084e58e42b30496a98760c1737b0a332_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0350e114f99c470694c8188da7224d5d_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i462548275c5d4e64805ca898b4d3310b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if9641c69b3744bcdaab718353895bff8_I20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="i249abfa0135244269274c5ba0e2a360d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib209a739b3e74cc4867507f26036f5d2_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98c2c43432e94729a89fa4a887a1c799_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0a79bc6396d84f5d9ba7d3576acf4bd7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fe2f7bfc0e54741ba6777b6c90e7a87_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iba56efe3069544b3b006005a13d5a1e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9d9166d3c1ac4c9484561dc49251117d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9f46952ca97049a89f6fbd21071e26cf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f7c3935399043749e14bfd46faba122_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i76168196746b4c5988651e89f27274b6_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5bb146412894240951a8f5f0074b9e2_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i2132296e191446feb126e32a24da326d_D20220708-20220708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-08</startDate>
            <endDate>2022-07-08</endDate>
        </period>
    </context>
    <context id="ia7836f44fe8142e2a7dc14272ef0dcc0_I20220708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="i74b1850ca53244f88adb790e0b1d0c38_I20220708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="ie8d5f88f4e904ac2940b5051a30bc4b1_D20201001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3514c3e5478e4ed1a2f4d1a8b0dcda20_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i299f22dc89ed4f02aad79a53bc36af3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0f3b2544ed2e40fc89cdf37aadc3f4a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f75fded4dc34e48948a02b7e07fd82e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id5a7da1d717d40f485a1fb19c1bbb868_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd9cfdc688ab47ae95c5b3623b07d4cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib874f688067b4ae3823dfe2d5cc52229_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9726349ec847475481516736bbee2e12_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4f3f870fa9724a6289cd90aaceca2dbe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i31e1acd9eb264a28a7f8a2ce38d04ff9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib0729cf15b424ad69a05e5b53e463218_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic3c41638864d45ff8f4f22cf139c92d0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i32f3184cfed4429d8cbbef7071a35cda_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id09e91a7f81146eb8f534664d90f3ab4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c9a9acd15ab40458715e433c95945ee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ida6efcde85aa4cb69f080c834193155d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d30f7a7174940b5bc8c54c3a014461e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ee4d084af8a45c0bc6632f602ca4885_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i578ce9b283054d468a9fcb74aad58206_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icf4baaa4a1b1440a8316bc6202886db9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifdfc3811ca444047a8ad3417384b63d7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i85b153258fbf4c22ab083ac660ddd90f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie3b6aea9f3d64a28b6b8dde5934fa0fd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i072081357d81444787fc75a77eec30c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a57713d420442a29ad35a7c6f6eaecd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i36da89f6527b4ee2b870bccdcf0fa0a6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if8d0fd8b1f204829b507748af614940f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i593bbbcd381b438f824786951159d60c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1e47d68d528444408ac6eae19b74435a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic420c820ffc14e059589b2f7c7483c62_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6cb48d12728f43e8a186351de2899d14_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31add50b09e042ad9d4989277f1a52ba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0fac4c8066e449919f984f9375260f9c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i680acdc5a46f4301848a1974ee5d87f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63a9b850b4964639b775e3da5e3929bc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib584577ec6214ad49aac83e30cb1140e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib99f8ae8742d44808ca61f58e0458992_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb34bf154a434e759ce53d263414bc10_D20211001-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ida71a393ea7a404baff5b677a2df560c_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="if98ad7600c774fbfa55d91feafc740d8_I20221109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV8zLTEtMS0xLTg3MjA_2922c56f-0ffd-43da-b766-bf407015b667">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV80LTEtMS0xLTg3MjA_b381c79a-f016-45b5-88e1-bf6c2c3ec0e1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV81LTEtMS0xLTg3MjA_a0716dcc-b3e2-4994-9bfe-9c14e24a3aab">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV80L2ZyYWc6ZGRkMzFkMzVhMGQ0NGRlNzhjOWYwNjEwYzg1MjhhMDMvdGFibGU6MjRmZGY3ZGRjOWUxNDAzZmEwNTVjMWFlNzYyOGIxN2UvdGFibGVyYW5nZToyNGZkZjdkZGM5ZTE0MDNmYTA1NWMxYWU3NjI4YjE3ZV82LTEtMS0xLTg3MjA_709f4c7a-3fd4-4bd6-a968-c3f1102a9c2b">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifb92b5d5298c4caeaca04ee1aa109a30_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU3_0f2a7030-e2ba-4ecf-8ebf-5145a9e124f5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6MDAyYTdkNWIxZDgwNDliZDk0YTM0OGViZWI4NGY3YzEvdGFibGVyYW5nZTowMDJhN2Q1YjFkODA0OWJkOTRhMzQ4ZWJlYjg0ZjdjMV8wLTAtMS0xLTg3MjA_48ee65f2-df84-413a-b1b1-88f4e82064e0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MTg5_c1dcb76a-2a2d-4a87-bbe0-199b81b68bce">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MTg5_cc66e0f9-78fb-4e2c-9615-cc9542e1ea79">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YzU3ZmYxMDRiYmY0NDcwNTg1NzkyYzFhZjgzZTY1ZTEvdGFibGVyYW5nZTpjNTdmZjEwNGJiZjQ0NzA1ODU3OTJjMWFmODNlNjVlMV8wLTAtMS0xLTg3MjA_203a7e91-e783-4a73-a92c-1ce08adacfc5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU4_798c027f-f29a-475f-a527-c721058814c0">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU5_7ee9c85f-27eb-498e-a524-2de38d715e34">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YjIwODE4YmFiOWQ3NDE0MDhiOWQ3OGUyZGY5ZTk5YjMvdGFibGVyYW5nZTpiMjA4MThiYWI5ZDc0MTQwOGI5ZDc4ZTJkZjllOTliM18wLTAtMS0xLTg3MjA_f612db36-50b7-4594-aae9-ed6a27b25dcb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YjIwODE4YmFiOWQ3NDE0MDhiOWQ3OGUyZGY5ZTk5YjMvdGFibGVyYW5nZTpiMjA4MThiYWI5ZDc0MTQwOGI5ZDc4ZTJkZjllOTliM18wLTEtMS0xLTg3MjA_533dcdb9-6d04-4634-8c9f-a7246dfeea4f">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYy_c2fa3f48-f72f-46b2-b36c-d48260094f15">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUx_c656f990-8522-4c44-ad3c-13ec1d697070">304-3400</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MDQ_5502a708-efd5-4511-b933-ec96efeb8c8c">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MDg_75962fe5-ee64-4bfd-830a-88914ea90508">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTE_4d714726-f014-4bf3-a134-4e44ec447a62">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTU_bd5040da-4275-4c4c-afbf-ca4474dc5991">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY182MTg_03950dd3-5b1a-47ab-9c77-de74bb7ce9f6">91105</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTAtMS0xLTg3MjA_93828e87-043f-482e-8296-34acc678c3f1">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTEtMS0xLTg3MjA_060ae765-e61a-48ff-b186-bf61f6812fc1">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YTIzNzkyMGNkMGIyNDg5MWEzMGViYzdjODRkMTlhNGYvdGFibGVyYW5nZTphMjM3OTIwY2QwYjI0ODkxYTMwZWJjN2M4NGQxOWE0Zl8xLTItMS0xLTg3MjA_4d2e2fd0-96bd-4def-a345-19d7491cade4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUy_499496b3-1ba1-4c26-9520-f20be1a212bc">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzUz_db4402b0-0884-4f3c-b3a3-1d2a36d2bf42">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYz_3cf7294e-6d52-4bc0-99f6-4f4b163e0b46">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU0_b91c1ecb-8a35-4dbd-ab55-a8aa851cfba6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8wLTAtMS0xLTg3MjA_d43d17f9-82d6-444b-93f7-2f37f5c6cff4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8wLTktMS0xLTg3MjA_92fb8355-a942-4aae-a6d3-6135e01ed5a1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGFibGU6YWEzNzZiYmNhYzI2NDQxOWE3ZjdjYjNlYTI1YmRiZjIvdGFibGVyYW5nZTphYTM3NmJiY2FjMjY0NDE5YTdmN2NiM2VhMjViZGJmMl8xLTAtMS0xLTg3MjA_4a5efbdb-4249-4382-b9e6-091ff3fc15ce">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzYw_8db7407f-ef7d-40ea-aa29-ee736e0f853b">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzQ5_4133ff79-1d28-4968-9910-9550a93f66d8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="id7421ed853be4b3d9e96b38143d48ac5_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMDIx_70cbf89a-c872-4755-9599-21c32bc69f09"
      unitRef="usd">4100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id99da0a6e99b4466a612f719b4091471_I20221116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zMjk4NTM0ODg3MDk5_3c8ac554-67d6-46fc-82ab-bfb5bb24eba3"
      unitRef="shares">106005722</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xL2ZyYWc6NDk5ODM4MjI3Nzc2NGE2YmJiODk0ZjgxNjU2NjFiZGMvdGV4dHJlZ2lvbjo0OTk4MzgyMjc3NzY0YTZiYmI4OTRmODE2NTY2MWJkY18zNzU2_aa75170e-ad90-4a1b-a2c8-23a557e1316a">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTIvZnJhZzo4N2QwOTg5Y2FmZTM0MDFiOWJlODkzNGZlMjgzYjhkMS90YWJsZTplM2JhNDEwYmJlMGU0MDYyOWM3M2Y5OGU1NTRmMmE2OC90YWJsZXJhbmdlOmUzYmE0MTBiYmUwZTQwNjI5YzczZjk4ZTU1NGYyYTY4XzAtMC0xLTEtMTE1NTYvdGV4dHJlZ2lvbjo3ZTRkYmRiZTllOTY0ZDE1OWVhNzFlZWNjNDNhYTIwMV8zMjk4NTM0ODgzNDE3_06c805b8-f34e-4552-a820-877af3e8e6f2">468</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTUvZnJhZzozZGE0OTk1MzA2MmM0MzdlYjljZWIzYWVkMjJmNTU2Ny90ZXh0cmVnaW9uOjNkYTQ5OTUzMDYyYzQzN2ViOWNlYjNhZWQyMmY1NTY3XzMyOTg1MzQ4OTMzODc_fb8fadf6-feef-48bf-9cea-31236ddf831f">Rose, Snyder &amp; Jacobs LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMTUvZnJhZzozZGE0OTk1MzA2MmM0MzdlYjljZWIzYWVkMjJmNTU2Ny90ZXh0cmVnaW9uOjNkYTQ5OTUzMDYyYzQzN2ViOWNlYjNhZWQyMmY1NTY3XzMyOTg1MzQ4OTMzODk_1fd8ce74-9cc6-43a8-9b11-46dde1c0946c">Encino, California</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMtMS0xLTEtODcyMA_32437954-bd58-4107-b52c-f765980c8fc8"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMtMy0xLTEtODcyMA_40785792-b3c9-4d40-9c89-b3428baf71ea"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzQtMS0xLTEtODcyMA_4f4ff155-1fca-4fc8-81b7-aa5e1465bb05"
      unitRef="usd">1410000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzQtMy0xLTEtODcyMA_264b7732-f254-4cd2-b3e6-e42616924fb9"
      unitRef="usd">10255000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMS0xLTEtMTQwNTQ_46ca5eab-565d-46bd-8ef9-e60d923ca651"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMy0xLTEtMTQwNTQ_585635e6-ecac-4d45-92d2-326134ccad04"
      unitRef="usd">56627000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzctMS0xLTEtMTQwNjE_95d04933-a756-4fbf-8d49-d7eb34ddb268"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzctMy0xLTEtMTQwNjE_1a7ea3f4-b72e-4a11-bdc9-81c7c4d3262a"
      unitRef="usd">126728000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzUtMS0xLTEtODcyMA_39dd4c3d-ba4e-4c4f-a7c4-558afdaf98be"
      unitRef="usd">7289000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzUtMy0xLTEtODcyMA_4587d0ea-1fd6-4068-aa54-fece9412c610"
      unitRef="usd">4362000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMS0xLTEtODcyMA_03ed707c-1118-4493-a871-cec80190945e"
      unitRef="usd">20204000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzYtMy0xLTEtODcyMA_4a3df44a-d433-4e7d-82b9-b74a93e8eac5"
      unitRef="usd">2191000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzktMS0xLTEtODcyMA_551f9552-391e-4cca-8cf0-a876412d3ed0"
      unitRef="usd">405299000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzktMy0xLTEtODcyMA_01ee3d99-282e-4037-b792-a215fde2a933"
      unitRef="usd">384597000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEwLTEtMS0xLTg3MjA_38b9bd11-c31d-4d42-b292-f53191af815a"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEwLTMtMS0xLTg3MjA_3fcb2535-85e2-4feb-8342-03ef18efa32f"
      unitRef="usd">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzExLTEtMS0xLTg3MjA_e99408c6-9cd8-4bec-b9c7-ca3194e9ce00"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzExLTMtMS0xLTg3MjA_5cbde035-8165-4372-9242-6b7b82826956"
      unitRef="usd">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEyLTEtMS0xLTg3MjA_58e13c22-e8b8-4b09-a8b1-936e27d5aee1"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEyLTMtMS0xLTg3MjA_78147cfa-74ab-4941-809e-3eeac2f3867e"
      unitRef="usd">245595000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEzLTEtMS0xLTg3MjA_256a2bca-336f-489f-88a9-13690736eb0e"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzEzLTMtMS0xLTg3MjA_2df41f5d-c81c-46fb-9e94-ecb07366a995"
      unitRef="usd">17346000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE0LTEtMS0xLTg3MjA_b55442bd-3dc3-425b-b78e-51e3d764bf58"
      unitRef="usd">218000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE0LTMtMS0xLTg3MjA_b5623413-723f-4572-93a7-6b13adf0a90e"
      unitRef="usd">272000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE1LTEtMS0xLTg3MjA_2e1cfa87-6b44-4c40-b991-71e3051a717d"
      unitRef="usd">691939000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE1LTMtMS0xLTg3MjA_87e7c041-0fa1-47b4-b9f9-a28f325c8f6f"
      unitRef="usd">710148000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE4LTEtMS0xLTg3MjA_f148f3b4-609f-4cfb-ae15-c78d5df8de76"
      unitRef="usd">2868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE4LTMtMS0xLTg3MjA_d72f486d-336f-4d4b-b575-1257b7edf660"
      unitRef="usd">9457000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE5LTEtMS0xLTg3MjA_49c9bc96-23f2-4c12-8e03-2e87981d337b"
      unitRef="usd">46856000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzE5LTMtMS0xLTg3MjA_cae61f38-4464-4883-8b1c-6806a0552375"
      unitRef="usd">14001000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIwLTEtMS0xLTg3MjA_204f3012-bc2c-47f9-86f4-946adfa5f799"
      unitRef="usd">12251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIwLTMtMS0xLTg3MjA_97b05153-6436-45e7-93c4-7ba3ba325e70"
      unitRef="usd">9773000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIxLTEtMS0xLTg3MjA_62d95e8c-cdce-4900-bad1-9cdb46f61fd6"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIxLTMtMS0xLTg3MjA_d149da14-5c0c-47c1-96e4-78f7fffd6073"
      unitRef="usd">2250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIyLTEtMS0xLTg3MjA_6d83e9de-2cc9-4746-a07c-3ce5150af043"
      unitRef="usd">74099000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzIyLTMtMS0xLTg3MjA_cb8ce456-74b8-4007-9f59-733a0862478b"
      unitRef="usd">111055000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI0LTEtMS0xLTg3MjA_aab58056-52b7-4d5b-94b2-37b16c98e307"
      unitRef="usd">138850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI0LTMtMS0xLTg3MjA_4b232cd0-bff1-43ff-b84d-9b0541ed50e1"
      unitRef="usd">146536000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI2LTEtMS0xLTg3MjA_a5a78e1c-8512-4ff5-8d0f-7a850cddac2e"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI2LTMtMS0xLTg3MjA_d087de7f-2d7c-4f8a-ad9a-45e15e987ae9"
      unitRef="usd">23295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI3LTEtMS0xLTg3MjA_88203b08-a24b-46fc-a36d-0ecb813dc2bf"
      unitRef="usd">55950000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI3LTMtMS0xLTg3MjA_46aadbb5-29dd-454d-8b51-3b917ded8de3"
      unitRef="usd">131495000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI4LTEtMS0xLTg3MjA_eabb2abc-435f-43d7-8a4b-3a7655a4cd30"
      unitRef="usd">134750000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI4LTMtMS0xLTg3MjA_1ece59cd-a176-4184-9779-17b7eb78a30e"
      unitRef="usd">154790000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI5LTEtMS0xLTg3MjA_d09b25c0-e68f-4c70-9c0e-6c812768f99c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzI5LTMtMS0xLTg3MjA_7b5e58e5-c416-4238-875f-4fbd29a4be01"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8xOA_ca7c9c56-b2dd-4b8c-b5b0-989a03931916"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8xOA_ecd10626-953d-4133-96b0-8882a0cdf158"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8zMg_636963af-c27d-407b-8f69-1ec9b6455200"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV8zMg_bb49a493-dd1d-4533-8ece-dc50d023c60c"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV81NA_3d0f673e-e395-4074-9555-884ed2a3135d"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV81NA_f9378062-6e8f-41ff-89ae-a95e88b5d2d8"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV82MQ_82f85142-7674-4abf-b8cb-da321c56156c"
      unitRef="shares">104327000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTAtMS0xLTg3MjAvdGV4dHJlZ2lvbjo3MGQwNjc1OTc0ZGE0MWQ2YjliYmRhYjZmZjA2M2I0ZV82MQ_a48ece63-8f41-4691-b3ff-7e03163726ec"
      unitRef="shares">104327000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTEtMS0xLTg3MjA_3b3ad371-da1a-4547-81bc-583ccb183f8e"
      unitRef="usd">198000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMxLTMtMS0xLTg3MjA_68c0ea58-1509-43a5-8b7e-bc3591861f0a"
      unitRef="usd">197000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMyLTEtMS0xLTg3MjA_3d1163c0-57a0-4399-b31f-7b90ae4ab2cc"
      unitRef="usd">1219213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMyLTMtMS0xLTg3MjA_6d7be6c4-f506-46a6-a432-3eb0a6fa3d91"
      unitRef="usd">1053386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMzLTEtMS0xLTg3MjA_f0ff8676-de97-4a42-a552-0b95272ac2f4"
      unitRef="usd">-136000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzMzLTMtMS0xLTg3MjA_aea5a2e1-9012-4ea0-ab72-e73171b86488"
      unitRef="usd">-69000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM0LTEtMS0xLTg3MjA_f249c7c4-f12d-4e96-bf61-741b0db2ff1f"
      unitRef="usd">-820755000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM0LTMtMS0xLTg3MjA_832840e6-e9f0-4075-b5e4-f8716b39806a"
      unitRef="usd">-644692000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTEtMS0xLTkxNjc_aa3962f3-231b-4e4e-8e43-56830901143a"
      unitRef="usd">398520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTMtMS0xLTkxNjc_6b1b9517-c0c3-40bf-bcb5-ef92a61257f9"
      unitRef="usd">408822000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTEtMS0xLTkxNzQ_216e695a-6216-4d09-ac3d-809d5051d8bf"
      unitRef="usd">19819000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTMtMS0xLTkxNzQ_9ca2cd6a-6ec8-41cf-8575-42bcc95999a7"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTEtMS0xLTg3MjA_b41391ad-8814-464a-986d-65b82d1a2e29"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM1LTMtMS0xLTg3MjA_40d38e68-36fc-42c0-a685-671460bfe642"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTEtMS0xLTg3MjA_3bcfae95-a22b-4b34-b188-65a5d6d98ace"
      unitRef="usd">691939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjQvZnJhZzoxOTk3MzVmNzc0NTc0YTU4ODMxN2QyM2NkYjc4NWRiMy90YWJsZTpiM2UyNmJkNTE0NDE0ZGI1YWJkYjM4OWVkY2M5YjAwMi90YWJsZXJhbmdlOmIzZTI2YmQ1MTQ0MTRkYjVhYmRiMzg5ZWRjYzliMDAyXzM2LTMtMS0xLTg3MjA_f3a16046-4dbf-4230-a62d-14febacbbad8"
      unitRef="usd">710148000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItMS0xLTEtODcyMA_a93248f7-b1cf-4281-97eb-67a17b74c910"
      unitRef="usd">243231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItMy0xLTEtODcyMA_7aecdc81-7b83-4199-9ebd-73833ce7634a"
      unitRef="usd">138287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzItNS0xLTEtODcyMA_87dce40e-89fa-4afe-a897-3c79adb37306"
      unitRef="usd">87992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtMS0xLTEtODcyMA_17f43c4d-f7b2-4e0d-9ada-e987f2c08120"
      unitRef="usd">297307000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtMy0xLTEtODcyMA_5ca4b7ef-ffb6-4183-ad1b-eb270ee14347"
      unitRef="usd">206342000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzQtNS0xLTEtODcyMA_e8c45d99-8006-43df-b865-28aec6fb785a"
      unitRef="usd">128875000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtMS0xLTEtODcyMA_14876b95-f2b8-43ea-bebc-a1a21f79026a"
      unitRef="usd">124431000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtMy0xLTEtODcyMA_f3d46897-3cca-48d7-926a-e2bfe10d5d4d"
      unitRef="usd">80981000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzUtNS0xLTEtODcyMA_68ff0f14-edfd-4087-82f5-401583d4f1a3"
      unitRef="usd">52276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtMS0xLTEtODcyMA_1fc48167-f0ac-436f-aa27-ed032c1b6112"
      unitRef="usd">421738000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtMy0xLTEtODcyMA_e325a650-172d-439e-8c5d-53d8462180ad"
      unitRef="usd">287323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzYtNS0xLTEtODcyMA_33935536-9efa-41f2-a91d-0f237820a1e1"
      unitRef="usd">181151000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctMS0xLTEtODcyMA_986cc7a1-23f5-4e8b-9476-be706e0bab03"
      unitRef="usd">-178507000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctMy0xLTEtODcyMA_7d552c93-25ac-4bcb-ba5e-519979be1fe4"
      unitRef="usd">-149036000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzctNS0xLTEtODcyMA_ba489b41-46d1-4072-b919-1e11727c9b9c"
      unitRef="usd">-93159000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktMS0xLTEtODcyMA_4a6d208b-c426-4f52-a5b4-422c014460f7"
      unitRef="usd">5033000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktMy0xLTEtODcyMA_2d362d64-85bf-418d-87f2-fecbf37b10df"
      unitRef="usd">6120000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzktNS0xLTEtODcyMA_233e6617-8b91-4369-91bb-a91d2a735c69"
      unitRef="usd">9191000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTEtMS0xLTg3MjA_65d75c02-cee4-464c-98ef-54dbbfcc7e4c"
      unitRef="usd">765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTMtMS0xLTg3MjA_0b698522-f3ab-4171-9d9f-87dc89b93adb"
      unitRef="usd">2070000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEwLTUtMS0xLTg3MjA_66c15eb3-9c2c-41d2-b735-3102a9ab1067"
      unitRef="usd">-583000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTEtMS0xLTg3MjA_bf8536a7-ddd2-44c5-b5a6-92d6d373fb6a"
      unitRef="usd">5798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTMtMS0xLTg3MjA_35493a87-8e86-4b58-9865-3c43b2426e26"
      unitRef="usd">8190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzExLTUtMS0xLTg3MjA_3719e178-6461-48a9-ba5c-c3de05179130"
      unitRef="usd">8608000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTEtMS0xLTg3MjA_6b4f1c1d-9561-4506-8c9d-b50f26ae53b2"
      unitRef="usd">-172709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTMtMS0xLTg3MjA_d3b8109b-5882-4a09-b5cf-bc4bb9bce063"
      unitRef="usd">-140846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEyLTUtMS0xLTg3MjA_54f6d050-7356-48cf-ba37-49965e12c475"
      unitRef="usd">-84551000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTEtMS0xLTg3MjA_32b1853f-c684-4267-8767-d148ddee2227"
      unitRef="usd">3785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTMtMS0xLTg3MjA_7a9e7f5a-83e3-447f-8089-e4d05c853b2a"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzEzLTUtMS0xLTg3MjA_a194c7b5-dcf9-4abc-9c48-6fc4267788b7"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTEtMS0xLTg3MjA_32ebca50-f62d-479f-b69f-b24b934bfd9c"
      unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTMtMS0xLTg3MjA_c6deb9fc-31d8-4fa7-bf2d-a4295dcc0a6d"
      unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE0LTUtMS0xLTg3MjA_f3b63913-e28d-4472-9848-2a27abfcda16"
      unitRef="usd">-84553000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTEtMS0xLTE0Mzg0_d282c3b3-c7df-4846-8ecb-a8c155a73d0c"
      unitRef="usd">-431000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTMtMS0xLTE0Mzkz_0918ca25-18e8-436b-97d0-b1e4e1c621e7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE3LTUtMS0xLTE0NDAz_a2bfae02-87b1-4f5e-949c-a2787cc674f4"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTEtMS0xLTE0NDEx_0a90c1e1-cccc-4cd0-88b8-e2be4b1196af"
      unitRef="usd">-176063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTMtMS0xLTE0NDEx_70bb1c99-5b20-4da2-adff-fbbc4dcb7964"
      unitRef="usd">-140848000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTUtMS0xLTE0NDEx_70c3e7dd-b4ea-47a8-aad6-58dc107609ff"
      unitRef="usd">-84553000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTEtMS0xLTg3MjA_1242d106-5015-4728-86c9-86ebda0ac97b"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTMtMS0xLTg3MjA_fa0fea48-2765-40e4-897f-071d44146c57"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE1LTUtMS0xLTg3MjA_d99967e3-de58-4e60-b5d3-357242eb0ad1"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTEtMS0xLTg3MjA_7e62ebc5-c699-4452-90a2-6d7e0ca7722b"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTMtMS0xLTg3MjA_c73060eb-a106-4431-9d54-8cca6ef1142e"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE2LTUtMS0xLTg3MjA_f27c3158-8255-4af6-9908-72148132aaf9"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTEtMS0xLTg3MjA_72126ed5-2d54-4129-8993-4eed52e82d27"
      unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTMtMS0xLTg3MjA_e0cf526a-2bb6-4bd7-b245-e14c886354ac"
      unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzE4LTUtMS0xLTg3MjA_bc094309-6e00-48fe-8789-53f485864034"
      unitRef="shares">100722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTEtMS0xLTE0NDQ0_87e633c5-61d0-4fc7-a803-6714c2bfc4f9"
      unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTMtMS0xLTE0NDQ0_cbecd19a-6fb4-413a-a5f7-6bbb02653b74"
      unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzI1LTUtMS0xLTE0NDQ0_d2299778-60aa-4e06-8414-824143594a81"
      unitRef="shares">100722000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTEtMS0xLTg3MjA_aa7e0c4c-fff5-4edc-90f8-8efc79ffe58f"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTMtMS0xLTg3MjA_9e78e4ed-d87e-4b06-9116-7d94228b12d9"
      unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIwLTUtMS0xLTg3MjA_958d098d-a564-4b59-84df-58976cdf411a"
      unitRef="usd">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTEtMS0xLTg3MjA_5d0b48cb-b603-49f7-aaca-dac3888d6141"
      unitRef="usd">-176561000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTMtMS0xLTg3MjA_0dba563e-8aaf-49c1-bace-9986ba3c8711"
      unitRef="usd">-140935000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMjcvZnJhZzo1ODYwNWQwMDFhMTk0ODE2YmZjN2JiZjhmMzgzY2Q3Yi90YWJsZTpiOWY1NzYxZWY5NTE0MDU2OGIxOWZjMzNmZjU4ZDUxOS90YWJsZXJhbmdlOmI5ZjU3NjFlZjk1MTQwNTY4YjE5ZmMzM2ZmNThkNTE5XzIxLTUtMS0xLTg3MjA_90188d08-3875-4261-a706-ca1f6313d438"
      unitRef="usd">-84143000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMS0xLTEtODcyMA_d8a6ed35-d2eb-4801-b9f6-90470ef56ceb"
      unitRef="shares">95506000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c0b7af7991947e5b9ddb69d174fbea2_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMy0xLTEtODcyMA_f5d547d7-c3bd-4674-baea-77b0a8bc1cf4"
      unitRef="usd">188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ada9eeb31fe445ab0ddd2906a6caf3d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtNS0xLTEtODcyMA_62fe6467-bf65-454e-8c26-fa118ed36215"
      unitRef="usd">664086000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a9805470dd04665b4e60fa414b2154c_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtNy0xLTEtODcyMA_df03b362-31b6-48b4-924e-bcead9a3b4e8"
      unitRef="usd">-392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74d9b7bcca044446b494a1d25fac4d68_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtOS0xLTEtODcyMA_855d1c60-c583-4b1a-b60a-93614229d15c"
      unitRef="usd">-419291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b91bb8802b14d459682008730c71bdb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMTEtMS0xLTg3MjA_41cc24f1-403b-4782-9120-c8a8dc02cff6"
      unitRef="usd">-555000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzEtMTMtMS0xLTg3MjA_42857561-4cfd-4cc4-8bd0-19c95544d145"
      unitRef="usd">244036000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzItNS0xLTEtODcyMA_9bc456e6-84c6-44af-8491-369c35160486"
      unitRef="usd">43383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzItMTMtMS0xLTg3MjA_28c33854-5b3f-4210-84b8-efa39ad27ec9"
      unitRef="usd">43383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMS0xLTEtODcyMA_9069dc88-fbad-433e-96fe-1cf2ab9dd59c"
      unitRef="shares">1111000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMy0xLTEtODcyMA_8d2e6df2-57e7-44e9-8a14-2433c3e710ef"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtNS0xLTEtODcyMA_bf022ddb-7f87-49b8-b235-a79a0762ebc5"
      unitRef="usd">7468000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzMtMTMtMS0xLTg3MjA_3dcc5d3d-6b5a-45dd-b31a-58e89ce099b2"
      unitRef="usd">7469000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMS0xLTEtODcyMA_375dd613-ca96-42e4-a4ec-bf21f6d9567b"
      unitRef="shares">1159000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMy0xLTEtODcyMA_1e7b3840-683b-41e4-a8d1-2a80c3105fd4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtNS0xLTEtODcyMA_68da341d-5bf8-441b-8615-34a82ec4f7b5"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzQtMTMtMS0xLTg3MjA_095d7c44-2c67-440c-aebe-0bb460535872"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMS0xLTEtODcyMA_96be866b-1087-4676-a5b9-0f34377c7300"
      unitRef="shares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie986e603c2424e8e8aae43ccc090bcb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMy0xLTEtODcyMA_cf005b6c-9709-4243-8002-36d3c76d4ea2"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1023ce1585824f1ab3945066b2616be2_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtNS0xLTEtODcyMA_95c790c4-aa03-4959-b1c4-da34b92cacec"
      unitRef="usd">250474000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzUtMTMtMS0xLTg3MjA_f7f4a0bd-3567-4ecb-93f3-aabf6270b719"
      unitRef="usd">250479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idc91136601b54b3db1507e8c9cdb15f0_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzYtNy0xLTEtODcyMA_41dfd3b7-04d7-40d9-b333-de0f381f1bb0"
      unitRef="usd">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzYtMTMtMS0xLTg3MjA_c36f10a1-dfc2-4261-9a3b-1e8f3cc2be12"
      unitRef="usd">410000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <arwr:NoncontrollingInterestIncreaseFromDeconsolidation
      contextRef="ic18f5d11bc984e7794a39d04db8c9fb9_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTEtMS0xLTE0NjQ0_2711cb13-a784-4a0a-9120-9c42496ba73f"
      unitRef="usd">555000</arwr:NoncontrollingInterestIncreaseFromDeconsolidation>
    <arwr:NoncontrollingInterestIncreaseFromDeconsolidation
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTMtMS0xLTE0NjQ0_88e6c993-74dc-4aa3-ada4-7214e16de017"
      unitRef="usd">555000</arwr:NoncontrollingInterestIncreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="i161077d110d5481c9db46e19e59e25b2_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctOS0xLTEtODcyMA_befcf672-ee4d-4531-b21f-a487132db6a5"
      unitRef="usd">-84553000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzctMTMtMS0xLTg3MjA_451622a7-e2a9-4310-a0a7-eea96100e6b5"
      unitRef="usd">-84553000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMS0xLTEtODcyMA_8eebb5e3-74bb-4f5e-8ce1-0494e0bea6e3"
      unitRef="shares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMy0xLTEtODcyMA_1303a24a-2597-4697-93cb-da8318fc1a81"
      unitRef="usd">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i581a193e673a43ee927c51ce5fa8bc57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtNS0xLTEtODcyMA_e7bee41e-188f-439d-8af9-3d613ec41ecd"
      unitRef="usd">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i565f0aec40984903ab31509ccc107152_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtNy0xLTEtODcyMA_ae38d981-4c0c-4b2d-bbdf-9a9686146b3c"
      unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8471847377104689b2acf51a693ccb46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtOS0xLTEtODcyMA_625ef8fb-8fee-46c2-9685-546dc2248ba8"
      unitRef="usd">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27eb4fa099754665885890250ac463e9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMTEtMS0xLTg3MjA_1016d51e-7840-4f02-badc-3078ca589c39"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTplYTQ2ZDY0NmM4MGI0YzFkYjkyOGRlNzM1NTk5ZjljNS90YWJsZXJhbmdlOmVhNDZkNjQ2YzgwYjRjMWRiOTI4ZGU3MzU1OTlmOWM1XzgtMTMtMS0xLTg3MjA_67c10dba-b24a-4511-bc88-7d9b507fa096"
      unitRef="usd">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMS0xLTEtODcyMA_aef61665-19a3-4c26-b531-2e4e532b6cd5"
      unitRef="shares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66ac603c8f5b4a8e890cd249e848355a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMy0xLTEtODcyMA_76a4eab0-22a9-44f0-9445-5ea4af7a5849"
      unitRef="usd">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i581a193e673a43ee927c51ce5fa8bc57_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtNS0xLTEtODcyMA_1dde7e39-bf10-4a0c-994f-e73c3109daf7"
      unitRef="usd">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i565f0aec40984903ab31509ccc107152_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtNy0xLTEtODcyMA_9f79ca1b-32ad-44ef-98f9-bf9448567440"
      unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8471847377104689b2acf51a693ccb46_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtOS0xLTEtODcyMA_373f6d74-d144-48a8-9640-91d09891d54b"
      unitRef="usd">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27eb4fa099754665885890250ac463e9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMTEtMS0xLTg3MjA_8055194e-48ad-4fe0-b6bc-1459efe250a2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzEtMTMtMS0xLTg3MjA_eef405b6-e97e-4362-a71f-655b959ed23c"
      unitRef="usd">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzItNS0xLTEtODcyMA_000c40ff-9cce-4c34-bb65-93b434fc150b"
      unitRef="usd">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzItMTMtMS0xLTg3MjA_313b4ecf-25c6-4e98-a70e-676636091837"
      unitRef="usd">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMS0xLTEtODcyMA_46acdad0-881a-456b-a54d-767dfc501a2b"
      unitRef="shares">1052000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMy0xLTEtODcyMA_696bcf7d-7c9f-46ff-9630-47e5a97dbd77"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtNS0xLTEtODcyMA_9ceaabd7-dbb5-4ad6-90a2-808c555d60a1"
      unitRef="usd">11304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzMtMTMtMS0xLTg3MjA_45f96000-d463-441f-97c4-e917963e94be"
      unitRef="usd">11305000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMS0xLTEtODcyMA_acfcfd44-f74e-430c-90f7-8f3f191ed1fc"
      unitRef="shares">899000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i359029c46a5a49938725dac7c0770303_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMy0xLTEtODcyMA_2298ac54-0416-432a-8d32-c04af998c9fc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie06486358de84f199abc55dc5b52f0ad_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtNS0xLTEtODcyMA_493b121b-a61d-49e3-92f0-1935452b7722"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzQtMTMtMS0xLTg3MjA_498e9022-69a9-465c-a80d-95ce2dca9fda"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id8b52d362ef24d56892538907287fb19_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzYtNy0xLTEtODcyMA_7be577a1-5914-4456-a0e3-69d71bc53c94"
      unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzYtMTMtMS0xLTg3MjA_26314fd5-8bb5-42c1-81c2-fddd33ea61ea"
      unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ia7897c16d6d54a919ae876c9750f0852_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzgtOS0xLTEtODcyMA_b000639c-8946-4e21-b291-cf406ea26d43"
      unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzgtMTMtMS0xLTg3MjA_e7ae4bb3-e99f-4ca3-9e81-58e6cd169853"
      unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMS0xLTEtODcyMA_081c8410-e113-4b87-b68c-898f9952287d"
      unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMy0xLTEtODcyMA_8c8efda1-35e2-448a-98cc-36cdac5c8bbb"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1089994c19ef4e178fc178cb7fca23c2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktNS0xLTEtODcyMA_2f93e0bc-7ccd-4d18-b480-4f11248e272d"
      unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktNy0xLTEtODcyMA_7e3cffcb-08e4-4ffb-ab5c-7180472943b9"
      unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76bd52f2644744feb3d658807f3cd6c9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktOS0xLTEtODcyMA_4928670b-d975-4208-b3b7-fb43c0c86d1b"
      unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib80c3d1b3390496eb0b757a895741ff6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMTEtMS0xLTg3MjA_19fdd0a2-c11c-4ea3-94e9-1da6e19f27e7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTpjYjUyODc2OTVhZWE0ZWYzYjE4ZDIzMGI2NTYxOWU3NS90YWJsZXJhbmdlOmNiNTI4NzY5NWFlYTRlZjNiMThkMjMwYjY1NjE5ZTc1XzktMTMtMS0xLTg3MjA_5ef60c7d-66e5-4913-a3c6-b858353c1dbe"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMS0xLTEtODcyMA_14f01243-f1ce-4779-bb9e-e2a303be9b72"
      unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc9289c53cbc4f4abf44684d7a804d50_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMy0xLTEtODcyMA_d9af9c86-f145-4f9b-a77e-624afd60f9a8"
      unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1089994c19ef4e178fc178cb7fca23c2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtNS0xLTEtODcyMA_a695e30b-2dcc-476b-b000-f61a28ad7f71"
      unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad0605ccb05240e2b5f7adbe6bfa912a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtNy0xLTEtODcyMA_3c33185b-43ec-4b9d-89bb-d060263c6716"
      unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76bd52f2644744feb3d658807f3cd6c9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtOS0xLTEtODcyMA_d1bcc8e7-3210-43c0-9055-4ad21ca338f0"
      unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib80c3d1b3390496eb0b757a895741ff6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMTEtMS0xLTg3MjA_257c30f5-dd57-4325-b561-8441b4b455b2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzEtMTMtMS0xLTkyNjA_c0119674-f815-47d4-855e-c906ec479701"
      unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzItNS0xLTEtODcyMA_352071a8-38c5-45f9-9779-a6b221fdc966"
      unitRef="usd">120893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzItMTMtMS0xLTkyNjA_4e945e7a-fcc5-4474-a842-1e38e732a049"
      unitRef="usd">120893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtMS0xLTEtODcyMA_e3d2ef89-3d0b-439b-a2a1-4a935d1e7305"
      unitRef="shares">606000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtNS0xLTEtODcyMA_5b30573e-f9c6-40ed-8e36-44295d263fb5"
      unitRef="usd">5185000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzMtMTMtMS0xLTkyNjA_b3d98891-c952-411f-aae8-1b0de9e173c2"
      unitRef="usd">5185000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMS0xLTEtODcyMA_6937125e-0ede-4069-8d95-b2a1a2018f06"
      unitRef="shares">1027000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i9fdea37e22564e77917e651b70c9ca2f_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMy0xLTEtODcyMA_5a8c83ef-047f-4504-96dd-d8d095de6ad4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtNS0xLTEtODcyMA_637ecbab-f70d-4d98-bfc7-61c1d66f2e27"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzQtMTMtMS0xLTkyNjA_e38bf0c7-219b-442e-8e25-761a4c85165e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idb486426d4d441729abee7d2481a2a1d_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzUtNy0xLTEtODcyMA_b8c9a313-3725-4090-9cca-6210b039528a"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzUtMTMtMS0xLTkyNjA_5f688856-222d-4316-afe1-835229afe1f7"
      unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ifb46f729289a4c779625248e99ad7c6a_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtNS0xLTEtMTQ2NjA_68e514a3-81ea-4b73-a751-6ff3f29b574e"
      unitRef="usd">39750000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTEtMS0xLTE0NjYw_09625d35-30f5-44e9-b350-a557d986c4e0"
      unitRef="usd">20250000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTMtMS0xLTE0NjYw_6a89c3d2-9fef-4b86-b6e4-e5d97778c936"
      unitRef="usd">60000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="i7ca354a33143401aba048d9836285871_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtOS0xLTEtODcyMA_b7875e16-0df3-40c8-b6fc-d20cdc8b9f1f"
      unitRef="usd">-176063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iac32f52999c64d8db2fc5f833f56e7f0_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTEtMS0xLTg3MjA_59e4b705-787a-467d-8bd5-aeea2108a303"
      unitRef="usd">-431000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzYtMTMtMS0xLTkyNjA_fd068b87-68d9-4cb4-8b81-633a9863f4e0"
      unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="i411e86d4599445cd8332b7c1f8beafc9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMS0xLTEtODcyMA_861ee228-4b55-472b-9ddf-1c51c77ffe31"
      unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i411e86d4599445cd8332b7c1f8beafc9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMy0xLTEtODcyMA_6b9cd3b1-cd51-4b94-a626-743cee3e7988"
      unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff05358bb4d14f5b937c35181dff107d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctNS0xLTEtODcyMA_ffb85a34-bf4c-4101-adf2-7c14e5c9ea40"
      unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f294cd4e58b4aaba50d623ebeaf06c6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctNy0xLTEtODcyMA_43ad0a22-7632-42a6-ae82-9474b1f0a876"
      unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabdc3ed836bd43d192665281d701b948_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctOS0xLTEtODcyMA_cd2c71c1-4b7b-4985-9c14-ec30c97858e6"
      unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id483571f939d4e63b7389598f61b6608_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMTEtMS0xLTg3MjA_5a30279e-819e-42c0-8952-14e5a35819e7"
      unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzAvZnJhZzoyMzNlNzUzOGI3OTk0NDBlYjI1YTJhNmE3ZTZkNDMzZi90YWJsZTowNjcxOWE4N2JiM2I0MTI3ODdkMjkyMWQyYmM2ZTE1YS90YWJsZXJhbmdlOjA2NzE5YTg3YmIzYjQxMjc4N2QyOTIxZDJiYzZlMTVhXzctMTMtMS0xLTkyNjA_b9c278e9-691d-4366-a3fd-c22d7d1b0ce0"
      unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtMS0xLTEtODcyMA_a78cb239-b173-4814-8cc0-200b2c9df0d6"
      unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtMy0xLTEtODcyMA_b2bb941a-5ae6-4939-8d19-78d4bbdc140c"
      unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMtNS0xLTEtODcyMA_30084904-747f-4999-bf16-ac7a27f7cc38"
      unitRef="usd">-84553000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtMS0xLTEtODcyMA_2bc31f40-2880-4a46-9d72-93e71d78defc"
      unitRef="usd">120893000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtMy0xLTEtODcyMA_ae6167d4-199e-4aa5-aa0e-c62a8ae8d129"
      unitRef="usd">76673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzQtNS0xLTEtODcyMA_13286722-4cc3-46b1-ac7c-8570e029395a"
      unitRef="usd">43383000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMS0xLTEtMjMzODQ_e591f5c0-aa7f-47e8-a5ff-bb2d866455f4"
      unitRef="usd">-4432000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMy0xLTEtMjMzODQ_0a7bafcf-0249-461a-a213-cc57399f01cf"
      unitRef="usd">1708000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtNS0xLTEtMjM1MTM_7cc27d7a-058c-4125-84e5-042997dd5184"
      unitRef="usd">20000</us-gaap:GainLossOnInvestments>
    <us-gaap:DepreciationAndAmortization
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtMS0xLTEtODcyMA_1c4ccb8f-7df9-4845-bdb6-5d3cd8ff855c"
      unitRef="usd">10421000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtMy0xLTEtODcyMA_d3bb6d5d-b400-49ae-9f4b-50c763515c5a"
      unitRef="usd">8267000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzUtNS0xLTEtODcyMA_111fce78-b010-4ad7-917b-1fdc7330cb48"
      unitRef="usd">5942000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMS0xLTEtODcyMA_348f77c5-bf48-48d8-b62e-747f7efb06ae"
      unitRef="usd">-2910000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtMy0xLTEtODcyMA_6036399b-36a0-4a3a-8476-a506ba9b6b65"
      unitRef="usd">-266000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzYtNS0xLTEtODcyMA_1504e112-4b6b-42bf-991f-63f520527979"
      unitRef="usd">-525000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtMS0xLTEtODcyMA_14551058-d312-4e95-b00a-699a8e593124"
      unitRef="usd">-8845000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtMy0xLTEtODcyMA_5ea1fec1-3a7b-4cad-af66-812513ed04b4"
      unitRef="usd">9409000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzgtNS0xLTEtODcyMA_86441d65-9b04-4adf-992f-d1485430359c"
      unitRef="usd">184000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktMS0xLTEtODcyMA_29cac1fc-ef4e-489f-9e8d-26ef3c78b840"
      unitRef="usd">19291000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktMy0xLTEtODcyMA_11dd3161-73ad-482c-9185-18c22eeb0320"
      unitRef="usd">360000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzktNS0xLTEtODcyMA_72f6e1b5-856f-41d2-9bbf-2156d90624cf"
      unitRef="usd">387000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTEtMS0xLTg3MjA_a371506b-3a00-48dd-84e2-a6d917b55a92"
      unitRef="usd">-6589000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTMtMS0xLTg3MjA_63b75c31-e233-4ee7-b55a-db117826bbd9"
      unitRef="usd">2628000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEwLTUtMS0xLTg3MjA_50cbef59-9339-4fe6-b5a1-8b127a6138a0"
      unitRef="usd">-821000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTEtMS0xLTg3MjA_1c133b08-b176-4c45-8929-78545cb73de8"
      unitRef="usd">17750000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTMtMS0xLTg3MjA_f0e9edf0-ccd1-46d1-b255-40fab73a4281"
      unitRef="usd">9522000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzExLTUtMS0xLTg3MjA_9a41ad48-4411-43ae-837b-60137c3fc614"
      unitRef="usd">1989000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTEtMS0xLTg3MjA_674e9116-743d-4a2f-ae73-5fea01036a1b"
      unitRef="usd">-112501000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTMtMS0xLTg3MjA_f3fc5a9c-c064-4fb0-b53d-cea4729828e3"
      unitRef="usd">223258000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEyLTUtMS0xLTg3MjA_bf1bdd37-bba5-435d-8178-99b9a15e71f4"
      unitRef="usd">-63514000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTEtMS0xLTIzMzU3_05c20811-bd9b-4e69-80cd-0d2de87f3731"
      unitRef="usd">13428000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTMtMS0xLTIzMzY2_6ba202c9-b653-45d0-81db-9bfb3aae533f"
      unitRef="usd">3192000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE1LTUtMS0xLTIzNTIx_de4b6a31-d855-44ee-ba42-72dfe25cbb58"
      unitRef="usd">1124000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTEtMS0xLTg3MjA_5dbc8c0c-86ae-4be4-95b2-727a1487519a"
      unitRef="usd">65000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTMtMS0xLTg3MjA_bae00372-5ba7-487e-a043-ab75573d479c"
      unitRef="usd">-169000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzEzLTUtMS0xLTg3MjA_c1fdc905-0980-4603-8c01-673c11d4acf1"
      unitRef="usd">715000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTEtMS0xLTg3MjA_ed0b3e53-cf6d-4351-aa3a-f5493d0b091c"
      unitRef="usd">-136131000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTMtMS0xLTg3MjA_d5322922-ea57-41d5-952e-afa3325a18be"
      unitRef="usd">171312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE0LTUtMS0xLTg3MjA_c3d28064-982a-44b1-ad9e-8d8b1451af37"
      unitRef="usd">-95801000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTEtMS0xLTg3MjA_d2dd672e-a41c-4313-9d19-f89ae39cf4c9"
      unitRef="usd">52777000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTMtMS0xLTg3MjA_2a8f26a2-2ceb-4dce-a9b4-76feeb714af1"
      unitRef="usd">23567000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE2LTUtMS0xLTg3MjA_8bd19033-e456-4217-bd08-cf13dd12aba6"
      unitRef="usd">11952000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTEtMS0xLTg3MjA_8881e3bd-fe2b-4237-8252-19ed31d74971"
      unitRef="usd">223391000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTMtMS0xLTg3MjA_33b3967d-710d-4ce2-9013-6dee9b647eb0"
      unitRef="usd">240703000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE3LTUtMS0xLTg3MjA_d40d2839-4e63-497d-89a8-1e0ba9a6caad"
      unitRef="usd">278964000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTEtMS0xLTg3MjA_0a67ca1d-0c34-4733-bc92-68e5d540ab8d"
      unitRef="usd">270751000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTMtMS0xLTg3MjA_34ea4881-14f2-49d3-aaaa-412da9d7375b"
      unitRef="usd">122592000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE4LTUtMS0xLTg3MjA_1ef78c8b-32e0-41cb-ba0c-c4dec42a39b0"
      unitRef="usd">50138000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTEtMS0xLTg3MjA_35cf3d60-2d87-4cca-bdbd-77bce1770814"
      unitRef="usd">-5417000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTMtMS0xLTg3MjA_1b95a538-5f45-4bef-ae72-1d2ede626809"
      unitRef="usd">-141678000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzE5LTUtMS0xLTg3MjA_eeb4c316-9e03-41a8-a189-c5d8993e7094"
      unitRef="usd">-240778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTEtMS0xLTg3MjA_453054f2-13b4-466f-9815-882d8deaf72b"
      unitRef="usd">5186000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTMtMS0xLTg3MjA_61b4207c-f534-4d6a-9278-130ccfcca89c"
      unitRef="usd">11305000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIyLTUtMS0xLTg3MjA_c57bddbb-4f2e-44b3-a6f8-7fbba52cd0f0"
      unitRef="usd">7469000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTEtMS0xLTg3MjA_3a506ea0-6b38-420d-b4e9-31a0684b5b24"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTMtMS0xLTg3MjA_21f9f42f-49fb-4738-99e2-58d5017be4ea"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzIzLTUtMS0xLTg3MjA_cfad3061-1e49-4fa5-9c27-215a0ae35793"
      unitRef="usd">250479000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTEtMS0xLTE5NDIz_6066a79f-ee0b-4957-8954-e5aa720e281c"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTMtMS0xLTE5NDIz_8120e0f0-0c49-4385-96c0-ffaf43cbecf0"
      unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTUtMS0xLTE5NDIz_8e98e9a2-cbaf-4fb6-b8b9-d7f938560ce8"
      unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTEtMS0xLTg3MjA_c91c2e4f-63d0-41e8-94d5-473242228509"
      unitRef="usd">65186000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTMtMS0xLTg3MjA_6fb9bca3-e5be-42f5-af8a-f9a86e664186"
      unitRef="usd">11305000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI0LTUtMS0xLTg3MjA_2d5720cd-0244-440c-8cd9-dbc839cf6f77"
      unitRef="usd">257948000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTEtMS0xLTg3MjA_472994a9-b5f9-4246-b0c5-3b4f931967b6"
      unitRef="usd">-76362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTMtMS0xLTg3MjA_d3668952-275e-4453-a95a-14a07f18a7a1"
      unitRef="usd">40939000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI1LTUtMS0xLTg3MjA_ba1c7bdc-b587-4db6-a724-8721fe4d3e34"
      unitRef="usd">-78631000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMyLTEtMS0xLTIzNDE5_4f0bc459-02e3-4695-aa0f-784bb7ab73f2"
      unitRef="usd">-67000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMzLTMtMS0xLTIzNDY5_799b32c6-fbbe-4c26-8ccd-1fe5dfeecc9d"
      unitRef="usd">-88000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMzLTUtMS0xLTIzNDk5_28ce1a3a-63fa-496a-95c6-e4e50f13ee7c"
      unitRef="usd">410000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTEtMS0xLTg3MjA_1ac30d81-99a7-44f0-b9a6-698ab2d66a81"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTMtMS0xLTg3MjA_bd3fbb47-77c9-4b7b-90c2-10dde8cda09e"
      unitRef="usd">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI2LTUtMS0xLTg3MjA_d330dac0-dc3d-42f8-bdf9-671c4a1b25d2"
      unitRef="usd">221804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTEtMS0xLTg3MjA_a974ba34-54bd-47ac-8127-0ce76d31dacb"
      unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTMtMS0xLTg3MjA_6f0f072f-4c54-47d1-b001-1cbd54229937"
      unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI3LTUtMS0xLTg3MjA_ffdac880-3ef1-46bf-ad7f-17e89179ff3c"
      unitRef="usd">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTEtMS0xLTg3MjA_803ebf05-0de5-4887-816e-e09f9b2d0fef"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTMtMS0xLTg3MjA_364f6bf5-2c44-4e68-a00b-af8ec95bcc71"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzI5LTUtMS0xLTg3MjA_f8f1a601-44d2-4328-a4e3-5bb93eb61316"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTEtMS0xLTg3MjA_44765a72-3de3-447e-878a-fda55c2440c5"
      unitRef="usd">-2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTMtMS0xLTg3MjA_16a0324f-176d-4aa9-8528-4899ededef67"
      unitRef="usd">-2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzMvZnJhZzo3ZDdkZDMzNDExYTk0YmM4ODdiOGRiMmE0Mjk0ZjU3Ni90YWJsZTpjY2ViNTQwYWJiZjY0ZWRmYTBkMmI5Mjg1MGYyMDBmMy90YWJsZXJhbmdlOmNjZWI1NDBhYmJmNjRlZGZhMGQyYjkyODUwZjIwMGYzXzMwLTUtMS0xLTg3MjA_b908fb4e-2061-4b6e-8fb9-2b08e517fec9"
      unitRef="usd">103000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzQ5MjMwMTM_8dca75cb-a2b2-4257-89e1-be9240284395">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-HSD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-AAT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-XDH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-75220795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity that the Company is the primary beneficiary in). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s primary sources of financing have been through the sale of its securities and revenue from its licensing and collaboration agreements. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded significantly. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, the Company had $108.0 million in cash and cash equivalents (including $7.3 million in restricted cash), $268.4 million in short-term investments and $105.9 million in long-term investments to fund operations. During the year ended September&#160;30, 2022, the Company&#x2019;s cash and cash equivalents and investments balance decreased by $131.1 million which was primarily cash being used to fund the Company&#x2019;s operations, offset by the $120.0&#160;million upfront payment received from Glaxosmithkline Intellectual Property Limited (Note 2) and $60.0&#160;million cash infusion from the formation of Visirna (Note 2).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $4.9&#160;billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At Visirna&#x2019;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company has determined that Visirna, in which the Company is the primary beneficiary, meets the definition of a business. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid interest-bearing investments with short-term are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were $7.3 million and $2.4 million restricted cash at September&#160;30, 2022 and September&#160;30, 2021, respectively, that are primarily held as collateral associated with letters of credit for the Company&#x2019;s facility leases. The increase in 2022 was mainly due to the Company&#x2019;s expansion plan in Verona, Wisconsin and San Diego, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents and investments. As of September 30, 2022 and 2021, the Company&#x2019;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are mainly held-to-maturity investments and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#x2019;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all marketable debt securities for $122.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#x2019;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#x2019;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-then-temporary impairments of its investment for the years ended September 30, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September 30, 2022 and 2021, intangible impairment assessments indicated that there was no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $0 at September&#160;30, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2018, the Company adopted Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 606 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue for Contracts from Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#x2019;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its ongoing licensing and collaboration agreements. See Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended September&#160;30, 2022, 2021 and 2020, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expenses for all grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update 2019-12, I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ncome Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for change in tax laws or rates. The Company adopted the new standard which became effective for fiscal years and interim periods within those years that begin after December 15, 2020. The adoption of the new standard did not have any material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3MjA_f2f14d0c-03ed-4cc1-963d-7a9ef5747855">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-APOC3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ANG3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-ENAC2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-HSD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-AAT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-XDH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-75220795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Muscle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzg5OTU_da5a61c9-f0a1-4d9e-a973-73dab68f5a0e"
      unitRef="usd">108000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkwMzg_d3217e24-d110-4cb3-9489-598ad6b83ce2"
      unitRef="usd">7300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkwNjI_2d96b703-933c-4836-8ca3-8c29a6bc3d70"
      unitRef="usd">268400000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkxMjg_52155fad-c976-4bd2-bf1c-6b9b77df8dc9"
      unitRef="usd">105900000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzkyNTg_c5e6aa71-5740-496b-8e11-c8860964ea27"
      unitRef="usd">131100000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:UpfrontMilestonePaymentReceived
      contextRef="i38c33bdda82049d3a3cdcf2e2b470a41_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwMTc_66de96c9-f26d-4250-a437-10f6b2248116"
      unitRef="usd">120000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i6be7d6ac7c6843cfa78f8297acbba259_D20211001-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwMzE_c5ca9502-244a-47f2-9ae6-426ebeff5757"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="id5eb370c7c5f408f97b13ca719ad8160_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMDIwNDQ_9b4f2775-a7f7-47fb-90c8-5257d1cfb46b"
      unitRef="usd">4900000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ5_a543a91d-5566-4609-a1ed-bfd80e599864">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NzI_81e68c2d-aecc-487e-b69e-1dedf5492164">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;At Visirna&#x2019;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company has determined that Visirna, in which the Company is the primary beneficiary, meets the definition of a business. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODYw_9cdf5492-c3a1-4f4d-9572-cecbedd751df">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid interest-bearing investments with short-term are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were $7.3 million and $2.4 million restricted cash at September&#160;30, 2022 and September&#160;30, 2021, respectively, that are primarily held as collateral associated with letters of credit for the Company&#x2019;s facility leases. The increase in 2022 was mainly due to the Company&#x2019;s expansion plan in Verona, Wisconsin and San Diego, California.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzIxOTkwMjMyOTU2OTU_d3217e24-d110-4cb3-9489-598ad6b83ce2"
      unitRef="usd">7300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzIxOTkwMjMyOTU3MDM_8263c41f-8380-418f-b8bf-bfa9c3669abe"
      unitRef="usd">2400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU3_a1940df1-a647-49ed-95de-151d70b9f99a">Concentration of Credit RiskFinancial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash and cash equivalents and investments. As of September 30, 2022 and 2021, the Company&#x2019;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="i65482bab6bd34d03bbd7d32bad1c394b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzExMjQx_7a4b07a3-a724-45fe-b0f1-3fee66a3cbd7"
      unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUz_7c77bf7e-0099-4dfe-9e43-9653d20d1c9e">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are mainly held-to-maturity investments and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#x2019;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all marketable debt securities for $122.3&#160;million. &lt;/span&gt;&lt;/div&gt;The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#x2019;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#x2019;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-then-temporary impairments of its investment for the years ended September 30, 2022, 2021, and 2020.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia46257ffa533499ababde9281223cdfe_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzQ5NDAyODA_c4f0a2a9-0bdf-487d-a1ec-ce75db25b571"
      unitRef="usd">122300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ0_0d56834f-1a09-4366-87d9-1cbd9ffbc0b6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjI5_9ff607a2-e1a9-483f-a301-f1c9b76e77c4"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during 2022, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i56df8fd74028436c99ef6ff3b54f10dc_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE0MjM1_65ec1bf9-95db-4480-8e3e-452f51e53ed3">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU4_6b8728cf-e9d5-4fd9-b825-5c1fba14cbfc">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September 30, 2022 and 2021, intangible impairment assessments indicated that there was no impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NjE_9825197a-c701-4ca4-b710-48f9e4118731"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NjE_d637f8d7-31af-4484-868c-1ba2835a89e6"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzMyOTg1MzUwMTM3NzE_42ea4cf8-ea50-4953-b8a4-00fe4303af00">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are &lt;/span&gt;&lt;/div&gt;recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term minus the present value of any incentives, rebates or abatement expected to be received from the lessor. The Company did not include the extension option in the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <arwr:ContingentConsiderationPolicyPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU0_afbc55f5-af6f-4f24-b2f2-7d248c605872">Contingent ConsiderationThe consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. The Company determined the fair value of its contingent consideration obligation to be $0 at September&#160;30, 2022 and 2021.</arwr:ContingentConsiderationPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE2OTg4_5eda82fe-0d96-497a-a8a8-32880a74bf8e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzE2OTg4_b2f0c1af-d86f-43d6-8be0-bf45f996dfb0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODU5_c4687a50-9607-468b-b052-8c2624ead6ba">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2018, the Company adopted Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 606 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue for Contracts from Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#x2019;s adoption of the revenue standard did not have a material impact on its Consolidated Financial Statements. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its ongoing licensing and collaboration agreements. See Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ1_367aa5ca-3539-44f2-9735-6fb8f7e82535">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of FASB Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, &lt;/span&gt;&lt;/div&gt;the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ2_cf3ca8c2-7dbb-4efd-a4f6-3e4ff9262e7a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUw_aa366b1c-6e93-4703-bef6-b112dcc87529">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. &lt;/span&gt;&lt;/div&gt;During the years ended September&#160;30, 2022, 2021 and 2020, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ3_923b5d1d-6d7b-4018-b24d-a4244a853d74">Stock-Based CompensationShare-based compensation expenses for all grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODQ4_efa74e9b-6aaa-4051-bfb8-1416ef6a4be2">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xMzkvZnJhZzo3ZDYxNDAwNTBhYjQ0YjllYjVlYmFkNGNmMzA5Yzg4ZC90ZXh0cmVnaW9uOjdkNjE0MDA1MGFiNDRiOWViNWViYWQ0Y2YzMDljODhkXzM2ODUy_eb4bde2a-fb08-42df-aa4b-b075d8f65af9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update 2019-12, I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ncome Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminates certain exceptions related to the incremental approach for intra-period allocation, deferred tax recognition requirement for changes in equity method investments and foreign subsidiaries, and methodology for calculating income taxes in an interim period. The guidance also simplifies certain aspects of the accounting for franchise taxes, the accounting for step-up in the tax basis of goodwill, and accounting for change in tax laws or rates. The Company adopted the new standard which became effective for fiscal years and interim periods within those years that begin after December 15, 2020. The adoption of the new standard did not have any material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzE0MzMy_bc0bbfdf-7c58-4c27-bdd7-407fb8de1a7d">COLLABORATION AND LICENSE AGREEMENTSGlaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;). Under the GSK License Agreement, GSK has received an exclusive license for ARO-HSD. The exclusive license is worldwide with the exception of greater China, for which the Company retained rights to develop and commercialize ARO-HSD. The Company has completed its Phase 1/2 study of ARO-HSD, and GSK is now wholly responsible for all clinical development and commercialization of ARO-HSD in its territory. Under the terms of the agreement, the Company has received an upfront payment of $120.0 million and is eligible for additional payments of $30.0 million at the start of Phase 2 and $100.0 million upon achieving  a successful Phase 2 trial readout and the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial readout positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibility to complete the Phase 1/2 study, (the &#x201c;GSK R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of the GSK R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the GSK R&amp;amp;D Services, which are the responsibility of the Company, GSK will be responsible for managing future clinical development and commercialization in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the initial transaction price totaled $120.0&#160;million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-HSD license and the associated GSK R&amp;amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0&#160;million was fully recognized as of September&#160;30, 2022. There were $0 in contract assets recorded as accounts receivable and $0 in contract liabilities recorded as deferred revenue as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has also performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $4.8&#160;million in connection with these efforts for the year ended September&#160;30, 2022. There were $4.8&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for ARO-XDH, a previously undisclosed discovery-stage investigational RNAi therapeutic being developed by the Company as a potential treatment for people with uncontrolled gout. The Company conducted all activities through the preclinical stages of development of ARO-XDH, and Horizon is now wholly responsible for clinical development and commercialization of ARO-XDH. In July 2021, the Company received &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$40.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as an upfront payment and is eligible to receive up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$660.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in potential development, regulatory and sales milestones. The Company is also eligible to receive royalties in the low- to mid-teens range on net product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of ARO-XDH (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of ARO-XDH. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the initial transaction price totaled $40.0 million, including the upfront payment. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocates the total $40.0 million initial transaction price to its one distinct performance obligation for the ARO-XDH license and the associated Horizon R&amp;amp;D Services. Revenue is recognized on a straight-line basis over the estimated timeframe for completing the Horizon R&amp;amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts will be expended evenly over the course of completing its performance obligation. Revenue for the years ended September 30, 2022 and 2021 were $26.7&#160;million and $6.7&#160;million, respectively. There were $0 in contract assets recorded as accounts receivable and $6.7&#160;million in contract liabilities recorded as deferred revenue as of September 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $2.5&#160;million and $0 in connection with these efforts for the years ended September&#160;30, 2022 and 2021, respectively. There were $1.3&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop its ARO-AAT program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit sharing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda will lead the global commercialization strategy and will receive an exclusive license to commercialize ARO-AAT, while the Company will be eligible to receive tiered royalties of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on net sales. In &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$300.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $595.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the initial transaction price totaled $300.0&#160;million, which includes the upfront payment. The Company has excluded any future milestones or royalties from this transaction price to date. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;amp;D Services. Revenue is recognized using a proportional performance method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company recognized $85.8&#160;million and $90.8&#160;million in connection with these efforts for the years ended September 30, 2022 and 2021, respectively. There were $0 of contract assets recorded as accounts receivable and $123.4 million of contract liabilities recorded as deferred revenue, of which $67.4&#160;million was classified as current deferred revenue, as of September&#160;30, 2022. The Company also recorded $8.6&#160;million as accrued expenses that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, and the Company entered into a License Agreement (the &#x201c;Janssen License Agreement&#x201d;) and a Research Collaboration and Option Agreement (the &#x201c;Janssen Collaboration Agreement&#x201d;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#x201c;JJDC&#x201d;), Johnson &amp;amp; Johnson's venture capital arm (&#x201c;JJDC Stock Purchase Agreement&#x201d;). Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989 (ARO-HBV). Under the Janssen Collaboration Agreement, Janssen was able to select three new targets against which the Company would develop clinical candidates. These candidates were subject to certain restrictions and did not include candidates that already were in the Company&#x2019;s pipeline. The Company was obligated to perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, would have been sufficient to allow the filing of a U.S. Investigational New Drug Application (&#x201c;IND&#x201d;) or equivalent, at which time Janssen would have the option to take an exclusive license. If the option was exercised, Janssen would have been wholly responsible for clinical development and commercialization of each optioned candidate. Under the terms of the agreements taken together, the Company has received $175.0 million as an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upfront payment, $75.0 million in the form of an equity investment by JJDC in the Company&#x2019;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $1.6&#160;billion in development and sales milestone payments for the Janssen License Agreement, and up to $0.6&#160;billion in development and sales milestone payments for the remaining target covered under the Janssen Collaboration Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement. During 2022, Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of Janssen License Agreement and Janssen Collaboration Agreement, the Company identified one distinct performance obligation. Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. The Company also determined that Janssen&#x2019;s option to require the Company to develop up to three new targets is not a material right and, thus, not a performance obligation at the onset of the agreement. The consideration for this option is accounted for separately. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989 (ARO-HBV), and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services. The Company has recognized this transaction price in its entirety as of September 30, 2021, as its performance obligations were substantially completed. Future milestones and royalties achieved will be recognized in their entirety when earned. There were no contract assets and liabilities recorded as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has conducted its discovery, optimization and preclinical research and development of JNJ-75220795 (ARO-JNJ1), ARO-JNJ2, and ARO-JNJ3 under the Janssen Collaboration Agreement. All costs and labor hours spent by the Company have been entirely funded by Janssen. Janssen&#x2019;s option period expired unexercised for two of the three candidates (ARO-JNJ2 and ARO-JNJ3) under the Janssen Collaboration Agreement during 2022. In May 2021, Janssen exercised its option right for JNJ-75220795 (ARO-JNJ1), which resulted in a $10.0&#160;million milestone payment to the Company. This $10.0&#160;million milestone payment was recognized entirely as of September 30, 2021. The Company recognized $3.4&#160;million and $0.5&#160;million of revenue associated with these efforts during September&#160;30, 2022 and 2021, respectively. There were $0.1&#160;million of contract assets recorded as accounts receivable and $0 of contract liabilities recorded as current deferred revenue as of September&#160;30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen has received a worldwide, exclusive license to the Company&#x2019;s novel RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the prior collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license to ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under both agreements, Amgen is wholly responsible for clinical development and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Olpasiran Agreement and the ARO-AMG1 Agreement, the Company has received $35.0&#160;million in upfront payments, $21.5&#160;million in the form of an equity investment by Amgen in the Company&#x2019;s common stock, and $30.0&#160;million in milestone payments, and may receive up to an additional $400.0&#160;million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. The Company has substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement. In July 2020, Amgen initiated a Phase 2 clinical study of Olpasiran, which resulted in a $20.0&#160;million milestone payment to the Company. There were no revenue recorded associated with the Company&#x2019;s agreement with Amgen for the years ended September 30, 2022 and 2021. There were no contract assets and liabilities recorded as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#x201c;Visirna License Agreement&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#x2019;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#x201c;Visirna SPA&#x201d;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#x2019;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <arwr:MilestonePaymentEarned
      contextRef="i239542cd95804d368929cbe8296c90bf_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1NjY_c24beca8-f1cb-4d6d-89fb-45a990df65f5"
      unitRef="usd">120000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentReceivableAtStartOfPhaseTwo
      contextRef="i239542cd95804d368929cbe8296c90bf_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1OTU_9fe64b6c-fc95-4491-bd86-7854cbb661fb"
      unitRef="usd">30000000</arwr:MilestonePaymentReceivableAtStartOfPhaseTwo>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree
      contextRef="i239542cd95804d368929cbe8296c90bf_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg1ODE_34f7a129-d89c-4101-b351-0b7373bf5500"
      unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale
      contextRef="ia4b56dc494ac43218654da036bf8f658_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg2MTA_9821f96b-7d42-40d5-ad89-55c1f4dd63a6"
      unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments
      contextRef="ia4b56dc494ac43218654da036bf8f658_I20211122"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwODg2MjU_b69e3203-fd99-4d89-837b-84b63e1e6bf3"
      unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:InitialTransactionPrice
      contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2MjQ_8c8b8a53-3ae3-4c92-a931-c05ce961639d"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NTQ_8c8b8a53-3ae3-4c92-a931-c05ce961639d"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i63738435aba549e9813b380730f41e49_D20211122-20211122"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2Nzk_8c8b8a53-3ae3-4c92-a931-c05ce961639d"
      unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i2326885925904bb9bbf356f129cc9a0b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NTc_55427bb7-389f-4e38-b248-98f8d2b76d29"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2326885925904bb9bbf356f129cc9a0b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2NjE_9b9c489b-f1bb-4e41-8068-88c17cace649"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7692cd01c9aa41649a62cbfade2efe6f_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMDg_028b4b21-0712-4b3c-b0ff-d3ba085c6bed"
      unitRef="usd">4800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i9e25f65ec4394c019914b93112fd60a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5OTA_6f662bec-e8c0-4524-b798-004c4052ba01"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9e25f65ec4394c019914b93112fd60a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMDQ_6948b759-9819-4365-941d-1ed55f40932c"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i5afacc79e97d47baba530c5a7adb3b40_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTA5NzY_c12883eb-7546-4827-9761-fb082ce101aa"
      unitRef="usd">40000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="id0ca7c57f3904478a1cd7317601e0d4e_I20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTA5OTE_67077e2d-1c04-447b-b09c-879d3acf3b06"
      unitRef="usd">660000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTE4ODY_4561850a-dc9b-45e8-82ef-83bd88ebf0c2"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="icc5c56ca344a41b3aff1f08e6a787ef6_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTE5MTc_cd557f98-c4ce-4ae7-8958-b722aec98e21"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTIxODg_911a2c66-f470-44b3-b12a-9bf6435d7d9a"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4ODg_911a2c66-f470-44b3-b12a-9bf6435d7d9a"
      unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="if3138c853e8a455f9a77625afebd539e_D20210618-20210618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4OTA_50092fe9-9883-46dd-b157-8f22b1e2f5c1"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dd0a2669a28454588c20d1c395a052a_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4OTk_9e43d2b4-47ef-43cb-a9fb-ea93c0a40b9b"
      unitRef="usd">26700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3bde044abb649a48ecd1191afb3f05d_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5MTQ_51f50bd1-ae93-4ecb-b3c8-653b634e4ee5"
      unitRef="usd">6700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5Mjg_3d6de71b-ce1c-462f-a073-a4fc12feb84e"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4ffb47ec591c4813b13d6fb7fac4ba95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NDA_79c3e286-6eac-42e8-a119-2e06d27c35dd"
      unitRef="usd">6700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0019512decda4b7990aafbc1a7e248d0_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NTQ_48eaccf5-9ffa-4f6a-844b-2c422403ea1d"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0949381581ff4af3b82881ca7e331bf6_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5Njg_e20c668d-9766-4bc5-b65f-fd12f710b33f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i0c37b9188bae4800a6595d3418a0fae6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5NzI_6df57a52-0030-4416-9788-5585149d2811"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0c37b9188bae4800a6595d3418a0fae6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg5ODY_a5d635bf-3c70-439d-b5d9-c1d0255855e3"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="i17e4962b3a1642f3aa8710b99691c60d_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4NjA_793ddf47-0212-4790-9bee-964207a15d03"
      unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="i2fe6b533bcf74101bd5976bd6846dd09_D20201007-20201007"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4NjY_7a427e9f-f071-4cd2-a877-47ab46f39015"
      unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="i8ef38d1d9fc4434fadb646e8a3dfeb79_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTI4OTg_91c4f052-dc4e-4152-8cd5-3353439a8a9a"
      unitRef="usd">300000000</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i871d9ae6597e4d0d95bc94bb785a706d_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2ODI_33263781-ff11-4e26-b8d8-ba9d6d928e72"
      unitRef="usd">595000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MTU_d5296387-20c9-4bde-8ab6-b8c7c5de794a"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MjM_2d321ee0-1c60-40f7-abad-89bae5b996d3"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg2OTg_11fd96a7-f418-473a-a8c6-3af8d081a8c9"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice
      contextRef="i0099c77fa04444af9ec33cf2f5b03bf8_D20201007-20201007"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3Mjg_11fd96a7-f418-473a-a8c6-3af8d081a8c9"
      unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86729ae38276427b8f27b306b25909e2_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3MzE_b3e373e7-deb4-49c9-a3fc-be7ddd5c9bd4"
      unitRef="usd">85800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie544bcf5262b43bc9e9b768016c61906_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NDY_6bf72373-6908-46b3-9eb8-e3223b3d662b"
      unitRef="usd">90800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i05164f990274472cb23e6e2da5920f02_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NjE_c23ba1f7-7591-4743-ad35-cb75e984fbe6"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id93baee844644d37b56a5574a3dfc2c8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3NzM_4e75a90f-f754-4ad8-a919-37ccb1f84692"
      unitRef="usd">123400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id93baee844644d37b56a5574a3dfc2c8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3ODE_bc095c67-99a3-447b-a8a7-799cf8937293"
      unitRef="usd">67400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6f1d06f484244cafbb6712b67dd5e5c7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg3OTY_5b93eaf8-9848-4158-8a4a-634d93571bf1"
      unitRef="usd">8600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="ibb795196cbc24edfafc6f4b579915985_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTY0OTI_6c5f6515-bf54-4af7-a4cf-4000166a5dde"
      unitRef="usd">175000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic0868f45959c4a9083e418da9c188745_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkwOTY1MDg_da92400b-86ed-48d2-ad17-a54dd3c9f638"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="i37b7661cd1834368bdbc8265bf19edd4_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4MzI_46cc016b-5f66-48ba-ae83-f328aed98fa8"
      unitRef="usd">73000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i5e3ffe024b534c88b962b31bde7d7c6a_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4NDc_0eebb63a-8103-4273-a5d8-76dcae7fab59"
      unitRef="usd">1600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="idc323ba26f8a48859fcb26ec988dac7d_I20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTg4NjE_375daae3-4e2e-481a-9353-6ff4e28a531c"
      unitRef="usd">600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="iccd2623ae6e34732b7abc8fb92562252_D20181003-20181003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTYxOTk_46530fa8-5702-4766-b7e8-67eec7a87cba"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTcyMDI_c5eeace3-fb4d-4c45-855d-4be79d998734"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="if21f342da4904bf7a53c62826f1b14b5_I20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTczMTQ_8f382736-021b-4bf2-a9c1-cd7331b5cb20"
      unitRef="usd">25000000</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="i4055ff1cb13f4faa9503eca6f2a8118e_D20181003-20181003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzI3NDg3NzkxMTc0ODI_5da08bb5-e002-4bd3-b22f-16a3fd8686d2"
      unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMjE_159dbbcc-f78f-4310-bf29-f19262ab3e43"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ic65f0bd0ec10437e928f8b5bf095f31d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMjE_8960cfe2-9fcb-416d-a596-52416eaa5512"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:MilestonePaymentEarned
      contextRef="ia5534ed7a218413bac198deed25bcfc0_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzY2MTI3_6a4ac7ea-2069-404c-98e2-b8901bdb3ace"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <arwr:MilestonePaymentEarned
      contextRef="i04804bc83aae49eeb388934d6474807c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzY2MTIz_47e84311-3ec2-4be4-8117-58db97e7b6c2"
      unitRef="usd">10000000</arwr:MilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadad9a7e9ae24932ba60d057d20788cd_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwMzA_3c14f648-2a38-48ba-a9f3-49bb83b8a09c"
      unitRef="usd">3400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36ca4cce11534def83440361284f2151_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNDQ_b6b6831c-2e3a-4358-921a-a9f39f9fdc28"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5f50957118724116aade42a087a6e5f4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNTg_742c2f49-c342-421f-919a-abab1b34cc8e"
      unitRef="usd">100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5f50957118724116aade42a087a6e5f4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkwNzI_a76bc793-177a-46ca-ad27-1ee778bf502f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:NumberOfAgreements
      contextRef="id8f6a7cc3aa148ba86425faae6df475a_I20160928"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxMDM_850e597e-47c0-4079-97d3-d4285ab846c9"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMDU_bea83525-c46a-41c6-bf78-0b78a1926299"
      unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if74e4e59c845466cbb516e26ede08adc_D20160928-20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMjA_1e25fb81-f745-471a-a642-9c21be6091c1"
      unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="i8fddaa78aa9e4413be71a69a9e690ee6_I20160928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyMzU_82519a32-4baf-4fea-93e7-2aa0a591dc7f"
      unitRef="usd">30000000</arwr:MilestonePaymentReceived>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="i00c0415f2ff94135b02ad71902b05a2b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyNTA_1e26aa0a-c7a3-45ef-a60c-4c8dfb2bdabb"
      unitRef="usd">400000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:MilestonePaymentReceived
      contextRef="ie72f2076c3c244c595b91d7c4fc96de6_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxNzM_f715b1a2-99b1-4e55-838d-7262fe2b803d"
      unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbbbc50aed91458f9e1cd5ca2b297e7f_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODc_85651699-4b63-46c9-a82b-340afd728ef4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2396a0b95284dc1b37555872c67d544_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODc_8ea67638-16f6-4ecc-a3df-2f8c3fee8402"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODg_24d7ea4b-3d19-4905-9f38-bf3207ca6890"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i14130fa05d0a4ad0a0bb52ac390a1e0d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkxODg_cdfa7461-d31a-4bae-9abc-306b5d974c30"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="i885b30b505e24a9f94b50732d67bf577_D20220425-20220425"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNDUvZnJhZzo0OWJkOWIxMWRmY2Y0NGU2OTE5NmE3ZDVlNGFkNDkwMS90ZXh0cmVnaW9uOjQ5YmQ5YjExZGZjZjQ0ZTY5MTk2YTdkNWU0YWQ0OTAxXzkzNDU4NDg4OTkyNjY_58d91809-c919-4749-9483-933f1631b325"
      unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI1Ng_1049f01d-6a26-45be-85ce-6eefed95c446">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers, software, office equipment and furniture &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2022, 2021, and 2020 was $8.7 million, $6.6 million and $4.2 million respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in the construction in progress during 2022 was mainly due to the developments of manufacturing, laboratory and office facilities in Verona, Wisconsin as well as a new laboratory and office facility in San Diego, California. See Note 7.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI1Nw_1cf0722c-d15a-4810-84c1-d0a1a719b558">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers, software, office equipment and furniture &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzItMS0xLTEtODcyMA_fabc4277-2832-44d6-b4a6-21444d61dd26"
      unitRef="usd">2182000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzItMy0xLTEtODcyMA_99e75460-6a05-47bb-8dba-5a473952cf86"
      unitRef="usd">2170000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:Land
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMS0xLTEtMTE5MzA_df5088df-1825-42fb-8e82-8afe55851d2e"
      unitRef="usd">2996000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMy0xLTEtMTE5MzI_5ab12957-0beb-41ef-b17a-15d2ab8d7ca9"
      unitRef="usd">0</us-gaap:Land>
    <arwr:ResearchEquipmentGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzMtMS0xLTEtODcyMA_5721ec5b-224d-47f5-9a7a-6db8bb36ca47"
      unitRef="usd">38283000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzMtMy0xLTEtODcyMA_5d2f5323-adeb-4c3d-a64c-97b2bd9aa514"
      unitRef="usd">27500000</arwr:ResearchEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMS0xLTEtODcyMA_eb0d097b-cdda-41ea-ba9f-80be114bfc45"
      unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzQtMy0xLTEtODcyMA_890ff271-b40a-4dfe-be1e-030bc6bb1e41"
      unitRef="usd">41524000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzUtMS0xLTEtODcyMA_5a9d42eb-357e-46bf-b120-3afe000b7d61"
      unitRef="usd">56373000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzUtMy0xLTEtODcyMA_312e9eff-1ee3-4109-86b4-c8b1f06b8b64"
      unitRef="usd">345000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzYtMS0xLTEtODcyMA_e9a7dac3-6d37-40f2-b637-8ebe441d9d05"
      unitRef="usd">141851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzYtMy0xLTEtODcyMA_48504903-7594-4131-8362-a68e474888a0"
      unitRef="usd">71539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzctMS0xLTEtODcyMA_040c5674-c93d-4be7-a33c-620fe520f37b"
      unitRef="usd">31554000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzctMy0xLTEtODcyMA_937d52e9-977a-4a79-aa03-b7cf875fd9f5"
      unitRef="usd">22864000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzgtMS0xLTEtODcyMA_fc1d37a0-550e-4a00-88fb-c9de9bd4aac7"
      unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90YWJsZTo1ODJlOGUyMGMzNTM0Y2FmOGY0ZmIyOGJmMTUyMGI0NS90YWJsZXJhbmdlOjU4MmU4ZTIwYzM1MzRjYWY4ZjRmYjI4YmYxNTIwYjQ1XzgtMy0xLTEtODcyMA_66a69ffa-c4b3-464c-9bc8-a2b03e678352"
      unitRef="usd">48675000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzIyOQ_3f94b908-8112-40d1-ab27-6af7f4daa3e8"
      unitRef="usd">8700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzIzMw_e7e4c56b-9b33-4446-afba-3b017d6e80fc"
      unitRef="usd">6600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTEvZnJhZzo4NjQyMWM3NWU2Y2I0N2NiYmE2ZjQ4ODA1MmMzMjRjZS90ZXh0cmVnaW9uOjg2NDIxYzc1ZTZjYjQ3Y2JiYTZmNDg4MDUyYzMyNGNlXzI0MA_d682fcf5-031f-42cc-bd0c-9efb585ef8bb"
      unitRef="usd">4200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90ZXh0cmVnaW9uOjg2MzBlYjFlOWJlMTQ5ZGQ4MWQ4ZTJiYzcyZDkyMjIyXzEzMTI_a554a1ac-8c5e-4a53-a614-cb6f8a2060bf">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity certifiate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90ZXh0cmVnaW9uOjg2MzBlYjFlOWJlMTQ5ZGQ4MWQ4ZTJiYzcyZDkyMjIyXzEzMTM_05c6192c-12c5-4659-802e-4a1ab6e0d3c6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity certifiate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held to maturity certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;246,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtMS0xLTEtMTIxMjc_43977965-2b63-404c-8aee-15752569dabd"
      unitRef="usd">218391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtMy0xLTEtMTIxMjc_dabc9d77-6b0a-4bbe-ae8f-c5b4d31eeb3a"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtNS0xLTEtMTIxMjc_70397efb-12ac-416a-8bdc-0551820f385a"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzUtNy0xLTEtMTIxMjc_cc4b9a82-ba91-426d-a431-4503dd3b4126"
      unitRef="usd">214730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtMS0xLTEtMTIxMjc_f0285747-d8b2-4205-8eda-bbb5755dd62d"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtMy0xLTEtMTIxMjc_9de822f4-bf6e-4c16-8d63-a2c9ee7a5d19"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtNS0xLTEtMTIxMjc_e7e7a428-3708-4f58-8283-46fc54140ba4"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="ie44ad6fc7f3048128d384a807baf8f9f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzYtNy0xLTEtMTIxMjc_8c07a0c1-a56e-4afb-8fb1-4b629170dc9b"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctMS0xLTEtMTIxMjc_f49b7bf0-1704-45dd-b767-3caaf84a0fbb"
      unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctMy0xLTEtMTIxMjc_6b9033f0-6f09-4601-8a5b-42abdd830d73"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctNS0xLTEtMTIxMjc_a584e4cf-1a6c-4e51-bde3-bbcb519a343b"
      unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzctNy0xLTEtMTIxMjc_179a018c-b3ae-4aeb-9c5d-9336f5f23610"
      unitRef="usd">264730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTEtMS0xLTEyMTI3_73170470-8641-4af6-9cd6-439b698ddc10"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTMtMS0xLTEyMTI3_2e15d977-211a-48d7-820b-c97a2e1364f4"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTUtMS0xLTEyMTI3_f57fb093-a780-46fb-855b-c31b802239fd"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="ica7aa5158d8a4572841de66b301948f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEwLTctMS0xLTEyMTI3_98cfebaa-bf4e-4fbf-be1d-62009b07ebd8"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTEtMS0xLTEyMTI3_b9e3afbb-4df4-4485-9a7d-d42ce2fc58b4"
      unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTMtMS0xLTEyMTI3_a3cf0f36-dfea-4471-8ddd-251494b9513b"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTUtMS0xLTEyMTI3_e2598e2c-10e2-49d3-902f-eb2c099d110b"
      unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzExLTctMS0xLTEyMTI3_a0b556a7-167f-4ba5-ada0-d42fac41b4f2"
      unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTEtMS0xLTEyMTI3_b283e30c-af58-4b3d-84c7-c2773a295ff9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTMtMS0xLTEyMTI3_f0f5423f-3ee3-48c5-8daf-c6f80b9b5339"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTUtMS0xLTEyMTI3_0874ffc4-2bd7-462f-a2a8-aaa47e20abd5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZTo0YmY3YTUyMTljNTE0M2ZkYmE2ZWRlYzliYjllZTMxOC90YWJsZXJhbmdlOjRiZjdhNTIxOWM1MTQzZmRiYTZlZGVjOWJiOWVlMzE4XzEzLTctMS0xLTEyMTI3_32ade154-fb79-4b8a-a500-776fdc168cbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtMS0xLTEtMTIxNjg_fa06cfa5-7939-4683-ac6a-1293f73af2ec"
      unitRef="usd">56627000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtMy0xLTEtMTIxNjg_96b1f13c-3132-4532-9433-d8e0ae2d8f11"
      unitRef="usd">803000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtNS0xLTEtMTIxNjg_bb901f27-7a7f-479c-a294-bb14c3623133"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzUtNy0xLTEtMTIxNjg_17f94eb9-c018-444e-9c82-5ccb606970d5"
      unitRef="usd">57430000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtMS0xLTEtMTIxNjg_694a1296-74b5-4b4b-9d3b-7dfecd92de23"
      unitRef="usd">56627000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtMy0xLTEtMTIxNjg_2b17eefc-0fca-4ba1-950a-1804309fd009"
      unitRef="usd">803000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtNS0xLTEtMTIxNjg_93c564d8-e1ee-4568-9b3f-43edf0e27c9f"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzYtNy0xLTEtMTIxNjg_c5ece433-3553-47c8-83f2-db0cb2c8a119"
      unitRef="usd">57430000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktMS0xLTEtMTIxNjg_6695839a-d106-44b6-92ac-9b7f75a4d297"
      unitRef="usd">195595000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktMy0xLTEtMTIxNjg_44612bc8-1340-4e51-8efc-51861b09456f"
      unitRef="usd">1151000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktNS0xLTEtMTIxNjg_8eb514af-0520-4d49-ac21-aaf7e589ae4c"
      unitRef="usd">103000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="ib50cf07473c341bb83c937e0734c6bf8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzktNy0xLTEtMTIxNjg_316f6c62-61dd-4c6a-914b-7a3a15ca2994"
      unitRef="usd">196643000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTEtMS0xLTEyMTY4_1f380e3c-c9ec-49be-9595-64beaf51defa"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTMtMS0xLTEyMTY4_c86c8096-9c59-40d6-9ac8-1a9c073fd248"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTUtMS0xLTEyMTY4_de619fe2-e3f0-4210-bd59-517c34924c58"
      unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="iddebd9cc23f2403f9d2fbe55c2d5de8b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEwLTctMS0xLTEyMTY4_2b84f27b-ef2d-4ab6-ad16-37052e51ae4d"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTEtMS0xLTEyMTY4_38edee3e-8de6-4ea4-a851-900834f2149e"
      unitRef="usd">245595000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTMtMS0xLTEyMTY4_c04a0fef-4944-404d-97c4-d6f7c5f2c04f"
      unitRef="usd">1151000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTUtMS0xLTEyMTY4_2d0a722e-cc4e-4b60-8fca-6c368a5edc0a"
      unitRef="usd">103000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzExLTctMS0xLTEyMTY4_b483f3e9-3b37-45cf-bf4b-806ede27cde1"
      unitRef="usd">246643000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTEtMS0xLTEyMTY4_10e176d9-0908-4102-95bb-aac4d8b78c2d"
      unitRef="usd">127481000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTMtMS0xLTEyMTY4_8b271b70-d3af-4f74-8917-fa656634dfef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTUtMS0xLTEyMTY4_ffe24d12-5fc2-4325-b525-02947adec9bb"
      unitRef="usd">753000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTQvZnJhZzo4NjMwZWIxZTliZTE0OWRkODFkOGUyYmM3MmQ5MjIyMi90YWJsZToyYzg4MTZkM2Q3Njc0ZmY1OWU5YTVmOTcwYWI0NzU1Yi90YWJsZXJhbmdlOjJjODgxNmQzZDc2NzRmZjU5ZTlhNWY5NzBhYjQ3NTViXzEzLTctMS0xLTEyMTY4_9f4b29fb-3d07-4824-88af-23af30efe329"
      unitRef="usd">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzkxMQ_2c286b2b-94a5-44f2-bf96-b7fd52a292fd">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible asset: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2022, 2021, and 2020 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzMyOTg1MzQ4ODYzMzk_ade54a8b-f9f9-43a8-adcf-1d9caad86122">The following table presents the components of intangible asset: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(amounts in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtMS0xLTEtMTMwMDg_d276faf8-47a6-43cc-ba83-87b6128056bc"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtMy0xLTEtMTMwMDg_270e87e7-6999-4d6a-9dd3-5aa4966cb560"
      unitRef="usd">11770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtNS0xLTEtMTMwMDg_50120928-10f9-4bdc-85d3-f3968f758d82"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f89654b9f74474292d999d71129a6fc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtNy0xLTEtMTMwMDg_ec4f986d-6ef7-419f-a756-a2ff4898ee3a"
      unitRef="usd">9958000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i58d9cb60633a4c7ba224716bf2e67384_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzMtOS0xLTEtMTMwMDg_0e00b322-62ca-449a-96af-579ce2670bf7">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtMS0xLTEtMTMwMDg_5af63f96-0dd4-4407-988c-29d1bf607629"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtMy0xLTEtMTMwMDg_83da24af-b40f-4d4b-9395-e708b7e810a7"
      unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtNS0xLTEtMTMwMDg_50e4e09e-67d5-41e5-b4ae-d8bf2333f7da"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib1623ebd76b9429f91c1adfbae86766c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtNy0xLTEtMTMwMDg_da8a1866-81ca-41d4-a824-3c396808e745"
      unitRef="usd">2004000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5b16903a80c34cbebbaa904142f4545d_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzQtOS0xLTEtMTMwMDg_ebb60600-e9bb-43a4-988b-18c482f1ec71">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtMS0xLTEtMTMwMDg_228865e4-8868-4893-9df7-16beabdc89ea"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtMy0xLTEtMTMwMDg_43677e23-949e-4243-b4a8-a6ba862494ca"
      unitRef="usd">12895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtNS0xLTEtMTMwMDg_e38cec87-e19f-493a-8ab9-553d54bb87f0"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic4ec44177d044f55bd6f14baa4539fa4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzUtNy0xLTEtMTMwMDg_792020e4-6083-4a60-a57b-434a26d592ce"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic2217a769eda4c6f894237f46441005d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtMS0xLTEtMTMwMDg_3331e100-ecce-46a8-bf60-632e3f5f0fe0"
      unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic2217a769eda4c6f894237f46441005d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtMy0xLTEtMTMwMDg_dcf1c490-ae0e-4e21-ba8c-9730698df1bf"
      unitRef="usd">10217000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="ic2217a769eda4c6f894237f46441005d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtNS0xLTEtMTMwMDg_0135cb14-4f37-4d72-86ed-e4611d6d2a7c"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2217a769eda4c6f894237f46441005d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtNy0xLTEtMTMwMDg_cab6fcd7-4055-47c9-aefe-85b923e58b54"
      unitRef="usd">11511000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3b02e88c51804f51b4b08d70e9573b4f_D20201001-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzgtOS0xLTEtMTMwMDg_638e6f9f-72b3-488a-8b61-0abf0f645c5d">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktMS0xLTEtMTMwMDg_bb8df758-db04-4b7f-8d0d-913e2c54e00c"
      unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktMy0xLTEtMTMwMDg_2d7f73d0-6564-47ef-bc30-5ea7a4afc9a1"
      unitRef="usd">977000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktNS0xLTEtMTMwMDg_f826560d-44d2-438a-99fc-fefa8bc2315e"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iff24be97ac644b7db7e5782fc8875f11_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktNy0xLTEtMTMwMDg_40f46b5e-eec2-4121-b344-86871111cd1f"
      unitRef="usd">2152000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9ba50d541c9b45b1a0b65b7a3bc2d634_D20201001-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzktOS0xLTEtMTMwMDg_13d1e8ad-a5dd-4d31-b710-699765c81fe9">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTEtMS0xLTEzMDA4_e5ccf3ea-614f-489c-978f-46bebfddce41"
      unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTMtMS0xLTEzMDA4_2744f313-4f98-49e7-bdad-5663daa4e58d"
      unitRef="usd">11194000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment
      contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTUtMS0xLTEzMDA4_b89eb183-ea79-4454-8b33-4d929940d73c"
      unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a14a234b0c64f3db010016f3e349b47_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTpmZTBjYWU3ZjIxNzc0OWFjOTg0MzM5MzMxNzc5ZGZjNS90YWJsZXJhbmdlOmZlMGNhZTdmMjE3NzQ5YWM5ODQzMzkzMzE3NzlkZmM1XzEwLTctMS0xLTEzMDA4_fbc353e9-74cc-43d6-87ed-3b8a6fccc57b"
      unitRef="usd">13663000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_6c9b3826-942e-4750-a5aa-c401dba58847"
      unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_a878774b-b823-49ca-a05b-9244d3484248"
      unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzIxOTkwMjMyNTc1MDk_e06e0753-4f85-4f3a-94aa-6dc6b3d2e9d2"
      unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90ZXh0cmVnaW9uOjQ3MmU5YzA4ZmRhMzRkNWU5MDg4MTk0ODMxMTk0NTJlXzMyOTg1MzQ4ODYzMzg_e1e46fe4-bc72-4866-882e-6e021adbf807">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzMtMi0xLTEtMTMyMzM_d3f6a374-e1f8-4db4-a23a-499373299022"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzQtMi0xLTEtMTMyMzM_ef737378-112a-47b6-83e8-9cb5e0ad750d"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzUtMi0xLTEtMTMyMzM_09d53972-6fe9-466f-b99b-dec10c7fb45c"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzYtMi0xLTEtMTMyMzM_09898828-10dc-4887-9cb2-51c240b72e54"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzctMi0xLTEtMTMyMzM_790cb2ca-83e3-474c-92b8-3b372287d330"
      unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzgtMi0xLTEtMTMyMzM_89954f59-9f6f-4e78-9754-a88054ee3e00"
      unitRef="usd">3462000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNTcvZnJhZzo0NzJlOWMwOGZkYTM0ZDVlOTA4ODE5NDgzMTE5NDUyZS90YWJsZTphMmI1ZmU1MGE3ZDk0MjUzYmQzZGNkYjE3NTdlYThhMS90YWJsZXJhbmdlOmEyYjVmZTUwYTdkOTQyNTNiZDNkY2RiMTc1N2VhOGExXzktMi0xLTEtMTMyMzM_ab394812-2b98-49af-be26-bf9ca34b2dd5"
      unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEzOTM_21099de8-0946-4e00-81d2-23edf580b58c">STOCKHOLDERS&#x2019; EQUITYThe following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,000,392 and 15,228,479 shares of common stock at September&#160;30, 2022 and 2021, respectively, were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;In August 2020, the Company entered into an Open Market Sale Agreement (the &#x201c;ATM Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September&#160;30, 2022, no shares have been issued under the ATM Agreement</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzMyOTg1MzQ4ODU2NjU_9653bb0f-4172-441a-a984-528526491ec5">The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMS0xLTEtMTMyNjQ_8f316c3b-4570-4b2c-96dc-6796afdcb459"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMi0xLTEtMTMyNjQ_c2a6156f-75f1-4ba6-9fe2-7ee214f5867d"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItMy0xLTEtMTMyNjQ_78dadb89-f1b8-45d4-8b8f-2ec2742cfcb6"
      unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzItNC0xLTEtMTMyNjQ_9ea06d60-46bd-4d32-b776-0b18fdacc6e4"
      unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMS0xLTEtMTMyNjQ_fa12398f-25b8-4a5e-99c8-91ca29d05afb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMi0xLTEtMTMyNjQ_208afa53-b355-49e8-b248-8428401086ed"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtMy0xLTEtMTMyNjQ_5a53ce25-616b-4c4e-983e-9e3d5cc52054"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzMtNC0xLTEtMTMyNjQ_b962158d-bf3b-4f25-91c2-23647eb3753f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMS0xLTEtMTMyNzI_b3c0507e-fa6d-4db5-abf4-f98cfae9ec40"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMi0xLTEtMTMyNzI_4fb23784-de89-4913-a533-7d265c6c1e4b"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctMy0xLTEtMTMyNzI_ff4713b3-4b2d-4eb9-b3a4-c9c3d7790525"
      unitRef="shares">104327000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzctNC0xLTEtMTMyNzI_aa8a3bea-2502-43c7-b042-e50ac92e6782"
      unitRef="shares">104327000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMS0xLTEtMTMyNzI_9b0d2b79-6fb7-4bd4-9e3f-8c53bcb5a44f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMi0xLTEtMTMyNzI_f49bbe4a-824c-4211-87de-2e078983fdd5"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtMy0xLTEtMTMyNzI_9c275814-fb2d-483e-994f-bb895d3cd077"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90YWJsZTo2ZjJmOTQ3MWJhNTk0MzI2OGRkMWFhMjc0ZTQ1OWViYS90YWJsZXJhbmdlOjZmMmY5NDcxYmE1OTQzMjY4ZGQxYWEyNzRlNDU5ZWJhXzgtNC0xLTEtMTMyNzI_0d6da3ac-ac94-48c9-9743-265257dd3fbe"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic4b2ef96e1ad4c0f884bfbb000ec421d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzIxOTkwMjMyNTc4NzQ_be7c5c0d-1e7e-4be0-80af-1bb834d560cc"
      unitRef="shares">14000392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i945e065f941c41089f590861be2be53b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzMwMg_307fbcf5-017f-4aca-ac5d-b1cdef23ded9"
      unitRef="shares">15228479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="i7df31e5a41964923a5bf827d1e46ccc8_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzc5OA_5ce1f4db-b555-4690-ba32-c6f0add824e2"
      unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="i81ad9b35ad9945e681373c342ced19be_D20200801-20200831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEwODA_71659253-9a73-4cc5-9072-d06812bd2f68"
      unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="ib800ee136c204f7ca7d6ef70fe9e6bd8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjAvZnJhZzphNzFkMGFlZDQ0NTk0ODBlODQ2ZmVhNWViN2YwNmNmYy90ZXh0cmVnaW9uOmE3MWQwYWVkNDQ1OTQ4MGU4NDZmZWE1ZWI3ZjA2Y2ZjXzEzNDM_efad2696-2c27-41ef-87e1-82410bc1e20a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzE2MTE_8baec2f6-82a3-42dd-aa7c-abb419be8056">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of the year ended September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#x2019;s process development and analytical activities. The Company intends to invest between $200.0&#160;million and $260.0&#160;million into the build out of the facilities. As part of this acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax incremental district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Incremental Financing program is not guaranteed and will depend on future tax revenues generated from the developed property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will also receive up to $2.5&#160;million of refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives to invest in the local community and create new jobs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Technology License Commitments&lt;/span&gt;&lt;/div&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company made milestone payments of $0, $2.4 million, $0 for the years ended September&#160;30, 2022, 2021, and 2020, respectively. The Company did not reach any milestones during the years of 2022 and 2020. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzM5Mg_db6facf2-584c-41af-b9e4-6a90dc8f5bef"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:NumberOfAcresOfLandPurchased
      contextRef="i7aec9e8e7c804df6bbe9ef108587e7e9_D20211220-20211220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MDY_da66640f-8dfd-4c07-82b9-890202084e25"
      unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand
      contextRef="i20b2347df25f44adb7fd8c6f8ab94841_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MTA_22f9bda9-c7d3-4500-bd91-aa73f2526616"
      unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="i10f071832c694c79898be3703116f022_I20211220"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3MTk_1c57ce23-8173-4f4d-b91e-1467e2680534"
      unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i598cccc6787b498eb6eeded5080d12fb_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3Mjg_327f3bd8-2d9c-43cd-aade-6bb032a80c88"
      unitRef="usd">200000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities
      contextRef="i98b23103c13b4614a1ee88bf196be447_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4ODg3NDI_8fe250f1-a357-4bbd-8b9f-8fead7c5dea4"
      unitRef="usd">260000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:TaxIncrementFinancingAward
      contextRef="ib1cbc59142a346ab848b67c243bece56_I20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4OTIzNDI_30bf06ad-0312-4702-bfbb-4fa8e207a080"
      unitRef="usd">16000000</arwr:TaxIncrementFinancingAward>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="id417cd70ff1e486fa32a39bf2ea4e409_D20211220-20211220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzMyOTg1MzQ4OTIzNTU_eb7d2f79-342a-4d51-ad0f-ef628159cfc1"
      unitRef="usd">2500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <arwr:MilestonePayments
      contextRef="i24d3f2b9861345109a3431f21d36390e_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjQ0Mzg_67f463b3-86cd-424d-a373-1277fa803e45"
      unitRef="usd">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="if70fc35468fb4978af2a43b1fceb0798_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjM5Njk_fffce75b-c1b5-48ca-afaf-b26772f3685c"
      unitRef="usd">2400000</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="ieee2e0cf0d164b389f68d128f6660757_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjMvZnJhZzozYmIxM2U4MjcwYjQ0NDNlOWI1MmRlZmYzMTNmNTY5Ni90ZXh0cmVnaW9uOjNiYjEzZTgyNzBiNDQ0M2U5YjUyZGVmZjMxM2Y1Njk2XzIxOTkwMjMyNjQ0MzM_0d10e6a3-01a5-4012-a374-21255dd1ba8c"
      unitRef="usd">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzQwNjk_2e342d87-7f71-461d-bb5c-01c75563f729">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company entered into a new 15-year lease for approximately 144,000 square feet of office and research and development laboratory space under construction in San Diego, California. This facility will replace the Company&#x2019;s current office and research facility sublease located in San Diego, California. The increased capacity of this new facility compared to the Company&#x2019;s current research facility in San Diego will accommodate increased personnel for its expanding pipeline of current and future drug candidates. The estimated rent commencement date for the new lease is in April 2023 after construction and leasehold improvements have been completed. The lease payments, which begin on the rent commencement date, will be approximately $119.0 million over the initial 15-year term. The Company also estimates payments for operating expenses to be approximately $3.0 million for the first year of the lease, and these payments will continue throughout the initial 15-year term. The Company expects to pay approximately $31.0 million for leasehold improvements, net of tenant improvement allowances. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Significant Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases office space located at 177 Colorado Blvd for its corporate headquarters from 177 Colorado Owner, LLC. The lease began on September&#160;30, 2019 and expires on April&#160;30, 2027. The lease contains an option to renew for one term of five years. On October&#160;23, 2020, the Company entered into a lease expansion to add an additional approximately 24,000 square feet of office with a lease expiration date of April&#160;30, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company subleases space from Halozyme, Inc. for additional research and development facility in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and will end on January&#160;14, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases space for office and laboratory facilities, which had an expiration date of September&#160;30, 2026. The lease was amended in January 2019 and May 2020 to expand the rentable square feet by an additional 40,000 square feet and to extend the lease expiration date to September&#160;30, 2031. The lease contains two options to renew for two terms of five years. In November 2020 and December 2020, the Company entered into amendments to expand the rentable square space by an additional 10,743 square feet for the remainder of the term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost along with its classification on the Company&#x2019;s consolidated statements of operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost primarily related to operating expenses associated with the Company&#x2019;s operating leases. There was $0.3 million and $0 short-term lease cost during the years ended September&#160;30, 2022, and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjI1ODU_d871941c-6e13-4e63-b75c-510124e06d12">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNTk4Mjk_76ee8485-f2c1-4b35-9000-8eb2ef218fbd"
      unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA1MDA_1845d0f6-20bc-462d-98e3-54db6e25c5f7"
      unitRef="usd">119000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyMjk_d871941c-6e13-4e63-b75c-510124e06d12">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:EstimatedPaymentsForOperatingExpensesYearOne
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA2MTQ_4d2da4f5-cf51-419d-bade-ad7abf84c839"
      unitRef="usd">3000000</arwr:EstimatedPaymentsForOperatingExpensesYearOne>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyMzU_d871941c-6e13-4e63-b75c-510124e06d12">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="i1ac223b0321a49138fb4f0d6b53af948_D20211119-20211119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA3NjI_9b3e4832-6278-4799-9e26-ae04a98b3935"
      unitRef="usd">31000000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyNDE_d871941c-6e13-4e63-b75c-510124e06d12">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="i7836ff9fc4254208a4ff43eb773872c8_I20211119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjA5ODA_57b4f3dd-8795-4982-87d0-9caca1d76f0c"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i36b4626c667d49489d40619ab73dfd32_I20211119"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ4OTAyNDQ_97b616f2-8c4a-4ebc-920e-69eb31960ade">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:NumberOfOptionsToRenew
      contextRef="ic89a1f5369f449baba38fde031911868_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQzMDI_72ed345f-38b5-452e-99fb-30d1f0ec8695"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic89a1f5369f449baba38fde031911868_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQzMTQ_ef94b330-8314-4a06-abf3-6a1968ce9f73">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i31744253af624e368277cea062fec33b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjQ1MjI_33ef445b-5a57-49aa-bccd-4868bb5b42bd"
      unitRef="sqft">24000</us-gaap:LandSubjectToGroundLeases>
    <arwr:AdditionalLandSubjectToLease
      contextRef="i16e72a6872cc4f52ad4d28a752176455_D20190101-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc2NzE_8eb44de0-2e1c-4c46-bd1c-689ca8462a1b"
      unitRef="sqft">40000</arwr:AdditionalLandSubjectToLease>
    <arwr:NumberOfOptionsToRenew
      contextRef="i6d1c2d58f05843da801c500579193e65_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc3NTQ_fc2e0d46-f0b8-4378-b0b3-a4a0f222155b"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <arwr:NumberOfOptionsToRenew
      contextRef="i6d1c2d58f05843da801c500579193e65_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ5MDI2OTg_d121ea82-825f-4d8d-81d1-e988983a8aca"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6d1c2d58f05843da801c500579193e65_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc3OTI_1d5d0f30-ca51-4d7c-8f05-5d001fd327d1">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:AdditionalLandSubjectToLease
      contextRef="i58f3846145b84a9d86539d94479612f5_D20201101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzIxOTkwMjMyNjc5MTI_4229a157-f2f7-4e9a-ac8a-3b75cb083438"
      unitRef="sqft">10743</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzMyOTg1MzQ5MDIwMTg_fe814052-caa0-4f65-9ae5-e1522712b051">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost along with its classification on the Company&#x2019;s consolidated statements of operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzQtMy0xLTEtMTc1NTI_5d7dd049-ad55-4efe-acd6-9f74f4af8cd3"
      unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzQtNC0xLTEtMTc1NTI_ebd64a17-6b3a-4c92-b235-dab3de2ab6d9"
      unitRef="usd">17346000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzYtMy0xLTEtMTc1NDQ_607de04f-7c92-42f4-809d-d8c9a4d87844"
      unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzYtNC0xLTEtMTc1NDQ_2493eb25-e457-44ef-8660-384461ecfbfb"
      unitRef="usd">2250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzctMy0xLTEtMTc1NDQ_e668ab53-44b1-4897-80e2-9605d5620db1"
      unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTozZDYyMTJlZWM3YTM0MjRkYjYzODdmN2QwMmI2ZjRiMC90YWJsZXJhbmdlOjNkNjIxMmVlYzdhMzQyNGRiNjM4N2Y3ZDAyYjZmNGIwXzctNC0xLTEtMTc1NDQ_74a7acd7-4dc5-4a7d-89b1-2633cfeef266"
      unitRef="usd">23295000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i32848b6466e0410c988feb7b33651971_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtMy0xLTEtMTc1ODg_6f005386-f42a-4026-b24b-9a9848be4b7b"
      unitRef="usd">7278000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtNC0xLTEtMTc1ODg_a8d82a18-efd6-45b8-b770-46c47e02b6fb"
      unitRef="usd">3649000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i084e58e42b30496a98760c1737b0a332_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzMtNS0xLTEtMTc1ODg_65c2687a-d89a-4036-b57d-5f5fb9bf4be7"
      unitRef="usd">925000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0350e114f99c470694c8188da7224d5d_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtMy0xLTEtMTc1ODg_e986b531-4c3b-4651-ab2f-8306f51da1ed"
      unitRef="usd">1757000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtNC0xLTEtMTc1ODg_9b0f335a-d379-4bf8-8443-e2dced322017"
      unitRef="usd">1498000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzQtNS0xLTEtMTc1ODg_e099ad5b-2a28-40f5-9878-8ffcc4364154"
      unitRef="usd">1474000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i32848b6466e0410c988feb7b33651971_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtMy0xLTEtMTc1ODg_f32f7d9b-05e8-4dfe-9d9f-f0169ef8af9d"
      unitRef="usd">728000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3c15ec6d71bb4348876475d52217ac12_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtNC0xLTEtMTc1ODg_98cadd86-6aec-438a-adc2-f473123a20b1"
      unitRef="usd">814000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i084e58e42b30496a98760c1737b0a332_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzYtNS0xLTEtMTc1ODg_54778e5b-f895-4c03-9d4f-ffc5efe543b4"
      unitRef="usd">802000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0350e114f99c470694c8188da7224d5d_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctMy0xLTEtMTc1ODg_2145d025-3ad9-423d-b947-06b11eb5dadd"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i16b4cd5eaddb49a18e88c02d55a776a3_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctNC0xLTEtMTc1ODg_f58d4f5a-b510-43ca-a2d1-ad5859ad52d4"
      unitRef="usd">1000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i550475fb5f354979ba6244b67d3344cb_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzctNS0xLTEtMTc1ODg_600097e2-02cd-4b0b-9640-7ab2cfa0cf55"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktMy0xLTEtMTc1ODg_d0f5c9be-bf48-4314-b8f9-ca714386f3b9"
      unitRef="usd">9763000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktNC0xLTEtMTc1ODg_c3e186ad-fb95-497f-a21b-91dfab391996"
      unitRef="usd">5962000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxN2QzZGNmZmI0MzY0MzgwYjJkYTRjODBlNDNlMjk2MC90YWJsZXJhbmdlOjE3ZDNkY2ZmYjQzNjQzODBiMmRhNGM4MGU0M2UyOTYwXzktNS0xLTEtMTc1ODg_22998c79-dded-4b51-ad2c-53145fee076a"
      unitRef="usd">3201000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzEwOTk1MTE2NDY5MDA_d40ac91d-05b1-4d38-8503-17132c3bfdd1"
      unitRef="usd">300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzEwOTk1MTE2NDY5MDY_1365ddb0-a7e7-48fe-a307-12f28e336ae0"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90ZXh0cmVnaW9uOjZjMmVkYjUyNzEzZTQyN2E5MmRjZjMzOWM0ZGZjNmNmXzQwNzA_9b7b0fd1-e5ea-4d24-8e1b-9d843aaed856">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzEtMS0xLTEtODcyMA_7d74cbfd-f7f4-41b2-bede-f9e187445259"
      unitRef="usd">5802000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzItMS0xLTEtODcyMA_87ca8710-f129-493f-a9f8-1885ba8c8966"
      unitRef="usd">8094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzMtMS0xLTEtODcyMA_d27d50f6-419f-4df1-9570-c0b57fe4c59b"
      unitRef="usd">11800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzQtMS0xLTEtODcyMA_bc03067f-ca9b-4114-bc30-ae14d60e2cd2"
      unitRef="usd">12138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzUtMS0xLTEtODcyMA_2b3d7bec-6a91-4db9-85d4-6ef8c9a19169"
      unitRef="usd">11297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzYtMS0xLTEtODcyMA_b60ae689-adcf-4191-ac37-24f28957aa42"
      unitRef="usd">102813000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzctMS0xLTEtODcyMA_d320ac83-505e-4394-b7b8-5a9a7666ca1b"
      unitRef="usd">151944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzgtMS0xLTEtODcyMA_9345ccbd-8874-4f89-93e1-4c31defb5cab"
      unitRef="usd">70368000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZTo2MzZkMjRjMGUyMmE0ZTIwYjBkYTE2NzM0YTBmOGQwNS90YWJsZXJhbmdlOjYzNmQyNGMwZTIyYTRlMjBiMGRhMTY3MzRhMGY4ZDA1XzktMS0xLTEtODcyMA_fcee779f-398e-465c-99b6-dc1646a4b9f8"
      unitRef="usd">81576000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzQtMi0xLTEtMTc2NTY_7063798a-1d11-4aa3-965d-1254bb6aa683"
      unitRef="usd">4500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzQtMy0xLTEtMTc2NTY_df334cb2-59ec-4ca5-990b-5a1324702259"
      unitRef="usd">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzctMi0xLTEtMTc2NjQ_913062df-1199-4787-b1e3-128399b3cbf8">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzctMy0xLTEtMTc2NjQ_d00cb1bc-d07a-4a07-8298-416ce0ab4ab4">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzgtMi0xLTEtMTc2NjQ_fd521ac4-74ea-4164-b018-c8fb91c7f3bd"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjYvZnJhZzo2YzJlZGI1MjcxM2U0MjdhOTJkY2YzMzljNGRmYzZjZi90YWJsZToxNWQ3OTE2OGFjNDk0Yzg3YWVkZTc1NTVjZWIyYWY5Yi90YWJsZXJhbmdlOjE1ZDc5MTY4YWM0OTRjODdhZWRlNzU1NWNlYjJhZjliXzgtMy0xLTEtMTc2NjQ_5a459adb-9fcc-4fcc-b33d-845451867299"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4Mzc_069ce7b6-8d98-4190-950d-c58bdaa7a2b5">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#x201c;2004 Plan&#x201d;) and 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 175,083 and 4,072,137 shares, respectively, of the Company&#x2019;s common stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others as of September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;18, 2021, the Company&#x2019;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), which authorizes 8,000,000 shares (subject to certain adjustments) to be awarded for grants of stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2022, the total number of shares reserved for issuance under the 2021 Incentive Plan was 7,190,077 shares, which includes 131,897 shares that were forfeited under the 2013 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there were 778,425 shares reserved for options and 838,625 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,543,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,145,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,689,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,790,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,456,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(606,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,114,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,351,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,889,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company&#x2019;s closing stock price and the stock option exercise price) that would have been received by the stock option holders had all stock options been exercised on September 30, 2022. The total intrinsic value of the options exercised during the years ended September&#160;30, 2022, 2021, and 2020 was $27.6 million, $66.9 million and $44.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options for the years ended September&#160;30, 2022, 2021, and 2020 was $10.8 million, $12.4 million and $9.7 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $12.0 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4 &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40 &#x2013; 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2 &#x2013; 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.0 &#x2013; 92.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,831,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,396,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,027,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of 800,000 shares, equal in value of $38.4&#160;million, that was 100% market-based awards. The revised awards consist of 99,521 RSUs and 149,282 performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).&lt;/span&gt;&lt;/div&gt;For the years ended September&#160;30, 2022, 2021 and 2020, the Company recorded stock-based compensation expense of $113.6 million, $64.2 million and $33.7 million, respectively, related to shares of RSUs. As of September&#160;30, 2022, there was $140.7 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 2.4 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzE4MA_2ac0bc40-7ab9-4ec6-8354-701aa8ea9e08"
      unitRef="shares">175083</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzE4Nw_54252e7f-19b1-4669-9861-9ecde30d6a7c"
      unitRef="shares">4072137</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if9641c69b3744bcdaab718353895bff8_I20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNjc1NTE_35588de2-3f9a-4897-812e-cbc55c36e37d"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzAxNjM_1d4fae93-7e6f-4799-b305-41345a418046"
      unitRef="shares">7190077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ib209a739b3e74cc4867507f26036f5d2_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzAxOTA_cdcba48c-7265-41e7-a742-bc668d08ceff"
      unitRef="shares">131897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i98c2c43432e94729a89fa4a887a1c799_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzEzNjk_a5ea95eb-892c-4c6d-af7a-501a8bd58c9e"
      unitRef="shares">778425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0a79bc6396d84f5d9ba7d3576acf4bd7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzE0MDU_04c44359-3d90-44fd-ad2d-08e3fdfc0d9d"
      unitRef="shares">838625</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTA5NTI_c40f42a5-67de-4e1d-ab10-20d089b33396">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,543,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,145,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;923,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,689,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,790,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzItMS0xLTEtMTU0OTQ_3eb8efd3-c966-4fc5-aff6-5212388c16a7"
      unitRef="shares">175083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzItMi0xLTEtMTU0OTg_551d2d3c-4608-4641-9f68-1fabae130b57"
      unitRef="shares">2543301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzMtMy0xLTEtMTU1MzY_2cd9acb7-11fd-4187-806b-e14645a37955"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzMtNy0xLTEtMjQ1OTk_7d62e7e7-0edc-493e-94d0-d82c95ef4e59"
      unitRef="shares">2721384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5fe2f7bfc0e54741ba6777b6c90e7a87_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMS0xLTEtMTY1MjY_9ae05db4-5d71-463f-a6cd-a69fdccfa734"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iba56efe3069544b3b006005a13d5a1e0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMi0xLTEtMTU1Mjc_f78461d8-9ce7-4b55-9469-bd14a8d3b977"
      unitRef="shares">3145886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9d9166d3c1ac4c9484561dc49251117d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtMy0xLTEtMTU1NDA_c5b9dc9a-5c46-43b5-b923-8cc59c509606"
      unitRef="shares">923545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzQtNy0xLTEtMjQ2MDc_2d59aace-bc42-4717-85dd-af842bf4af55"
      unitRef="shares">4069431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i462548275c5d4e64805ca898b4d3310b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtMS0xLTEtMTY1MjY_86084ff6-85e9-4cca-aa7b-7d891d4dc573"
      unitRef="shares">175083</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="ie2b7ce2d73d3487a88f71573531ea3fa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtMy0xLTEtMTY1MjY_080376ee-865a-412e-ac4e-b69b1ac3ba00"
      unitRef="shares">5689187</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i249abfa0135244269274c5ba0e2a360d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtNS0xLTEtMTY1MjY_0b6056c7-4e14-40bd-b7f3-21a8883cb9db"
      unitRef="shares">926545</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NTZkODA1OTkwZWI0NDRmOWMwNTc5NTYxZDQ5NDNmYS90YWJsZXJhbmdlOjc1NmQ4MDU5OTBlYjQ0NGY5YzA1Nzk1NjFkNDk0M2ZhXzUtNy0xLTEtMjQ2MDc_87fdf785-3d5e-4d8e-aa5d-28f0d9a6580d"
      unitRef="shares">6790815</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzQ_39f4c49c-af46-4d46-885a-8cf9062ba997">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,456,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(606,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,114,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,351,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,889,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzEtMS0xLTEtODcyMA_bb205a66-6edc-4f7c-b9fe-9f7840dbd1df"
      unitRef="shares">3456239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzEtMy0xLTEtODcyMA_bbb20d2f-b430-4fe5-81f7-528bd6b9d4ff"
      unitRef="usdPerShare">19.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzItMS0xLTEtODcyMA_ec43af9c-e981-4bd4-af94-eb1e7691606c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzItMy0xLTEtODcyMA_755dcf87-8563-472b-940f-981c25823666"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzMtMS0xLTEtODcyMA_17719df2-2e0a-4c5a-8882-afdcd78b8bbe"
      unitRef="shares">128635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzMtMy0xLTEtODcyMA_77b9d53c-4033-40bc-bb4a-e80c8a17d6a4"
      unitRef="usdPerShare">47.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzQtMS0xLTEtODcyMA_c8fd5ced-bb81-4207-9589-0f2cdd04b2c9"
      unitRef="shares">606220</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzQtMy0xLTEtODcyMA_c8d565dc-bbde-4712-b465-dbf7a574056d"
      unitRef="usdPerShare">8.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtMS0xLTEtODcyMA_bba9c2d9-4d45-4ac8-95df-27b765bf26d7"
      unitRef="shares">2721384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtMy0xLTEtODcyMA_83fd37e0-2d88-4955-86a4-9edb8085f0e3"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtNS0xLTEtODcyMA_44c41bbc-1ff6-4f13-b32a-d692adfcf32e">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzUtNy0xLTEtODcyMA_5578cbb4-2de9-4a01-8b64-6ff9c8c26bba"
      unitRef="usd">48114746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtMS0xLTEtODcyMA_879a69bb-9eb3-4f0f-bbca-218e7556a4c6"
      unitRef="shares">2351641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtMy0xLTEtODcyMA_159711cf-4854-4674-b4df-3a99e6290c7f"
      unitRef="usdPerShare">16.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtNS0xLTEtODcyMA_d441e138-ffe9-438d-942b-9edf95944328">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTowYzI0MGM2ZjI0MWI0ZmZkYmJlMGZjYTdjZGFhZmEzYy90YWJsZXJhbmdlOjBjMjQwYzZmMjQxYjRmZmRiYmUwZmNhN2NkYWFmYTNjXzYtNy0xLTEtODcyMA_9f80c787-e8d4-4139-8ae5-8a6e0b58c945"
      unitRef="usd">46889825</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzODE_737c20fa-7350-425d-aa92-f2885cd6d197"
      unitRef="usd">27600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzODY_b067391f-86be-4fdc-b75e-480c5be8ac3a"
      unitRef="usd">66900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyNzQzOTQ_d324e26b-47c6-4dd6-b6d1-c5105c0aa50f"
      unitRef="usd">44100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MTQ_2e5f6e8f-c511-43e4-b399-c87cdf4185bc"
      unitRef="usd">10800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib13dd085d8e44cf99ad4ead2719190cc_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MTg_bdf7bf7c-df27-4e03-8462-baccd3a56cb4"
      unitRef="usd">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4a2a799cd14495e99d6d30384411c86_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzI1MjU_64e63c5e-d0b0-4540-9c58-82051a47f4b0"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i8f7c3935399043749e14bfd46faba122_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMwNTY_7204d07d-f228-42b6-977f-0d8181a33108"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMxNTE_d49e77a3-1d96-4130-ab45-c1beacddbbe5">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzU_f46bad93-01ed-44f2-8985-516207592f9c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4 &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40 &#x2013; 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2 &#x2013; 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90.0 &#x2013; 92.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItMS0xLTEtODcyMA_d422eb74-0cca-4c48-b0fe-15995318435f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItMy0xLTEtODcyMA_7f22bda0-45ee-43ed-8cdb-7b1dc2b2d878"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzItNS0xLTEtODcyMA_fbc2dc9e-4720-40c4-b6ff-46a274b499e9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmY0MWRmM2FjNDAwOTQ2MWI5MzU4NWI2ZWZjNmRjZTNkXzQ_6edb29c3-ddc7-47a9-88d7-ea10a6ecde34"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmY0MWRmM2FjNDAwOTQ2MWI5MzU4NWI2ZWZjNmRjZTNkXzk_3126a71d-c38d-4621-88a1-80716fca746f"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjcyMDJkZmYxYTE3ZjQyM2Y5YjA0NmUxNWJkYWZjZGNiXzQ_c67ea011-57ed-491f-b709-9bb20ef0efcc"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzMtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjcyMDJkZmYxYTE3ZjQyM2Y5YjA0NmUxNWJkYWZjZGNiXzk_0ebf9be9-d4b9-46da-ae12-d4acabd83402"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmM4ODllNzBmMzkzYTQ1NTliMThhOWE4OTBhMWRhZWVjXzQ_13fb6421-6f36-40fc-92fe-4058e658fd16"
      unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtMy0xLTEtODcyMC90ZXh0cmVnaW9uOmM4ODllNzBmMzkzYTQ1NTliMThhOWE4OTBhMWRhZWVjXzk_8ea890d5-52bb-4a4f-b192-15048a8cc7dc"
      unitRef="number">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjIxYzQ2ZTQ4MThlYzQ4ZGNiZjI2ZDVlZjNhMWIwYjYwXzMyOTg1MzQ4ODMzNDg_186de4da-14ca-4777-9157-4bb40e73a895"
      unitRef="number">0.900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzQtNS0xLTEtODcyMC90ZXh0cmVnaW9uOjIxYzQ2ZTQ4MThlYzQ4ZGNiZjI2ZDVlZjNhMWIwYjYwXzMyOTg1MzQ4ODMzNTY_b1aaa6c7-fd15-4610-9733-01433b6f21de"
      unitRef="number">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzUtMy0xLTEtODcyMA_dd569202-04b1-441f-accb-5b5f864a5698">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzUtNS0xLTEtODcyMA_a9f397e0-6d86-4953-8c20-ebd595abc151">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzYtMy0xLTEtODcyMA_003c9e5c-18a4-4593-a1f1-bb5dc300f278"
      unitRef="usdPerShare">48.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZTo3NWU2N2M0OTFmZDc0OTU4ODgwODJlNTM5MjhmZGM4OC90YWJsZXJhbmdlOjc1ZTY3YzQ5MWZkNzQ5NTg4ODA4MmU1MzkyOGZkYzg4XzYtNS0xLTEtODcyMA_1a8b555a-3b29-4bd0-aae0-a14825fa42de"
      unitRef="usdPerShare">36.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQxMTc_3f8b3470-643d-4439-85b8-def8fb975a68"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzU4MzY_0d42a78f-511d-46f7-8d57-01b8b42c3bb1">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,831,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,396,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,027,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(131,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzEtMS0xLTEtODcyMA_7e169931-b383-464d-98e9-112acf0f9a3e"
      unitRef="shares">3831850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie0649e59c63046ec83567bbb9dfbb2b8_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzEtMy0xLTEtODcyMA_0ca2560b-51f2-4abc-9d53-ea9351fba254"
      unitRef="usdPerShare">61.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzItMS0xLTEtODcyMA_a845c679-4186-4ac0-a0d4-00ef973be75b"
      unitRef="shares">1396170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzItMy0xLTEtODcyMA_18cdff8f-6738-4b6b-bee7-31f80d3c2305"
      unitRef="usdPerShare">57.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzMtMS0xLTEtODcyMA_00d96541-fe0b-42cf-a9a7-820db19a6f08"
      unitRef="shares">1027088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzMtMy0xLTEtODcyMA_1be337b9-66be-4476-890a-b6332035a22a"
      unitRef="usdPerShare">49.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzQtMS0xLTEtODcyMA_6ef74e9a-09d2-434d-8856-19fb675a6070"
      unitRef="shares">131501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzQtMy0xLTEtODcyMA_9ad5412f-cc6f-423f-9109-7b64dadc6e35"
      unitRef="usdPerShare">64.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzUtMS0xLTEtODcyMA_562c822c-d1b5-4e28-86fb-5f9723334f19"
      unitRef="shares">4069431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90YWJsZToxMzYxYzA2MDIyN2E0NmI4OTRmYmY1ZWUwZTE0NmJmYi90YWJsZXJhbmdlOjEzNjFjMDYwMjI3YTQ2Yjg5NGZiZjVlZTBlMTQ2YmZiXzUtMy0xLTEtODcyMA_428b5c8e-9dfd-48cd-bf32-54b7d2d6f0e3"
      unitRef="usdPerShare">62.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia5bb146412894240951a8f5f0074b9e2_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2MTk_8c7b62c5-9cf6-4e2b-826b-18e071f577e5"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i2132296e191446feb126e32a24da326d_D20220708-20220708"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTMzMjI_8f23d8c9-8539-4343-b18a-4c9c2fb1e649"
      unitRef="usd">38400000</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia7836f44fe8142e2a7dc14272ef0dcc0_I20220708"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2Mjg_2b89fd3c-eed2-4554-951e-22052d30dafe"
      unitRef="shares">99521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i74b1850ca53244f88adb790e0b1d0c38_I20220708"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzMyOTg1MzQ5MTI2MzY_052fc47e-9edf-487e-894f-79653260522f"
      unitRef="shares">149282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NDQ_684a6c58-a779-428b-bb4e-8e919038580d"
      unitRef="usd">113600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8d5f88f4e904ac2940b5051a30bc4b1_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NDg_26f6ce38-a18e-4f91-8698-602bf1b09987"
      unitRef="usd">64200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3514c3e5478e4ed1a2f4d1a8b0dcda20_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzQ3NTU_22b5b5d7-d1ad-4fb1-901f-d6ef4ef29df6"
      unitRef="usd">33700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9f46952ca97049a89f6fbd21071e26cf_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyODA2NDQ_ee8403a5-cb3e-41b3-b5eb-e03b3276838f"
      unitRef="usd">140700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i76168196746b4c5988651e89f27274b6_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNjkvZnJhZzo1MDg0NDhmOTFlOTg0ODk1YTAzMzNhZjczMDU4YjZmZS90ZXh0cmVnaW9uOjUwODQ0OGY5MWU5ODQ4OTVhMDMzM2FmNzMwNThiNmZlXzIxOTkwMjMyODA3OTI_67bbf4bb-9101-411a-b73d-6d6049478047">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90ZXh0cmVnaW9uOmQ0MzQyMjYxMjMxZjQ4ZDhhOTU4MDYyYzZkNTcwMzlhXzMyODg_9dc03f0c-0bc9-41f7-877f-dac435f4b11b">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#x2019;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;     Quoted prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;     Quoted prices for identical or similar assets or liabilities in non-active markets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;     Either directly or indirectly observable inputs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the transfer. At September&#160;30, 2022 and 2021, the Company did not have any financial assets or financial liabilities based on Level 3 measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2022, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90ZXh0cmVnaW9uOmQ0MzQyMjYxMjMxZjQ4ZDhhOTU4MDYyYzZkNTcwMzlhXzMyODk_1ae56bb9-6bb3-49f8-a475-274d6e55deb4">The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;254,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i299f22dc89ed4f02aad79a53bc36af3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtMS0xLTEtMTMzNDA_d56d24cb-027b-4ec4-a9de-246f8cf06474"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i0f3b2544ed2e40fc89cdf37aadc3f4a8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtMy0xLTEtMTMzNDA_d95c623a-d0e8-4527-a7cf-49c2e9cb30d2"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2f75fded4dc34e48948a02b7e07fd82e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtNS0xLTEtMTMzNDA_a97b0999-ad4f-4b73-8f2e-6440610d591c"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id5a7da1d717d40f485a1fb19c1bbb868_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzQtNy0xLTEtMTMzNDA_5ac9c4db-8b84-44cb-b404-9de14ef2459e"
      unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ifd9cfdc688ab47ae95c5b3623b07d4cc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtMS0xLTEtMTMzNDA_fe86d637-fc97-47a3-9957-2d18bbc224b1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib874f688067b4ae3823dfe2d5cc52229_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtMy0xLTEtMTMzNDA_24a9b6de-9ff0-4ccf-ae6f-35e4f30d778c"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i9726349ec847475481516736bbee2e12_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtNS0xLTEtMTMzNDA_3b4724c9-f4be-49cb-bcf1-163b2cd74574"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i4f3f870fa9724a6289cd90aaceca2dbe_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzUtNy0xLTEtMTMzNDA_77de5dc6-8322-477d-83d1-435a7abbe4da"
      unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i31e1acd9eb264a28a7f8a2ce38d04ff9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtMS0xLTEtMTMzNDA_82844afb-765a-4505-81cc-7070d761df64"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib0729cf15b424ad69a05e5b53e463218_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtMy0xLTEtMTMzNDA_f0af141e-b9dd-4424-99a8-dddfc5756514"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic3c41638864d45ff8f4f22cf139c92d0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtNS0xLTEtMTMzNDA_b4e6a7f5-904a-462e-b3b8-2318b02eff56"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i32f3184cfed4429d8cbbef7071a35cda_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzYtNy0xLTEtMTMzNDA_530579ce-32f8-495a-be55-797b33c5a6de"
      unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id09e91a7f81146eb8f534664d90f3ab4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctMS0xLTEtMTMzNDA_1cb5bd25-09ad-4c34-8a1f-c8efbf08284b"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i7c9a9acd15ab40458715e433c95945ee_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctMy0xLTEtMTMzNDA_23778ad3-bd66-4866-9a14-0b78db764805"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ida6efcde85aa4cb69f080c834193155d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctNS0xLTEtMTMzNDA_66ec13b1-513b-4080-881c-d700e126f726"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i2d30f7a7174940b5bc8c54c3a014461e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzctNy0xLTEtMTMzNDA_fec1f036-3634-44fe-939d-5d1a4e346b8f"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3ee4d084af8a45c0bc6632f602ca4885_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtMS0xLTEtMTMzNDA_2b8984d7-3474-47a3-ac10-130059dcfdc6"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i578ce9b283054d468a9fcb74aad58206_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtMy0xLTEtMTMzNDA_60fac0d4-1a79-42a2-b3fe-70011782eca2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf4baaa4a1b1440a8316bc6202886db9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtNS0xLTEtMTMzNDA_f686a965-192e-49d8-af1b-cfa0205a2450"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifdfc3811ca444047a8ad3417384b63d7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZToyZDQ1NjhhNjdkY2E0MzBhYmY3NWUzZTc3ZDI1N2I3ZC90YWJsZXJhbmdlOjJkNDU2OGE2N2RjYTQzMGFiZjc1ZTNlNzdkMjU3YjdkXzgtNy0xLTEtMTMzNDA_2bff73fc-01df-475d-b1d0-28abea16483c"
      unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i85b153258fbf4c22ab083ac660ddd90f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtMS0xLTEtMTMzODM_3d792de9-36e2-4d49-8911-5e3bc24144a7"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ie3b6aea9f3d64a28b6b8dde5934fa0fd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtMy0xLTEtMTMzODM_4a45cfcd-c672-49a7-b52c-cc24d1cebf75"
      unitRef="usd">254073000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i072081357d81444787fc75a77eec30c7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtNS0xLTEtMTMzODM_82b6c36d-ed78-430c-abae-8a2b4b46f3dd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i6a57713d420442a29ad35a7c6f6eaecd_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzYtNy0xLTEtMTMzODM_b3b8b903-3029-4298-8c14-1292ab25dabd"
      unitRef="usd">254073000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i36da89f6527b4ee2b870bccdcf0fa0a6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctMS0xLTEtMTMzODM_8402bb77-1861-4bea-a381-29264ff8d27a"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="if8d0fd8b1f204829b507748af614940f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctMy0xLTEtMTMzODM_937a11ac-e4b1-4190-8591-944908a0b9ad"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i593bbbcd381b438f824786951159d60c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctNS0xLTEtMTMzODM_1765324a-e593-4bbd-b9b4-da0a4cfb8d73"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1e47d68d528444408ac6eae19b74435a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzctNy0xLTEtMTMzODM_b0b79646-b91b-4ee6-9be5-332610a1bbd5"
      unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic420c820ffc14e059589b2f7c7483c62_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtMS0xLTEtMTMzODM_98fda6d6-3ccd-42cb-a4ff-ee0b6ba52e58"
      unitRef="usd">160032000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6cb48d12728f43e8a186351de2899d14_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtMy0xLTEtMTMzODM_d7db2fb1-c046-472c-a97b-82283073190b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i31add50b09e042ad9d4989277f1a52ba_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtNS0xLTEtMTMzODM_528f1fb2-98de-4607-9dfe-efcfd2f34653"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fac4c8066e449919f984f9375260f9c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzgtNy0xLTEtMTMzODM_ce1cc4ad-350f-498a-9388-83790b4ec4e0"
      unitRef="usd">160032000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i680acdc5a46f4301848a1974ee5d87f6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktMS0xLTEtMTY0MTg_e971e2fd-3c05-46c8-b100-a9f60044602d"
      unitRef="usd">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63a9b850b4964639b775e3da5e3929bc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktMy0xLTEtMTY0MTg_fa40b485-cc1a-4bc6-bd3c-e25d3e62f886"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib584577ec6214ad49aac83e30cb1140e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktNS0xLTEtMTY0MTg_39cc980a-9f47-4f9b-bdfe-b35cf3bffa85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib99f8ae8742d44808ca61f58e0458992_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzIvZnJhZzpkNDM0MjI2MTIzMWY0OGQ4YTk1ODA2MmM2ZDU3MDM5YS90YWJsZTo2NjkxZGUyZTRjNDI0NDliODAxMjFhOGNhNjM3YzEzZi90YWJsZXJhbmdlOjY2OTFkZTJlNGM0MjQ0OWI4MDEyMWE4Y2E2MzdjMTNmXzktNy0xLTEtMTY0MTg_ef605276-1593-4052-8ce4-918006acc9c8"
      unitRef="usd">126728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzM2Nzc_3eafdd0e-43cc-42cb-979b-321073dd1a75">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Provision&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;At U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized Research &amp;amp; Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;California Alternative Minimum Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Operating Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of Use Assets/Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded, in accordance with the applicable accounting standards, that it is more-likely-than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from the Company&#x2019;s estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset. This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had available gross federal net operating loss (&#x201c;NOL&#x201d;) carry forwards of $504.8 million and gross state NOL carry forwards of $626.5 million. The NOLs expire at various dates through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at September 30, 2022, 2021 and 2020 were $3.5&#160;million, $0 and $0 respectively, that if the Company recognized, would affect its effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. During the years ended September 30, 2022 and 2021, the Company recognized $1.4&#160;million and $0, respectively, of accrued interest and penalties related to gross unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company does not foresee any material changes to its gross unrecognized tax benefits within the next twelve months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company and its subsidiaries file income tax returns with the Internal Revenue Service, the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the Internal Revenue Service and by state tax authorities until the net operating losses are settled. The Company is under examination by the state of California for the years 2018 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyODU_b8fb0c2f-e894-4965-bf8a-faeb870b0844">The provision for income taxes consisted of the following components:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzQtMS0xLTEtMTc5MDg_07ef1c8c-36bf-45f7-b509-6ff7f49df8ac"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzQtMy0xLTEtMTc5MDg_a0d9d461-f6f0-484d-90c6-38e58c08ff40"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzUtMS0xLTEtMTc5MDg_ec4dd582-619d-4fc1-9b8b-2f6a5d3f0435"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzUtMy0xLTEtMTc5MDg_98764d4d-86ef-4543-8898-8e66381cf3eb"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzYtMS0xLTEtMTc5MDg_ae710e2a-c367-4ce9-b90e-ff16fa0151f4"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzYtMy0xLTEtMTc5MDg_160cf226-bd95-461e-98f3-a366730d8298"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzgtMS0xLTEtMTc5MDg_98a67c21-9395-4c58-94a3-950e8181df6e"
      unitRef="usd">304000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzgtMy0xLTEtMTc5MDg_7812064a-6005-46ca-b36c-e9d7a3ab3ab7"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzktMS0xLTEtMTc5MDg_f94b0880-869b-4a74-90b4-281905106b74"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzktMy0xLTEtMTc5MDg_50640528-32b9-4da2-9a33-ab7a1771a172"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTEtMS0xLTE4NzQy_aec4c3d1-7ed5-4eca-9347-68469a00c49a"
      unitRef="usd">304000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTMtMS0xLTE4NzU0_c3cd6057-4a98-4bb0-968c-1476256a5949"
      unitRef="usd">2000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTEtMS0xLTIyMzEy_768d2250-6661-46b2-9951-3e0df998a960"
      unitRef="usd">3481000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTMtMS0xLTIyMzEy_9afe440d-a6a4-48e4-9052-cb1fc6be85dc"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEzLTEtMS0xLTIyMzEy_7c23ec44-bbf1-4d7f-b449-d61d327b0162"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEzLTMtMS0xLTIyMzEy_b55c929f-cf04-4da6-8d76-b36494b0a5cd"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzE0LTEtMS0xLTIyMzIz_66a7725a-c3f3-4ba3-b0ee-87fa060e5bed"
      unitRef="usd">3481000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzE0LTMtMS0xLTIyMzIz_0fea7f93-05d0-4683-8917-b63ce3b9fb6f"
      unitRef="usd">0</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTEtMS0xLTE4NzQy_e3710ef3-3b46-4d80-a1e5-ca26105f264c"
      unitRef="usd">3785000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEyLTMtMS0xLTE4NzU0_7d2d3ba7-79cf-4bd4-abad-de016a40cd95"
      unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTEtMS0xLTE3OTA4_bcd29522-0be2-4a8b-bab0-44b27def30e6"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzEwLTMtMS0xLTE3OTA4_544b2a09-ce2a-458f-9741-d988b0fcdc8a"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzExLTEtMS0xLTE3OTA4_9f72b810-fa80-493d-b603-13ee945f49ac"
      unitRef="usd">3785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZToyMzFlZjgxZTVlNWI0MTdlOTE4MDA4ZTU5Njg3ZjhhNi90YWJsZXJhbmdlOjIzMWVmODFlNWU1YjQxN2U5MTgwMDhlNTk2ODdmOGE2XzExLTMtMS0xLTE3OTA4_dedf6c7e-7e61-402c-ae54-4e000b3878f7"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyODY_3be709d8-00b0-4c34-8d77-126040052eed">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;At U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItMS0xLTEtMTc5MDg_122f278a-20e7-420d-961c-1a488049672c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItMy0xLTEtMTc5MDg_de7c37cb-758b-42e6-868d-00d21bb9211d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzItNS0xLTEtMTg2NzY_e59c2d9b-adb5-4267-a72d-06c96813f1a0"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtMS0xLTEtMTc5MDg_ac53a138-236e-4a0c-8e09-d20eb0b283ca"
      unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtMy0xLTEtMTc5MDg_1900b26a-2899-4dd6-b4de-6eac7d6946d2"
      unitRef="number">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzMtNS0xLTEtMTg2NzY_34d59692-7a2b-4937-8624-76421204da53"
      unitRef="number">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtMS0xLTEtMTc5MDg_de8a405f-6a75-47fc-89b4-5fd4a13d1233"
      unitRef="number">-0.017</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtMy0xLTEtMTc5MDg_d5dac325-f873-41a5-b5ae-37b8990e1285"
      unitRef="number">0.013</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzQtNS0xLTEtMTg2NzY_47f076b2-f455-4af2-9500-059df97d173f"
      unitRef="number">0.133</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtMS0xLTEtMTc5MDg_64f23be3-2536-42e7-a4bf-e8f2eecc5e56"
      unitRef="number">-0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtMy0xLTEtMTc5MDg_039a6fea-9f22-4b4b-9b08-975299ce578a"
      unitRef="number">-0.293</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzYtNS0xLTEtMTg2NzY_d178ff54-1761-4b50-bff9-e75ac301f4d1"
      unitRef="number">-0.433</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctMS0xLTEtMTc5MDg_9d87a0b5-ac00-467d-a364-3a14fbdca3fb"
      unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctMy0xLTEtMTc5MDg_07073ed9-c9e8-462d-b3ac-d39e66c83c2b"
      unitRef="number">-0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzctNS0xLTEtMTg2NzY_cb1ac397-49a1-4fcd-8db6-d587bc6e56f5"
      unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTEtMS0xLTE3OTA4_d3f3403f-d662-4137-8adb-f811a499db93"
      unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTMtMS0xLTE3OTA4_fb7d418c-e7ac-4905-8305-dc9e029811e1"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpmMWQwMGU0YmZkMTQ0ZGFjOTZiYTM4YTJiOWY1ZmEwNC90YWJsZXJhbmdlOmYxZDAwZTRiZmQxNDRkYWM5NmJhMzhhMmI5ZjVmYTA0XzEwLTUtMS0xLTE4Njc2_a537cef9-ffef-4348-b903-7078c47c0563"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzM2Nzg_8a1b8596-bd0a-4d55-9c23-3b91c7a48e04">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued Compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized Research &amp;amp; Development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;California Alternative Minimum Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Operating Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of Use Assets/Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzQtMS0xLTEtODcyMA_5022e8d6-9efd-4f6c-b13d-b7f7bb564593"
      unitRef="usd">2961000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzQtMy0xLTEtODcyMA_fcc90529-d64f-4fb1-9da2-0890bba8f028"
      unitRef="usd">2371000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzUtMS0xLTEtODcyMA_57b62b53-472f-46e9-a624-3900cda197d5"
      unitRef="usd">41479000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzUtMy0xLTEtODcyMA_596268da-f3e6-4413-9591-986615f91ba9"
      unitRef="usd">22454000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzYtMS0xLTEtODcyMA_ac9e32e8-1e30-4cba-8dcb-dd693f850d55"
      unitRef="usd">324000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzYtMy0xLTEtODcyMA_ee808ee6-7366-4f73-a945-89fd9b7d96f2"
      unitRef="usd">324000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzctMS0xLTEtODcyMA_c0b76f3a-ebc9-46e5-8d7b-50e9fefe2882"
      unitRef="usd">483000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzctMy0xLTEtODcyMA_fce35c24-0ce9-4ff2-9777-12bf7d6e2a13"
      unitRef="usd">179000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzktMS0xLTEtODcyMA_da6c775f-168c-4e6c-bb71-86a8d556c82b"
      unitRef="usd">171319000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzktMy0xLTEtODcyMA_b8afc7ca-8a56-4c5f-b440-5d7e2b34a245"
      unitRef="usd">185431000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEwLTEtMS0xLTg3MjA_784ef9f6-e9b4-44c0-a7ec-fabfef2125f2"
      unitRef="usd">2973000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEwLTMtMS0xLTg3MjA_b40a59e7-51a7-4288-bf4e-0476a886bcb2"
      unitRef="usd">3562000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzExLTEtMS0xLTg3MjA_0c176101-7fcb-439d-964f-7338e2557aca"
      unitRef="usd">38810000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzExLTMtMS0xLTg3MjA_d159003b-275b-41ee-9dce-196b221e80b2"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEyLTEtMS0xLTg3MjA_ca777e0e-570c-4d8d-9dc4-b02d0dc0c31c"
      unitRef="usd">2844000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEyLTMtMS0xLTg3MjA_9bd2fbd8-1582-49af-b150-6c817cb2e505"
      unitRef="usd">1938000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEzLTEtMS0xLTg3MjA_e70ec1e2-4c92-4538-835e-9b3ba2a3b047"
      unitRef="usd">1679000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzEzLTMtMS0xLTg3MjA_565d70b8-4b6e-4909-9731-df360b463054"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE0LTEtMS0xLTg3MjA_6c5cbb4d-a2db-44ac-ab2d-622e831afd5d"
      unitRef="usd">262872000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE0LTMtMS0xLTg3MjA_91617777-18cd-4287-bfd3-9006da06f0b8"
      unitRef="usd">216259000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE1LTEtMS0xLTg3MjA_7e803097-274f-484f-903f-831ca5b07cd3"
      unitRef="usd">242394000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE1LTMtMS0xLTg3MjA_4f44fe92-903d-4fde-b91f-5c9d0e80d27a"
      unitRef="usd">194255000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE3LTEtMS0xLTg3MjA_3ab95cfd-e09a-4ee9-96bc-d8f35073f367"
      unitRef="usd">1088000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE3LTMtMS0xLTg3MjA_c0d23ae4-95f8-4eac-83a0-16f774bbd712"
      unitRef="usd">6360000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE4LTEtMS0xLTg3MjA_6b7a34d8-e922-48d3-bea0-a90fff9094cb"
      unitRef="usd">19390000</arwr:DeferredTaxLiabilitiesStateTaxes>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE4LTMtMS0xLTg3MjA_0779edd9-11ee-4218-b444-4b4ef97f6beb"
      unitRef="usd">15644000</arwr:DeferredTaxLiabilitiesStateTaxes>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE5LTEtMS0xLTg3MjA_75880378-9c94-4a20-ab27-f9f2474cedc3"
      unitRef="usd">20478000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzE5LTMtMS0xLTg3MjA_b39010cb-8188-42ef-b525-f75163507111"
      unitRef="usd">22004000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzIwLTEtMS0xLTg3MjA_06c90ba0-2587-48da-a0e7-62dcdce7df07"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTpjZmQ2NDc4YTM2OTI0YWVjODAzZDdjNjJmZmI4MWM1OC90YWJsZXJhbmdlOmNmZDY0NzhhMzY5MjRhZWM4MDNkN2M2MmZmYjgxYzU4XzIwLTMtMS0xLTg3MjA_5e5eb7df-f70d-450e-a179-c359b60bee61"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <arwr:PercentageOfValuationAllowance
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzEyNDQ_bc2456c4-8ce7-435e-b7f7-6ea799bbff12"
      unitRef="number">1</arwr:PercentageOfValuationAllowance>
    <arwr:FederalNetOperatingLossCarryForward
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzIxNzE_e16c24c5-1ca5-47bf-8ab3-92526f23b66e"
      unitRef="usd">504800000</arwr:FederalNetOperatingLossCarryForward>
    <arwr:StateNetOperatingLossCarryForwards
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzIyMTI_c0c07f4d-7758-45c3-871a-c4504dad749b"
      unitRef="usd">626500000</arwr:StateNetOperatingLossCarryForwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjk_2ad9657c-6dd0-414a-9332-430231971784">The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMS0xLTEtMTg4MTA_f330da59-0926-434a-af27-c60cb3d7ec26"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMi0xLTEtMTg4MTA_a995c008-3e49-4422-9983-166146aebd31"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9195ae78bd0c4e018feb06bc6f39941e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzMtMy0xLTEtMTg4MTA_3e219ff9-8cc4-4f1d-ac51-b63ff4e1cf14"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMS0xLTEtMTg4MTA_44867010-2824-4995-b9bc-ff7fb366dbff"
      unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMi0xLTEtMTg4MTA_7eb582d1-90d2-47e3-a8c7-9d9072c0aa07"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzQtMy0xLTEtMTg4MTA_f7ad461a-8cb7-4d9c-820b-175ecd966f44"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMS0xLTEtMTg4MTA_9fb295ba-15dc-41b6-8f6d-582ae05a00c6"
      unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMi0xLTEtMTg4MTA_4204f193-ca03-454a-8969-d19e7236831d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90YWJsZTo2NTJiZjcxZDFlYmE0YmNiOWFjODU5ZmM2ZWE3YWM1Yi90YWJsZXJhbmdlOjY1MmJmNzFkMWViYTRiY2I5YWM4NTlmYzZlYTdhYzViXzUtMy0xLTEtMTg4MTA_f9a17793-a8de-4bc2-bd18-24c4abe3cfa5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0bf14984d3584db6b48db0c38f9a5ca3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQyOTA_248fa6de-4b36-41e6-af0e-849b94616213"
      unitRef="usd">3500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7033dda081f6486dabd109e810a7b896_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMDQ_a94ca005-bce1-4064-b1ab-0c52ea3c83da"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i153aae9fbcc94761892a18a2f3831c92_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMDg_a2328591-ebcc-4efc-9f4b-9bdd85b1b851"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMTI_74d79f26-ed0d-42dd-bfd4-e280d01d1131"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMTI_d99590ce-c30c-49c8-9132-16c8dbf34791"
      unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjY_85fa2cc4-165b-4e0d-a03a-a641a126f956"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzUvZnJhZzozNGJmOWNkZDY1NDk0MjExOTlhNDM0MDEzMGMwZmIwMC90ZXh0cmVnaW9uOjM0YmY5Y2RkNjU0OTQyMTE5OWE0MzQwMTMwYzBmYjAwXzMyOTg1MzQ4OTQzMjY_ca197836-6202-4b1f-8fa1-222697fcaa2b"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzg5OQ_926f8372-6be1-482b-8021-a0056adc42f2">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#x2019;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#x2019;s first 3% of compensation contributed plus 50% of each participant&#x2019;s next 2% of compensation contributed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended September&#160;30, 2022, 2021, and 2020, the Company recorded expenses for the matching contributions under this plan of $1.7 million, $1.3 million and $0.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzQ2NQ_2e1f9b25-f50c-49cd-af50-d0e94a97518a"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ie1d5f3836fb04ead9c22ecc8b24a370a_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzQ5Ng_3a121cfd-4319-4be7-bad7-25eadc530562"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="icb34bf154a434e759ce53d263414bc10_D20211001-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzUzMg_afe89d8f-1e4d-4892-a102-1170939dc15c"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="icb34bf154a434e759ce53d263414bc10_D20211001-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzU2Mg_d91cace5-8257-4e17-b298-ec70a1d0ea9c"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY4MA_79a3a891-e92e-4510-b506-65a9801bdfe0"
      unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i41f898dddb034047b93f962c444848c2_D20201001-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY4NA_eee843e9-58c1-48d3-9a6d-b2b3c151e648"
      unitRef="usd">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idd81ba75785748bda660e8e36adcdb39_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xNzgvZnJhZzo4YWE1ZDY0MDhmMjM0MDJlOTg2NjdkZWJkODlkNDcyMS90ZXh0cmVnaW9uOjhhYTVkNjQwOGYyMzQwMmU5ODY2N2RlYmQ4OWQ0NzIxXzY5MQ_3747b422-8355-422a-8fb5-d92e59c3159d"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMwMTg_3c119295-c202-44ff-b02f-d652ddd0525c">SUBSEQUENT EVENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, the Company and Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) entered into a Royalty Purchase Agreement (the &#x201c;Royalty Pharma Agreement&#x201d;), pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in Olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0&#160;million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the planned OCEAN Phase 3 clinical trial for Olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of Olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#x2019;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Royalty Pharma Agreement contains other customary terms and conditions, including representations and warranties, covenants, and indemnification obligations in favor of each party. The above description of the Royalty Pharma Agreement is a summary of the material terms, does not purport to be complete and is qualified in its entirety by reference &lt;/span&gt;&lt;/div&gt;to the Royalty Pharma Agreement, which will be filed as an exhibit to the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ending December 31, 2022.</us-gaap:SubsequentEventsTextBlock>
    <arwr:InitialTransactionPrice
      contextRef="ida71a393ea7a404baff5b677a2df560c_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAxOTI_6fab7f21-e845-4c96-842b-599cb9b6c8ca"
      unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMDY_14040944-26de-4b2c-b27c-732790a4df20"
      unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentReceivable
      contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMzM_759fadb7-7712-4fe2-96b7-1fd1c9186571"
      unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial
      contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNDc_c432bbd1-907a-4958-a851-6deaf55b4d6c"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval
      contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyMjA_b0b659b5-8ae6-4839-aea7-ea572ea59f50"
      unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments
      contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNjA_fb4a57a4-3ac9-4143-846f-5f0d9d3db633"
      unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold
      contextRef="if98ad7600c774fbfa55d91feafc740d8_I20221109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxN2MwODZiZmMxZTQ5NGQ5MTI4N2IwMDgwOWJlM2ExL3NlYzpmMTdjMDg2YmZjMWU0OTRkOTEyODdiMDA4MDliZTNhMV8xODEvZnJhZzo2OGRlYjI3ZjgzMTY0MzE5OTA1NDE5ZTcxODQxMzVkZS90ZXh0cmVnaW9uOjY4ZGViMjdmODMxNjQzMTk5MDU0MTllNzE4NDEzNWRlXzMyOTg1MzQ5MDAyNzM_9167e093-5f34-4b49-b502-f905bae46b35"
      unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZJC#&A,[AU.Q"Z=BUZQPVA';%3I5,U/+W7^7$M/J4G2IE8D5+L6NY5)<@,8
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M/5+)T-/].:I^@4EX>P[#.RDL!O+@VH="J:BX;FJL6^TZU+PIS'_N37M[)O)
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MM8W1?7( N5+BT2IDH%?BI]<?M\6S$@ &ODY!.0FXEICBT)?!P+S$/QUVVZ6
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MI)K#:L:;O$PDCC#V\2BQN"<66XD-\SA7*RI$)S8>?8;#R(<J$()ZL>,&)B$
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M%EJLT@#U_P/G<G^A'] ?:R[^!U!+ P04    " #.@'Q5>;21LIX(  "020
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MYPJ5A9D*"SU7&3TC33D4R".L6F;JVB1P'+G-U8+V0._H+2ATQH,2&W+X"L9
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M>MUA0=NH6YU]]X(NW)D]O@Z+;#:VHZ=P:3BV[0!@<$8+%RNW0 Q^A[!S337
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M$"!<?$;:$/_X=NA*MK76#%6 0#I"O^W:8<.[>5,3RHF[04)U+&?QOAU(OV8
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M8&!=%5H*/&;7][MGIU__4%Q3\W5*<*GUD/4S\1$J(^(O;?E8.H23&$2KCUP
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M'?T3_6O;X0/P_;H%!T[^P WBCZ;__#]02P,$%     @ SH!\59+*S<3Z$P
MA5   !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6S=7&ESVTB2_2L(C:;7
MCJ HDI)LN7U$T);;Q_A:R_9,Q,9^* %%LMH@@$8!HCF_?E]F50&%BY)L>:9G
MO]@B64?>^3*K@$>;-/^J5U(6P;=UG.C'>ZNBR'X]/-3A2JZ%'J>93/#+(LW7
MHL#'?'FHLUR*B">MX\/99'+O<"U4LO?D$7_W(7_R*"V+6"7R0Q[H<KT6^?:I
MC-/-X[WIGOOBHUJN"OKB\,FC3"SEN2P^9Q]R?#JL5HG46B9:I4F0R\7CO?GT
MUZ?'-)X'?%%RH[V_ ^+D(DV_TH=7T>.]"1$D8QD6M(+ ?Y?RF8QC6@AD_&'7
MW*NVI(G^WV[UWYAW\'(AM'R6QG]74;%ZO'>Z%T1R(<JX^)AN7DK+SPFM%Z:Q
MYG^#C1E[C,%AJ8MT;2>#@K5*S/_BFY6#-^%T,C!A9B?,F&ZS$5-Y)@KQY%&>
M;H*<1F,U^H-9Y=D@3B6DE/,BQZ\*\XHGX"86%VDNC(R2*'BC0LA<!O-E+B7$
M7^A'AP5VHO&'H5WUJ5EU-K#J=!:\39-BI8/G222CY@*'(+&B<^;H?#K;N>*Y
MS,;!T604S":SV8[UCBJ^CWB]HVOQ/>_E._B?^84N<AC.__:)P&QPW+\!.=.O
M.A.A?+P';]$ROY1[3W[YR_3>Y.$.\H\K\H]WK?[=:KMBU?=OWLR?OO\X__3J
M_;M@_NXL>//JV?-WY\^#^8N/SY^_??[NT_F+6'Q+]5H5JZ\T/7B5%' I^%@I
MXN!#CFB1%]O@SKL4ZKH+JC!21L&=7_YR.IM-'KXX_QO_-7UX-WB?!._22[F^
MD'DPF[%FIZ, (YB?8B6#9^DZ$\DV #<RQRHJ*5+\&#S_%L:EAC=WN0[NT,1Z
MM^X(M_\X^ S;S'FCWH&&EI70"#ZAQ&X1[2VKO6,[ 9$QF']\?_#R_&P<?,)J
MW2%*4W"*(_BVA(,7*]X5XV3&"DP7 785X#)XME*)&/&BFY4*5PU!Y+) G 4A
M.04;'4 <D;Q$9,U89F&Z7LL\5")6_Y1-FMP*Q Z&9;$DM2BL\0%?R6!Z. MT
M449;HL7.'/&B) 30G\! -RN8'5&ALQ1A^2(VS(LX#D(8@PIA I8>UD6;)N&8
MM1M H4P"^,Y5D>9;7R?X<JUI,'T0M5**%C>^<LILD2/N!)G8,@&8O3^=3<83
MA,XX=JX";F2LEC7]4:2(,E!O)_*^^T>-B07OK N1\[I&;#-><'\Z\8>6&:>;
ME9*7*ED& ADO#*76BS*NIA4Y)!)0&D6FK Q^H7)-U!>*J(]2S4:/%<RT(S-M
M'/Q6YAB>K]-<C@*]2LO8S&\,JU;/4JTH]\7;4;53EA;8@D8ER)QK&:F0O-D*
MDZ2Z+&-!.@E$EN7I)4:"DK7X'0)#^OXJ"VUT$4F2&T; MC7+LU8YB40BAV'E
M2K*P65^%$&69T9?[TP<M>1MI>*MI$4O#@IURTI@"^FB$/L@E2(?HNKLWG0&&
ML#"2K T"RUHA!- "19T\W8H8?\,H$DBK(&:C,BS,9D8_N4B6DGA9J^B@D'!Z
MYG.#/;<!0B+"0#$.YL:&5.+Y_8[PXXL)PH6Z%@KT$#^1T@66*6AM1F98,D@O
MP 3[6)/-2)(O<=PH5M:.OTKZ/@:;N;@P;"!H1=)8AXM;[, (Z @ZP<=?Q#I[
M>!90*L//T+Z90B;N44KA=7K_H:ZCA(H5A !QN+CCF6H5=D:=P.WV.[?[U7'[
MK)3.BG0F;;B+C%TDZ@_\FHBBS*4OWO9JSA%4#EE"X47 1@/9Z97*ZAAM)=%4
M1H] M6R*,Y><]9.BK;"+,HEBEBRM64*,;)\#:GPJMZGUV#XN1C9'B-P(M25S
MR[\EV^2S#9PEN)"=((Z]Q9)TN2A9=C<(Z-TH/FA]9/R*PPYP5:*%@>99#F:@
MT@(.%;4B=MO,6B'>26##>8V!B(F9KT52HLI@O-A-@9RB(S::K>,8H4*MFW$#
M+I][_H^=UR "8:./^B#"Y.Y6R(YIR,MR5B,FVTEIETQ8M-=P>58B[>!RJ^_#
MG$*U3J$U(J3/E!"==">W-I'"P,8NVK)+0C:M7'UU3B;=(3<RL@C396*\F7,P
M8']A$*+#_BQ@:&M#_^Q/2-4AEB>43BPB+?$J>636$&&8EDGA8 (YITG9S9FQ
M$NPS2C:GH[Z#55,2@!<DI=Q-5DOO.G4BDW48;;L3Q%DN0$*9,U:@(I7)\.T^
MRLLE0 2*$98]3>.O7"*JUX"X&4"]>/N!F#.X1ALX25K/RER7 EO;^#F0>?K1
M)W%U@=P&8:CU!58"6S22;"-,=3N[>LK</QZ?^FD:I"6V+'>1%@3(!58K=&7)
M6RF0F*F O-(._/6AG^^T"'_FD$6$)>R!P-GU+>-EFJM_@C B6&2R+%2H@U?D
M-MCV;/ZLJH[L0+]">EW"]:>GKCIR2^VND#@2-LO#*AKT%DINV6L52PU@/CBS
MIK4&Z%X1-%Q&_>/L)3 >;!OH.2TUH@),6NDP9C1,?Z%HS+<'<(8EI9-+BMLF
M%"&$?GPW5T28$S0,ECW(>!T6N-@V!$<&X8'A@JHP%@^1D\D4X<^8:)FP:5"*
MB8(E8'73V,G92LX]5 W5;HS-\K1<&D<"3U5:9?)9C'Y$L+61D0'4YF2XNP"[
M>?&%#<8HW6%>\=::5K/.M"K;/VY@<MU79+5+*@]!6YA^[UX+IM<"]R@>-8H.
M+&KP=9V,.^"=0VS?OG7*QF8,X]+- 0VHX;E%[#V(?ABG[S#V_T=8G:TV=19]
M6_;<&V]N#>/K6CG_^4A_B),;HGVWS$] _'X4^3&L?WQ]J/]O0_$.P6L?P1__
M5 !/#K,#P ]9R#CX:-&(TC[^HM@=4"N;VH8'W+>]$!IC*)6:7F0E-OPO%[E8
M2]?+H0K J61XXZN"6-_N!/RYNP1986_*+R0LAP.=X<IOF4&!Q!OR544T@!Q
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M&H#?%RD8L1]H@^K-@T_^#U!+ P04    " #.@'Q5KR)0NM8#   M"   &0
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M9:DK^-^"VC!JYT#K2Z7L=N(2=(U]\@]02P,$%     @ SH!\5=<6/THR!0
M@0L  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULG5;;;MLX$/T5PBV*
M7<#P1;FT:!,#B9/N!F@N:++MPV(?*&ELL:5(E:3L^._W#"G?VC1[>;%%<>;,
MF<.9$4^6UGWU%5$0C[4V_K17A="\'0Y]45$M_< V9+ SLZZ6 4LW'_K&D2RC
M4ZV'V6AT/*RE,KW)27QWYR8GM@U:&;ISPK=U+=WJG+1=GO;&O?6+CVI>!7XQ
MG)PT<D[W%/YH[AQ6PPU*J6HR7EDC',U.>V?CM^>';!\-/BE:^IUGP9GDUG[E
MQ55YVALQ(=)4!$:0^%O0E+1F(-#XUF'V-B'9<?=YC?X^YHY<<NEI:O5G58;J
MM/>F)TJ:R5:'CW;Y.W7Y'#%>8;6/OV*9;(^RGBA:'VS=.8-!K4SZEX^=#CL.
M;T8_<<@ZARSR3H$BRPL9Y.3$V:5P; TT?HBI1F^04X8/Y3XX["KXA<G4UK4*
M4#EX(4TIIM8$9>9D"D7^9!@0@@V'10=WGN"RG\"-,W$-A,J+2U-2N0\P!+<-
MP6Q-\#Q[%O&>FH$X&/5%-LJR9_ .-@D?1+R#_Y.PN%"^T-:WCL2?9[D/#E7S
MUU,RI""'3P?A3GKK&UG0:0^MXLDMJ#=Y]6)\/'KW3 J'FQ0.GT/_[V?V#W"W
MU]=7#]>7-P_WXNSF0DQO;QZN;GZ[O)E>7=Z+#RJHN8P=]-[96@2TI @V_O=%
MJ CAZT::%:IR)7)">^=?T')LLY!.V=:+0DM5)ZZ:YE*+QMF"J 1I+Y2)*-9A
MB;$@"MLZC_5,Y*T'5>\'XFH6;1H;D+0" ,[(BQGSX<@1OR^DA]*!2F")UJQ7
M?5Y^'U8HL+(8+24Y.& CE[FF2)$CR=JV)K 5)IVW!ILK01Y)L]E^WDNE-:9+
MX5KX":UDKK0**X&)&>V2&_-BU@/Q4"&F6/*/L<PB'5[8N'(A.BJ@"'RD9RD8
M9T72">*V$FB*0'5.;M,9 [%;%;=&7%"1++)D,=XG7>!?$Y.2HFE=4<FD^?@
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M+W=O<FMS:&5E=',O<VAE970Q-2YX;6R=6&UOVS@2_BN$-[?8 DILR79LITF
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M,AE:F3L7[YE@+AX+F?R%4@U!7RM#?TP:+&B=R3''/:@60)RLT F4US&"7@8
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M7):5I0/87QG4F_J%!+3?-*__!U!+ P04    " #.@'Q5>\[\-D$)   K&
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M%_X%\/:X?XW^11I43"MR-0=I.#PZ' CC7TW['ZY<\^O@6>E<N>*O2R5A'!W
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ME%R6J)TT&BQNI]'EZ&)^POI!X0^)>W>T!HYD8\P]"S?Y-$J8$"K,/",(^GG
M*U2*@8C&MQ8SZEVRX?&Z0[\.L5,L&^'PRJ@_9>Z+:70>08Y;42N_,OO?L(WG
ME/$RHUSXPK[1'9/'K';>E*TQR:74S:]X;/-P9'">O&*0M@9IX-TX"BQ_%5[,
M)M;LP;(VH?$BA!JLB9S47)2UMW0JR<[/%F6ES $1YJAQ*STLE=!N$GO"9HTX
M:W'F#4[Z"LXHA5NC?>%@H7/,GP/$1*IGEG;,YNF;B&NLAC!.!I F:?H&WKB/
M=!SPQJ_@K=!+B]1/OHO5P=^7&^<M=<8_+T7<X)V\C,>WY<)5(L-I1-?!H7W
M:/;AW>AC\ND-MB<]VY.WT/]'7;Z#<[O\_/M?BP7,%U\6US=WL/Q\^64-=P7"
ME2DKH0_@*J.=L0X$MS/9YY!1*:W<U+ZY>GWB*B(!^T)F!4@'-57:PKJ]7R?)
MZ,?[G\!LP1/XC?9HM5"PP@?4-7O+$83.V3!')W?LQQL0>8$6>;58W:POX5KF
M=29I/H#SI"YL[H:PKC<L>2F4.@!].C=M#!_>G:>CLT\.L$T;!4.@J.1.;E1
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MFQZ&3[S5ID6P;;Q)3FQ \N(KQ@EJ0@2P7UI4SW(A!M9_+4[_ U!+ P04
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M"=WA!7J^:2FR=%\P0?A[/R__#U!+ P04    " #.@'Q5U E%MS #   (!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q]56UOTS 0_BM6D'B1V)*F
M+=U&6RG+QL:@6[1V@(3XX";7Q)IC!]NAP*_G[*1IF;I^:6W?/<\]=_9=QFNI
M'G4!8,COD@L]\0ICJC/?UVD!)=7'L@*!EI54)36X5;FO*P4T<Z"2^V$0O/-+
MRH0W';NS1$W'LC:<"4@4T7594O7G'+A<3[R>MSFX9WEA[($_'5<TASF8ARI1
MN/,[EHR5(#23@BA83;RH=W8^L/[.X0N#M=Y9$YO)4LI'N_F83;S "@(.J;$,
M%/]^00R<6R*4\;/E]+J0%KB[WK!_<+EC+DNJ(9;\*\M,,?%./)+!BM;<W,OU
M-;3Y#"U?*KEVOV3=^ [1.:VUD64+1@4E$\T__=W680=P$CP#"%M Z'0W@9S*
M"VKH=*SDFBCKC6QVX5)U:!3'A+V4N5%H98@STSN54\'^TJ9$(B-SE@NV8BD5
MAD1I*FMAF,A)(CE+&6CR>D&7'/2;L6\PO"7QTS;4>1,J?"94+R0S*4RAR:7(
M(/N?P$?=G?AP(_X\/,@XA^J8](.W) S"\ !?ORM&W_'UG^';E^_W:*F-PL?S
M8U_&#=]@/Y]MJ#-=T10F'G:,!O4+O.G+%[UWP?L#:@>=VL$A]ND<&S2K.1"Y
M(K$L*RK^O-(DKI4"O+N$56 1^U0?YET40%:28[O:0AA[W<3)%T83@\8VV,L7
M)V%O]%[C,VU"5FW(,X(4BE90&Y:2"&<%N:4ED+G!-B>)DEF=&N+Z'_52E3%9
M L:Q)2?1_=U1E-S%?;)82Y(4V'$D7+JG*06T!WUDQ6H5.(4:P.W5$_^M_8Y7
M5#-%Q19;YH"[FI=2X"!R#)>W41RB-CB*,05\_OQ)B/OHZK)EZ/GA$^/L(1Y&
M\=9,G]IGR6@O^#..).5<KN<7.QY7\T]-8M%BDQ-9T$?(J*O$EN#F]N:H?WIR
MVGG=4*'QJASZV\7UAI-<2\7^RN8<B[M/C.4:#<,P&)T..]R&;U;K%!^"A5\\
M?!L\4ZI]S]K?F4XEJ-S-8'PUMM6:0=6==F,^:J;;UKWY1LRHRIG0A,,*H<'Q
M:.@1U<S=9F-DY6;=4AJ<G&YI98&R#FA?26DV&QN@^_A-_P%02P,$%     @
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M#:K2)=9B59NPGW8F,GA@ZAF-3?]>D(ZI.GON<55/.5)$RXJ)U_?O!F'0O]'
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MH9 L5"O0G9K('49VGC\1FH0C.D8C06,4H_'ZU9@F]"U:DW"2C4F28KP</T5
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M7ZYPW&;:">#_"Z7L=N,,M /\]#]02P,$%     @ SH!\5;JM%*8$!@  [ X
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M?1\-/QV0Z7&'W<G>EVQ/R4_;DI_VOW#P:)!5F'=,W^^6^STW+P"LL^]UR5\
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M :7YH#0"13,5W'$LW*X*9DP4)EL:[.[EI9;4NK._+&NRRFIM3&=9(6D^*(U
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M%+SV@-S>"RGU4,,(2O.AM !*8RB:F1^U7>7:_:K_9A*Z+>[3G@J/-)5\*"V
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MIW52#O\:KXF(U$/:O'>VJ6:FG?MH@M)<4)H'2O.A:+K*.T4&_#8R=]4/J/B
MI+F@- ^4YD/1]/BPF_BPS8MJ(E:(TX J\4-$! HSBK(T5$D]T!=WQN1@'[P]
M.'W+VGM[FYO[<K:JD#0/E.9#T715FVH0-M84_N=;?P779FC</U03M'P#2O-
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MN,"/$"@;@.]G4IKMQ&[0?M:ROU!+ P04    " #.@'Q5>YV>DA@%  !&(
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MP/4$-;YD3#YW].[<'L;B?U!+ P04    " #.@'Q5$AGZ<J$$  "!&@  &0
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M*7>#_7XAI7DZ<16TN]UF_P)02P,$%     @ SH!\5<99;]K8!@  <CX  !D
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MR9-B<\EHR++\ G5^P;E\W,D+J)>93_\'4$L#!!0    ( ,Z ?%6A[>E0!00
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M?&)4;@3X@^8X/P5P%:F6&7QF=@<'$1]P=0T"[QV 'H26@!:7N_L6]^QR=V^
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M.D.S[K,@L41W1+>2:0;K,/O64$DTJU?(GD6WC,P9[[?AM=;HJ2Z86HBVUK1
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M>0JU(;OKI9MHT=B6/A<:+@@[+.%*IM(<@/VE$/IU8FZ)X9+/_P)02P,$%
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M[/^S*$J_O\D;V#Q [^)O4$L#!!0    ( ,Z ?%7Z&\!.; 0  %0=   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;,59:X_B-A3]*U8J55VI,XF=!V$*
M2#.LVEUIJT5#I_U0]8,'#$23Q*EMAAUI?WQMD\F#@'DT$5\@";[GWG/B2X[C
MP8:R%[XB1(!O29SRH;42(KNS;3Y;D03S6YJ15/ZRH"S!0IZRI<TS1O!<!R6Q
MC1PGL!,<I=9HH*]-V&A UR*.4C)A@*^3!+.W!Q+3S=""UON%QVBY$NJ"/1ID
M>$FF1#QE$R;/[ )E'B4DY1%- 2.+H74/[\8H5 %ZQ)\1V?#*,5!4GBE]42>?
MYT/+4161F,R$@L#RZY6,21PK)%G'OSFH5>14@=7C=_1?-7E)YAES,J;Q7]%<
MK(96:($Y6>!U+![IYA/)"?D*;T9CKC_!)A_K6&"VYH(F>;"L((G2[3?^E@M1
M"8#>@0"4!Z!3 ]P\P-5$MY5I6A^QP*,!HQO U&B)I@ZT-CI:LHE2=1NG@LE?
M(QDG1E-!9R\W#U*(.1C31,X.CK6^-V"ZO;. +L!O#*="CL#I''Q="R[D090N
MP72%&>'@IX]$X"CF'V04UY<&MI#%J13V+"_D85L(.E0(R6Z!Z_P,D(/0GO#Q
MZ>&P'FY+20I=4*$+TGCN(3Q% ^S1Y9Y)+99$SF0!'MY ==P$O^G+]QO,YN#O
M+Q(2?!8DX?_LDV.;W]N?7W7O'<_PC PMV9Z<L%=BC7[\ 0;.+_O$:0FL)I5;
M2.6:T$=?,R6,G 51FM_]#_OX;D$"#:+^7%Y'J(>@&WH#^[5*I3G.]?P N?UB
M7*U*KZC2,U;Y!Q4X/E:CU\@=]/I."/V=&HVI+I3;+XCX1B+R#]H#DQBG^P@8
M0\^=5"V!U5@&!<O@ROT7M"E52V UJ7J%5+TV^J_7F-NPYSNANS.UC;DN9!(6
M3,+_WZ/A:3R,F2[DT2]X](^T*'0/MJ@Q]-QYUQ)8C25T2N_@7+E)\P):4JLM
MM+I<%:L%VVC4'*7VI/0]UW7@SA0WI[N43NF0H-%5G-:M.4:5C!^$?1CV=LET
M86%@Z6&@V<0HVWBP9<VQ9\_"EM#J3$L?!+UK-VU+]BB7JPNS!4NW!<UVZ]2F
M]9NVU7&<W4G>A:6"I:>"1A]R8L<&#29]%/C>K@<VY[J42VEZH-GU/!(N6#13
MJU*]A@5/:23D;7J</AW@U9*SR=EWX9-@:91@>.TF;LE Y7)U8<=@Z<>@V9!I
M&6Z>M0Q9+@/6,AQKAGZC&3PGZ'MNXUG<'.B&+@Q]9_^R%94F"QE=B7FB@^_
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M4ZFWS)*G:G:)T3>:[>!5V?5WTDE<.A^UE2+".!@%/<I*FK9%K)W%!M;^KGO
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M#D$*?#JY/F$WV9W,T_)3MLC25:=+N#7;C:12,V/3H$IW3#E0KX8J=D1J9NP
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MZ?9O5+:M'N^VR)3*-M7+6QFM9%X.T)^O,TU*]9ORB7&')P3._P=02P,$%
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M1_KN)(H2MV@HGMNB;\Z5+B'MXPIP"L(8Z/<+SM5CPPQ0_:-A_ ]02P,$%
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M064GT/A,2O/8L?=M\[L4_0-02P,$%     @ SH!\5;BM90Y( P  RA0   T
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MH<*/RI:1C^>B+G44([NZ&&H15D)@);Q85W#LC"[A[J6XE$;:0HEV> ,"3 G
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M9_\IZZ.UJS^.'Y]%9YK^,Y^-_^VY>@=02P$"% ,4    " #.@'Q5!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( ,Z ?%6?-0?'[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,Z ?%697)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MSH!\5=I 0@VZ!P  /S   !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,Z ?%6</X/80 (  ,,%   8
M          " @?T/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #.@'Q5P+%RW+0&  "#'0  &               @(%S$@  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ SH!\52#UF?B9 @  ; <
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M965T."YX;6Q02P$"% ,4    " #.@'Q5DLK-Q/H3  "%4   &
M    @(&>6@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MSH!\5:\B4+K6 P  +0@  !D              ("!SFX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #.@'Q58<5L'Y<#  "U"0  &0
M            @(';<@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( ,Z ?%7POJMK<P0  '4*   9              " @:EV  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ SH!\50KPW"AW P
MY <  !D              ("!4WL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #.@'Q5UQ8_2C(%  "!"P  &0              @($!
M?P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,Z ?%74
M."/680@  /H5   9              " @6J$  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ SH!\52[F":4K#   8R   !D
M     ("! HT  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Z ?%7'_."G 1\  /MG   9              "
M@5*T  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ SH!\
M5=0)1;<P P  " <  !D              ("!BM,  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #.@'Q5+ER41QD#  "0!@  &0
M        @('QU@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( ,Z ?%5AX0[/IP,  .T)   9              " @4':  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ SH!\5=\;#M." P  SP@
M !D              ("!']X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #.@'Q5S?.;OK@"  !/!@  &0              @('8X0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,Z ?%4Z1(LI
MLP0  ,P+   9              " @<?D  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ SH!\5;JM%*8$!@  [ X  !D
M ("!L>D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #.
M@'Q5V6D76V@#  !?"   &0              @('L[P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,Z ?%6/K'5N=04  +X.   9
M          " @8OS  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ SH!\5:70Z;0\!P  VCP  !D              ("!-_D  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #.@'Q5",5BIO<%  #[
M+P  &0              @(&J  $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( ,Z ?%7@_ =5[ 4  -LO   9              " @=@&
M 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ SH!\51A;
M!-*D!@  <38  !D              ("!^PP! 'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " #.@'Q5D[I1JWL'  "G1@  &0
M    @('6$P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M ,Z ?%5:.V-[NP4  -@K   9              " @8@; 0!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ SH!\5<P42^0[ P  ]0P  !D
M             ("!>B$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #.@'Q5:9UMQ%$#  #@"0  &0              @('L) $ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,Z ?%6BVYKWE@(
M .(&   9              " @70H 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ SH!\57N=GI(8!0  1B   !D              ("!
M02L! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #.@'Q5
M"5&(\K<$  #^'   &0              @(&0, $ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,Z ?%4[8N<XN (  )@)   9
M      " @7XU 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ SH!\51(9^G*A!   @1H  !D              ("!;3@! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #.@'Q503P707X%  #Y)@
M&0              @(%%/0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( ,Z ?%7&66_:V 8  '(^   9              " @?I" 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ SH!\5:'MZ5 %
M!   RQ(  !D              ("!"4H! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #.@'Q58^Y/:] "  #P!P  &0
M@(%%3@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,Z
M?%4B/%.$T0(  )$'   9              " @4Q1 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ SH!\5:)8(P"L"0  3&\  !D
M         ("!5%0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M    " #.@'Q5^AO 3FP$  !4'0  &0              @($W7@$ >&PO=V]R
M:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,Z ?%6:WQ3^#00  /4.
M   9              " @=IB 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L! A0#%     @ SH!\51*(HZ)^ P  RPP  !D              ("!'F<!
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #.@'Q50D?P
MTU$#  #."@  &0              @('3:@$ >&PO=V]R:W-H965T<R]S:&5E
M=#4S+GAM;%!+ 0(4 Q0    ( ,Z ?%7T0P6;I <  "U0   9
M  " @5MN 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MSH!\5:9^\="P P  W1,  !D              ("!-G8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #.@'Q5!#%!FT #  !Q"P  &0
M            @($=>@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( ,Z ?%66MK29-@0  )0/   9              " @91] 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ SH!\53V(MHR  P
MN@X  !D              ("! 8(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " #.@'Q5U.%??.T"  "E"   &0              @(&X
MA0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,Z ?%5E
MSM7,=@,  '00   9              " @=R( 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ SH!\51[%W!,+ P  .@D  !D
M     ("!B8P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
M" #.@'Q5N*UE#D@#  #*%   #0              @ '+CP$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( ,Z ?%67BKL<P    !,"   +              "
M 3Z3 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,Z ?%5V^ED9Z00  &\H   /
M              "  2>4 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #.
M@'Q5]4F2S $"  !>)   &@              @ $]F0$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #.@'Q5UDS DN !  #C(P  $P
M            @ %VFP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     10!%
+ -H2  "'G0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/PropertyandEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Organization and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provisions for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arwr-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife -  arwr-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="arwr-20220930.htm">arwr-20220930.htm</File>
    <File>arwr-20220930.xsd</File>
    <File>arwr-20220930_cal.xml</File>
    <File>arwr-20220930_def.xml</File>
    <File>arwr-20220930_lab.xml</File>
    <File>arwr-20220930_pre.xml</File>
    <File>arwr-20220930xex231.htm</File>
    <File>arwr-20220930xex311.htm</File>
    <File>arwr-20220930xex312.htm</File>
    <File>arwr-20220930xex321.htm</File>
    <File>arwr-20220930xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arwr-20220930_g1.jpg</File>
    <File>arwr-20220930_g2.jpg</File>
    <File>arwr-20220930_g3.jpg</File>
    <File>arwr-20220930_g4.jpg</File>
    <File>arwr-20220930_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="731">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 206,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 544,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 5
   },
   "keyCustom": 52,
   "keyStandard": 298,
   "memberCustom": 44,
   "memberStandard": 28,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.arrowheadresearch.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Property and Equipment",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Investments",
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Intangible Assets",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-Based Compensation",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurements",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Employee Benefit Plans",
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "role": "http://www.arrowheadresearch.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Subsequent Events",
     "role": "http://www.arrowheadresearch.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Investments (Tables)",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Leases (Tables)",
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Organization and Significant Accounting Policies (Details)",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i239542cd95804d368929cbe8296c90bf_I20211122",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:MilestonePaymentEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i5afacc79e97d47baba530c5a7adb3b40_I20210731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i8ef38d1d9fc4434fadb646e8a3dfeb79_I20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ibb795196cbc24edfafc6f4b579915985_D20181003-20181003",
      "decimals": "-5",
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "shortName": "Collaboration and License Agreements - Amgen, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "id8f6a7cc3aa148ba86425faae6df475a_I20160928",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:NumberOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
     "shortName": "Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShortTermLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ic3db7fc1a9524caab82a8356e53316d8_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i7033dda081f6486dabd109e810a7b896_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ie0649e59c63046ec83567bbb9dfbb2b8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i76168196746b4c5988651e89f27274b6_D20211001-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ib99f8ae8742d44808ca61f58e0458992_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provisions for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails",
     "shortName": "Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i0bf14984d3584db6b48db0c38f9a5ca3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i7033dda081f6486dabd109e810a7b896_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i9195ae78bd0c4e018feb06bc6f39941e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "i9195ae78bd0c4e018feb06bc6f39941e_I20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "ic829887bb5ab4a5d945a285de1065da3_D20221109-20221109",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-20220930.htm",
      "contextRef": "icd873b3540b34ba6b0a9bc646df2ec50_D20211001-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "arwr_AROENacAndAROHIF2CandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-ENac and ARO-HIF2 Candidates.",
        "label": "A R O E Nac And A R O H I F2 Candidates [Member]",
        "terseLabel": "ARO-ENaC and ARO-HIF2 Candidates"
       }
      }
     },
     "localname": "AROENacAndAROHIF2CandidatesMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROHSDAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AROHSD agreement.",
        "label": "A R O H S D Agreement [Member]",
        "terseLabel": "A R O H S D Agreement"
       }
      }
     },
     "localname": "AROHSDAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH Agreement.",
        "label": "A R O X D H Agreement [Member]",
        "terseLabel": "ARO-XDH"
       }
      }
     },
     "localname": "AROXDHAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROXDHSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ARO-XDH supply agreement.",
        "label": "A R O X D H Supply Agreement [Member]",
        "terseLabel": "ARO-XDH Supply Agreement"
       }
      }
     },
     "localname": "AROXDHSupplyAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalLandSubjectToLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional land subject to lease.",
        "label": "Additional Land Subject To Lease",
        "terseLabel": "Additional office space for lease (in sq ft)"
       }
      }
     },
     "localname": "AdditionalLandSubjectToLease",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount intends to invest for buildout of facilities.",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "terseLabel": "Amount intends to invest for buildout of facilities"
       }
      }
     },
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "xbrltype": "stringItemType"
    },
    "arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and use of estimates.",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]",
        "terseLabel": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "xbrltype": "stringItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments at first commercial sale.",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "terseLabel": "Commercial milestone payments at first commercial sale"
       }
      }
     },
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommercialNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Notes",
        "label": "Commercial Notes [Member]",
        "terseLabel": "Commercial notes"
       }
      }
     },
     "localname": "CommercialNotesMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ContingentConsiderationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration obligations related to acquisitions.",
        "label": "Contingent Consideration Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "terseLabel": "Short-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "negatedTerseLabel": "Short-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "negatedTerseLabel": "Long-term investments, Held to maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.",
        "label": "Deferred Tax Assets In Process Research And Development Cost",
        "terseLabel": "Capitalized Research &amp; Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCost",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use assets/ lease liabilities.",
        "label": "Deferred Tax Assets Right Of Use Assets Or Lease Liabilities",
        "terseLabel": "Right of Use Assets/Lease Liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxLiabilitiesStateTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.",
        "label": "Deferred Tax Liabilities State Taxes",
        "negatedLabel": "State taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesStateTaxes",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DrugManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug manufacturing facility.",
        "label": "Drug Manufacturing Facility [Member]",
        "terseLabel": "Drug Manufacturing Facility"
       }
      }
     },
     "localname": "DrugManufacturingFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.",
        "label": "Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent",
        "negatedTerseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EmployeeContributionNextTwoPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contribution next two percent.",
        "label": "Employee Contribution Next Two Percent [Member]",
        "terseLabel": "Employee Contributions Next 2%"
       }
      }
     },
     "localname": "EmployeeContributionNextTwoPercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EmployeeContributionsUpToThreePercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contributions up to three percent.",
        "label": "Employee Contributions Up To Three Percent [Member]",
        "terseLabel": "Employee Contributions up to 3%"
       }
      }
     },
     "localname": "EmployeeContributionsUpToThreePercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EstimatedPaymentsForOperatingExpensesYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated payments for operating expenses year one.",
        "label": "Estimated Payments For Operating Expenses Year One",
        "terseLabel": "Estimated payments for operating expenses year one"
       }
      }
     },
     "localname": "EstimatedPaymentsForOperatingExpensesYearOne",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities.",
        "label": "Facilities [Member]",
        "terseLabel": "Facilities"
       }
      }
     },
     "localname": "FacilitiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_FederalNetOperatingLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating loss carry forward.",
        "label": "Federal Net Operating Loss Carry Forward",
        "terseLabel": "Gross federal net operating loss carry forwards"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryForward",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxosmithkline Intellectual Property Limited.",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "terseLabel": "Summary of Short-term, Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Horizon Therapeutics Ireland DAC.",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "terseLabel": "Horizon Therapeutics Ireland DAC"
       }
      }
     },
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase Decrease In Cash And Investments",
        "terseLabel": "Net increase (decrease) in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "J N J3989 A R O H B V Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JNJ75220795AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "JNJ 75220795 ARO JNJ1.",
        "label": "J N J75220795 A R O J N J1 [Member]",
        "terseLabel": "JNJ-75220795 (ARO-JNJ1)"
       }
      }
     },
     "localname": "JNJ75220795AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.",
        "label": "Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and office facility.",
        "label": "Laboratory And Office Facility [Member]",
        "terseLabel": "Laboratory And Office Facility"
       }
      }
     },
     "localname": "LaboratoryAndOfficeFacilityMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableAtStartOfPhaseTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable at start of phase two.",
        "label": "Milestone Payment Receivable At Start Of Phase Two",
        "terseLabel": "Milestone payment receivable at start of phase two"
       }
      }
     },
     "localname": "MilestonePaymentReceivableAtStartOfPhaseTwo",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "label": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable Upon FDA Approval",
        "label": "Milestone Payment Receivable Upon FDA Approval",
        "terseLabel": "Milestone payment receivable upon FDA approval"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments"
       }
      }
     },
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NoncontrollingInterestIncreaseFromDeconsolidation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase From Deconsolidation",
        "label": "Noncontrolling Interest, Increase From Deconsolidation",
        "terseLabel": "Deconsolidation of Ablaris Therapeutics, Inc."
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromDeconsolidation",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAcresOfLandPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of acres of land purchased.",
        "label": "Number Of Acres Of Land Purchased",
        "terseLabel": "Land purchased (in acres)"
       }
      }
     },
     "localname": "NumberOfAcresOfLandPurchased",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OutsideOfEquityCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside of equity compensation plans.",
        "label": "Outside Of Equity Compensation Plans [Member]",
        "terseLabel": "Outside Of Equity Compensation Plans"
       }
      }
     },
     "localname": "OutsideOfEquityCompensationPlansMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfValuationAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation allowance.",
        "label": "Percentage Of Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowance",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Facility in San Diego.",
        "label": "Research Facility In San Diego [Member]",
        "terseLabel": "Research Facility in San Diego"
       }
      }
     },
     "localname": "ResearchFacilityInSanDiegoMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RestrictedStockUnitsMarketBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Market-Based",
        "label": "Restricted Stock Units, Market-Based [Member]",
        "terseLabel": "Restricted Stock Units, Market-Based"
       }
      }
     },
     "localname": "RestrictedStockUnitsMarketBasedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RestrictedStockUnitsPerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Performance-Based",
        "label": "Restricted Stock Units, Performance-Based [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsPerformanceBasedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_RoyaltyPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payment Threshold",
        "label": "Royalty Payment Threshold",
        "terseLabel": "Royalty payment threshold"
       }
      }
     },
     "localname": "RoyaltyPaymentThreshold",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "terseLabel": "Royalty Pharma Agreement"
       }
      }
     },
     "localname": "RoyaltyPharmaAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SalesRelatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-related milestone payments.",
        "label": "Sales Related Milestone Payments",
        "terseLabel": "Sales-related milestone payments"
       }
      }
     },
     "localname": "SalesRelatedMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Current Products",
        "label": "Schedule of Current Products [Table Text Block]",
        "terseLabel": "Schedule of Company's Current Pipeline"
       }
      }
     },
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value",
        "terseLabel": "Equity award value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "totalLabel": "Total (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arwr_StateNetOperatingLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State net operating loss carry forwards.",
        "label": "State Net Operating Loss Carry Forwards",
        "terseLabel": "Gross state net operating loss carry forwards"
       }
      }
     },
     "localname": "StateNetOperatingLossCarryForwards",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TaxIncrementFinancingAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Increment Financing Award",
        "label": "Tax Increment Financing Award",
        "terseLabel": "Tax increment financing award"
       }
      }
     },
     "localname": "TaxIncrementFinancingAward",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one incentive plan.",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_UpfrontMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment received.",
        "label": "Upfront Milestone Payment Received",
        "terseLabel": "Upfront milestone payment received"
       }
      }
     },
     "localname": "UpfrontMilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_VeronaTechnologyParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verona technology park.",
        "label": "Verona Technology Park [Member]",
        "terseLabel": "Verona Technology Park"
       }
      }
     },
     "localname": "VeronaTechnologyParkMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "terseLabel": "Visirna Therapeutics, Inc."
       }
      }
     },
     "localname": "VisirnaTherapeuticsIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20220930",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r93",
      "r209",
      "r213",
      "r218",
      "r457",
      "r458",
      "r465",
      "r466",
      "r515",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r93",
      "r209",
      "r213",
      "r218",
      "r457",
      "r458",
      "r465",
      "r466",
      "r515",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r91",
      "r92",
      "r221",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r220",
      "r232",
      "r346",
      "r351",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r552",
      "r590",
      "r592",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r220",
      "r232",
      "r346",
      "r351",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r552",
      "r590",
      "r592",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r197",
      "r204",
      "r205",
      "r206",
      "r207",
      "r220",
      "r232",
      "r298",
      "r346",
      "r351",
      "r386",
      "r387",
      "r388",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r552",
      "r590",
      "r592",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r197",
      "r204",
      "r205",
      "r206",
      "r207",
      "r220",
      "r232",
      "r298",
      "r346",
      "r351",
      "r386",
      "r387",
      "r388",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r552",
      "r590",
      "r592",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r91",
      "r92",
      "r221",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r268",
      "r270",
      "r591",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r268",
      "r270",
      "r591",
      "r601",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r142",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r12",
      "r193"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r45",
      "r46",
      "r47",
      "r578",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r463",
      "r513",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r397",
      "r398",
      "r399",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r354",
      "r401",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r78",
      "r180",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Planned area of site (in sq ft)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r87",
      "r128",
      "r131",
      "r136",
      "r164",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r457",
      "r465",
      "r488",
      "r516",
      "r518",
      "r560",
      "r577"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease Assets and Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r32",
      "r87",
      "r164",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r457",
      "r465",
      "r488",
      "r516",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable debt securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable debt securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r150",
      "r172"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Marketable debt securities, Adjusted Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r146",
      "r151",
      "r172",
      "r564"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Marketable debt securities, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Fair value of contingent consideration obligation due to discontinuation of clinical trials"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r81",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r489"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Amount insured in FDIC per account"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposits"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r448",
      "r449",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r565",
      "r583"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r208",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserve for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r272",
      "r275",
      "r352",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss, net of tax:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r58",
      "r455",
      "r472",
      "r568",
      "r585"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r122",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r464",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r256",
      "r258",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r256",
      "r257",
      "r269"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r256",
      "r257",
      "r269"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r299",
      "r338",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r426",
      "r434"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r426"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r426",
      "r434",
      "r436"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r426",
      "r434"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Current",
        "terseLabel": "Short-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent",
        "terseLabel": "Long-term investments, Held to maturity, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r427",
      "r434"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r427",
      "r434"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r88",
      "r427",
      "r434",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r417",
      "r561",
      "r576"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total gross deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r427",
      "r434"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital Loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net Operating Losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": {
     "auth_ref": [
      "r423",
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax",
        "terseLabel": "California Alternative Minimum Tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Accrued Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefits costs"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percentage of compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Discretionary match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r78",
      "r191"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r391",
      "r392",
      "r394",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r110",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r479",
      "r480",
      "r569",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r112",
      "r113",
      "r114",
      "r117",
      "r118",
      "r479",
      "r480",
      "r569",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net loss per share attriutable to Arrowhead Pharmaceuticals, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r89",
      "r409",
      "r437"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "At U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r409",
      "r437"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r409",
      "r437"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r409",
      "r437"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State taxes, net of federal effect"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r119",
      "r165",
      "r246",
      "r253",
      "r397",
      "r398",
      "r399",
      "r430",
      "r431",
      "r478",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r513",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r482",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r484",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r222",
      "r299",
      "r300",
      "r305",
      "r338",
      "r482",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r299",
      "r300",
      "r305",
      "r338",
      "r482",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r482",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r338",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r485",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r88",
      "r408"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r156",
      "r158",
      "r160",
      "r161",
      "r162",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r223",
      "r244",
      "r476",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r185"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r185",
      "r188",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r185",
      "r556"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r181",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r185",
      "r555"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total Foreign"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign:"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Computers, software, office equipment and furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r62",
      "r78",
      "r149"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Net loss (gain) from investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r179",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets subject to amortization"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r148",
      "r154",
      "r166"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term investments, Held to maturity, Adjusted Bases"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r155",
      "r157",
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held to maturity securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r148",
      "r154",
      "r166"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term investments, Held to maturity, Adjusted Basis"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r78",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Intangible assets subject to amortization, impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r128",
      "r130",
      "r132",
      "r135",
      "r137",
      "r557",
      "r566",
      "r570",
      "r588"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense and noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r410",
      "r415",
      "r422",
      "r432",
      "r438",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r106",
      "r107",
      "r127",
      "r408",
      "r433",
      "r439",
      "r589"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax provision",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Total:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r406",
      "r407",
      "r415",
      "r416",
      "r421",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "State income tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income Taxes (Paid) Refunded"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r77",
      "r553"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r77",
      "r506"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r72",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of note premiums"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r558",
      "r572",
      "r600",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office space leases (in sq ft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r87",
      "r164",
      "r488",
      "r518",
      "r563",
      "r581"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r87",
      "r164",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r458",
      "r465",
      "r466",
      "r488",
      "r516",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r16",
      "r17",
      "r87",
      "r164",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r458",
      "r465",
      "r466",
      "r488",
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r87",
      "r164",
      "r209",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r488",
      "r562",
      "r580"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market instruments"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r50",
      "r55",
      "r57",
      "r79",
      "r87",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r111",
      "r128",
      "r130",
      "r132",
      "r135",
      "r137",
      "r164",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r480",
      "r488",
      "r567",
      "r584"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r55",
      "r106",
      "r107",
      "r460",
      "r471"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r254",
      "r456",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r253",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r128",
      "r130",
      "r132",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r503",
      "r511"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r499",
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r507",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r94",
      "r123",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r31",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r30",
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from upfront capital",
        "verboseLabel": "Proceeds from investment in joint venture"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r66",
      "r67",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r396"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r50",
      "r55",
      "r73",
      "r87",
      "r98",
      "r106",
      "r107",
      "r128",
      "r130",
      "r132",
      "r135",
      "r137",
      "r164",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r455",
      "r459",
      "r461",
      "r471",
      "r472",
      "r480",
      "r488",
      "r570"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss including noncontrolling interest",
        "totalLabel": "Net loss including noncontrolling interest",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r11",
      "r192"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Total gross fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r194",
      "r518",
      "r573",
      "r582"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r194",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r10",
      "r80",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r253",
      "r518",
      "r579",
      "r596",
      "r598"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r165",
      "r397",
      "r398",
      "r399",
      "r430",
      "r431",
      "r478",
      "r593",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r124",
      "r125",
      "r129",
      "r133",
      "r134",
      "r138",
      "r139",
      "r141",
      "r267",
      "r268",
      "r554"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provisions for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of the Net Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r181",
      "r184",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r181",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r370",
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Awards Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r353",
      "r355",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r361",
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r85",
      "r120",
      "r121",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r227",
      "r228",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r414",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 2.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of period (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "terseLabel": "Share-based payment award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "order": 1.0,
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r360",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r400",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r504",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r88",
      "r408",
      "r433"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total State"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r119",
      "r165",
      "r246",
      "r253",
      "r397",
      "r398",
      "r399",
      "r430",
      "r431",
      "r478",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r513",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r119",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock - issued for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r246",
      "r253",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock - issued for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r22",
      "r23",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Common stock - restricted stock units vesting"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r246",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r87",
      "r145",
      "r164",
      "r488",
      "r518"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r87",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r164",
      "r165",
      "r253",
      "r397",
      "r398",
      "r399",
      "r430",
      "r431",
      "r453",
      "r454",
      "r470",
      "r478",
      "r488",
      "r490",
      "r491",
      "r495",
      "r513",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total noncontrolling interest and stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling interest and stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r253",
      "r255",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r496",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r496",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r496",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r496",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r156",
      "r158",
      "r160",
      "r161",
      "r162",
      "r223",
      "r244",
      "r476",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government bonds"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r405",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "terseLabel": "Unrecognized tax benefits, penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase for prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r457",
      "r458",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r505",
      "r511"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares used in calculating"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r618": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r619": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r622": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r623": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r624": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r625": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r626": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r627": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r628": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r629": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r630": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r631": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r632": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r633": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r634": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r635": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001628280-22-030869-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-030869-xbrl.zip
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MB-&.@,Y+Z7Z/NJ/5Q'+/B5:..1.,,XB%@(W!2!OZ-76/">>+MT7O)!2#B[?
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MM%9(3."/]SQP)Y<9IM=V^BJ&P;_)C<T[Y:XI%5B7$JS62LVQ%LXZPH*/)CJ
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MG(9.K\1 X_PD)057<<R".LR#$UYB:QEE2@'-D-SS<OVPPV2)QBP67L%S&3]
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MV(/@N+A&/\' [ YM/_<YQ$2)8_Y"KEY^&75NI-"H>S?RO!/"#?O/KK.G\:]
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M,('QS\WDF-S0O+F@AXA?Z@#YTC8%EB!CD2M8<E)4#0M-9[.Z-B"41>BRO:2
MI\,STTD2R??3<])I=.M+R.%A15I&DFDDAB2KU:*:Z>W^R:N'R3"OZXO*06.Z
MK_LOLM:Q;X6WW^N]Y9G84.5-8:77ZN:<9>>!1%[ [KCC&3+FQK<A^4]B\O]8
MWQE'SW.F&,G%->>84I=<5=219LUF8,NTC5"P8:#ETDXF3B0YY76M4[+=MRQ(
MFEI7T9#3<*'_ZIGLSA_^%Z5KU();*5-#O+6QOXRY[&Z3"7$R@]^*.XH_W<6
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M #<R^% HXZD"94PB1LY_Q@@$E.WIIQ(,Z_Q"$2W_Y X=-W\G@J'L&G]A8X&
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M=1(X[7]6)PP=U'?P&-IH3YO)?UB@/2O3H0,3%1RD@4](!*:^)#.#E_,H!1Z
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M6%ZZ&P5U334'+#]";C:J1<F6:I"YAQ8'8GUB5FH<ET$55N*YMO4WC#Q;&!L
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M4^[Z; 8I(ZZ#SXAVFJS&=*\YZ37/-CKV*C*RD;UM @]?ERD;WLGO>J_7-GQ
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MIY( U&JE/I_ZGM.AZ8FY9LOT1:Z>LI1N2J?SLBS"Y<ZE!,&K[5%GL5D9Y/Z
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MZ,BE]=:V40_GK'@)@\Q5-<:K:DYKYQ>2PHMT73+H&^:\8\Q3O2AW"18S/JS
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M190^V6V$19'K\W5YES47$-05!695DZ;PDQK966UD$9]$Y2*8 D6D$.904H/
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MP14(%NE@F&^_;)9:U/E%5I[S*6MY%.%)JS<5$+U, I]IXQUK/?L.:K"U7&2
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M#[@(YS!'1S\PQW;XU C6]&71S&D:=M/)RVAC.8!_,<08\(9F@4[)KVO,1OW
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M-G.!>1\V;<-4,.&X) J@,AM@)9KECFD;:(MBPR)%4A%"]&;\#K1S9SG]F76
M,==MZ7H$A*P39>W?E (]S/0^L/% C*4V%WM0X9^45N"8O&')V)WR<"!'%3[
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MHA\HSRTAU-"O;,F)NU$%3LT_=4Z\^Q;LR**<BV[[%+DE!9;D[G4H"#D]?V2
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ML>7^'&OP<D:D/\XF82\*(T>05) VFRQP@7 *A1UM#'T)Z6>NAQB4.U@&1[C
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M37__Y_?W'\D<Z<H-C+H[VR)6] L;$=$Q#Q:RWQ!)T3L"-DP;-SF-O[19/O&
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M+'^-C0CAV<XSQC.A*>54%!R#B"UHF<$6.T?)3(ALI)[_/C<X!H]_R8#;P?5
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M3'4FBUOGA;]\$%#)@0>"3K()=6!1LFW$V \&@71H\<O!1<DB=*C!I#3>$AS
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M<$BT2+3G2K7/9)%L9OY&>6<L3D&@LKZ4XPRK0K:2SU%3NO7N38C4Q'1[*1V
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MS[XRUT!J$T/L7D&%9+KO$_GCSGEW1!)L-9 ?K*]AW$06Q$DHBAIA^1-D"_B
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MJ%,25^<IT4H\Z7Y1Z2!52J4(?,>$%O$=!,IAVERNB,C*FO#"&Y[7,'0#5+&
M3Z3-6%;,&18[P6)T-I)MQZ%:SV#U7\SNTSE)TC@N5'#"7(0O8T&.=-MG^?JL
M,WO\]IP/(FW>\RI2QEQ($'FFY029EE!Q**<@QD0TE/I4O,N8ZD4=0]I$965M
M@ I3CXMJ\0U3F'W,9!0Y+:FM<<TZ<2C&7TK+8MN=1B'S?J;,?"Z;6)D@*..)
M&S*C@5N@ 7NS8@T\18,T7X8Y5UC'D61_<>9G"BLH<95/$?+G0GU,1Z]3VK2/
MWC44\ZQH@7E@4Z]G%0T4#]'C65"*#3AAA(+1II+FRA!!,*!L3!$_S[X(O]X
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MU@3B("_KJS@->3EZ'N^VW^-Y338*=M )F/,7I1,6BY&U( Y>%-%@2DSL14.
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M&]YA=4,[I:?&>G$RSR25>3;/'YC%E)H2))X:I09)DEI32K7,2HL=U$NJUQF
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M8 XI'I\B!S4/M5^+CY5G[V1L?W07P&[O:!XUS8:TA(8BL@FYBH)@0,3!2$B
M@!,&#5X0BYB/?E$@CYD H,V+@TC.+ Z=S!+#+]GXXLUIC61S:+R12RD.K6?\
M_>3XBL%8HDUEBIV64:1H=^0;R13A<U8]I\7,3YR/3Y-N87M9,7CP6 :3\K"M
MM'^*DU:N.*W0)*7]8ENT+9S5N9%(QJ)>(DF/^F,>_=EJK2 >V*F#[)MA(CCU
MV$"_GVX[S%.7S&E/ EYHL/.V'.PFEAANHR,FR*6>I),G)OH/X"AB^#!ZP6X\
M'R-;R@?X^S3R@2[9"PSJB6,'(OM3Y"JLD^Y("0[!V+N+%8J0N<!Y0Y'-M]59
M,:WP,NTY.4IY3G8'*87_,<$Y2E))50T71HB*'4JQ1RJ3*23>%CM=F%LHG5>%
M6.B3@R2)X.*4VB@,O,@W\&'R).46-A>)2N1_-)TZE 04>O<XP7SV!I8$EXR9
MR 5@ 3CQ0$@1#@$%U#B 0:.BRCZ<+(LM@2(H\6Y3TW1YU*,49+!<(96!1J[@
MP(]L(,Z:<@CH 3!S;9T6=JJ;C"B_XE=<T,S2^4S\+;.\@XWTY ,!I60WF5B#
M9['(3A).09^R\5.9PX7AC&8 W]IFM,B/" KR#S"1,83EYYZA.&#B;<NNA(&-
M04)7#-\+ LR9,KB) *?KXC!VNA!_A'V]8 _"WY\"<0P)CG!S&)@<H;@#E@9[
MY^EN<7Z5B3$\U.R$'PO8I!_&:7%)'A9<\IC9(6"80ME2 *92#[8[L%4PF)J-
M@X;3 XRP@ECBD>_O@?2WM]N9T/UBBV9@-]5ZOU5^>=V9ROUZN_L4\Y^;O99<
MJUSKOJ^UMQS%\K[A.5.>2X9<PUG?NV,_:\O,'7^^+K&]U9GU_.#<N2:K3[3S
MYW1G+#<_^/K.<F[+6W)69)6G<,>XW)BJR"JI6VS5%UEBH^?<0:N1P:+1W*M1
M3_4&;/\#-%%RF'&3GGX^9 Z3F;(FWW@\@$EV(]E-E1=9S&[RN0>2W6R&W?2W
M$T@GH@/VJR.+_?0Z"YIBQ98',DHF*2P[-;C:H)D;A[#65A=1V&[!ZQ^%B+/"
M!"_#LK9KDM)AUL>Y_+PJMM/]G*R^TMXK/51$;79J_49KU='JJP#@R:?F96FN
ME%EI#[_C-["Y<B?;ZE3L4#< @W^L-V9V,4))EKC;++&OU3I:KV+$(SGB(W#$
M=L4.57)$R1&W@2.V6C6M6S5U0G+$1SC8JHFYC7/$/9B=+-*V<LE,I8)A$4TL
M.R:T<J?>;M6:*UM(U9O?NMN'I*[*GA[G@#;.A"1R+ &RIE;K-E=U7$D*?F8*
MW@R+E12\#<BAJ;6.JDD*KO0A=?:4@O<@]'>E.SI6>:VE^1=L=SL0NJW6^DUU
M/;MW2UT6VW=(*VO^CW- &^<Z$CF6\5HU:FJW+RFXTH>D;N: ) 5O!7*HM6Y[
M5<U?4O SFV=[2L%[$ +XD%25\WKC_?+^JUJMOW+L2WH>GEG-VT_'@\2-)4#6
MK77ZTO=?[3.2]"MQH]0)5]/:DGZK?4:=/8V^[X'G_YJF&SS44*?&9YIA6Q[7
M<P\,/1B+:[).:+]20+5VIZ:NZQ&0.: 5/ME>U1)[-RX 9%:\9(G+.)&ZS9K6
MK%I-B62)C\ 2JU8/*UFB9(G;P!)[6JVWLE].<L3J<T19*+2'4<(KG..2:7'\
M.U'"72*'IE9K=E?-(5P)#EODV=RE@U6K=J@;YW,2H7[3;U;KMM:L<9"<HL('
MNV[ABN04$J&*PVVUSLK^=<DHJG^NVIH%5+O+*/8@P'JT: #,?M5;]6J]1E>F
M>E?ZC)K[F>DM<6.I5,MF9\T@EZ3?BJ9:2OK=']Q0:ZV5'1"2?I_91FCL)P%O
M=1#EX?&&*^1:KFD=\K%_33A[-IJ>68A[&4=_3,A4FH:T/NAD*]M4CPB>[?,D
M/3Z=5 XKX-^MPHB-"Y]'PD;)J26G+M?K.K7F;X;_)*>6G%IR:LFI):=^2I#T
M&[7^RFY.R:AWFU&WUBQ1WE<^3>Z<-Z$.6_VC9 2I[9J6&P\59\_B3,ME!I?^
MB(+0'LW>E;SH&1T[JC8_.4^Q^1A*4WG9:M6;"GS2P?!OZ"DOU6:GWH__,O)\
M)1Q;RLS2?<7"N:U*R1QFRK[5?;@!W]+7ZIW57Z+6E>NQG:Q/N=,#9>K;$]T'
MH"AF9.'+\553W[OQK2# UWLC^M,A?M^=_?/_]32U^PZ>LZ<6@@*O&P( ^&YX
M!;JVPC$0Q,U8,> FQ%$E]&W="6K*W=@VQN@&BYP0EFJ[RAA@:?F*%X6!%_D&
M_''NH="[MPT[G,'11N:,/@#'%HUT(XQ\+$LFR->5#P +ZUZ?3!VK5KAL0_=-
MVYM8@)M ;D9JZ35E<'E^,#C[V*37TR\7YX?-FC+6;RU%-V]UUZ %PPXOQ@@_
MC>YD/S?SBZXKI:@, +^Q72+\3I;S50>SM043(M(8#EC5R6!X.XWRZR)X4ZMW
M'PG!4V@-//HN')=A=+)):P2?A&WBZ1H )-N-X)L< \A92TC@PMT.OLK7IU8$
MG%C1\;,,_>T@P _/IM9.8()H$4R;"^;J 83W&L$5V$&(, [PD5E-&7IN%"!]
M3?69[SD ,?T>?^4-QY2AY5HC.RQ]M3C^_'D)Y)Q:?N"YKN7@Z5OQX2,:L#7,
M+ULL-U#N+-^:YX$ WQB'X"WB2V-+-PT0\R&L1P^!+P2*9QB1CU@+/Z<62=?@
M(SIA*VZNF%_6\/4H[$-./KKK1L!"DDW@PF&' (0)8I^ 9EV9+\J(#P'1?DCD
M&4WQM;"N6]V)V$UX,O2H-\7?V1> '0/7,O XV,7(Q47?^+H;,I*T@*=Z,PN7
M;-J^982>SPD$E! ==H$G#RP='E@5X3>/W4D;O .!E0*6<!).A(?H$#8P_E>&
MDJ7!G5'29P] =04[/+*M&Z^F' *UP]M<6Z=G3G7@0IY;4[XB,P)2<D&FS2]N
MC@NW\VJ&MJ26H0C^6\LRX.Z2_%=9Q'HG@!=9Q4*@.J X@Z< <XY\&.D4\61X
MD8WH KQ1<>'T33^Z21'4+O#:-!=#<C47Y1 F/5KTN=XL@L<2U#)O@?]S]*%B
M_3>R&8+B:^E$QIX##&L"&N MB3H@\I".)D'A78&Q0#9@6:!<3AF@QD#",<./
MQ03 3R@"A('B= !MRYD[Z1N<@W.%FKT*S\17IJ0WSJFZ.8%@NR.'S@QD*;P&
MWA&!Q()K-YYG!F]@^[>VP>4$'A,<*Y KG,-/*UQP4!P8K39 :^H%]+FWA"WV
MK?7NSC;#,;?LTD]Q0[:1/*(/P6R-PO)'YJ:\;\!(:V-6?3,+B_2_8U^L9JK?
M6 =#.-N?!_H(%OM6=^[T6?#B31;+ <73 "S;.S?C#]#M]Y"ENXB45.TIZ83>
M^-8.X9",#""[A93S$=0U'_"52$09F  ,4/A\0ASEF!/,ELE_Y 8C4$V].[0E
MR6^!)'L+D@9D$!B+MA.4F0TW'![$F+/0$.SC[;(,$[;//A[3&WF(  R./@VL
MM^*'=R 7IXX^>POR%3=##[WC[^)$BHB9<Q 1M-GE!&?K#8:W//N&?YE?KM.E
MG+N+76NJ]7ZK_'*CKI9>6_3:?KW=U=9ZZ^)KS5Y+KE6N==_7VEN.8GD^7DY;
M:#(YE LUH)*3"QE4(BVO]Z" *W9EO[+19/:B "V0UXOBCX^X\^?4F'HYF3@G
MYUFZXIWEW%K+N.,WN<I3N&-<KFY49)7':#17?9$ECMF<FEH>:WPPI+@RQ3!H
M/#.W6 BC?X 62,H[5W3IYT,PYVX\,,^6R%5X?"!)MB+92I4761*JD6QE6;;R
M&%REOYUP.1%^ME='%OOIM3*?:#"GIZJ%>NH*^%256Y?.$*GV,;Y<1C(^O-?]
M =@_"K%\A1JZT:@Q,JI1'?5[(VC+MR@;A>Y"NJ7:J75:56L\+AN%/L+!5JW[
MZ\:3(F7K9,D1ER&<9JW36W,LN>2(53[8-9L?28XH.>)><T1MC8H<R1"KSQ"U
M-;O1["Y#W.HV*,MM^,+W1JRR1'=J5/-AFY8BTMAJE$;C84[]G"M@E=*T[2,&
MM57K-N4DZHH?TIH5_-O.ER1R+&>XJ9J<95OQ0UJS6Y*DX'U CEIG9;>E)& I
M@BMI&FQ?## I=!.UH?O5(%VK]5?&;MF@]9G/:#_[LTK<6(I^FRLWBI'T*^E7
MTF\U0-;NK#G<5%+O<U'OGLXWV(.X .N.?I,I+BXNIZW!#]B3 TMU\QT/9/K@
M?H6&FZV:UI?I@SL8&Y9SQF6RC.2(Z\R$J*FM5<>'2HY8?8[8K)J8DQQ1<L1M
MX(AM8(A52[V5#/$1(H%21=R_&.%\U]/U8H1LX[M$#KU>K:VM7#>R"AR>G,]E
ML7$]/K=[!]NMVJ%NG,])A/H]A:A1ZS>KAE3R8'__8#LKCV^7G$(BU"*?0[?6
M[J\\DEARBLH?;'?E0.JN<XH]"+$>I3K OTGWD-^O-,MULKQEHL<SG]%^YGE(
MW%@"9/W&9K!#GI"D7DF]O^_-6ME(E=3[O">T9O; MI/O'D1/ED^R7-,PE".S
MGP8RE28C56O56K_I4*[TS.S'=R+MP<QL^'>K,&+C\N>1L%%R:LFI2W,$&K7^
MZKTE):.6C+I"&"$9M634N\ZH6\U:J[U=9"D9]5,C1?OW@K9[QZ?)H?.&9J/^
M\>!\W0K/JA:S,=(SZ<7@]V:]D1W\WJEWEAK<GAWREAW^KC:7G/Z>'>F$(^"M
M[ 1XT[=O+5<9SN@5\)&A[?()Y"-%=]U(=^('@IHRM7SX' #,L)2AYT8!'VR=
M;'ALZ:8!.!XJKF7A6G*#X\<Z&[OM+C>DO.(GOWRSU#1N.!&.+7:L&WS(\-P@
M<D*@8P"O'N*L=S&6N*8,HP"^&03P5!#Y!/;D(KVXX*.AK]]:#OLXG.@DPOGE
M\6SZT#+&+H#G9A:_"O'"+L1>-86LA'BM=1!O'GO5Q\'>B6Z[SDPQV=#WP!N%
M=_ 5Q9Y,'6L"D$QVC9R2AK0[BF\9?F0CP!>-A,8Q[T$TG7I^2*20/!]C>'VE
M(=J5Q-_YCEXQ%DQ]&[8!GTPPUD>0.G"801C$!Y<?MVUX/@ -7D6 ^F^D^R&B
M/X#S0@]TV+!>4PX!&/"\:^MU9<$24HC8R"&B5N\OA4)*,0IJ]>9*CQ<A7P(@
MCG\9'"-(\8WL *+,EW4DW1[TN2X/M=31@6AYV>SFCJ_7J[=_FX^T&TLBP4(^
M0L.$0?1%/AX:2CC;,YELY,>:D7HZ<!CX_%@/Z1[=&-O6+>*L[CNVA6O0D>.
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MW]I[J7-)0^UX/EK28D=(GZN#9D[Z5(&P-@&H)*>8!%!?"B I@!8)H"JXL*4
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MS26VL+H'V0I?RK;':84O!9P4< );-+6N_D\%*$5:;;]CM:TGX-1&N]OK]82
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M9C5Y1*EY5N(Q!C[I@O2ZM P/N#4=/>F4ZCLE=^T78!E:OPHNJ8I\927+=%$
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MM/*!S4K9N:34(IX)?N.G!)8=Q#H-(N@8G@,52*@W0 S</D-$1BK7N8\%;XZ
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M-!?4M2L7!=0/#>I)94-1HA@* H*.*"?%<; \)(PKB86E.D^N3LH&8VVA23-
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ME*RY!PLV0VTIXRT69H :3);" (_$ %-U7)YSXC2%9,0X8-99L(8'X%AKJ6W
M,;#$ $RW$9UULQ8&6%4&J,%R*0SP. PP9<18PY2V#$/2WW >+DS :JPAV2Y8
M$NFTU6YM7=-DP\PVZ&T8 8S-EZG6@'S4QJMFKT:Y1CW76"J3\X::L^%!Z+<Z
M%9^U?AM'R?Y9ZLY*W5E]A_?/,0VC;=9N=4.I.7NP:.O%ZH]TEK'S=:?7_1D;
MWPDE];Q&+>;KM">#&>$)4A8<(P)8Y 0,MPP8(0YAQ@2*<FV=)RNFKAC,$XVT
M+#6N:P^E%EP_.*XG_1/$4T&\8*!X;D"/E8=<+0HQ.!NIM!CYN+8NVCBW(BRX
M7E)<UQXG+;A^:%Q/>1T(I4$(+$%9C7/"E :-K:WBI\1(RIW0:^NZG:3:(%RO
M4J'8]4;KW>V*54A KS^+,POA*B]-$%8AH;E(://[]'0RP;WD#A%P(50S;AUH
M%2)PYJV-SLG W-JZ% L7JY:BD<9BMO[TR[_!;-$JZ@3TY+PJ9(56G"3[@!J;
MS 6)07L=(7=J4SJ)UGB[MD[:2"YL+A1(KV1TLAS(]>+WP^2!+!SFP5+0CKB$
M7T_ )F, *$;$:)/,?9'=>&K6B3=W)+(4>]VIV.N*55#*O![?0"AZQD/PU(]I
MP\%&Q=-I(B'IC008<QPL-P(T\<)32:/-721X6^I2[548X%[-C<( #\0 DY9&
MXO!D3>2B]* $,,L5Z-SKBCI&+6%$!))[/[>QKBLP41A@.1B@]F!&88 '8H!)
M6X5*K .6"I+ZAH$IHW/JM -'?4 <2XV3X!(#"/0T=( ZDB=KS.BJ9])>N<,Y
M[G"IYO==S],YG;QE0^+%<!';&IH?%YU+JJZ(":>9K_N]HZ-<)=@9AXI7*YFN
M&?6 ER4 %S-/.MW3M)"7<ZI_KT0Y^KL]\R,,-G\,^R9M^T[7],^VAN%XL#,A
MSXO(?SD;:SP;SV8":Y9%[+ 'S?/9R)$ Y;1/1C**1)C DXZ<"PM)6Z)%J@I*
MSDYS:>'^B@0++3P96I@TFCVU*@G: E>* #,HJ<S<1;".69O.C(!$KC=FJ*W8
M(M6&A1::2POW%YLKM/!D:&'2DN8L"H\X DFY2)9T9@1#)3"M!0\X'1F2)TN:
MM?DU;50>A156*1%P:\9,*OE_#U=7-*:JL4?O]] -L5/HJ$XZ.I\V7BBQ6'$:
MP0F5*XB$!"73%X]94F=#((3(M77:3B=822):6BS?0RW1#5@N<)T3KI-&A30Z
MR,@-*!HH,"8C**0T!)9T"J>RJ\&LK2\\8*I M;%0O8?RH +5>J ZJ>@;K)F3
MEH-W42?[WSK0CBD0,9?M2JF4E<V"Z@J$1';"L&J%F.,AH\EI]Q$"6:9@?S."
M(V_ZO<1)I3]2S:2%9LV!8)WA"*+(#9ZECF!%_D)8T@F9C3XW2,)2M)EFB[LG
M2IK/DB#__N(?!?GWA?Q)R\()'ZR.#BCV"E@T$FQ,'& 8T=P[AXSP%^&*V1R?
M@OQ51?[]A3@*\N\+^9.&2J164(TI!*)\]BD0T GC0 R1QD;G#1;CB,0BI4BE
MIWO-)HP9#OL=>SHT]BBTAKV;#)FJBT&K%W-08[6"&0]HNFSM_'$CCR6!749K
M-ZX(;:]W4P"V,-H\C$8OK9CT&>=?T&=/%'%)G."DCY!44 $J. M&.<RYD=2C
M9,9<-_3V44HKBX^T4>&,"LP+8_BJRA([/X*'\]#O%6S/C>WM*]C^>OX9::R<
M(1RP"GFHM;"@I4=@<6 !.T%PD&OK_^?_4023%PWRKA:0-RH04D#>*)#_G%V/
M=EYMG'\VQ$83$ $E+<XM3@-HIATDDT1)YX1DD341Y*L40IFV/S;Z_=[W@V!\
MZ\V!2;!PX;2ZYT&[E6#U['X,Q6MIK6D]T?]Q3\_>$"J__J&;$3B:X/3B1ZJ1
MM-E5JVOGU>:/STEHR.& P:5_@+FDE"EE%01B [,8:V'B*'B$1.,]236YD O+
M%9:[_R!98;E[9+GM29:3R%KLM 9N"0+F#0'C8X1HK6/>6:D%6[5 66&YPG+W
M'Q L+'>/+/=AFN4<#=)[L"P88-(H,,8+X,H[C*1 .L8G%A1L8+,/FI[(]TZS
M =W47AK+<HNKY)DY"6FS'YA^&/EH;NVBN=N4MJ<P>*\IUUBE6LK?S:#C%G'"
M-DP?O/XI;Z\/7O>$#='Z[I _\2;TWV>*J=>31VY4_C9-OYN6;7#QN=7N^JGG
MH:+GW4;/P]/YWI@PXC%*>AW"/*EY1($23J<O(6GNR#@M;3)FGPFY5)D2A866
MFX46]+05%KIO%IK,/8\&Q6!RRJD4B8508*"TC( D]HQA)AR7F87H(GUR"@L5
M%GI8%EK0$U98Z+Y9:#(/WFNMA0P4?. *6! (+/<4*)=)2PI)D_5X;1T]4XL4
MOC4OU^1)V)*O.D>GP^ 7:7^T9 QZW1,N'8,^F#4YWE^%0^?C4#)M3\H@<@4Q
M!R>T!L8X 8T, >%E0,Y(2<CB]F3S.AX6'EIN'GHP>[+PT%UY:*J:65*4E&T+
M)CNW&*-Y-B)/9J5S1H2(<5+H%K8H"P\5'EI2B[+PT%UY:*JVFDA'<3(G%>$<
MF(D"M$8*),%,84J,B7IAF[)YO5Z;3"D?JQ^"!Y-NRGP)HTCYH'4Z"+[5Z;;2
M7;K3HVK T)W"X37F."S]-5;)A7%M./Q6U7Q/ME7ZC2?<"'+WW5#X ND;(Z#O
MG![;T-^-U0$WV#T=#H:FFU=T[#XM^83W41LR]@L03$3P'$C6PADF&I36%%A(
MOR1!$9_;#&/$VXS,JN1WFR#6(+V\P/P>>PT7F#>@.&($\X!<Y$08(-;F0:%>
MYLZ!' )F3BF1N-WD]H&(MB5;N)]X@7F385Y[G^("\P94!XPG@CND&44:1$ (
MF(H!E%0:.(U,<2588O8,<]269.$&Q\VS;I^$N7%#Q/16%+5\[4,>U> 8BV*&
MJ0I)U4=26WBR'/TM^JQD$)0Z#@+[Q%+123 *41 R:2/$1L>R[ZTFFZ-YV64%
MZ0]O<Q2D/PS2MR>1[FQP'FL#(MKL7: &#(\2A+46$<&IE:PVLZ,@O<E(?RBS
MHR#]89#^81+IGA"MI50@D#' 0IZUS# #1=)7RC4S"M=F>=2?JSE5@HS97#7(
M3Z' <9FNL0+!T-WA0>BGASL^Z8>#T!UTOH6JA/AJT^B[504_A?!C4ZZQ2F'0
M/WK]]&.WY4[[_=!U9ZUA/UWLJ)I9W#+^\'0P/ [=X6"U(J7-:)97L<'+JV1P
M9<ST2&XOQV+;RU(;W>M&U^]=RG#CIPAWPG W[ID?1>N93^OY/AT\-28G3S,'
MB4!X4GJ\ XVB A6BDSK&P%5<6U^RE.J"]_MO&U?PWA"\3T91=9 J))A#(OH
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M2F- 8(5U@!G7(88L;[)\U3.%A1M"2(6%2XW+ZE+Q9(U+")$A;@4$+1,?4T'
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M7HAD4!)Y':)O7W-;P/P4W#U%2D5*14I/1$HE-? 1'*&W]!Z4>OB[&QM3?M!
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M4@5>LQ8\->'12B5YP *0CQ08<BKIP-&!)\AYIZR..*ZM8RG:2,RV;2TI0LL
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M_+X\FXQ&5V1R.8;G]3["[_/@"_QB*_W*>K@'+**<7?DR[@Y_E94O&L9"\*M
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M+3.!/R@;E [JZ4\@^!OSO.Y4@HH!+42AV\>,M+61>_E&W&[$<=O*>7_GB26
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MALUF76.AJU-NNK#+G];F"2[ "G7C3[%9"U9/6JP'_-+LP&WNU5S5?\=%,3^
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MJ> L70VUZ9@' Y#\;Y#!I],3V&:E\T@0J2,))D!L" _S!,>)R@AL U%0_5A
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MD2,P$!42.CBCHG+2TSM2Q?FX.7"%H?,4_GLILV&##<:"[F4CY8919R4.6*@
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M@TM/#O</3P]./[$#^K%VL'_8R$Q7W?YZ<7!9O=C]L%O_S^4.V3T^(IB;A$E
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MYS\?3UPCU/=.O_)JXRL_W-\Y!^.#5"\_GQY\.^"'IY\;!Z<[_"#/.U\[_43
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M,%%!1HV37]N4&]-)Y$,*6+H#:0B:.*N$TD)Q[8*5$D<=F;3!!\=,T>C6#(D
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MYJ%!!Z&@B# <4V349)-&KBNJGRS(L'3AO=07%AO\>^'Y@G]#[<?FD,AV>PW
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M;-%\=2@0UZV-V51K8YR[N\[J@OPR'S4S>RM/=%4NCRB_3EME?=]!VN)<\'7
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MG$<!*PLA$59(4Z,1)])';!VW1?/8.]7@)VAU-&4M1W5.-9#>A[1MK3I0/RS
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M%Z/;S;Q3,343=RK<\/K<IP#SX?,ZM6.HYPZ# (3P"ZQ>BJV\PK<6HML[J[7
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MS :;Q7@8UV<OBV.753"V4("Y[7 (H;1WCH/#D3EF+5@3[21',B7CM:<2HC4
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M]-/M(W_OY9BZW3J[7,D8GSTGQK]_[=Y/C/\Z'2W>LRNU$OMD?U^K<^5*/=E
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MSR,#5_0!W1J8?(OE+OC2_U7,%BGCQNF?G[LVY$>&R?_O>2__4TQGN:K7&EH
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MGF&O*K=IZ8"I.>$V:>JD9S*@&)1&'%8-66<CTI8Z[K@$PQ,JMZD"IB48VB.
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MCMDR'<"ISM4M.&?N'=>!4$5UXBQJ2[1D@H1(M3&!\)?6Z\JS?[I*3W@5005
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M8Q#'"R[6:YMG\Y:K?NN6H15 9,YJQ_9[K.47 !#Z&:T+"1A[B$ZT.8%9UG/
M/>%SJ=6U7=^R[9H=#&)^N7_[Y7;+NE:[>,P)V9A6_BPM!>8GHCS6TB5/(C<\
M&$*U<AAK;%QDEAR1?+KW3ADC^A4$:(INIQ"@)IB4&B'KM:$-;L*"_/_MO7E/
M6TG3/OQ5+/0^KV8DFNE]R=Q"8@(9,;H-64@RY!_4*QB,S>TE!#[]K_H<&[Q
M,,& ,6<T(F"?M;OJJJNJJZLZ#3^1]1&T8D"/P'MAW%GI,#BD'GS1D&CT A]L
M9G4"6T[0=?G5<7N[W?+MT[AG?US'EO?@^G\UV_[DV8WGYX'Q;%_N_/W/Z>[7
MG9-OF_MD9_,$#-K6C]V]YE%A5#>W+NM_U\^_G<(]WQK\[=\C[$^_M.Q7T]\]
MKN/]TWVQ3S^>[!SG^WVXJ.]MB=VON9;JA_/Z7OU\__*OT_WCC?-_+^MTY](?
ML&A3"#@BSKPO<R^, C+*@+\H%@*Q(#BU@=3%L)$Y2 "I"L%S%UWDUBKM"26*
MLL"3H ;SE5H$2G(& P^J%5?6MW?>[M:W:GL;_VY]&MK/P12OCTOXA( /IN3.
MVXT_GHG.>!R5H3%Q[L#?=9I[EI++_4H9/-"]4/;Q=**XXIM&#V[G9]"24GIK
M(+ZU]YWV]T871NCE&X]'5OE/_BB&?C/NI@S>[59&XMUT!01;I5'Y*[9B:O3V
MLM5YQ8APL;MW2.!SGH_;W?Q\X'1RV-.$HC8<\5S[W('G Y(0B_UF6/-I]=.6
M<^EYY!QT5CH3>%9&[R/C6#LQB0Z9/9P-Y3D[.F"3"T'OV1\@9G#Q;J/;R[9\
M0+[:S6;[/!M:?S6C;WX.*S<;SO$*;CS7'2ZV%L(!;SJQ"4=^CX-RPP,/<>2L
M08E ?'V*==UVL]^[_92IBG=/KW%$P#.]0U1.C,_(SZ/.M?-R&)'K1'N";(+'
M?6.;Y_:BN_+'.-  RHP.X6UO/W"%4%Y\&\6;]?^XSA^3\_4SFD*'<#:-73==
MZT:3<J>)F)!I)[!SN>$2CIHG++610<:HI8TLP!FWFI3\M"NW/<1=BO+41;5A
MTM9P.7'WK:JMR!J [_S+*=,UK'^MOO//O^-8/L[#LB>I_6R6H/1S5?7Y9T.5
M^<SL)7&KJK<SC.=\ZXR;99.XNVO>WB.7+B6<_&+LPKF;%16O_R[")-KFFUF4
M[J[WG47GGOP:]Y[$5/QW8ZZ66O#)?-OO=$#!9DY+N^%5G[G6THPO.GNQI9M>
M\9G6XV9\M_OL"/N50,'/5N8& C0 A:E P9W+XOB%!@^&K9CJE^^:WXX/X;F^
M-'>^;F.X=Q/NQ?-]ONU]%CO'A^Q;;M4TM1:7U_N^G.YNOH/S/I/]XP_PGI_A
MO0[AG8Z:.WLG%)[W-+=J^O?RPTB*F!?P;@=8Q42\]HA)EQ 7*5>IQ ;)E%3B
M)B1M_=R2S'\"<(^59#YQRYF+P54 ];(!BI.DC0XA.,QRRSAG6#*2>LZYYMK3
M J#P$*!F2!VH .J) .IB'* LSGN8)$%))HQ@\@(RV$O$=!3:8YT2GU\/R#D"
MU)PH_(M@?YLQ1=".\&L;Z*??^[GSEUX 7QH.^0"/;EE?J5!I+JCT>8HV1<]#
M[A".)#$!\>0),DX[1).T(K"$.?O5;,)[(<.C[<V;T3=^]8H]=YY1*?;3*O8$
MW3!:21Z 9&@9LS_$&=(ZUZ"-4C)-?&)QCOOHYZ?8#PTV_9*&#ZXQ6SQV^71_
M[D;]YSK_MES0A/'</8/#\M/=O5V@PH%9<&!_RL#;J B.U"+/I$+<1X.<P1&E
M1&2RF B2^+S=CIG7-9XS8E(!PS.0@@H8G@\8)@@"*+9/E.8]?";OJ241&9T8
MLDQ*Q7#0U.B7!0RO8;'Q4\_V8K74N,1+C?>Q2\MM?1YK;:[0H8U6^&_;WQ@
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M)/.1.9.<3-7.JT4+8^RU>U61QVKAZU5$R!]MX6LF;[7BJ/-:]QID6D66:P
M/66.2W!9-4:61(&\I9)@D:CD/G-4I<4"Q<BK=:^%9Y5W:76EN+^XO#5(CU*!
M!N:L0LKX!,YEX,@Z&P 9,9&68Q^,J+9C50M;BXHXC[>P586]GRQ;F^WN;? #
MYP,U@E*$7:2(6^V0LP[<5^ZH"D N</S5YM_5BM9+TNG'6]&J=/K)LJ]+G199
M>2TVR.<"85SHA(SB! 6CM0-)#E[;1=3I.<4J%II<;%^ULKON<?>+0;]!>QX&
MHQW:_=P7[![]>9:T6/Q<AF9I,'WNN^JJ.,_CX_F/*8YFDJ).$PSRI(&9&1:0
MDY@APF(T7"1N[)SC//-0HP7OG%&!: 6BS[,ML0JKS0LG)WAOB"%)KR)2,>\#
MP=0C&P5'/((P.::53G.L<O2<&%DPY3^*OJ[K-S0SOFIT^R1]M+=2BC[W1KX2
M[(^V%S]&N*-O-!O%,U6-M,<::>\?,!<5-D$CD$RPZ9[QG&ZH$*$2 V0)&F.8
M;(Q]5SOWY^_=OC?6CKML5GS6B=W<DKMF:YTQF1CV[\Z^4"RAL.9L-S?V;A5?
M='NVU^^U.Q>U#@A4K=<N/LUMVVWKHG!?U9]P6=_KV^;851KE^;E3>-8[FYN%
MYXO%T^)!X+[MJWR8ZZ7_.WI,PY"^F.[+0J\13JONRR_K8?F3M(HFHNH5?:N7
ML1R=>Y^A5_02#!FIANR^0X:7IRNTF<EOW.C5/J]]6JNELN'!!$5YR(KQR\B)
MGFV4T*WN=:N?$?S1EY-G<4DVAKTR/PWG<.S@*W<<T1?JKI3^.-SK*[@C?W\&
M=^7;27WO _[V][OCW;UOC?V].M_?^Z>Q^W6??#O=.M]Y.^&/PWM]V]PX_[;W
M$=X+?/'-CR?[7^MBY_2?H_KET5']=%M\._YRNK^W@?^]W)XJ[TDH351I"Y,6
M%>(4!V0D\8A8KC7F1BKJ 46 %LUI#>K1?.YG4*'_>]2,Y J/?H9'\U\*K_#H
M.?!HHAYIB,HSY1U20CO HRB1ECH@C ,ESADP,:'"HPJ/GF#YX9Z %((FSBJA
MM%!<NV"EQ%%')FWPP3&3 8F8(2#A"I 6$Y!VK@C2(=VYW#^(PG@:C$,V. &
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M1!N*+,$4$:)@_$WP1/C<)^">D%&XHT\J'15BS$<H* @%^&O>PO C385"/!)
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MOD+]8?AV_?G#M<,%_'/4.VVN_S]02P,$%     @ SH!\55:2!D)7%   !>
M !$   !A<G=R+3(P,C(P.3,P+GAS9.U=W7/;MK)_[U_!ZY?;SE2V9<>)[6ER
M1OY*G'$LCRWG]#YU(!*2<$,!*@#:5O_ZLP!)D1(_0%)2C1ZZ#XTL87>!_2V
MW<77;_]ZF?K.$^:",/IQI[N[O^-@ZC*/T/''G<?!5>=XYU^??OKIM__I='X_
MN[]Q+I@;3#&5SCG'2&+/>29RXOS;P^*',^)LZOR;\1_D"74ZGS31.9O-.1E/
MI'.P?W"P^BL_=0_?O_>.N[BS?_SAI/-N_SWJG.P/W<ZQ]^YDOWM\Y+T_0;^.
M3T^\P^/NA^YQ9]]S]SOONET7BF'UO^YP^/[]L7MX=*B9OHA3X4[P%#G0,"I.
M7\3'G8F4L].]O>?GY]WGPUW&QWL'^_O=O=^_W3SHHCM169_0'TNE7X;<C\L?
M[JF?ATC@N#CBSWRI..*</4\P\C@6&'%WLNNRZ9YJ]_[)X7Y,IIB2$C&$"HFH
MNQ#C2=Z1\QD6^33P\Y[Z6<G9[^QW.P?=M"1/+LC28H[VPA]W'"0E)\- XBO&
MIQ=XA (?2 +Z9X!\,B+8 X/PL8)\J4#J9XGX&,M;-,5BAEQ<1R6??G(<!1F9
MSAB7#LWP&"$QU'467&JR'2>$]X:Y2&J;525%W+Q,^3WL2Z'^ZJB_=E^$M[-7
M76H@.F.$9K4DIVE"Z=$W=6J0LM7NR<G)WHLROOP:Y!J1+M]1'SO=@\YAMX;8
M(FNL+AO^ZL1TFZA#TO'JU2&F6[,.N3VLR!9,E/IO4;$:^3VVHA)B M7ZHSH"
M!79WQ^QIS\.DBN&O%E<?ZICZ$A,A9[R.T$5Y_2E'+**42<U!?1-]-YL1.F+A
M%_"5LI/3V%CN\2@>/C/S04Z/U/_ 5.!RYANZ[]Z,LQGFDF"1GDLT@PG'HX\[
M:D;IQ(/C'SX:[D)-XB(9 <L6KW[> Q+LWR0MB6F5T7W<$8"!CT/=V-SP&<=U
M&SY3\PL-@?['M]]%?MWV XD;^/\=S??PJ&[S@810TJ#UBGH OSO$^[ASSL 1
MOD-CJ)WZ_O'^NH(OH^4GE#'[6$!2LT_[^K^NTTF<Z(ZC*1U%^MO>*L$*JT!@
MKT\_Z<^K]AX11T5*"%<,I3+=LH9SR:(O8Y66*+H7>$1>PQ#,I[HFM?6=86!4
M^\&RVC4#)\6A1=H_9U0PGW@J?#M#OO+2'B882]' [(LX&?$X!! >0(-XT0\2
M5D[$RPF9O4$CQ1WBT*H)E@3JN3F<EMD:07M7'33GYR7>O[04Q(6V!!OU81+4
M51.(>N=L"JV<8"K($[YA8KW.5T.,$>2C,I 300X;.8DH!V0Y2\(<)>T-]=&#
M9.Z/"?,]S,7EGP&1\XTAG</:B.[[ZNBFV?^O$PIX W1TCL3DRF?/F^NQ"4<C
M?!^JPZ>X.IIMBT#K\S&BY"]="QB2'LB8DA%,0%3V7)<%5!(ZO@.%N1",U,:O
M%G,CE,?*(R7"]9D(.(8_TNSU>)H2X"02G%A$BV ]9[Z/AHS'JK\A+LPRN#?F
M.#3X!GW1Q-$(X,DJ@$L\-8(15R=AVR+0[L*P?PZ*4)/'3+6_-DZY3$S0=/=7
MH8G9:%06C%H$QC5]PD(VZRMI6J/JNZNJ3U&W2M\2T3$9^K@G1)/8.L/ J/F#
MK.9C%D[(HT7ZWX#;W<"][AZN8M!Z)WHZ)6'GU]&H]F P;>1^E?$R O,N.UDO
MN$7!:XI?BQ"ZP4@T ",B,^K]:%7O(6&+%*Q'@#-HM$[&@#O8+.5=P,8(P/O<
M$:FC.3EI5BV"Y H1_AWY ?X&Q@A::>86Y7,Q O)A%1#%Q]&,G#2G%N%Q34&I
M>(!>&@Q$:5JC[C,Q=TCM:/(6*?QR.O/9'.,S3(&MO/,1K:_Y7"9&"#)1<\S&
MB?@XFE&+P'@(A@+_&4 #+I\:#409!B80#C+Q<<+""7FT2/]UTGI_2^ZP<@[Q
M(!-LU\TA.C_'G]JT0E<'C &"^'F[>$<BC&AG OSZ:(>BVH1U7@*Q(:8EK(S8
M91(#^1G)-B*42A V!";+P8A')A^0XM%.$);3C8V1R&5CA".3)LCD+ML(2C8#
MV1"60D9&8/+3!RL)S39B$^:Q&N*Q1&S$(),Q",G;J/7\+-@ZO:*(F1&53"ZA
M*+'61IQR<V,-82KC940IDVXHR+:U$:14ZJSQ=+_*P03(82;UD$[!M1&%.I'B
M!9:(^-N-1F,91B0WD'R(9+4);N/&H\\^>F%B2N3D!U!C<(2Q[V-7!LB/8\9;
M=GA#H 3VFAK$=FIA-)E,!J/*EBDHME(;)UV=))+^^9;M.H>_.%&MWLPK#]@O
MC)._P,N98(YF.)#$%=<<^U#THG>^-7.J)-5H/IDD2D7SB:0[:?%.)-^!"KQ9
M2AYF _0#>^AN@O@4N5IIR%=^+:+S;8\^U44;;29GXT<EFPFKX"S7P8DJ\3;$
ME*'W%5$![5M6G0 _;VOV8I1H-)-, JJBF4225^Q$_*K<VMTW\\@#JS<=8[I-
M:U@58 0_D^2J"+X6] 9U2;]DA,KO\ G4FO.[NCOH.Q&$4[3D&6QSI%BW1D9C
MRF3KJHXDJF9.5+7\8N%E2U']EKR9%AMAWJK<0S"=(CYGH[P?F]I68T%&D\FD
M$@L6!]4^#2U/G>\J6D!\,P&MB)[G:?;(3YWRWR3TI0*,D&?RDH60)W+2]Q6T
M$N?4&NVBXSU,&)<2\^D-HV/U;ZH0J/(;XC] 44,?/V WX$2ND47;L'B3C;S+
M294F:]1+8X&N14>)_]51%=$?EXHKJTHJXR2U::DA+2]3JWL O<#';+3Z2W-;
MJ2O!: XY)ZM6U\C!*"(YRBIRUM#?L!:7+S/L0NQ^%2A'JS>%GA/EK#>%M5F"
M$6OS62ZU<S:2XX2"G+2D5D*=W>;0%-)B3D;H*AT!:R4\)0>X-NJM-95CA+;>
M(;(WWRV[7^868(.*/.&FV!:P,4)7< X-/BQXM1@6E=9F-+R-1'\3SC$Z08*&
MQ%_+;6X@P@AG)F.W@#.1HUP@_74\8X8YE86P%N.]"%^^(1G% 8N+H^A8ETDI
M2F72'JD'ZE8K^.H*,4'6M(8-5L!H*T7;YY8BJ*0>J8NMZ#@RH+35Z!R>DZZ.
MH^OS9DX;0/./[JL;%%3AS:0L,*G9++QV'OGQ_5@P?O?E!/.4*W6/?77UE60A
MU;J#TCHRC4:3R?*FC"81G-S;I><K+7S)>8S$.Y(M]@&WT$KR]^ZN[5Y69&O$
M.I/>+=P<W'8'-%_CB^'\,T=J/%3=,)#J20'U,LG#!/'FG7U]B2;XC[+G:XOA
M3\T8D>BPXR?"G5#ZFWFL@$7^PJF!$0U9('7Q_DS]O17[J"C2:""97*[10$#R
MTC2@98=D3B3]S4 6:H.(+YB&6GD4:J[6._ZW9QW5Y1E-(Y/Z+3&-E%A'R55.
M07BVX<TP#,/\_<.CZ+DP[:Z;):XGP@A_?OK8.'4H64XLK)5XYQX3ROT2!M&\
MY%-4Q$-R0:6<?3?@'";AM9(>?V?=C!:6R6(7'8DJ_@5J6914BVOJ()DFUX%+
M5-T6![>I U-WG#T1]>R>PCSU??-5R,JLC2:2<QP[=4A+;U:)!&A36#["U6Y8
M%Z/_Y6B$U7B,%S_>0]P.G8!1%SK+FBO.Z\DS&D FO[YB *F99R$W5<91HIUE
MV6TWC/0"B)S@6RPO\ AS&"KAYW@$53O,],"Z <MH)M!H&IG<YXII+"_ @& '
M)#NQ:&T=/R^D_Z+G#UV!MMO'VKFK,EY&5$MOQFM]DBJEVL^<"?%(.8QM8PI!
MN>I,T<UUFYBZJ[ W@IG)/JZ J84X:2FZ6\9R6@EQWFV&&]V54EN ">;WF2QC
M_E6*;_M0EM("*Y<E;A3C6LR-^&:3A*NW-+86VM_VEM]Q#?]>>NM5O?0:O5RM
M@5>/3/ZA,^G9[!W,;72LBY[-DR)W:*XW^C\C[H7;]JZID%R_(2CTPMQ@@FB4
M8XMR]]?T#G/"O$68ON.@(1 A5W[<&2%?/7VIWL %0WR%JE"BCB*I]S2!5CW"
MJ=XB/YWI8@/]3*87A.>4XM^&X:MN\ ,>$O7X,)B@)#)096 :"68?=\*"1.+I
MCA.^M1E^,P4O4$*0< V_*.;)H[R;@R5J<8^:M9):4-D\)DWK808D?$B[GN:%
M7B^JH/<+/)3)48 OV/<&+-JV,.^Y;C -]%ISVE-0S[K=0E@7</6\7Z$F-\"Y
MAF[^3EO]1GPL))2/\(<H%Y,G5=%'B'NN+GJ]V8RS)_5,8X%N:G"P5 =JCT)2
MZYYXG(TXHS)JST6 'ZF'^=+!Q\4AQD*UK,?44DT-GME@P@*5SA6#">$2ZZ/)
M4 9B*>6>?</3(>9II83U#W52F;S.R%ZII9[D'?5)G'ILB@BMTE;L3BCSV7@>
MG5Q-;8\V-+,"I0TM5&,W\7!_%([RZ4E"N]KEK:Q*;4-+XW-$_='RV)V,Z;W\
MTVWZ J\B#:S+=0.:\>3I!$IR-QCBZ^S,*=4"1<U^?<4"'D_[C7JV@8$-]@##
M+HRY'NL_4\QO;L[+&U=4VH:6) '3/58D@/<%?L(^FX5S\5AY)HS/P1(?$$S4
MB]E:1#.1*)S!-L&Z^3SF<NR]EMO3<R<$6JI^Z(_N)N >@WU#,Z\(%S"#0Q>&
M&9P)'93H7R<P<3=TD!K*LM1!^'K[]?#D^*1WW_]R]GWASY1WKW(:&SI9Y+OE
M XF]0N2-=&M$L-OM'Q!KJZ$;C6%R4]%VZ)_Z>@NQ6VSJ)K)-!X@)EK-0<J4H
M,5R[N8=>1]5VA3+;+"AL@U%"M_EP='"P_^'D"+H._-4U=K."\C:TIB<'$QSZ
M2A6'C3(*&UJT'-IE+^<Q^AR5J&UHZ>KX5NQ2Y)2T=@C<E!OU7^,S)>'.>9C4
MNN/,"]SH]NH!?I%G/G-_%*<CJ])OT:9E+*52!^8SU0'Q%XR\/P/$)>8"O# D
MD(<I,O7?2L0V=-_T1<<]PW7*-^KV7& I"K,"S9AM7 \U ^#&H;Q1(9O@_-K:
MN<>JJ+J<0V_??:1$"G#U]/H<##QZ_:"\.]3A8$.?N(\60Z^0JW?V7-,'1"\(
M'C-C.PUT-K0NOE(R'J,,X!46MZ$M>AJ-3A%6=T0,5)9&U^"W_W[QI:I_G%_8
M!LR*,R(-DBC6HE4[7;!.GL"V-%I//@"/5$JK ;(Y//XA4%\B3FL '1>W%>8D
M$WRCWML(AO^/73D(3XQ72!_G$6UQ&$(<HPJ-N@W4@-@?71!@3EV9<D?Z0Y^,
MM?#B&:0J^99\-T(E'F->*8R93C%W"?)OF<2&1;V"PC9,&KVI"A_46QEJ]9B%
MUT%>,7X6$-]C 0P3D=.E'[0M,LI:3"P=;?+>$Q#*I5;>-7@THC_J 8KP=74?
M;SV>-MC' +U U<(S75>$ @X0W.CM3(764$9B*?;Y;P- "/F53:C0,7?TZ9I2
M]J1U_O7KQ7F"&GQA2!1O4H0-EA$/U=&6M0&[QQ0_&T?VU>+;V=U6?2#/O\F]
M',MR&AO *7U+I[QQE4AM:..5VA6,;Y0OOWJ[ZO5TA@@OW4E6D=I6YS&.JOOA
M17GJZE"H-F?AFK>XQ3#I#C ,OC+U]6+-L'@J7YNOK=N'&VXV/=_.'M9SRS>P
MQJ-U\OJ$<6!/%WWM07UQQZJ$3VH_76AQ.D4^#_]O7EFIQ\22Y97"5X[6\U.L
M]4+R4N!AWK]A_CR'V(9V5CNYK1;^E'>EF[.T=S3<R%%HZYMBOT555=^+LD&G
M_1_JF]^S.?+E/)K,U>8VH6;R0O@+R]OJ_H1I>'TGXKQ6YKZ Q ;0;L&RN"2&
M7-)J*1MJWO=G""(B1"M"45S>BM;46&POW<G>@)$]F]<;.+:?0;_;.?:URMG6
M8>D2>$Y5Y>,PZHKQQ:6^ZBD.*K#X/XQXGQ:G^.LQL545^OZF_N@N=5H8^L"C
M4$=;H@:*>O[X&APM<<[5.@"CH?>$9D0B/[RU4Y^\59L<^!/V .WPK99K(8+2
M?<%-V=EJ,JFK9Z)$#+WCS,5"Q!M  ._4QK]S)LI&F2;,+ W'K["*/GV5?5E<
M5ZZR"(CS.0!<FHZO1&MIN_,/<M;9XVNE@[%P?Z@'7FGOV^=N;<>IF-*&%C8Y
MN5=QO^LF6-LR'2P.,V.O)]8^$5V%B:W9V?01%WVN5ZB; _M0=:C[&&9V?1V1
M'L"Q)ZXXFZJ]9F'9: JL='RF,6\K$AO0Y2]OD1MV_B_75P?GZHX(#QDW(%0@
MM&'8*#_3I_^:R?YH.5M1_5Q$57:63H;?,6<4)<?@[V"X,ZQ3EE#8@+?> U'F
MF)1L-:U :BF..3<LPD2E&Z0O7ZOBTA80VNK9USBL>TDYS%WJ<W0T]_#<)U0M
M0@PX:7QA2CT1EAI.?%I-O5=X%>C;@2KZC54H;1@04A<>%-QWD"H1WW5B*/4,
M7\_[%.<4 WU<4R]P=2WTC5BF.TBLJ9\-:.E=7M!]+G#X[S55SJBN].)1Z<+^
M6HW8VG.,V2,IWY!'A&E!R4AF Z[)=M7,(8Z>U#<H)"64JUR:H*K'R-*1-Q4*
MW 4 'ZIQXMA,:0/F#9/R6]@>L\365H<FDUV\)^,)N!:/\9NE?;[ZGF#U3&45
M7I9V%!5>/EQ47Y'-*VQ#=S!=%"!Z48N:WC208O#:YU![ 724U+VPIJ85EW_M
MEJ0S/9<^T5LZU49CG1T;$*RN'-'!/G2A/H7H41]8K)0XJL/.BES1!0_&WQ -
M1M"N0.DO=CD,5[.8R&SHG7GN<[-KU<K);6AKO0M.;+[0Y+./7IB8$CGYX:M3
M^%1BW\=@9LB_XPSJ(N<W9$J,AVKJ\[&A]<D)J/+69<O94'NU^8)1J?(F:B@&
ME7/PY^,83N7,+]1>0<%\E57652G:+ER?D[5!X+6ZEEQEC1 52&^-O..D9,&^
ML+RU+5P]CWD64*\DX"LJ_NK'->-7#]2>;DZ&FKEXG V8OO@OFNC+.V8M%C;T
MV;P*W^(7"=-?XP;GT]O0VL4Q!.@0ZO0*3.YQP%V\-Z*<Z/5/4]^$(41XM55_
M-(+!HIH;5X'0!M#B=)C*?<[")"<3Q0YY47%+@^%X85$?I:CHP)73_*V8Z?<R
MA#O!4_3II_\ 4$L#!!0    ( ,Z ?%50KGQUJR0  (5R 0 5    87)W<BTR
M,#(R,#DS,%]C86PN>&ULY7U9<ULYDNY[_PI?S^O-,O:EHKLG7%YZ'.$J.VQ7
M]]PG!I:$Q2F*U)"4E_GU-W%$R=3.!8<ZJHFHTD::YP/R0VY()/[Z[]^.)T^^
MX'PQGDW_]I3_Q)X^P6F:Y?'T\]^>_O[I-;BG__[WO_SEK_\'X#]_^?#VR<M9
M.CW&Z?+)BSF&)>8G7\?+HR?_RKCXXTF9SXZ?_&LV_V/\)0#\O?M'+V8GW^?C
MST?+)X()<?75^<])&I,=1V#.>E#,!/ L)G!9><:=SL:'__OY9Y^EXY8[8#DQ
M4)PG>AO6+SQ&8UR26G8?.AE/__BY?HEA@4]H<--%]^O?GAXMER<_/WOV]>O7
MG[[%^>2GV?SS,\&8?';^[J>KMW^[]OZOLGLW]]X_ZUZ]>.MB?-,;Z6/YL__\
M]>W'=(3' <;3Q3),4WW 8OSSHOOCVUD*RV[.[\7UY-9WU-_@_&U0_P1<@.0_
M?5ODIW__RY,G9],QGTWP Y8G]?OO']Y<>F28SV=?CS#D.2XPS-/13VEV_*R^
M\]F+V70QFXQS%?,O85)'\/$(<;F@<72?N_Q^@G][NA@?GTSP_&]'<RQ_>QKF
M7^=0!<Z\9!7-O]W^8<]^ $UADDXGW;R\I=]7'UG!-,:,WY8XS7@V2>=/G\S2
MI3=-JHAF\_-_.0D1)]U?1Z<+^!S"R>CC<I;^.)I-,JV?5_]].EY^'QF=>18B
M@I8\@Q)8P$EN@6&(7!4CLQ67YZH.;$$CZT1;PB)V\ET]XEF=Q&<X62[._])-
M:S>EMZ,XF]/=Q_5B=GP\FW:?^\\P.<5183E&D6GY\4+++](7;V@U!IN+T39Y
M+6SC45W%<'E,:TQY/D]/9G,:/*FOIT^^8E4V*TUV!H@8<HU"E]?1ZAW/%J?'
MQ]UGPGB)Q^?_OJJUIG)?SAI.]YE,:03["OUYSN,Z]C!Y'\;YS?1%.!DOPV0-
MW"BXJ)*,') %2;@8A^B<)GT<;!)9YQQ38QK<CVH38HC'28S&(FE'E41.0)UE
MS.^61S@G0"=S/,+I8OP%WY#[<(QO9XO%;[A\5SZ%;R-F59'&"_"9)8)&MCKD
MP"")8#C9<J,=;\V;[2!N0B+Y2$G4H[":,>H#+L-XBOE5F$_)]5RL@7Z)99S&
MRY'STL3@R%/DH1 NS\ A-^0S!F3(%!.E-8GN1[4);]3CY$UCD;13/HL%^7.C
M*#F+9 RA.$O/QD"$+2X!+YX5ID-4NKDMZIZ\+_[W\]D)SI??WY-WNGP^S554
M)S6DHA4X8D$A2S06D9 $)CVG2$AX0&%#UE:0,+'QJ.[",R2G:P>Y7Z5TLZEO
M1N;7XRF-^BUI8C+O%"1^'L<)GHVT8LI2&R:8H\$:TL4^(H3(,D0NA X6@S6Z
M,1WN1C0D9ZL!(1I.?S-*O".*TO"GG]\B1?4?ZD2^*[\OSF"-;/;..%,@^\))
MHT<%,28/R9B2C-?)V-R8$7<"&I+CU( 0[2:_&1_^ R?YT^S7L#R=DTG_B*E^
M'^/BM]F4?IR3]J(@P$4>C(#$1"!</M"(:0(LEI*-C+I(UY@4]Z,:DFO4@!F-
MQ=#8'7JQ@I!9+%DG!&$X:2QK#03.#%@72U'"F<A:&XQ+ #81NGX\0M]]<MN9
M@QJSK4S2#ZKEF$,0P0,G'QR45I;"M42D*\QE;Y(PKK0V S<!V43>YO'(>__)
M;B;WM^,0QY.K*L:RD"@"9V!#4*!4SD3!K,%RJY/4] ?)&LO]1B!MG9SS1WQ?
MGW2*(24SGBPL1YKJ6" J&\&'P!5/3K#0>J3W@AI2.+0_/^[V??:52;.%\&(V
M7<Y#6OYKO#QZ<;I8SHYQ?A,X'[UCUD>0O*8@K T03;'T*R)JPS&9UBIQ0VA#
M"IK:TZ8/^30CS_6<V)MIFIS6[>WWLWDG@^5R/HZGRT"1WZ=9Q5O',YO0)WZF
MF!#GN%B.-$JEI"S >-U^9JJ <XILBI'>:0S!J=#[KMXNR-O/WPAYXMH)"UR0
M*Z2B8N!LY)!-"%HJ4RWE@7<XA[8;V#O'KJ[!/<74;+G].I[.YMT$K ;EG/5,
M2 =%NPS*4%P4-!/D,C-EN&928NN%<Q7#D+3O *BREXCZ\&[/HRO&$LVIID&)
MFERQ+)$-*@C!<O(NA&*Y.56NHVBP,SH[G2X7[\/W*L'SL:$6RFDG09#8ZAQ'
M",E1!&$8)ANBD5RUWP"] <F0].:>'+AAGW/?J6^Y03X_Q7S#"%4F/\M'"4R3
M,E:!(9!79, 5)HU*VA"V]DRX&<R0-&-[,C000#,^O#H^F<R^(W[ ;O_T!E@A
MT9"RY. +?5&NCK/6\S'/=40K(N>M-_[N!36DW'YC?K052$][/Q=1U#DFEX17
MQ0=(00M0'A&\R[5(PRJ+G*'G\3 YD2T8<J@<?V.&-!3%85(A%PH.L\Q8,H@B
M:QT8\S3>D(%;E((T74BE=7RV":XA[0PTIDISL?2T.90$C\)S#S&1%Z2,XN $
MBV!40+2!<R]:;Q/>L3FT0W09YG]@%QG]V'X['YL((FL*5P@"DIM7.)EU%.3U
MD;KFIA2116L/^PXX0W*S=^? M="QT?RW=+,[E_\#)AQ_J<!^P^4Y(FN+LSE8
M<O<3(<J.0^0:04O&O!8N6&=ZBKENPC,D9[L=)9I)H)V-#(NC^G]-KWP)$^S
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MM'?N0/2\M\SU83=H'S\]]Q7_0VC/:+(I(D4H,1E0EI:/KY?^1H'('"9'4<)
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M@5@8-TXC;UU[= N41YE4V88Q=V>F=Q/)8>SP^GI]]2W16Y\?U]]&1O*28R[
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MR4<A05I;C\L;#4Y8 ;)PGHLBM1U:V^%[( W!>O;)DI82.1A-1-%>**% ,L]
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M5-QJ<2T-M'BAP;"ZO&OO? J\#(FC4) 4M+.Y=7:Q@7MT*/7<D"W;ND+;".;
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M_:&9)5R\8M51[R;U!O/DS_&,_"5?7)V1+9["1YH&!%X0;,PJ<>=2'N"X^QY
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M3&]<2_7WT!O74<&0E+@^.(Z0WKB6^%=QXS:1W9"Z1&&<K!$"HF+U%M"#XSX
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M=XUE-4#?A;MIJ-DKBLAICXC>U0/L9"BBRAZ0E:R+2?K69=6W @,#;+OME'0
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MJPT.+8.@R/YH#?*1"2.T:UW9["L 3SMVVUP7^\B 72F(ZVE,\M++U&=. X6
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MQ(@V@F>8:)G@DFGM*8 YF/IVJR9Q@.%J6_MM741E.S,XI,)O:Q.'A!72^5R
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M,57[AQ@!)J*2*B1FL;7Q??I,W>7<G3I1NRBU!X+^^?GODZL\'5=(#S,S;M_
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M=AXY$P ((!(^)DH _M7)KOV>]%S0(UBJX%R'? CR^&<8!B8[NI]_ EE0:A<
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M>'\A2 \GD[O*< V?U!\BO&G3^%&1?OVFJ/6SHB42Y,4]RUNOJ -NI(-_;U\
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M]71D-WQC6;E^= LU<@$PT-_B52"M"EC^+;+'>:\4#@TR)+SB01V%L6G<#*A
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MOX<+SO=*&T=EH$W^=[MEW=/)MF<92[_]SMFX"^%V@I0I164/D,\YFX]Y"W+
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M.YWY)(@X/":?.05>^-@P*N\:8&HZC';DJR4J?;K_=CG%B,O:Y:H^YT(0U)>
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M!V9HH:>7Z&=W5KC[_1;4H#A[%!,R@ )Z>:-SJBHSJ(I9<-]D"WY]SC5R,5F
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M53 3PJ:4 JK<[_-\,+!95;O9H) U!XOQ][W+^AQ?4-'&Q+^YJ^%9B?-.JUV
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MD%9S%]$1]U(M1_9%E,8L[B8["5>?BF'G.RTQE1^^<GXYG]R)KDJ>W]0^EGZ
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MM"==@PXK72-:@WU..O8VC$;N_9/'EK=(17:^?TC^\+. ^@VY+YNBJ'[@JJG
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M%6 \UMC$'4D#7E>N^3=X!<CA:'0VH_S9Y)U!_E\?D>S_CSXB9)J:?2WQA+]
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M>MP)_?]I3-R.O0+,G76"P,3D;$2_(:XON8B8T\W'89HG;S5B/V@>]W'60NV
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M<N]#LRB!76=@D(LZ9DJFG5E>/-].URL/'>DC!\_;N3UF[RU:0&JT^+#(1GS
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MHBP%A>.MIPY<7;/T:O2BS]^_3!^-_N9CB!A(_W(">%V.".%_C-E9^HJ8%<_
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M:P7]05J?N]SR( _YUYC\T>3 @D>@!,+>"C&0@SX^<,-G'<FL40(D45N]B)#
M5D3;(L3A!'!([WP"( G4G0#F/*A3B'],P4 D_6D$@7TO8RW7Y01PYR!@ZP00
M#]9?!P./:;LVH8N!*B> _\>%_V,5MC\G?F^$NWH"L+J). 2DS)P NB'?\)!=
M5E MX@-I__B#)U5L4J#["ZC6N/7>TH-=ZL]1$A3VH_,G .#[XXP3P+)$$6(V
M>.T$$)Y% 4D?04X @Q;4$*;E#/H$P*)UN))&G:!MVJ>H'8<%G0 ^OS_N)0]T
MH?Y8B^T/BI3^U"?Y_ZZ)<@)0<[&E!GF<4+(&"'\01PWX*,&3791SDBA2) 1]
M'T-Y+;*/V@;^;Q/@G_B&_0@<. 'L<HQ#\&I4'-L-*'7VU/$IJ<83P#O$TUG$
M\A7(JQ/ 3<+6'TN!)E*@.RO4GP=:D,6(K'^#+UG5]O<;$Y^K?M_)2U]*$8S;
M&U&@CL\';)'?' %IJ'A)'Z4<9,0A_ECJ*N4'%:H,W=*C;0P6^BWC/^&+W0%5
MG ".SR#CR,Q6OQE8\@%U#-#=0LR#?L)!A^?C?J%^D/W^7$6+^ Q-/K1"8)*I
M!N3X[=_@^S?\._;HHXY/0_U.  *4MF8J9O<#%R@.<Y@_%X-42**6AM<HY&J2
MR;KH?\;W;_BWENMV KA]\0AS0$?DIZ,$V^Y+[?PNP/*OE0S^%#34T_^,\/]?
M))9R][\.[(=_ HN%_"\<*SP!_ .!F"&JU&)VI7Y3X8#Y3Y;-<TML_"CD]5(H
MU^ZZD.^Z_B/@-?NNPCKUC[1-I ]']V#CY=9."C.,^!*\*]+JP:\V,=&7M(QA
M\0,VM]5^?7Q">4T%O\4.XG!4'P+=Z+L'TDI4JWL(X4O:I*:<$"?@:<J@DK(U
M7*I]\@&*07$G>?SALS<JX.Y^/LCL;9/$CR\[7UY@%!?+.5[R=FL1.SSN<J4)
MP\OD%S^#B#P[K+(D2>'?J)/.XT>T\!FA&ZI=.8[X<Y?O+[S?<W G/_BA*[UI
MFKJ&SA':R^8]%B.L)HD^>N#N[6:,,0[84'KY]K%-4;P(FX'VYW\6.,_ZCUME
M_JZ=O=KQ]]=W_:-%2O_S"5;DU<\T;#;4Q3HN948"I#6I;H;A_X7)?^O2_F@,
M.P;Z,FVLRLP%6<+IKQ]UO\"$^* V G"]<:<">Q',R#0%Q\U*#!!C>7?U17<O
MS3NMF@WSI\M']\JRFT9TM[QN%AL8ODE;+@DT0K3H(MP:+8AYI$_Y<'>MIE0,
M=B;LU?AXU6 3JVF"_.62G"[,H^8#9_@%&MN7<PO?G^LLW"D\'CRCA"K8_E@2
M2D//J\IGD4+8"7Q.AO)$YD<4K#[V?D[US'L/;OQ-C?D_V[?_Q H7?V525*F_
M,*$X+KQ!NL#*L6X\_6BVOOKYC3UC/C[@G:(+\:/&$NPQSFQKAAZKA7EUDI^T
MZ/KXN(YBCH"!D[[Z&X9'$%-2*J'8H]%YW##/F1BY])S36<9KZ5-LC6?_"QXN
M86[B&5+<EZ]4X_T7J)1DLJA 9CZR^N2O05#0_85Y=L21$<@*%L\TLYG>FYP/
M/(U2\^_<*UTL$>YQPMZ\_MX7RCABK9.]L=T8AY:Q]"B[9/HX^0B26#:%:.T8
MI"J<"-T:5>FI?=0_NNSM!S%K6N]GD+@ 8WZ'P@VF*0J'9 C5 %R%0/%9?_1+
M1'^XF8,[][)6O^T ';TP^#(/J</S:H?4E +T1_^EJJWOT*)",<@H[+V?>A5U
M)NH+8O >$$V^^D=?+&*'9SQ.NM'QL C<-LE731:WHJ<$/PQ$8;7^U;74?S]3
MZ4.%;NSI(O_@!@IKLPS=O?AF[[?A_J./HZ*?185-M1!X@QA&C2CH.>]03=UO
MTAG\.3!AI8+%3X5NS]0GK%+9C61:QWE,^_D8T1KWKVY-!A6HW[ 5M/U0^3+U
M+SK]#<DJJ11[^M\$^V^"_3?!_IM@_U\1[!#T/ZCTB;.=[Z)MI;-Q[0G J8R\
M%D8%+O4!=@!B#GT<[J?I&]"PYGZQX7E)3/?U5\"Y1^B4%?/L&8Z:(XW2PX9%
MV,O]*]8DOK1!BN>*<8I3 (QWJ&IY\>%R@!H7>Y]QXIOMZS*U<FP&9G_]%^I*
MHOX/ZDI>UF S^K^/X1KQ4]B\<-4;\$YTVPS7B*M<C#/!ZG/%ZZ\)#R.MNG_=
MQJJI^)E\AA=2G67/+()QE;NS>);/INO^B$1V74.-SU,Q6NE\!_<PT5-J8*:Q
M$42+A(3P*,0ECFFJC5+EHFP4(S.E.6=[@Y<XOU>$XJ"TG  XP.Q81G6CT=S!
M*?T1E^S:.A92U8RW=&;R<\WRA"4 ^?-%7Y->>ZY&<Y^P,5MCYGO2@=O>25/&
MYB6]6;_VOI$4=8$;M<]$O2HGS"1V P8@I"R\:#OFK >"'@,/[I\9G^I4>K4Z
M::CAD<CE,D7+<2%0L^U:R]X>'6] P#7\/E%]T!]!R)C5"J7&L#Y%%!&XR9'Y
M7M-@SOK"U*M619EL89\(N,"><T]<"X*:3@23H2> <ZZU^? CR]&$I2/5$T"'
MN>4XWLE+0;GJICI-OL_G&)+D#_HSPJ<ZE, :9_AU1&]-5/=R5M\T&6LL1FX>
M"CJD].*,H[W&]LH#&HX<X8SL:\:HLH$(R1, 3$47>WW:M N1/7,_)35[0M<"
MIIC8Y]<U<!F<R<.UVN(^4XWD04SD#A]7*FZJBOT2! F3:KFGUA<.?=9L-.?.
M^G2J)^V7?*_=N%29+ZJ<(^5I/>2GL#;D>BAT:=9!^%=JS">DUY@KJAA(E]GT
M%RGHB!V.:$8A15LP *U2R]5)1%R1N"22\5Z_QL2UFN2[,N8)#9H&1BEP8;LE
M.?4N$%"5ADQ#>I,/5V_?MX80['/R9GI<OJZF\K5SC/NJ,6BE<&N'E/!+QZQ[
MY3]IT7C*?Z7MP??(O](L>T2&-Z 6GE:>ZU"BBRGF0W9B56EQB?^>AN] [ G
M3L]=_;A@CF3V>=IB#>V;C9=/#(B3%"N\A6/M>C'W*5)0)*-$7E[9F)B3%]B/
M8MISDE4>()FEWZJI=#^SV)AC.?ESHO(U-G6<CF%8X%9+?.A6CL?HP-5)R03W
MQ7LZ&@$I%=[(TN'#IBCUJ[/.5CM('F48IMHBW0EO.%L:CG#4#Z\*9,,CBSA3
MQW9?]3(86HJ?,Y:5G*]_H<C^PWI2)V]FP$UF(W5&,U2C6]E,YY&,(OB--0&?
M2'R%A[:#ICA;FUCP6[%RC&ZMZ<+(5***9I]>;'X>"TP69?^>!6EO''UV*NGZ
M=$5D*XD'S]FF@&&0DPK'7/2,,=3":\2< (AZ,>E)W*HY.)Y9A<H;;@="=Q]8
M:\YZL ^('WZ\LG!EPQ');]+G(Y]2Z#7Y?=REWB5O5!B78#X]/6W>(WJX%: /
M*IZ^B:TJ*_)7'FLP<7,N_;RL8$Q4J#YKQ,@V$BI]]?[FK9^_@H)B8<O0B7UB
M($GHR(IL/42^B4W;XH5?.=2)^N4T.=;.J5M@<3WA!&!?<_=XNC6HWB[2*,F"
M3K 6<M:B.&Z=BQ \_<H8T^DK>T__$5M_%B3)P3 \\?B7X.A(R&A248XD5 MM
MC\9%Q5H/+R8^D%"6/<Q!;(.O1%XMS04W_Q'-TVR"2()TY+_<(C*(9[]1K5%R
MZ> A&4_5)P%$CR;IPPG@"0QX?,WY$#J76TC81!,K2#YT0;+'%Q$A-Z^? %KU
M5;J2%CN]J],:RG8X63:D#VXO[-3_KL'G9*%0N$U=S^ PC.$$4-,U1G&HM5J5
MG_1KKN:4']]P%TTZW7N]TP&Q*2#LZO:T3UM4']S1"!Y[V*G2!C=L%O;L5%OZ
MB7Y+&4_G&A0E,#1=;RK#HZ,16."@78HYOK. $!4R/.EV V-6 ?KUJ_!NL\+I
MV_4*66?D?I#M1AMT9C.B0*P-+M@3 "?4IPK%6"PG(=FY]*!*?BBEIHY9:!$B
M6R!OUR:/LPH2!M!U[TRY+P/SOI9R,,Y9V>+N(X #[3ZR:7TWU:,LZL9,M,N5
M0I'"._="!"(&6Y.)%%/&MT[ ]VGO Q:79(&1@1 2$@>A(R'T"(%)V>)HZ\OE
M8\@-!=U(K&?X[H%+5N3BD B&]_FBL7&/!ZW.ZY^6)C= F@90R#*4 PR=^V1[
M%W^'E#FE/FHWNC>MNM6.F!B4&\^6G9B+$:H.VCG]2[L\#)'TVO1C@?OV7D:%
M=S3RV+T3>E%6Q;O]$!%%]U8NS4JU_W!\6,S^'-'@?H],U[9/RZ^PSK.^9XX^
M1Y?0?>U0LCQMFW#K=)GFU9:J;[-O8N=J-O1+WS?P^>$D;K9@V/VULOWO#_E#
M8%@@!VR?,4<G=ZK/D4O4YQZ&ZKN:#$4UME/!9Q\II*Z25>:H[L#?G2!?,SXC
M%8:-086*>QPECXB,%)?DOOLUT>6!YG1Y(5/UO=_FM$K8C6[=-\VW!ODQ2Z49
M\YM0!=?CM-"-VLYUSTYXGVJ3UB#$D=%WJN50*VY3LA(VP.(,8MP ;^AE3N4V
MCZREJS5X6H(J.DL76>*3K+5[Y-#^FH326%4ZT@Q:%Q%AG"X>]Q"?%R[WQ<TS
MQVQJIDTN)[.'=F4>D#OEL_S]P0N%&N'SQ$@TS7*!V%(W192T-=N?A&TT;/<E
M$7[7AVK**=++5<]1?\:8,Y83[>V<W'=IYX+\HN9%3MLVAH#)Y0;Z8GB*%C\W
M@2.' %$G/,N+%)^OY98U]ZQDQH J9+$>M8*J,/:I-XL?9&I%84\,EY;IO@U!
MKY'%CC.IFT5B6OFOUG\C:(QE1):Z9&;<3]$;*J[4_O*I^1KLE63?4*K(K8.V
M#PS/&1P?<$XBG&*@'4I2P<_CWI;R#V\@V8YLS3M<Y#.),-XXJ9^X6L%KSWB,
M(OGOPZY@TMC<K2R!MW6&=<S8YQSB>$9OB'^8M_/DXKLYG@&5=O3-BP2_Q$$B
M*!+XC-ABV2E%?T@F[.&OJ>7X[W*UZ'L^6N\37:4MRK]^OWSQ]-(2CZ:A]?$7
M<@!!K#-T1 U)\(K+^PGWNS?6@U],S%F]:*GG\US4X3WF08A+HJHIRU=QHQW!
M^$CKH5.[>S)FPWQ-=O%=C<&21/K:. VN5?VGXTWV:(3C0'CZ3<3I9:*O?KB'
MW[1;VP[,_.,,=\7P'D]OQ,79YGQ7R1(&>A::OE>Y]J?O6L::MLWQ&79"N9I8
MX%=<],W'&L3RG1 L11YM+QF34[=7+SN<%LL7-*Z)Y,H2"8J!NLY.6#)_)H8#
M\Q;3E1WW=81?7KG]:YW-[N.IQ%5MFE\C:UTH%PR3,[\ B8O!2U6@:7"&T4U;
MIL?%Q4VZMO_+\ZB:>]%GQP75*AF2  LZ['PSQ;B!<%4((3?-@2 XU?*"#$F@
MOR,\O"$I,GIILNLF=.;@\YGJ5_-GPGI!]8E+ _143P9\EMGT\C@3Y81A@R,H
MYY$!!%T-F!6P@^Y>96/(.(M*PX-]@[O]$5=O10Q62,X^0%N3T4#W(QU_#9(;
MX?1<VQN<0FC3]>J(0'[G&;&*VF'9*#BHS=NX:E';XOG]-9&&(J_/*>+:2S-6
M=U\?<6?6-567W=U9"OZEC9.5Z<YO'-#@$A+W.]53&M? =61#FNI*S0MV\9!B
M@=L^;!A3I;>$5Y&LW@M61)D]BN)-D6'P8=D2OW"Q<%4%G-6)X?.'$4:(?GA*
M"D["&*LJ1(+BMD+7%Z.,AB2PW!KM^4*=F.5UP;JW34MWY/G2U/K5V3=,;D.T
M'$LO'L<TB9#:.JRODO*Q(&Y85;KHJ"H__+.3_.$/\U=.6WZT[X1[%]6Y?G)Y
MLR2M0I1V5.B((82EC@P.$L9*/\KZ-.EI+DFT8QCN"J*'F5M>/,Z]NJ#=7NVN
M(]A?JKK>M?#4UWUTS+W0$ECB6!K5I$@9A3)O[B'BS)/C"3=;,Y@D*$S*9DX4
MOE'9-+^T3\^//VI7RX"+>,^;5;4MY'-USOHMD1*)T:2>.0F#+*JOBI4] 3!9
M.)X SE2> ,(5BB6#W.#[U>NQ_6]>\)OK5#-&A] L #X.$[\":YR1N14.7R]1
M!OR>O5P2 P<:M4+>%[SH>/'@-OBB$C^C?\#GP/% 9=+!'!](KYJP]9;"/#E)
M5AH!.[E+?LEM\Y([V,R4N)Z7OGIQ7/#&%!->'ZI/<YP6*#U-/DO2Q?=V<%M'
MY:QQQP;AJSOJ<KX=R2\YL9J\8U!L"]?$K6<5A.YE37Z&/+1O"IY9O&J7?FZQ
M9B")M;M@QS81J=/[Y-7+X9S28%$"-()NP_-("6:^WXYB))O5I6FAD4<P/9X'
MU96I/1GW'+;?M?8U<5YGH7]]E%21WC\(@:$BT#-,)*DY+U+M[-0N*7^.GE'^
MJ)7#5^YKFDY5PJN$%M[Z5!M;@#@U6A*O-_56*:#9HH>M^6%N=J>>)Z=(]RQH
MER[4K!:_:6.:W7F$7AP(H\CY:QRG^,L1+H*8UH1,1QO<" 4G@#;4\S2]\K C
M5:,8N^0%,#J6%3R;>?T>3F[[@8QYXY4!8O+Q%\G 4Z0BK6=/)>N_D$([O_<^
M2G 1<)[\E%:('&OP&AR0*)V:F\QA/M[U?RO\B%CX%>0Z:NP]Z"R/@SG-UH9$
MG-:V,V-^]^)%<WP+KF& :$0JAFRP'UV'^[57U>VBE4*K\_I Q*+4>^:Z[-\K
MXSEA5C^"XM%)# :1\T]X@7$0FQ- A*H"/JX%]!;*)(OB7TEGJ28<+X4C3^'T
MU+6K$H_D7"2G]4+*E<]EISJ!>Z+NO?I"_-K,]FOC"43C:FDX"HL"N^#WL<B\
MN 8-GSQ25,L,+:$D9Q;#BG$<OU!%N?*&ZA7OC#Y9M153%7K)PR9RK*2&5R9B
M2"US&:QJV!AW33\(N[_RB!R"'3XS+';I!(![YD2TR] M#P]ZZ\3PO<B0,5S_
MUI4XQ]='"9$DAV8,4JJ]-RUN8L>ZCM0R>P)@L2#;$!B+S#-"/8ZYQZ]Y%/Z^
M4S7R=I_DSWZA=S5,(%>>K])P=6(9J<+]2)JDWL$=%UOI9[$5R2_K=L'"&5TG
MTN"ERE05Z?>^KW>C.=7,/\=HYT944.<KG8V'('>M #>)7^^$\2KM K+OBB+M
MHOE#4FX!B-V+.:6O/1#L_G?Q^EWZDX_F6IMD\1EQX(#<96N>BLJQ23&+2R7
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M6A:!I+\F;/3KJ/+G$S^/-P "\@5J>P0\#$]K=]<EQ+6IBJ,(6E$28#J<Z>X
M21/)=V7N^S"'V:EIMZ\6,AG)Z^4^[HJM\P*.4V=BG_T$Z@\'GB<IJY4/2A3Y
M2WV9M" 9^TA6FF96&EE==U+P2;@-"4ISMXNMC_'8VREM+N5?PW!19$A3;9Q-
M@@W#16!&7/U1,M)LPI//"U3)<EKH987^VYAHYF1OGDN9T9!BLC4IQ7N6WHI_
M1&LX:YRLA8.= -:GK_=;9)1/?:!UDTWHDQR_QO92<]VK4+K9B LL.U9"!]6
M0R,13AF\9-64=B+W4M"NT6@#)-?4V<#*=#7QUTJUM.5T8WW_O-I2%V/-G>W
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M9()W\!(X/%#)9SY0$M<6!7XM2><44U*TY@]YKYVRW<[DPE@5&W!KJXW M9M
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M?R,NQS;[VDFZQ])AHV!J9LVA547OVQ1?S00*]0S5@_AC2WF?^C(-Q+W!VG-
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MJU7GANJN0Z/I'P(GNEJB/VQL0T\:1%G';46U?PSP*9$";8DTQB.2DE;+8FW
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M<(%88*7BRI<:<*R>5Z\:UK[^ML0;V6IG!K\VO+=# 7/L'%']+',.N.:2N'Y
M^4MY3.:I\L_6>G)_D^:/[PL\&$<-GB] /F+DYE-<&P<) 1FVZ%)5&FL10/D-
M>.'ZZ1Q_C#U?$LKJ:::-*OS=]D'P;P/SWY=)5A6(7//U8TJLY5:Y?%/@0%5-
MSBR.,NG/(U-;@9+YD$;*@(FFV^8WE$L0=G$2,FV;7@O :":8EF,R7.'X1#94
M_1R@3+-YHA,)DDQSF&Y86NMV)H4>. XK:^!1#3\#\6*N<LZNCLW#$G44? F!
M$I5#-37MM:E32[U_>W[$+54NO3;--;I8X-"6TZP6L&>)N/%ZFG\ANMD'+Z9O
M/#LOM)7:_2MXFQ'D3'5-=>-1>VIZI3:E*_DQR;Z(;#*,JQGG.QNU$"M ?T6/
M;=/5+6=Z?J*1D:;=>LGY(>1Z=8W8Y6NLPR,&J9>6L*:;938%ZTT]7]!W29&2
MT;+]4 OG_4;9U)/7>JYB_<#TJ"[M2TG!:J"T[]E].K>:>"7G@R+SR8S?")2W
MR$Z^_H&#V3()JALE;"N_=@ND&1/N9IB^7@ T4/"8VFC<>?:N_1P0[E5\#NC0
MP%4\]1G"PH7M5<(3=ZEZXNUBY&?O[O(\_*CLA80L5X(=K.G^6/^QO+>>8S^V
MX4;ZQC%8_J7!["C@*L;QT&]P?4]1I/JEWW+%R7US R\>+#B:#,7=YAJ=[=M;
M]4^VB#-6$&!\-$8=U_M1P!#]V@8$H/M#JU]Q-GBLVEJQ*F_*U1:#[>U<'M7>
M*Y[(L1#[66%6U[(;3:$]FL_;'5KYE^KT-^OL/]8<-='FN /<L.(<KYV*+^88
MEYV"Z_'^87?@'E \TYQ;L>C[S-&7]>X^A\/3;TQBTL I+W6D]B3_1!V"!99B
MC&'"<E=8/T>;NS]BVZWH,M2JEXT7"8OA*-649](1G$_0S8M_1GU[P2"4"]@%
M9K9>S^B29Y=V@8 />$;$EQ7(";6!GQ6W.@7+1&@KRZ]O<2PZU-1*OMLHRNP9
M5X82V;LD?!PEP@R^;(1Q<RSV++__J=V;^;VKDDLMGCLEYV_,?9-Y3VN@*NT:
M DA6*E_;\B@AA;?H> A-5OF6]S6P<^6WZ-'X-3]GYC,6M7E&2^^I(]NW-E?-
M%VU;2GIKWJ*_,*/;V<%.6.?B2P\H/ZJ'V'9Q&CW<!(J&O\H?]!55,!:;6,U/
MO=0Q=**RNH [!T3L<8MM(;13.NY>K0V$=!#4OTS197(SN8JT8R),'\8%I\[;
M>N%VWE%W;JGB[U7 4KK835/\#MFQ$T=-WY)"P@$ -H5Q@*K9B&E)SQ.H?\Q;
MB^#%V?NG\2TJ"V62#,Y#*-B<#F$E!N+LHT+]>.)LH/B%GMSCZBN_[?0W?:4%
MRE]/B4=Z.1IT@VOD4O&\;@?'_=;$] B0>8R(3U2MRM/-).AEA2[=T9"X>@.)
MAYS\=QL-J;:I5+AB7GRAM]4A:>4[F2KNI;WWNDYZ;U _=D=@MT'0T.([05-@
M4%N)9S'9\PWT<N>!!0&-S+><$H "7OQ>,S$:3"\2RQ0HTAS!&M!&46A)1PA^
M70]XF1C(%0/_0F^!F^ND)M#G>@5XX)$<L#+#IC@;>:[EO%M_;8W-Q#TTD[HB
MA85"W)3MHUA-O\_5G /"T+Q.9R)C>P/\0E7$[-.>W#*UV])"_8/-=K$4AZ]Z
M'G[&^<HI_IO3HN=N!U_&M ?=J$&KWB4%5T#67E8BB]8SAK(=':Y_ (GFM?Q^
M&KS2\G$#D[&D;'3""'/L5N5H(VR0(GOK@X!M#@B2EH0L4E*_W@%Q[Q#Z]4=5
MY%&8ICH#N#U>;$JDL.^==<O$%/G?9?[B-VI)SN< ?A7DI,$IQ\10#$G5?NS/
MJDA>#$[VO[O_EFOFOV;\^N/62)BDL]FJ3XA7YX 8W7PO^?!] &#_1 EC97EV
MJ$<V(H_TQYT#?)'Y8"JGW"?/C*PG]\Y8@O@[8D1*_^T>J\H=;=+(Z:<3.2@2
MB*CQ1;PFA4Q;GB"R$X1_AG4O^<%6[@]N$M=>"+&&PV7$NC7SIHIWGZR.9NL\
MW%9YCMX=]49@V8=.LW;0/*3W.A<X&AI/$!&HH)&E%S#/I;;),*$G)"&0OWAP
MLO;]'IDSEK-1[)-4 NJ,]1S0!;IVX:\\YC>@Q>C1+O;E7N-A8<1^!/8-AY_[
M1+Y-;0[TQVJEZ"<Y-@^/I;JE@7R7"R*Y%[@%G3ET&.EYKJ^T65'M_S;PS+$&
MUGN03A@,)_2;$2([@93Z.!H0,[]:I0LV)_<TM\Q%2LR-#7=0JG[M)0TEYVO:
MC$B<8X][.)J3,!EY$<@D.S+CH%TYO"D#(<>=ELF#<\]?GMDA7H>5.4)?.DA+
M?Z:]3CP6 V\^EJSR3I>KW-K5W<)BFV?6"C,;_IAB2G>]G*?M[3$:;BL5,/!!
M)Z96,C9'DFA55;2F*EA%"G,P8%HU#4[K-8[0_"/ <93O-*C< ))>0.M[YX!.
MB\[8X;P3W%T@^C.6=;8@J4B)HEE2I-79:.UPX8U@<09*:VF-P6<_G@!EYV6>
M/<.160[?Z_Z4*13,@ B..JO(8(J":3O*O5MG#YWED"DN&XUS9,;3/%F#4 2S
M+)#QA84%*0?$8/'B-RFDT_C5R$8:AMK[IQB].ELG%2\'1?S$W!JH#MR)"GW_
M91U)<\;ED@,BAN_7UJ<UH6M0O&HR@JFZVI-58=:SKJ\H&G\<+H(NY:$8DVW$
M#')T-NQ&76^E]>G(( =</S_M-0GS<U_+<_67+SWB701SD9%3G@81;5.-N\J&
MRCJG!8XK[XW<%X]@YX!@MYFMF&8"\T%,"HXJLYR$,!G>5+:=MV8^<C0==K=S
M2C,7. >8>E#V[ZHK'GA,<_+0^M6QUO1)56:5>*X)^Y;--044Y]55N$4@+$H+
MBG)*+):FAY8#BC)/U.%B))L5%SY*D@%L5C!9/GYRMSNC;[T^P\9'U$K)B*L@
M_I+2X\;>%UQ+Z,MG(R!"B4R%5R=V)7*3[#COSG+D6KKJ^U2V4;K'BW>@I>\>
M[=JP%(= B +'KJZ8R"+,2N=IZIQLY9^"V8PRN>WR?1.7H:<&J.?+QB8FF\F0
MG<+RG<F5EHN=7 <,5@4Z'V) UX/XUB' F+JK@G66".M)JD*/@F[^U)3-JE)1
ML50A>$\_ !I/ A-I<#V1.)H*4"\"Z*ZL/>![T.SZ5'<29(".=;WN.G<S'_;D
MWK"4^!,#CMV8VUH"G9J915F56[X#=USE#E$!=S#US=284KGBPG0],>@2%'ZH
M\M[X](L,F/ML3-$@%OY\'LIKT<$E40"Q+ YG6_SXLCKD5LRLY%WTT4/UY$[:
MJ1_=?HXQ==SZCMV*V<O(ETTF2!]?\8/ZVS>37N<YBB=1*7_5N.GIC_]B9&GV
M&AU'E2TXD1Q7N66_%&!M>1AHGOKXT;HDHO7 $E$1$B-2N?"_N0ZO&:Y!B.S(
MN4-$)^!=33LS[N3C)>FWN1P*/5Q07C8Y:(L<+6.MW/L<L@0DF>$<\!_*Y/D@
M5(DH<KSH.6"Z[5@7;(A#'G(<M_U:0@7Q]GL1._6);YJC;;X.NWG;NACNO$W#
M<X8%-P$H']ER'H4[P+5('GBE(1"$U-!^W)-B4ZE5+)?DZUH!T?&R^6+!"1\?
M^K FZ"FP??-#HCJ#UD.E/K&E^T9[U&F0H"%(*,P-O$7G3W,.8)B#H?N[L:WK
M6 [7Y>29O.X61BHA!HWK_&D.RFRO="H%\-:; L 85?X-;,\G]WGN*+C1V\-#
MXXUCRYF);:12:7D$!5V7QX](IY?)J#X=[AB":DQ>8;N4 N@*&9CPO0D931=[
MD+AVW!-9[%2?-J*V]%ZVMB&#9Y['5=7IINGV.PT'DM8!O(DP@8S@#S3!VE[P
M@<OZ\RO\;'SPA$5$ 3U,;1'Y87>7'H8RS$.*4O3 02=@6/_\?F7:&2U1.,)X
MK9;WGN9DWJ3WSVV)2J&J=VJ\2VVI_(IROT*YD\LO9Y50*X*N7&CIN*>XBP 1
M45EGP-!>.;-:K]A=-]$Q=9J-*FAKTVN3$1%ZZF1<J.75R[H^;M3W[N^,[8%_
MVS=+R(D!YO-8W1C^@/@VP7LR B9A)U?R^F4.?^<O337^*A-C^9 "UI5[YJ=9
M9'TBWVD=DAT6JI9IJ2-#<KTQ6BX4^:2JMKXMYD"#S[:V6N]>U^<:AK*Z!U8%
M)Q(LGI\5W+'0>8W(K?N$IY8$JWP_KZ+NLJC%B+]7Z(2RB+HUZB)/.UV]C9_M
M<_*8)@Z<L,)V\+W=4<IJ1(O>8^KH6B).PJ!#^K<35F"MN*_U08+"VZ3=FR<#
M62(WKG ,!$IJT-]N_JKZDC"T^91X&VY 2%76(5[HR)5P58;UVZK9-M21LY,[
MAL$WG)B',G_9+)?;B6!S/9(]H>S/+R2J+^P8')X&HI-!1F-YVSIY::Q#(6/B
M=[RI A]K\<YA-<H;Q&Z-QBS%5!?A/;X%=P=Z:1C41($45D%?<_+SX0]K,-Q=
M6'@TE*AG1(I>K"@(SN N\[J.=528;?P9%#GZ-8@)T:X*MSY17@L"3L 9%V:H
M>GOY>$=1WMP;V>J:R3MZ$^*.Z&0B]0=!<X$TX90(6G7;I)CCZAB4(X.J+\G@
MA H9=F&UJJP;523D"<3]\NP&MKY&=J X7:XQL+0T6BCVYM3ULML=NW\7LA8G
M@2%M\\A9$9)! 4GI.0$9[QT Y"4IGD"<MG>\BQO'9&EX=7%%R5@SW_+@Q*1(
M$Y[0Z>+Q<:--/'4_&'C1,T>8<!CCG0VU)DZFHUS2D,R"I/  #[X/DVVO@4[U
MRS.&=Z].<5(+VE)4^*-ZYVA(^=:DBRB]T8%A-+-<\\W(&K/\,R4[\\%E4KR,
MMZ-,3%0[R+"O/;CGWO!Q'$LCD\D#/[KTS;5*:)!L%=$QVF?F0EQ7;9BP[Q:&
M?TC\;3$UU>V=!/E>.7#SU:&Q]JCV!>T' ,H4$SHD>6%>YD06*SJB=63M +#;
MM\;%5*S46=IR=HV=N;1\Q^4GOR8N9H=&.C'60+Q-9!]RH8*5$PQ(E_"28?YA
M3&0YC(R2DHY,F83H<6?7VZ>6W9*_%^ZJ>?$DMKA5'SE"2_KD+G%KK\AW@FJL
M8UOH"M<44Q-B953T>C*LZLK7C:U<(,_>%Z\;KGM>$XK1SGM#E&:)+1, -88F
MZJ#<_E$E<6O(&D14BX![(=1?.'HO=Z',HN+)CF'.KO[;41_KK6O&SCBI_.A7
M&C#\W>I&FR7R= ./^[KU=;C!@N1ELRE22E=&X%D5,*K<YZ=@W5>Y@[<C%B^T
MI&J#Y=FGHWX !>ZQ>3ZA8O'_9PO=MXZUIBL@Y>*T75_O4^2O8ZURW<O63,^T
MLUW=Y@-':GJTF30]^_H3=:O:J:E:,#V(FLB$((F9#7DK4:)U.&L=\/HLR6VR
M7V>T.'YRH/)6B/J;(?$XP<A#!;'OH#M*&8>Z(AZ/@4JD;L)E4.RLL,X.:G9:
M'T'OPD5+[&A;NU1I7Y\DK'G?T%;NJ)U:,'ZJ7&DNS)I9V17O3MV/1W+"- /%
M.B!;Z"IQ?ZMH&7:NJ6A!0P?'U+1;1X=78ETELK( 8K]%\E.EE!,ZP9=0+18$
M>:LQLI8,5C*:;%^FA^>>?N^@,_>XF;D@+:;56.VRVNN/)^6,D?XE"P93)SUS
M7#(;7<2&Z!:IOY U__#X%/KWA4/N@&_-]5"'YL9=N[>OJIHOL=B)S#ZQB U0
M^<?; +&@3OF,],WF!0GN)Q$!S6MP60][5];:@*4T@QMY85:>70L45#7>0V%H
M&:)6-%D>'*>L]]E%$1RV;6I<%?IX=+&N:=QMDCWFMMO4HIUEB);23<"]1!V
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M@UMH)+@W!&L<-K^YLW-W9N[NWIF]L\]NG>?]YU0]=>I]ZJOZON^M.D^_GM8
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M'RUU# >];*NKWT6')A;.*V]T@;<7IH9?B_-F#9>P69BDC3_KH>]^3+&8;YY
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M=S<6YE<^)M"U\/1X5VX$M'D@Q^B8]<9+$77:*"FS[R_.Z58@TZ;44B #_ ^
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M$_<S<S?W^^L\/.%5FL;&68_1V53+5[D?'0O0H_GILG+$[T,N*[^WHV$D&WU
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MQ2H&5*CR4N[7';C"N?0_4CE1SW/./#]F3G=/)LC:Y5!T#98#S#3F4ACNP3-
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MK4T9],=VTRR7=\; JUBJM:D1^DVSP9MU(DLU'<!T.HRZ&KP8O=&F.UD/$3:
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M&7>GAH9)E=W#ZNBX;PP4BAM^ZANO)^U.H":T2BS,=*%G;"?9K?;'\H^Q]<3
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M"A6ULH'K685\4_NADM>?2;\\]O^.3MHAM#N7$YD%5MH4ZYU>YQ>"VY6,#10
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M(.Q%7QBX_7__=/_3H'B9_R]02P,$%     @ SH!\57+)>M8!D@$ -*,! !0
M  !A<G=R+3(P,C(P.3,P7V<S+FIP9^2Y9U137;0V&IIT0D=JE"(J3:376%Y
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M97'ZF&+(!;@OFG+)#C-9 0^>@^;)"U@5D@RK>J1AC\7"-N[OMNJ$FJME"\9
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MAV_90QOEHMK#_?'VII.5?KY[+N-\HZT-9$RJR4TAVI3X&S98O>%V%B>T EF
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MMF_=](47UNM':7O,1S/U5K$I)(Y.48)\I0C;-$F+!O":B-2SRI<(:8 J] J
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M>HT"''X_'/-;@*=]'*YKL7SC,=NP- IQ&;]O+?TS3KOTK^E_>2_R?Y#J83E
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MT.;V<&0BZ!;A#GA'"W5*MT+4+?MFLT1M-Z9</#_JR(G,V(PW4<7,*6U#\$_
MNP>X4>=3B;/7VM1A&CU_]ZL?D67'I8.=B[8F'72*;[O[9"ULR)=QO/<<6EP#
MO_EKO8-/H'WWKJ#XM6]/D'A ZE4:?"B9N85(KQ)%X1SE=OZ#4!'X)2"-$+&B
M\@(NX_O143):3C+! K^WWAIN8#]T.<;7M(N3HPG]C6GE%(G70<T5KJCLL1)M
M;A/ /<NU8Y0:.#X+QKKN8-+K>(/0]+)*A'DA4_4PKF(T'1'R^,M7U+7%!Z_
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M^:<UNKRJL6K7;W:Y9"2>^0$6Q #2-:"7*'674*=#:$Q=9E[_$JEK]&P;5KN
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MB'(4 GD-Z9XVU]1?^^]?D B.,,,>S.Z';*+!1;N(KYEUF:FV.1CY!08]GF4
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M;+83=CV'+U)Z&\FI2+:6E0KR68R<Z[4_D+@@5IH!J'U<0XD#/OFS7BC8_GA
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M1RS,2J#XEA=7'KN<LBRE&*T6D/T.>7!%4<NJ")7+5I;O\@<JL('80ASK'PM
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MZ9=#K\CL]X^%W^\9OTSI7&-[?^JXY#<Q> C.>R$ZRYA\A@!EHS\ [(H0(N;
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M*CEPH@\BE=L:3(IM!L<ASP0>YA-&/MFIOE+^6L]CIY\C&#:,^!OSX')HP_E
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MSN^8G!(>JH$7>2:<K:E85RP7:XK8[B]X<?';R]XMG&BH)K/K*=>%CD"/CD#
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M8069[<9W411!-;%KBPEH+J#>4E/<SY5WCA6HTH7FWM_1B2HOHD(TP-?;@8A
MDD.$>KD!J?U9P C0XV*\G;-?AE;#[.;[?B."TB\F-:ZU8[DCO2U@V#HUEB)2
MQ)>+NE^);<97@:,PQ+/<POV--6KU._GW!]K):C5A[=_)WTV"*Z\/4,8 L%$X
MR!P3C$;$R:=72]=6[*.X,J+^6$M'.UF111C,V3SBS#WR48CV[T4+9N#?V36,
M<6!_F,RH<-IE7LA"%6>4'DQM6U_C7'YN6,:Z"^//Q;ZNJ&L[<+MC4^#S6WG"
M]R5]AZU:!;T%,>_:&D^1([_["0$^C(]2UA@YC+[V.I\EDNOT;K[8%R2]1R M
MU"FT=_<L=M<O\_ 4LK/,UI[H7OFTH\X'0?T<Y8\CS3FQZ*&]!G@2 ,I3'[O:
M#Z/ )D6);+:#OV[/^@8'2R7ZJW/HWG1K>QL_9EVWR"LK6S<<"YB<[>(M=9-G
MG1/V7:56E!2J:'R_YMA*,BH*^G*#,/0Y3VYTRFH7Q@:;) +P_#X5^IM3I'BM
M?E./">29/H=6:SVX,6='G?ZA5^"N(O@:($H:.(&#N[@G2T.--K^4&4$/X:_%
M'K3-G,)9(>S .Y#L?I\QC$":*VSN7K*CBY)Y7KRQ6N4ZH]EA_;4Y/>_ CO3:
MD^ EMC:2_."T^20#BIUUK4Y9BVGHKX=/EH2J5MHU<DL^9:I7\VK^;,'JYI>[
M%=!E7@%<II;-3?'V.-C<B)W84I="Q7X6>;)/$>2=.A81S:)RS5#1!>TI<J*E
MB21\"?R#PZSAVM\ S_LK1@56Q."NRM&H\L'/!%>_:^Q_A_1++G?\R)+J]-"F
MPO#8,)Y0<(8<YIB[:P#>!>7W3=WZ'21IY;<;"94+*.]S.G<R:]S[.$KCG]2D
MV%%H4O0 U:XBG5O,&^L]T/-^G1:OOA4P Q+8,J2%.&JFQ2E&I98-N'K>X[W9
MY%-5R?=&ATNHK"A4SIL9>AMKG@2EIHL\G;H%<;3$+GQY$:V#G-ULJX\0[(^,
MG"_:?",NB['*H\6*QF"/!EHZE*/_)$BHS0J;>S8GYGJDMRQNS_"J,&E-F]4R
MDFB981=S$=]7]$,<7 -%LY51GMP0,\WF#'?[)T^TQE8MHS1I*4_K M#*!Z>;
MP'@K9&X%I+./^RY.G_CQG>.[ZE]G?QLM<W;_>M]_;!#X3[NN/Q8P%+TU$EV[
M&V7Q1X1;SO/(:;[(KS%>TMR@E-M/]FM:VF<6X&,:5=!2-'$NOX$B#B9$4&E;
M@LIM ^E&R^VM!LAV([H\MTIQ M$HM];  ']<)F^P94N[^?*0$U6FD2;X5Y4@
MZ5"/$WQ%#;ZR8\_P6_[OA]6A=0E<Z5#7>4LI=UZ6YZ?'UFH\S0U-S?%I42C6
M8R8]"?K#;X-Y"M[1UTQXS5P11-Z>19#(]>[AP68+JBRM'68)WJX^_I2C]#KL
M0C(\W(96![\*:$3>;<&CN@P=:ZP][+AGI*B][Q1I50WY.3*.5E8E5 G0E.@"
M6#E.PDP@#%N+8=C._K,.@2A??8$!E$AL6LO<GW%MC(AGG]P]WG@RF]0\LM<S
M__L1VU*3&@^A[/'2;B1N5>P]L9*8&Q;TY^>3$X?93O<#TR6$'&5MDE/C__RI
MR!C.<OH8K==6.LIS:S60SQ5$5TBH/.[IRH/4BGH86XC@.)XQPR#)\<$!?_I0
MY'HOSYC@*CA&;KX6]]I!I'9(U6$;/9;VYRGGC$N8CF+<G__)IWM(V5M *EO6
MZ!(E)_D)8*PAB10D61D2;Y64</F88T3!<J'YFX4;B+^]37WA/HM"CVNWY\G9
MQM8X.PK(<9XA!I57EE25&8@@]SRZF7OSI[7 P0!UHY:F=+]Z48$,WS%GN5>=
M 8\!N#9?.<2ZOM>05 +W_JQ-8(!1ES!5%.M++?6^<W9BX'\7."F@%I=Y/6YZ
MF<)="N*IV@O/SHVS9.C*&L:<R'AM>&@9I9^H4,2[]*AN9JZG!8G/&K[X77_2
M/B&#<1#--5P6FL+SM?9I(H.S@71ZY9)&77?X)!B8&AH>O;RW3<68G'/\XQ(4
M/@+$JG@#]N6[+S>BNS2J?NT%ETM5).Y+M1\+*&CEU+S1EGV].^]8"D$,)*&\
MSSHN:_S@+1!K:XO=N?MY3R0[M8L;-3\*T<G9W&V7H^Y,1GTQ/=.X;(3Q0'1#
MM(;DEQ*\RM-1GLH'R;_Y^=R([K>6V50UG7L=1V5);^1RTCI$5%RV/!'WGNCI
M?OQNRY6C/W)R=Q"(]93.\''@6"$\RUK'6C].L6PZ2JX+>#.F_M-Q^8UYZD>Y
M87??*P#^_A4@!GD7C\GNS[\#5497B#1Q='KJ*FJDK]7:#,(FD%(N]Z@!J_CA
MN3RA2<+#:[X<NJPE.!2[^^<]P.6@#&(]?[#TH-;O>Z:'M43^>YZ:HH0]2BSJ
M)C6X KQ7(3S'6^+,5JWG8/?=&]T[#G//N,Q.3RGOK^YHSM"/AY^%,L483^-F
MFR#[TZE^C^N]"3*$L)F(6;MQ'$ABJ.?+Q@?B'0^6A"J",]Z^_+NUM5?>K+XO
MZ%B"E_$SDUIA3MF-4TY.=%?J()%MT5<1;##9OE5K/5$?&ZB1,!@@EF$"+7.B
M$$G1 ?@D-O^-?G\%V,Q2!G3173RUP-^QA,P-Y?&]7SC--3D__D'-AGYJDOS%
MB,1DE81ZY8N!A%WT=K8<4=Y#D$@RZ^M-]<M\9U=E\6AWIBCZ^<R/Z)\Q& 8W
M,G4O4KA&7U'^W:V]A?B27,V_<VELXZ*I<6 ](!=L2DD(GR'63W=7)H+@6H;:
MRWJ=;/FYCG1(JG.,];,#'[F1%BXH[,B(P(5+.O-.*)LG6.(<AZW6<L9%UHM+
M]UA2E[^KLW\L<^ASI_*;4D^.CSV9BKD"-'@/P>D)JNW8C0\@#71:_?1N5]2)
ML47\8PXU:BN[= HO=(^8S:-ZSG=V"Q><Q#XD'[X6XN6+N*[-+ERDH[/(E3?#
M;+SO91-[J>\XF0HUYJYI3I,P_7F72*GFMRM8,667(<OXZ$$Q]??+6Y?)<#<(
M3  BT'_\BV&J F)'O!DU<3B@$\AJ\^/KCQ1#SM1)\"\>[;.O"*;+>.57RG2P
M83ORSCG?SNQ<@PNS3OG(RV^[/T[&-C^;$BT1S<'F080D\3.[=8.X+L.Z?LT2
M]U)SGRGN:5HW]3 5.1O8\]G'-EJJ+V4D?WH]8MT0,S&Z^8DT5G4V/93).@OV
MSGBV^E4H4 .P\W_[>8OBFMCH3)/U],U[R_\_Z4C^_]NCZ:.A'NR;[H\1CJ>7
MG6]\3+Q#\2"4_G!?04-$.(8]\>T! )%^!7!#X!^*11'NOJMV1W)UR'SY547;
MB+[%J.=0_)9V&,HD^ERF(<>U%HJ[ I Y7E:"_.@203*%$%/C)/V&GH7-J$7B
M(JG?@T^;&'#F_)TR9BV@$.=?1!Z2&S;Y7[#"%AT'WG1+*Z()R("W-EY8(VC[
M*60&[+.\=6!_N5_UV5#XR3!E?TJ[(OBP <E>S/YX:-LNJ=A?;XF0E/+M7?ND
M]^W(F;]RRIRPE3F"#?X"34=#4$,NG&+LK@#&>D<4UM>SIY2,J?4_<CS^\CR0
MQ"C1VGTOU%"Y] I 2Z! '\4J<<^^;%S 0+E"G,LC$R>'4>H,:IJDVA9DPI2/
M_.LG)>S UQSS]YH]I#6PO'I89#F.UW@.:EL#\9I?7>D]T]5H.'WAJASL"B 9
MN8$\^=(09]"8>(M7VR'2O\1-NBJQEVH+#9JB-/,IC5K*J#*SYZWFZS,W]GO4
M/26+=]W2IW<B?FN?JSN24F! ZE4G2(/=N.8#G8:_ 885;KS+.UW VX]T<%?6
MC!=9V-Q?W_OZ-!VI-VBLNIK<!C '.3F9:^7,62F.'\HSH)!V)O&Y*$5\WY"5
ML#^D9.*E6_[MIBF:WQE!B?F<Z8WKX;N:J<HKWU/;6C\9]*X0>4A&F.C"FT.\
M)+N2!LVDF>&.\+5UE&$V^.N%N-F_(MYB(2?78O8\^Y]"F2)L<ZZ,PZ_GGA:9
M#HGHV(HRNL1J730!XN=1@@*, %?&_GD)E\]VH>12)T>8V@M*?,!9WHR8G^'!
M'C_.QNKU6<LXUV_+@8I#(R91-DW=]^2*4=\WEZ:!N[_UY\4*9U__S LT$>11
M._ZZ>RM6CB__F;DF Y/Y[1=F!1@^9[M/CT;2W0BW\!H7:@3-RS E&; YDG/:
MKY;E0C%>OLF<$CEB$BF=OZX1UOS\!@O%&XI:6"9$@$C5#OP 8W"3:>5FS1-C
M]I"N]@ET8T).T.>6EJH\V1&/9XL9IASYI@&Y A"8P-OO(!R#3\ HYOSBD'([
M;4F]$.W*MNP)'3/MGTY&6FDI,BE/U! WS:<6UV5Q=+U),7GRBW\F: VY(2-F
MC3$@0_[N,6MU,#LS37KR8W[C\2@:O.=,V!S3><AK+L[)!)!^D%YF[5%/M9)=
MFM4GOKW9].C "T=XG\KIQAVH'1:95(<_OP+T;]#5.<@$="!SO=E:LB!)S/_^
M97AG1KH"T@ I0GMTRQDCLVX;-^T-NNSO[(NO><C<]S0UG7_ZOM^+(U^&S&A+
M+8U,]2LPJ.<)00*K9$D 5NT19>;NN %1$VBN!X/PD@U+X6^9'WK>?FOG\3F1
M"J%#&\8Y#J(HHI6X\?([OU7F7/3@O'IM2'JVPT^A<S4'3^H/1RYX;R:GODC:
MVC<M9-<%50=GJC,)3DSJMP.+[6_QY@\C>1<]7?(F=QZDR.D/=8]]E],OU=SA
M8NKIW&!:AUAO)B9O8:S.<<5ZF<T4YI\;')P>B9?$G_:2*OX6.'N&%W+&"FV6
M9918@UC,4Y.:/<S%GW1,^>*?.&2\)_FG-;?>K;8^K9T=HZQ+&& 0U*Q.4$S/
M*Y_?VAOJDSLTTK^_J& *: D?=6@N/A[N5[RU9S+BE2S*Q*3RB_$E[5H5X8RG
M_*NX1^;FDH1GM439N"^CL89($X""<>_QL-QVOH>GL&=XDK'*#4XIW81DH_F/
M+60 W=H)9;F*O@EY>8#??RQ.$6L5[U?Y_WS)H7Q7<NSY;Q6Z_^NS@GDIUJ9.
M2X&\IU&WGG>E:&_12_V7Y_PPRZ 9C+ 8\G/V(5MK^MTA5YCLE*BZSTI_Z]R(
MK$JP*/1.FUV)<<[2UQZLF?WJW-!&/2P!.ZZ)Y4[>JD8P$\QQ/-B=_$I\UE;M
M'WVN6/(343X[U5?/!;]2[/RI1438MVQ\@%'")OS7!2YK:PA<6$=;^0L\3.[E
M/'&F;-\SY5Z6-$?\*Y4ZE7>]-BED@!!U#4C2P<@U)?/@.2Y<(-76TT06@AYV
M(]XOB3;A[YF_R9<LOLF-QR\6GB7OD@9YV6F!8G>1CZ\ ?78]+DDK5X!M7S@M
MR!&7W1<$3&!W;DG5S]K+0>DNDP@D,Q6'M7-JCP46T!7_$F#ZN='4@RG'5I_)
MXM]=.Q\!_.^!=6KLY>J'6J]FZ@(EU,\ LC 6,0G/W5LU/E.ZQSUWX'TF,&:"
MPV64$A_!'"^!T]M:;V:)D(S+9#!9$,@4ELQ>BU 1*Z(2O1__U11/\A(R 0C1
MZ4C8GC?_(9  W^P ,H@H@X%A/3<ECU@(I'-=MH%;LB MG(!YM[Z:)_]A2;S-
M;:6O!>N)BR7/V,)(X?P^X:=)!^W7ZR T!V6ZYO(S[-0P$&6(-NP7H16[LVY[
MF62)/?TV7N)AA@YD_FY=4SR98AMS\JA2SG0($)*18T)!T8;(%.[9K.BA0"H2
MO]K?A0E ^?&EFYYOQ_O8-=8&E_ZFZG&5I;[]4A^Q/M1DR*G1.[HR]J,._".?
M#-X7A !17UC )N%42OR0_"T5) X>OKL$N^?1P1F0:F6U9DB9K1LUN"V7)\&0
MYNS%M\UI1+&?QK3]-[]UJ6]"^<S,,.&$H#+]"F_,=]\7)Z2]X>3WY!\O4/1X
MV#[5Z_L/7X3!-,'< >U-B0+[F_Y#.5\6V?7)I(_OJ/WBLG8GB7H>_EX"H\)^
MKU'/7I X_%^4W@WB',L5@$U_*48R3@@8976)%IEO:95FQOZ:'O :#_ 1Z7\D
M%)@DSLL3&HHA3=T@ *X+7Q*!X;*BRVN= RN3Y(MQM;U0L!UPYF\>^M0Z_7!
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MS48#'2HLQ_A;.V.&7\Q$WV1?^5]K/")PHUWL@Y*(A63UJK7"!Y=Y]+.AUPV
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M*3!]ROT;T4B>N:8-5C"1>;%PUOE+B+0AT%+U=E='6&NB2@3UKWMYXK34&>,
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M!-9=!VZ@YE$$27TOX?[-<?B+:S83KPZQ5DZRH?XNTRU?Y\);:D@.79ASK:D
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M^2Q/.E29=W'\)%V8Y)O&87J-]\:/8(57)TIY$(.N88KR@YVB25&-.DPQH+Y
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MBK&@T23UB&_*C2SV]$73C0YQ-Y[4)(6]P*-\586IYKW!H]10"?>@EZ[8.35
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MBND/\VVB5"Q$YS]3O+$"BD,'K)1V=VPG#J7/VA)UM#ZB?BLDR_1]AO!Z^OE
MQ>674=J6F^O[9*]8Z'FT.W@2#@<L*FGRH]K*GX'\_35X0,JLG5'@"Y7^S>O_
M,@87<1#SK_<TMG7[6E4W<VLRUP(0E(YVO.80SIHSA@;W(!' "#'%^NC@RSG"
M#UL^] GQIAMO<YDPAFUXCY6A[(_28(FATBB>T1U!E1 &8\""Q%IN[P$1=I"3
MEW@/:ZS;(CX\=6_S@T9O-T. RJE%>Y&C$CHD="2H,E;UI+?AQ0!;!&6YPZ9E
M+,[-CW083PXF7UU;0LK/3:\=@^0*3S]-D4RQ2*NZV75Z :P506<IIP;WY+ !
M.OPQH8* D_%)GF/ 0&;KEIOF+@T/BT%7=RU-+B%]EM8/Y1])S3/];I,0*UZ8
MGW0B.ZPUE@"Y>H!1!>T&#@@FB3Y;?32TKOV =V4."0GNRPIN^'@(L=R8&=BZ
M';MTZ9.A^:)WDLM" .T"4S>4=1<3'I UCRG3AH=0.GKFKE$SRC_#7'\.5B3:
MRXSH<H4:_S9L/H-I.NT8])-)OS1T""U&ET99CM)%:$K#H7SR-92Y@2YM+]+@
M>;E5-\XOCUHS3[>W#PB>68_-MBO,<#QO'!_SG#PH3&<Y$7T1>!Y@+50.8.J@
MBU"EVD5M=2ESV<Z/RS*JJ:+TTO-;E_G-/Y^?UJI66[[GA FE6+MCUR6H']%/
MH=,%W>.A0D#\ CIZ*@8C*ZNP&Z),"LW6P<:@#+2OQSZX-ZS*+.DP;\0MJ=QZ
M=,>UE6U3VV6MX/#B*AC+&45PK>1UIVO2I[UBQ>1^^E4R ;]4%&HF1/4-L7$%
MC=4U:;GJL*0%Y@?!ZA^2OP5D3W]F: *L3Q0EC J+"E5!RMP"XDF;DQW=6?R=
M<C:BIV?IPJO;/TJ000<O4*]4+C2'?)G\$/C,E5:=\.VVAV32>_JY$]#B@ZVW
M'=Y52/#$@W]\["$A+EYS.Q<D;[[P5^T*I\+ DW %\0IJPK_FV'\(+.!-X2='
MUU'UV\?Q2CA @PAC!SSU ]"<X3LEA2U4[3:6PI<F?@)\&43,VW[P.PE>BVW0
M0 AX ;IVB*:DDAVZP3QV[GR9_O/<==,Z-D/,!<XI?1>'/<H%):6B+^<]$UAK
M#],  ])>ZS\\#KEIVI2U-Y\BU%_C BL,B(,<!A4K^F9#*8OD%'@#KD'\GS^E
M2[C9@_$]RQ>E&>3FVO9)&!2H=QL/=?_DLM'L2.@P>_415" "J:W\WQ\%?\J9
M&[R'?55\*/_113+E=FQO69\F9'@Q_:)510AY;^HHM8+@-LB)M#P&Z8W4SO+W
M0#EV:ZG\T95U,M#ZB9 \ TGNZ5G]-_;G\K*,I]W8&MF*K\GP+V2VSL=7HUY4
M4:%)FZ$"2$3'U.4//Z>!X#8;WQ2T^TSOZ:/\E0V2BI_5B%IOOE[_8O971E"H
M$]*%.-_Y[Z31)=N,55[)IEA4T"50CM&#MC@$ZWP=\ H6+QE'(H1,9BG4/M<M
MS-UQ[$\<W8-UY4[OVP*"5+[I!:\(/\SD('$\%L= /!0>O+ B=A67U:-7G;%H
MG?=U6+8 N?2&QS+Y7;:ERE/BVP5_(07:!?U.&X<UP2*4A-<%U_(O?X]!Y_F[
M8:'BF6M;-[5O^?EPS+<T=*-P.[.#MU="%4-[Z*J48]"Z5B7J 6 #$5E1AV@,
ME\NB[N<!W\:<//Q4LYILYJ9GVBNHQE7&3LAO2II?P.G1K@R#*,:3BQ!&'P'8
M2:;QV1<Z<JX!1<1YG@FDV* ));H>FR7UVD]']^S7C*'=S'W_K8L!J=\9%\[?
M9GY2$/"%)D>56C?Z2-/[]8!T]A4%T2G&.W;%M?(W)7%QMV@SNNUFGPQK=5^@
MV )7?2!L^RRSH>Y2'6&"OP?,1W"Q/5+NANC\VCD&Q;F1@M&"2!\+REQLQA0\
M8K.<6>U-F^>\3B<+0QG>QS,-IC#3V^.T@&&G#\U=HBY'3W?]]R8YC /I8I(Y
M.':APS\S<QPOT9Y^'E/':'HC[N)$9=8Q2/I>1ZHNF(\F?U2,OQ'ZS0:S;D=J
ML81&8<?^4@T'3;*HJ0_XQ,2:&NN'+]%_-FO(-CWGVQ#3;?#XIY4.<3\Z?Y2E
M;4OF%*!)#BO0O-3#%51+\]>P^/--&62C$8_MMQ47E9S3-!?69P#ZH5^E],\3
MQ>45Y\"T$:KB3F<9I9U#GPP9*LY>,KR_4PVKX/@<TN6!4/W0K=QHAXN^9 "_
MGYSF:> [_Y5SK;*$W@=F]*IEMR3?5 \ZD>K@\_79>1V20FKA\HMSLF7FL+>Z
M'Y+?-+J\Y-5C >D,_!^\9?'_MMC W*OJ30%Q*EK!KMK]P:OO))I3W2#FS-9I
MOWW[01J[Y5_5A99#+R(RZ6*8NSG=(W/G5+40P9]'697T)-;<0.!9247(:T2!
MWFNO6V6W9Y-_L/0R>^H)B.] HU!>AV[H-IGU8Y ;^#R"+O65:HGE'1F[,R8F
M:G3^;RYB$J-1_SB^GH=/.XPQY 2&@U*:OEI--=Q^7<[T+,'[A@TR]N5#N-'V
M-)5,/^=&K6D%"_JZ7J$8UG@@T*[\#XY!D7?]L[0:_G$5OV_CX%C_9DQ\NU1.
M;W>X0)=%G3LJKW2^L,)G W]%;MXF-IYH'U;$UM/;U-]\J#3]<7'?RC_"G\N"
M,2!7[-47PL;#Z&%F=8%Z V6GPTX.Q(I4M\6U7^G71H:;L#L8UB.[A"O%MX/1
MMCE2%/6]Z52RVM<I9TQ,9<6S5_!U^/U;\T^')Q*^?%OCX1./J'MII)\ #WQ,
M'9+3-VK!FSTPV/+]<[FQ4<PT(^K2 .TS*EPMAUFPU&:\512R#4L::E\Y!IG4
MF<[7ORWW%)+[49OX,2V:Q:1/L*T+25B/H0184V):19%_U"RYF\M2+KB<LHV/
MT;!0JE[ ZW6XZ/ DI6\WW'Y8:I$H5:R,+1HTQ)7^S%]L-BI'*1[EU0XF9#EG
MST?3S(@A=UD/G7$Q_4FZ/RZ(?OSZ*. ,U[CJ9/IX&QC_JW'YZ&$NS2)4=^Z/
M#:9# 0S<G#9J<-LM%WWV==0W2LEPW":RE_[H4Z#WHNVF%.+4=J#3Q\JF8Y"+
M0BR:JW8S>MR2;[R/-#W/T>?"%7)[I&S_VH+V&T,JK;Q*\,6:"7GI1_ DECW$
MDJ5.\!-N4$I^L,BFN+J<'84IG%(X?X&.-3P&$<S1U(=C&'L9>K/1\I@@%/CR
M:]C/>//7GHOT"R1YA=-[\T'6/ZTZJL3?T:RF( %-C\HXC[4"V_<M?*07T,!+
MTR8"/JO8P*Z[3N.QQR#;@F/0? D:^#*>GPE]\P_N_Z0LB"JU/Z5^=)!Y#'I=
MJ+A*V)XV.CFHTC&(:E';W_3.2#F$(3W@F;)!126M?@BZ^9U LU#\.'X='5*(
MGG]WLM/,)]Z"W%X-^+NX&KO!@W4).JW_&-1E$7(3?*'/VV7/#0?]?53$^"?C
M*E8X-. ?\GE@MF*.#B(OY?,JY.)72MW[.7>X_Y[:YYNU-;U<IW3.PGCOIWKV
M,:;8U >Z], FGPR2Q-)](.D^/D4KSU<U7%O]TQ2N7+?5TO<5]QZ\3?MXE%^K
MD BM32HJ0VE3H&&X!QYNQ8*.(QM"/6M\^[(I5=9ZF:<>.J+Y; 5W> _*#V'T
M<1N7-L[H?:$*C'?A:J:[]Z+PQVK5C=\E?R -E6KC:*^3%EFZX!6#,RN?F".;
M?XTQ'\%I4I<"GS]ERPD]&U#P5*G2O$QY#)\K^]V[0?/1=M1(?>/"$\J$3;I%
M=M8-](36@DL79J*&6-=(A74.LB-CVOVQJ7TE;C8>J3/]T0DJ"5BYZ,#T]L3/
MS;=W^E0WP>?I<I-_X4TA8\4:F2;XNO=PHQI+;YVR>X'=IQ7;_%9_GF=>?103
M'1.K.NM@BJ?$Q*Q=!&S]BKJ"'XO<>[M<CT._9_<*L[!1,W^)=%3LL@3>E0+D
MA?GVD)!/%/LBDMNE.E??M"0N;Y[8GH#-7QR_$Y2Y:I^FW_\ SS;WZ;9<SE50
M7G<^4BY_>3.[KHJ86T58YRP"XO?P5'I<$>#4+21?3"J.M9N8!2O JN(N6:O;
MAAD;>72F//3<^^N@CSI]E):84Q-8@M TGUCQ']^>F?XA27!_9IE6+=K)^>Y-
MQ5IP$H(,8PV=!/- !%$F(S@3[SRW ]'N*E6<>8=8CI-IE(7(YG,"0T3J:@_O
M[GP$>J%0* 2?&!Q(0CA\M;669E?4%[%VUF)^Z5]/TJ%F[6T_>L_KIZG8Y.8W
MLOWU[<JU1^G.7LF;5RFV'9E9W9A2A[^:(1LU>7%\W5326=O'XJ?:L8_.:X([
M>$=?O<*T!J,_P'NA-5XTO@@BO ?*99"W,N].N8N7>#O34V(*GB"Z3K/D.^IZ
M]$4SB5(0JV;\]M74*^F\>]D!'FCG&[,\>UME5=\TG:VXV5'URDQQ'9!'=VQT
M:#KNRI:%MOEOA&S(=4EAQ;>40C\,NPTY27@5@=2U<X-2>&>NQNU_>?A75W!J
M/'Y-6R> AU_I]I5WIOE&K-^ZC,X0]5I_P!UBIZPVT<>@L MH*L\2E/KRXC'H
MZ]/< PU$@+_[_#43J]S MU!*U0[!3O\8!+IR(LG^L\C%%!W,GZ#5F7F:@9=G
M@9\9>?*(V"^_+(R@\AMZ\=CU/J^37DZZ03ZT=1LB^6J]?R+:J&6B(2!2AU#H
M;)'%_(M%+YPY!M$,7AZ#1-'N\Z?HW]<=41X5GR(X"M%^/IKJ*02EO!F@??&=
M[F Y*I>Z3V=I_NPJ!(WUT_*-Z;"Q3_2\,J1=\G%$GF;BLUS-?,=Q(QPJQUKE
M*(RX^F"LA45 J&Y<Q7%]9BA'J  ^=02K\X1(_^6C*..P][[X!3Y?,G HN<:(
M>GQXZQC4YO01<"H$8CH/6%SA>#[*VI8;P;G9VK 4'2@X+:'/[>)['_NMIQQE
M2PV@L]20$A6(,_@KU-'9S,3?&29YM931J#W?CB7;#*VB;I?)EAL.#=2F#^,8
M)':/ZZB0+CNX\+Z2E29(%>W"1OAJZ?A+^[%9V[IS:UQQ_95=(UG\_<Q9K:\?
MED_CXYE2B*[!$^/%)=-WTZY"YU2^X36/ZK0O'#Y"!5'M/^'Y\1CXF.=:7;D&
MX\Z@D\AUF7\E<A6"M#U_0P;ZNYR(,OI_/AAJ]*%C4%UFE$?H%2 4=G8.0)#/
M5'64VCK,18VH-!M76&O_GFN&GPIXS$&ZY^W@?7+N_-"%E),.< IE/(:_B'*/
MEE-X$'__T#*>",CGX<*M<1'@O82!L&2EPD2ASQ(,&J(R.]NF0PN_UOGFIN98
M726($E&G+X6 %N!7H#IN(0YLY<PMJOC<CY%4>?M-_46'B0[Z.3/*)OT<@7)P
M>!] .P>4HFZ>0 'Z4)/\:$0JQ<U/ZDXOVM?V26"*XYL\%_<$JH/%WYH^G30Y
MZ6D9P[*_F*9.'VLPUZZ=J0DE<2U+M?G12J2D_^<+ 0,;I0V8C8H L"Z[9V<4
MCV?;<\?D.?S+(I.1_:6-R1_^B_Z:Z9I##]/?_+QOP /Z?UBG1.K[M$J52IX.
MC$FD'P0]:)VZZOI_C6<L-N,QLMJF'K]7U"PS*6<Y+C5&.>MV?.PXK;QI^01K
M#&(^_>6SQ;WK/!QA#]/^/S%)8_2X+6@_X%6C=/E78J29^#<9\F+O:L)NV6;,
MU.)^+ U<;.]NJ?!IY8(N^VAITN.T%PLO0Q^%ZVTHVC)]&->1M!G-Q/P:[L_5
M:ZR1D41+!VM%/H\6G;2[R[QV+RBKZ$N5@I%/ODSJG:+$:D+BQ4</5T?R_K,8
M^L0SHR44PG-J !E#A,?08!5H-X<_>P$!=+VZ"SC'INY@']HA7(&"V0L<HI^U
M6NDO7LGZ,<.__XP2/XU1[[7+$Q@A;] **K7]*DU_!&+6X631!VUH9C^M%K4!
M4T+JT[E;\7N1EF3% B?OW]X-(KX5,]HK(PC.P8V^HHJ>LU?2A4Q()YWLSC_"
M7L1)XF?U4'KLQY]2Z!B^0KQH,F36UVZ=A+VS()'"[)2 [=\WFNL*B3D16EVL
M9,PIUZFA?UI^" '/8]!+DG&;+YO_UX6DH'&2PCHCL6@8?VD&"#ULAZ@-[V9S
M/!S7_EMYI=GCMI%CG%"A9,]UYT!F9L@#@=D<Q)[7GCO%;_D5! 3HF^#3BYNK
MAQ:2X,Y3IL^9SH 4$\@"E9](SPE,T1WF2.?2EOD0+N*+/04NRSH#6\\<(P\#
MC6XW%A+^^D';U2*WD7MG?,7<;SM=<3V=U%AJ@PPP:<"W9,N5RY+=GF7H1R4R
M268!#_:2CYHX$_'2UDB!.=L_>T%_K'>"2^.5Y"KO<QN]2W%ZLY7W4 8L.#N?
M=>"SMPKD$)A.Q V&#W'EQM([CSMJ% (-F]PDOJ\*]!S>1CVI XY!A1.PSQ6Y
M5V(]\3,I;<K3*^X#/+%['FR)PD2+D;";'Y;PTY%;07Y$60.#?/_&!9<;Q6<_
M=TWL5,;>G:]GZM)"^MK^L+6D<D:J3GNM8=A#$I^3,N8]_UZ>*XE/Z%5^M74Z
M3YT]N84XR()" QKDP0O&OH,\0,K!S$W/YQL["IK=<S^Y23=&GIYYXO]$Z;JF
M$X.8QX(7( WM' R;4VX:QVD0O5AF9[K<Q'*PV'MQ8D,ZV7J66Z-O/V %OZUK
MI]K:H&G\B+UD,YO^>UO:BMZ?;*>_;=N:% >ZLM#*GDYOR\\)<(4I1[3Q[MWX
M)O#G@7?1W0O%1\OEA^6<\C$U[MMIJ3LJL.[YJ>K]3G[(Y9_EH1>MYHS8W/@2
MB_]4HUULVONQY[B8W!G;!"5I!:^+B?-3X+U20+_$"I'5DMN9AK4=,2[ 1WO5
M./Q@6-!=>=CT[UWR"\UE_*GR<BDZ:_;A32!>_Q61,J*>.61?/II0+_1 M?XC
MRV]M@<,AZ=\9#Y*Q0TW0R'F*1>Z4X6&/36B1=^&GE@*$YH<'L$_UJ9+WIZ7_
MV4\)ODZ)24Y:^+#S(_!E<5P1T[6TJY,[2R<3VG<J]=?=.]OG(!KT(0=^FA&D
M25N&%-QLHAI(SIH_O+I8'_;-.L'Q^:K O08)D;TK-:&75W*%<&;L]%<5R&?T
M?=,L<*U<6I-P=S7T_=M\J_8#)Y&<?W_MYP]/I%J;*=I-QB&.>P:PU24,J[ +
M6UB&R(_?#7@W:V*&N6Y6?6M @REU?*C1@0O=]O 8Y$Y@ 0+@S4V_-N7DRU0%
M-N2S0MC*6W!>0LE"-<7,=_U?]<F-\[:(W%68_> V/%QT0@J"WZ*N;$S_*U@D
MQ$*81FG0_$?6@T03WW-E[VB]9A_B BY*\D'L7YY^HW=#4 0^/$\Q04\UD\!1
M--$*I*GA.*T4$<RI-C)GU7(4E3[<'SO&O%7&*OVD_\.+F:=P0=+\=.Y>)%6]
MTS;$\BGAO</HXW,(D1RA1-KGQ5C(!&?:HT[# 'DT3F^I<3 "R@&1<<^1_QJA
M][,.S%09>R5I+L1PV*1!]IND@N3/B*V+K V)L]7*]AF7:LJC?!5+/%;PJPK?
MN[E\%X,\<NN.0:<@\C.H.Y2B< 0?U0K(TI)>'"E_?*:+IY"=Z-/;)A%QM.9?
M<4"0VB0L?&Y"MT-?LQ(GXA$_G-SOYOH]FQ9SXX(B[1H8EHA8AFT9L=T#B4,1
M^L]YRBBX9B^1[+#6GRAU:-R;<Z=0S5_1;J4C7%BP=[_RN_*C)#PWV#K-XQS8
MX%5/=\V>%TGGEL+&]K\'KL52MRD8XX>PK$(&GKQG.1&GPZZ?J*SX9'!]IA0]
MT6965(;/ZY\T%3VA!#L2JJO5O'<0Q"6&SQ_ZLO1>^I*RO;4/-: 3SC]WI1Y;
M]\NCPO?S4L;8%&6@^ELR&/_B=&]%[G77B?5>]K[RJT-I=*Z[^5&5(]N<P%7,
MF@P),^W3'N3YCG@,XG8-TO9/_B'RU7W/R\?S^Z'_;=Z@ZK .IB2]%9G%..A"
MQ!R4:O]*/KL2N=_AP;2WH/9D3M!<1QUV/2H%&?US_>4/7.SL-WGD\Z?P&?5C
M4*T:X6/;1]9>W/5QFZ*H.J ZR01W.*A#^3J]7!IV3D/@@.5/)41--29J9]W<
M3L>X";'PIYKL-=D?"<J!/"F0W#ES *\T%4XJ,E2Y2@CXU%JU,H.%. &,QZ S
M+,!5BE-7EMT1<8QF5_PG6-ZW1<+B;<CK]OWOUL^:#!*N0IR^I ISAW'XC.$7
MMUH&AW"#7?3KU/E(G*!?B0F">*6A/D6-N?H1S]9LN(<.QZ(D:I93FP7K1U4W
M_[6^R;TQ],VV7Q0.&_I]O3GV[4R@<': S]8_',.XQPOXWNY4NM'W8Q QDJH8
MU+O#^ I>O%T\'NXV7P<I"B26]@\J= R_S;@BYR&Y=>7#TP:KR("+>D\.;5^<
MZYM"]JB.Z5%]X!&=-KS94ZY_W3X;<:6L9Y $-K(GHR=83W-ELF[=UH<07P]8
MW4[^57"#5-*O7_ZNKC0WC@4:X$4\-+V3DWCYJ ,+V^-6!5,DI/+'#>Z$A6[2
M#+39QMC^UL5<^_V@A,?1?.A_<Q3\__OJLAPI<R+49 BJ/\]F\ZA[_8$K(EQ#
M-&@TR_#W_?K/LDT?,E+]^-MA+-,VJTV4G%/^<K(;FV?'KRV?[Y%89B-O;-Z8
M[0[4WG7<A Z5(C3EZEN*?[@%>K&/%K4++$4_Y$BYNL*L\\54QFJGWY48=^O%
MS5<2]W\]!(%HBF:U?7#;E.MM^8W"\TET<'7=B-3LYWZ.MQC)0=[(@;+D*FM1
M9H=LB^ASCTAE;FA^%9T'#X?+##KW]IO*"S/'QO;YAFZMLYP7C)5(:@1MZ4KZ
MJH9VYX]]ST4PU6BZ:\$E\E%>E#W<MZK! (:^WP(I2T/&-L[9>[?^-K!_^\[<
M2WZ-.P9=\(TH^KM_'Z;:[OZK3RZK@P&7>8JGQN.>\@>.M.RKY3]'C>M\!XS(
M#NMZ^2B>YAJ,>1+I<?"+^F_U_4MW3%8C5\,T#I[AIKN%0@F'NL@(\V'9WX?H
MF(*Z1"^5YOAG=1P;5F7)S4[Y:[/=+\\R5]X]H?6.5IOL(SPV\/F;V6.0ZS'H
MB='E]?C2R\..:^))G'K->0/GRA/521L1@>4.4[&JK-9KSDFL[ZX,%\8Q-.H)
M;4J<J=_MJ?.]J8R9'.F^JX3FVH:O\1^R(SN(7IU.Y-PXGXF^"ENWP<=.;FXO
MM_5=Q0QE=25?;2UPF/S+PG?!TD%[%9;]9/68S3I8=8^W3TS@I=?$<DE;1)S$
MP$Z2>;-UM'!8X)3W!XMC$ O*Z!?*R\M)/AV5F>QN&7TPF6S,?5/@JJ?1&660
MWF^QF?OQE0Y<E\V_U*5G(EC9;Z<+;#T(?I\6^=1\Z?5OS6BE]<*2JYRW0<X\
MS>S"9J# @/5X2O@QB(Q9.RK_8W.GGK(R;;G156S^2S!?:]0*=)>#>2&@<GF9
MC)HZ!D5HNQ_<$7KJ8F5;:%334)W,S=?WC=:51!PXQ^ J_LIA"!OTKV>O_H13
MGP/PO5KJ".3BB)\=S!#W^INIM7G?O<O#7%O&R\+8J_N_O1WL.D3T1%A\96C<
M8ZN^R'\9CU8)")C/UN8"/XU/N!O*&<IF\X>;)D_Q>AW]+C0_N/G'Y?L_<.;2
MS#>EX>DL]9*>)E,]61LHEV,08_YH1<7F,TI ZV",IME8B?;@RZ;$KUG!Y=.6
MSY+#OV03_9,'@G<J(4=?3V9S^CPOVIE54+4YV'8VV*BZ08:CN*C_L';PDF&]
MO<7-< [R&-Z3 NV"\=@BX^03%]OG?J"HK=6%[NOG!;3BF,!JG"],=GGW?94^
M$/CH-;>'[.U"8.PD11XO03O;WD.MMES*B]P3'4)9Z;\S3.<%+K5O##V+DPJ_
M@JW&!CRY&9LJ;#+ P?GH8)0 H.%=E8(H/<I>=A$0T-K$FU1Z27+CJTH?*].I
M=]D3C,\][1>>;G>YHC2/<(64W7 C]3:%Z*RH[N(7\5]6,M58L/Q85]QMR@+;
MHI%,VVI"UOH.!I!^EEUB(U?>T^85#1?RK*8J3.9CK5 -U7/!O?XB(MAOBMF3
MO(OPMOO%&J8K[O,DS3&YAD\KT[\#,0G0A2:P"%T(Y3!>5CQ$$RQSX_.9/<K@
MK9NKX.HU&[Y%UC*\WDIK#1Y%GD20< P20.D70%+5HVCG=(Y61![)%2;45WR_
M];14T5"" 70 _VF)Q@:\PBE\AL88M1V#&/[FB"3F(2/W5JLIWZH]XTPP9Q]@
M)5+;VKJ"HE]1L>WH"[L 2@7"[+H_GGDBU1%M9]2DOZQ?"!.<_\:2P&GVV[.'
M=YETT9#K00:[P@>TI9VV$22YM/(CM3@*NE"+%E&9!Q?5[69&[C)AGZ:5-:FG
MQ][>XLU</G/>J'A "UYG31_-K<WM'F0 (GK4O?_@V0"S&VJV:W*XZ5+C]-#
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M!]:.<-O]\-^6,/*3_E=TMU?XR'Y)HAP4,F\%YJ9?_I/+1.,M 3([I^JS\X
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M5UX[S1X.\&'?OMW^Z-IA<M-;P_$:69BRD8#4TF,1S]^<Q)O!#T+Y3@IFOYL
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M2S7)8[TKMO0ASUNRT!",;']RC8MJ)Q"S1QNA<Z @1^_Q'("/'8$BL>)PSI?
MA["7JJ-XC+^N>%[.)R!7OEZ^+FYDD6)]IJCH[7,##(CO<1CGT,%2J#C*D3+>
M7KEVGV3F8_ISNC/K@Z9\&K:F3.H>_CW$HC80JH*I)1I)G<6?/^&]0^K[3C ;
M7<E53##&!L@E<9YSY9N:CT+92G6TZ.ME[%YN.#\[;58\D-SC'>PA=L(FCC4E
M!E/%XKM3_.O*GU?GF>BLJY:YW-I2U$_C70Y\.T>LA^Y>K ;%=FX_:R^\<\R8
MAOX9IYH(LT]+^+&'YWTXR:W/)B+#I618).%\Z WZ3*:]/#4WG"[Q!\V*.E>
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MMYM::;[[?<:!XMA+B/(,S!.W$<,.ZCUB/-4 \*[?8-.VD^IZ/^^]JU6W<KY
M*OV3\)>%MY'67"0S<A(L^7^B;2^YNB*M LAB:))U.L29Q'V*OW)C-JLPYK6A
M>4;+C\I=YF4P8+/2ZXD583L%0FPEF8T\T$8N#NRBZ;8=]ERG],C0#^M$4CAF
MX7MD:R"0V&G&OH";HVIW$G=_:J7BQ(VB@Y^+OJ27VE$L_ 4*,%W 7AKP1H0>
M9_Z%S7&MH!.H+K5.WZ>B^7ZT++'->]'N*OGD'=4HW58_^"+;\G@%M!Z^F4IV
MT?'7ZVF RL.W:1=T6;$#L P1$%%'CWZJ&T8<NC<!"QYRM!X@'R$$?A[H>1=?
M K,X4S13]C2?\#T(_?6 @2\1O?PF6D%=CX68G!&MOK6H!MPFGH >-/QLCF%!
M)\OO*OX^ 34M2$S@T3]Y;TTKW2 -SMB4*?/GAVM>WZ6ZGRK%\035<1GZ7$ 0
M7DP^3Q.'[P]A<^ZWI@R[RC?G<3*["Z)"8)]DY@,,7\\C6G:,20D8 >FTYE%6
M'Y0X<;&0L. TZR_?;!MBH[_[I7?^\;-/V7?.<G18,_)XF@*]>%8H-G^1IX5D
MF*R ,']_1T$Q&-XBXT0;5Z9CDZ#K[G?@&)(12@4!7;0+\I3SQA\1_$!'2(4#
M/ W: 4R3V'J/*O[EY7.DKM]-FEHW:7ZYG*ULOYHZ_]U-],GUE=2_"[?)9TEM
M S$<WNIH7CTU'PB['ACP?)A@W4B<UQ-N&Q=\6#QW4[*>7/3]J5*73?G#J)07
M9=T^WR\J08TJ,YNO(V1"5J=4W_^@(IN%[S@:DLUDJW*&1X:1NYX\123!%<.$
M:#8@0MA^8%&6.)K87#5OR/.[H:K7%2;+\:):HN:CD3#HM-1QDC\-$G\OFE(.
M]B"#4.MK,HVP7HF,2=&2:G!E,0K"RULL?A.\NRB,RW:[PL5HRW<Q1XLCGM4?
M(73\6D]L$\FSHV-/TEXQJ%PY[(9P_]@4,,@O-<0/BZF_4=<=^,XQ).MHTG:9
M&=4_/V I+3Z]%RT'6!H#T0C;0 *4#0<\O*$PTB15<L&;P#4.U6G+__0+@6O8
ML]/C)YGFKT2=F;8:"Q%DA1JCTHW]PMT#\GD/SD<HWWU6S1;@17_K_V;SM,!U
M6"L5E-Z;<Y A8C;\D\8CR4W'-]NFP,RU9\I^E&-6FO@^Y7QB*^.B;I )1V"\
MT0E(H#B'FX[+$$F C;S5Y%YS*#!)BN5,/3_P?X8YS((?K[4ST53F3U6&&_*I
M&^+]?HMLYT5OUTD)L)IX@R+X@7Z[IJ]D7J^!X<"$Q"4,.M',KWP!9^<[MX-T
M;?*>EA5 _FL$'SRDN5GW0YDA?AS+K/3]GC=3)VM@&:_,4R:SM[0;.CPYO\PW
M4>/B8*_H,X.<:-;95@,NJTX<:/_D-VG?Q0U*WX_^@'+"/\]M\WJOG4OF- D8
M_IS!JXPAZ9R*B*!-X_1?88N!@?XC3[*OXY>I!-$770U=E($(Q1B?P]L$:RJW
M=+]A7P%OAB]QNW\.G=ER-IM\Q2]_9&*-/>?3X%9%>=^NQ:U89:S$]/=B1<"0
M\H@:0')?3XH>^C"S&2U98 *U:&GP>J+:A<R]?7^O?6>NQ-HEVN:ILFP9\XM'
M:+7PC]YA/P?K7$R-\Y ]097'Y2>@Y6P(.\17V&ETT*IIM+2NB:X%>2?'TC[P
MO;XX:U62<ZGA?=:/FK@EM7&JPG^B#\<8YF'Z4,) ,A%I//DWJ7W<_V]"J$?[
MPUQQEL:KL<(SHG(?-<7K[4@QR1"B*7KN@!"U5N;B%U2]<60V-\4$"^FQN259
M(.EN>Z;:7_S<K<;X:P8JC@S_;1GZ'9<CM G"NJI@7D#=SQ?3]F#Q>4W(0KZ=
MPTX8[> J_\KUTQ+UWPG([B%A\]B?KPTVVK8</L0R9W(3=S1S,%0/2,,^P^)1
MUWVA&5#NTLF0#(M-@6DC8V0#QKLK=E5Y@/V7Y^\/7^KO_Z )T0:@K'^E4@67
MSCIA*QU29BM^.OUVD7/32K_R"U%BR.^R_^>M]0A-]/1[!1$/ 'R-[@FH_P24
M-G>N+>5WG9-]9*)\8.!3^]P;-E6RZ/2G 9H\#9XG((85']Y0SGJJ7"%,><LW
M7.&1G.3L]=O9_?ERY_UO" <HZX<_VG;^-5&=D7NTOX&R$PY(?%A[X=YBY)NE
MEG%:?TPS3^$BSL?:B7%:E9(EO5N@][+Y6QUV'6Z?E&'SYT<J]8!$UP)PQ(2'
MX!4Y9GPYP$IR_LZM2L?UZ]KGA:T,CU:59?_EG!8+\2#XA3GC+.W!SH5?!L/X
M9B5]?K=.?[=<7-%* %A:9*V26$D57">.WB.J_2ZL^:]UN[@B\'*V+!"*2WML
MH-RP7]'A;T2[NML;*$7/R&BJYBY945^_@20$_1S:GLS.274</07!>+,34*_+
M$\0Y/T@"36QAWL'>X5M519JZ+[81@?@6/M*G-!)-U F"UD6$_(W(0[)^ET<)
M/K,U3R;)LB0<"E 9CLLA'FFC,RLKK;5X^3,G(.-/R88P*3__K4'-2GNS5X-F
MX&N/^]^ZK<=!*]#$N_5S4P<KBDG4F\M%GH^T%O82\P0S]*CM8EO?]!]T!:BT
M&('\UXN-ZA1DOU;=2_W^J4O7SM[>).8[3GY0<_*HFV8XYZ/LO?PX]HKOGY6-
M_R2*A?<$E)W/=YP /@$9RL.LF$] 7XV3:;U9)Z"RO+8J5/$SK'-IK(KQIW&9
M>U=N_3$= (G:A?R_#%VYNQ0\/O;?H$(HH(2'I<<0[??.@;F]CD*[P,EZK#[6
MY-#I'W)$B>%:._TU_AF>QQ^QWJ*[TN(,[5FSGI@3T+GZ$%CF>/0/WB4V*:!2
M,2/$BWI/QU^>Y=-&O)7 @U:*H3';S@E(M"2+N7L(B0R) A8%)Y#]]%;JO(:/
M[%T]%.\SD^/HG-<4501;>>E:UR^!"!U+*3%-![$HA6UUK:Q4*@<>S+4EX,D;
M9M>:!8M4J[Q^C/N2;ED,%R\ 41>!1S6&1&QO3*-&AMK0@@$&;Y:L)P,O-"/^
M;JC_MC6EQ;K:6L:0<J \_$?"M-C.8/_E?K?HRY?0._!(:R)VE^/T]0.FW,?J
M@LTN 4&8I?.0!K5-^3E9"K]GU^2S,;O[F&#W11E;:M/(/.<U_2AOPBB#MYX6
M<7(QH];;SK^A;*G?N>,3JM4XS?[5RB_X/(_[<H"!YD<(JQX[W&P9G3R2<PJ:
MS$!D7X']70]?74&3I,&%M_^>OKQ:MQ(WHG(#G$5C X)XVG:$*<(#]'#Z/B3;
M/S->WR9XWG:_G;@#$/K'TJB>ZYZCJ6;Y,RT8IYR'YWY_VGGG:'.GB67(,SOC
MZ.EB48'D@:6$@D>UHY@HCPEL*)I%1T,AQ_NX4/GJ[<@/CFE5?KN_13W"XEXS
M74(LX7F.]$Y K%0=&G,.QO/FF%FR1T9)SCUUI:CG8\\]+"\N/.,T$A?*]DD^
M]6K<X@7 !(^K%>]#L1'12<W5:_)![A7>#VSMYSG5LTF#J35W5UZ.Q^J9GD:3
M);S0D C)I+H2\Y:, 9>/6]'G?S1[$TBCL;4N\=C^(X=X>,W4/_$O2<=G+52P
M/9-YCT)$U<<J3VW/TDQ\7TFQIYY))LRTP1+Z3.P,3>Y?^8'L=Q&E#0MDGH 6
M=O8S\,G#ARRXF#2_*"/B-)[M&8UUD\N;QD%L2T9<<0E2:L_#&4ZX-"39FC$8
MW,V]Z1KW]1*AN=L2+R^+%1'I' ^I53&;4JW^M5_WI+[VM)K":^V>.LIE1Q^$
ML%Y&L_TW2V&YBGP:4@RUW1!(\AZ5J4J?9#J!(7T^XJX<CO6^A1<3,</9:SBS
MH5P6NE9QCGQ4]L+>.8VD4\04 ;6/-_>HF&73'!_]+F]JO9LQ(54-3QUYR#KP
MZ%9\4"RH_@--B"I-;.L]IJ?(]CD)_-!1K#A,@C9L"B#4K5:_@-KR.3_^6@[*
MG*S [[%Z+W*,E4XTU^H-W9]87EBUF[OQ"2.R)H<SOV&>)_'VHI%T#PAA7#Z+
MT.TYM?D[A#LT,PW_YE_O^TTHL:Z,9/-L$W/J-P]H2R$=Y'?W7MOA"<A+EO(]
M_-*A^O0(^0<0C<%G[?Y%-J7GEV&^?H2'C8@(*]RQBG%/IKAYZX=?D(^>7CV$
MR$0M6A.GM\P&V.*++P(+Y1B7%0@3W'-@2GT\_!/.U\Z!CW3G6./JMQJZ@S/-
M5(WE6G OJ7T\.$/EWA_Q5%[>T"J&7\]#[U1Z@:\J?BL##.FYZ0YS3OVL/0YQ
M@Z.7WQ:$3,=B,9KUXAUC]I__P*V_T'Z^I"WX,+! 4%[I]MU[&NF>,<.I!]!D
M:)-U7+1R3*\=VBLC;  E,-9M&5X!P/HZ_=YJM92'Y9%?#IU;N6=UA5XFK"\>
M&)D<##")4BNE#2VQ(G1K?3ISLS#H,S-;=ANX*D?<AGK#\(>,7I+*,U;I[_2(
M_GVZ;<>HRN0=.;7(GEO,LG=A_^@$%ARP%VJFQ:[=8@Q0QMW4_+HB+>Q%OY^U
M#-VI(-*F:>>+2.O]?$X"XVKRKO<+!^O+MS0^R0^LI?$61L$+@JV:/BG?%/[8
M"W[5\((]/=VC :7L]9R4@P?O0BJWVE36!Q8U '.1,AW.UPK@774MQH(AL>7J
M%[M)_*+%UWS_U2U]CA!&)OT.]FKVNRHO=C!,T4^U,VB=."QO[EJA]X7)#33J
M/<9>'[Y] KHPBO&0??7?T+$[LY$27 Z*,X_[]T WZ35Q?_C[O=B+K1^O\'/3
M[4]CD7%ZYX^1)R!?Y*S_0:\3]VGQ\VQ/BB15B=]T'Z]Q;8ZL9AQ3=/<-OP=R
M,U->O'3M\+",=5IMGZ\/S0H/^R^D?:AG@6=SHWWV>^RGNH22> M($^@QQX6$
M*"F3F\,SL1W?^8Q_E99O94+@YM.^OZ([M@3.9=:&>P:&N'L'!5;>\VC.LWFT
M.'6K@GGP[K<&*_<OO1B.'].*!+/94?Q>>G.1&,::"$X(L1<^8ZF7[Q=>BC/C
M+;RLW?:YYIG![/I5NF$0XCK)]S[1>I!M[@1$=B1EU,>K]EQ5Y$!(DZ1J_3QC
M*FXIRG$\"=Z4+T74W<8ESZ'G#QO2IPL!V'),8C1;3"\'Q#,R)3CF-/'0 4DQ
M+%"JW4_5&>ANVQS+8<'&_!#_GV+<*/SL?%$KS9G>60QM6=\M6[%54-MR/%+H
M$ACER?W"?M[8/TN.XVN<F#A'KM5<5ZRFYJ5-LPG$]<J-.1:M1Q6)175O8*#6
MU!%^'M%44?642= <]T7UN/0'C.N*NW\JHD=X8_YKM[9%7-!A8DP?'8!=E,I&
M,5,T.6?"3T"0N8'Z;WZ@N0=#G_.'9K^J)9Z&R 7 &Y^A[7C<U2*CH_L.MV5.
ME?\A17&P,C<,J-<@(PL6G1U[R^<TA%9;T__R'%U:SII%XK$8JW8]82!J.8OM
MN&Y-]NMI41LL:P_5@V=NK,+D&=8-)*I%'KY-<+Q8NRS,["20CVMVE#J@>)QM
M_:E#T?Q%"3;J<GOZ"ZQD'>1B+^JOUTQ'4GA91M6<A"Q7Z%V/R=C$'\)$B9DI
M:-8RDEU?<$/%:T&*?LTI2'92S'#*4MB]LX_9\&I_T+OB>/!%WZ4&]&Y("4+[
MS3M N J8[FM%">>8OLA0$#:PQ_%,,;S>"A#E?'V8LF.;CM.RWJKOAR5$LP,#
MI;?? UU]*$&2:9$_P:8V)$I9<$,LX-HEBT?NC,*?JXV)*YBORX".CJHPMQ=O
MM<#M]\PR-.SYC 11F]8=.MN;_$+LYS=O@*5H$U!Z!!]%DS8&;3Q5QSBJ_#NX
MQ0F(QO6F6\M?=4AF=ZW]$_(NRMLY]R=#KFW)\Y']V6#6Z8*CIL]H;E7P<PV[
M7UHBM:X?C? ]!B;BEKSC, K/+Y\:(J0\5?BIMC]/934\ FM?,.+;):C=T;R)
MFO#Z<ZM1K;GKWE[ZB]#6*9=V9WS*G@V:*9K3"WH.(2^5A5_0\29S.<UO652]
MK,B.+'Q3'+[Z<B;/,USX=7;DRKO3&,W?+4=Q=_S/+Z5BR2O@F4*\/=S77$_
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MZ$TX"((TZ;V$CDJ)=*0D\B)-1,!"AZA($P(B"$%"0I'>! 04E(B@@)1(1UJ
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MELQ\$2H2F]J]9G/(@/T;W3;)4A+KPMC-SV](9&2#T->*,/;LOS86@DQJT3,
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M$>;H1)!K'JM_1%B!F<'3I)[/!IJN*8E&ZA*6S78MH@GR1W4)JM^_=HO3G=C
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MWKW-H3!U']8VPLTP\ V@'FW$BOEXQ+(!WM?M9+XTN$+JH\\?'3?1GWP[*)O
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M%/=<<RWX#!X=Z/R;)"H]F+4+XS^, &$,T55?HKY",147[N[CH35V8)EY9NA
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MCJ3 ;HVOXJ%Q_%N)F3"&\J;"F30/?!/<\=VK0KOG:*GAG1$A'<J%[OWZD:G
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M-S?L"$-4;J.)]4:TD'W5 CO6@5_0\IO;'I4*LM*.[J5+]6*73A\0MF,1GGJ
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M(:%JL\"E&:WC6FB"R"WR?>>'%,H+:T+<PG#; PG_9+V^O<\_[.'W BB9A/5
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M?E@<+IV04+-98O8CTA'4I^4\;."(]1TBU<2##=3!&60C3Q5Q;C<&SG%<=#;
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M])][35. N8HF3<HX0(+P32PX*+MYSYC/UIP UKFEC4NM=.F5#Q1 UG3M$JW
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MFVR93(XT3-[K2QC,3S3+CHY[D!1W'XR9"_TY+#I710YZ.U@[5@XG]B.M=]C
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MK=Y57#*LX4\ZP,I7_@_E^>#YX FA -_(=Q>U!N6LI%"#D_Y<[I1J.U![???
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M(B@Q23<&@0H$%W9G_E<\^X4(!8@Q5C6$BA$:J^B<M59E]6P\5C#G[!=H'.*
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MG68JL@Q=2!)5LLQ\O59JZ5'?T.R%Y;JZS]&=#]L:;WCX[H^A'N[;O-M4=(W
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MU- 5]ZW?U3B[PHUB>/@Q6E/$/S5VXZW'^2I*43M'I0Y+6SP':NC([<!7O@:
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M,>E@9&(=HMD(PA%6*,K#"JBI3C,5-Y(&A75%?]OM/%0\K<D. A"O1NAZ<^W
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MI@P,>(4C.L.)'_U\)D]<_V(:&Z:UZGPC5CGKBF7U@%F @(F56IX=!0IH?RY
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M;-T\&D[W9N@RRU 'D,<*O/>6JV=C$D+4YS''[;H)<^>_?8\WF+%H_(K?'.A
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M"RJ(M'0@J'UJ^"%C?G0R<G5".QD;<F]'A3_\XV!+GI53\1.(AQIOI@^FN3.
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MN4VY.7">LM@<4AF#ZS%V]HH)_@L8YZH]?=?H<<%5^GS^K8 [7,EI,<I*79Y
M-#D'T&%#/F$@!"3G."Y@1 :><['90T&YMR3CNN>H$%^';^^O^[DGKT X]:0_
MR;V/@%=-.O)V8R@7,8 JK ^=@)$Q1(/DV$TU.-S:FQ7H*6=O$F8U\$V1B#%?
M=G>]'?1-.E,K]KRUCV 8QQG0PG50Y)9;-]7HDD *R0&/$&1#;@,)VXX3:RT3
M21M&J^?3UXV19E]2^1PO"PJ1.=4.=.6\>F@&DEPK)7I9[1/T6_XG-!]+*Y#3
MGBJ2XQ?97EAVXA5F,$@GH, :*,[-'I1DU-PG-R.KZ$? #F' 4F-X,AM0&BQ0
MK% <<0];5'L\VYYWFK[\=3BI]C="94:NX&%K >5(@DJ:O:_29?TF\N][(*>F
ML 3 !L.5!ZA1>6DWIWZS(;/&M/L46CYY6+,C9.10D%-?X%[\+4'M#COEXY";
MT3Z''KI+E.QNIZ,;MC<'J.4L/CI)=+;*&["VZ84*Q.0M&HRMS6Q8.E1Z[/_D
M3+O(NE"0?FTBZ$ZXF,EW 284!/))E+ %&\(+8? #[B^1BA2=C06213D0[6"O
M;;I94I>CTN7\>WZ)H!R^UX<J"<QY-UA^W0YK*1D]$B+[,5OBB?N]+%)<8H!4
M,+AW3E=F&BZH% .<,( WS\.$=RD;!LX8,73(=1]N"O!>>7 7N;%/]C>*W._:
M-A@%M&0V^.EG&8% ,Q%*R*"=H^1.FMUX\7YN/2/TC8>'/71V16)V0:/L_%7U
M52NS0GQ.IL; #RFPNC?!"DIF9L-"EN9"2&OXCP@2 O^MKGE![C*NJ(]P9&;C
MQNG0D4DCH9OBETX/J+LEN\YG]JQPW9*?O _OPP F_I-SUV$;;XFBJGJI%TL*
MGV>5<^897OS]6Q;[E:#.F0_\(<4A!J"<9D%$K/#UM#\*OMWWLPHQG+9O5,H\
MW)6MYGNYAT_*JG L=H'DDJ#*&L1!0>F!2U34I<QL<A.5272F1Q]_Q(U@0D'S
M8)Y4ZWF=TEB5*W+Q$''^_O!,"=IK28X=7H94!XM_=!DV5_KIM$R:N>1Z2V&9
M(27Q2^0/[(INSQL/^_I.GK.BA:3RJ]:P$_:<#^>*UD9\^S"4.S9978?LZ<;K
M&,[?PQ'15<]/T_N]H_+@=IPZA1LS2A1\6]W=G]#B+ZY;>.SD<77.50QP;&U#
MD@VI#_A4C1&,*;W>/-GIMJRYTD4]MI*]K63D.BO59/7P1&["0#BD,/<+Y!-6
M&HSJ'*MWJ6ET T^W0+I1L0-0D&J^E?AW92AF13%K@\)IC;2W*I^O';OGU/!D
M)>'/@.-9.@O4?&O4E U-NBN2]]_G;M]04TN-QCW033AG3/Z5[+4^41YL4%C+
MV +KEY--MKO3?&+[SWMON8O/#CIKOJ?:;$33K8)A% \O3EI+(X""DOZ4/1Z,
M6!;=M'<$[4G#EO:]?56X"<;HO+?$H5-?.)2W0)FSC "TBA@2I7UL2(M;0I-.
M&NS ;],0'#3&;Z2^,6]+T_?MSRW[0X_>OW\1\WU_(D*]-V\WCSL23K&&S_J2
MHS=RZ5HA,-$N<^#R&8GKDYU1T>\L?4HR9:Q"%\>_2&E13"OMSZYQI/7K9RYW
MM;YZ**#^O^;_ZZ8F40=03QD J0;=,TJP_M6#;K#!(S9'.4_D!AT#-1Y#^?'\
MZLJ3_>&/WWD3LW7[8@(8AEB&?!H;8CW"AA3ZX=@0!>S8W6WA1J%A#GLIH7O2
M N'.3L^C9#5_Y[7DM)]ZG9ZI,J-)SYG6#NDM$4U!C3([JBU":&][C5@1Y =E
M#]'/KJP#94L@0 ^;19%"97HQ"IVPNI_W-PAW!:N%'URR=S_Z6'21VY8-B6Z]
M=\?QL;6>'=:0^086B 6TW!(Z7:IB$#0S0*WNUWVIKF>O=M@0-TJ%A/5XP,K!
MCO>?UV7>^EB'-^6Z?R4*69^H4)_H<\[\T_%L,N@GH_'7WS)SF3,QF:$71)[D
M91-"=KUTOC*57N&4V1!2+9KXW>&O$8+1J,V& )MQ=+#=;%,'-D.HHK2P9JK:
M)I8(*C28? LV6J$OA7;?X^;LM5CMAD/9UK&CAH.]\L*9I/D#?5?Z2.MU?HK7
MK[BNU"YLY$U<@K_<=.FUKJEY-?/NC.7R4M]H"NP 2C$8+M6E!;Q2D.GY>TXY
M^/ 3:D>-Q?=K7T.SW)\613E*BMN+:,)[NHZ,(3U(=*A4#,(Y???RY,9R1WWG
MHQ6UA/,B>1I;LK;*WV;^P[3">Y]S7@'HE$:B8@<1*Q:3;_V^L[0?I3N.U"5U
M9#G[MS9?37&PNQ%_:-\A5G7GFJ_1PRBESAS\DD)G-!$-J.;THI-1/--_V! A
MH(HDFEX;J2U.OCZQVCAY8]Q_<O/6A'\)_[EVGL9G5DWDN[T+V0Z]I9@7D6Z#
M.$64 O(: '^#5 0T2%!"U< J6HYAUY'1VZ4Z::B^^C%OH2FDJ.20-5Z>[^(Q
MLN/K&[D];_9=K_Q$:I)%4V'-H#E][S4SL 0-,C]$@?:$PES3R0Y4L12WF;JM
MK;J;=*N^'W ]6Y+M@4U/GNCAPD^2''^.25%U'IF;(4,IV"2&+GE)&NDTV1PG
M1QK=%'T;P]G[MW;XW8G65Z-'&UH^=NYTEP]S_S<]Y,FQJYP_>)M*,-Y\0+=8
M1PD!.22/'(6%R@_4!+K#I#GWD(KI;Z;IE:FJ\<?GEWJ^6P@9QQX:>.:1^?UA
M7!\)G:EXD!K=IR/%.#)N/L7$$G_%G0[U'7FHY8%P=DOQ#5@U2=N[HSMP?3V$
M7 LCNJ6:J[,(2_*_SQB39[+,M!&5,1[=@2J4+Q4M>S+1L)L=8IX.YN-;RH2U
M82[E8OX[WR!WK\*:UC;YJ8V?X(W8Q*YALO8%N!S#O&NFTWM)]$^(L*;+5%63
M-.7=ZY%)VD^!L.+*)^=)@^J2W MGH;%.<.5K (XL^A =0,?RLR9*,'UG>,BN
M0)D!)D7ZOGGMZX68*L^&0@X#:>?Y.7NMX_CI[P;]UY:&6KDK///FCXUNRE#W
M2,;XG)Q%Z889Y(V*A1B7WD79"89V!%6<->H\U<07E=/09Y#O@#"@7FPH+@O,
ML%VQ5(_ 0S@W/J+)O(D,8VI(#XZ[6?4#BT"U+GX#_WG31%^FP-]' H%D5#&5
MS(3D=R>D7,AJFX(4- W=/'&"I1V# YN+&R+DM75)7-]_12Y:_M:NMLKW3*RT
M8OJYD;M^%!1H;=88DG"2>89:_Z@TT#*]]DE1/4\.?6@]Z$%$P)%0$SNED0;X
M+9S.UMSQ2M79A[TBB;3-*8;O"]97>&-_+5&4IV]9V!LJM[XZ:E/JZG&L3>U\
MAY#0?]D2 NX?7)ZW;9= ?C_ S>G3[L.XM\W-8R(&^.MBHB]/:QMT[$>F9HR&
M1H='<[^STM)I7@X_UFM5T%WO\DQ1?SV*4K1I0=%?GDG"^6UGX>3,5;MR2&R(
M!,.!.I,8ICP6*9<8%_K*)N3=S\)ZZ5QRIN?E.]Z6#:[/.!YK3B!-HY=QLSC:
MAW8 L>Q D.LK64LR1">V%Z4UA^!DX#;W_H9N9JTT.43Q* F*'ZJ3;SK>=4V]
MS3/\+-31"2Z!E =>D[.,:<6 ?@1Q(81LQCH(%"EB%;9>4FVNU9=->":?.>[Q
M*Z3:([ JJ&8I\L*W'>W)BJ=SA%J&G$/&W[4-$M675DIUV)0EVR\XV* 5O@$(
MFTL7;6[<X*Z=VCG7?_)#X:V8G;Q&/TGK=,CEL^9?7G7)U5/8D 'Z&1M:;(G.
M'._ 2 2UZ%+>7/_[2^$(E:!#XR*OA#.U9>U/V>1]37NBO_FX0SJ\[7<9%*B*
MHY3C87(L,88SL$F>>ZZ/7SK85*O<36 ^&EN,R7:=U*XYH33QLM!V;B1WY3G)
M71[A^N3YSV:OL^:?7G6)PPDZY*(-:@#U[Y?^B64NIQ@WTI64M$[M"H;+5$VS
M!UUPL&Q'YHE]2,2=P_-/??.'\BX-^88W2^[^A$G^QJ5B&F8VGI,=",;=F":9
M++.06@(2EA>5V'?X6?2T#JI;J>214ZSO()^]<8&LF.1M*17.LU!G)[@&ZLM?
MG4V_%T@$)>LG!=L'!\X;"A_?@4&7&!>H92EOYH:-9WL+6^^%SWJ/J(A,:%AG
M&UYKN2C"\RFDZ"O+E'&EB,7_EH);]IOI';D(Y+@!2:^N+:UOWD>-1<D!F19:
M6@O7#EW)+:*_2.P/Y-S(T!$'(IRGL9W&52$TM\/93QN,7M_@'C>C)3A>M';E
MC;S1W>#U*4P@_-G5Z!Y8FO=!X",Q0R>UC+.K[<-X%%1_(]\K:/?ZYT5/K(2_
MQI@*_/DAY) >1/E( @K!Q+ .\N&(Y4OR9O9LB*!-OS"SI$NND_4E+L*H%1[<
MW&5^<6QC?SFCPBZW7NC6C 0E?QG7#\V"B\("$(F@;^Z'B_T,H@H![^E]YBKC
M?T0U73]>THO>T2)_.-+DT3GE?ZMGHY7 Q_65=[Y@&.D"X$FBB50 !9>)JU8\
M1KU4E/)[Z?TG*%/O9WH?+K=9KTK[RQGAF-;^7PJFI-J4!!;$&WD#F%JN15S]
M,%EG$ ?%_QUY=KJK"B%3N!6&_6Y$.MHJ_BHEB!RP*ZG[.-LL^@*02.4=P!SH
M4KC&L)ML+NW8%D+-T-JY.[M42A:][$)KHV3S#FU];XU.=Q_CL\F5+4B_I1\0
M#J&/I^_#+\YT'47J,>M68$VXM*ZC[G,QI0/BUQE&4[^S@E0HS2LUCZ&-0=%&
M:?_)F+B9?L_1.[WB-S ,=W7DD4DV5XV1ZT>I4V42&/K8U]-O2:;?0LTL NO;
M2T^]CC^A?,[][.T^T!7D?N'G$O-HIF#[H?+  *DRB1X4\PLD@M0Z@^<!EZ@B
M\2<P;PBGW(^@-YZ?NLM'4XGCQ]K.4DUIMY@UR*.D()1Q#&[@,#JKDW=9<S/B
M,E7[^]TJ6G(I3</YP?GS3B&=GK;)ZI\RA3O%.5Z(OGF#+47?R.&/V5Y.Z1$]
MP)I&&3++&7[O0A2/CW]Y6QO(Z9+Y([M5;+!EW-1!*U7ZP&#R.15M_L7_9)/B
MCIWEEG3ZWZ<4-8 AG4^&,:3TB0,]HMS!:(J]PR/0>1>&[+7_Z?4^WLKJ3F=#
M/C<>Y)3;S)T\<8NL;+A/9D.$9T'OBT2/E8HRC LQ#%17M29)ZVI(0K;JH9*3
ME_]>?I79=&_*8TOW>4SWU49ZSAQ4DO$ N$2LO8\6 DK[T/Y=+7-K>)KL4MB*
MR"G;SS!-3ORV35+7&88JM>XC;S)2?QG7M.2YM7.$+O2S([C(K--'M,#N.PT[
MBI[M&$ W[_6.)OPUSF)#$ X\;$@WC'IS;Q-&*?@)G1T,HL45Z0V$T"O\71>"
M"S?QIQ;*?J/&S4V9V"Y9ALPT$D'G!HQ9XJ(9TO  -N21BRWKBSVN"?$AW12[
M8'J\:\ZM+<RV?YZ&S?W>BPYE0P(BSK$F9G?A\\"'V \M*[]&0IN-VFG(13?8
M977LJ"B@M+0I"-KJ:F"4:MK?'L"0TB%&,Y3N<Q<F(G22PF"DP\D]HYWZN4IA
MV=;:J?OX/E3*3'6)WY1>S>WZB6?^4\V//I2_Z\K959)PR=JXBY-%&2,UF64,
M49U>3&:77NO72),32@E>UNO&M]Q50M^T6?D.TL@?KU.A?0XI("6*#&)C*A<E
MJ6&UTL6D04>#M+@H+;U1^<#/?/NODJV%;#UUO*V1"): 1440Z@APA1C*ZUF?
MOC5$)[L]TM[6#C@[:.!0?:XN4]31];'-2RQGVU1S3N*29)<XJ[O,!%?R  -A
M1$_H=/*B(U<P+I2:O][UVI<=3M#J#H^-<GY/94.D8OLP@<CSP#X%33+.--,D
M0E.[3C>--^?(!8OZDD+D'MV=V1-L5'_MFK1Z7O;FBR)'$5LI:#^<($?<W@!/
MMFJ!X49-G<"XM<5$EFH^$,P8[IBQFE^6>Q#XO<2K.J'/,8DK0%8*;$WPY4!T
M(#P#+KO]&Y'",IOZH\,3.(V2!;QJ8MSPQNU9S64?_.Z4/)^LC/'U2W=H&0@(
MF_]^[,/GGHC-OV7Q9,2<X"<T/SK,839_X+1U&OF29D_CB%\ED#RR%=GQ#5&>
MZGW-<_^6/;^=C\"QS$(7N0.'%"%G8->9#3!_-D04J35F;K".$U]V$ 8R7$^'
M9:"E2Z,TYQ=%30S;DI3T:M)#5[G=.5SD.!/[@I$*S H6#Q+U@(Y^A!;7,LRH
MU2B(NG3&LB<ZH&.K.'35M?!D;(_>PSMW+FNN(N117]W8D";O'(IR;YD2Q8&A
MW$Y+I#N(B@(8VVR*9P]/>8#O.ROC_),0>UF3H_6G<[_H/6!#LA__O H6I[-#
M?'29N)AJATY*Y^6N$R&>_'*6'N=/,LOE]\_M#>WLA7>@3HU 'DCM#8PF_D7T
M=\!FQ^D#5W.!&<>QTBN-7V6A(X5C[D\^RX7AAV!#'N%\O4('@G4R<4T.^)Q9
MUI?N7\M+V3[C2U>>OQRO<5X,*>U8<RH\.'<VQV#.@KOEZ%SNLUMN:WN9J%/7
M@RF_,*V5.13<P,Q]4$7<$Q4+O+^"B=\NO5S4+:W;4D(1'(,^:1B\M5>D-=>2
MDI__..0G&\(1W"X*.D7B&T65Z:B0MA//&!)C6V;\NCY7?N]CPR[-U[,A']4>
MRZ:8?!,]]$+T%J!//\<XS'SQ>WC3A22:7?LGO-(S(\YY$J_]<2JSXI8*;?>5
M/?\1<>,77T3T$Z]TZ;$FH%RX *:ES;BY5LQ(T_#'N# YF^84^_:.PA6?'<9R
M-4+R$?>N[^"1.)*WQPV%O'^?2B'@W?$\V_&:; A_RFS7SS;6M$-][#?0R7:Y
M$5JV]CL;?J;_Q\2Z+-=@6J&?D@##"-*/YE' NM-O!9=&++-WT/$O:A/CU-P:
ML'QV_RMO_2QK$L/Q!_Z(BKSS%8F6?DM*:^:[;5U>,3L:.1QQK-NCQD'2=KR<
MW^M*HKK&LQ9>PQ]2%)XB\G8:G)MU 'F;<F7U-3.7JF8+4%\$>Y^<[M2_O^33
M&1K@,B$O=_%=IV[IN:,Q\ C.ML:6W1SOB2:$ FH*H\C2^4%8&V!#9 %C!^!!
M#2&P[/!XY]'J#.B1+HSPQ+H,3,/XV.)M);NGW599%7F!G#]!)0#JC0M3&P;"
M+O#W+;@I;ZOQC;H3N:J=@5\[$U34(I,<I7U>D"S4TCO@F.LJ90;,FC^CL]!E
M3"\\W5Q]O!DG_@U(GG#LH'QYHU50-N/0P89<BC\G)EG$P7&W7%B.&P+1K .R
MR#""/IEW4X+J\<E<9(RE[74=X&ABJG7C*%BD6_G/>H+G<)7-783.5=H.OX["
MXHTDOQAD&S6A[PWGYOV52E!*\*&,/!@'T,UHA"=P'7'0)I4WEV92=[/E=A?H
M!(J/D\(GU QWZYZ_17V%*Z!. 9JTN\ 2E1-.,5PMI5R8Z#/7::1<Q2J\[G]9
M.WPO])AEA @;,G_NIO^L1*CVG6*M%YP>_4O<2*ME[!P9#QK<2N /6="J'A!&
MMF-3#>;>A/ZY=%5E:M-5>=[FT,[3#UFSRZ[^NN0C^K<X?PUIDMZ:'T>B)G$!
M2WP SP2YJR.H!DR\C#>DM-^VX0QSL9A[X4][$[YHN!"N+5'H+&A=,S1P:IP*
MZBEH!JYA$M>DEFQF3%7K5=1II13U*.CT*4KF]QMC$&T3V!/>.XN.?L</VUI:
MR,_))1$^^4B<A0;-:%-RR+R/S T!,/;>+D&ZVVS3TL'UPX:C!*)8*^%VG??B
M;<AE-V1HT]XA$P7-M8_H\T 670=I"^C4_8 UI61V!G>94Y$H*-6_:-G+/6RS
MF6]M8NN$,+/) ]*T4Q'O(19Z*:<I<7)_K0<C!RQ/?#*7 ]2(VW+P&&_15%S3
M:&;32$AOB:_2@@?!\L%;+X.#IM5\KXM?7IN^*/ZB9?'.6=Y%2;<^F Q*G>'/
MS/^#R8+Q,WBII>XSFP:8A*] 8_??G$R$%7,Q[>U@5+B_=J&_\T1LUW4[<?N.
MO41HY#,"X$29(>OTB::9*T\P.*DVY/XLD@NE*\2VV2%U3V9:WP,HN4NMJ.^[
MD[K#1U:U#L0G>;D,JXBK<VX,:7Y'S/ZB/0%RZ0X G;B=L/F'/J*WUZ,H-6F(
MS;QW;V??[X]F+-0VN]_QH]2V^ [Y!K'VO6(,MB[P__JG^1>/>>RP@Z!0@S4C
M&/+N5<">9ST%OC&[]H,2(J/[4Q_=K1"VZ/=^J%MUL.C9"Y>R/]M0RN71+"CE
M"B;]<%76!@P!?[36TWZE+DFH#%H<J5XK-%'<<'Q%(>.FUC.WO,;@NZ''(WYU
MWFYRFZ<JESD_F[]RO&@F9C80^X%6Q5#MDJ('?$.WO-S5SZ9'L&A&K.8W?,I'
M9M)F].DGD>>9[\TLZ9X,.PJ\#\$U&D#!V(W7B/:,>*]=N'9]QU<>'J@8:%KA
MN'KI ^<*)_;ZVO!N^M-WBU_N+/FW@]J]>+1PK4"W@%E@BVBTF_WWB]\%4OLP
M*B^ME@U)S#!@0Q1_%2H*,DO-F(K"-U?/J"( R]JY_UK<KYV?U=M](A"QB'-&
M0;UCBAPITBEHLCU<^1K&IB7_:HH/_,3**Y?CQ,B>PD.;WH4R<D*N%>6RFM%7
MZ3DNO$]=^K\X91Y3A*]F87_.#U#@8!]:.LA2CBDB01/-'OBAEQWXS.R7SRB>
M^668^]C/3NC%R3_';;D>VJH(3%!@O3E<#+O&201# FN#%LFM70PZG%$15F:U
M65,KW*L6(ZNA5*!R2_Z6^"EL"K3G[W:/:#I,!A<&32FY/7.ZJ@>=[4:-Z;C<
MY#E8#7C'J=D:?R7&K24&+PSD/[P1SK@2X !LF:G1N1C>5&CW@G4(TV%@2;[S
MRDM -51Q8<NOO=1YZK7M:JLM/LC=)TC-\47^RAW-^FWS 4"-NDWBW90E\2,?
M4!P&C+J.C!^9]&\HI(TI7 E3ZO]]=,J!XTEBYL%/"18\'T8/H CP1K7>I=23
M2%V*6A]?L\+UK>5E04Z1XGO:.G[Q7I7V#UI2/>;UM.Z**^=FB^4$[]-I,*K-
MPRXIULSIF4]07J0Y-3K93):\S3'K!:!&^UC2'>/\D[^K8S;"R/$!YW<%9YEY
M;G[;$A()L3]0,@Y4T&K^PC)@8!Z#C K(HDFHH]2#E*7X3IO;R7/N8V''["I;
M6SH?^9L^I?7_7!MH2![_TOGP[!G3?W]F$L\::(>FZ71JUS%N-]:W31@6-SVW
M7J5?[DC^0MC1N.A\;L_A8/R%MN-VR%M1V,M4>';G42*:*Q@JCKRR+/B_L?<>
M4$U]Z[[H0E"D29<.*DB1$I6F@$1$0$!$47J)2 <!D=X25'H+14!1B0H(2)/>
M$SHJ(DJ5A!*"5"D)8(BDO?SO/F_O_SEGG_/>'?>]>\_9VY$QQYAKS/G+^N;\
MYIK?[_O6FG-&FG&8C,J,@7YJ^'XU\!%W-\Q3?-%Y3"XU&Z.^0P?6#7SG.88?
M@464H<?T763CY/JKQ;G<U$^CW#50:-5PI!\=R',?PM3UJSHQS<\EA@[2 995
M$BM9-RS!@"!;(P1OV/.9T33^N@G:6L3'(TH'@P[T\-6G5M]MY GJ'WQ4<!"(
M)N G<1X/=$^'L5XEO<)C>N^MM1ZI\58)VC 4=+,M_"#2$_-1CX6GDT>/Y8#B
MD NCN?'0_EK2 QT=A/C= -E71.&?+B4S:<J;H;[;_:\6HS,:-\_E50ON',HC
MF-M]H0/N4NAR8C1>*"'*])5N2K%W@3Q>%U'M:2WJ]CU"I4R@=EKI^M6W\\=;
M[,<Y#^D&=PU%\Q-.#6#CFBC\^M9U-O5?L98D/;EOG6S?HY^1P:<?;[1ILV?N
M^*.-AI*!/?2V1"!QEYK9?GXA$I& 1O5WZ&J3E2_;0(8DBC_E6N49//S%[R3C
MCA9AYBEVNGCKN;AHPKP.'1"H8) G1(%X:Z8?/.T$Z8(G]IQL8%F:\I7/X3LZ
MTQ[4MY\8K0RTI9R#D>3H0,])_$=;TS<.I%-HQ]OOK-)-)^":2PYX^PU=*'6F
MBT$2.P2WU=-*>F'H.S\6_'O3;A(S"?!'KB38@H3Y17S!T_E*6U^E^MYW]<D&
MK:V)KX3<K3/>=_L.+N98<DS4,.9WC@7S#6<"*[8 CN-.09[$1^>EZC)-AV7W
MA4 %6X["HX.:M"+BTSYF^[>\F94X/<]VL?.\&A,Q3? 7B7:,^EI'G2Q/JB/"
MQV#>U:)K6EO=<TE-6H<2O$Y^.C,%625&K-F>G>O-A#>:*ETE%P=FQJ*9."'?
M@KDY*1=)9+(WQ9)D7@K]6J".'TC049U'''%<11O%_G2KRYB>,0H3=5:P"KZU
MK7>F2G!J#(E]*\^\=DIQ?OB1E 14 SH*%26QX5/ZZ(!0</11\-$5FGP'P2B)
M<O[4U)S/@E''T9!5SH\E[_D5A,X*=[H#!T^Q5?:V4-\NU9)6&7.R!.E%55CN
M7F?K<H(<?JFR; T_4&%:,MLG,41\TO3YV<'.)!F;DL='(?6R2]C3P'[) (*O
M_3A^A.O40K_0)(]L0Q5Z93_@CT_'YT+OD4\8\A2&>YO;2AU&]7;7!_T/7F8]
M'LS%:C*Y7E5=_U0:;EG;U&J4._0]]4K*J0-7W3)S.F^?K3B,74(:M)#FB?YQ
MDARC2*&P+=R%]%<^Y,MAD3TTE1$=6*E:?N-SV5QI#812B[\6:]K7GO"L<K9K
MXJFGJKO,F1TH:M1RE%=U<BZ81\?E[?"\X@^.;T'V'?<ZD&]&PD(4<N0N/LUV
M]LV\KW'JV+(O$)UF$*5.5O.A XT(.,-JQ-(!\2#($<J-,3F"^A("MC!CWJNK
M\@71$QIA,.VV[&-_N-K.QU_QDV&"JX**-.;8R2?<+9[_.[?!.9#>,-_!V@OQ
MH,V,W&XE*^%\8.=5:P8N@3^?^BE@>?Y#GT''T=[2/N/Z!F<#@5N/ ]%&W=5,
MGC"^8$0*VN]176\$-:XXO:RL8ZQ6+9?8K\]IDMIWPO+L^RL&CGVUF$26P%E-
M:@[R ,5P/,JLDM33>6=MN5]#*[HDZ86Z=JD!Q4I5I%*SPN)M?-IG_5).HX_&
M3HI?2E]R<@M%G<9KIE,,YH<%2=7Z9*=7\Q>NF>GW[$EYY>@.WL<;^PTW""LN
M*;@ZG'/>\1 !T@,7N->;\)"% E0)"340<>259%,Q^H./6Y6GY/&.D6J+J<_+
M,<-N:A8ZEW<6:Q2SK@!9/HS['#FT170BL87C1?VGTB'Q$SY8^Q157XT'+"/]
M5?'F:C69XJ9+(N PU[EVI$WC-6\%F!OWU*8_7QAKWTB4>B/M"PE2T@!_X"$4
M^."-_1,K*27Y[+N=)^1ORM\O\G,X(]MQ)!E8WC6/0[+@E],I^@20X9?V%_Y]
MUVU[JF>I;ZS(%G9%2<"W3S<T*JIT+Q9M_JI[D*Y]BYJ*\KAP<[XZCB; ?6#:
M=M6)31B?BG;OB/2)+HHJ-L^,%!B\_^SQ/"I\A]/O\\&(- &FQ7WX>C">WYKD
MP]U=:=^SWS'QPK=*ML$G,A@W8^)HPF4LQ+#IT,E#JR<Y.MTR;O-UL D@Q:EI
M8/<Y#I)I'_1P#>ENDU9H^IW+A-B(QK+0:-F*&^Q*V:8!BFW&\7*?IL6?:ZS'
M&)5\O2AICQ\@GJ:^0/*&C0S@S!]1Q")FI4<K2NKJ)QM@?) U(1]?^52U0_9E
MWST2#X^=T+ "/WEIL6E?2X!T#S.1YOH*1 D#R6J@!N\"'F3!3D\3A*'*#VH3
M6_[2&X8<LG<R)X\(<WX'+DJ_?!US6E>6PM!_/_C0,)X.X'03J,5%#C-VTV9>
MQ*?.,\H-O:&G&U>>VOCF"V, [$;7>QEA]:U'""X=\X4&4@Y.BET_O*(D?K.>
MNWY8+36MQ.&#>#:FWKZ]T=JS4"9'.:[S&!^WF0$0+M53_<V#Z$FRQ74P]]/X
M\4Y%P6"V7^7S/FDW^R)R\%]Q66S*LQRN+<U!\?P"54B+&$30PGT%IS9]$B^^
MI ?!]1,>:P>*BT(<^;'M;>&-AF%*_"]4?\\UK5M2S8.<6<J@5&AL=F\ 3),W
M+HHGDOCQQ6[XJSW=*,V>8D7L*'&*T3 GKD);Q )U:U^[%KH'<YP+8[:%JE!S
MH ?"?I@3H$]Q<";E3U"ML4IU;GY-8MK'"WTS%?<&_'7\:@\U9:D_5*YDN\3N
MMV:L&\=H3$D,'7 %3Y'G9Y8ZRE:0[ 7;.WUV6JM.<DC"H:;PMV;E:(5LWNF.
M[R,BS3F3@:[KQU4;+ T@\:@:Z_4Y_!O%'_X<),DU' ?UB".?J5EDKQ"ZZ/1J
MEN!9FQZ)[R-%&ALU@:('6;T?911*EC-NANB&3XEA$5V.$7.]DDPU!,[[-AAU
MY%.O,A+&$E7_+BZ>\YZ]P_0'3FEQKM+3YX3%K7@8EC:"]AZ%V<*)Z J^WZ*V
MMXX79Y/B*5/?O \LJI@-538AOJ/;3))M>E/:_0P_JBH0\^69X\? 'E*Q^0G]
M[\&>+J]F,:0JQ7,;[LB:296-^?;D,\<2'3!]IWH"WYG*CIXZXS@=Y.#R0ZHF
M;WVA,@KT!<D]A%7PW85PS'5LQ:-[[#N:VD<V);Z'YG*\7Q+BK?&"G,MFT> &
MF-;4KK-FK8'?,3C87&E8Z"7\-LG<LMZ?:\9Q>F4?^0RW<6WR9KQ]1719_KYB
M7$OVY\X=S?>8QBKH2C\\ >P*FAKMUN4?C>*:1\43T%Y:X)0%PK47'I+%P8G!
MKKZ#@=DJ-IO+SB?9UMYTR"8#.XK@*5;L!7CO-YHR'>@^_];1>P+=N]^0UEB(
M>V&X;%Z'>@9[&GSP<5U#_5G$&5I0JJ"2"38?070FB03BI3OS<Q%5/WB]1>E
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MT3C@[#9B4MQK$:#$ZOH?/TPMDM. UH;\\P4:MZY;OG@@+5?@X]*%J)OLFDM
M2H]$V6/G#@ZXE'I"A?R/K 8.A&H?#IIX*N<94I=SQRU-_'WG^RM@3;D++P28
M.OO(IRE<\2.S_2#F!X+5<#="$1NU.'#[1Y:I3'4H0O5Y>ZV4$FW%K_,BP/S'
M:J2\[@[K/L:4DZ[N?P@SLZ8KCZ=H225*;AKE*F[H2I\Q#8U[,M!$/7%W7N\V
MZ<Y%(/C6==8<B@(U!>QA_DA2L990_8 B!0WFDATQ=60W\^AMC2_*U^$#J@6?
MAP:^SWU[RU?W.B1OD=QN.>1/-*061!G@E[;F#<OQ!)FO(!UC<**HX%B5E:>Z
M<4ED0GM\<(:9/^B9]#O/F9#X4\TWD_\8XYVZRC3&/ *;*L&Q=H-BCK[SVF<(
M6^D,MYR@6+^=]5;U?JAYM2<X]-ZHPUW/RQGE!Z(0:K4J1@PO='V5+$>YB)<;
MJ)3&I25TH[@HBGA:SFNGJ;4",7QU6K6Z,T[DS7:L\EEC?Y8S,MHBF3%>PL@C
M7R=7&>KJ0[E)3;W9P:+2D8H42X)*=K'=#PB?3J3N&Y<15X\KNZ2!/.\J6Z,M
M>U4SV7-S]SKY4R?KOQH  C?^)?$<[A*X<5$$AH\+L]Y ^-'Z$CY]CMP8)K=@
M]JU> IQ,!H+/%2R*H5>*H1_[@U9&_I+K,A"PBD_0G@?%27&W<X&35*+.S/<^
M:'>L^/"6E&BLDZV\@>D2X#YN*_+PD< 9E3XF78<%F>SW%# U%>8.BVOUB ^"
M,$6=3C&OQ8>TA5:0_(:"M9N2/^\O::;;=NM4B*]G=B=P2L]L'^RLOOXZYCPD
M$7%05XAB,[ZK'(GCCET8\Z.H!U_H3U%U,!5I"G\9&?Z MS:)%Y?YM3#Z?>=V
M48R1!'Z.*$[-1PJ&#5\C[,7I")4:EZZ4G?!DM248%I;V%"E631[-F!F6"9FR
ML#[S-J.H])BX=26#O2J6PKIT8*X77"!C%+V*J--M'5H3#0'EWJUNRRGJMD&8
M\@^+JF:*WSH^-&A_UT[^91_I(F[]V@ ?.5\OQ:<$5=:;]RR<K!_FUHTK<2P:
M.;P11,PYZ>D2J_GXJ>>H$H\&CTI(JC6#5 9J)71MQ>^7]!V&JLZ1G&4(2I*2
MS_0=+T^;,*^.?*R[T-8O-I@9U<>I678J\*&F^"_9%CK @J*FJF_(;O5D4[3&
M7X[XI<(E$SP6+E@I:XU8R_QZ9ULY/#4??,<VI/] TS'V_4/)P"+R"(FC#\:E
MPROTJ-V18&U)>#Q1]UXYN/+^80L\9GDOX-.7MQ6?"Q\I7!\>;_F@"_MC4[*?
MU,QJRLUPW%/=H\8\8\'<36M:ZM6)H/D1O\V40ZJF)0/G&C*31+0+CQ5<D<O_
M@WQ]0,I >^A G74?3,3;28L ?P@RVVP1-\;)UP_S>1_5:!WI?W7="8.YENGH
M?!$R6^YF.)K9%Y(1)47R]5K84,4%Y\4Y/[+[VJZM$E<\C?E(&/ M,98Y>Z&U
MN^($1^OA1.U0^:L'F([MUE]G98XDGX[B'-,5]9ECW=+AE.HID)U444_SOT8;
M:9'RZBA8=S(%/9&9?5;"1"P_* %P](7G):)N;[%%65/+=(]3G$D]Q3K[3JB7
M*R&2$BU?=8PC2^8,WQF%Y7UY3\RZ/'OUM8VJ2(CU-S:@M/KURDON<X2\]6RR
M+FFALT"<%%A& 9M>T.PB@^?Y?;FO-X]6!=TO6UQ"XR:N+*4H]CC38+@A_1+H
MP!P0!(NW!K/5^[-#IKSR\IN(E3.+B"00;JP$M4!5WIH("-JY=VA'X1P3=$MP
ME=&F?!*,J$]%M*O/1X+8;,).>/E61$%8DZUP>_;MS:W-$\YNGEL>S;GNN;B+
M-V 3=0KL FDOV;^83Z'F!<!B2]372KMB@_Z"CA@9T;CQ-TVA@AW;1<J<O@'>
M62GA,R="#,*EW:\;'NX<"&:0<?,'=. .8NK'?%.R;_L-+.S(#[O[WV8[EA"O
M]18D;I)E1T)D\E+,-<%N\%P9>;BGW#'VG][_!19&_S.E=A2QA%H.%:<-2C(W
M$[B3_!@FSZF@>\F?*\P$;4AV;U(S;ON8Y&(LKF(2G^U\:YIMC>DG.\$<3@<
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M VSP>/"*.BOUIS6XKIX._"(DT*CL?\H")7^J8T21U16F R_'I/;&'6B?1^G
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MK0,(K,0"$A.^O-=W'I2($%3KD+:X8F%5UY;Y*-;/LIGUD=-QPB Q@R1",%^
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M<@^JA+<-;N\>_[N!^U/>BCNC1?]&K1?N_H^7!F]>QX"/P["EB'>(WCF2'&S
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M?>J+$CHPG K>6[GQM^RM,2OF_TA!\@>D_NX['89Z_GM#$((-]2Q/E+^RK=T
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M[H&D.JG 1,,*(02##DQGQI-=!.^0[Y$Q8=8[XAYC>W^$=\C*43HD?<(@]N=
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M@;IYH8V1CEC+ZLKJNZNO7/*.%,<.BJC.Q"9L)%FFZ.^2)5%M6B@7].>.MB0
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M:X,83^[)#*PA/H!@?QT0)":<%TR_6B*XL13+H!?7'KKXI;53/"E'FS6'J>1
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M-FU?#FI.2;0(8\P^,W^3<^D8R^H\31S5IK,?K>2#"380(5N$-Q6C+^F)9"=
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M]UJ^(D5\':KG&V3;;I=6-S;6KG_+/Y?)OX'.OO8Z6GZQ_]P_ [?Y'VS<@VA
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MV+E%)!&X-D"H<OL>*,Q82JEO9J!!Y-W2?<![&$RID]L1Q][?3"B10*=!G?N
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M8:YX2?#V8<TNU<?<F"Q$HM>0JX9P%\>21 Q2"R\,S)L@FU82UE=';GZX*NU
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MS<T@U[,(7!U(7K(HVSM7'W!LB8*#T+/).Z][3C_P.^' \D+3%0$NIC>D R)
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ML=_&E.#=6S?_=:0Y?GK6/!B<U0"F]V^[*?@8='FD$487Z P8 5V(8*6_19?
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MG2TY7]&$F;&!!]ZVKYUW$XQ'3JTB!3;VH(#:*/5TCW@X^RODS /$K4$%U[8
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M0Y5Q"RR-4DWJW3Z?G7&^I#5\*/RCTNU>J5+1<_,UC(K=(6-_-]OSD;F\B'S
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MB9WC@89L&E%EY@VD^VNEU2_@UZV&-);$):PD70P_?LJ</MXB-WY61#7JN;;
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MC:%+;\5LN)OYS%3P9?\*IY@K,L-XJO_ 9@@AZ[OI\-2/E^,,[*O]I4]^KE9
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MS]Q_R<_;#*^,.]R'; )$C.VU/Q\>QV^Q+ F@PO?VT]RR1KZFRY7T.7^_\_B
M\I>VQHB,/<A+6RWOA ]44FT2,&7FL[$4[7CD!N!#'IQX88!M]1)^E%*=4-#=
MK4G3]#^KU]5^K/FH9N\I>6O5I8,JPW>P6YTC*9@4KA%"E?.6!KU.3(;)X"G'
M>FKMR=DE08UKM+%87[<P[S#OH*T.,F^KWJ2U2NYK.//VPI&,@U8A6)5>Z+6
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MH]-9"/F<Q[/0\80]-;&>B6?FR >G/V\_0=@=8_\/UNCZB?&):X&)1\T*>?-
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M\.Z[W7)?8W0V_.H7&GO\"D84ZEC.$>RYW(H;MGAQZ4:VW/=\]*/Q&JQ0+S0
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MO0NE5$ >RT!O4'D,:28%5"+#6&:<I8'3C>70 D^-ZO;U!4L%=C6NSZ+6.M^
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M)+:^S?1QR:;?ZA2*IIW7^4(OA^:FM/:/8#%-)(TX3!315)9F'!)!" QY(H-
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M. ?+("X<1YT]H\/&.<6[W3/.ON4>/]M$_>UXM]67A;OEGF<,LY1*O7\+4II
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M(-;6*"0T"_7.4\0A1FE,0ZM@VJLEF9KY6M\N%;4R4@!: K&28&7DU]O3'04
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MIPO]3(UX6A?]M:R@$1:TTKJ&,9R&MIM?/ (V,*7TQ*I'0$,G$E<$-9QN=^3
MAD[ECH,;NA_O9Y<TF0EKN_,C+3X4->\T*:\_RJ+.>C$+98)8BA4D:8(@IC&#
M&8M2F%*&$A$3BKB3LYM%GU,CA]T$CC?@D1;@J4Y/8S(W"FV(TZ(T)2^;+(Z.
M21QMAL#.,/$,[, DTF+ZN<%4"VP"HAJ1V^0_6N@F39 _P\0!(D]VB4V/HYHE
M#A <6B4NK_8(N/HP?Z1E7M#%[4+<?OIP^^X7='M?R-H.:B\48L%5$H4(9IP@
M$V*5P2P,% P8DX(%.!,\L ZQNMS?U'AH(W%]\JAEAD9HL)':(9S' NQNUAD
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M1%S)),EXEJ1.R16<)9@:9^CO*G8M=.D*NAUO# KEP)S2R+YK.M3B[U7?K9:
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M(L68L(RS).5.^RG.(HR-0AIB@J:<COLJ[D-AN9_2*\!][Z,4PL-"^N-$M#?
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MQ,H$!W!(6)AD<4)IDCG%3QYW,39&:U1W_>!:=:0%2,O#\ZO@Z?MXVPV9[C$
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MM'?Z.ED_K( XF_?#[NZ.;'0^!]K?EHN5YB&,6402!)-0"+T HZ$I#H,A9EE
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M44(9I,PL,!6*$$VS($1.13:L>QX;J33-@=*Q>4_TK6.*X7A'#WC[T; TU_K
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M Y]OSUJG^?IC/I.KM5[R5H_<%\FE"6V=!CQ)0H4BS8%8LR&),,1<99!(%HJ
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M2%<!QL9@^D%,W4C)&7([>NH3R)Z)JA3]IN&Z4M6;WLI_8YQ>F$D)D8L;8%0
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M&O]G\^0T5?J7']E:?#/3'OQ]7:;_1E=_.1%:$"%H!C-AG7E4Y) @G<("9:Q
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M!,N,*HBQ+" I=0H+K?)49#F5:;F)_KY;K-G,CR^/S>FT20_#MG<S][=AJSG
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M+BM'Z]_43-XM/K*U_?WI4IAGZ'%FF[K\-E\JL?@ZG_Y+R5_8=&Z_4!^72_.
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M?@[3_/KWSSA?X0432EF1-44MV7A=.ZM'<.@$,$R:Z6@$LZW#V7L)&:<#\7#
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M]%!,^/-BGBX\^L0+&= "7I0Z6<8DVAA)@%+DM)&1#NS1OD0M _,KJGH(J9K
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M08BU17HH&:VGXUNU]N0>)6CD5^'F\&DG_1Z@]/28D7/&!-/1AAS %T[&.9L
MSM4>A!Q+T0&5DZV3H+8F;MQ2FP$@-HA6.H#;[:DAYUR$;&-(R" G[T%9IR$X
M,L?)!QVY01^;Y_[>3\FX)<SM@=1 WAV@YOZ[KW->(B\V6HQ@4XRU7"*#UR2C
M:)P2,4JN6.OK_L?H&;=,JCV"FLF^ QQ=1A\_T9[8/ -/O!,R%PR CCE0]:7
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M-:,?G#%.FDA1%^TQ98J'.OV/I$A<%>.MT:U+LG8@K[>BZF/AL(FZ.D#B]LD
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MY@A92V(QI@1.1@/(6+%&%)MYZZGJ0V7:/X_*N7U >BP%[XWA+[B,BR.6UJ'
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M"IRT HK&R'ED)JJT#79ZKG [J<KL ZZ.1@/&V*[W5<[MS5OCA&)(D7D.P"F
MH#V--9W;4^001 H^T,:VV_6/^/F[7U"UVDY*?BC+>4^)CPV8G8KMI+7.8C3
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MH?>H0&O/O; 2D]KND?7^-X^;T#LH) X28@]5L9<W!SDC\ZD Q_J8)B-"M#Z
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M^] ]2=#(AWIO*&RGO+&CC8<X^2,L_H6KM2ROIGQ;I[)SY/Q8<HB4)(<HJFR
M>18TN4/1L^WN,[9:;MS8M!NP#:2?'A'W'A?K;#\*W6^SY6W144@+1=46D$$G
M\#S748 EI,1(;/=3]7> W<-KCAOG]H^]!IH:$8#+Q6KR:;JJX>&;69Y^G^:+
M<+YVINM#1\F%@RUUQE<@+AP:#M&Y8I,0L>!643.M<.NPI7^[.6@?77QD>S=J
MQ-Q&([U!ZC^GJR_K[( ZP_++]-NG^6^SU73UXZJI?.+9*!D@B3IYWJH 3NL
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M&Q*NOA/8\>5\.9VOX/(<9O/)]&IJ/W:XF'Z8+5?3Q732I/G[\?CRTWPUFW^
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M^L0GN'\&_/-6F'UERW0"<2IW&F*I@+,P*4XH@.PY4[HI+),HSIUB"NSA0D;
M\X@_PH3<,^%Q;!UL,>5<E[A%T67M95QP,TJF8$.C(!:Y=;:PTU7<BHOU*>_9
MV"4B3&I-2W^S*2#5(!_U=KX][-RT <#(^?T%4?VO5^#W;:,+^YYIPS+?V]##
MZQ/JG\%O+)1K#1<75S\VM:G-EURV86S!V+3-!?NQ^3SH44]"/G[>;63UNAV4
M+</6V8,'7V.UEL;(;(#N3=C:-I>M>6CRS!NQ_E;OU?+E//H'4$L#!!0    (
M ,Z ?%7*0]\!%@@  'TB   7    87)W<BTR,#(R,#DS,'AE>#,Q,2YH=&W=
M6FMOVS@6_;Z_@N-@.PG@MYU'G31 QG&GQG:3PG6VNY\6E$39W$BBAJ3L>'[]
MGDO*L1,[K8/IM)T4J&.)E^3E/8?G7DH^^^GRNC_^SX<!F]HT81]N?GD_[+-*
MK='XU.DW&I?C2_9N_,_WK%MOMMA8\\Q(*U7&DT9C<%5AE:FU>:_1F,_G]7FG
MKO2D,1XU:*AN(U'*B'IDH\KY&=W!I^#1^=_.?JK5V*4*BU1DEH5:<"LB5AB9
M3=BG2)A;5JN55GV5+[2<3"UK-]MM]DGI6SGCOMU*FXCSY3AG#7]]UG"3G 4J
M6IR?17+&9/2F(E^WCX_#(&ZUCF+>C<+62:<9\\YAT&V+P^/V4?#?%IQLP-SW
M,7:1B#>55&:UJ:#Y>]W#W)[.962GO5:S^?>*LSL_BU5F,9E&9__5C[$QDA5W
MML83.<EZ;CT5WW79'*I$Z=Y>T_T[I99:S%.9+'H_CV4J#+L2<S92*<]^KAI@
M4#-"R]@;&OF[@$]PSUW.O;_'&">1F5CZWVJ3TX.[J0RD99U6O?70X_55<SW!
MPJW*T0O#KOD>(M)"?R?G^X/1>/AVV+\8#Z^OV/5;UG\W'+QE@W\/^C?CX;\&
MN(76P8@]N;(?924?;D8?;RZNQFQ\S48W[P>LU>&U5G>?'[#K47GG,"KO_/"K
M 1+C=P/V$3",AN/AX",@Z;^[N/IUP"[Z8P*J];K3?7H=G^';_PIC9;SXTQ?6
MW;JP897UIUH:>#85FEUDO_-$98+N2A&SP9T("RMG@EW'L0QAH6)VH;6:DP2Q
M#U.N4QX*F(0\,54VS,)ZE<&.EL3LE-M7>X<GISL%YFAK7/PMF46 O]<^SO]\
M6=D>J%:=#=F4(Q):S*280\[M5!I$+"MXPD8B5]HRE;&W2J>LU:S]8X=0(3BO
M7T)PVG7V"S<("=:?+MAMIN:)B":@D8N1]L&)%&;,%/(A!N0R8SQ;L"*SNA!P
M&!G2)4M$C;,45UHBKC$/<0NT2R'I5GF[#8-,A,(8KA=DDO);@7G7QC2X%\$9
M3)FX3(LYR""4&ID59AFZPY,(_)Y/93AEIJ"/5?^YT*(<A!:02I, 5,KF<VFG
M6*#)1>@<I'%SN*8B+'.&;A$+%NMA>"F8=SZ#N6"QS!!5 F@5Q2H A[DEH5FU
MRRS&CN%4<>%[F!01Q@12:R&K F6IDP7+$6CB"'$G258D*.-O'DT-GD6NE*N2
M19'  ,@KP..F,\Z?D)LIBQ,U-TM::#&!(*(.M(S33>\WO*RNH6N6SFQX^U(
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M:8$<_.?VBYR[2'Y=+Q5<X:DDPZKI%0FCY9[\J/[;?J^W_?+K&SGMG^6:1RX
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M:_UEP7SCV/L'4$L! A0#%     @ SH!\5?.:<4'>F0, HCDB !$
M     ( !     &%R=W(M,C R,C Y,S N:'1M4$L! A0#%     @ SH!\55:2
M!D)7%   !>   !$              ( !#9H# &%R=W(M,C R,C Y,S N>'-D
M4$L! A0#%     @ SH!\55"N?'6K)   A7(! !4              ( !DZX#
M &%R=W(M,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( ,Z ?%5'J$GR]%L
M -X2!  5              "  7'3 P!A<G=R+3(P,C(P.3,P7V1E9BYX;6Q0
M2P$"% ,4    " #.@'Q5Y,-R,$ W 0 '9 $ %               @ &8+P0
M87)W<BTR,#(R,#DS,%]G,2YJ<&=02P$"% ,4    " #.@'Q5(&0MXE!R  #2
M@   %               @ $*9P4 87)W<BTR,#(R,#DS,%]G,BYJ<&=02P$"
M% ,4    " #.@'Q5<LEZU@&2 0 THP$ %               @ &,V04 87)W
M<BTR,#(R,#DS,%]G,RYJ<&=02P$"% ,4    " #.@'Q5I":U0T,! 0 GW $
M%               @ &_:P< 87)W<BTR,#(R,#DS,%]G-"YJ<&=02P$"% ,4
M    " #.@'Q5M2[B?7,T 0 9WP$ %               @ $T;0@ 87)W<BTR
M,#(R,#DS,%]G-2YJ<&=02P$"% ,4    " #.@'Q5&(#TKX$! 0#XP H %0
M            @ '9H0D 87)W<BTR,#(R,#DS,%]L86(N>&UL4$L! A0#%
M  @ SH!\5>K.(5$9GP  :4X' !4              ( !C:,* &%R=W(M,C R
M,C Y,S!?<')E+GAM;%!+ 0(4 Q0    ( ,Z ?%7>K08V'@0  )0+   7
M          "  =E""P!A<G=R+3(P,C(P.3,P>&5X,C,Q+FAT;5!+ 0(4 Q0
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4!08     $  0 "T$  #V80L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
